<SEC-DOCUMENT>0001213900-21-026511.txt : 20210514
<SEC-HEADER>0001213900-21-026511.hdr.sgml : 20210514
<ACCEPTANCE-DATETIME>20210514170534
ACCESSION NUMBER:		0001213900-21-026511
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210514
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		21925820

	BUSINESS ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2020_nlspharmaceutics.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>



<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORM
20-F</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the fiscal year ended December 31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
File No.: 001-39957</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NLS
PHARMACEUTICS LTD.</B><BR>
<I>(Exact name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Translation
of registrant&rsquo;s name into English: Not applicable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Jurisdiction
of incorporation or organization)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Alter
Postplatz 2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6370
Stans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Address
of principal executive offices)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Alexander
Zwyer<BR>
Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel:
+41 41 618 80 01</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>az@nls-pharma.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Alter
Postplatz 2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6370
Stans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; width: 53%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Shares, nominal
        value CHF 0.02 per share</FONT></P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0; text-align: center; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLSP</FONT></P>

<P STYLE="margin: 0; text-align: center; background-color: #CCEEFF"></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0; text-align: center; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq
        Capital Market</FONT></P>

<P STYLE="margin: 0; text-align: center; background-color: #CCEEFF"></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to Purchase Common Shares, nominal value CHF 0.02 per share</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLSPW</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(g) of the Act: None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act: None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
the number of outstanding shares of each of the issuer&rsquo;s classes of capital or common stock as of the close of the period covered
by the annual report 6,960,000 Common Shares, nominal value CHF 0.02 per share, as of December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9744;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9744;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9746;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T during the preceding 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9746;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &ldquo;large accelerated filer, &ldquo;accelerated filer,&rdquo; and emerging growth company&rdquo; in Rule
12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 25%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
    filer &#9744;</FONT></TD>
    <TD NOWRAP STYLE="width: 25%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD>
    <TD NOWRAP STYLE="width: 30%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer </FONT></TD>
    <TD NOWRAP STYLE="width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company
    </FONT></TD>
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards &dagger; provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&dagger;The
term &ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
GAAP &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">International
Financial Reporting Standards as issued by the International Accounting Standards Board &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
&ldquo;Other&rdquo; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Item 17&nbsp;&nbsp;&nbsp;&#9744; Item 18</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this is an annual report, indicate by check mark whether the registrant is a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9744;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 75%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">iv</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">PART
    I</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">ITEM 1.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">IDENTITY
    OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">ITEM 2.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">OFFER STATISTICS
    AND EXPECTED TIMETABLE.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">ITEM 3.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">KEY INFORMATION.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">A.</A></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Selected
    Financial Data</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Capitalization
    and Indebtedness.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Reasons for
    the Offer and Use of Proceeds.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Risk Factors.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">ITEM 4.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">INFORMATION
    ON THE COMPANY.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">History and
    Development of the Company.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Business
    Overview.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Organizational
    Structure.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Property,
    Plants and Equipment.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">ITEM 4A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">UNRESOLVED
    STAFF COMMENTS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">ITEM 5.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">OPERATING
    AND FINANCIAL REVIEW AND PROSPECTS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">Operating
    Results.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">75</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">Liquidity
    and Capital Resources.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">E.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">Off-Balance
    Sheet Arrangements.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">85</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">F.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">Tabular Disclosure
    of Contractual Obligations.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">85</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">ITEM 6.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">DIRECTORS,
    SENIOR MANAGEMENT AND EMPLOYEES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">86</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">Directors
    and Senior Management.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">86</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_023">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_023">Compensation.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">89</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">Board Practices.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">90</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_025">D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_025">Employees.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">91</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_026">E.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_026">Share Ownership.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_027">ITEM 7.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_027">MAJOR SHAREHOLDERS
    AND RELATED PARTY TRANSACTIONS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_028">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_028">Major Shareholders.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_028">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_029">Related Party
    Transactions.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">93</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_030">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_030">Interests
    of Experts and Counsel.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">96</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_031">ITEM 8.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_031">FINANCIAL
    INFORMATION.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">96</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_032">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_032">Consolidated
    Statements and Other Financial Information.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">96</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_033">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_033">Significant
    Changes.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">96</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_034">ITEM 9.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_034">THE OFFER
    AND LISTING.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_035">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_035">Offer and
    Listing Details.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_036">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_036">Plan of Distribution.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_037">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_037">Markets.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_038">D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_038">Selling Shareholders.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_039">E.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_039">Dilution.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_040">F.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_040">Expenses
    of the Issue.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_041">ITEM 10.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_041">ADDITIONAL
    INFORMATION.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_042">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_042">Share Capital.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_043">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_043">Memorandum
    and Articles of Association.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_044">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_044">Material
    Contracts.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_045">D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_045">Exchange
    Controls.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">98</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_046">E.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_046">Taxation.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">98</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_047">F.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_047">Dividends
    and Paying Agents.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">107</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_048">G.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_048">Statement
    by Experts.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">107</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_049">H.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_049">Documents
    on Display.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">107</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_050">I.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_050">Subsidiary
    Information.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">107</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_051">ITEM
    11.</A></FONT></TD>
    <TD STYLE="width: 75%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_051">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</A></FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_052">ITEM 12.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_052">DESCRIPTION
    OF SECURITIES OTHER THAN EQUITY SECURITIES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_053">A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_053">Debt Securities.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_054">B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_054">Warrants
    and rights.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_055">C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_055">Other Securities.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_056">PART
    II</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="4" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_057">ITEM 13.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_057">DEFAULTS,
    DIVIDEND ARREARAGES AND DELINQUENCIES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">110</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_058">ITEM 14.</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_058">MATERIAL
    MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">110</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_059">ITEM 15.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_059">CONTROLS
    AND PROCEDURES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">110</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_060">ITEM 16A.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_060">AUDIT COMMITTEE
    FINANCIAL EXPERT.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">111</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_061">ITEM 16B.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_061">CODE OF ETHICS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">111</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_062">ITEM 16C.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_062">PRINCIPAL
    ACCOUNTANT FEES AND SERVICES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">111</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_063">ITEM 16D.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_063">EXEMPTIONS
    FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_064">ITEM 16E.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_064">PURCHASES
    OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_065">ITEM 16F.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_065">CHANGE IN
    REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_066">ITEM 16G.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_066">CORPORATE
    GOVERNANCE.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">113</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_067">ITEM 16H.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_067">MINE SAFETY
    DISCLOSURE.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">114</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_068">PART
    III</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="4" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_069">ITEM 17.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_069">FINANCIAL
    STATEMENTS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">115</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_070">ITEM 18.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_070">FINANCIAL
    STATEMENTS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">115</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_071">ITEM 19.</A></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_071">EXHIBITS.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">115</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_072">SIGNATURES</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">116</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this annual report, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;NLS&rdquo; refer, prior
to the Reorganization, as defined in this annual report, to NLS-0 Pharma AG, or NLS-0, NLS-1 Pharma AG, or NLS-1, and NLS Pharma AG,
or NLS Pharma, and, after the Reorganization, to NLS Pharmaceutics Ltd. and its wholly owned subsidiary, NLS Pharmaceutics Inc., a Delaware
corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">NLS-1
and NLS Pharma were incorporated in June 2015 and NLS-0 was incorporated in April 2016, each in Switzerland. In March 2019, and pursuant
to Swiss law, effective as of January 1, 2019, NLS-0 and NLS Pharma each merged with and into NLS-1. We refer to these transactions throughout
this annual report collectively as the &ldquo;Reorganization.&rdquo; As part of the Reorganization, all assets and liabilities of NLS-0
and NLS Pharma were transferred to NLS-1 by way of universal succession (pursuant to which, under Swiss law, assets and liabilities are
transferred as a whole and in one act), and NLS-1 was renamed NLS Pharmaceutics Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
the context otherwise indicates or requires, the NLS logo and all product names and trade names used by us in this annual report, including
Quilience&reg; and Nolazol&reg;, are our proprietary trademarks and service marks. All trademarks or trade names referred to in this
annual report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this annual report
are referred to without the &reg; and &trade; symbols, but such references should not be construed as any indicator that their respective
owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other
companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
reporting currency and functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references
in this annual report to &ldquo;dollars,&rdquo; &ldquo;USD&rdquo; or &ldquo;$&rdquo; mean U.S. dollars, and references to &ldquo;CHF&rdquo;
are to the Swiss Franc. U.S. dollar translations of CHF amounts presented in this annual report were done on different dates in accordance
with the date as of such entry in the Company&rsquo;s books and are derived from our audited financial statements included elsewhere
in this annual report. U.S. dollar translations of CHF amounts presented in this annual report that are not derived from our audited
and unaudited financial statements included elsewhere in this annual report are translated using the rate of CHF 1.00 to $1.1313, based
on the exchange rate provided by the Swiss Federal Tax Administration on December 31, 2020.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
annual report includes statistical, market and industry data and forecasts which we obtained from publicly available information and
independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications
and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee
the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently verified
the information contained in such publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>RESTATEMENT
OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 10, 2021, the Company, in consultation with the Audit Committee of the Board of Directors of the Company, concluded that the Company&rsquo;s
previously issued financial statements as of and for the fiscal years ended December 31, 2019 and 2018, included in its Registration
Statement on Form F-1 (Registration No. 333-236797), should no longer be relied upon due to misstatements described in Note 3 to the
Financial Statements included within this annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_001"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Some
of the statements made under Item 3.D. &ldquo;Risk Factors,&rdquo; Item 5 &ldquo;Operating and Financial Review and Prospects,&rdquo;
&ldquo;Business&rdquo; and elsewhere in this annual report constitute forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo;
or &ldquo;continue,&rdquo; or the negative of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forward-looking
statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory pathways that we may elect to utilize
    in seeking European Medicines Agency, or EMA, the U.S. Food and Drug Administration, or FDA and other regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the use of Quilience in a compassionate use program,
    or CUP, and the results thereof;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining EMA and FDA approval of, or other regulatory
    action in Europe or the United States and elsewhere with respect to, Quilience, Nolazol or other product candidates that we may seek
    to develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commercial launch and future sales of Quilience,
    Nolazol or any other future product candidates;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dosage of Quilience and Nolazol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the timing of commencing
    further clinical trials, the process entailed in conducting each such trial, including dosages, and the order of such trials with
    each of our product candidates or whether such trials will be conducted at all;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improved convenience relating to the prescription of
    and use of Nolazol for prescribers and patients (and their parents);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the supply of mazindol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payor reimbursement for Quilience and Nolazol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding anticipated expenses, capital
    requirements and our needs for additional financing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the narcolepsy patient market size and market
    adoption of Quilience by physicians and patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, cost, regulatory approvals or other aspects
    of the commercial launch of Quilience and Nolazol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission of a Marketing Authorisation Application,
    or MAA and New Drug Application, or NDA, with the EMA and FDA for Quilience and Nolazol, respectively;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion and receiving favorable results of clinical
    trials for Quilience and Nolazol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of patents to us by the U.S. Patent and Trademark
    Office, or PTO, and other governmental patent agencies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new issuances of orphan drug designations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and approval of the use of mazindol
    for additional indications other than narcolepsy and attention deficit hyperactivity disorder, or ADHD; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and commercialization, if any, of any
    other product candidates that we may seek to develop; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the use of mazindol controlled release, or CR, for
    treatment of additional indications other than narcolepsy and ADHD; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our management team to lead the development
    of our product candidates; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding licensing, acquisitions
    and strategic operations; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the impact of the COVID-19
    pandemic, including on our planned clinical trials, operations and financial position.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our
or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this in greater detail under Item 3.D. &ldquo;Risk Factors&rdquo;
and elsewhere in this annual report. You should not rely upon forward-looking statements as predictions of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_002"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM&nbsp;1.</B></FONT></TD>
    <TD STYLE="width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>IDENTITY
    OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_004"></A><FONT STYLE="font-size: 10pt"><B>ITEM&nbsp;2.</B></FONT></FONT></TD>
    <TD STYLE="text-align: left; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OFFER STATISTICS
    AND EXPECTED TIMETABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_005"></A><FONT STYLE="font-size: 10pt"><B>ITEM&nbsp;3.</B></FONT></FONT></TD>
    <TD STYLE="text-align: left; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KEY INFORMATION
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>A.
    </B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selected Financial Data
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
selected historical statements of financial information as of December 31, 2020, 2019 and 2018 have been derived from, and should be
read in conjunction with, our audited financial statements and notes thereto appearing elsewhere in this annual report.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
historical results do not necessarily indicate results expected for any future periods. The selected financial data should be read in
conjunction with, and are qualified in their entirety by reference to, our audited financial statements and related notes set forth elsewhere
in this annual report and &ldquo;Item 5. Operating and Financial Review and Prospects.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have not included selected historical consolidated financial data for the years ended December 31, 2017 and 2016 in the table below as
we qualify as an emerging growth company, or EGC, as defined in Section 2(a)(19) of the Securities Act of 1933, as amended, or the Securities
Act, we make use of an accommodation for reduced reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    ended December 31,</B></FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(as restated)</B></FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; background-color: white; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(as restated)</B></FONT></FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: white; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: white; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99,580</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">897,788</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">708,455</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,199,790</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,299,251</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,740,406</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,299,370</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,197,039</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,448,861</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,299,370</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,197,039</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,448,861</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense), net</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(328,365</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,445)</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,035</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(86,792</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(992</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense on related party loans</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146,908</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(818,719</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,084,708</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on conversion of debt</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(364,950</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(629,232</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other expense, net</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(562,065</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,250,106</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,713,940</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,861,435</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,447,145</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,146,766</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive
    loss:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
    pension plan adjustment</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(683</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,444</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,261</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    loss</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,862,118</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,454,589</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,148,027</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted net loss per common share</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.41</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.80</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.82</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common shares used in computing basic and diluted net loss per common share</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,960,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,840,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,240,000</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #202124; background-color: white">Comparative
figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification error of intellectual
property expenses between research and development expenses and general and administrative expenses. For further information, see Note
3 &ldquo;Restatement of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Previously Issued Financial Statements</I><FONT STYLE="color: #202124; background-color: white">&rdquo;
to the financial statements.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>B.</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Capitalization
        and Indebtedness</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
        applicable.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>C.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasons for the Offer and
    Use of Proceeds.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>D.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should carefully consider the risks described below, together with all of the other information in this annual report. The risks described
below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be
immaterial may also materially and adversely affect our business operations. If any of these risks actually occurs, our business and
financial condition could suffer and the price of our common shares and Warrants could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Summary
of Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Risks
Related to Our Financial Condition and Capital Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investing
in our common shares and Warrants involves substantial risks. Our ability to execute our strategy is also subject to certain risks. The
risks described below may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute
all or part of our strategy. In particular, our risks include, but are not limited to, the following summary of such risk factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ongoing COVID-19 pandemic may
    adversely affect our planned clinical trials, operations and financial condition;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to successfully
    use mazindol, on which we depend substantially, as the drug substance for each of our current clinical mid-stage product candidates,
    Quilience, for the treatment of narcolepsy, and Nolazol, for the treatment of ADHD, and which outcome could prove costly to our business
    and could prevent us from obtaining regulatory or marketing approval; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to immediately
    initiate our Phase 2 clinical trial in Quilience without additional pre-clinical studies, chemistry, manufacturing, and controls,
    or CMC, work or early-stage clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior results of mazindol for the
    treatment of other indications may not be replicated in the clinical trials that we conduct for the treatment of narcolepsy or ADHD;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we require regulatory approvals
    prior to any attempt to commercialize our product candidates. Prior to commercialization of Quilience, we must receive approvals
    from the FDA and from the EMA in order to initiate our Phase 2 and 3 clinical trials. Similarly, the FDA previously accepted our
    IND application in 2016 for Nolazol; however, before we may commercialize Nolazol for the treatment of ADHD, we must receive additional
    approvals from the FDA, including approval to conduct our Phase 3 clinical trials. Our planned clinical trials for Quilience and
    Nolazol must be successful if we are to seek and obtain regulatory marketing application through the submission of a marketing authorization
    application, or MAA, and new drug application, or NDA, with the EMA and FDA, respectively. Advanced clinical trials are often not
    successful even if prior trials were successful, and even if we are able to conduct advanced clinical trials and those trials are
    successful, we may not obtain necessary regulatory approvals for Quilience and Nolazol or we may be unable to successfully commercialize
    either, or both, even if we receive the necessary regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our data from future clinical trials
    may not satisfy the FDA or other comparable regulatory agencies, or the FDA or other regulatory agencies may require additional time
    or studies to assess the safety and efficacy of Quilience, Nolazol, or other product candidates that we may seek to develop in the
    future;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to date, we have not generated any
    revenue, and we do not expect to generate any significant revenue unless and until we obtain marketing approval to commercialize
    Quilience or Nolazol. We are unable to predict the extent of future losses or when we will become profitable based on the sale of
    any product, if at all. Even if we succeed in developing and commercializing our product candidates, we may never generate sufficient
    revenue to sustain profitability. As of December 31, 2020, we had an accumulated deficit of approximately $29.8 million;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have no sources of revenues,
    have a history of losses and expect to incur losses in the foreseeable future and will need to raise substantial additional capital
    to successfully complete development and seek to commercialize Quilience, Nolazol, or other product candidates that we may seek to
    develop in the future, and such capital may not be available to us or available to us only on unfavorable terms;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the report of our independent registered
    public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
    <FONT STYLE="background-color: white">If we are unable to obtain additional capital, we may not be able to continue our operations
    on the scope or scale as currently conducted, and that could have a material adverse effect on our business, results of operations
    and financial condition</FONT>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and when, we seek to commercialize
    Quilience and Nolazol, we may be partially dependent upon prescriptions from physicians for the sale of both such product candidates,
    and therefore, the loss of a significant number of patient referrals by physicians prescribing Quilience or Nolazol may have an adverse
    effect on our future revenues, if any, which could have an adverse effect on our business, financial condition and results of operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Chief Executive Officer, directors and shareholders
    who own more than 5% of our outstanding common shares own approximately 53% of our common shares and will therefore be able to exert
    significant control over matters submitted to our shareholders for approval; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a public company, we will need
    to comply with extensive securities rules and regulations and Swiss governmental and Nasdaq regulations, which will be expensive
    and which will require significant management attention;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F1E; background-color: white">for
    as long as we remain an EGC, we will be exempt from certain securities laws requirements, including the fact that we are not required
    to conduct an audit of our internal control over financial reporting; however, once we cease to qualify as an EGC, we will no longer
    be permitted to rely on such exemptions and as a result we will incur additional legal, accounting and other expenses</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have identified material weaknesses
    in our internal control over financial reporting and put in remedies. If our remediations are not effective, we may not be able to
    accurately or timely report our financial results, or prevent fraud, and investor confidence in our Company and the market price
    of our common shares and Warrants may be adversely affected.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Risks
Related to Our Intellectual Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain
    and maintain effective patent rights for our products, we may not able to compete effectively in our markets. If we are unable to
    protect the confidentiality of our trade secrets or know-how, such proprietary information may be used to compete against us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to maintain
    effective proprietary rights for our products, we may not be able to compete effectively in our markets; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may in the future be subject
    to future claims that our employees, consultants, or independent contractors have wrongfully or unavoidably used or disclosed confidential
    information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Risks
Related to the Ownership of the Common Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Jumpstart Our Business
    Startups Act of 2012, or the JOBS Act, allows us to postpone the date by which we must comply with some of the laws and regulations
    intended to protect investors and to reduce the amount of information we provide in our reports filed with SEC which could undermine
    investor confidence in our Company and adversely affect the market price of our common shares and Warrants; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
        a &ldquo;foreign private issuer&rdquo; we follow certain home country corporate governance practices instead of otherwise applicable
        SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic
        U.S. issuers.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We depend
substantially on the success of our two product candidates, Quilience and Nolazol. We cannot give any assurance that any of our product
candidates will receive regulatory approval, which is necessary before they can be commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have invested almost all of our efforts and financial resources in research and development and general and administrative costs of our
two product candidates, Quilience for the treatment of EDS and cataplexy associated with narcolepsy and Nolazol, for the treatment of
ADHD. The process to develop, obtain regulatory approval for and commercialize pharmaceutical product candidates is long, complex, costly
and inherently uncertain of outcome. We are not permitted to market any of our product candidates in the United States, European Union,
or the EU, or any other jurisdiction until we receive the requisite regulatory approvals. We cannot give any assurance that our current
clinical development plan will proceed as planned, or that our product candidates will receive regulatory approval, or that such regulatory
approval, if received, will be within a timeframe that allows us to effectively compete with our competitors, or be successfully marketed
and commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our initiation
of clinical trials for Quilience is dependent upon the review and approval of the relevant regulatory agencies and authorities and if
we are required to conduct earlier-stage clinical trials, approval of an NDA or MAA, if any, for Quilience would be delayed and we may
require additional capital as a result thereof.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based
in part on the prior use and FDA approval of mazindol to manage exogenous obesity, we believe that we will be able to commence our Phase
2 and 3 clinical trials for Quilience without having to do prior pre-clinical and/or early-stage clinical trials, such as Phase 1 trials.
No assurance can be given that the EMA or FDA will agree to allow us to initiate clinical trials for Quilience without conducting such
pre-clinical / earlier-stage clinical trials. If the FDA or EMA, or any other applicable regulatory agency, were to require us to conduct
additional pre-clinical/clinical trials, our planned development strategy for Quilience would be materially impacted and approval of
an NDA or MAA, if any, for Quilience would be delayed and we may require additional capital as a result thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we plan to request a PIP deferral in order to delay conducting clinical trials for Quilience in children until after we receive
an MAA from the EMA for the use of Quilience in adults. A PIP deferral, as can be agreed upon by the EMA, allows an applicant to delay
studies in children until after there is sufficient data on use in adults; we anticipate that we will be able to receive a PIP deferral
from the EMA for Quilience; however, there is no guarantee that this deferral will be granted, which could impact our planned development
process and would make the product candidate approval process more costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The commencement
and completion of clinical trials can be delayed or prevented for a number of reasons.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may not be able to commence or complete the clinical trials that would support our submission of an NDA to the FDA or MAA to the EMA.
Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials.
Clinical trials can be delayed or prevented for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties obtaining regulatory approval to commence
    a clinical trial or complying with conditions imposed by a regulatory authority regarding the scope or term of a clinical trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching or failing to reach agreement on
    acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to
    extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient or inadequate supply or quality of a product
    candidate or other materials necessary to conduct our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the FDA or EMA elect to enact policy changes, as
    a result of the COVID-19 pandemic or otherwise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties obtaining institutional review board,
    or IRB, approval to conduct a clinical trial at a prospective site; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges recruiting and enrolling patients to participate
    in clinical trials for a variety of reasons, including fears resulting from the COVID-19 pandemic or due to government actions enacted
    and as a result of such pandemic, size and nature of patient population, proximity of patients to clinical sites, eligibility criteria
    for the trial, nature of trial protocol, the availability of approved effective treatments for the relevant disease and competition
    from other clinical trial programs for similar indications.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, a data safety monitoring board overseeing
the clinical trial at issue or by other regulatory authorities due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the
    clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial
    sites by the FDA or other regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues (including those that result
    from the COVID-19 pandemic) or lack of effectiveness; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The results
of pre-clinical studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies may not be
indicative of results in future clinical trials and we cannot assure you that any planned or future clinical trials will lead to results
sufficient for the necessary regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
results of pre-clinical studies may not be predictive of the results of clinical trials, and the results of any completed clinical trials,
including studies derived from real-world use and studies in published literature, or clinical trials we commence may not be predictive
of the results of later-stage clinical trials.&nbsp;Additionally, interim results during a clinical trial do not necessarily predict
final results.&nbsp;Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences
in trial design, different trial endpoints (or lack of trial endpoints in exploratory studies), subject population, number of subjects,
subject selection criteria, trial duration, drug dosage and formulation and lack of statistical power in the earlier studies.&nbsp;There
can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our
product candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical
development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a
negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
find it difficult to enroll patients in our clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identifying
and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical
trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience
delays in our clinical trials if we encounter difficulties in enrollment. The evolving COVID-19 pandemic may directly or indirectly impact
the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians&rsquo;
offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Additionally, such facilities and
offices have been and may continue to be required to focus limited resources on nonclinical trial matters, including treatment of COVID-19
patients, thereby decreasing availability, in whole or in part, for clinical trial services. See &ldquo;Risks Related to Our Business
Operations &ndash; We face business disruption and related risks resulting from the recent outbreak of COVID-19, which could have a material
adverse effect on our business and results of operations&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, as a rare disorder, there is a limited patient pool from which to draw for our clinical trials for Quilience. Further, the
eligibility criteria of our clinical trials will further limit the pool of available study participants as we will require that patients
have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them
in a study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients
to complete our clinical trials because of the perceived risks and benefits of the product candidate under study, the availability and
efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients
and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline
for recruiting patients, conducting studies and obtaining regulatory approval of our potential product candidates will be delayed.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our
product candidates will be harmed, and our ability to generate product candidate revenue from any of these product candidates could be
delayed or prevented. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate
development and approval process and jeopardize our ability to commence product candidate sales and generate revenues. Any of these occurrences
may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
approval of an NDA or a MAA even after clinical trials that are believed to be successful is an uncertain process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are not permitted to market Quilience or Nolazol in the United States or the EU until we receive regulatory approval of an NDA from the
FDA or MAA from the EMA, or in any foreign countries until we receive the requisite approval from regulatory authorities in such countries.
We have not received regulatory clearance to conduct the additional clinical trials that are necessary to be able to submit an NDA to
the FDA for Nolazol. Similarly, we have not received regulatory clearance in the EU to conduct clinical trials that are necessary to
receive approval of a MAA for Quilience in Europe. As such, we have not submitted an MAA for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we complete our planned clinical trials and believe the results to be successful, all of which are uncertain, obtaining regulatory
approval is an extensive, lengthy, expensive and uncertain process, and the FDA and EMA, and other regulatory authorities may delay,
limit or deny approval of Quilience or Nolazol for many reasons, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate to their satisfaction
    that the product candidate is a safe or effective treatment for a given indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical trials may not meet the level
    of statistical significance or clinical significance required by the regulatory agencies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements regarding the number, design, size, conduct
    or implementation of our clinical trials, or with our interpretation of data from pre-clinical studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lack of acceptance of the accuracy or sufficiency
    of the data generated at our clinical trial sites to demonstrate, among others, that clinical and other benefits outweigh its safety
    risks or to support the submission of an NDA or MAA;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties scheduling an advisory committee meeting
    in a timely manner or the advisory committee, or such other similar committee, may recommend against approval of our application
    or may recommend that such regulators require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations
    on approved labeling, or distribution and use restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we develop a REMS, as a condition
    of approval, which may or may not be feasible for us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the identification of deficiencies in the manufacturing
    processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in approval policies or the adoption of new
    regulations by such regulators; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to be granted a PIP deferral which
    we intend to request from the EMA for delayed clinical trials and subsequent approval in children; this may delay our clinical trial
    program or approvals for adults, or we may have successful clinical trial results for adults but not children (if we were required
    to conduct pediatric studies prior to the receipt of an NDA or MMA for use of our product candidates in adults), or vice versa.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Before
we can submit an NDA to the FDA, we must conduct pivotal trials, in addition to human pharmacokinetic and bioavailability studies, that
will be substantially broader than our Phase 2 trial for Nolazol. An NDA must be supported by extensive clinical and pre-clinical data,
as well as extensive information regarding chemistry, manufacturing and controls to demonstrate the safety and effectiveness of the applicable
product candidate. The number and types of pre-clinical studies and clinical trials that will be required varies depending on the product
candidate, the disease or condition that the product candidate is designed to target and the regulations applicable to any particular
product candidate. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining
approval. The FDA review processes can take years to complete and approval is never guaranteed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this respect, we will also need to agree on a protocol with the FDA for the pivotal trials before commencing those trials. Pivotal trials
frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore, the results of the additional
trials that we conduct may or may not be successful. The FDA may suspend all clinical trials or require that we conduct additional clinical,
nonclinical, manufacturing validation or drug product quality studies and submit those data before it will consider or reconsider the
NDA. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years,
or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed,
may not be considered sufficient by the FDA to approve the NDA. If any of these outcomes occur, we would not receive approval for Quilience
or Nolazol at such time, if any, when we seek FDA approval. We may face similar risks with respect to obtaining regulatory approval from
the EMA for Quilience, and for Nolazol, at such time, if any, when we seek EMA approval. The risks that we face in obtaining applicable
approvals from the FDA and EMA for Quilience and Nolazol, or any other product candidate that we may seek to develop, may also exist
with other regulatory authorities, such as those in Latin America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we obtain FDA, EMA or other regulatory approval for Quilience or Nolazol, the approval might contain significant limitations related
to use restrictions for certain age groups, warnings, precautions or contraindications, or may be subject to significant post-marketing
studies or risk mitigation requirements. In addition, even if we obtain a MAA from the EMA for the use of Quilience in adults, there
can be no guarantee that we will receive an MAA for Quilience for the use in children. If we are unable to successfully commercialize
Quilience or Nolazol, we may be forced to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interim
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we
may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues
and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may
result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary
data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final
data could significantly harm our reputation and business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The results
of clinical trials conducted at clinical sites outside the United States may not be accepted by the FDA and the results of clinical trials
conducted at clinical sites in the United States may not be accepted by international regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
plan to conduct some of our clinical trials outside the United States. For example, we are planning to develop Quilience in the United
States and the EU. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data
is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well-designed and conducted and performed
by qualified investigators in accordance with ethical principles such as IRB or ethics committee approval and informed consent. The study
population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical
practice in ways that the FDA deems clinically meaningful. Generally, the subject population for any clinical trials conducted outside
of the United States must be representative of the U.S. population. In addition, while these clinical trials are subject to the applicable
local laws, FDA acceptance of the data will be dependent upon its determination that the trials were conducted consistent with all applicable
U.S. laws and regulations. There can be no assurance the FDA or international regulatory authorities will accept data from trials conducted
outside of the United States or inside the United States, as the case may be, as adequate support of a marketing application. If the
FDA or international regulatory authorities do not accept the data from sites in our globally conducted clinical trials, it would likely
result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt the development
of one or more of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our product
candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the
commercial potential or result in significant negative consequences following regulatory approval, if obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the conduct of clinical trials, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal
outcome. It is possible that as we develop Quilience and Nolazol, or other product candidates that we may seek to develop, in larger,
longer and more extensive clinical trials as use of our product candidates becomes more widespread if they receive regulatory approval,
illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did
not occur or went undetected in previous clinical trials, will be reported by subjects.&nbsp;Many times, side effects are only detectable
after investigational products are tested in larger scale, Phase 2 and 3 clinical trials or, in some cases, after they are made available
to patients on a commercial scale after approval. If additional clinical experience indicates that Quilience or Nolazol, or other product
candidates that we may seek to develop, have side effects or cause serious or life-threatening side effects, the development of the product
candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked or limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
if any of our product candidates receives marketing approval, the FDA or EMA could require us to adopt a REMS to ensure that the benefits
outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to
patients, a communication plan to health care practitioners, and restrictions on how or where the product can be distributed, dispensed
or used. Furthermore, if we or others later identify undesirable side effects caused by Quilience or Nolazol, several potentially significant
negative consequences could result, including:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may suspend or withdraw approvals
    of such a product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require additional warnings
    on the label;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may issue negative publicity
    regarding the affected product, including safety communications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is
    distributed, dispensed or administered, or conduct additional pre-clinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may need to voluntarily recall our products; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to
    patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could significantly
harm our business, prospects, financial condition and results of operations.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
product candidates proceed through pre-clinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA or EMA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials
or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize
our ability to commence sales and generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We will
need to obtain FDA approval of any proposed names for our product candidates that gain marketing approval, and any failure or delay associated
with such naming approval may adversely impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark
registration from the U.S. Patent and Trademark Office, or the U.S. PTO. The FDA typically conducts a review of proposed product names,
including an evaluation of whether proposed names may be confused with the names of other drug products. The FDA may object to any product
name we submit if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product names,
we may be required to adopt an alternative name for our product candidates, which could result in further evaluation of proposed names
with the potential for additional delays and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
regulatory approval for clinical trials of Nolazol in children will be more difficult than obtaining such approvals for adult clinical
trials since the requirements for regulatory approval to conduct pediatric clinical trials are more stringent.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pediatric
drug development requires additional nonclinical work (such as animal studies in juvenile animals and additional reproductive toxicity
work), as well as staged clinical work in determining safe dosing and monitoring. These additional tasks involve investment of significant
additional resources beyond those needed for approval of the drug for adults. Approval of Nolazol for use in children may be significantly
delayed due to these additional requirements and this may have an adverse effect on the commercial prospects for Nolazol and our ability
to generate product revenues would be delayed, possibly materially. In addition, we do not know if as a result of the COVID-19 pandemic
there will be a smaller pool of children from which we can enroll for our clinical trials. We cannot guarantee that we will receive any
regulatory approvals to commercialize our product candidates in children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes
to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of
successful completion of our clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need
to amend clinical trial protocols. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval,
which may impact the cost, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate,
any of our clinical trials, the commercial prospects for Quilience and Nolazol would be harmed and our ability to generate product revenues
would be delayed, possibly materially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
development and regulatory strategy for our product candidates depends in part on published scientific literature and the FDA&rsquo;s
prior findings regarding the safety and efficacy of approved products containing mazindol. If the FDA does not conclude that our product
candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory approval pathway, or if the requirements for our product
candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly
more and entail significantly greater complications and risks than anticipated and in either case may not be successful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section&nbsp;505(b)(2)
to the Federal Food, Drug, and Cosmetic Act, or FDCA, or Section&nbsp;505(b)(2). Section&nbsp;505(b)(2) permits the submission of an
NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which
the applicant has not obtained a right of reference. We intend to seek FDA approval through the Section&nbsp;505(b)(2) regulatory pathway
for Quilience and may seek this regulatory pathway for other product candidates that we seek to develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the FDA does not allow us to pursue the Section&nbsp;505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical
trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time
and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. We may need to obtain additional funding, which could result in significant dilution to the ownership interests of our then
existing shareholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain
such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section&nbsp;505(b)(2) regulatory pathway
could result in new competitive product candidates reaching the market faster than our product candidates, which could materially adversely
impact our competitive position and prospects. Even if we are allowed to pursue the Section&nbsp;505(b)(2) regulatory pathway, we cannot
assure you that our product candidates will receive the requisite approvals for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to confer
benefits such as a faster development process or an accelerated regulatory pathway, but there can be no assurance that we will successfully
obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able
to realize the intended benefits of such designations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA, and other comparable regulatory authorities, offer certain designations for product candidates that are intended to encourage the
research and development of pharmaceutical products addressing conditions with significant unmet medical need. These designations may
confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority
review. There can be no assurance that we will successfully obtain such designation for Quilience or Nolazol. In addition, while such
designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we
obtain such designations for one or more of our product candidates, there can be no assurance that we will realize their intended benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
example, we may seek a Breakthrough Therapy designation from the FDA for one or more of our product candidates. A Breakthrough Therapy
designation is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or
life-threatening disease or condition, if preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For therapies that have Breakthrough Therapy designation, interaction and communication between the FDA and the sponsor
of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in
ineffective control regimens. Therapies with Breakthrough Therapy designation from the FDA are also eligible for accelerated approval.
Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates
meets the criteria for Breakthrough Therapy designation, the FDA may disagree and instead determine not to make such designation. In
any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process,
review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our product candidates qualify for Breakthrough Therapy designation, the FDA may later
decide that such product candidates no longer meet the conditions for qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
may also seek Fast Track designation from the FDA for some of our product candidates. If a therapy is intended for the treatment of a
serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the
therapy sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even
if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to
grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared
to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. The FDA may
withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even if
we obtain regulatory approval for a product candidate, our products will remain subject to ongoing regulatory oversight.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated
uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. The holder of
an approved marketing application also must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are
subject to FDA review, in addition to other potentially applicable federal and state laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, requirements and adherence
to commitments made in the NDA or foreign marketing application. If a regulatory authority discovers previously unknown problems with
a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured
or disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we fail to comply with applicable regulatory requirements, a regulatory authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue an untitled letter or warning letter that we
    are in violation of the law;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek an injunction or impose administrative, civil
    or criminal penalties or monetary fines;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any ongoing clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve pending applications or supplements
    to applications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict the marketing or manufacturing of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize or detain the products or require the withdrawal
    of the product from the market;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to permit the import or export of the products;
    or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to allow us to enter into supply contracts,
    including government contracts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States, Switzerland or the EU.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
than our headquarters and other operations which are located in Switzerland and our wholly owned U.S. subsidiary, NLS Pharmaceutics Inc.,
a Delaware corporation (as further described below), we currently have limited international operations, but our business strategy incorporates
potentially significant international expansion, particularly in anticipation of approval of our product candidates. We may plan to maintain
sales representatives and conduct physician and patient association outreach activities, as well as clinical trials, outside of the United
States, Switzerland and Europe. If Quilience or Nolazol are approved for commercialization outside the United States, Switzerland, or
the EU, we will likely enter into agreements with third parties to market the drugs in these additional global territories. We expect
that we will be subject to additional risks related to entering into or maintaining international business relationships, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different regulatory requirements for drug approvals
    in foreign countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing United States and foreign drug import and
    export rules, tariffs and other trade barriers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for intellectual property rights
    in foreign countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the
    use of our products in various countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different reimbursement systems;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political
    instability in particular foreign economies and markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations
    such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental
    approvals, permits and licenses;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple payor
    reimbursement regimes, government payors or patient self-pay systems;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty
    collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure
    to foreign currency exchange rate fluctuations, which could result in increased operating expenses and reduced revenues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor unrest
    is more common than in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events affecting
    raw material supply or manufacturing capabilities abroad;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining
    accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices
    Act, or FCPA, its books and records provisions or its anti-bribery provisions.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability resulting from development work
    conducted by these distributors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from a local or worldwide
    pandemic, such as COVID-19, geopolitical actions, including war and terrorism, or natural disasters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even if
any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients,
third-party payors and others in the medical community necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
commercial success of Quilience and Nolazol will depend upon the acceptance of each product by the medical community, including physicians,
patients and third-party payors. The degree of market acceptance of any approved product will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy and safety of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential advantages of the product compared to
    available therapies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the convenience and ease of administration compared
    to alternative treatments;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings, including use restrictions
    contained in the product&rsquo;s approved labeling;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution and use restrictions imposed by the EMA,
    FDA or other regulatory authority or agreed to by us as part of a mandatory or voluntary risk management plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of alternative treatments, including,
    in the case of Nolazol, a number of competitive products already approved for the treatment of ADHD or expected to be commercially
    launched in the near future;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing and cost effectiveness in relation to alternative
    treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the product is included under physician treatment
    guidelines as a first-, second-, or third-line therapy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of sales, marketing and distribution support;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of third-party coverage and adequate
    reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of sales, marketing and distribution support;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients to pay for drugs out of
    pocket in the absence of third-party coverage; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the willingness of the target patient population
    to try new therapies and of physicians to prescribe these therapies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
Quilience or Nolazol is approved but does not achieve an adequate level of acceptance by physicians, third party payors and patients,
we may not generate sufficient revenue from the product, and we may not become or remain profitable. In addition, our efforts to educate
the medical community and third-party payors on the benefits of the product may require significant resources and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either
to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we enter into
arrangements with third parties to perform sales, marketing and distribution services for our products, the resulting revenues or the
profitability from these revenues to us are likely to be lower than if we had sold, marketed and distributed our products ourselves.
If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize any
of our product candidates that receive regulatory approval. Depending on the nature of the third-party relationship, we may have little
control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell, market
and distribute our products effectively. If we are not successful in commercializing our product candidates, either on our own or through
collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even if
we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third-party
coverage and reimbursement policies, any of which could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement
for these products and related treatments will be available from government health administration authorities, private health insurers
and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations,
decide which medications they will pay for and impact reimbursement levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining
and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain an adequate
level of reimbursement for our products by third party payors. Even if we do obtain adequate levels of reimbursement, third-party payors,
such as government or private healthcare insurers, may carefully review and increasingly question the coverage of, and challenge the
prices charged for, our drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance
plan and other factors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and
third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for drugs. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement
or the level of reimbursement relative to other therapies. If coverage and reimbursement are not available or reimbursement is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval,
and the royalties resulting from the sales of those products may also be adversely impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for
which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement
does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may
not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may
be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services.
Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and
by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than
in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private
payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country.
Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause
delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed. In many countries,
the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription drug
pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted.
As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that
delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate
from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates,
if they are approved for sale in the United States or in other countries, will be considered medically necessary or cost-effective for
a specific indication, or that coverage or an adequate level of reimbursement will be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The FDA
and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become
subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about
prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information
about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory
agencies as reflected in the product&rsquo;s approved labeling. If we are found to have promoted such off-label uses, we may become subject
to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion
of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter
into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed
or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant
liability, which would materially adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our product
candidates Quilience and Nolazol contain the active ingredient mazindol, which is a Schedule IV controlled substance under the Controlled
Substances Act of 1970, or CSA. Failure to maintain compliance with applicable requirements under the CSA or other applicable federal
or state regulations could have an adverse effect on our operations and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Controlled
substances are classified by the DEA as Schedule I, II, III, IV or V, or CI, CII, CIII, CIV, and CV, substances, with CI substances considered
to present the highest risk of substance abuse and Schedule V substances the lowest risk. The active ingredient of our lead and follow-on
product candidates is mazindol, which is classified as a Schedule IV controlled substance under the CSA, and regulations of the DEA.&nbsp;Under
the CSA, subject to certain exemptions, every person who manufactures, distributes, dispenses, imports or exports any controlled substance
must register with the DEA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
the CSA&rsquo;s restrictions governing substances in CIV are not as stringent as those for substances in CI, CII or CIII, they could
still limit our ability to market and commercialize Quilience and Nolazol, if approved for marketing.&nbsp;In addition, failure to maintain
compliance with applicable requirements under the CSA, particularly as manifested in loss or diversion of regulated substances, can result
in enforcement action that could include civil penalties, refusal to renew registrations or quotas, revocation of registrations or quotas
or criminal proceedings, any of which could have a material adverse effect on our business, results of operations and financial condition.
Individual states also regulate controlled substances, and we along with our contract manufacturers will be subject to state regulation
on distribution of these products.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. Our failure to obtain regulatory approval in foreign jurisdictions
would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United
States would not assure approval of product candidates in foreign jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding clinical trial design, safety and efficacy. The research, testing, manufacturing, labeling, approval, sale,
marketing and distribution of drugs are subject to extensive regulation by the FDA in the United States and other regulatory authorities
in other countries. These regulations differ from country to country. Even if we obtain and maintain regulatory approval of our product
candidates in one jurisdiction, such approval does not guarantee that we will be able to obtain or maintain regulatory approval in any
other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional nonclinical studies or clinical trials as investigations conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved
for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our
products is also subject to approval. These regulatory procedures can result in substantial delays in such countries. In other countries,
product approval depends on showing superiority to an approved alternative therapy. This can result in significant expenses for conducting
complex clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finally,
we do not have any products approved for sale in any jurisdiction, including international markets, and we do not have experience in
obtaining regulatory approval. If we, or any third parties with whom we work, fail to comply with regulatory requirements in the United
States or international markets or to obtain and maintain required approvals or if regulatory approvals in international markets are
delayed, our target market may be reduced and our ability to realize the full market potential of our products will likely be harmed.
The inability to meet continuously evolving regulatory standards for approval may result in our failing to obtain regulatory approval
to market our current product candidates, which could significantly harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as &ldquo;Brexit.&rdquo;
On March 29, 2017, the country formally notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty, scheduled
to be effective March 29, 2019. The withdrawal of the United Kingdom from the EU took effect on January 31, 2020. Since a significant
proportion of the regulatory framework in the United Kingdom is derived from EU directives and regulations, the referendum could materially
impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the EU. Any delay in obtaining,
or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product
candidates in the United Kingdom and/or the EU and restrict our ability to generate revenues and achieve and sustain profitability. If
any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EU
for our product candidates, which could significantly and materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our market
is subject to intense competition, which may result in others commercializing products before or more successfully than us. If we are
unable to compete effectively, Quilience and Nolazol may be rendered noncompetitive or obsolete, which may adversely affect our operating
results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
development and commercialization of new products is highly competitive. Our potential competitors include major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide with respect to Quilience or Nolazol or any future product candidate
that we may seek to develop or commercialize. Our competitors may succeed in developing, acquiring or licensing technologies and products
that are more effective, have fewer or more tolerable side effects or are more convenient or less costly than Quilience or Nolazol or
any future product candidate we may develop, which could render any product candidates obsolete and noncompetitive. Our competitors also
may obtain FDA or other marketing approvals for their products before we are able to obtain approval for ours, which could result in
competitors establishing a strong market position before we are able to enter the applicable market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
of our potential competitors, alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and commercializing
approved products than we do. There is a trend toward consolidation in the pharmaceutical and biotechnology industry, and additional
mergers and acquisitions in these industries may result in even more resources being concentrated among a smaller number of our competitors,
which may adversely affect us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These companies also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, if we enter the markets of our product candidates, with such entrance remaining subject to various additional regulatory approvals,
too late in the cycle, we may not achieve commercial success, or we may have to reduce our price in order to effectively compete, which
would impact our ability to generate revenues, obtain profitability and adversely affect our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
be unable to obtain orphan drug designation for our product candidates and, even if we obtain such designation, we may not be able to
realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory
authorities in some jurisdictions, including the United States and EU, may designate drugs for relatively small patient populations as
&ldquo;orphan drugs.&rdquo; Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to
treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United
States or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation
that the cost of developing the drug will be recovered from sales in the United States. In the EU, the European Commission grants orphan
drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening
or chronically debilitating condition affecting not more than five in 10,000 persons in the EU community. Additionally, designation is
granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and
chronic condition and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary
investment in developing the drug.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA granted orphan drug designation to mazindol for the treatment of narcolepsy in the United States.&nbsp;We also received orphan drug
designation for mazindol in the EU. This designation of a product candidate as an orphan product does not mean that any regulatory agency
will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory
agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates
prior to our product candidates receiving exclusive marketing approval</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generally,
if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which
it has such designation, the drug may be entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving
another marketing application for the same drug for that time period, except in limited circumstances.&nbsp;If another sponsor receives
such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our
product for the applicable exclusivity period. The applicable period is seven years in the United States and ten years in the EU, which
may be extended by six months and two years, respectively, in the case of product candidates that have complied with the respective regulatory
agency&rsquo;s agreed upon PIP. The exclusivity period in the EU can be reduced to six years if a drug no longer meets the criteria for
orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity
may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is
unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from
competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA may subsequently
approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior
in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EU, marketing authorization may
be granted to a similar medicinal product for the same orphan indication if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the second applicant can establish in its application
    that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise
    clinically superior;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holder of the marketing authorization for the original
    orphan medicinal product consents to a second orphan medicinal product application; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holder of the marketing authorization for the original
    orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>While orphan
drug product candidates are typically sold at a high price relative to other medications, the market may not be receptive to high pricing
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are developing our product candidates to treat rare CNS disorders with high unmet medical needs, a space where medications are usually
sold at high prices compared with other medications. Accordingly, even if regulatory authorities approve our product candidates, the
market may not be receptive to, and it may be difficult for us to achieve, a per-patient per-year price high enough to allow us to realize
a return on our investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If product
liability lawsuits are brought against us, we may incur substantial liabilities, even if we have appropriate insurance policies, and
we may be required to limit commercialization of our product candidates.&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of pharmaceutical products. Currently, we have no products that have been approved for marketing or commercialization;
however, the use of our product candidates in clinical trials, and the sale of these product candidates, if approved, in the future,
may expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our
clinical trials, patients, health care providers, pharmaceutical companies, our collaborators or others using, administering or selling
any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities,
even if we have product liability or such other applicable insurance policies in effect. We may not be able to maintain adequate levels
of insurance for these liabilities at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims would add
to our future operating expenses and adversely affect our financial condition. As a result of such lawsuits and their potential results,
we may be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims
may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination of clinical trial sites or entire trial
    programs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation and negative media attention;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls or increased warnings on product labels;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of to defend the related litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management and our resources;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to, or costly settlements
    with, clinical trial participants, patients or other claimants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher insurance premiums;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of initiation of investigations by regulators
    or other authorities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to successfully commercialize our product
    candidates, if approved.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
a limited operating history and we have incurred significant operating losses since our inception, and anticipate that we will incur
continued losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are an emerging biopharmaceutical company with a limited operating history. To date, we have focused almost exclusively on developing
product candidates using the active ingredient mazindol in a CR formulation. We have funded our operations to date primarily through
proceeds from the private placement of common shares, convertible instruments, related party credit facilities and shareholder loans
and a certain license agreement, which we refer to herein as the EF License Agreement. We have only a limited operating history upon
which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated an ability to
successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
in the pharmaceutical industry. To date, although we received an upfront payment of approximately $2.5 million pursuant to the EF License
Agreement, we have not generated revenue from the sale of our product candidates (see &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations&rdquo; for additional information). We have incurred losses in each year since our inception.
Our net loss attributable to holders of our common shares for the year ended December 31, 2020 was approximately $2.9 million and for
the year ended December&nbsp;31, 2019 was approximately $5.4 million. As of December 31, 2020, we had an accumulated deficit of approximately
$29.8 million. Substantially all of our operating losses resulted from costs incurred in connection with our development program and
from general and administrative costs associated with our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect our research and development expenses to increase in connection with our planned expanded clinical trials. In addition, if we
obtain marketing approval for Quilience, Nolazol or any other current or future product candidate, we will likely incur significant sales,
marketing and outsourced manufacturing expenses, as well as continued research and development expenses. Furthermore, we expect to incur
additional costs associated with operating as a public company, which we estimate will be at least several hundred thousand dollars annually.
As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous
risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses
or when we will become profitable, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to continue to incur significant losses until we are able to commercialize our product candidates, which we may not be successful
in achieving. We anticipate that our expenses will increase substantially if and as we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and development of our product
    candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand the scope of our current clinical studies for
    our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing approvals for our product
    candidates that successfully complete clinical studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing, and distribution infrastructure
    to commercialize our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license, and/or
    develop other product candidates and subsequent generations of our current product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual
    property portfolio;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support our operations
    as a public company and our product candidate development and planned future commercialization efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
not generated revenues from any product candidate and may never be profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to become profitable depends upon our ability to generate revenues. To date, we have not generated any revenue from our development
stage product candidates, Quilience and Nolazol, and we do not know when, or if, we will generate any such revenue. We do not expect
to generate significant revenues unless or until we obtain marketing approval of, and commercialize, Quilience and/or Nolazol. Our ability
to generate future revenues from product candidate sales depends heavily on our success in many areas, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining favorable results from and progress the pre-clinical
    and clinical development of our product candidates, namely Quilience and Nolazol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and obtaining regulatory approval for registration
    studies protocols for our product candidates, namely Quilience and Nolazol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to successful completion of registration and
    clinical trials of Quilience and Nolazol, applying for and obtaining marketing approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining supply and manufacturing
    relationships with third parties that can provide adequate (in amount and quality) products, and at acceptable costs, to support
    market demand for our product candidates, if marketing approval is received;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and/or developing
    new product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying demand for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued consumer interest in treatments to the symptoms
    of narcolepsy and ADHD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of our product candidates,
    if approved for marketing, as viable treatment options;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration, licensing
    or other arrangements into which we may enter;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining CIV labeling (no FDA imposed
    boxed warning, commonly referred to as a &ldquo;Black Box&rdquo; warning) of our lead and follow-on product candidates, Quilience
    and Nolazol, respectively;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and nurturing relationships with the leading
    prescribers of narcolepsy and ADHD prescriptions in the United States; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and retaining qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We believe
our current cash on hand will fund our projected operating requirements into the second quarter of 2022. This raises substantial doubt
about our ability to continue as a going concern. In addition, the report of our independent registered public accounting firm contains
an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining
new financing on reasonable terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our current cash on hand will fund our projected operating requirements into the second quarter of 2022. This raises substantial
doubt about our ability to continue as a going concern. In addition, the report of our independent registered public accounting firm
contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
<FONT STYLE="font-size: 10pt">This going concern opinion could materially limit our ability to raise additional funds through the issuance
of equity or debt securities or otherwise. Further reports on our financial statements may include an explanatory paragraph with respect
to our ability to continue as a going concern. If we cannot continue as a going concern, our investors may lose their entire investment
in our common shares and the Warrants. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs
through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all.
If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our products.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We expect
that we will need to raise substantial additional funding before we can expect to complete the development of Quilience or any other
product candidate. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital
when needed may force us to delay, limit or terminate our product candidate development efforts or other operations.&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, our cash and cash equivalents were approximately $0.1 million, and we had a working capital deficit of $7.0 million
and an accumulated deficit of $29.8 million. Based upon our currently expected level of operating expenditures, we expect that our existing
cash and cash equivalents, including the $17 million net proceeds raised with our initial public offering, will be sufficient to fund
operations into the second quarter of 2022. We expect that we will require substantial additional capital to commercialize our product
candidates. In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need
to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our clinical trial results and the costs for conducting
    pivotal trials;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of seeking marketing
    approval of Quilience and Nolazol;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of filing and prosecuting patent applications
    and the cost of defending our patents;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of prosecuting patent infringement actions
    against third parties;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development of other early-stage development product
    candidates;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with commercializing Quilience
    and Nolazol if we receive marketing approval, including the cost and timing of establishing sales and marketing capabilities to market
    and sell Quilience and Nolazol;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to receipt of marketing approval, revenue received
    from sales of approved products, if any, in the future;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to
    our products;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel;
    and</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with being a public company.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all, during or after the COVID-19 pandemic. Moreover, the terms of any financing may adversely
affect the holdings or the rights of holders of our securities and the issuance of additional securities, whether equity or debt, by
us, or the possibility of such issuance, may cause the market price of our common shares or Warrants to decline. The incurrence of indebtedness
could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations
on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through
arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we may be required to
relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have
a material adverse effect on our business, operating results and prospects. Even if we believe that we have sufficient funds for our
current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic
considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the development or commercialization, if any, of any product candidates or be unable to expand our
operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We are
dependent on a sole manufacturer for mazindol. Any delay, price increase or unavailability of mazindol could materially adversely affect
our ability to conduct clinical trials and, if this were to occur after we obtained commercialization and marketing approval, could cause
us to cease operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Currently
we rely on a single manufacturer for mazindol for our clinical trials conducted to date pursuant to purchase orders and do not have any
existing contract with such manufacturer for future supplies. The FDA requires identification of&nbsp;raw material&nbsp;suppliers in
applications for approval of drug products. If&nbsp;mazindol&nbsp;was unavailable from a specified manufacturer, FDA approval of a new
manufacturer, assuming one is found, could delay the manufacture of the drug involved or delay any clinical trial we are then conducting
or planning to conduct. Either such occurrence could have an adverse effect on our operations and reputation and could cause us to cease
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
there is a risk of a sole approved manufacturer significantly raising prices. If prices for mazindol or other raw materials were to be
significantly increased, our&nbsp;profit margins and sales, if any, would be greatly reduced and, assuming our products were approved
for commercialization or marketing, delay product launches, or delay clinical trials at earlier stages of development. Such price increase
occurrences could be resolved by the successful FDA approval of an alternate supplier; however, such approval process can be lengthy
and costly. There can be no guarantee that a resolution would be reached in the event of a significant price increase by our supplier
of mazindol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We rely
on third parties to conduct our pre-clinical and clinical studies and perform other tasks for us. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing pre-clinical and clinical
programs. We rely on these parties for execution of our pre-clinical and clinical studies, and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol,
legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and
our CROs and other vendors are required to comply with current cGMP, Good Clinical Practices, or GCP, quality system requirements, or
QSR, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the
Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical
development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators,
study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data
generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require
us to perform additional clinical studies before approving our marketing applications. We cannot assure you that upon inspection by a
given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In
addition, our clinical studies must be conducted with product candidates which are produced under cGMP regulations. These risks may be
heightened as a result of the evolving COVID-19 pandemic. Our failure to comply with these regulations may require us to repeat clinical
studies, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
no manufacturing capacity and anticipate reliance on third-party manufacturers for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not currently operate manufacturing facilities for clinical production of Nolazol or Quilience. We do not intend to develop facilities
for the manufacture of products for clinical trials or commercial purposes in the foreseeable future. We will rely on third-party manufacturers
to produce bulk drug products required for our clinical trials and commercial sales, if any. We plan to continue to rely upon contract
manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our drug product candidates if and when
approved for marketing by the applicable regulatory authorities. Our contract manufacturers have not completed process validation for
the drug substance manufacturing process. Process validation involves a series of activities taking place over the lifecycle of the product
and process. If our contract manufacturers are not approved by the FDA, or other regulatory bodies, our commercial supply of drug substance
will be significantly delayed and may result in significant additional costs. If the FDA does not consider the result of the process
validation or required testing to be satisfactory, regulatory approval and/or commercial supply after launch may be delayed. The FDA
and similar foreign regulatory bodies may also implement new requirements, or change their interpretation and enforcement of existing
requirements, for manufacturers, packaging or testing of products at any time. If we, or our contract manufacturers are unable to comply
with such process validation or other requirements, we may be subject to regulatory, civil actions or penalties which could harm our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
purchase finished mazindol, the molecule in both of Quilience and Nolazol, from a single third party, currently under a development agreement
with us. In addition, we do not have an agreement in place for, but we have identified, a secondary fill/finish supplier. There can be
no guarantee that we will enter into an agreement with such fill/finish supplier or that an effort to enter into such an agreement will
be on favorable terms. If we need to identify an additional fill/finish manufacturer, we would not be able to do so without delay and
likely significant additional cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
existing manufacturer and any future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing
business. In the event of a natural disaster, business failure, strike or other difficulty, such as difficulties involving production
yields, quality control and quality assurance, we may be unable to replace a third-party manufacturer in a timely manner and the production
of any product candidate or commercialized drug would be interrupted, resulting in delays and additional costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, because the contract manufacturer of our drug substance is located in the United States, we may face difficulties in importing
our drug substances into Europe as a result of, among other things, import inspections, incomplete or inaccurate import documentation
or defective packaging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We and
our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates.
The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Manufacturers
and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality control and manufacturing
procedures conform to cGMPs. These cGMP regulations cover all aspects of manufacturing relating to our product candidates. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may
not be detectable in final product testing. We, our collaborators or our contract manufacturers must supply all necessary documentation
in support of an NDA or MAA on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and other regulatory
authorities through their facilities inspection program. Some of our contract manufacturers have never produced a commercially approved
pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality
systems of some or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable
regulations as a condition of regulatory approval of our product candidates or any of our other potential product candidates. In addition,
the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates
or our other potential product candidates or the associated quality systems for compliance with the regulations applicable to the activities
being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners
for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval
of the product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of
the regulatory authority, if ever. Moreover, if our contract manufacturers fail to achieve and maintain high manufacturing standards,
in accordance with applicable regulatory requirements, or there are substantial manufacturing errors, this could result in patient injury
or death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other
problems that could seriously harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Any collaboration
arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize
our current and potential future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our current
and potential future product candidates. We may enter into these arrangements on a selective basis depending on the merits of retaining
commercialization rights for ourselves as compared to entering into selective collaboration arrangements with other pharmaceutical or
biotechnology companies for each product candidate, both in the United States and internationally. We will face, to the extent that we
decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration
arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish
and implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. The terms of any
collaborations or other arrangements that we may establish may not be favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disagreements
between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the
development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement.
These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Collaborations
with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party.
Any such termination or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our reliance
on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that
our trade secrets will be misappropriated or disclosed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek
to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements,
collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and
consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third
parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working
with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become
known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&rsquo;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
filed multiple patent applications and have a very limited number of issued patents. There can be no assurance that any of our patent
applications will result in issued patents. As a result, our ability to protect our proprietary technology in the marketplace may be
limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have filed patent applications in many countries worldwide. These applications cover a range of areas including: the therapeutic use
of mazindol for the treatment of ADHD and combination therapies containing mazindol (add-ons with iron or stimulants) as well as sleep
disorders such as narcolepsy or IH. Unless and until our pending patent applications are issued, their protective scope is impossible
to determine. It is impossible to predict whether or how many of our patent applications will result in issued patents. Even if pending
applications are issued, they may be issued with coverage significantly narrower than what we currently seek.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our proprietary
position for our product candidates currently depends upon patents protecting the method of use, which may not prevent a competitor or
other third party from using the same product candidate for another use.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary patent based intellectual property protection for our product candidates will be any patents granted on the method of use&nbsp;and
formulation. We do not have patents or patent applications covering our products as a composition of matter (i.e., compound claims).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Composition
of matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to
be the favored form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard
to any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use of a product
for the specified method and dosing. These types of patent claims do not prevent a competitor or other third party from making and marketing
an identical API for an indication that is outside the scope of the method claims or from developing a different dosing regimen. Moreover,
even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may
obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label
use may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult
to prevent or prosecute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even if
we are issued patents, because the patent positions of pharmaceutical products are complex and uncertain, we cannot predict the scope
and extent of patent protection for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
patents that may be issued to us will not ensure the protection of our intellectual property for a number of reasons, including without
limitation the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any issued patents may not be broad or strong enough
    to prevent competition from other drug products including identical or similar drug products;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we are not issued patents or if issued patents expire,
    there would be no protections against competitors making generic equivalents;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be prior art of which we are not aware that
    may affect the validity or enforceability of a patent claim;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be other patents existing, now or in the
    future, in the patent landscape for Quilience and Nolazol, or any other product candidates that we seek to commercialize or develop,
    if any, that will affect our freedom to operate;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if our patents are challenged, a court could determine
    that they are not valid or enforceable;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a court could determine that a competitor&rsquo;s technology
    or product does not infringe our patents;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our patents could irretrievably lapse due to failure
    to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing; and</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we encounter delays in our development or clinical
    trials, the period of time during which we could market our products under patent protection would be reduced.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the term
of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure
to respond to office actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
not be able to enforce our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States and Switzerland can be less extensive than those in the United
States and Switzerland. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws
in the United States and Switzerland. Consequently, we may not be able to seek to prevent third parties from practicing our inventions
in all countries outside the United States and Switzerland, or from selling or importing products made using our inventions in and into
the United States or other jurisdictions. Competitors, for example, may use our technologies in jurisdictions where we have not obtained
patents to develop their own products and further, may export otherwise infringing products to territories where we have patents, but
enforcement is not as strong as that in the United States and Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal
systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical and biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce our
patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our
business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly
developing countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited
remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially
diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If we are
unable to maintain effective proprietary rights for our product candidates, we may not be able to compete effectively in our markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to the protection afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret
protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes
that are not easily known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and
any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and
processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors.
We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining physical
security of our premises and physical and electronic security of our information technology systems. Agreements or security measures
may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise
become known or be independently discovered by competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed in violation
of our confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual
property could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken
to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties
for misappropriating any trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Third parties
may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
and could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
commercial success depends upon our ability to develop, manufacture, market and sell our platform technology without infringing the proprietary
rights of third parties. There is considerable intellectual property litigation in the pharmaceutical industry. While no such litigation
has been brought against us and we have not been held by any court to have infringed a third party&rsquo;s intellectual property rights,
we cannot guarantee that our technology or use of our technology does not infringe third-party patents. It is also possible that we have
failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain
applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications
in the United States and elsewhere are published approximately 18 months after the earliest filing, which is referred to as the priority
date. Therefore, patent applications covering our technology could have been filed by others without our knowledge. Additionally, pending
patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our
technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our technology, including inter parties review, interference, or derivation proceedings before the U.S. PTO and similar bodies in
other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual
property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such third
party to continue developing and marketing our technology. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in the introduction of
our products or lead to prohibition of the manufacture or sale of products by us. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court
order, to cease commercializing the infringing technology. In addition, we could be found liable for monetary damages, including treble
damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our technology or force us to cease some of our business operations, which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants
or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims
challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. In addition, we may receive less revenue from future products if any of our employees
successfully claim for compensation for their work in developing our intellectual property, which in turn could impact our future profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Under applicable
employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting
from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions
irrespective of their agreements with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our employees
and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients
for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees
work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants
developed while working for us. Under Swiss law, a non-compete agreement could be invalidated if, for example, the geographic scope of
the non-compete agreement is too broad, or, alternatively, such an agreement could be deemed by a Swiss court to be an occupation ban.
Such actions would make enforcing our non-competition agreements more challenging and could make it easier for our competitors to employee
our previous employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, under Swiss law, if we wish to obtain ownership over inventions developed by our employees, which inventions were developed
while performing their employment activities, but outside the performance of their contractual duties, we are required to compensate
the employee for the rights to their respective inventions. There can be no guarantee that we will be able to obtain any such inventions
and the failure to obtain such ownership rights over employee inventions could have a material adverse effect on our operations and ability
to effectively compete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Business Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We manage
our business through a small number of key employees and consultants.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this annual report, our key employees and consultants include our Chief Executive Officer, Mr. Alexander Zwyer, who co-founded
us in 2015, as well as our Chief Operating Officer, Silvia Panigone, our Interim Chief Financial Officer, Subhasis Roy, our Interim Chief
Scientific Officer, Eric Konofal, our Head of Business Development, Herv&eacute; Girsault and our Interim Medical Director, Carlos Camozzi.
With the exception of our Chief Executive Officer and Chief Operating Officer, our senior management are not engaged as full-time employees.
Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees and key consultants. The loss
of the services of our Chief Executive Officer or any of our senior management or the inability to hire or retain experienced management
personnel could adversely affect our ability to execute our business plan and harm our operating results. Although we expect to enter
into employment agreements with senior management, these agreements will likely be terminable at will with minimal notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, laws and regulations on executive compensation, including legislation in our home country, Switzerland, may restrict our ability
to attract, motivate and retain the required level of qualified personnel. In Switzerland, legislation affecting public companies has
been passed that, among other things, (i) imposes an annual binding shareholders&rsquo; &ldquo;say-on-pay&rdquo; vote with respect to
the compensation of the members of (a) the executive committee and (b) the board of directors, (ii) prohibits severance, advances, transaction
premiums and similar payments to senior management and directors, and (iii) requires companies to specify various compensation-related
matters in their articles of association, thus requiring them to be approved by a shareholders&rsquo; vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because of
the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific
and technical consultants. In particular, the loss of one or more of our senior management or key consultants could be detrimental to
us if we cannot recruit suitable replacements in a timely manner. We do not currently carry &ldquo;key person&rdquo; insurance on the
lives of members of senior management. The competition for qualified personnel in the pharmaceutical industry is intense. Due to this
intense competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit
suitable replacement personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
face business disruption and related risks resulting from the recent outbreak of the COVID-19 pandemic, which could have a material adverse
effect on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, a novel strain of&nbsp;coronavirus, COVID-19, was identified in Wuhan, China. This virus has spread across the globe,
impacting over 200 countries, including the United States and&nbsp;Switzerland. The spread of COVID-19 from China to other countries
has resulted in the World Health Organization declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo; or a worldwide spread of
a new disease. Many countries around the world have imposed and continue to impose quarantines and restrictions on travel and mass gatherings
to slow the spread of the virus. Authorities around the world have and may continue implementing similar restrictions on businesses and
individuals in their jurisdictions. While a number of vaccines have been approved in the United States and other countries, COVID-19
is still spreading and the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected
the lives of a large portion of the global population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout
Switzerland and the world. Although we cut our operating expenses prior to the COVID-19 pandemic, there can be no assurance that this
or other remedial measures that have been enacted will enable us to avoid part or all of any impact from the spread of COVID-19 or its
consequences, including downturns in business sentiment generally or in our sector in particular.&nbsp;In addition, the impact of COVID-19
may cause delays to our future clinical trials, and may make it difficult for us to enroll patients to clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">It
is not possible at this time to estimate the full impact that the COVID-19 pandemic, the continued spread of COVID-19, and any additional
measures taken by governments, health officials or by us in response to such spread, could have on our business, including the timing
of our planned clinical trials, results of operations and financial condition. For example, we do not yet know the impact, if any, of
COVID-19 on our ability to enroll patients in our clinical trials. The COVID-19 pandemic and mitigation measures have also negatively
impacted global economic conditions, which, in turn, could adversely affect our business, including the timing of our planned clinical
trials, results of operations and financial condition.&nbsp;We continue to monitor our operations and government recommendations. A significant
reduction in our workforce and our compliance with instructions imposed by Swiss and other European authorities may harm our ability
to continue operating our business and materially and adversely affect our operations and financial condition. Moreover, even though
there are vaccines for the treatment of COVID-19, we cannot foresee whether the Swiss or other European authorities or the U.S. federal
government will impose further restrictive instructions, which if implemented may lead to significant changes. The spread of COVID-19
may also result in the inability of our suppliers to deliver components or raw materials on a timely basis. The extent to which COVID-19
impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and
cannot be predicted, including new information which may emerge concerning the severity of COVID-19&nbsp;and the actions to contain COVID-19
or treat its impact, among others. See &ldquo;Risks Related to Product Development, Regulatory Approval and Commercialization &ndash;
We may find it difficult to enroll patients in our clinical trials. Difficulty in enrolling patients could delay or prevent clinical
trials of our product candidates&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We will
need to significantly increase the size of our organization, and we may experience difficulties in managing growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
currently have a very limited number of employees and in order to commercialize our products, we will need to substantially increase
our operations, including expanding our employee base of managerial, operational and financial personnel. Any future growth will impose
significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional
employees. To that end, we must be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials and the regulatory process
    effectively;</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop our administrative, accounting and management
    information systems and controls;</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire and train additional qualified personnel; and</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate current and additional management, administrative,
    financial and sales and marketing personnel.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy
and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among
other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both
the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits,
    among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly,
    to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program,
    such as the Medicare and Medicaid programs;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil
    monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented,
    claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Insurance Portability and Accountability
    Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit
    program and making false statements relating to healthcare matters;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology
    and Clinical Health Act, and its implementing regulations, which imposes certain requirements relating to the privacy, security and
    transmission of individually identifiable health information;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine requirements under the
    Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, requires&nbsp;manufacturers
    of drugs, devices and medical supplies to report annually to the U.S. Department of Health and Human Services information related
    to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment
    interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of each of the above federal
    laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including
    commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary
    compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments
    that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
    and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each
    other in significant ways and may not have the same effect, thus complicating compliance efforts; and</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">European and other foreign law equivalents of each
    of the laws, including reporting requirements detailing interactions with and payments to healthcare providers, and the European
    General Data Protection Regulation, or GDPR, which became effective in May 2018 and contains new provisions specifically directed
    at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-EU companies under
    the regulation, including companies like us that conduct clinical trials in the EU; we anticipate that over time we may expand our
    business operations to include additional operations in the EU and with such expansion, we would be subject to increased governmental
    regulation in the EU countries in which we might operate, including the GDPR.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,
convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages,
fines, imprisonment, disgorgement, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid,
reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar
settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of
the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable
laws, they may be subject to similar actions, penalties and sanctions. Efforts to ensure that our business arrangements comply with applicable
healthcare laws and regulations, as well as responding to possible investigations by government authorities, can be time- and resource-consuming
and can divert a company&rsquo;s attention from the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Healthcare
legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
industry is highly regulated and changes in law may adversely impact our business, operations or financial results. The PPACA is a sweeping
measure intended to, among other things, expand healthcare coverage within the United States, primarily through the imposition of health
insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law may affect us and
increase certain of our costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare
payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, following passage of the Bipartisan Budget
Act of 2018, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our
customers and, accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Further, there
have been, and there may continue to be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S.
Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility
payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is
commonly referred to as the &ldquo;individual mandate.&rdquo; Additional legislative and regulatory changes to the PPACA, its implementing
regulations and guidance and its policies, remain possible in Congress. However, it remains unclear how any new legislation or regulation
might affect the prices we may obtain for any of our product candidates for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize
our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and
health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of
products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory
burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict
or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently unable to predict what additional legislation or regulation, if any, relating to the healthcare industry may be enacted
in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our
business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our common shares or Warrants
or limit our ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization
of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The use
of any of our product candidates could result in product liability or similar claims that could be expensive, damage our reputation and
harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
business exposes us to an inherent risk of potential product liability or similar claims. The pharmaceutical industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to cause
or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products might
necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may not
be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at
reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim,
regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer
dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in excess
of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Unsuccessful
compliance with certain European privacy regulations could have an adverse effect on our business and reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data in the EU are governed by the provisions of the Data Protection Directive, and as of May 2018
the GDPR. These directives impose several requirements relating to the consent of the individuals to whom the personal data relates,
the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities
and the security and confidentiality of the personal data. The GDPR also extends the geographical scope of EU data protection law to
non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and
new rights for individuals. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national
data protection laws of the EU Member States may result in fines and other administrative penalties. The GDPR introduces new data protection
requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR regulations impose additional responsibility
and liability in relation to personal data that we process and we intend to put in place additional mechanisms ensuring compliance with
these and/or new data protection rules. In addition, other jurisdictions, including Switzerland, are currently discussing or implementing
regulations similar to GDPR. Changes to these European privacy regulations (and similar regulations in other jurisdictions) and unsuccessful
compliance may be onerous and adversely affect our business, financial condition, prospects, results of operations and reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The market
price of our common shares and Warrants may be highly volatile, and you may not be able to resell your shares or Warrants at or above
the initial public offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
trading price of each of our common shares and Warrants is likely to be volatile. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of such securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain the approvals necessary to commence
    further clinical trials;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results of clinical trials;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory approval or the failure
    to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of therapeutic innovations or new products
    by us or our competitors;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by regulatory authorities with
    respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes or developments in laws or regulations applicable
    to the treatment of the symptoms of narcolepsy, ADHD, or any other indication that we may seek to develop, or the use of mazindol
    to treat any such indications;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to our relationship with manufacturers
    or suppliers;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual property infringement actions in which
    we may become involved;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements concerning our competitors or the pharmaceutical
    industry in general;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement of expected product sales and profitability
    or our failure to meet expectations;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or involvement in, litigation;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our board of directors or management;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit and retain qualified regulatory,
    research and development personnel;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United States relating to the sale
    or pricing of pharmaceuticals;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depth of the trading market in our common shares
    and Warrants;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination of the lock-up agreements or other restrictions
    limiting our ability or that of any of our existing shareholders to sell our common shares (or any other securities that we may issue,
    if any);</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political
    instability in particular foreign economies and markets;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from a local or worldwide
    pandemic, such as COVID-19, geopolitical actions, including war and terrorism, or natural disasters;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the granting or exercise of employee stock options
    or other equity awards; and</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in investors&rsquo; and securities analysts&rsquo;
    perception of the business risks and conditions of our business.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the stock market in general, and the Nasdaq Stock Market in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry factors
may negatively affect the market price of our common shares and Warrants, regardless of our actual operating performance. Further, a
systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
identified material weaknesses in our internal control over financial reporting. If our remediations are not effective, or if we experience
additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we
may not be able to accurately or timely report our financial conditions or results or operations, or prevent fraud, which may adversely
affect investor confidence in our Company and as a result, the market price of our shares and Warrants.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a public company, we are required to maintain internal control over financial reporting and will be required to report any material weaknesses
in such internal control. <FONT STYLE="background-color: white">Section&nbsp;404 of the Sarbanes-Oxley Act, or Section 404, requires
that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on
Form 20-F beginning with our annual report for the fiscal year ending December&nbsp;31, 2022. In addition, once we cease to be an &ldquo;emerging
growth company&rdquo; as such term is defined in the JOBS Act, our independent registered public accounting firm must attest to and report
on the effectiveness of our internal control over financial reporting. </FONT>According to the U.S. Public Company Accounting Oversight
Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there
is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.
If we fail to remediate the material weaknesses, or are otherwise unable to maintain effective internal control over financial reporting,
management could be required to expend significant resources and we could fail to meet our public reporting requirements on a timely
basis, and be subject to fines, penalties, investigations or judgements, all of which could negatively affect investor confidence and
adversely impact our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have had limited financial and accounting personnel, which has resulted in a limited segregation of duties to fully execute
our accounting and financial reporting processes to maintain effective internal control over financial reporting. <FONT STYLE="color: #201F1E; background-color: white">Additionally,
we identified a material weakness related to our lack of sufficient and competent financial reporting and accounting personnel with appropriate
knowledge and experience with technical accounting in accordance with U.S. GAAP and to</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">prepare
and review financial statements and related disclosures in accordance with U.S. GAAP and SEC reporting requirements. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
began to take steps to remediate these material weaknesses and strengthen our internal control over financial reporting, including the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring of additional finance and accounting personnel
    with prior experience working for finance departments and technical accounting experience, supplemented by third-party resources;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">documenting and formally assessing our accounting and
    financial reporting policies and procedures; and</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increasing the use of third-party consultants in assessing
    significant accounting transactions and other technical accounting and financial reporting issues, preparing accounting memoranda
    addressing these issues and maintaining these memoranda in our corporate records.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
we believe that these efforts will improve our internal control over financial reporting, the implementation of these measures is ongoing
and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial
reporting cycles. We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to
maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a
misstatement of our accounts or disclosures that would result in a material misstatement of our financial statements that would not be
prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our Chief
Executive Officer, directors and shareholders who own more than 5% of our outstanding common shares currently own approximately 53% of
our common shares. They will therefore be able to exert significant control over matters submitted to our shareholders for approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Chief Executive Officer and directors, and shareholders who own more than 5% of our outstanding common shares beneficially own approximately&nbsp;53%
of our common shares. This significant concentration of share ownership may adversely affect the trading price for our common shares
and Warrants because investors often perceive disadvantages in owning shares in companies with controlling shareholders. As a result,
these shareholders, if they acted together, could significantly influence or even unilaterally approve matters requiring approval by
our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests
of these shareholders may not always coincide with our interests or the interests of other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The Warrants
we issued in our initial public offering are speculative in nature.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Warrants we offered and sold in our initial public offering do not confer any rights of common share ownership on their holders, such
as voting rights or the right to receive dividends, but rather merely represent the right to acquire common shares at a fixed price for
a limited period of time. Specifically, holders of the Warrants may exercise their right to acquire the common shares and pay an exercise
price of $4.15 per common share, prior to five years from the date of issuance, after which date any unexercised Warrants will expire
and have no further value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If we were
to be characterized as a &ldquo;passive foreign investment company&rdquo; for U.S. tax purposes, U.S. holders of our common shares and
Warrants could have adverse U.S. income tax consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, we will be treated as a passive foreign investment company, or a PFIC, for U.S. federal income tax purposes in any taxable year
in which either (1) at least 75% of our gross income is &ldquo;passive income&rdquo; or (2) on average at least 50% of our assets by
value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among
other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale
or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment
of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share
of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into
account. We do not believe that we will be deemed a PFIC for 2020. If we are a PFIC in any taxable year during which a U.S. taxpayer
holds the common shares and Warrants, such U.S. taxpayer would be subject to certain adverse U.S. federal income tax rules. In particular,
except with respect to the Warrants (unless exercised), if the U.S. taxpayer did not make an election to treat us as a &ldquo;qualified
electing fund,&rdquo; or QEF, or make a &ldquo;mark-to-market&rdquo; election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer,
and any gain realized on the sale or other disposition of the common shares by the U.S. taxpayer: (1) would be allocated ratably over
the U.S. taxpayer&rsquo;s holding period for the common shares; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to
each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for
that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to
each such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year
with respect to which we have determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market
election. U.S. taxpayers that have held the common shares during a period when we were a PFIC will be subject to the foregoing rules,
even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election.
A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions
thereto. We intend to make available to U.S. taxpayers upon request the information needed in order to complete IRS Form 8621 and to
make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. taxpayers that hold the common
shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility,
manner, and consequences to them of making a QEF or mark-to-market election with respect to the common shares in the event that we are
a PFIC. See Item 10.E. &ldquo;Taxation&mdash;U.S. Federal Income Tax Consequences&mdash;Passive Foreign Investment Companies&rdquo; for
additional information.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We have
not paid, and do not intend to pay, dividends on our common shares and, therefore, unless our traded securities appreciate in value,
our investors may not benefit from holding our common shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid cash dividends on our common shares. We do not anticipate paying any cash dividends on our common shares
in the foreseeable future</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover,
Swiss Law imposes certain restrictions on our ability to declare and pay dividends. See Item 8.A. &ldquo;Dividends&rdquo; for additional
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The JOBS
Act allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to
reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our Company
and adversely affect the market price of our common shares and Warrants.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
so long as we remain an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain exemptions
from various requirements that are applicable to public companies that are not EGCs including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring
    that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control
    over financial reporting;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 107 of the JOBS Act, which provides that an
    EGC can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with
    new or revised accounting standards. This means that an EGC can delay the adoption of certain accounting standards until those standards
    would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. As a result
    of this adoption, our financial statements may not be comparable to companies that comply with the public company effective date;
    and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any rules that may be adopted by the Public Company
    Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report on the financial
    statements. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to take advantage of these exemptions until we are no longer an EGC. We will remain an EGC until the earlier of (1)&nbsp;the last
day of the fiscal year (a)&nbsp;following the fifth anniversary of the date of the completion of our initial public offering, (b)&nbsp;in
which we have total annual gross revenue of at least $1.07&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated
filer, as defined in the rule under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and (2)&nbsp;the date on which
we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot predict if investors will find our common shares and Warrants less attractive because we may rely on these exemptions. If some
investors find our common shares and Warrants less attractive as a result, there may be a less active trading market for each such traded
security, and the trading price of each may be more volatile and may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The requirements
associated with being a public company will require significant company resources and management attention.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the reporting requirements of the Exchange Act, Nasdaq listing requirements and other applicable securities rules and
regulations. The Exchange Act requires that we file periodic reports with respect to our business and financial condition and maintain
effective disclosure controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented
by the SEC and the Nasdaq Stock Market may also impose various additional requirements on public companies. As a result, we will incur
additional legal, accounting and other expenses that we did not incur as a nonpublic company, particularly after we are no longer an
EGC as defined in the JOBS Act. We estimate that these expenses will be at least several hundred thousand dollars annually. Further,
the need to establish the corporate infrastructure demanded of a public company may divert management&rsquo;s attention from implementing
our development plans. We have made changes to our corporate governance standards, disclosure controls and financial reporting and accounting
systems to meet our reporting obligations. The measures we take, however, may not be sufficient to satisfy our obligations as a public
company, which could subject us to delisting of our common shares, fines, sanctions and other regulatory action and potentially civil
litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
we are no longer an &ldquo;emerging growth company&rdquo;, we expect to incur significant expenses and devote substantial management
efforts toward ensuring compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 and the other rules and
regulations of the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Swiss Law and Our Operations in Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We are
a Swiss corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws
of U.S. jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a Swiss corporation. Our corporate affairs are governed by our articles of association and by the laws governing companies, including
listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors
may be different from the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions.
In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our Company, our shareholders,
our employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible
that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. Swiss corporate
law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our
shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of directors but are instead
only permitted to seek damages for breaches of fiduciary duty. However, if a board resolution has been invalidly formed, anyone, including
the shareholders, may claim that such an invalid resolution shall be declared null and void. As a matter of Swiss law, shareholder claims
against a member of our board of directors for breach of fiduciary duty would have to be brought in Stans, Switzerland, or where the
relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must
be brought exclusively in Stans, Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our common
shares are issued under the laws of Switzerland, which may not protect investors in a similar fashion afforded by incorporation in a
U.S. state.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are organized under the laws of Switzerland. However, there can be no assurance that Swiss law will not change in the future or that
it will serve to protect investors in a similar fashion afforded under corporate law principles in the United States, which could adversely
affect the rights of investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our status
as a Swiss corporation may limit our flexibility with respect to certain aspects of capital management and may cause us to be unable
to make distributions without subjecting our shareholders to Swiss withholding tax.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
law allows our shareholders to authorize share capital that can be issued by the board of directors without additional shareholder approval.
This authorization is limited to 50% of the existing registered share capital and the authorization must be renewed by the shareholders
every two years. Additionally, subject to specified exceptions, Swiss law grants pre-emptive subscription rights to existing shareholders
to subscribe to any new issuance of shares. Swiss law also does not provide as much flexibility in the various terms that can attach
to different classes of shares as the laws of some other jurisdictions. Swiss law also reserves for approval by shareholders certain
corporate actions over which a board of directors would have authority in some other jurisdictions. For example, dividends must be approved
by shareholders. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise
where greater flexibility would have provided substantial benefits to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Swiss law, a Swiss corporation may pay dividends only if the corporation has sufficient distributable profits from previous fiscal years,
or if the corporation has distributable reserves, each as evidenced by its audited statutory balance sheet. Freely distributable reserves
are generally booked either as &ldquo;free reserves&rdquo; or as &ldquo;capital contributions&rdquo; (apports de capital, contributions
received from shareholders) in the &ldquo;reserve from capital contributions.&rdquo; Distributions may be made out of issued share capital&mdash;the
aggregate nominal value of a company&rsquo;s issued shares&mdash;only by way of a capital reduction. As of December 31, 2020, we had
CHF&nbsp;26.357&nbsp;million (approximately $28.040 million) of qualifying capital contributions and CHF 139,200.00 (approximately $145,139.00)
of registered share capital (consisting of 6,960,000 common shares each with a nominal value of CHF&nbsp;0.02 and no preferred shares))
on our audited statutory balance sheet (which audit was performed by our independent registered public accounting firm), as required
pursuant to Swiss law. We will not be able to pay dividends or make other distributions to shareholders on a Swiss withholding tax-free
basis in excess of that amount unless we increase our share capital or our reserves from capital contributions. We would also be able
to pay dividends out of distributable profits or freely distributable reserves but such dividends would be subject to Swiss withholding
taxes. There can be no assurance that we will have sufficient distributable profits, free reserves, reserves from capital contributions
or registered share capital to pay a dividend or effect a capital reduction, that our shareholders will approve dividends or capital
reductions proposed by us, or that we will be able to meet the other legal requirements for dividend payments or distributions as a result
of capital reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generally,
Swiss withholding tax of 35% is due on dividends and similar distributions to our shareholders, regardless of the place of residency
of the shareholder, unless the distribution is made to shareholders out of (i) a reduction of nominal value or (ii) assuming certain
conditions are met, qualifying capital contributions accumulated on or after January 1, 1997. A U.S. holder that qualifies for benefits
under the Convention between United States of America and Switzerland for the Avoidance of Double Taxation with Respect to Taxes on Income,
which we refer to as the &ldquo;U.S.-Swiss Treaty,&rdquo; may apply for a refund of the tax withheld in excess of the 15% treaty rate
(or in excess of the 5% reduced treaty rate for qualifying corporate shareholders with at least 10% participation in our voting shares,
or for a full refund in the case of qualified pension funds).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
can be no assurance that we will have sufficient qualifying capital contributions to pay dividends free from Swiss withholding tax, or
that Swiss withholding rules will not be changed in the future. In addition, we cannot provide assurance that the current Swiss law with
respect to distributions out of qualifying capital contributions will not be changed or that a change in Swiss law will not adversely
affect us or our shareholders, in particular as a result of distributions out of qualifying capital contributions becoming subject to
additional corporate law or other restrictions. In addition, over the long term, the amount of par value available to us for nominal
value reductions or qualifying capital contributions available to us to pay out as distributions is limited. If we are unable to make
a distribution through a reduction in nominal value or out of qualifying capital contributions, we may not be able to make distributions
without subjecting our shareholders to Swiss withholding taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our securities
are not listed in Switzerland, our home jurisdiction. As a result, our shareholders will not benefit from certain provisions of Swiss
law that are designed to protect shareholders in a public takeover offer or a change-of-control transaction and may not be protected
in the same degree in a public takeover offer or a change-of-control transaction as are shareholders of certain U.S. companies or in
a Swiss company listed in Switzerland.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
our securities are listed exclusively on Nasdaq and not in Switzerland, our shareholders will not benefit from the protection afforded
by certain provisions of Swiss law that are designed to protect shareholders in the event of a public takeover offer or a change-of-control
transaction. For example, Article 120 of the Swiss Financial Market Infrastructure Act and its implementing provisions require investors
to disclose their interest in our company if they reach, exceed or fall below certain ownership thresholds. Similarly, the Swiss takeover
regime imposes a duty on any person or group of persons who acquires more than one-third of a company&rsquo;s voting rights to make a
mandatory offer for all of the company&rsquo;s outstanding listed equity securities. In addition, the Swiss takeover regime imposes certain
restrictions and obligations on bidders in a voluntary public takeover offer that are designed to protect shareholders. However, these
protections are applicable only to issuers that list their equity securities in Switzerland and, because our securities will be listed
exclusively on Nasdaq, will not be applicable to us. Furthermore, since Swiss law restricts our ability to implement rights plans or
U.S.-style &ldquo;poison pills,&rdquo; our ability to resist an unsolicited takeover attempt or to protect minority shareholders in the
event of a change of control transaction may be limited. Therefore, our shareholders may not be protected in the same degree in a public
takeover offer or a change-of-control transaction as are shareholders in certain U.S. companies or in a Swiss company listed in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>U.S. shareholders
may not be able to obtain judgments or enforce civil liabilities against us or our senior management or members of our board of directors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are organized under the laws of Switzerland and our registered office and domicile is located in Stans, Switzerland. Moreover, a majority
of our directors and senior management are not residents of the United States, and all or a substantial portion of the assets of such
persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within
the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions
predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss
counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of
U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original
actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things,
by the principles set forth in the Swiss Federal Act on Private International Law. This statute provides that the application of provisions
of non-Swiss law by the courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, certain
mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Switzerland
and the United States do not have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial
matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles
set forth in the Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss
court may be recognized in Switzerland only if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the non-Swiss court had
    jurisdiction pursuant to the Swiss Federal Act on Private International Law;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment of such non-Swiss
    court has become final and non-appealable;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment does not contravene
    Swiss public policy;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the court procedures and
    the service of documents leading to the judgment were in accordance with the due process of law; and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no proceeding involving
    the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated
    in a third state and this decision is recognizable in Switzerland.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exchange
rate fluctuations between the U.S. dollar and the Swiss Franc may negatively affect our results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
our existing agreements, we make a significant number of payments in U.S. dollars and Swiss Francs. Since our reporting currency is the
U.S. dollar, financial line items are converted into U.S. dollars at the applicable exchange rates.&nbsp;As a result, changes and fluctuations
in currency exchange rates between the Swiss Franc the U.S. dollar could have a material adverse effect on our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>We
are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions
applicable to U.S. domestic public companies</I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif">, which may
result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of the Nasdaq
Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
are required to file an annual report on Form 20-F within four months of the end of each fiscal year. In addition, we intend to publish
our results on a half-yearly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq. Press releases
relating to financial results and material events will also be furnished to the SEC on Form 6-K. However, the information we are required
to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S.
domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you
investing in a U.S. domestic issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>As a foreign
private issuer, we are permitted, and intend, to phase-in our compliance with certain Nasdaq Listing Rules, as permitted by Nasdaq Listing
Rule 5615(b)(1), instead of otherwise having to be in compliance with such rules as of the date of our initial listing on Nasdaq, which
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers and if we do not obtain compliance
within the allotted time, we could become subject to delisting by Nasdaq.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with Nasdaq Listing Rule 5615(b)(1), as a foreign private issuer, we are permitted, and intend, to phase-in our compliance
with certain Nasdaq Listing Rules, instead of otherwise having to be in compliance with such rules as of the date of our initial listing
on Nasdaq. For instance, although we are a Foreign Private Issuer and have opted into following our home country rules, which are the
laws of Switzerland, in lieu of following certain Nasdaq Listing Rules, we are still required to have an audit committee that satisfies
Nasdaq Listing Rule 5605(c)(3) and ensure that such audit committee members meet the independence requirement in Nasdaq Listing Rule
5605(c)(2)(A)(ii), provided, however, that in light of Nasdaq Listing Rule 5615(b)(1), we have up to one year from the date of our listing
to have an audit committee and members who meet such requirements. This phased-in period of compliance may result in less protection
than is accorded to investors under rules applicable to domestic U.S. issuers and if we do not obtain compliance within the allotted
time, we could become subject to delisting by Nasdaq. In addition, due to the resignation of Pascal Brenneisen, we are relying on the
cure period allowed for under Nasdaq Listing Rules to fill such vacancy with a qualified individual, and if we fail do so, we could become
subject to delisting by Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Raising
additional capital would cause dilution to our existing shareholders, and may affect the rights of existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic
and licensing arrangements. To the extent that we raise additional capital through the issuance of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. Future sales of our common shares or of securities convertible into our common shares, or the perception that such
sales may occur, could cause immediate dilution and adversely affect the market price of our common shares and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Failure
in our information technology systems, including by cybersecurity attacks or other data security incidents, could significantly disrupt
our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
operations depend, in part, on the continued performance of our information technology systems. Our information technology systems are
potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptions. Failure of our information technology
systems could adversely affect our business, profitability and financial condition. Although we have information technology security
systems, a successful cybersecurity attack or other data security incident could result in the misappropriation and/or loss of confidential
or personal information, create system interruptions, or deploy malicious software that attacks our systems. It is possible that a cybersecurity
attack might not be noticed for some period of time. The occurrence of a cybersecurity attack or incident could result in business interruptions
from the disruption of our information technology systems, or negative publicity resulting in reputational damage with our shareholders
and other stakeholders and/or increased costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized
dissemination of sensitive personal information or proprietary or confidential information could expose us or other third parties to
regulatory fines or penalties, litigation and potential liability, or otherwise harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We may
be subject to securities litigation, which is expensive and could divert management attention.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the past, companies that have experienced volatility in the market price of their shares have been subject to securities class action
litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs
and diversion of management&rsquo;s attention and resources, which could seriously hurt our business. Any adverse determination in litigation
could also subject us to significant liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sales of
a substantial number of shares of our common shares in the public market by our existing shareholders could cause our share price to
fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sales
of a substantial number of our common shares in the public market or the perception that these sales might occur, could depress the market
price of our common shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable
to predict the effect that sales may have on the prevailing market price of our common shares. In addition, shares held by our shareholders
prior to our initial public offering may be available for re-sale upon the expiration of the lock up period set forth in certain lock-up
agreements executed by certain company insiders relating to our initial public offering. In addition, shares issued or issuable upon
exercise of options and warrants vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of shares
by these shareholders could have a material adverse effect on the trading price of our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If securities
or industry analysts do not publish or cease publishing research reports about us, our business or our market, or if they adversely change
their recommendations or publish negative reports regarding our business or our shares and Warrants, the trading prices of our shares
and Warrants and trading volume of our shares and Warrants could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
trading market for our common shares and Warrants will be influenced by the research reports that industry or securities analysts may
publish about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any
assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our shares and Warrants, or provide more favorable relative recommendations about our competitors, the trading price of our
shares and Warrants would likely decline. If any analyst who may cover us were to cease coverage of our Company or fail to regularly
publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price of our shares and
Warrants and trading volume of our shares and Warrants to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>ITEM&nbsp;4.</B></FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION ON THE COMPANY</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>A.</B></FONT></td>
    <td style="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>History
    and Development of the Company</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
was formed in June 2015 as a Swiss limited company. Our registered office is located at Alter Postplatz 2, 6370 Stans, NW, Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
2016, we acquired several patents from Assistance Publique &ndash; Hopitaux de Paris, or AP-HP, in France, including for our lead compound
mazindol. Since our founding, we have assembled an experienced leadership team with a track record of developing and repurposing products
to treat rare neurological disorders. Our Chief Executive Officer, Alexander Zwyer, has held a variety of senior leadership roles of
increasing responsibility in the pharmaceutical industry, including global roles in business development, marketing, commercial, operations
and general management. We complement our management team with a group of scientific and clinical advisors that includes internationally
recognized North American and European experts in CNS disorders, including the areas of our current focus, rare hypersomnolence (specifically,
narcolepsy) and complex neurodevelopmental disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A><B>B.</B></FONT></td>
    <td style="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Overview</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare
and complex central nervous system, or CNS, disorders with unmet medical needs. Our lead compound mazindol, a triple monoamine reuptake
inhibitor and partial orexin receptor 2 agonist, in a proprietary CR formulation, is being developed for the treatment of narcolepsy
(lead indication) and ADHD (follow-on indication). We believe that this dual mechanism of action will also enable mazindol CR to provide
potential therapeutic benefit in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that include neurological,
psychiatric, and substance use disorders. According to the World Health Organization and based on data from the Global Burden of Disease
Report, CNS disorders result in a socio-economic burden of more than $317 billion annually in the United States alone. Additionally,
CNS disorders were expected to account for approximately 15% of the global disease burden in 2020, the largest of any disease area. However,
treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally
trails behind other therapeutic areas. We are pursuing the development of the next generation of CNS therapies with high medical impact
to address this critical and growing unmet need. Our dual development strategy is designed to optimize the outcome of our clinical programs
by developing new chemical entities, or NCEs, from known molecules with strong scientific rationale, and also by re-defining previously
approved molecules with well-established tolerability and safety profiles, as determined by applicable regulatory agencies. We believe
that our streamlined clinical development approach has the potential to advance our product candidates rapidly through early-stage clinical
trials, while carrying an overall lower development risk. A lower development risk, we believe, exists with respect to the development
of our lead product candidate, Quilience, and follow-on product candidate, Nolazol, due to their use of mazindol as the active ingredient,
which was previously approved and marketed in the United States, Japan and Europe to manage exogenous obesity (obesity caused by overeating).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
discovery platform currently focuses on single molecules that operate through multiple mechanisms designed to target the complexity of
the CNS disease state, and, we believe these may potentially offer new treatment options for patients, including for those patients who
are refractory to currently available treatments. Our current focus is in the therapeutic areas of rare hypersomnia disorders (conditions
highlighted by excessive daytime sleepiness, or EDS) and complex neurodevelopmental disorders, and includes our lead product candidate:
Quilience, for the treatment of EDS and cataplexy associated with narcolepsy, and our follow-on candidate Nolazol, for the treatment
of ADHD. We have not yet conducted sponsored clinical studies for Quilience and we intend to initiate our clinical development with a
Phase 2 clinical trial in the second half of 2021, in adult patients with narcolepsy, subject to authorization from the FDA and other
applicable regulatory agencies.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">We expect to have top line results
from our Phase 2 clinical trial by the end of 2021<FONT STYLE="background-color: white">.&nbsp;</FONT>We also intend to apply for expedited
development program(s) facilitated by the U.S. Food and Drug Administration, or the FDA, such as Breakthrough Therapy and/or Fast Track
designations and by the European Medicines Agency, or EMA, such as Priority Medicine, or PRIME<FONT STYLE="background-color: white">.
We have completed a Phase 2 clinical trial evaluating the safety and efficacy of Nolazol in adults with ADHD in the U.S. and, given the
positive outcome of this trial, we may initiate Phase 3 clinical trials after we receive approval to commercialize Quilience. We intend
to seek FDA and other regulatory approval for Nolazol for use in children with ADHD, which requires additional nonclinical work, as well
as staged clinical work in determining safe dosing and monitoring.<B>&nbsp;</B>In addition, f</FONT>ollowing our current focus on the
development of Quilience for narcolepsy in adults, and if approved for marketing, we intend to seek a label expansion for the treatment
of narcolepsy in pediatric patients, which may require additional nonclinical and clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Quilience
and Nolazol both contain mazindol as the active ingredient in a proprietary CR formulation developed for a once-a-day dosing. Mazindol
has a well-established safety record from its extended history of clinical use across the United States and several countries in Europe,
where mazindol was previously approved in an immediate release formulation for the short-term management of exogenous obesity. It was
marketed for nearly 30 years, into the early 2000s, before being voluntarily withdrawn from the market for commercial reasons and is
no longer available nor marketed in these regions. In addition to the 30-year period in which it was marketed, mazindol was also widely
used off-label and prescribed under compassionate use for the treatment of narcolepsy for approximately four decades, during which time
it demonstrated a well-tolerated safety profile in patients over long-term, chronic use of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that our lead product candidate, Quilience, offers a meaningfully differentiated product profile over current treatment options
for the following reasons:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mechanism of action</I></B>.
    If approved, Quilience would be the only partial orexin 2 receptor agonist approved by the FDA, as well as the only triple monoamine
    reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing
    neurons and a partial orexin 2 receptor agonist may help to replace the missing endogenous orexin peptide, addressing the underlying
    orexin deficiency and reduce disease specific symptoms. In addition, its unique dual mechanism of action as also a monoamine triple
    reuptake inhibitor further acts to reduce disease specific symptoms, offering patients a treatment option that may address simultaneously
    and in concert the two primary symptoms of narcolepsy.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Low potential for
    abuse and misuse and diversion</I></B>. Mazindol is a Schedule IV controlled substance as classified by the DEA. The DEA defines
    Schedule IV controlled substances as those &ldquo;with a low potential for abuse and a low risk of dependence&rdquo;. Unlike Xyrem
    (sodium oxybate), the top-selling medication for narcolepsy in the United States, historically mazindol never required a REMS to
    manage known or potential serious risks associated with its use.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Quilience is expected
    to be administered as a monotherapy.&nbsp;</I></B>Narcolepsy is a difficult disorder to manage and even with available approved medications,
    the majority of narcolepsy patients often require multiple medications to treat their symptoms. &nbsp;<FONT STYLE="background-color: white">According
    to the current treatment guidelines&nbsp;(initially published in 2007)&nbsp;of the AASM, approved medications for narcolepsy, at
    best,&nbsp;provide only moderate improvement in narcolepsy symptoms and their respective side effects may limit their use. The AASM
    specifically highlights that future investigations should be directed toward development of more effective and better tolerated therapies
    and primary prevention.&nbsp;The Voice of the Patient report from the FDA&rsquo;s patient-focused drug development initiative, published
    in 2014, concluded that, based on the overall benefit-risk assessment of currently approved medications, there is a continued need
    for additional effective and tolerable treatment options for patients with narcolepsy.&nbsp;</FONT>A retrospective analysis (Nittur
    et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant
    hypersomniacs, including a clear benefit on the two primary symptoms of narcolepsy, EDS and cataplexy.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Quilience is being
    developed as a once-daily oral tablet administered in the morning upon wakening</I></B>. Patients have identified a need for treatment
    options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping and provide full day coverage of symptoms.
    We believe that once-daily dosing with Quilience may address this need and may help improve patient compliance and adherence with
    treatment. Quilience utilizes our proprietary controlled-release formulation and is being designed to optimize its pharmacokinetic
    and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral
    dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leveraging
our scientific insights and direct hands-on clinical experience, we are developing compounds that we believe have innovative mechanisms
of action with positive therapeutic profiles and represent a differentiated treatment option to overcome the limitations of the current
therapies. For example, Quilience and Nolazol are agents that differ from available treatments in their apparent dual mechanism of action.
In addition to their action as a triple monoamine reuptake inhibitor that blocks serotonin, norepinephrine, and dopamine transporters,
they also target the orexin pathway as a selective (in relation to the orexin-1 receptor) partial agonist of the OX2R. This activity
could provide cortical regulation of the lower brain, and thereby lead to improved attention and inhibitory control, while also improving
regulation of executive function and inhibitory control which would provide both &ldquo;top down&rdquo; and &ldquo;bottom up&rdquo; regulation
of the brain. Orexin neurons (located in a part of the brain known as the hypothalamus) are multi-tasking neurons that serve as key modulators
to several vital functions, including sleep-wake states, attention, feeding behavior, energy homeostasis, reward systems, cognition and
mood throughout the cerebral cortex, and as such, the orexin system is a central promoter of wakefulness. A drug that targets orexin
could potentially increase arousal in individuals with ADHD, which could be useful in individuals who have a low level of arousal or
motivation, as is not infrequently the case in individuals with ADHD. To the best of our knowledge, no currently available medication
for ADHD or for the treatment of EDS and cataplexy, the two main symptoms associated with narcolepsy, has effects on the orexin system.
In addition to narcolepsy and ADHD, we believe that our product compound, mazindol CR, may have therapeutic potential across a range
of diverse CNS conditions such as RLS, IH, OSA, Kleine-Levin-syndrome, daytime sleepiness due to myotonic dystrophy Type 1 (DM1) and
Prader Willi Syndrome, given the mechanism of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Relationship
Between Narcolepsy and ADHD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Narcolepsy
and psychiatric disorders have a significant but unrecognized relationship in which the two can coexist. However, narcolepsy is frequently
misdiagnosed initially as a psychiatric condition, contributing to the protracted time for accurate diagnosis and treatment. Narcolepsy
is a disabling neurological condition that carries a high risk for development of social and occupational dysfunction. Deterioration
in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of
psychiatric symptoms can lead to the deterioration in function and quality of life. The overlap in treatments may further enhance the
difficulty to distinguish between diagnoses.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ADHD
is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated
prevalence rate of approximately 4-12% worldwide, as reported by the paper, &ldquo;Understanding Attention Deficit/Hyperactivity Disorder
from Childhood to Adulthood,&rdquo; by Drs. Timothy E. Wilens and Thomas J. Spencer. On the surface, ADHD may appear to be the opposite
of narcolepsy; however, there may actually be significant clinical similarity between the two. Cumulative data about sleep problems in
children and adolescents with ADHD has shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime
sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance
disorders because shorter sleep onset latency is assessed by the Multiple Sleep Latency Test, or MSLT (an objective physiologic measure
of sleepiness), in ADHD, rather than in the control group irrespective of the presence/absence of sleep disturbances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
the other hand, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents
with narcolepsy has been found to be about two-fold higher than in the general control population and adults with narcolepsy have been
found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity
seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy and ADHD symptoms contribute to
poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all
of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS and researchers suggest that the symptoms
of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia
disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our Portfolio
and Lead/Follow-On Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quilience
for Treatment of EDS and Cataplexy in Narcolepsy (Lead Product Candidate)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Narcolepsy
is a rare chronic primary sleep disorder characterized by two main symptoms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-indent: -17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="font-size: 10pt; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EDS</U>:
    This symptom is the inability to stay awake or alert throughout the day and, in general, EDS interferes with normal activities on
    a daily basis, whether or not a person with narcolepsy has sufficient sleep at night. People with EDS report mental cloudiness, lack
    of energy and concentration, memory lapses, depressed mood, and/or extreme exhaustion.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-indent: -17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cataplexy</U>: This
    symptom consists of a sudden loss of muscle tone that leads to muscle weakness and a loss of voluntary muscle control, while being
    fully conscious. It can cause symptoms ranging from slurred speech to total body collapse, depending on the muscles involved, and
    is often triggered by intense emotions such as surprise, laughter, or anger.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-indent: -17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nearly
all patients diagnosed with narcolepsy require lifelong treatment to combat the daily and debilitating symptoms, yet, most continue to
suffer because of the current gap between their medical needs and effective treatments. One FDA approved medication for both EDS and
cataplexy associated with narcolepsy, sodium oxybate (Xyrem), although marketed with significant limitations impeding its use, generated
revenues of over $1.74 billion in 2020 based on fourth quarter and full year financial results issued by Jazz Pharmaceuticals plc. According
to a September 2019 press release from ResearchAndMarkets.com, the narcolepsy market generated $2.42 billion in 2018 and is projected
to reach $5.36 billion by 2026, growing at a compound annual growth rate of 10.3% from 2019 to 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
an agonist of the OX2R and a triple monoamine reuptake inhibitor, we believe that Quilience reflects a scientifically supported mechanism
of action to address the shortcomings of the approved medications and the unmet needs of patients. Quilience is being designed as an
oral, once-daily treatment, intended for long-term use. Through the use of mazindol in Quilience and the expected benefits of our proprietary
controlled-release formulation, we hope that regulatory agencies will conclude that Quilience has a desirable balance of efficacy, safety
and tolerability to support marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also anticipate developing additional mazindol based CR product(s) for broader hypersomnia indications, such as IH, where there is a
critical unmet need and no currently approved treatments available, in addition to other disorders, such as neurocognitive disorders
implicated by EDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quilience
has been granted orphan drug designation by both the FDA and European Commission for the treatment of narcolepsy, and if approved for
marketing in adults, this designation is expected to provide 7 years and 10 years of market exclusivity in the United States and Europe,
respectively, and with the potential for additional market exclusivity, if and when further developed and approved in pediatrics (extended
for an aggregate of 7.5 years and 12 years in the United States and Europe, respectively). Additionally, we have filed an international
patent application under the Patent Cooperation Treaty, or PCT, for proprietary controlled release formulation, and, if granted, may
provide patent protection through 2037 in the United States. We held a pre-IND meeting with the FDA in December 2016, and we plan to
submit an IND in the second quarter of 2021. Additionally, we received scientific advice with protocol assistance from the EMA in March
2017 and are planning for the development of the Clinical Trial Agreement, which upon approval, will allow for clinical trials to begin
in the EU. We plan to pursue an expedited development program with the FDA under the Breakthrough Therapy and Fast Track designation
programs, as well as potentially a similar program, PRIME, with the EMA. Collectively, these programs are designed to expedite the development
and review of drugs intended to treat serious conditions and fill an unmet medical need. We believe Quilience may qualify for these programs
based on (i) positive real-world evidence, namely, previous off-label use of Quilience&rsquo;s active molecule, mazindol, in treating
narcolepsy, which was prescribed under France&rsquo;s Authorization Treatment Use program for 17 years in patients who failed to respond
or could not tolerate the available approved treatments, (ii) its dual mechanism of action as a SNDRI (serotonin&ndash;norepinephrine&ndash;dopamine
reuptake inhibitors) and partial OX2R agonist, which we believe are crucial in addressing the underlying symptoms of both EDS and cataplexy,
providing a pharmacological profile targeting multiple CNS pathways, and (iii) the limited availability of treatments that successfully
treat both cataplexy and EDS in narcolepsy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
we are planning to leverage the demonstrated biological activity of the active molecule in Quilience to further expedite the clinical
development, as well as drawing on the data from our ADHD program to support our clinical development efforts of Quilience and the FDA&rsquo;s
previous approval of mazindol (in its immediate release form in the pharmaceutical product &ldquo;Sanorex,&rdquo; as manufactured and
distributed by Novartis (through its Sandoz division) as safe in the management of exogenous obesity through the 505(b)(2) regulatory
pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that previous off-label use of Quilience&rsquo;s active molecule, mazindol, in treating narcolepsy, which was prescribed under
a regulatory authorized CUP in France for 17 years in patients who failed to respond or could not tolerate the available approved treatments,
supports our development of Quilience. We believe this positive real-world evidence in improving both EDS and reducing cataplexy demonstrates
the potential for Quilience to be a treatment for patients suffering from narcolepsy, and notably, also the potential to provide an alternative
treatment for patients who have not had a successful outcome with approved treatments, such as sodium oxybate, modafinil, methylphenidate-based,
and amphetamine-based products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
most patients, narcolepsy is caused by the permanent loss of orexin (also called hypocretin), which has been identified as the major
regulator in the brain that modulates the stability of the sleep-wake cycle. Individuals with narcolepsy often emphasize that their symptoms
go beyond falling asleep during the day and report feeling chronically tired, fatigued, or sleep deprived and also struggle with cognitive
difficulties that interfere with their ability to perform at work or school and devastating cataplexy attacks that can be debilitating
and frightening. These impairments are associated with an increased risk of accidents, trauma, and difficulties in maintaining personal
relationships. The economic burden of narcolepsy is also extensive and people with narcolepsy have above-average rates of health care
visits, medication use, and unemployment, and those employed have lower income levels. According to the Narcolepsy Network, narcolepsy
affects an estimated 1 in every 2,000 people in the United States, which equates to 150,000 to 200,000 patients in the United States
and 3 million worldwide; however, it is estimated that only 25% of those living with narcolepsy have been diagnosed and are receiving
treatment. Most people with narcolepsy begin having symptoms in their teenage years, but the diagnosis is usually not made until adulthood,
suggesting that narcolepsy is both an underdiagnosed and an undertreated disorder. According to the August 2018 National Know Narcolepsy
Survey, most narcolepsy patients remain unsatisfied on current treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
symptomatic improvement is possible, patients&rsquo; needs are usually not met and the therapeutic effects of the currently approved
treatments remain inadequate for most patients, including lack of symptom control, variable efficacy, rebound sleepiness and rebound
cataplexy, troublesome side effects, inconvenience, and high potential for abuse. Given the considerable burden of the condition, the
adverse effects on the health of narcolepsy patients, and the limitations of available medications, there is a critical unmet need for
additional treatment options.&nbsp;Quilience is a triple monoamine reuptake inhibitor (SNDRI) and partial agonist of the OX2R that may
mimic the natural sleep-wake process by activating and further enhancing the brain mechanisms that promote and regulate wakefulness.
We believe Quilience may bridge this considerable treatment gap and that the current narcolepsy landscape may provide an opportunity
to establish ourselves as a leader in this space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Real-World
Evidence in Narcolepsy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
use of real-world evidence may improve the quality and efficiency of clinical development and clinical trial design, with the potential
to accelerate the development of therapies that may provide meaningful benefits to patients. Real-world evidence is the analysis of real-world
data, which can originate from sources such as CUPs, and may provide a more complete picture of patient experience to inform patient-focused
drug development, and support the advancement of randomized, placebo-controlled clinical trials to support a marketing application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
no longer commercially available in the United States or Europe, the active molecule in Quilience, mazindol, was previously widely used
off-label and for several decades for the treatment of narcolepsy. Additionally, it was prescribed under a long-term CUP administered
and regulated by ANSM (&ldquo;L&rsquo;agence nationale de s&eacute;curit&eacute; du medicament et des produits de sant&eacute;&rdquo;),
the national agency in France responsible for overseeing the safety of medicines and health products, helping to address the unmet needs
of patients who did not initially respond, later failed or were unable to tolerate the approved available treatments, such as modafinil,
methylphenidate, sodium oxybate, and amphetamine-based products. This CUP ran for 17 years, ending in 2016 due to unavailability of the
product, and more than 200 patients with narcolepsy who were refractory to available treatments were prescribed mazindol for the treatment
of EDS and/or cataplexy.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
retrospective, multi-center, observational study of this real-world data, financed by the French Health Ministry, and conducted in part
by certain members of our team and members of our Scientific Advisory Board (prior to their work with us), was performed to evaluate
the effectiveness and safety of mazindol in real-world, clinical practice. A total of 94 patients with narcolepsy, and suffering from
cataplexy, including adults and children, with a mean 30 months of treatment exposure were included in the analysis to evaluate the effectiveness
of mazindol on improving EDS. Mazindol noticeably improved EDS (p&lt;0.0001), as measured by the Epworth Sleepiness Score, or ESS. The
ESS is a validated patient-reported measure of the patients&rsquo; recent likelihood of falling asleep in everyday activities and is
the same primary outcome measure widely used in other narcolepsy-related Phase 3 clinical trials. An analysis was also performed assessing
the effectiveness of mazindol in controlling cataplexy in 62 patients and demonstrated a statistically significant reduction in the frequency
of cataplexy episodes (p&lt;0.0001). The ESS score before mazindol was 18.0 &plusmn; 3.1 and decreased to 13.6 &plusmn; 5 after mazindol,
for a change of -4.2 (p&lt;0.0001). In addition, the change in weekly cataplexy rate before and after mazindol changed from 4.6 &plusmn;
3.1 (before mazindol) to 2.0 &plusmn; 2.8 after mazindol (for a change of -2.7) (p&lt;0.0001).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
retrospective study with analysis of real-world data, provides positive real-world evidence that the treatment was well-tolerated and
effective, in terms of improvement in EDS and the reduction in cataplexy events, with a conclusion of an overall positive benefit-risk
ratio in the majority of patients. In their report concluding the results of the study (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6),
the researchers found that Mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant hypersomniacs, including a
clear benefit on cataplexy and that the data, taken altogether, suggest that mazindol has a major effect on sleepiness, possibly greater
than that of modafinil (Provigil).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Narcolepsy
Overview and Market Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Narcolepsy
is the inability to stay awake and arises from the dysregulation of the sleep-wake cycle, and in most individuals is thought to be caused
by an immune system mediated destruction of brain cells that contain orexin. Orexin is a neuropeptide and is critical to the maintenance
of wakefulness, continuity of sleep and coordination of the timing and features of REM sleep. Narcolepsy is often debilitating and incapacitating
for those affected and with no known cure, it usually requires life-long symptomatic treatment. Narcolepsy symptoms significantly interfere
with and cause a negative impact on cognitive, psychological and social functioning and can greatly affect daily activities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
clinical hallmark of narcolepsy is EDS, which is present in all narcolepsy patients and is generally the first symptom to occur. EDS
manifests as sudden irresistible bouts of sleep throughout the day, which can strike at any time, leading to inadvertently falling asleep
during a variety of situations, such as while at work or at school, when having a conversation, playing a game, eating a meal, or, most
dangerously, when driving or operating other types of machinery. A prominent and distinctive symptom of narcolepsy is cataplexy, which
occurs in approximately 70% of those patients with narcolepsy. Although the severity of cataplexy is variable, it can be very frightening
and usually causes additional disability. In addition to cataplexy, individuals with narcolepsy may also have symptoms indicative of
altered REM sleep. REM sleep is normally characterized by dreaming and muscle paralysis that prevents an individual from acting out their
dreams. In narcolepsy however, REM sleep can occur at any time of day and elements of REM sleep can mix into wake, manifesting as cataplexy,
hallucinations that occur when going to sleep or upon waking, and sleep paralysis, a transitional state between wakefulness and sleep
in which one is aware but cannot move, speak, or react.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Narcolepsy
is classified into two subtypes, narcolepsy type 1 and narcolepsy type 2. Type 1 is characterized by cataplexy or an undetectable or
low level of orexin in the cerebrospinal fluid, or CSF. In type 2, patients generally have less severe symptoms and do not experience
cataplexy attacks. The underlying cause of narcolepsy type 2 is unknown and many patients have normal CSF orexin levels; however, 25%
of patients with narcolepsy type 2 do have intermediate CSF orexin levels and these individuals are more likely to develop cataplexy
and subsequently be diagnosed with narcolepsy type 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cataplexy&nbsp;is
a symptom that occurs almost exclusively in people with&nbsp;narcolepsy type 1, so its presence strongly suggests this diagnosis.&nbsp;However,&nbsp;cataplexy&nbsp;can
sometimes be subtle or mild, making additional testing sometimes necessary, with the diagnosis depending on ruling out causes of secondary
hypersomnia and performing an overnight sleep test with MSLT. On the&nbsp;MSLT, it takes less than eight minutes on average for people
with narcolepsy type 1 to fall asleep, and REM sleep is observed on at least two naps.&nbsp;People with&nbsp;narcolepsy&nbsp;type 2&nbsp;show
the same results on&nbsp;MSLT&nbsp;as those with&nbsp;cataplexy.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In
addition to EDS, cataplexy and other symptoms of altered REM sleep, people with narcolepsy type 1 are prone to gain significant weight,
which may be due to the loss of orexin. Soon after narcolepsy onset, children can rapidly gain 5&ndash;15 kg (approximately 11 to 33
pounds) and adults with type 1 are often overweight or obese, despite normal caloric intake and activity levels. Given that the active
molecule in Quilience was previously approved for the management of&nbsp;exogenous&nbsp;obesity and its multifunctional mechanism of
action targets two pathways known to be implicated in obesity, Quilience may also help to counter this negative effect of weight gain
associated with narcolepsy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Prevalence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the European Narcolepsy Network, narcolepsy affects only 20 to 40 out of every 100,000 people; however, it is estimated that only
one out of four people living with narcolepsy have been properly diagnosed. Although it usually has an early age of onset during the
adolescent years, a diagnostic delay that often exceeds 10 years from the time of symptom onset suggests that narcolepsy is both under
diagnosed and under treated. This delay may result from several factors, including lack of clinician and patient recognition of the signs
and symptoms of narcolepsy and leading to multiple physician visits before receiving a diagnosis, as well as misdiagnosis of narcolepsy
as another condition, such as epilepsy, depression, or ADHD, which further delays treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Current
Treatment Landscape and Treatment Limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
a cure is available, the current treatment of narcolepsy focuses on symptom control, with the goal of keeping the patient alert during
the day, primarily by improving EDS and minimizing the occurrence of cataplexy.&nbsp;More than 90% of individuals with narcolepsy require
chronic use of medication to manage symptoms, in order to allow for important everyday activities to be performed safely, such as attending
school, going to work and caring for a child.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
current available treatment options require the careful balancing of the drug&rsquo;s efficacy, convenience of administration, development
of drug tolerance, adverse effects, comorbidities, monitoring for evidence of drug abuse, and new life circumstances, such as school,
pregnancy and parenthood. In narcolepsy, several classes of drugs are used for the treatment of EDS, including a CNS depressive agent,
wake-promoting agents, a histamine 3 receptor antagonist/inverse agonist, and CII controlled stimulants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sodium
oxybate (Xyrem) is the legally manufactured form of gamma hydroxybutyrate, an illicit drug of abuse. It was the first FDA approved treatment
for cataplexy and is also approved for EDS, and as such, is often used as a first-line therapeutic. While it has been reported to have
a positive impact for patients, sodium oxybate also has many challenges with significant limitations that can often impede its use. As
a severe CNS depressant with a rapid onset of sedation with both hypnotic and amnestic effects, it is abused to incapacitate victims
for sexual assault. Sodium oxybate is a CIII controlled drug and with the potential for an adverse outcome, it is further subject to
higher CI controls for abuse and is only available through an FDA imposed restricted-access REMS program. It carries a Black Box warning
for respiratory depression and abuse, which can lead to seizures, decreased consciousness, coma and death, and at doses lower than those
used to treat narcolepsy. The occurrence of experiencing adverse effects is more common with sodium oxybate compared to other medications
used in narcolepsy and adverse effects, even at recommended doses, include nausea, confusion, CNS and respiratory depression, neuropsychiatric
depression and confusion, bed-wetting, sleepwalking, automatic behaviors, and involuntary movements. Sodium oxybate has a short half-life
and is administered in a split dose, once at bedtime and again two and a half to four hours later, which can be difficult for patients
to manage. In addition, generally, an extensive titration period is required, which can take upwards of seven months to achieve a complete
optimal response.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
patients with narcolepsy have cardiovascular risk concerns, including hypertension, and treatment with sodium oxybate contributes 1,100-1,640
milligrams, or mg, to an individual&rsquo;s daily sodium intake, in comparison to a total daily intake of 1,500 mg as recommended by
the American Heart Association. Additionally, life-style changes are also often needed when being treated with sodium oxybate, including
the avoidance of alcohol and other medications that may cause sedation and due to its profound sedation and hypotonic effects, a change
in living arrangements may be needed if living alone or the need to seek different and multiple treatment options when becoming a parent.
Yet, despite these severe limitations, Xyrem continues to be the market leader in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
Solution: Quilience for Narcolepsy - A Well-Suited Approach for the Disease Pathology</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Narcolepsy
is a debilitating neurological disorder and the currently available treatment options are not considered sufficiently effective for most
patients. This is highlighted by the results of the recent 2018&nbsp;<I>&ldquo;Know Narcolepsy Survey,&rdquo;</I>&nbsp;conducted by Versta
Research, that emphasizes the continuing and substantial burden of narcolepsy with an astonishing 88% of patients indicating that their
current treatments are not effectively managing their symptoms, while 94% and 93% stated that new treatment options are needed and expressed
frustration with current treatment options, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quilience
has a mechanism of action that is distinct from existing and emerging therapies and we believe that, if approved, Quilience may represent
a substantial improvement to existing treatments. Mazindol&rsquo;s mechanism of action, which may restore orexin signaling in the brain
and further enhance monoamine availability in promoting wakefulness and reducing cataplexy has the potential to be a breakthrough treatment
and thereby offering a significant treatment advancement. Furthermore, in November 2019, the Swiss Narcolepsy Network endorsed Quilience
as a potential novel treatment of narcolepsy. The Swiss Narcolepsy Network stated that its decision is based on several decades of highly
promising off-label use and compassionate use of mazindol in patients with narcolepsy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Quilience
Label Expansion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Following
our current focus on the development of Quilience for narcolepsy in adults, and if approved for marketing, we intend to seek a label
expansion for the treatment of narcolepsy in pediatric patients, which may require additional nonclinical and clinical studies. We are
also aiming to develop Quilience for the treatment of IH, a rare and chronic hypersomnia disorder for which there is currently no effective
or approved treatments available. Its hallmark symptom is chronic EDS and a craving to sleep during the day, regardless of how many hours
slept at night, which results in such persons taking daytime naps that are usually long and not refreshing. Individuals with IH struggle
to wake, despite setting multiple alarms and may have difficulty rising from bed, called sleep inertia. Sleep inertia also includes feelings
of grogginess upon waking and can result in impaired alertness and interfere with the ability to perform mental or physical tasks. Similar
to narcolepsy, people with IH may also suffer from hallucinations and sleep paralysis when going to bed or upon waking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
active molecule in Quilience was also prescribed under compassionate use for the treatment of IH, providing positive real-world evidence
of its benefit in improving EDS specifically in patients with IH. We plan to request orphan drug designation from both the FDA and the
European Commission during 2021 for the treatment of IH and, if granted and later approved for marketing, this designation is expected
to provide us initially with 7 years and 10 years of market exclusivity in the United States and Europe, respectively. Additionally,
we have filed an international patent application under the PCT for a proprietary CR formulation, and, if granted, may provide patent
protection through 2037 in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Quilience
Development Program</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to submit the IND to the FDA in the second quarter of 2021. We do not anticipate being required to conduct additional nonclinical
studies or studies enabling an IND, beyond those studies that were already included in our IND for ADHD with mazindol CR with further
reference to the prior FDA approval of mazindol to manage exogenous obesity. We are also planning to commence a Phase 2 randomized, double-blind,
placebo controlled clinical trial in adult patients with narcolepsy in the third quarter of 2021, subject to receiving authorization
to proceed under an IND. Our primary endpoint will be the change from baseline in daytime sleepiness, as measured by the ESS. Our key
secondary endpoint will be the change from baseline in the mean weekly number of cataplexy attacks averaged over the 4-week treatment
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to receive topline results from our Phase 2 clinical trial by the end of 2021. Once we have those results, we expect to hold an
End of Phase 2 meeting with the FDA during the first quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
our Phase 2 clinical trial is successful, we intend to commence a Phase 3 randomized, double-blind, placebo controlled, parallel study
in adult patients with narcolepsy type 1 and type 2, subject to receiving authorization to proceed into Phase 3 development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
clinical studies may be required for regulatory approval necessary to commercialize Quilience, such as clinical pharmacology studies,
and, if needed, we intend to conduct these studies in parallel with our Phase 3 program, subject to agreement with the FDA and other
applicable regulatory authorities. Assuming an End of Phase 2 Meeting with the FDA takes place in the first quarter of 2022, subject
to raising additional capital, we currently expect to commence a Phase 3 program during the second half of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
our Phase 3 study is successful, a confirmatory Phase 3 study may also be required for regulatory approval, which would then commence
following completion of the first Phase 3 study. Additional nonclinical studies may also be required for regulatory approval and we intend
to conduct these studies in parallel with our clinical program. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to submit the NDA for Quilience under Section 505(b)(2) of the FDA. This NDA pathway was created, in part, to help avoid unnecessary
duplication of studies, including nonclinical studies, already performed on an existing or previously approved drug. An NDA submitted
pursuant to Section 505(b)(2) is one that relies, at least partially, upon data that a company does not own or have a right of reference
to, including published literature. A 505(b)(2) application may also rely upon the FDA&rsquo;s finding of safety and/or efficacy of a
previously approved drug, and as such, we intend to rely, in part, on the FDA&rsquo;s previous findings of safety of the listed drug.
If successful, our nonclinical and clinical programs may potentially be streamlined and/or reduced. To license the innovator data, we
entered into an agreement with Novartis in February 2021 to obtain all pre-clinical and clinical data for studies previously conducted
on mazindol by Novartis. This data may potentially provide us another avenue to streamline and/or reduce the costs of our pre-clinical
and clinical programs. Our ability to rely on the FDA&rsquo;s previous findings of safety studies published in the scientific literature,
and the extent to which licensed innovator data may be utilized will depend on our ability to demonstrate a scientific bridge to Quilience.
We intend to meet with the FDA, and other regulatory agencies such as the EMA, to discuss about our proposed development program and
obtain further feedback and agreement on the various program elements required to support approval of Quilience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also intend to apply for entrance into an expedited development program(s) facilitated by the FDA, such as Breakthrough Therapy and/or
Fast Track designation, during 2021. The Breakthrough Therapy designation program is designed to expedite the development and review
of drugs which may demonstrate substantial improvement over available treatments, and the Fast Track designation program is designed
to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. We believe
that Quilience has the potential to meet the requirements for one or more of these programs and, if granted, one or more of these designations,
we anticipate the potential for an expedited development program to be applied in collaboration with the FDA. If we are successful in
entering into an expedited development program, this may allow Quilience to reach the market and patients sooner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Compassionate
Use Objectives in Narcolepsy in Europe</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
&ldquo;compassionate use&rdquo; originally was understood to imply that the drug product is supplied for free, there is a growing understanding
with policymakers, payers and patient organizations, that paid-for CUPs are justifiable. In Europe and other regions of the world (excluding
the United States), it is recognized that CUP funding can provide an early source of biopharma revenues and incentivize the increased
availability of potentially transformative treatments, especially for rare disorders and orphan diseases. Given the extensive therapeutic
experience with mazindol, including off-label in narcolepsy patients, we believe that there is ample precedence to justify a funded CUP
in selected European countries for a defined group of patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to conduct either or both a cohort program and a named patient program, or NPP, each of which is highlighted below in a variety
of European countries. Although we have yet to determine which countries we will initiate CUPs in first, our current plan is to target
the following countries in the following priorities (priority in each wave has yet to be determined):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Wave: Austria, Belgium, France, Italy and Switzerland;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Wave: Brazil and Latin America, the Czech Republic,
    Denmark, Spain and the United Kingdom; and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Wave: China, Germany, Japan, Sweden and Taiwan.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="image_003.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to the potential benefit of generating revenues before Quilience market authorization from the regulatory agencies, the collection
of data within the CUP is a key potential benefit for the overall Quilience evidence generation strategy, as we believe that a CUP program
for Quilience would:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complement the clinical data package for regulatory
    submissions;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">support primary regulatory approvals with longer-term
    follow up effectiveness and safety data and patient lived experience evidence;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">support label expansions in broader populations than
    included in the Quilience late state trials (e.g., in juvenile narcolepsy);</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially accelerate regulatory approval in China
    if we were to seek regulatory approval for Quilience;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enhance the evidence package for market access and
    pricing and reimbursement;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide qualitative live-experience data and information
    on the unmet needs from the patient (and caregiver) perspective that may contextualize the net therapeutic benefits offered by Quilience
    within the narcolepsy management paradigm;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bridge patients from the end of Phase 2 and 3 clinical
    trials to commercialization (assure continued patient access);</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow us to generate hypotheses for label expansions
    in broader populations (as compared to clinical trials);</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow us to leverage real-world and patient-centric
    data collected (board populations, quality of life, satisfaction); and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow us to professionally address patient and physician
    requests (formal published policy and process).</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to these potential benefits of a CUP program for Quilience, commercial objectives of such a program would include the ability
to (i) generate pre-licensing revenues in selected countries, (ii) receive post-authorization revenues in non-priority countries for
commercial use, (iii) potentially establish an early market presence with a key opinion lead, and center of excellence strategy and (iv)
more rapid revenue uptake (than a non-CUP program) upon commercial availability (patients already on product and treated).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nolazol for
the Treatment of ADHD (Follow-On Product Candidate)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nolazol
is a triple monoamine reuptake inhibitor and orexin receptor-2 partial agonist and its unique pharmacological profile is expected to
yield import benefits compared to existing treatments of ADHD. Enhancing the function of the three neurotransmitters well-known to be
implicated in ADHD, norepinephrine, dopamine and serotonin, along with its activity on the orexin-2 receptor, Nolazol may produce an
optimal reduction in ADHD symptoms over available treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nolazol
is supported by a positive pilot clinical trial with mazindol in 24 children with ADHD and a positive Phase 2 clinical trial in 85 adults
with ADHD. The Phase 2 clinical trial in adults met all primary and secondary study endpoints and was well-tolerated. A robust effect
on ADHD symptoms was demonstrated with a large placebo-adjusted effect size of 1.09 in the investigator-rated ADHD symptom scores.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
more than 25 different products have been approved by the FDA since 1937 for the treatment of ADHD, many of which are no longer available,
there still continues to be a large treatment gap with no optimal treatment currently available. Physicians, patients and their caregivers
press for improved treatment options to address key shortcomings with currently available treatments, including the need for a more tolerable
safety profile, more consistent efficacy with no rebound effect, and the need for lower risk of abuse, dependence, and misuse.&nbsp;Currently,
doctors, patients, and caregivers must choose between treatments that may be effective, but come with significant safety liabilities,
such as high potential for abuse and risk of diversion coupled with tight restrictions on writing and filling prescriptions; or treatments
that are unscheduled, but are also typically less effective. We are seeking to develop Nolazol such that, if approved for marketing,
it could be the drug product to close this treatment gap and address this unmet medical need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>ADHD Overview
and Market Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ADHD
is a chronic neurodevelopmental disorder affecting children, adolescents and adults and is characterized by an ongoing pattern of inattention
and/or hyperactivity-impulsivity and is associated with clinically significant impairments in executive functioning. In addition, ADHD
is one of the most commonly diagnosed neurodevelopmental disorders in school-age children and it often persists into adulthood. It is
characterized by symptoms of inattention and/or hyperactivity-impulsivity, and affects cognitive, academic, behavioral, emotional, and
social functioning. An estimated 8.4% of children and 5% of adults in the United States have a current diagnosis of ADHD, and if left
untreated can lead to poor occupational and psychosocial outcomes. In the United States, the research firm GlobalData has reported that
the ADHD market was worth $8.5 billion in 2018 (of which 95% was generated in the United States) and projected to reach a market value
of $14.4 billion in 2023. Furthermore, based on a report by Grand View Research, Inc., ADHD is the 12<SUP>th&nbsp;</SUP>most prevalent
therapeutic indication for dispensed prescriptions and is predicted to grow at a 6.4% compounded annual growth rate until 2030. Despite
their CII classification and black box warnings and safety liabilities, revenues of the market leader Vyvanse, as reported by Shire,
were $2.1 billion in 2017, and revenues of the leading methylphenidate product Concerta (Johnson&nbsp;&amp; Johnson) were $1.1 billion
in 2012, as reported by Johnson&nbsp;&amp; Johnson. Furthermore, based on a report from LifeSci Capital, it is estimated that CNS stimulants
&ndash; amphetamine and methylphenidate containing products, represent approximately 90% of all ADHD drug sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Across
the lifespan, ADHD may impede cognitive functioning as well as mental health and development and can have a significant social impact
on patient&rsquo;s lives, causing disruption at school, work, and in relationships and can also be associated with risk-taking or criminal
behavior and other far-reaching effects on wider society. Over the past eight years, ADHD diagnoses have increased 30% in the United
States, a trend indicating the need to focus on the diagnosis and treatment for a growing number of patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
Centers for Disease Control and Prevention, or the CDC, reported that 6.1 million, or 9.4%, of children and adolescents in the United
States have ever been diagnosed with ADHD and 5.4 million, or 8.4%, have a current diagnosis, and 62% take medication, while 47% receive
behavioral therapy and 23% receive no treatment at all. Furthermore, the CDC reported in 2019 that among children aged 2-5 only 18% are
receiving ADHD medication, in contrast to 60-70% of children aged 6-17. Additionally, ADHD is the second most impactful condition affecting
children and adolescent health in the United States, as measured by the Blue Cross Blue Shield Health Index, and children diagnosed with
ADHD struggle with paying attention, controlling impulses and being overly active. Social skills in children with ADHD often are significantly
impaired. Problems with inattention may limit opportunities to acquire social skills or to attend to social cues necessary for effective
social interaction, making it difficult to form friendships. Hyperactive and impulsive behaviors may result in peer rejection. The negative
consequences of impaired social function, such as poor self-esteem, increased risk for depression and anxiety, may be long standing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Once
believed to only affect children and adolescents, ADHD is now well understood to be a lifespan disorder that persists into adulthood
in up to 65% of patients affecting 1 out of 30 adults worldwide, as disclosed by the ADHD Institute, an educational platform developed
and funded by Takeda, and, based on our own assessments of data from the U.S. census Bureau, there are approximately 11 million adults
in the United States with ADHD. Research firm GlobalData reported that since 2015, the adult ADHD market has become larger and begun
growing at a faster rate than the pediatric ADHD market. Adult ADHD is often characterized by recurrent problems with restlessness, impulsivity,
problems with time management and finances, as well as problems regulating emotions. Rather than being hyperactive like children, adults
with ADHD report experiencing an internal sense of fidgetiness and restlessness and with signs of inattention more apparent through problems
communicating with others. Upon entering the job market, many adults also experience obstacles in employment, and are at increased risk
to be terminated due to repeated tardiness or absenteeism. Such difficulties contribute to poorer employment outcomes and a lower likelihood
of being employed in professional environments. Adults with ADHD often find it difficult to generate effective solutions to social problems
and these deficits in social cognition can increase the likelihood of peer rejection, and social isolation, adding to struggles with
depression and social anxiety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Throughout
an individual&rsquo;s lifetime, untreated ADHD can increase the risk of psychiatric disorders, educational and occupational failure,
accidents, criminality, social disability and addictions and ADHD treatment is usually initiated with stimulants, such as amphetamine
and methylphenidate-based products. While these drugs may provide a generally effective treatment option for patients, they also have
serious safety concerns and are misused recreationally with both diversion and abuse being a common and significant risk. As a result,
they are controlled substances and classified under the CSA as CII stimulants. Consequently, they all carry an FDA imposed Black Box
warning on the drug label to call attention to these serious or life-threating risks. Further, not all individuals respond optimally
to or can tolerate CII stimulants and their use is contraindicated in numerous patients, including those with tics, anxiety and other
certain psychiatric disorders, cardiovascular concerns, substance use disorder, or stimulant refusal. A few non-stimulant treatment options
are available; however, their efficacy is not as robust, and their tolerability profile is not necessarily improved when compared to
CII stimulants. In addition, the few non-stimulant treatments available are generally considered as second-line treatments and are often
used in conjunction with CII simulants rather than as a therapy that uses one type of treatment, commonly referred to as a mono-therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
availability of a treatment that has robust efficacy on par with CII stimulants and that is well tolerated with lower potential for abuse
represents what we believe is an important unmet need to persons with ADHD. The magnitude of the treatment effect demonstrated in our
Phase 2 study is comparable to what is typically seen with the leading CII stimulants, and, mazindol, the active molecule in Nolazol,
is currently a CIV controlled substance under the CSA, meaning it has an already established low risk of abuse. We believe Nolazol, whose
active ingredient is mazindol, a CIV stimulant, may be the transformative treatment for ADHD that physicians and patients have been waiting
for, by providing a treatment with what we believe will be similar efficacy as CII stimulants, but with a low potential for abuse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have a robust method of use patent for Nolazol for the treatment of ADHD expiring in August 2028 in the United States and in December
2027 in Europe. Additionally, we have filed an international patent application under the PCT, for a proprietary controlled release formulation,
and, if granted, may provide patent protection through 2037 in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Diagnostics
and Patient Sub-Types</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Healthcare
providers use the guidelines in the American Psychiatric Association&rsquo;s Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition, or DSM-5, to help diagnose ADHD and this diagnostic standard helps ensure that people are appropriately diagnosed and treated
for ADHD. The DSM-5 identifies three sub-types and each presentation is distinguished by a distinct set of symptoms that physicians use
to diagnose the condition. The three presentations are: (1) Predominantly Inattentive; (2) Predominantly Hyperactive-Impulsive; and (3)
Combined Presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
diagnostic evaluation for ADHD includes a comprehensive medical, developmental, educational, and psychosocial evaluation. This comprehensive
evaluation is necessary to confirm the presence, persistence, pervasiveness, and functional complications of core symptoms, exclude other
explanations for core symptoms and identify coexisting emotional, behavioral, and medical disorders. In order to meet criteria for ADHD,
core symptoms must also impair function in academic, social, or occupational activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Two-thirds
of individuals with ADHD have at least one other neurodevelopmental, psychiatric, or other CNS disorder, including anxiety, depression,
autism, and sleep disorders. Substance use disorder is a common comorbidity associated with ADHD and may have a direct underpinning in
the pathophysiology of the disease, amplifying the need for treatment options with a lower risk of abuse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adults
with ADHD, with a delayed diagnosis in adulthood, are often diagnosed after several attempts to find treatment for comorbid disorders,
such as depression, substance abuse, sleep disturbances, or anxiety. The presentation in adults is typically related to problems with
work, disorganization, and tendency to procrastinate, as well as anxiety, sleep disorders, and impulsivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe Nolazol could provide a transformative treatment option for all individuals with ADHD and further could draw substantial market
share from patients who have failed or couldn&rsquo;t tolerate stimulants; current patients, or their parents, with concerns with stimulant
use; current patients seeking the convenience of a CIV product compared to a CII product, allowing for generally no limitations on quantity,
the ability to refill, phone-in prescriptions, and less frequent office visits; individuals where abuse and/or diversion is a prominent
concern; and individuals or parents of individuals diagnosed with ADHD who have avoided treatment due to stimulant concerns and the associated
stigma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Current Treatment
Landscape and Treatment Limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
there is no cure for ADHD, medications may help to reduce symptoms and improve functioning. The current treatment options for ADHD can
be broadly classified as either amphetamine or methylphenidate-based stimulants or as non-stimulants. Based on data that we have collected,
we believe that stimulants represent a majority of the ADHD drug market in the United States, with a market share of approximately 90%.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amphetamine
and methylphenidate-based products are all classified under the CSA as CII stimulants, due to their high potential for abuse and the
risk of severe psychological or physical dependence. These drugs are heavily controlled under U.S. federal and state laws, and are subject
to criminal sanctions for abuse, diversion and misuse and require a CII level prescription, and despite being a chronic disorder and
need for daily medication, this limits the quantity to a 30-day supply and is also not refillable. Consequently, all CII stimulants contain
Black Box warnings, similar to narcotics such as fentanyl and oxycodone, which are also CII substances. In addition, CII stimulants have
the potential for numerous adverse effects, as indicated by their warnings of serious cardiovascular reactions such as sudden death,
stroke, and heart attack, psychotic or manic symptoms in patients with no prior history, and are associated with peripheral vasculopathy,
including Raynaud&rsquo;s phenomenon. CII stimulants are also sleep-affecting drugs and shorten total sleep time, increase the time it
takes to fall asleep, adversely impact the ability to stay asleep, and increase daytime sleepiness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
long-term use of prescription stimulants has been widely reported to cause drug tolerance, which is the loss of efficacy over time and
requires a complete change in treatment, or an increased dose of the existing treatment, or the add-on of another medication to the existing
treatment in order to achieve therapeutic effectiveness. This leads to an increased risk of developing serious adverse effects that are
unrelated to ADHD. Another concern in treating patients with CII stimulants is the potential &ldquo;rebound effect&rdquo; that occurs
when the medication wears off, resulting in the return of ADHD symptoms and which may also occur in an amplified form. In children especially,
this often triggers increased irritability and/or aggressive behavior and the rebound in children and adults may be exacerbated by multiple
drug administrations, often used to obtain the desired duration of effect or to address drug tolerance. Additionally, studies have highlighted
that primary limitations of CII stimulants are intolerable adverse effects that interfere with patient adherence rates and sub-optimal
efficacy with the onset of drug tolerance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the 2002 practice parameter for the use of stimulant medications from the American Academy of Child&nbsp;&amp; Adolescent Psychiatry,
approximately 30% of patients do not respond adequately to or have dose-limiting adverse effects with CII stimulants. Additionally, certain
patients, or parents of patients, prefer not to use CII stimulants due to their stigma and known abuse potential. There are a few non-stimulant
treatments available, such as atomoxetine (Strattera), clonidine (Kapvay), and guanfacine (Intuniv), that were developed to address this
need; however, their efficacy is sub-optimal to stimulants and while unscheduled, their overall safety profile does not necessarily provide
an improvement to CII stimulants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Strattera,
a norepinephrine reuptake inhibitor, was the first non-stimulant treatment option for ADHD and while its initial launch started strong,
underscoring the demand for an alternative to CII stimulants, sales steadily declined as patients and physicians found it to not be nearly
as effective as CII stimulants. It is now considered a second-line treatment and is typically used as an alternative to CII stimulants
for patients who have a substance abuse problem, a family member(s) with a substance abuse problem, tics, or intolerable side effects
with CII stimulants. Strattera carries a Black Box warning for increased risk of suicidal thoughts in children and adolescents and additional
warning statements for liver damage. Moreover, Strattera takes four weeks to reach initial onset of action and six to ten weeks to achieve
full clinical effectiveness, related both to the prolonged titration needed and the delay in the onset of action of the compound. Today
Strattera (branded and generic) has about 3.6% market share, despite initially climbing to nearly 20% following launch on the basis of
being an alternative to CII stimulants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clonidine
and Guanfacine are also non-stimulants that are alpha-2 adrenergic receptor agonists and were both initially approved for managing blood
pressure. They have been approved for use in children and adolescents, generally in conjunction with CII stimulants as an add-on therapy.
While they are used in children and adolescents, there is little study of their efficacy and safety in adults. As a monotherapy, they
are usually reserved for children and adolescents who respond poorly after several trials of stimulants and Strattera, have unacceptable
side effects with stimulants or Strattera, or have significant comorbid conditions limiting the treatment options to these products.
These two drugs have not had significant commercial success, with a combined peak market share of about 5%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our Solution:
Nolazol &ndash; Next-Generation ADHD Therapeutic</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe a large market opportunity exists for a non-CII stimulant, such as Nolazol, that uses mazindol controlled release as its active
ingredient; mazindol has been classified as a CIV stimulant, due to its low risk of abuse and tolerance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Given
its unique binding profile (specifically, as an OX2R agonist), in addition to its classification as a CIV stimulant, we believe Nolazol
could be transformative for the ADHD treatment landscape.&nbsp;Nolazol is a triple monoamine reuptake inhibitor and also a partial agonist
of the OX2R, which we believe is an important, unique and differentiating factor relative to other ADHD treatments. In our clinical studies
conducted to date, Nolazol has been well-tolerated and there were no treatment-related serious adverse effects or discontinuations. In
terms of abuse potential, Nolazol has an already established low risk of abuse, as previously determined by the DEA when mazindol, its
active ingredient, was scheduled as a CIV substance, underscoring the awareness and agreement that Nolazol has a lower risk of abuse
than CII stimulants. In addition, based on the current DEA classification of mazindol as a CII stimulant, we expect that Nolazol will
not have a Black Box warning, which is another important differentiator relative to both CII stimulants and the current non-stimulants
in use today to treat ADHD.<B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Phase 2 trial showed significant improvement in ADHD symptoms, met all primary and secondary study endpoints and was well-tolerated and
with no clinically significant adverse effects over placebo. In light of its innovative mechanism of action and low potential for abuse,
we believe Nolazol, if approved for marketing, could represent&nbsp;a highly differentiated alternative to the CII treatments in use
today to treat ADHD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Nolazol
Clinical Trial Results</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Phase 2 Clinical
Trial</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
completed a Phase 2 clinical trial in 2017 in the United States, in which Nolazol was well-tolerated and demonstrated statistically significant
improvement over placebo. The clinical trial met the primary and all secondary endpoints and had a robust effect on ADHD symptoms with
a large placebo-adjusted effect size of 1.09 in the investigator-rated ADHD symptom scores. We believe that the magnitude of this effect
is comparable to currently leading CII stimulants and considerably larger than the available non-stimulant treatment options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
table below summarizes the results of our Phase 2 clinical trial in adults in terms of adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="image_004.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Phase 2 clinical trial evaluated the efficacy, safety and tolerability of Nolazol in a randomized, double-blind, placebo-controlled,
multi-center, parallel trial in 85 adults with a diagnosis of ADHD. Subjects were administered Nolazol or matching placebo once a day
for six weeks, dosed flexibly (between 1mg/day and 3mg/day) during a three-week double-blind optimization period, followed by a three-week
double-blind fixed dosing period. The figure below provides an overview of the study design.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="image_005.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Efficacy
Results</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary efficacy endpoint was the change from baseline in the total ADHD-RS score at Week 6, as compared to placebo, and measured by
the clinician-administered ADHD Rating Scale with DSM-5 symptoms, or the ADHD-RS-5. ADHD-RS-5 is a standardized, &ldquo;gold standard
endpoint&rdquo; validated test for measuring severity of ADHD symptoms and assessing response to treatment. The scale is based on the
ADHD diagnostic criteria as defined in the DSM-5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary endpoint was met, showing statistically significant improvement versus placebo, in favor of Nolazol. The least square, or LS,
mean improvements in subjects&rsquo; scores from baseline were -18.9 for Nolazol and -5.7 for placebo, with a LS mean difference between
Nolazol and placebo of -13.2 (95% CI, -18.7, -7.6). The results were found to be consistent across all sensitivity analyses, establishing
that the large placebo-adjusted effect size of 1.09 was not biased by any of the statistical methods used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, Nolazol provided a significant reduction in ADHD-RS-5 scores starting as early as Week 1, which was also observed throughout
the full treatment period. After six weeks of treatment, patients treated with Nolazol demonstrated more than three times the improvement
in the ADHD-RS-5 total score symptoms as compared to placebo treated patients. The figures below summarize the results of the primary
endpoint observed in our Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="image_007.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
p-value&nbsp;is a conventional statistical method for measuring the statistical significance of experimental results. A&nbsp;p-value&nbsp;of
less than 0.05 is generally considered to represent statistical significance, meaning that there is a less than 5% likelihood that the
observed results occurred by chance.&nbsp;In the figure above and all subsequent figures where&nbsp;p-values&nbsp;are included, a&nbsp;p-value&nbsp;of
less than 0.05 is represented by &ldquo;*.&rdquo;&nbsp;P-values&nbsp;of less than 0.01 or less than 0.001 are represented by &ldquo;**&rdquo;
or &ldquo;***&rdquo; respectively, and are considered to have higher statistical significance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Secondary
efficacy endpoints included patient response to treatment, as measured by the reduction of the ADHD-RS-5 score by at least 30% and by
at least 50% from baseline, and as measured by the Clinical Global Impressions-Improvement, or CGI-I. The CGI-I is a standardized and
validated assessment used by the clinician to rate the severity of a patient&rsquo;s illness and improvement over time. There was a significant
improvement in ADHD-RS-DSM5 scores by Week 6 for Nolazol compared with the placebo. At Week 6, 70% of the Nolazol-treated patients, compared
with 21% of the placebo-treated patients, had at least a 30% reduction in their ADHD-RS-5 score (p &lt; 0.001), and 55% of the Nolazol-treated
patients, compared with 15.8% of the placebo-treated patients, had at least a 50% reduction in their ADHD-RS-5 score (p = 0.002). There
were significantly more &ldquo;responders,&rdquo; defined as a&thinsp;&ge;&thinsp;30% reduction from baseline in ADHD-RS-5 scores, present
in those receiving Nolazol compared with placebo at the first assessment point Week 1, and at each subsequent assessment. Furthermore,
there were significantly more &ldquo;excellent&rdquo; responders, defined as a&thinsp;&ge;&thinsp;50% reduction from baseline in ADHD-RS-5
score, compared with placebo present by Week 2 and at each subsequent assessment point.&nbsp;The excellent response by Week 2 was also
evident in the CGI-I analysis, which indicated significantly more CGI-I responders on Nolazol compared with placebo on Week 2 and at
each subsequent visit (p&thinsp;&le;&thinsp;0.003). The sensitivity analyses resulted in a similar magnitude of difference between Nolazol
and placebo for all responder definitions. The figure below summarizes the patient responder results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_008.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Safety
and Tolerability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nolazol
was well-tolerated and there were no deaths or serious adverse events reported and no discontinuations in the Nolazol treated group due
to adverse events or lack of efficacy. Adverse events reported were mild to moderate and the more prevalent reported events in the Nolazol
treated group, as compared to placebo, included constipation, dry mouth, nausea, fatigue, somnolence, middle insomnia and heart rate
increased. Relative to placebo, on Week 6, the Nolazol treated group had a minimal increase in diastolic and systolic blood pressure,
a small increase in heart rate, and no significant changes in electrocardiography, or ECG, parameters. There were no remarkable findings
on physical examination, hematology, serum chemistry, or urinalysis values from baseline to Week 6 between Nolazol and placebo groups.
Mean weight loss of the Nolazol group was 1.73&nbsp;kg, compared to a mean weight increase for the placebo group of 1.07&nbsp;kg.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Phase 1 Clinical
Trial</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
completed a Phase 1 randomized, open-label, cross-over clinical trial in the United States in 2016, which characterized the pharmacokinetics
and evaluated the safety and tolerability of Nolazol following a single dose in the fasted and fed state in normal healthy adult subjects.
Subjects received a single, fixed dose of Nolazol under fasted conditions in one dosing period and the same single, fixed dose 30 minutes
prior to a high-fat breakfast in another dosing period. Nolazol demonstrated a predictable, dose-dependent, and linear pharmacokinetics
profile. This study is intended to serve as the basis of our Phase 3 clinical trials, if any, by providing a preliminary understanding
of the concentration-time profile of Nolazol under the fed and fasted conditions.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Food
administered 30 minutes after administration of Nolazol resulted in similar exposure and a slightly lower peak concentration compared
to administration in the fasted state, while the time to reach the peak concentration was similar in the fasted and fed states. These
results suggest that our Phase 3 trials will not need to include dosing restrictions in terms of meal timing relative to dose administration,
which is an important feature for increased compliance in ADHD patients. A definitive food-effect study with the final formulation of
Nolazol will be conducted during the Phase 3 program. The figure below shows the pharmacokinetic curve of Nolazol under the fed and fasted
conditions utilized in this clinical trial.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nolazol
was well-tolerated and there were no deaths, serious adverse events or withdrawals due to adverse events. Adverse events were reported
in 30% of the Nolazol-treated subjects and included dizziness and somnolence and there were no clinically significant changes in laboratory
values, ECG, blood pressure, or heart rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Phase 2 Pediatric
Clinical Trial</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
Phase 2 open-label pilot study in France was conducted in 2015 by Eric Konofal, one of our founders and Interim Chief Scientific Officer,
and others while at AP-HP. This study evaluated the efficacy, safety, and tolerability of mazindol in 24 children, aged 9 &ndash; 12
years, and diagnosed with ADHD. All enrolled patents had a low rate of response to methylphenidate, which is a first-line treatment in
children with ADHD. All patients received the same fixed dose of mazindol daily for seven days, followed by a three-week drug-free safety
observation period. The mean change from baseline in the parent rated and clinician rated ADHD-RS-IV total score after 7 days of treatment
was -24.1, with &gt;90% improvement in ADHD symptoms from baseline (p&lt;0.0001), pointing to a viable long-acting treatment option,
assuming it is shown to be safe, as determined by applicable regulatory agencies. Additionally, the mean change in the parent rated and
clinician rated ADHD-RS-IV total score from end of treatment (Week 1) to the final observation visit (Week 4) demonstrated statistical
significance (p&lt;0.0001), indicating significant alteration in the level of symptomology of ADHD after mazindol withdrawal. The figure
below summarizes the results of the primary endpoint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; margin-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_010.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mazindol
was well tolerated in children with ADHD. Adverse events included decreased appetite, headache and abdominal pain and there were no clinically
significant changes in laboratory values, ECG, blood pressure, heart rate, or body weight. This clinical trial provided proof-of concept
data, potential benefit, and supported the advancement into a more expansive Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Phase 3
Development Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Having
successfully met both the primary and secondary endpoints in our initial Phase 2 trial, we plan to further the development of Nolazol
as a follow-on candidate to support filing for marketing and commercialization approval initially in adults in the United States, followed
by children and adolescents. We intend to have an End of Phase 2 meeting with the FDA no earlier than the fourth quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
first Phase 3 clinical trial is planned to evaluate doses of Nolazol in approximately 260 adults with ADHD, with subjects randomized
to receive Nolazol or placebo for 6 weeks. The primary endpoint will be the change from baseline in the ADHD-RS-5 score, which was the
primary endpoint in our Phase 2 trial. Our second Phase 3 clinical trial is planned to evaluate doses of Nolazol in children and adolescents,
with an embedded placebo-controlled sub-study in a laboratory classroom setting for the children age group. A laboratory classroom study
provides a simulation of a real academic environment, including the potential for interaction and distraction among children, and allows
for assessment by trained observers over the course of a typical extended school day. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Given
our stage of development, we do not currently have an established internal sales, marketing or distribution infrastructure. If our product
candidates are approved for marketing, we intend to commercialize our product candidates either alone or in partnership with others,
where appropriate, to maximize the value of our product candidates. We expect to build our commercial infrastructure using a focused
and efficient approach, initially, establishing market access, sales and marketing capabilities in a targeted manner that is appropriate
for the relevant product opportunity. We believe that this approach will allow us to effectively reach patients and physicians and to
maximize the commercial potential of our product candidates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our Development
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to our product candidates, Quilience and Nolazol, we have early and mid-stage compounds that we may seek to further develop
in the future. We may seek to develop these other compounds, comprising of NCEs, as well as repurposed compounds, in order to build a
pipeline of product candidates at various stages of development that further complement our rare hypersomnia and complex neurodevelopmental
disorder franchises. Additionally, we intend to continue to invest in our discovery research and development programs, with the goal
of adding what we believe to be promising new compounds and indications to our product candidate development pipeline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11pt 0 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
goal is to continue building a differentiated, global biopharmaceutical company that is patient-focused in the development of transformative
therapies that address critical unmet needs in rare and complex CNS and neurodevelopmental disorders, such as narcolepsy and ADHD. As
we navigate the competitive landscape of our industry, while focusing on development of our product candidates, we also intend to continually
seek out-licensing and asset sale transactions that we believe will allow us to drive greater value for our shareholders. The key elements
of our business strategy are to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">globally develop Quilience for narcolepsy in adults
    (lead project);</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue new indications beyond narcolepsy (e.g., Nolazol
    in ADHD) (follow-on projects); and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">explore expansion of our growing product pipeline either
    through in-house innovation or in-licensing.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>License
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Pegasus
Advanced Research SAS License Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2015, Pegasus Advanced Research, then named NeuroLife Sciences SAS, or Pegasus, a company owned by certain of our founders,
who are also shareholders, including Eric Konofal, Eric-Jean Desbois, Bruno Figadere and our Chief Executive Officer, Alexander Zwyer,
or the Pegasus Founders, entered into a license agreement with AP-HP, or the AP-HP License Agreement, to obtain a worldwide, sub-licensable
license, covering four different compounds, which included the use of mazindol for the treatment of ADHD, or the Licensed Compounds.
As part of the AP-HP License Agreement, Pegasus was given an option to purchase the Licensed Compounds. In February 2016, after the AP-HP
License Agreement was assigned and transferred to NLS-1, pursuant to an Assignment and Transfer Agreement, or the ATA, NLS-1 purchased
the Licensed Compounds from AP-HP for an aggregate consideration of approximately 2.65 million euros, including reimbursement of certain
expenses. On April 1, 2017 and September 20, 2019, the parties entered into subsequent amendments of the ATA, or the First Amendment
to the ATA and the Second Amendment to the ATA, respectively. Under the Second Amendment to the ATA, NLS agreed to pay Pegasus a royalty
of 1.8% of annual net sales (including sublicensee sales) realized upon the commercialization of products developed on the basis of the
Licensed Compounds during the terms of their respective patents; provided, however, that under certain circumstances, the rate of the
royalty payment will decrease. For instance, if a competing generic product using mazindol for the treatment of ADHD were to become available
during the term of the patents covering the Licensed Compounds, there would be no royalties paid to Pegasus.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exclusive
License Agreement with Eurofarma</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2019, we entered into the EF License Agreement. The EF License Agreement provides Eurofarma with an exclusive, fee-bearing,
non-transferrable (i) distribution right to distribute Nolazol in Latin America and an (ii) exclusive, fee-bearing, non-transferrable
license to our patents and trademarks in connection with the commercialization, if any, of Nolazol in Latin America. The EF License Agreement
is in effect until the later of either (i) ten years from the date of its execution, or until February 2029, or (ii) until the expiration
of the last valid patent relating to Nolazol, subject to early termination under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the EF License Agreement, we are responsible for obtaining regulatory approval to market and commercialize Nolazol in
the United States and Eurofarma shall be responsible for obtaining regulatory approval in South America; provided, however, that Eurofarma
shall inform us of any additional information that regulators in Latin America may require in order to seek marketing authorization which
otherwise may not be required by the FDA, or the Supplemental U.S. Data. Although pursuant to the EF License Agreement we will undertake
the efforts to generate the Supplemental U.S. Data, the parties have agreed to share the costs associated with generating such data.
Eurofarma will be responsible for seeking and covering the costs relating to obtaining the required regulatory approvals in Latin America
and, once approved on a country-by-country basis, for commercializing Nolazol in Latin America. Furthermore, the marketing approvals
obtained in Latin America, if any, shall be owned by Eurofarma until the end of the term of the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the execution of the EF License Agreement, Eurofarma paid us $2.5 million. In accordance with the EF License Agreement, we are eligible
to receive milestone payments as well as royalties from Eurofarma, which consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Clinical
Milestones&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    successful completion by us of Phase 3 clinical trials for the treatment of ADHD in adults in the United States</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    successful completion by us of Phase 3 clinical trials for the treatment of ADHD in children in the United States</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regulatory
Milestones</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    price approval of the licensed product in Brazil by the relevant agency</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    receipt of marketing approval by the relevant agency of the licensed product in any other country in Latin America</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sales
Milestones (single payments)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon reaching
    annual net sales of $10 million</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon reaching annual net sales
    of $50 million</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,000,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon reaching annual net sales
    of $75 million</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,000,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon reaching annual net sales
    of $100 million</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Royalties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual
    net sales in Latin America</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Royalties
    in percent of Net Sales</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under $10 million</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$10 million to less than $20
    million</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$20 million to less than $30
    million</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$30 million and above</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have developed a robust patent portfolio in the United States, Europe, and other major countries (e.g., Canada, Australia, China, Japan,
Latin America countries). Our patent portfolio for Quilience and Nolazol currently includes issued patents in the United States and Europe
covering the use of mazindol for treatment of ADHD and patent applications filed in major countries to protect our proprietary controlled
release formulation (Notice of Allowance recently received for Europe and Canada) for treatment of ADHD and narcolepsy. One of our patents
in the United States covering the use of mazindol for the treatment of ADHD received patent term adjustment, thereby extending the patent
term of such patent to August 2028. Our patent covering mazindol controlled release, if issued, will expire in March 2037.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table provides a description of our key patents and patent applications and is not intended to represent an assessment of claims,
limitations or scope of those patents listed. In some cases, a jurisdiction is listed as both pending and granted for a single patent
family. This is due to pending continuation or divisional applications of the granted case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 33%; border-bottom: black 1.5pt solid; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Name and Application Number</FONT></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="width: 13%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">Jurisdictions</FONT></FONT></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="width: 13%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted/Allowed</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">Jurisdictions</FONT></FONT></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="width: 22%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazindol combination in
    the treatment of ADHD</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">PCT/EP2007/053512</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">China</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">United States</FONT><BR>
    <FONT STYLE="font-size: 10pt">Europe</FONT><BR>
    <FONT STYLE="font-size: 10pt">Canada</FONT><BR>
    <FONT STYLE="font-size: 10pt">Australia&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 10pt">Israel</FONT><BR>
    <FONT STYLE="font-size: 10pt">New Zealand</FONT><BR>
    <FONT STYLE="font-size: 10pt">Morocco</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    11, 2027</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">(August 22, 2028 for a U.S. patent receiving patent term adjustment of 499 days)</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of use</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lauflumide and the enantiomers
    thereof, method for preparing same and therapeutic uses thereof</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">PCT/EP2012/050881</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">United States</FONT><BR>
    <FONT STYLE="font-size: 10pt">Europe</FONT><BR>
    <FONT STYLE="font-size: 10pt">Canada</FONT><BR>
    <FONT STYLE="font-size: 10pt">Israel</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    20, 2032</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of use (United States),
    compound</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <BR>
    <BR>
    <BR>
    <FONT STYLE="font-size: 10pt">(ex-US)</FONT><BR>
    <FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phacetoperane for the
    treatment of ADHD</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">PCT/FR2012/052749</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">United States</FONT><BR>
    <FONT STYLE="font-size: 10pt">Europe</FONT><BR>
    <FONT STYLE="font-size: 10pt">Japan</FONT><BR>
    <FONT STYLE="font-size: 10pt">China</FONT><BR>
    <FONT STYLE="font-size: 10pt">Israel</FONT><BR>
    <FONT STYLE="font-size: 10pt">Canada</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    29, 2032 </FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of use</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A mazindol ir/sr multilayer
    tablet and its use for the treatment of ADHD*</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">PCT/IB2017/000352</FONT><BR>
    <FONT STYLE="font-size: 10pt">&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 10pt">*includes narcolepsy and IH</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">Australia</FONT><BR>
    <FONT STYLE="font-size: 10pt">Brazil</FONT><BR>
    <FONT STYLE="font-size: 10pt">China</FONT><BR>
    <FONT STYLE="font-size: 10pt">Israel</FONT><BR>
    <FONT STYLE="font-size: 10pt">Japan</FONT><BR>
    <FONT STYLE="font-size: 10pt">South Korea</FONT><BR>
    <FONT STYLE="font-size: 10pt">Mexico</FONT><BR>
    <FONT STYLE="font-size: 10pt">New Zealand</FONT><BR>
    <FONT STYLE="font-size: 10pt">Hong Kong&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 10pt">Morocco</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">Europe&nbsp;</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    8, 2037</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulation</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazindol treatment for
    heroin dependence and substance use disorder PCT/IB2018/001138</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">Europe </FONT><BR>
    <FONT STYLE="font-size: 10pt">Canada </FONT><BR>
    <FONT STYLE="font-size: 10pt">Brazil</FONT><BR>
    <FONT STYLE="font-size: 10pt">China </FONT><BR>
    <FONT STYLE="font-size: 10pt">Japan </FONT><BR>
    <FONT STYLE="font-size: 10pt">South Korea</FONT><BR>
    <FONT STYLE="font-size: 10pt">Mexico</FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    Applicable </FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    6, 2038</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of use</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, on March 10, 2021, we entered into a License Agreement with Novartis Pharma AG or Novartis, whereby we obtained, on an exclusive
basis in the U.S., all <FONT STYLE="color: #1D2228; background-color: white">of the available data referred to and included in the original
NDA for Sanorex&reg; (mazindol) submitted to the FDA in&nbsp;February 1972. The agreement encompasses all preclinical and clinical studies,
data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation data and know-how for
all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety reports from 1973
onwards. Under the Agreement, we have obtained the same rights on a non-exclusive basis in all territories outside of the U.S, except
for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed territories. The Agreement
includes the right to sublicense or assign the license to third parties, subject to such third parties meeting certain obligations. As
consideration for the license, we agreed to pay Novartis $250,000 upon the signing of the agreement with milestone payments due as follows:
(i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies
must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of </FONT>Quilience or Nolazol; (iii) 1% of any
upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon our product candidate reaching
$250 million in cumulative sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to our patents and patent applications, we also rely on unpatented trade secrets, know-how, and continuing technological innovation
to develop and maintain our competitive position. We seek to protect our ownership of know-how and trade secrets through an active program
of legal mechanism including invention assignments, confidentiality agreements, material transfer agreements, research collaborations
and licenses to protect our product candidates. For a more comprehensive discussion of the risks related to our intellectual property,
please see Item 3.D. &ldquo;Risk Factors &mdash; Risks Related to Our Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Competition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition. While we believe
that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many
different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental
agencies and public and private research institutions, which may in the future develop products to treat those diseases that we currently
or, in the future, seek to treat. Any product candidates that we successfully develop and commercialize may compete with existing therapies
and new therapies that may become available in the future.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
of our competitors have far greater marketing and research capabilities than us. All of these companies and institutions may have product
candidates in development that are or may become superior to Quilience and Nolazol. Our commercial opportunity would be reduced significantly
if our competitors develop and commercialize products that are safer, more effective, more convenient, have fewer side effects or are
less expensive than either or both of Quilience or Nolazol. Public announcements regarding the development of competing drugs could adversely
affect the commercial potential of either or both of Quilience and Nolazol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Narcolepsy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
face competition from established pharmaceutical and biotechnology companies that currently market products for the treatment of symptoms
in narcolepsy. There is no cure and many patients report that their medicines do not improve their complete range of symptoms. For the
treatment of both EDS and cataplexy, we believe that currently our only competitor is Jazz Pharmaceuticals plc (Xyrem). Although only
indicated for EDS, our competitors also include Novartis Ltd. (Ritalin), Teva Pharmaceutical Industries Ltd. (Modafinil/Armodafinil (Provigil/Nuvigil),
Jazz Pharmaceuticals plc (Xyrem, Xywav and Sunosi), and Harmony Biosciences LLC (Wakix) as well as amphetamines, such as Adderall and
Dexedrine. Other early to mid-stage stage compounds currently under development include TAK-925 and TAK-994 (Takeda Pharmaceutical Company
Ltd.) and Inexia/Orexia (Sosei Group Corp.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
below table highlights the limitations of certain drug products approved for use in the United States by the FDA for treatment of EDS
or cataplexy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    </B></FONT></td>
    <td style="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cataplexy
    Approval</B></FONT></td>
    <td style="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    of </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>Abuse</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Diversion </B></FONT></FONT></td>
    <td style="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td colspan="3" style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-top: 3.6pt; padding-right: 7.2pt; padding-left: 7.2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
    </B></FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amphetamines</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(Adderall, Dexedrine)</B></FONT></FONT></td>
    <td style="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></td>
    <td style="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High: CII</FONT></td>
    <td style="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 25%; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&ldquo;Grandfathered&rdquo;
    approval only (pre-1938 indication) for Immediate Release (IR)</FONT></td>
    <td style="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top; width: 31%; padding-top: 3.6pt; padding-bottom: 3.6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Tolerance
        and rebound hypersomnolence</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Short-acting</FONT></P></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Methylphenidate</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(Ritalin)</B></FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High: CII</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&ldquo;Grandfathered&rdquo;
    approval only (pre-1938 drug) for IR</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top; padding-top: 3.6pt; padding-bottom: 3.6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Tolerance
        and rebound hypersomnolence</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Short-acting</FONT></P></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Solriamfetol</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(Sunosi)</B></FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low: CIV</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;Efficacy
    for controlling cataplexy not available</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;Risk
    for drug induced high-blood pressure that can go undetected</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modafinil
    /</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>Armodafinil</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>(Provigil/Nuvigil)</B></FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low: CIV</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 3.6pt; padding-bottom: 3.6pt; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Potential
        for serious rash, including Stevens-Johnson syndrome</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 14pt; text-indent: -14pt; background-color: white; border-left-width: 0pt; border-left-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Cases
        of major fetal congenital malformations</FONT></P></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;Substrate,
    inducer, and inhibitor of CYP450 isoenzymes, which significantly increases the risks for drug-drug interactions</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pitolisant</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(Wakix, Bioprojet)</B></FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not determined</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-top: 3.6pt; padding-bottom: 3.6pt; padding-left: 14pt; text-indent: -14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;Pitolisant
    may reduce efficacy of oral contraceptives, and so alternative methods of contraception should be utilized</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-top: 3.6pt; padding-bottom: 3.6pt; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Unclear
        efficacy; partially failed Phase 3 program</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Data
        suggests it&rsquo;s only effective in 1/3 of patients</FONT></P></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top; padding-bottom: 3.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sodium
    oxybate</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>(Xyrem)</B></FONT></FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High: CIII,&nbsp;CI penalties
    for diversion </FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 3.6pt; padding-bottom: 3.6pt; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Very
        short acting; requiring two nighttime doses</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Not
        effective against EDS, so used in combination with stimulants or modafinil</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Because
        of the risks of depression, abuse, and misuse, Xyrem is available only through a restricted distribution program called the Xyrem
        REMS Program</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Potential
        life-threatening adverse effects</FONT></P></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: top; padding-top: 3.6pt; padding-bottom: 3.6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Can
        take up to 3+ months for response</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Known
        as the &ldquo;date rape drug&rdquo;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-indent: -14pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&nbsp;&nbsp;&nbsp;Xyrem
        is a CIII controlled substance as sodium salt of gamma hydroxybutyrate (GHB), a Schedule I controlled substance. Abuse or misuse
        of illicit GHB is associated with CNS adverse reactions (acting as a CNS depressant), including seizures, respiratory depression,
        decreased consciousness, coma, and death</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>ADHD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
face competition from established pharmaceutical and biotechnology companies that currently market a range of CII stimulants to treat
ADHD. Our primary competitors include Takeda Pharmaceutical Company Ltd. (Vyvanse, Adderall and Mydayis), Neos Therapeutics Ltd. (Adzenys
XR-ODT and Contempla XR-ODT), Eli Lilly&nbsp;&amp; Co. (Strattera), Novartis AG (Focalin) and Janssen Pharmaceutica N.V., a subsidiary
of Johnson&nbsp;&amp; Johnson (Concerta).&nbsp;The below table provides a more in-depth breakdown of Nolazol against certain competing
pharmaceutical products, based on the current scheduling of mazindol by the DEA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<IMG SRC="image_011.jpg" ALT=""></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are conducting research and development activities to expand the commercial potential of both Quilience and Nolazol, while continuing
to examine the development of compounds that could serve as effective treatments for other CNS disorders. We sponsor and conduct clinical
research activities with investigators and institutions to measure key clinical outcomes that are necessary in order for us to be able
to file an NDA with the FDA and equivalent filings with other regulatory authorities. Our research and development efforts are focused
primarily in the following areas and serve as a basis for future development, if any, of a more diverse product pipeline, of which certain
product candidate leads are in early development stages. As <FONT STYLE="background-color: white">we navigate the competitive landscape
of our industry, while focusing on development of our product candidates, we also intend to continually pursue out-licensing agreements
and asset sale transactions that we believe will allow us to drive greater value for our shareholders. Key elements of our business strategy
include the following:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>Efficiently
        advance our lead product candidate, Quilience, and follow-on product candidate, Nolazol, through marketing approval.</I></B>&nbsp;We
        plan to first advance the development of Quilience, followed by the development of Nolazol. If successful, we plan to initially
        file for marketing approval in the United States and the EU for Quilience and subsequently in the United States for Nolazol.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Find partners for out-licensing and asset sale
    agreements.</I></B>&nbsp;While we continue with our goal of progressing our product candidates, Quilience and Nolazol, on our own
    into further clinical development in order to initiate commercialization of such product candidates, we may seek to enter into transactions
    to sell or out-license Quilience, Nolazol or certain other product candidates or intellectual property that we develop. This strategy
    allows us to potentially create value for our shareholders ahead of our timelines.</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>Reduce
        clinical and regulatory risk, limit development costs, and accelerate time to market.</I></B>&nbsp;Our product candidates, Quilience
        and Nolazol, incorporate a known molecule in a proprietary CR formulation. The former immediate release formulation of mazindol
        has a well-established safety record from its long history of clinical use across the United States and several countries in
        Europe and, as a result thereof, a well-characterized safety profile that has allowed us to rapidly begin conducting clinical
        development of Nolazol and to generate supportive phase 2 data in a study conducted in 85 patients with ADHD in the United States
        in May 2017. We believe that this strategy also allows us to potentially seek FDA approval using the 505(b)(2) regulatory pathway</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;for
        both product candidates<FONT STYLE="background-color: white">.&nbsp;&nbsp;</FONT></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></td></tr>
<tr style="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Develop products with differentiated pharmacological
    profiles</I></B>.&nbsp;We are developing product candidates with dual mechanisms of action. For example, Quilience and Nolazol utilize
    a dual mechanism of action, resulting in a unique pharmacological profile targeting multiple neuronal pathways that are widely thought
    to be disrupted and lead to the disorders targeted by our product candidates. We believe that products with clearly differentiated
    features, as compared to currently available drug therapies, will be attractive to patients and physicians and will provide us with
    a competitive commercial advantage.</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</table>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>Maximize
        the therapeutic potential of our existing targets and product candidates.&nbsp;</I></B>Given the central physiological roles
        played by the distinct targets of our lead and follow-on product candidates, we believe that there is significant potential for
        us to address multiple indications and our goal is to expand the therapeutic and commercial potential of our existing product
        candidates to additional indications. For example, we would plan to explore the development of Quilience for the treatment of
        IH, another rare CNS disorder for which Quilience may receive an orphan drug designation by the relevant regulatory bodies.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></td></tr>
<tr style="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Deploy our value-driven approach to broaden our
    product portfolio.&nbsp;</I></B>Our team has extensive experience in CNS research and a strong record of publication in peer-reviewed
    journals and we plan to develop additional product candidates to treat indications with a high unmet medical need, and may seek to
    in-license from or collaborate with third parties to develop product candidates that we believe are highly differentiated, promising
    therapeutic candidates that address major unmet clinical needs. Our scientifically rigorous approach to evaluating new opportunities
    includes a robust asset evaluation of key factors, including the unmet medical need, biological rationale, safety profile, as determined
    by applicable regulatory agencies, feasibility of clinical development, potential for accelerated development path, regulatory approval,
    intellectual property position, competitive landscape and commercial potential.</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</table>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Manufacturing
and Suppliers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not own or operate manufacturing or distribution facilities for the production of our product candidates and we currently rely, and
expect to continue to rely, on third parties for the manufacturing, packaging, labeling and distribution of our product candidates for
pre-clinical and clinical testing, as well as for future commercial manufacturing, if our product candidates receive marketing approval.
We require all of our contract manufacturing organizations to conduct manufacturing activities in compliance with cGMP requirements and
although we rely on manufacturers, we have engaged with consultants with significant technical, manufacturing, analytical, quality, regulatory,
including cGMP, and project management experience to oversee our third-party manufacturers. This approach allows us to maintain a more
efficient infrastructure while enabling us to focus our expertise on developing and commercializing our product candidates. Reliance
on third-party providers may expose us to more risk than if we were to manufacture product candidates ourselves.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, we entered into an agreement with Cambrex High Point for the production of our drug substance, pursuant to which, upon
completion of purchase orders, Cambrex High Point may manufacture mazindol for us. We obtain our supply of the finalized drug product
from another third-party manufacturer, CoreRx, Inc. with whom we signed an agreement in February 2021. We do not currently have any contracts
binding us to use supply or production services provided for under such agreements. We expect to continue to rely on third-party manufacturers
to produce sufficient quantities of our product candidates and their component raw materials for use in our internal research efforts
and clinical trials and in relation to any future commercialization of our product candidates. Our third-party manufacturers are responsible
for obtaining the raw materials necessary to manufacture our product candidates, which we believe are readily available from more than
one source. Additional third-party manufacturers are and will be used to formulate, fill, label, package and distribute investigational
drug products and eventually our products, if and when our product candidates receive approval. This approach allows us to maintain a
more efficient infrastructure while enabling us to focus our expertise on developing and commercializing our product candidates. We believe
that our current supplier and manufacturers have the capacity to support both clinical supply and commercial-scale production, but we
do not have any formal agreements at this time for such supply and production, and we may also elect to enter into agreements with additional
or alternative parties in the future.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sales
and Marketing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Given
our stage of development, we do not currently have an established internal sales, marketing or distribution infrastructure. If our product
candidates are approved for marketing, we intend to commercialize our product candidates either alone or in partnership with others,
where appropriate, to maximize the value of our product candidates. We expect to build our commercial infrastructure using a focused
and efficient approach, initially, establishing market access, sales and marketing capabilities in a targeted manner that is appropriate
for the relevant product opportunity. We believe that this approach will allow us to effectively reach patients and physicians and to
maximize the commercial potential of our product candidates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2019, we entered into the EF License Agreement with Eurofarma, a Brazilian pharmaceutical company with a presence in 20 Latin
American countries, to develop and commercialize our product candidate, Nolazol, in Latin American countries. Eurofarma operates in the
areas of medical prescription, over-the-counter, generic, hospital, bids, oncology, veterinary and services for third parties&rsquo;
segments. In Brazil, their portfolio is composed of more than 330 brands, with around 1,000 presentations covering 28 medical specialties
and 48 therapeutic classes. See &ldquo;License Agreements - Exclusive License Agreement with Eurofarma&rdquo; above for additional information.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>C.</B></FONT></td>
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organizational Structure</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a Swiss stock corporation organized under the laws of Switzerland. Our Swiss enterprise identification number is CHE-447.067.367.
Our registered and principal executive offices are located at Alter Postplatz 2, 6370 Stans, NW, Switzerland, our general telephone number
is (41) 41 618 80 00 and our internet address is www.nlspharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
did not have any subsidiaries as of December 31, 2020. <FONT STYLE="background-color: white">In April 2021, we formed a wholly owned
subsidiary, NLS Pharmaceutics Inc., a Delaware corporation.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>D.</B></FONT></td>
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property, Plant and
    Equipment</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Our
principal executive office is located at Alter Postplatz 2, 6370 Stans, NW, Switzerland, and consists of approximately 25 square meters
(approximately 270 square feet) of leased office space under an indefinite term lease that may be terminated by either party with six-months
prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
consider that our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the
conduct of our business; provided, however, that we may require additional space and facilities as our business expands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>ITEM
    4A.</B></FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNRESOLVED STAFF COMMENTS</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>ITEM
    5.</B></FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPERATING AND FINANCIAL
    REVIEW AND PROSPECTS </B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in
this annual report. This discussion and other parts of this annual report contain forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated
in these forward-looking statements as a result of several factors, including those set forth under Item 3.D. &ldquo;Risk Factors&rdquo;
and elsewhere in this annual report.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare
and complex CNS disorders, which have unmet medical needs. Our lead compound mazindol, in a proprietary CR formulation, is being developed
for the treatment of narcolepsy (lead indication) and ADHD (follow-on indication), and is a triple monoamine reuptake inhibitor and partial
orexin receptor 2 agonist. We believe that this dual mechanism of action will also give mazindol CR the potential for therapeutic benefit
in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and
substance use disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
to our initial public offering in the United States, we primarily financed our operations through the proceeds from our private placements
of debt and equity securities, an upfront payment from our collaboration partner and a Swiss Government COVID-19 loan. We have no products
approved for commercialization and have never generated any revenue from product sales. Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. It may be several years, if ever, before we complete pivotal clinical
studies and have a product candidate approved for commercialization and we begin to generate revenues and royalties from product sales.
We have also incurred significant operating losses. For the fiscal year ended December 31, 2020, we have an accumulated deficit of $29.8
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
February 2, 2021, we </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">completed the closing of our initial public offering
of 4,819,277 units at a price of $4.15 per unit, raising $17 million in net proceeds. Each unit consisted of one common share and one
Warrant to purchase one common share, or the Warrants. The common shares and Warrants were immediately separable from the units and were
issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021 under the symbols &ldquo;NLSP&rdquo;
and &ldquo;NLSPW,&rdquo; respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
financial statements have been presented on the basis that we are a going concern, which contemplates the realization of revenues and
the satisfaction of liabilities in the normal course of business. We have incurred losses from the inception of our operations. These
factors raise substantial doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, to date, we have had limited financial and accounting personnel, which has resulted in a limited segregation of duties to fully
execute our accounting and financial reporting processes to maintain effective internal control over financial reporting. <FONT STYLE="background-color: white">Additionally,
we identified a material weakness related to our lack of sufficient and competent financial reporting and accounting personnel with appropriate
knowledge and experience with technical accounting in accordance with U.S. GAAP and to prepare and review financial statements and related
disclosures in accordance with U.S. GAAP and SEC reporting requirements. </FONT>We have begun to take steps to remediate these material
weaknesses and strengthen our internal control over financial reporting in the upcoming year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Components
of Operating Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Licensing
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2019, we entered into the EF License Agreement to develop and commercialize our product candidate, Nolazol, in Latin American
countries with Eurofarma. The EF License Agreement covers the grant of non-transferable licenses, without the right to sublicense, to
Eurofarma to develop and commercialize Nolazol in Latin America. The EF License Agreement also specifies our obligation to advance development
activities with respect to Nolazol in the United States. A joint steering committee will oversee the development and regulatory activities
directed towards marketing approval, manufacturing and commercialization phases. We believe that our participation in the joint steering
committee is not of material significance to the licenses in the context of the EF License Agreement on the whole and, as such, management
has excluded these activities in the determination of its performance obligation(s) under the EF License Agreement. The EF License Agreement
also provides that the parties shall enter into a separate manufacturing and supply agreement during the term of the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the EF License Agreement, we received a non-refundable, upfront payment, of $2,500,000 and are further eligible to receive non-refundable
milestone payments of up to $16,000,000, based on the achievement of milestones related to regulatory filings, regulatory approvals and
the commercialization of Nolazol. The achievement and timing of the milestones depend on the success of development, approval and sales
progress, if any, of Nolazol in the future. In addition, we are also eligible for tiered royalty payments.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amounts
expected to be recognized as revenues within the 12 months following the balance sheet date are classified as a current portion of deferred
revenues in the balance sheets in our financial statements included elsewhere in this annual report. Amounts not expected to be recognized
as revenue within the 12 months following the balance sheet date are classified as deferred revenues, net of current portion. As of December
31, 2020, we have long-term deferred revenues of $2,500,000, which will be recognized when the development services of Nolazol are completed
and the product candidate receives applicable regulatory approval in Latin America that allows Eurofarma to commence commercialization
of Nolazol in accordance with the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.A </B></FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>Operating
    Results</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Critical
Accounting Policies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
describe our significant accounting policies more fully in Note 2 to our financial statements included elsewhere in this annual report.
We believe that the accounting policies described below and in Note 2 to our financial statements are critical in order to fully understand
and evaluate our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
prepare our financial statements in accordance with U.S. GAAP. At the time of the preparation of the financial statements, our management
is required to use estimates, evaluations, and assumptions which affect the application of the accounting policy and the amounts reported
for assets, obligations, income, and expenses. Any estimates and assumptions are continually reviewed. The changes to the accounting
estimates are credited during the period in which the change to the estimate is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Revenue
Recognition </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, we have not recognized any revenue from the EF License Agreement as the upfront payment we received has been deferred.
The EF License Agreement provides for the development and commercialization of our product candidate, Nolazol, in Latin American countries
with Eurofarma. The EF License Agreement is within the scope of Accounting Standards Codification, or ASC, 606, &ldquo;Revenue from Contract
with Customers,&rdquo; or ASC 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will
collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer
to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services
are integral or dependent to other goods or services in the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.
The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable
consideration, we evaluate the amount of potential payments and the likelihood that the payments will be received. We utilize either
the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts
the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained
and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative
revenue recognized will not occur in a future period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
allocate the transaction price based on the estimated stand-alone selling price of each of the performance obligations. We must develop
assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract
with a customer. We utilize key assumptions to determine the stand-alone selling price for service obligations, which may include other
comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the
stand-alone selling price for material rights, we may reference comparable transactions, clinical trial success probabilities, and develop
estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more performance obligations
in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting
amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, we utilize judgment to assess the nature of the combined
performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if
over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary,
adjusts the measure of performance and related revenue recognition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within our control or the licensee&rsquo;s control, such as regulatory
approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, we
re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license revenues
in the period of adjustment. To date, we have not recognized any consideration related to the achievement of development, regulatory,
or commercial milestone revenue resulting from the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related
sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied). To date, we have not recognized any consideration related to sales-based royalty revenue resulting from any of our license
agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
the extent we receive payments, including non-refundable payments, in excess of the recognized revenue such excess is recorded as deferred
revenue until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration
is unconditional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Pension
Obligations </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have a single insurance collective pension plan that is fully insured and operated by an insurance company which covers the employee.
Both we and the participants provide monthly contributions to the pension plan that are based on the covered salary. A portion of the
pension contribution is credited to employees&rsquo; savings accounts which earns interest at the rate provided in the plan. The pension
plan provides for retirement benefits as well as benefits on long-term disability and death. The pension plan qualifies as a defined
benefit plan in accordance with U.S. GAAP. As such, the cost of the defined pension arrangement is determined based on actuarial valuations.
An actuarial valuation assumes the estimation of discount rates, estimated returns on assets, future salary increases, mortality figures
and future pension increases. Because of the long-term nature of these pension plans, the valuation of these is subject to uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Income
Taxation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
incur tax loss carryforwards generating deferred tax assets against which a valuation allowance is recorded when it is not more likely
than not that the tax benefit can be realized. Significant judgment is required in determining the use of tax loss carryforwards. Management&rsquo;s
current judgment is that it is not more likely than not that the tax benefits can be realized and a full valuation allowance is therefore
recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Operating
Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
current operating expenses consist of two components &ndash; research and development expenses and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Comparative
figures in operating expenses for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification
error of intellectual property expenses between research and development expenses and general and administrative expenses. For further
information, see Note 3 &ldquo;Restatement of Previously Issued Financial Statements&rdquo; to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development Expenses, net</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses are expensed as incurred and consist primarily of, costs of third-party clinical consultants who conduct
clinical and pre-clinical trials on our behalf and expenses related to lab supplies, materials and facility costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
trial costs are a component of research and development expenses. We accrue and expense clinical trial activities performed by third
parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical
sites. We determine the actual costs through monitoring patient enrollment and discussions with internal personnel and external service
providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
investment in research and development activities, including the clinical development of our product candidates has historically been
and is projected to be substantially the majority of our total annual operating costs. Research and development expenses represent costs
incurred to conduct research, such as the development of our product candidates, as well as discovery and development of new product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect that our research and development expenses will materially increase in the future as we enter into the Phase 2/3 clinical development
stage of our product candidates and initiate a number of new research initiatives that are complementary to our existing and planned
research initiatives and thereby recruit additional research and development employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
and Administrative Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Finance
Result, net </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
expenses include exchange rate differences and financial expenses related to our credit card fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
expense relates to interest paid for our financing obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Taxation
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
Pharmaceutics is subject to corporate Swiss federal, cantonal and communal taxation in Canton of Nidwalden, Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are entitled under Swiss laws to carry forward any losses incurred for a period of seven years and can offset our losses carried forward
against future taxes. As of December 31, 2020, we had tax loss carryforwards totaling $15.5 million. There is no certainty that we will
make sufficient profits to be able to utilize these tax loss carryforwards in full. As such, we have recorded a 100% valuation on these
tax loss carryforwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
effective corporate income tax rate (federal, cantonal and communal) where we are domiciled is currently 12%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the corporate income tax, the corporate capital is taxed at a rate of 0.1% (cantonal and communal tax only, as there is no federal tax
on capital).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Value
Added Tax, or VAT, is charged on all qualifying goods and services by VAT-registered businesses. An amount of 7.7% of the value of the
goods or services is added to all sales invoices and is payable to the Swiss tax authorities. Similarly, VAT paid on purchase invoices
is reclaimable from the Swiss tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
numbers below have been derived from our audited financial statements included elsewhere herein. The discussion below should be read
along with these financial statements and it is qualified in its entirety by reference to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Comparison
of the Year Ended December 31, 2020 to the Year Ended December 31, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019<BR>
    (as restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,580</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative
    expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,199,790</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,299,251</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,299,370</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,197,039</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expense), net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(328,365</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(65,446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(86,792</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(992</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest on related party loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,908</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(818,719</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss on conversion of
    debt</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(364,950</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,861,435</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Comparative
figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification error of intellectual
property expenses between research and development expenses and general and administrative expenses. For further information, see Note
3 &ldquo;Restatement of Previously Issued Financial Statements&rdquo; to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development activities are essential to our business and historically represented the majority of our costs incurred, except for
2020 where we paused certain research and development activities. Costs for certain development activities, such as clinical trials,
are recognized based on an evaluation of the progress to completion of specific tasks using information from the clinical sites and our
vendors. In addition to these arrangements, we expect that our total future research and development costs will increase over current
levels in line with strategy to progress the development of our product candidates, as well as discovery and development of new product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses during the years ended December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
    the Year Ended<BR> December 31,</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2020</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2019<BR>
    (as restated)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Development materials and expenses</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,580</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567,123</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Subcontractors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,890</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54,775</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,580</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses totaled $99,580 for the year ended December 31, 2020, representing a decrease of $798,208, or 89%,
compared to $897,788 for the year ended December 31, 2019. The decrease was primarily attributable the Company postponing all nonessential
research and development expenses and other consultants&rsquo; expense, until after the completion of our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
and Administrative Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
general and administrative expenses totaled $2,199,790 for the year ended December 31, 2020, representing a decrease of $1,099,461, or
33%, compared to $3,299,251 for the year ended December 31, 2019. The decrease was primarily attributable to the Company postponing all
nonessential business activities until after the completion of our initial public offering. The prior year period included additional
costs for consulting and legal costs relating to (i) the Reorganization, (ii) conversion of credit facilities, shareholder loans and
conversion of the Convertible Note to equity, as described below, (iii) increased marketing and communication expenses and (iv) intellectual
property expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Operating
Loss </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss totaled $2,299,370 for the year ended December 31, 2020, representing a decrease of $1,897,669,
or 45%, compared to $4,197,039 for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Other
Expense </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
expense consists of exchange rate differences and financial expenses related to our credit card fees. We recognized other expense of
$328,365 for the year ended December 31, 2020, representing an increase of $262,919, or 402%, compared to $65,445 for the year ended
December 31, 2019. The increase was primarily attributable to exchange rate differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interest
Expense </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
expense consists of interest and imputed interest expenses on the Convertible Loans (as defined below). Interest expense was $86,792,
including $48,088 of imputed interest, for the year ended December 31, 2020 representing an increase of $85,800, or 99%, compared to
income of $992, including $172 of imputed interest, for the year ended December 31, 2019. The increase was due to the interest accrued
relating to seven Convertible Loans entered into subsequent to the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interest
on Related Party Loans </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
on related party loans was $146,908, including $24,100 of imputed interest, for the year ended December 31, 2020, representing a decrease
of $671,811, or 82%, compared to $818,719, including $754,734 of imputed interest, for the year ended December 31, 2019. The decrease
was mainly due to the amortization of imputed interest in full for the debts that were converted to equity during the year ended December
31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Loss
on Conversion of Debt </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
loss on conversion on debt occurred for the year ended December 31, 2020. The loss on conversion of debt of $364,950 for the year ended
December 31, 2019 was a result of the conversion of credit facilities, a shareholder bridge loan and four promissory notes with an aggregate
principal amount of $7,658,250 in exchange for 580,000 common shares with a fair value of $14.00 per share and an aggregate fair value
of $8,023,200.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Net
Loss </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our net loss totaled $2,861,435 for the year ended December 31, 2020, representing a decrease of $2,585,710,
or 47%, compared to $5,347,145 for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Comparison
of the Year Ended December 31, 2019 to the Year Ended December 31, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Results
of Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,455</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative
    expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,299,251</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,740,406</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,197,039</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,448,861</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest and other financing income (expense),
    net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(66,437</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,035</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest on related party loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(818,719</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,084,708</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss on conversion of
    debt</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(364,950</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(629,232</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,146,766</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Comparative
figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification error of intellectual
property expenses between research and development expenses and general and administrative expenses. For further information, see Note
3 &ldquo;Restatement of Previously Issued Financial Statements&rdquo; to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses consist primarily of costs of third-party clinical consultants and expenses related to conducting clinical
and pre-clinical trials and other research and development expenses. We expect that our research and development expenses will materially
increase as we enter into the Phase 2/3 clinical development stage of our product candidates and recruit additional research and development
employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table discloses the breakdown of research and development expenses for the years ended December 31, 2019 and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Development materials and expenses</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567,123</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">324,097</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Subcontractors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,890</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">301,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54,775</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">82,969</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,455</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses totaled $897,788 for the year ended December 31, 2019, representing an increase of $189,333, or 27%,
compared to $708,455 for the year ended December 31, 2018. The increase was primarily attributable to an increase in development material
and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
general and administrative expenses totaled $3,299,251 for the year ended December 31, 2019, representing an increase of $558,845, or
20%, compared to $2,740,406 for the year ended December 31, 2018. The increase was primarily attributable to an increase in consulting
and legal costs relating to (i) the Reorganization, (ii) conversion of the credit facilities, shareholder loans and the Convertible Note
to equity, as described below, (iii) increased marketing and communication expenses and (iv) intellectual property expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Operating
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss totaled $4,197,039 for the year ended December 31, 2019, representing an increase of $748,178,
or 21%, compared to $3,448,861 for the year ended December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interest
and Other Financing Income</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
and other financing income consists of exchange rate differences and financial expenses related to our credit card fees. We recognized
interest and other financing expenses of $66,437 for the year ended December 31, 2019, representing an increase of $82,472, or 514%,
compared to income of $16,035 for the year ended December 31, 2018. The increase was primarily attributable to exchange rate differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interest
on Related Party Loans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
on related party loans was $818,719, including $754,734 of imputed interest, for the year ended December 31, 2019, representing a decrease
of $265,989, or 25%, compared to $1,084,708, including $1,090,412 of imputed interest, for the year ended December 31, 2018. The decrease
was mainly due to the amortization of imputed interest using the effective interest rate method on debt that was converted in the year
ended December 31, 2018. The decrease was offset, in part, by an increase of promissory notes, namely, the Notes, during the year ended
December 31, 2018 and the Convertible Loans entered into during the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Loss
on Conversion of Debt</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
loss on conversion of debt of $364,950 for the year ended December 31, 2019 was a result of the conversion of credit facilities, a shareholder
bridge loan and four promissory notes with an aggregate principal amount of $7,658,250 in exchange for 580,000 common shares with a fair
value of $14.00 per share and an aggregate fair value of $8,023,200. The loss on conversion of debt of $629,232 for the year ended December
31, 2018 was a result of the conversion of credit facilities with an aggregate principal amount of $3,418,520 in exchange for 260,000
common shares with a fair value of $16.00 per share and an aggregate fair value of $4,047,752.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Net
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our loss totaled $5,447,145 for the year ended December 31, 2019, representing an increase of $300,379, or
6%, compared to $5,146,766 for the year ended December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_018"></A>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
our inception through December 31, 2020, we have funded our operations principally with $20.7 million from the sales of our common shares,
convertible instruments, related party credit facilities and shareholder loans, Swiss government loan and the EF License Agreement. As
of December 31, 2020, we had $93,711 in cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
table below summarizes our cash flows for the years ended December 31, 2020, 2019 and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    used in operating activities</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(729,386</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(190,009</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,732,804</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">503,522</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">407,479</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">557,920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of exchange rate
    changes on cash and cash equivalents</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,308</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,881</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,369</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    (decrease) increase in cash and cash equivalents</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(126,556</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">213,589</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,176,253</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Operating
Activities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities of $729,386 during the year ended December 31, 2020, was primarily related to $500,000 for clinical
trials and other third-party expenses, including consulting and legal expenses, and an aggregate of $200,000 in salary and consultant
expenses. Net cash used in operating activities of $190,009 during the year ended December 31, 2019, was primarily related to $1,700,000
for clinical trials and other third-party expenses, including consulting and legal expenses, and an aggregate of $1,000,000 in salary
and consultant expenses. These expenses were offset by the receipt of the $2,500,000 upfront payment related to the EF License Agreement.
The remaining amount was for legal, administrative and other miscellaneous expenses. Net cash used in operating activities of $2,732,804
during the year ended December 31, 2018, was primarily related to $400,000 for clinical trials and other third-party expenses and an
aggregate of $1,400,000 in salary and consultant expenses. The remaining amount was for legal, administrative and other miscellaneous
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Financing
Activities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities in the year ended December 31, 2020, consisted of $362,436 of net proceeds from the issuance of
the Convertible Loans, including one with a related party for $113,130, $262,137 of net proceeds from the Swiss government loan and $565,650
in net proceeds from the issuance of a bridge loan, offset in part, by $686,701 of deferred offering costs relating to our initial public
offering. Net cash provided by financing activities in the year ended December 31, 2019, consisted of $512,800 of net proceeds from the
issuance of the Notes (as hereinafter defined) and $154,890 of net proceeds of Convertible Loans, offset, in part, by $260,211 of deferred
offering costs relating to our initial public offering. Net cash provided by financing activities in the year ended December 31, 2018,
consisted of $557,920 of net proceeds from issuance of a certain convertible promissory note for CHF 550,000 (approximately $557,920)
that we entered into in January 2019, and as amended thereafter or the Convertible Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2019, we issued four promissory notes, or the Notes, each for CHF 125,000 (approximately $128,200), with certain of our shareholders.
Each Note carries an interest rate of 10% per year, compounded annually and originally matured as of the earlier of (i) April 30, 2019
and (ii) five days following such time as we have received aggregate financing, in a sole or series of transactions, exceeding CHF 500,000
(approximately $565,650) in the form of straight equity or convertible instrument investments or other means of proceeds from third parties.
Pursuant to amendments to each of the Notes, the maturity dates were extended to March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2015, NLS Pharma Ltd. and NLS-1 Ltd., and in March 2017, NLS-0 Ltd., each entered into credit facilities providing the Company
with credit lines of $150,000 (non-interest bearing), $7.1 million ($500,000 of which bears interest at an annual rate of 10%, or the
Interest-Bearing Facility) and approximately $3.44 million (non-interest bearing), respectively, or the NLS Pharma Credit Facility, the
NLS-1 Credit Facility and the NLS-0 Credit Facility, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2017, we entered into a certain interest-free $2 million bridge loan, or the 2017 Bridge Loan, with the Shareholders. On March
12, 2019, simultaneously with the closing of the Reorganization, we issued an aggregate of 260,000 of our common shares to certain shareholders,
specifically <FONT STYLE="background-color: white">Messrs. Hafner, Bauer, Stein and &Ouml;dman, or the Shareholders</FONT>, in exchange
for the consideration of the conversion of the entire Bridge Loan and the entire borrowed amount of $1.45 million under the NLS-0 Credit
Facility, at a conversion price of $13.00 per common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 12, 2019, we conducted the Reorganization. In connection therewith, in addition to those 260,000 common shares issued in connection
with the 2017 Bridge Loan and the NLS-0 Credit Facility, we issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate
                                            of 280,000 of our common shares to the Shareholders, in connection with the conversion of
                                            the remaining $3,681,481 borrowed by us pursuant to the Credit Facility, at a conversion
                                            price of $13.00 per common share;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate
                                            of 40,000 of our common shares to Magnetic Rock Investment AG, or Magnetic Rock, a company
                                            that is controlled by the Shareholders, in connection with the conversion of the CHF 526,979.84
                                            (approximately $526,769) Convertible Note at a conversion price of CHF 13 (approximately
                                            $13.00) per common share; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate
                                            of 745,000 of our common shares to those holders of NLS-0 and NLS Pharma common shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 16, 2019, we and the Shareholders amended the NLS Pharma Credit Facility to extend the maturity date to December 31, 2019.
If we default on the NLS Pharma Credit Facility, we will be subject to a default interest rate of 5% per year. The Interest-Bearing Facility
stopped accruing interest upon the Reorganization and the accrued interest stands at $85,737. The NLS-1 Credit Facility was amended to
extend the maturity date covering the Interest-Bearing Facility to March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 23, 2019 and in February, March and June 2020, we entered into certain convertible loans, one of which was with our Chief Executive
Officer, in the aggregate amount of CHF 475,822 (approximately $501,358), or the Convertible Loans, in the aggregate amount of CHF 475,822
(approximately $517,326). Each Convertible Loan carried an interest rate of 10% per year, compounded annually and matured between June
30, 2020 and January 31, 2022, unless converted into common shares or repaid by us prior to then. During October 2020, we amended two
Convertible Loans entered into during December 2019, in the aggregate amount of CHF 210,000 ($237,573), such that our optional early
repayment date of the Convertible Loans was delayed by six months, or the Convertible Loan Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 26, 2020, in response to the COVID-19 pandemic, we applied for and thereafter received a COVID-19 loan, or the COVID-19 Loan, from
our bank for CHF 248,400 ($262,137), with 0% interest and a term of 60 months. We drew down the entire amount available to us under the
COVID-19 Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2020, and as subsequently amended, we entered into a certain bridge loan, or the 2020 Bridge Loan, which provided for up to CHF
600,000 ($633,180). In August 2020, we received the first tranche of CHF 300,000 ($339,390) pursuant to the 2020 Bridge Loan and received
the second tranche of CHF 200,000 ($226,260) in September 2020. In January 2021, we amended the 2020 Bridge Loan to an aggregate amount
of CHF 600,000 and received the remaining portion of the loan. The borrowed amounts under this 2020 Bridge Loan carried an interest rate
of 10% per year, compounded annually, and all borrowed sums, including interest, were scheduled to mature on March 31, 2021; provided,
however, that we could repay such loan, including interest, prior to the scheduled maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
February 2, 2021, we </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">completed the closing of our initial public offering
of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one Warrant to purchase one common share.
The common shares and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began
trading on the Nasdaq Capital Market on January 29, 2021 under the symbols &ldquo;NLSP&rdquo; and &ldquo;NLSPW,&rdquo; respectively.
We received net proceeds of $17 million, after deducting underwriting discounts and commissions and other estimated offering expenses.
The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share.
In addition, we granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase
722,891 common shares, of which the underwriters exercised the option to purchase warrants to purchase up to 722,891 shares of common
shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, we repaid all outstanding loans and notes in full, including accrued interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Current
Outlook</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have financed our operations to date primarily through proceeds from sales of our common shares, convertible instruments, related party
credit facilities and shareholder loans, the COVID-19 Loan and the EF License Agreement. In February 2021, we completed the closing of
our initial public offering raising $17 million in net proceeds. We have incurred losses and generated negative cash flows from operations
since inception in 2015. To date we have not generated revenues, and we do not expect to generate any significant revenue from the sale
of our product candidates in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to generate losses for the foreseeable future, and these losses could increase as we continue product development until we successfully
achieve regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all the risks
pertinent to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public company and we
anticipate that we will need substantial additional funding in connection with our continuing operations. If we need to raise additional
capital to fund our operations and complete our ongoing and planned clinical studies, funding may not be available to us on acceptable
terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, our cash and cash equivalents were $0.1 million. We believe that our existing cash and cash equivalents, including
the net proceeds of $17 million from our initial public offering, will be sufficient to fund our projected operating requirements into
the second quarter of 2022. These conditions raise substantial doubt about our ability to continue as a going concern for one year from
the issuance of these financial statements<FONT STYLE="background-color: white">. Additionally, </FONT>our operating plans may change
as a result of many factors that may currently be unknown to us including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            length of the COVID-19 pandemic and its impact on our planned clinical trials, operations
                                            and financial condition;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            progress and costs of our pre-clinical studies, clinical trials and other research and development
                                            activities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            scope, prioritization and number of our clinical trials and other research and development
                                            programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            cost that we may incur under in- and out-licensing arrangements relating to our product candidate
                                            that we may enter into in the future;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            costs and timing of obtaining regulatory approval for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            costs of filing, prosecuting, enforcing and defending patent claims and other intellectual
                                            property rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            costs of, and timing for, strengthening our manufacturing agreements for production of sufficient
                                            clinical and commercial quantities of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            potential costs of contracting with third parties to provide marketing and distribution services
                                            for us or for building such capacities internally; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            costs of acquiring or undertaking the development and commercialization efforts for additional,
                                            future therapeutic applications of our product candidates and the magnitude of our general
                                            and administrative expenses.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result, we may require additional capital to finance expenditures related to the manufacture of our product candidates for use in clinical
trials, conducting clinical trials and general and administration costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents
and short-term deposits, including the remaining net proceeds from our initial public offering, loans, debt or equity financings, or
by out-licensing applications of our product candidates. We cannot be certain that additional funding will be available to us on acceptable
terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development
plans for, or commercialization efforts with respect to, one or more applications of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><A NAME="a_019"></A>Off-Balance
Sheet Arrangements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for standard operating leases, we have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries,
structured finance, special purpose entities or variable interest entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect
on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><A NAME="a_020"></A>Quantitative
and Qualitative Disclosure About Market Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-. Accordingly, a substantial majority of our cash and cash equivalents is
held in deposits that bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates
are reduced. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail in the following
paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Foreign
Currency Exchange Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. As discussed above,
the vast majority of our liquid assets is held in USD, and a certain portion of our expenses are denominated in CHF. For instance, during
the year ended December 31, 2020, approximately 62% of our expenses were denominated in CHF. Changes of 5% and 10% in the USD/CHF exchange
rate would have increased/decreased our operating expenses by 2% and 4%, respectively. However, these historical figures may not be indicative
of future exposure, as we expect that the percentage of our CHF denominated expenses will materially decrease in the near future, therefore
reducing our exposure to exchange rate fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may
not adequately protect us from the material adverse effects of such fluctuations.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>JOBS
Act Accounting Election</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until
such time as those standards apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or
revised accounting standards, and, therefore, will not be subject to the same new or revised accounting standards as public companies
that are not EGCs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM&nbsp;6.</B></FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_021"></A>DIRECTORS,
    SENIOR MANAGEMENT AND EMPLOYEES </B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A</B>.</FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_022"></A>Directors
    and Senior Management </B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth information regarding our directors and senior management and directors as of May 14, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Age</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial
    Year of<BR> Appointment</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald Hafner<SUP>(1)(3)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman and Director</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alexander Zwyer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer and Director</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myoung-Ok Kwon<SUP>(1)(2)(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">50</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stig L&oslash;kke Pedersen<SUP>(2)(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">59</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Management <BR></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alexander Zwyer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Silvia Panigone</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Operating Officer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subhasis Roy</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interim Chief Financial Officer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eric Konofal</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interim Chief Scientific Officer</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herv&eacute; Girsault<SUP>(4)</SUP>&#9;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">61</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Head of Business Development</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carlos Camozzi</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">68</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interim Medical Director</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of Compensation, Nomination&nbsp;&amp; Governance
    Committee</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as defined under Nasdaq Stock
    Market rules)</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We provided notice of the termination of the consulting
    agreement with Mr. Girsault, which will formally terminate on June 30, 2021, pursuant to which he provides his services as Head of
    Business Development. We are actively in discussions with Mr. Girsault on continuing his engagement with us in his current role.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, members of our board of directors are elected by our shareholders and elected to serve for a one-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ronald
Hafner, Chairman of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Ronald
Hafner </I><FONT STYLE="background-color: white">has been a member of our board and served as Chairman of the Board of Directors since
August 2015. Mr. Hafner has been a partner at Deloitte Consulting AG since January 2016 and since 2018 he has served as the chairman
of Magnetic Rock, a private investment company. From 2015 to 2016, Mr. Hafner served as an independent director of the Pingar Group Ltd.,
a private company developing artificial intelligence software solutions. Prior to serving in these capacities, Mr. Hafner served as the
Chief Executive Officer of Infosys Consulting AG. Prior to Lodestone Management Consultants AG&rsquo;s acquisition by Infosys Ltd. in
2012, Mr. Hafner was Chief Executive Officer and partner of Lodestone Management Consultants AG, where he was responsible for the company&rsquo;s
global operations since founding the business in 2005. Mr. Hafner has an M.B.A. and master&rsquo;s degree in economics from the University
of Basel/Switzerland.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Alexander
Zwyer, Chief Executive Officer and Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Alexander
Zwyer </I><FONT STYLE="background-color: white">has served as our Chief Executive Officer and as a Director since our incorporation in
August 2015. Mr. Zwyer has over 25 years of international business experience. In 2007, prior to, and until founding NLS in 2015, Mr.
Zwyer founded a startup in the high-end luxury food sector and served as its chief executive officer until 2015 when he successfully
sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor
(International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company&rsquo;s global
regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently.
Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute
of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Myoung-Ok
Kwon, Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Myoung-Ok
Kwon, Ph.D.</I> <FONT STYLE="background-color: white">became a member of our board of directors in January 2021. Ms. Kwon has 16 years
of experience in the healthcare venture capital and public investments and pharma research fields. Ms. Kwon is Head of Healthcare Investment
at PMG Investment Solutions AG, or PMG, and Asset Manager of the PMG Global Biotech Fund. From 2004 to 2007, Ms. Kwon worked at Novartis
AG as a Senior Research Planner and Scientific Assistant to the Head of Corporate Research. After leaving Novartis AG in 2007, she joined
the Zurich-based venture capital fund Nextech Invest as Managing Partner. She led the investment team from 2007-2012 and made 10 biotech
investments in the United States and Europe. Her Board of Directors and observer representation included Sunesis Pharmaceuticals, Inc.
(Nasdaq: SNSS) (USA) (as an observer) from 2009 to 2012, MacroGenics Inc. (USA) (as an observer) From 2008 to 2012, TRACON Pharmaceuticals,
Inc. (Nasdaq: MGNX) (USA) from 2011 to 2012, Telormedix SA (Switzerland) (as an observer) from 2008 to 2012, ImVisioN Therapeutics AG
(Germany) from 2007 to 2012. She has been a venture partner of Arcus Ventures, a New York-based venture capital fund, since 2014. She
is also the founder of Julier Partners, a healthcare consulting firm active since 2013 and built up the Biotech Core Value Fund, a Liechtenstein-based
fund, as an investment advisor from 2014-2019. She holds a Ph.D. in biochemistry and molecular genetics from the University of Basel
and the Friedrich Miescher Institute, which is part of the Novartis Research Foundation.&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stig
L&oslash;kke Pedersen, Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Stig
Lokke Pedersen </I><FONT STYLE="background-color: white">became a member of our board of directors in January 2021. Mr. Pedersen has
over 35 years of business experience, having held numerous</FONT> executive positions and board positions over such period of time. Since
2012, Mr. Pedersen has been a member of the investment board in the Danish private equity fund Catacap A/S and from 2001 to 2011, Mr.
Pedersen served as a member of the executive management team at H. Lundbeck A/S (Denmark) (Nasdaq Copenhagen: LUN), one of Denmark&rsquo;s
largest public companies and a prominent, global CNS specialist pharmaceutical company. During his time as Chief Commercial Officer at
H. Lundbeck A/S (Denmark), Mr. Pedersen was responsible for all business activities in the group, including operations in more than 60
countries worldwide, a turnover of $3 billion and around 4,500 employees. In addition, Mr. Pedersen has served on numerous boards since
1992, including Chairman of the board of directors of Nuevolution AB (Nasdaq Sweden: NUE) from 2001 to 2019 and Chairman of the board
of directors of ChemoMetec A/S (Nasdaq Copenhagen: CHEMM) from 2009 to 2013. In addition, Mr. Pedersen currently sits on the board of
directors of nine other companies, including the life science companies Stemform A/S, SSI Diagnostika A/S, TAP A/S, Moksha8 Ltd., Union
Therapeutics A/S and Index Pharmaceuticals AB. Mr. Pedersen earned his MSc. (Econ.) from Aalborg University in Denmark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Silvia
Panigone, Ph.D., Chief Operating Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Silvia
Panigone, Ph.D.</I> <FONT STYLE="background-color: white">was appointed as our Chief Operating Officer in April 2021. Ms. Panigone combines
a profound understanding of corporate finance and private investments with a deep knowledge of drug development research and development
processes. Ms. Panigone founded in September 2013, and currently serves as Managing Director of, ADYA Consulting Sagl, a Swiss investment
boutique in the life sciences sector that focuses on value extraction, development and implementation of strategic plans, deal structuring,
capital raising and M&amp;A transactions across the globe. From 2013 until 2018, Ms. Panigone served as a coach for life sciences companies
though The Commission for Technology and Innovation, a body operating under the Swiss Confederation. Also, from 2013 and until January
2016, Ms. Panigone spent time as Managing Director, Europe and a team member in the United States for I-Bankers Direct LLC and I-Bankers
Securities, Inc. Ms. Panigone possesses a Molecular Biology degree from University of Milan (Italy), a Ph.D. in Molecular Oncology from
National Cancer Institute, Milan in collaboration program with the Open University, London and a Master in Finance - Management of Economical
Resources from SDA Bocconi, Milan, Italy.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subhasis
Roy, MBA, Interim Chief Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Subhasis
Roy, MBA</I> <FONT STYLE="background-color: white">was appointed as our Interim Chief Financial Officer in April 2021. Mr. Roy has o</FONT>ver
25 years of healthcare industry experience as a healthcare banker/advisor and more recently as a biopharmaceutical company leader. From
April 2018 until January 2021, Mr. Roy was Chief Executive Officer and Chief Operating Officer of Novaremed, a clinical stage Swiss pain
therapeutics company. From May 2009 to March 2018, Mr. Roy was Managing Partner and co-founder of Sirius Healthcare Partners, a healthcare
advisory boutique providing advice and transaction support to emerging healthcare companies. Prior to Sirius, Mr. Roy was a healthcare
banker at bulge bracket Investments Banks (UBS, HSBC, DKB), where he advised mid-large cap healthcare companies and executed numerous
financing and M&amp;A transactions. Mr. Roy holds an M.B.A. in Finance and General Management from Fuqua School of Business at Duke University,
USA and a Masters&rsquo; degree in Commerce from University of Mumbai, India.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Eric
Konofal, MD, Ph.D., Interim Chief Scientific Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Eric
Konofal, MD, Ph.D.</I> was appointed as our Interim Chief Scientific Officer in February 2021. Dr. Konofal is an IP expert and co-founder
of NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 27 years in the field of sleep research, including narcolepsy and
hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal serves as a senior medical consultant
for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debr&eacute; Hospital (APHP). Dr.
Konofal received his medical doctorate and Ph.D. from the University Pierre&ndash;Marie Curie, Paris / France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Herv&eacute;
Girsault, MBA, Head of Business Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Herv&eacute;
Girsault, MBA</I> <FONT STYLE="background-color: white">has served since December 2017 as our Head of Business Development and previously
served as our business development advisor from September 2016 until December 2017. Mr. Girsault has over 20 years of experience in the
healthcare industry, serving in a variety of senior positions, including Chief Executive Officer of Synarc Inc. in the United States
(now BioClinica Inc.), of Novartis Benelux and of Gerber France SA in France, and as head of mergers&nbsp;&amp; acquisitions, business
development&nbsp;&amp; partnering for global companies, such as Novartis International AG and Novartis Consumer Health (also serving
as its Chief Executive Officer), a division of Novartis AG, and as manager of mergers&nbsp;&amp; acquisitions of the healthcare practice
at Coopers&nbsp;&amp; Lybrand Consultants. Prior to joining us, from 2013, Mr. Girsault served as the Chief Business officer of Piqur
Therapeutics AG. Mr. Girsault co-founded TUROS Capital AG in 2018, and currently sits on its board of directors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carlos
Camozzi, MD, Ph.D., Interim Medical Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Carlos
Camozzi, MD, Ph.D. </I>was appointed as our Interim Medical Director in March 2021. Dr. Camozzi is an experienced Chief Medical Officer
in the biopharmaceuticals field with over 30 years of C-level expertise and experience in orphan drugs and other areas. From September
2017 until October 2020, Dr. Camozzi served as acting Chief Medical Officer and Head of the Bioelesonic business unit of Syndermix AG.
Prior to that, between January 2016 and October 2017, Dr. Camozzi served as Chief Medical Officer of Simbec-Orien Group. Previously,
Dr. Camozzi acted as Chief Medical Officer of Orphazyme, uniQure and Orphan Europe and served as Scientific Strategy Director of Basel
University Hospital and had managerial positions at Mepha and Roche. Dr. Camozzi received his medical doctorate and PhD from the National
University of Buenos Aires, Argentina.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Family
Relationships</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no family relationships among any of our senior management and our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Arrangements
for Election of Directors and Members of Management</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our senior management
or our directors were selected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B</B>.</FONT></td>
    <td style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_023"></A>Compensation</B></FONT></td>
    </tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table presents in the aggregate all compensation we paid to all of our directors and senior management as a group for the year
ended December 31, 2020. The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing
us with services during this period. Pursuant to Swiss law, we are not required to provide the compensation, on an individual basis,
of our senior management and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
amounts reported in the table below reflect the cost to the Company, in thousands of U.S. dollars, for the year ended December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary,<BR>
    Bonuses<BR> and<BR> Related<BR> Benefits</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension,<BR>
    Retirement<BR> and Other<BR> Similar<BR> Benefits</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share<BR>
    Based<BR> Compensation</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    directors and senior management as a group, consisting of 7 persons <SUP>(1) (2)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">869,109</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,052</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts include $671,723
    of deferred salary, bonus and related benefits and $19,795 of deferred pension, retirement and other similar benefits that have were
    paid in February 2021. </FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts do not include
    $30,162 in interest owed to our Chief Executive Officer. See &ldquo;&ndash;Employment and Service Agreements with Senior Management&rdquo;
    below and &ldquo;Related Party Transactions&rdquo; for additional information. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Employment
Agreements with Senior Management</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into a written employment agreement with our Chief Executive Officer. Our other senior management were not engaged as full-time
employees as of December 31, 2020. Pursuant to the consulting agreement with our Head of Business Development, he received a 1% fee tied
to the net proceeds of our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, our Chief Executive Officer and other senior management agreed to defer the receipt of payment of a portion or all of their
respective compensation until we raise sufficient capital, including through an initial public offering. In addition, pursuant to an
agreement between us and our Chief Executive Officer, compensation that was due and outstanding to him, accrued interest at a rate of
10% per year and was repaid to him in full in February 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
the initial public offering, we entered into consulting or employment agreements with other suitable candidates. All of these agreements
contained provisions regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability
of the noncompetition provisions may be limited under applicable law and, our assignment of inventions agreements with our senior management
contain terms and conditions customary under Swiss law. In addition, our senior management are subject to our directors&rsquo; and officers&rsquo;
liability insurance policy, which we obtained prior to the initial public offering. Members of our senior management are eligible for
bonuses each year. The bonuses will be payable upon meeting objectives and targets that are set annually by our board of directors and
compensation and governance committee, and, in certain circumstances, upon approval by our shareholders.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C.</B></FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_024"></A>Board Practices </B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board
of Directors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is composed of four directors. Each director is elected for a one-year term. Messrs. Hafner and Zwyer were appointed
at the annual shareholders&rsquo; meeting held on October 20, 2020 to serve until the 2021 shareholders&rsquo; meeting to be held in
June 2021. Mr. Brenneisen was appointed in September 2020 and resigned in February 2021. Ms. Kwon and Mr. L&oslash;kke Pedersen were
appointed to the board of directors in January 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Nasdaq Listing Rule 5615(b)(1), a company listing in connection with its initial public offering is permitted to phase in its compliance
with the independent committee requirements and the committee composition requirements. Accordingly, a company listing in connection
with its initial public offering shall be permitted to phase in its compliance with the committee composition requirements set forth
in Nasdaq Listing Rule 5605(d)(2) and (e)(1)(B) as follows: (1) one member must satisfy the requirement at the time of listing; (2) a
majority of members must satisfy the requirement within 90 days of listing; and (3) all members must satisfy the requirement within one
year of listing. We intend to rely on the phase-in schedules set forth in the aforementioned Nasdaq Listing Rule with respect to the
composition of our audit committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
board of directors has established two standing committees, the audit committee, and the compensation, nomination and governance committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the Nasdaq Stock Market rules, we are required to maintain an audit committee consisting of at least three members, all of whom are independent
and are financially literate and one of whom has accounting or related financial management expertise. We intend to phase-in our compliance
with this requirement in accordance with Nasdaq Listing Rule 5615(b)(1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
audit committee currently consists of Myoung-Ok Kwon and Stig L&oslash;kke Pedersen, each of whom meets the requirements for financial
literacy under the Nasdaq Stock Market rules. Ms. Kwon serves as the Chairman of the audit committee and our board of directors has determined
that Ms. Kwon is an &ldquo;audit committee financial expert&rdquo; as defined by the SEC rules and has the requisite financial experience
as defined by the Nasdaq Listing Rules. Mr. Pascal Brenneisen previously served on the audit committee but resigned from the board of
directors in February 2021. T<FONT STYLE="color: black">he Board has conducted a search for a qualified replacement for Mr. Brenneisen
and expects to have a replacement elected to the Board by its shareholders and appointed to the audit committee within the cure period
allowed for under Nasdaq Listing Rules.&nbsp;&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
audit committee is governed by a charter that complies with Nasdaq Stock Market rules. The audit committee has the responsibility to,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consider and make recommendations to the board of directors
    on our financial statements, review and discuss the financial statements with the management and the company&rsquo;s external independent
    auditor and present its recommendations with respect to the financial statements to the board of directors prior to the approval
    of the financial statements at the general shareholders&rsquo; meeting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversee our independent auditor and engage and determine
    compensation or termination of engagement of our auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine and pre-approve the terms of certain audit
    and non-audit services provided by our auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review and monitor, if applicable, legal matters with
    significant impact and findings of regulatory authorities, receive reports regarding irregularities and legal compliance, and make
    recommendations to our board of directors if so required, and oversee our policies and procedures regarding compliance to applicable
    financial and accounting related standards, rules and regulations; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">review
        and assess the independent auditor&rsquo;s report, management letters and take notice of all comments of the independent auditor
        on accounting procedures and systems of control and review the independent auditor&rsquo;s reports with management.</FONT></P>
        </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Compensation,
Nomination and Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
members of our compensation, nomination and governance committee are currently&nbsp;Ronald Hafner and Myoung-Ok Kwon. Mr. Pascal Brenneisen
previously served on compensation, nomination and governance committee but resigned from the board of directors on February 28, 2021.
The compensation, nomination and governance committee will assist our board of directors in overseeing our cash compensation and equity
award recommendations for our senior management along with the rationale for such recommendations, as well as summary information regarding
the aggregate compensation provided to our senior management. Swiss law requires that we adopt a compensation committee, so in accordance
with Nasdaq Listing Rule 5615(a)(3), we follow home country requirements with respect to the compensation committee. We are subject to
the Compensation Ordinance. This means that the compensation of our board of directors and senior management must be presented by the
board of directors to our shareholders and our shareholders must vote on the proposed compensation. In addition, in accordance with Nasdaq
Listing Rule 5615(a)(3), we follow home country requirements with respect to the nomination and governance committee. With respect to
the nomination of persons to our board of directors, our home country rules do not require us to authorize a committee of our independent
directors or alternatively hold a vote consisting of solely our independent directors in order to determine which persons shall be nominated
for election by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result, our practice will vary from the requirements of Nasdaq Listing Rule 5605(d) and 5605(e) which set forth certain requirements
as to the responsibilities, composition and independence of compensation committees and the nomination of directors for election by shareholders,
respectively. See &ldquo;&#8212;Differences between Swiss Laws and Nasdaq Requirements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
members of the compensation, nomination and governance committee shall be elected annually by the shareholders&rsquo; meeting for a period
until the completion of the next annual shareholders&rsquo; meeting and shall be eligible for re-election. Each member of the compensation,
nomination and governance committee shall be elected individually. If there are vacancies on the compensation, nomination and governance
committee and the number of members falls below the minimum of two, the board of directors shall appoint the missing member from among
its members for the remaining term of office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>Employees.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of May 14, 2021, we have six senior management members, of which only our Chief Executive Officer and Chief Operating Officer are full-time
employees, while the other members of the senior management are consultants, some of whom may continue to stay on as consultants. In
addition, we have four part-time employees and three consultants that we engage on a continual basis. None of our employees is represented
by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations with our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
of our employment and consulting agreements will include employees&rsquo; and consultants&rsquo; undertakings with respect to non-competition
and assignment to us of intellectual property rights developed in the course of employment and confidentiality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>E.</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_026"></A>Share
        Ownership.</B></FONT></P>
        </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<FONT STYLE="color: black">See
&ldquo;Item 7.A. Major Shareholders&rdquo; below.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_027"></A>ITEM
    7.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MAJOR SHAREHOLDERS AND
    RELATED PARTY TRANSACTIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_028"></A>A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Major Shareholders</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth information regarding beneficial ownership of our common shares as of May 14, 2021 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of
    affiliated persons, known to us to be the beneficial owner of more than 5% of our voting securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and
    senior management; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors and
    senior management as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as indicated in footnotes to this table, we believe that the shareholder named in this table has sole voting and investment power with
respect to all shares shown to be beneficially owned by it, based on information provided to us by such shareholder. The shareholder
listed below does not have any different voting rights from any of our other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">No.&nbsp;of&nbsp;Shares
    <BR>Beneficially <BR>Owned (1)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    <BR>Owned <BR>(1)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holders of more than
    5% of our voting securities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Magnetic Rock Investment AG
    <SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,845,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.6</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alexander Zwyer*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eric Konofal</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,020.000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AIGH Capital Management LLC <SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">827,921</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors and senior
    management who are not 5% holders:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ronald Hafner*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">410,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Herv&eacute; Girsault</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myoung-Ok Kwon, Ph.D.*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stig L&oslash;kke Pedersen*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Silvia Panigone</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subhasis Roy</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carlos Camozzi</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All directors and senior
    management as a group (9 persons)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,655,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates director
    of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership
    is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security
    if that person, even if not the record owner, has or shares the underlying benefits of ownership. These benefits include the power
    to direct the voting or the disposition of the securities or to receive the economic benefit of ownership of the securities. A person
    also is considered to be the &ldquo;beneficial owner&rdquo; of securities that the person has the right to acquire within 60 days
    by option or other agreement. Beneficial owners include persons who hold their securities through one or more trustees, brokers,
    agents, legal representatives or other intermediaries, or through companies in which they have a &ldquo;controlling interest,&rdquo;
    which means the direct or indirect power to direct the management and policies of the entity. The percentages shown are based on
    12,068,325 common shares issued and outstanding as of May 14, 2021.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnetic Rock Investment AG
    is a private company owned in equal part by each of the Shareholders. Ronald Hafner serves on our board of directors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 827,921 warrants
    to purchase common shares. Based solely on the Form 13G filed on March 21, 2021, with respect to securities jointly held by AIGH
    Capital Management, LLC, AIGH Inventory Partners, LLC, and Mr. Orin Hirschman with a principal address of 6006 Berkeley Ave., Baltimore,
    MD 21209.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Significant
Changes in Ownership by Major Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white">During
the past three years, there have been no significant changes in the ownership of our common shares by any major shareholder, other than
decreases in their relative percentage of ownership as a result of our initial public offering.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Record
Holders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this annual report, there was a total of 15 holders of record of our common shares, of which at least 1 has, to the best
of our knowledge, a registered address in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to us which would result in a change in control of the Company at a subsequent date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_029"></A>Related
    Party Transactions </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Employment
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into a written employment agreement with our Chief Executive Officer. Our other members of senior management are not engaged
as full-time employees as of December 31, 2020. In addition, pursuant to the consulting agreement with our Head of Business Development,
upon completion of the initial public offering, he received a fee of $183,067, equal to 1% of the net proceeds actually received by us
in our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
employment agreements that we enter into are expected to contain provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law and, our
assignment of inventions agreements with our senior management will contain terms and conditions customary under Swiss law. In addition,
our senior management are subject to our directors and officers insurance policy, which we obtained prior to the initial public offering.
Members of our senior management are eligible for bonuses each year. The bonuses will be payable upon meeting objectives and targets
that are set annually by our board of directors and compensation, nomination and governance committee, and, in certain circumstances,
upon approval by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Alexander
Zwyer Employment Agreement </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 9, 2021, we entered into a new employment agreement with Mr. Zwyer, effective as of May 1, 2021, relating to his service as our
Chief Executive Officer. Pursuant to his employment agreement, we have agreed to pay Mr. Zwyer a base annual salary of CHF 410,400, and
a bonus payment of up to CHF 200,000, subject to the discretion of the Board of Directors. The employment agreement also provides that
either party may terminate the employment agreement with 12 months&rsquo; prior notice, and that Mr. Zwyer will be subject to a 12-month
non-competition and non-solicitation clauses. The employment agreement also provides for standard confidentiality provisions as well
as reimbursement for certain expenses.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Silvia
Panigone Employment Agreement </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 9, 2021, we entered into an employment agreement with Ms. Panigone, effective as of May 1, 2021, relating to her service as our
Chief Operating Officer. Pursuant to her employment agreement, we have agreed to pay Ms. Panigone a base annual salary of CHF 270,000,
and a bonus payment of up to CHF 95,000, subject to the discretion of the Board of Directors. The employment agreement also provides
that either party may terminate the employment agreement with 6 months&rsquo; prior notice, and that Ms. Panigone will be subject to
a 12-month non-competition and non-solicitation clauses. The employment agreement also provides for standard confidentiality provisions
as well as reimbursement for certain expenses.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Subhasis
Roy Consulting Agreement </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2021, we entered into a consulting agreement with Mr. Subhasis Roy, our current Interim Chief Financial Officer, pursuant to which
we agreed to pay Mr. Roy a daily rate of CHF 2,000 for his services. The consulting agreement may be terminated by either party upon
30 days&rsquo; written notice or immediately by us in the event of a material breach by Mr. Roy that cannot be cured. The consulting
agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation clause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Eric Konofal
<FONT STYLE="color: black">Consulting Agreement </FONT></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">In
February 2021, we entered into a consulting agreement with Mr. Eric Konofal, our current Interim Chief Scientific Officer, pursuant to
which we agreed to pay Mr. Konofal a daily rate of CHF 2,000 for his services. The consulting agreement may be terminated by either party
upon 30 days&rsquo; written notice or immediately by us in the event of a material breach by Mr. Konofal that cannot be cured. The consulting
agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation clause</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">as
well as reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Herv&eacute;
Girsault Consulting Agreement </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">In
January 2017, and as subsequently amended in October 2020, we entered into a consulting agreement with CHG BioVenture SA, an entity controlled
by Mr. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Herv&eacute; Girsault<FONT STYLE="color: black">, our current
Head of Business Development]. Pursuant to the consulting agreement, we agreed to pay CHG BioVenture SA a monthly fee of CHF 17,500,
as well as an opportunity to a bonus of up to 15% of the annual fee, subject to our discretion. In addition, we have agreed to pay CHG
BioVenture SA a 1% fee tied to the proceeds actually received by us in certain transactions, such as, but not limited to, an M&amp;A
transaction. The consulting agreement may be terminated by either party for any reason at the end of each calendar quarter with three
months&rsquo; prior written notice, or immediately if Mr. Girsault breaches the confidentiality provision. The consulting agreement also
provides for a 24-month non-competition clause. </FONT>The consulting agreement also provides for standard confidentiality provisions
as well as reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
provided Mr. Girsault notice of our termination of the consulting agreement with <FONT STYLE="color: black">CHG BioVenture SA, pursuant
to which </FONT>Mr. Girsault provides his services to us, which will take effect on June 30, 2021. We are actively in discussions with
Mr. Girsault on continuing his engagement with us in his current role.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Carlos
Camozzi Consulting Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">In
March 2021, we entered into a consulting agreement with Mr. Carlos Camozzi, our current Interim Medical Director, pursuant to which we
agreed to pay Mr. Camozzi an hourly rate of CHF 230 plus 7.7% VAT for his services. The consulting agreement may be terminated by either
party upon 30 days&rsquo; written notice or immediately by us in the event of a material breach by Mr. Camozzi that cannot be cured.
The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation clause</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">as
well as reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Shareholders
and Officer and Director Loans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
entered into the following loan agreements with Ronald Hafner, a member of our board of directors, and the other Shareholders, and with
Magnetic Rock, all of which were repaid in February 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Credit
Facilities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2015, NLS Pharma Ltd. and NLS-1 Ltd., and in March 2017, NLS-0 Ltd., each entered into the NLS Pharma Credit Facility, the NLS-1
Credit Facility and the NLS-0 Credit Facility, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
entire principal amount of the NLS-1 Credit Facility was converted into equity. In July 2018, we converted $3,418,519 of the principal
amount (including the entire Interest-Bearing Facility) into 260,000 of our common shares, at a conversion price of $13.00 per common
share and in March 2019, in connection with the Reorganization, the remaining $3,681,481 of the principal amount into 280,000 common
shares at the same conversion price as the July 2018 conversion. The Interest-Bearing Facility stopped accruing interest upon the Reorganization
and, as a result thereof, the accrued interest stood at $85,737.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
borrowed $1.45 million, or the Borrowed Amount, under the NLS-0 Credit Facility. In connection with the Reorganization, the Entire Borrowed
Amount under the NLS-0 Loan and a certain $2 million 2017 Bridge loan agreement with the Shareholders (as discussed more fully below),
were converted together into an aggregate of 260,000 of our common shares, at a conversion price of $13.00 per common share.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Bridge
Loan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2017, in connection with the 2017 Bridge Loan, we received a loan of $2 million. The entire amount borrowed pursuant to the
2017 Bridge Loan was converted into shares of our common shares, together with the NLS-0 Credit Facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>January
2019 Promissory Notes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2019, we issued the four Notes, each for CHF 125,000 (approximately $128,200), with the Shareholders. Each Note carried an annual
interest rate of 10% per year, compounded annually was scheduled to mature on March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>January
2019 Convertible Promissory Note</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
January 18, 2019, we issued the Convertible Note with Magnetic Rock for CHF 550,000 (approximately $557,920) pursuant to loan proceeds
that were received in advance in each of August and December 2018 in the amount of CHF 500,000 ($507,200) and CHF 50,000 ($50,720). The
Convertible Note carried an annual interest rate of 10% per year, compounded annually and was scheduled to mature on March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Convertible
Loans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 21, 2020, we entered into a Convertible Loan with our Chief Executive Officer, who is also a member of our board of directors,
for an aggregate loan in the amount of CHF 150,000 (approximately $154,890). In September 2020, we amended the Convertible Loan with
our Chief Executive Officer to decrease the amount of the loan to CHF 100,000 (approximately $105,530). The Convertible Loan carried
an interest rate of 10% per year, compounded annually and was originally scheduled to mature on June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, one Convertible Loan Amendment, in the amount of CHF 60,000 ($63,318) was with Ms. Silvia Panigone, our Chief Operating Officer.
Ms. Panigone entered into a second Convertible Loan with us in the amount of CHF 20,000 ($21,106). Pursuant to a consulting agreement
that we have with a company founded and managed by Ms. Panigone, Ms. Panigone was due consulting fees from us in the aggregate amount
of CHF 129,779 ($136,956).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>2020
Bridge Loan and Liquidation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2020, we received the first tranche of CHF 300,000 ($316,590) pursuant to the 2020 Bridge Loan. In September 2020, we received
the second tranche of CHF 200,000 ($211,060) pursuant to the 2020 Bridge Loan, for an aggregate of CHF 500,000 ($527,650). The borrowed
amounts under this 2020 Bridge Loan carried an interest rate of 10% per year and was scheduled to mature on March 31, 2021. In January
2021, we amended the 2020 Bridge Loan to increase the aggregate loan amount to CHF 600,000 ($633,180).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_030"></A>Interests
    of Experts and Counsel</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Not
applicable.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_031"></A>ITEM 8.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL INFORMATION.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_032"></A>A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated Statements
    and Other Financial Information.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">See
&ldquo;Item 18. Financial Statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time we may become involved in legal proceedings that arise in the ordinary course of business. During the period covered by
the financial statements contained herein, <FONT STYLE="color: black">we were not subject to any material legal proceedings</FONT> that
has had a material adverse effect on our financial position. No assurance can be given that future litigation will not have a material
adverse effect on our financial position. When appropriate in management&rsquo;s estimation, we may record reserves in our financial
statements for pending litigation and other claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our common shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects
and other factors our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Under
Swiss law, we may only pay dividends if we have sufficient distributable profits brought forward from the previous business years (&ldquo;Gewinnvortrag&rdquo;),
or if we have distributable reserves (&ldquo;frei verf&uuml;gbare Reserven&rdquo;), each as evidenced by our audited stand-alone statutory
balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association
have been deducted. We are not permitted to pay interim dividends out of profit of the current business year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Under
our amended and restated articles of association and in accordance with Swiss law, only our shareholders have the power to approve the
payment of any dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_033"></A>B.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Changes.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
significant change, other than as otherwise described in this annual report, has occurred in our operations since the date of our financial
statements included in this annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_034"></A>ITEM
    9.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE OFFER AND LISTING.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_035"></A>A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer and Listing Details</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
January 30, 2021, our common shares and Warrants trade on the Nasdaq Capital Market under the symbols &ldquo;NLSP&rdquo; and NLSPW,&rdquo;
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_036"></A>B.
    </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan of Distribution</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Not
applicable.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_037"></A>C.
    </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Markets</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common shares and Warrants trade on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_038"></A>D.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Shareholders</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_039"></A>E.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dilution</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_040"></A>F.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expenses of the Issue</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_041"></A>ITEM
    10.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADDITIONAL INFORMATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_042"></A>A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share Capital </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_043"></A>B.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Memorandum and Articles
    of Association</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
copy of our amended and restated articles of association is attached as Exhibit 1.1 to this annual report. The information called for
by this Item is set forth in Exhibit 2(d) to this annual report and is incorporated by reference into this annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_044"></A>C.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material Contracts</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which
we are or have been a party, for the two years immediately preceding the date of this annual report:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
                                            Agent Agreement by and between NLS Pharmaceutics Ltd. and VStock Transfer, LLC, dated January
                                            28, 2021 (<FONT STYLE="color: black">filed as Exhibit 4.2 to form F-1 (File No. 333-236797)
                                            filed on November 13, 2020). See Item 14.E. &ldquo;Material Modifications to the Rights of
                                            Security Holders and Use of Proceeds&rdquo; for more information about this document.</FONT></FONT></TD></TR>                          <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">License
                                            Agreement dated February 2019 between Eurofarma Laboratorios S.A. and NLS Pharmaceutics Ltd.
                                            (filed as Exhibit 10.14 to form F-1 (<FONT STYLE="color: black">File No. 333-236797) filed
                                            on February 28, 2020). See Item 4.B. &ldquo;Business Overview&rdquo; for more information
                                            about this document.</FONT></FONT></TD></TR>                                                                                               <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assignment
                                            and Transfer Agreement dated August 31, 2015 between NLS-1 AG and NeuroLife Sciences SAS
                                            (filed as Exhibit 10.15 to form F-1 (<FONT STYLE="color: black">File No. 333-236797) filed
                                            on February 28, 2020). See Item 4.B. &ldquo;Business Overview&rdquo; for more information
                                            about this document.</FONT></FONT></TD></TR>                                                                                               <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">License
                                            Agreement by and between NLS Pharmaceutics Ltd. and Novartis Pharma AG, dated March 10, 2021
                                            (filed as Exhibit 4.6 to this annual report). <FONT STYLE="color: black">See Item 4.B. &ldquo;Business
                                            Overview&rdquo; for more information about this document.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_045"></A>D.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange Controls</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no Swiss governmental laws, decrees or regulations that restrict, in a manner material to us, the export or import of capital, including
any foreign exchange controls, or that generally affect the remittance of dividends or other payments to non-residents or non-citizens
of Switzerland who hold our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_046"></A><FONT STYLE="font-size: 10pt"><B>E.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Switzerland
Tax Consideration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary of material Swiss tax consequences is based on Swiss law and regulations and the practice of the Swiss tax administration as
in effect on the date hereof, all of which are subject to change (or subject to changes in interpretation), possibly with retroactive
effect. The summary does not purport to take into account the specific circumstances of any particular shareholder or potential investor
and does not relate to persons in the business of buying and selling common shares or other securities. The summary is not intended to
be, and should not be interpreted as, legal or tax advice to any particular potential shareholder/s, and no representation with respect
to the tax consequences to any particular shareholder/s is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
and prospective shareholders are advised to consult their own tax advisers in light of their particular circumstances as to the Swiss
tax laws, regulations and regulatory practices that could be relevant for them in connection with the acquiring, owning and selling or
otherwise disposing of common shares and receiving dividends and similar cash or in-kind distributions on common shares (including dividends
on liquidation proceeds and stock dividends) or distributions on common shares based upon a capital reduction (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;)
or reserves paid out of capital contributions (&ldquo;Reserven aus Kapitaleinlagen&rdquo;) and the consequences thereof under the tax
laws, regulations and regulatory practices of Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taxation
of NLS Pharmaceutics Ltd. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
is a Swiss company, subject to taxation in the Canton of Nidwalden. The Company is taxed at a current effective income tax rate of approximately
12% (including direct federal as well as cantonal/communal taxes). In addition, an annual capital tax rate of approximately 0.01% is
levied on the net equity of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based
on a vote by eligible Swiss voters in Switzerland on May 19, 2019, Switzerland reformed certain elements of its corporate tax law which
impact the taxation of NLS (including the abolition of the mixed company privilege at cantonal/communal level). These new federal regulations
went into effect as of January 1, 2020. Regarding the implementation of certain measures on the cantonal level, a referendum was put
up for a vote in the Canton of Nidwalden. Following a vote during the year ended December 31, 2020, the referendum passed and took effect
in the Canton of Nidwalden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Swiss
Federal Withholding Tax on Dividends and other Distributions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
payments and similar cash or in-kind distributions on the common shares (including dividends on liquidation proceeds and stock dividends)
that the Company makes to shareholders are subject to Swiss federal withholding tax (&ldquo;Verrechnungssteuer&rdquo;) at a rate of 35%
on the gross amount of the dividend. The Company is required to withhold the Swiss federal withholding tax from the dividend and remit
it to the Swiss Federal Tax Administration. Distributions based upon a capital reduction (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;) and
reserves paid out of capital contribution reserves (&ldquo;Reserven aus Kapitaleinlagen&rdquo;) are not subject to Swiss federal withholding
tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
redemption of common shares in the Company may under certain circumstances (in particular, if the common shares in the Company are redeemed
for subsequent cancellation) be taxed as a partial liquidation for Swiss federal withholding tax purposes, with the consequence that
the difference between the repurchase price and the nominal value of the shares (&ldquo;Nennwertprinzip&rdquo;) plus capital contribution
reserves (&ldquo;Reserven aus Kapitaleinlagen&rdquo;) is subject to Swiss federal withholding tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Swiss federal withholding tax is refundable or creditable in full to a Swiss tax resident corporate and individual shareholder as well
as to a non-Swiss tax resident corporate or individual shareholder who holds the common shares as part of a trade or business carried
on in Switzerland through a permanent establishment or fixed place of business situated for tax purposes in Switzerland, if such person
is the beneficial owner of the distribution and, in the case of a Swiss tax resident individual who holds the common shares as part of
his private assets, duly reports the gross distribution received in his individual income tax return or, in the case of a person who
holds the common shares as part of a trade or business carried on in Switzerland through a permanent establishment or fixed place of
business situated for tax purposes in Switzerland, recognizes the gross dividend distribution for tax purposes as earnings in the income
statements and reports the annual profit in the Swiss income tax return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a shareholder who is not a Swiss resident for tax purposes and does not hold the common shares in connection with the conduct of a trade
or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes in Switzerland, receives
a distribution from the Company, the shareholder may be entitled to a full or partial refund or credit of Swiss federal withholding tax
incurred on a taxable distribution if the country in which such shareholder is resident for tax purposes has entered into a treaty for
the avoidance of double taxation with Switzerland and the further prerequisites of the treaty for a refund have been met. Shareholders
not resident in Switzerland should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund
or credit) may differ from country to country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Individual
and Corporate Income Tax on Dividends </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident individuals holding the common shares as part of their private assets who receive dividends and similar distributions (including
stock dividends and liquidation proceeds), which are not repayments of the nominal value (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;) of
the common shares or reserves paid out of capital contributions (&ldquo;Reserven aus Kapitaleinlagen&rdquo;) are required to report such
payments in their individual income tax returns and are liable to Swiss federal, cantonal and communal income taxes on any net taxable
income for the relevant tax period. Furthermore, for the purpose of the Direct Federal Tax, dividends, shares in profits, liquidation
proceeds and pecuniary benefits from shares (including bonus shares) are included in the tax base for only 70% of their value (&ldquo;Teilbesteuerung&rdquo;),
if the investment amounts to at least 10% of nominal share capital of the Company. All Swiss cantons have introduced partial taxation
measures at cantonal and communal levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident individuals as well as non-Swiss resident individual taxpayers holding the common shares in connection with the conduct of a
trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland,
are required to recognize dividends, distributions based upon a capital reduction (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;) and reserves
paid out of capital contributions (&ldquo;Reserven aus Kapitaleinlagen&rsquo;) in their income statements for the relevant tax period
and are liable to Swiss federal, cantonal and communal individual or corporate income taxes, as the case may be, on any net taxable earnings
accumulated (including the payment of dividends) for such period. Furthermore, for the purpose of the Direct Federal Tax, dividends,
shares in profits, liquidation proceeds and pecuniary benefits from shares (including bonus shares) are included in the tax base for
only 70% (&ldquo;Teilbesteuerung&rdquo;), if the investment is held in connection with the conduct of a trade or business or qualifies
as an opted business asset (&ldquo;gewillk&uuml;rtes Gesch&auml;ftsverm&ouml;gen&rdquo;) according to Swiss tax law and amounts to at
least 10% of nominal share capital of the Company. All cantons have introduced partial taxation measures at cantonal and communal levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident corporate taxpayers as well as non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct
of a trade or business through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are required
to recognize dividends, distributions based upon a capital reduction (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;) and reserves paid out
of capital contributions (&ldquo;Reserven aus Kapitaleinlagen&rdquo;) in their income statements for the relevant tax period and are
liable to Swiss federal, cantonal and communal corporate income taxes on any net taxable earnings accumulated for such period. Swiss
resident corporate taxpayers as well as non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct
of a trade or business through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland may be
eligible for participation relief&#8201; (&ldquo;Beteiligungsabzug&rdquo;) in respect of dividends and distributions based upon a capital
reduction (&ldquo;Nennwertr&uuml;ckzahlungen&rdquo;) and reserves paid out of capital contributions (&ldquo;Reserven aus Kapitaleinlagen&rdquo;)
if the common shares held by them as part of a Swiss business have an aggregate market value of at least CHF 1 million or represent at
least 10% of the nominal share capital of the Company or give entitlement to at least 10% of the profits and reserves of the Company,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recipients
of dividends and similar distributions on the common shares (including stock dividends and liquidation proceeds) who neither are residents
of Switzerland nor during the current taxation year have engaged in a trade or business in Switzerland and who are not subject to taxation
in Switzerland for any other reason are not subject to Swiss federal, cantonal or communal individual or corporate income taxes in respect
of dividend payments and similar distributions because of the mere holding of the common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Wealth
and Annual Capital Tax on Holding of Common Shares or Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident individuals and non-Swiss resident individuals holding the common shares and/or Warrants in connection with the conduct of a
trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland,
are required to report their common shares as part of their wealth and will be subject to cantonal and communal wealth tax to the extent
the aggregate taxable net wealth is allocable to Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident corporate taxpayers and non-Swiss resident corporate taxpayers holding the common shares and/or Warrants in connection with
the conduct of a trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes,
in Switzerland, will be subject to cantonal and communal annual capital tax on the taxable capital to the extent the aggregate taxable
capital is allocable to Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Individuals
and corporate taxpayers not resident in Switzerland for tax purposes and not holding the common shares and/or Warrants in connection
with the conduct of a trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax
purposes, in Switzerland, are not subject to wealth or annual capital tax in Switzerland because of the mere holding of the common shares
and/or Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Capital
Gains on Disposal of Common Shares or Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident individuals who sell or otherwise dispose of the common shares&nbsp;and/or Warrants realize a tax-free capital gain, or a non-tax
deductible capital loss, as the case may be, provided that they hold the common shares, as part of their private assets. Under certain
circumstances, the sale proceeds may be requalified into taxable investment income (e.g., if the taxpayer is deemed to be a professional
securities dealer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital
gains realized on the sale of the common shares and/or Warrants held by Swiss resident individuals, Swiss resident corporate taxpayers
as well as non-Swiss resident individuals and corporate taxpayers holding the common shares and/or Warrants in connection with the conduct
of a trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland,
will be subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be. This also applies to
Swiss resident individuals who, for individual income tax purposes, are deemed to be professional securities dealers for reasons of,
inter alia, frequent dealing and debt-financed purchases. Capital gains realized by resident individuals who hold the common shares as
business assets might be entitled to reductions or partial taxations similar to those mentioned above for dividends (&ldquo;Teilbesteuerung&rdquo;)
if certain conditions are met (e.g., holding period of at least one year and participation of at least 10% of nominal share capital of
the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
resident corporate taxpayers as well as non-Swiss resident corporate taxpayers holding the common shares and/or Warrants in connection
with the conduct of a trade or business, through a permanent establishment or fixed place of business situated, for tax purposes, in
Switzerland, are required to recognize such capital gain in their income statements for the relevant tax period. Corporate taxpayers
may qualify for participation relief on capital gains (&ldquo;Beteiligungsabzug&rdquo;), if the common shares sold during the tax period
represent at least 10% of the Company&rsquo;s share capital or if the common shares sold give entitlement to at least 10% of the Company&rsquo;s
profits and reserves and were held for at least one year. The tax relief applies to the difference between the sale proceeds of common
shares by the Company and the acquisition costs of the participation (&ldquo;Gestehungskosten&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Individuals
and corporations not resident in Switzerland for tax purposes and not holding the common shares and/or Warrants in connection with the
conduct of a trade or business in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes,
in Switzerland, are not subject to Swiss federal, cantonal and communal individual income or corporate income tax, as the case may be,
on capital gains realized on the sale of the common shares and/or Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Gift and
Inheritance Tax </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfers
of common shares and/or Warrants may be subject to cantonal and/or communal inheritance or gift taxes if the deceased or the donor or
the recipient were resident in a Canton levying such taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Swiss
Issuance Stamp Duty </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is subject to paying to the Swiss Federal Tax Administration a 1% Swiss federal issuance stamp tax (&ldquo;Emissionsabgabe&rdquo;)
on any increase of the nominal share capital of the Company (including capital surplus) or any other equity contributions received by
the Company (with or without issuance of shares). Certain costs incurred in connection with the issuance of shares (if any) may be deductible.
There are several exemptions from issuance stamp tax that may apply under certain circumstances (e.g., certain intercompany reorganizations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Swiss
Securities Transfer Tax </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
purchase or sale (or other financial transfer) of the common shares, whether by Swiss residents or non-Swiss residents, may be subject
to Swiss securities transfer tax of up to 0.15%, calculated on the purchase price or the proceeds if the purchase or sale occurs through
or with a bank or other securities dealer in Switzerland as defined in the Swiss Federal Stamp Duty Act as an intermediary or party to
the transaction unless an exemption applies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Automatic
Exchange of Information in Tax Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 19, 2014, Switzerland signed the multilateral competent authority agreement on the automatic exchange of financial account information,
which is intended to ensure the uniform implementation of automatic exchange of information, or the AEOI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
AEOI is being introduced in Switzerland through bilateral agreements or multilateral agreements. Switzerland has concluded a multilateral
agreement with the EU on the AEOI in tax matters, or the AEOI Agreement. This AEOI Agreement entered into force as of January 1, 2017
and applies to all 28 member states as well as Gibraltar. Furthermore, on January 1, 2017, the multilateral competent authority agreement
on the automatic exchange of financial account information and, based on such agreement, a number of bilateral AEOI agreements with other
jurisdictions entered into force. The Federal Act on the International Automatic Exchange of Information in Tax Matters, or the AEOI
Act, which is the primary legal basis for the implementation of the AEOI standard in Switzerland, entered into force on January 1, 2017
as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based
on such multilateral agreements and bilateral agreements and the implementing laws of Switzerland, Switzerland collects data in respect
of financial assets, which may include Shares, held in, and income derived thereon and credited to, accounts or deposits with a paying
agent in Switzerland for the benefit of individuals resident in a EU member state or in a treaty state since 2017, and exchanges it since
2018. Switzerland has signed and is expected to sign further bi- or multilateral AEOI in tax matter agreements with other countries,
which entered into force on January 1, 2018 or January 1, 2019 or will enter into force at a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
list of such multilateral agreements and bilateral agreements of Switzerland in effect or signed and becoming effective can be found
on the website of the State Secretariat for International Finance (SIF).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 27, 2019, the Federal Council initiated the consultation on the revision of the AEOI Act and AEOI Ordinance. The consultation
proposal takes account of recommendations from the Global Forum on Transparency and Exchange of Information for Tax Purposes. They concern,
among other things, certain due diligence and registration obligations, the maintenance of a document retention obligation for reporting
Swiss financial institutions, as well as definitions thereunder. Some exceptions have also been removed or adapted. The amendments to
the AEOI Act and AEOI Ordinance are expected to enter into force on January 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Swiss
Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Switzerland
has concluded an intergovernmental agreement with the U.S. to facilitate the implementation of the Foreign Account Tax Compliance Act
(FATCA). The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax
authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance.
Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope of administrative
assistance on the basis of the double taxation agreement between the U.S. and Switzerland. On October 8, 2014, the Swiss Federal Council
approved a mandate for negotiations with the U.S. on changing the current direct-notification-based regime to a regime where the relevant
information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. The
new regime may come into force during the course of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Material
U.S. Federal Income Tax Considerations for U.S. Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EACH
PROSPECTIVE SHAREHOLDER SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR SWISS TAX CONSEQUENCES OF PURCHASING, HOLDING AND
DISPOSING OF OUR COMMON SHARES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE
FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR
TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
OF THE PURCHASE, OWNERSHIP AND SALE OF COMMON SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND
POSSIBLE CHANGES IN THE TAX LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences
to a &ldquo;U.S. Holder&rdquo; arising from the purchase, ownership and sale of the common shares. For this purpose, a &ldquo;U.S. Holder&rdquo;
is a holder of common shares or Warrants that is: (1) an individual citizen or resident of the United States, including an alien individual
who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax
laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership
that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United
States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income
for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of
the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury
regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income
tax considerations that may be relevant to a decision to purchase our common shares or Warrants. This summary generally considers only
U.S. Holders that will own our common shares or Warrants as capital assets. Except to the limited extent discussed below, this summary
does not consider the U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable
to determine a taxpayer&rsquo;s status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986,
as amended, or the Code, final, temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial
interpretations thereof, (including with respect to the TCJA), and the U.S./Switzerland Income Tax Treaty, all as in effect as of the
date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations.
We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our common shares by
U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based
on such holder&rsquo;s particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state,
local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a
U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or &ldquo;financial
services entity;&rdquo; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our common shares or Warrants
in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax;
(5) a U.S. Holder that holds our common shares or Warrants as a hedge or as part of a hedging, straddle, conversion or constructive sale
transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment
trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the United States or a former long-term resident of the United States;
or (9) a person having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax
treatment of a U.S. Holder that owns, directly or constructively, at any time, common shares representing 10% or more of our voting power.
Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through entities) or persons who hold common shares
through a partnership or other pass-through entity are not addressed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing,
holding or disposing of our common shares, including the effects of applicable state, local, foreign or other tax laws and possible changes
in the tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exercise
or Expiry of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
gain or loss will be realized on the exercise of a Warrant. When a Warrant is exercised, the U.S. Holder&rsquo;s cost of the common share
acquired thereby will be equal to the U.S. Holder&rsquo;s adjusted cost basis of the Warrant plus the exercise price paid for the common
share. The expiry of an unexercised Warrant will generally give rise to a capital loss equal to the adjusted cost basis to the U.S. Holder
of the expired Warrant. The holding period of the common share acquired through the exercise of a Warrant includes the holding period
of the Warrant. See &ldquo;Passive Foreign Investment Companies,&rdquo; for the impact of the exercise of a Warrant on taxation of a
U.S. Holder if we are a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taxation
of Dividends Paid on Common Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under
the heading &ldquo;Passive Foreign Investment Companies&rdquo; below and the discussion of &ldquo;qualified dividend income&rdquo; below,
a U.S. Holder, other than certain U.S. Holders that are U.S. corporations, will be required to include in gross income as ordinary income
the amount of any distribution paid on common shares (including the amount of any Swiss tax withheld on the date of the distribution),
to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined for U.S. federal
income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a non-taxable return
of capital, reducing the U.S. Holder&rsquo;s tax basis for the common shares to the extent thereof, and then capital gain. We do not
expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore, U.S. Holders should
expect that the entire amount of any distribution generally will be reported as dividend income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, preferential tax rates for &ldquo;qualified dividend income&rdquo; and long-term capital gains are applicable for U.S. Holders
that are individuals, estates or trusts. For this purpose, &ldquo;qualified dividend income&rdquo; means, inter alia, dividends received
from a &ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo; is a corporation that is entitled to
the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program. The IRS has stated
that the Switzerland/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, our dividends will be qualified dividend income if our common shares are readily tradable on Nasdaq or another established
securities market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend
is paid or in the prior year, as a PFIC, as described below under &ldquo;Passive Foreign Investment Companies.&rdquo; A U.S. Holder will
not be entitled to the preferential rate: (1) if the U.S. Holder has not held our common shares for at least 61 days of the 121 day period
beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make
related payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our common
shares are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &ldquo;investment
income&rdquo; pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amount of a distribution with respect to our common shares will be measured by the amount of the fair market value of any property distributed,
and for U.S. federal income tax purposes, the amount of any Swiss taxes withheld therefrom. Cash distributions paid by us in CHF will
be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend
is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such CHF for U.S. federal income tax purposes
equal to such U.S. dollar value. If the U.S. Holder subsequently converts the CHF into U.S. dollars or otherwise disposes of it, any
subsequent gain or loss in respect of such CHF arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or
loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as described below in &ldquo;Passive Foreign Investment Companies,&rdquo; ownership of the Warrants has no tax impact on U.S. Holders
since holders of the Warrants do not receive distributions unless and until the Warrants are exercised and common shares are purchased.
As described below, if we are a PFIC, ownership of the Warrants may impact the holding period of PFIC shares and impact elections under
the PFIC tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taxation
of the Disposition of Common Shares and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as provided under the PFIC rules described below under &ldquo;Passive Foreign Investment Companies,&rdquo; upon the sale, exchange or
other disposition of our common shares or the Warrants, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference
between such U.S. Holder&rsquo;s tax basis for the common shares and Warrants in U.S. dollars and the amount realized on the disposition
in U.S. dollar (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the
amount realized is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition of common
shares and Warrants will be long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time
of the disposition. Individuals who recognize long-term capital gains may be taxed on such gains at reduced rates of tax. The deduction
of capital losses is subject to various limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Passive
Foreign Investment Companies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Special
U.S. federal income tax laws apply to U.S. taxpayers who own shares and warrants of a corporation that is a PFIC. We will be treated
as a PFIC for U.S. federal income tax purposes for any taxable year that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro
    rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year
    is passive; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year
    and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are
    considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities
transactions and from notional principal contracts. Cash is treated as generating passive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not believe that we will be a PFIC for the current taxable year although we have not determined whether we will be a PFIC in the future.
The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets
which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our common shares. Accordingly,
there can be no assurance that we currently are not or will not become a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we currently are or become a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon
receipt of certain distributions by us and upon disposition of our common shares and Warrants at a gain:&nbsp;(1) have such distribution
or gain allocated ratably over the U.S. Holder&rsquo;s holding period for the common shares, as the case may be; (2) the amount allocated
to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as
ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in
effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with
respect to the resulting tax attributable to each such other taxable year. In addition, when shares and warrants of a PFIC are acquired
by reason of death from a decedent that was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value
as of the date of the decedent&rsquo;s death, but instead would be equal to the decedent&rsquo;s basis if lower, unless all gain were
recognized by the decedent. Indirect investments in a PFIC may also be subject to these special U.S. federal income tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder of our Warrants is taxed in a manner similar to a U.S. holder of common shares if the holder realizes gain on the sale of
the Warrants. If the holder of the Warrants exercises the Warrants to purchase common shares, the holding period over which any income
realized is allocated includes the holding period of the Warrants. The U.S. Warrant holder is treated as a holder of PFIC stock taxable
under the ordinary income allocation and interest charge regime described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has
held the common shares while we are a PFIC, provided that we comply with specified reporting requirements. A U.S. Holder of our Warrants
may not make a QEF election regarding our Warrants. Instead, each U.S. Holder who has made such a QEF election is required for each taxable
year that we are a PFIC to include in income such U.S. Holder&rsquo;s pro rata share of our ordinary earnings as ordinary income and
such U.S. Holder&rsquo;s pro rata share of our net capital gains as long-term capital gain, regardless of whether we make any distributions
of such earnings or gain. In general, a QEF election is effective only if we make available certain required information. The QEF election
is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the IRS. We do not intend to notify
U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend to furnish U.S. Holders annually
with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or
any of our subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, except with respect to the Warrants (unless exercised), the PFIC rules described above would not apply if we were a PFIC and
a U.S. Holder made a mark-to-market election. A U.S. Holder of our common shares which are regularly traded on a qualifying exchange,
including Nasdaq, can elect to mark the common shares to market annually, recognizing as ordinary income or loss each year an amount
equal to the difference as of the close of the taxable year between the fair market value of the common shares and the U.S. Holder&rsquo;s
adjusted tax basis in the common shares. Losses are allowed only to the extent of net mark-to-market gain previously included income
by the U.S. Holder under the election for prior taxable years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
Holders who hold our common shares and Warrants during a period when we are a PFIC will be subject to the foregoing rules, even if we
cease to be a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
on Net Investment Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including
dividends on and gains from the sale or other disposition of our common shares), or in the case of estates and trusts on their net investment
income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&rsquo;s total adjusted
income exceeds applicable thresholds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Consequences for Non-U.S. Holders of Common Shares and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as provided below, an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally
will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of,
our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our common shares (but not Warrants) or gain from the
disposition of our common shares and Warrants if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a
trade or business in the United States and, if required by an applicable income tax treaty is attributable to a permanent establishment
or fixed place of business in the United States; or (2) in the case of a disposition of our common shares and Warrants, the individual
non-U.S. Holder is present in the United States for 183 days or more in the taxable year of the disposition and other specified conditions
are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our common shares if
payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United
States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable
IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&rsquo;s U.S. federal
income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Information
Reporting and Withholding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of common
shares. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup
withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations.
Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder,
provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to recently enacted legislation, a U.S. Holder with interests in &ldquo;specified foreign financial assets&rdquo; (including, among other
assets, our common shares, unless such common shares are held on such U.S. Holder&rsquo;s behalf through a financial institution) may
be required to file an information report with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the
taxable year or $75,000 at any time during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance);
and may be required to file a Report of Foreign Bank and Financial Accounts if the aggregate value of the foreign financial accounts
exceeds $10,000 at any time during the calendar year. You should consult your own tax advisor as to the possible obligation to file such
information report.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_047"></A><FONT STYLE="font-size: 10pt"><B>F.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends and Paying
    Agents</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_048"></A>G.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement by Experts</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_049"></A>H.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Documents on Display</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to certain information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those
requirements will file reports with the SEC. The SEC maintains an Internet website that contains reports and other information regarding
issuers that file electronically with the SEC. Our filings with the SEC will also available to the public through the SEC&rsquo;s website
at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements,
and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained
in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports
and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the
Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required
by the SEC, an annual report containing financial statements audited by an independent registered public accounting firm, and may submit
to the SEC, on a Form 6-K, unaudited half-yearly financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
maintain a corporate website https://nlspharma.com/. Information contained on, or that can be accessed through, our website and the other
websites referenced above do not constitute a part of this annual report. We have included these website addresses in this annual report
solely as inactive textual references.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_050"></A><FONT STYLE="font-size: 10pt"><B>I.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary Information.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
wholly-owned subsidiary, NLS Pharmaceutics Inc., a Delaware corporation was incorporated on April 27, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_051"></A>ITEM
    11.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUANTITATIVE AND QUALITATIVE
    DISCLOSURES ABOUT MARKET RISK.</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&#9;We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-. Accordingly, a substantial majority of our cash and cash equivalents is
held in deposits that bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates
are reduced. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail in the following
paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Foreign
Currency Exchange Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. As discussed above,
the vast majority of our liquid assets is held in USD, and a certain portion of our expenses are denominated in CHF. For instance, during
the year ended December 31, 2020, approximately 62% of our expenses were denominated in CHF. Changes of 5% and 10% in the USD/CHF exchange
rate would have increased/decreased our operating expenses by 2% and 4%, respectively. However, these historical figures may not be indicative
of future exposure, as we expect that the percentage of our CHF denominated expenses will materially decrease in the near future, therefore
reducing our exposure to exchange rate fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may
not adequately protect us from the material adverse effects of such fluctuations.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_052"></A>ITEM
    12.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION OF SECURITIES
    OTHER THAN EQUITY SECURITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_053"></A>A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt Securities.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_054"></A>B.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants and rights.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_055"></A>C.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Securities.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_056"></A>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_057"></A>ITEM
    13.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFAULTS, DIVIDEND ARREARAGES
    AND DELINQUENCIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_058"></A>ITEM
    14.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MATERIAL MODIFICATIONS
    TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>E.
Use of Proceeds </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 2, 2021, we completed our initial public offering of common shares and Warrants pursuant to a Registration Statement on Form
F-1, as amended (Registration No. 333-236797) that was declared effective on January 28, 2021. Under the registration statement, we sold
an aggregate of 4,819,277 common shares and 4,819,277 Warrants, as well as <FONT STYLE="color: black">722,891</FONT> Warrants pursuant
to an over-allotment option granted to the underwriters. All of these common shares and Warrants were sold at a combined price to the
public of $4.15 per share, yielding net proceeds of $17 million after underwriting discounts and commissions. Maxim Group LLC acted as
book-running manager and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as co-manager for the offering. We paid
offering expenses of $603,610 in connection with the initial public offering, which included SEC registration fees, FINRA filing fees,
Nasdaq listing fees and expenses, legal fees and expenses, printing expenses, transfer agent fees and expenses, accounting fees and expenses
as well as other miscellaneous fees and expenses, but excluded the underwriting discounts and commissions. No proceeds from our initial
public offering were utilized in the fiscal year ended December 31, 2020. Except for the success fee of $183,067, equal to 1% of the
proceeds actually received by us in our initial public offering, paid to our Head of Business Development as set forth elsewhere in this
annual report, n<FONT STYLE="color: black">one of the net proceeds were used to make payments (other than compensation paid to our senior
management, directors and an affiliate of one of our directors, each as described in this annual report), directly or indirectly, to
(i)&nbsp;any of our directors, senior management or their associates, (ii)&nbsp;any persons owning 10% or more of our common shares or
(iii)&nbsp;any of our affiliates. The intended use of the remaining net proceeds has not changed from the information mentioned in the
prospectus relating to the registration statement.&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_059"></A>ITEM
    15.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTROLS AND PROCEDURES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)
Disclosure Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We maintain disclosure controls and procedures designed
to provide reasonable assurance that information required to be disclosed in reports filed under the Exchange Act is recorded, processed,
summarized and reported within the specified time periods and accumulated and communicated to our management, including our Chief Executive
Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of December 31,
2020, our disclosure controls and procedures were not effective as a result of our material weaknesses in our internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, has evaluated the effectiveness
of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December
31, 2020, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, we have material
weaknesses in our internal control over financial reporting. The material weaknesses included the lack of proper segregation of duties
and lack of sufficient and competent financial reporting and accounting <FONT STYLE="background-color: white">personnel with appropriate
knowledge and experience with technical accounting in accordance with U.S. GAAP and to prepare and review financial statements and related
disclosures in accordance with U.S. GAAP and SEC reporting requirements</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)
Management&rsquo;s Annual Report on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
annual report does not include a report of management&rsquo;s assessment regarding internal control over financial reporting or an attestation
report of the Company&rsquo;s registered public accounting firm due to a transition period established by the rules of the Securities
and Exchange Commission for newly public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(c)
Attestation Report of the Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
annual report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting due to an exemption for EGCs provided in the JOBS Act.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(d)
Changes in Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
described in Item 3.D. &ldquo;Risk Factors,&rdquo; as of December 31, 2020, we have <FONT STYLE="background-color: white">material weaknesses
in our internal control over financial reporting, relating </FONT>to the lack of segregation of duties and lack of sufficient and competent
financial reporting and accounting <FONT STYLE="background-color: white">personnel with appropriate knowledge and experience with technical
accounting in accordance with U.S. GAAP and to prepare and review financial statements and related disclosures in accordance with U.S.
GAAP and SEC reporting requirements</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2020, we began to take steps to remediate these material weaknesses and to strengthen our internal control
over financial reporting, including hiring of additional accounting consultants, documenting our financial reporting policies and procedures
and preparing accounting memoranda to address significant accounting and financial reporting issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_060"></A>ITEM&nbsp;16A.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AUDIT COMMITTEE FINANCIAL
    EXPERT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
board of directors has determined that Myoung-Ok Kwon, a member of our audit committee is an audit committee financial expert, as defined
under the rules under the Exchange Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq Stock Market rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_061"></A>ITEM&nbsp;16B.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CODE OF ETHICS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to Swiss law, we adopted a code of business conduct and ethics which covers a broad range of matters including the handling of conflicts
of interest, compliance issues and other corporate policies such as insider trading and equal opportunity and non-discrimination standards.
Our code of business conduct and ethics is applicable to all our directors, senior management and employees. We have published our code
of business conduct and ethics on our website, <I>www.nlspharma.com</I>. <FONT STYLE="color: black">If we make any amendment to the code
of business conduct and ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the
nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions
to Item 16.B. of Form 20-F.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_062"></A>ITEM&nbsp;16C.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL ACCOUNTANT
    FEES AND SERVICES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
March 4, 2021, we dismissed our independent registered public accounting firm, Marcum LLP, or the Former Auditor, and engaged PricewaterhouseCoopers
AG, or the New Auditor to audit fiscal years ended December 31, 2020, 2019 and 2018. The following table provides information regarding
fees billed by Marcum LLP and <FONT STYLE="background-color: white">PricewaterhouseCoopers AG </FONT>for all services, including audit
services, for each of the last two fiscal years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended<BR> December 31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit
    fees <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">202,567</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">195,421</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit-related
    fees <SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
    fees <SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    other fees <SUP>(4)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">202,567</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">195,421</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consists of fees billed for the audit
                                  of our annual financial statements, review of financial statements included in our initial public offering
                                  prospectus and services that are normally provided by the auditors in connection with statutory and
                                  regulatory filings or engagements.</FONT></TD></TR>                                 <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consists of assurance and related services
                                  that are reasonable related to the performance of the audit and review of our financial statements
                                  and are not included in &ldquo;audit fees&rdquo; in this table.</FONT></TD></TR>                                                                                    <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consists of all tax related services.</FONT></TD></TR>                                                                                                                    <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">There were no other fees.</FONT></TD></TR>                                                                                                        <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
audit committee has a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain
audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence
of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit
services, audit-related services and tax services that may be performed by our independent registered public accounting firm. If a type
of service, that is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval
by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited
non-audit functions defined in applicable SEC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_063"></A>ITEM
    16D.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXEMPTIONS FROM THE
    LISTING STANDARDS FOR AUDIT COMMITTEES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_064"></A>ITEM
    16E.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASES OF EQUITY
    SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_065"></A>ITEM
    16F.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGE IN REGISTRANT&rsquo;S
    CERTIFYING ACCOUNTANT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
March 4, 2021, we dismissed our independent registered public accounting firm, Marcum LLP, or the Former Auditor, and engaged PricewaterhouseCoopers
AG, or the New Auditor. We notified the Former Auditor of this change on March 5, 2021. Our board of directors approved the dismissal
of the Former Auditor and the engagement of the New Auditor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
report of the Former Auditor for our audited financial statements as of and for the years ended December 31, 2019 and 2018 did not contain
an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles,
except for an explanatory paragraph in such report regarding substantial doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the fiscal years ended December 31, 2019 and 2018 and the subsequent interim period through March 4, 2021, there were (i) no &ldquo;disagreements&rdquo;
(as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between us and the Former Auditor on any
matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if
not resolved to the satisfaction of the Former Auditor, would have caused the Former Auditor to make reference to the subject matter
of the disagreement in its reports on our financial statements and (ii) no &ldquo;reportable events&rdquo; (as that term is defined in
Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for the material weaknesses in internal control over financial
reporting related to improper cutoff of our accounts payable and accrued expenses in a previous period, and to the accounting for complex
transactions, including intangible assets and a licensing agreement as disclosed in our prospectus, dated January 28, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the fiscal years ended December 31, 2020 and 2019 and the subsequent interim period through March 4, 2021, neither we, nor anyone on
our behalf, consulted the New Auditor regarding (i) the application of accounting principles to a specified transaction, either completed
or proposed, or the type of audit opinion that might be rendered on our financial statements, and no written report or oral advice was
provided to us by the New Auditor that the New Auditor concluded was an important factor considered by us in reaching a decision as to
any accounting, auditing or financial reporting issue or (ii) any matter that was the subject of a &ldquo;disagreement&rdquo; (as that
term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a &ldquo;reportable event&rdquo; (as that term
is defined in Item 304(a)(1)(v) of Regulation S-K).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_066"></A>ITEM
    16G.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORPORATE GOVERNANCE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>Differences
between Swiss Laws and Nasdaq Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Sarbanes-Oxley Act, as well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply
with various corporate governance practices. In addition, we are required to comply with the Nasdaq Stock Market Rules. Under those rules,
we may elect to follow certain corporate governance practices permitted under the Swiss law in lieu of compliance with corresponding
corporate governance requirements otherwise imposed by the Nasdaq Stock Market Rules for U.S. domestic registrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with Swiss law and practice and subject to the exemption set forth in Rule&nbsp;5615 of the Nasdaq Stock Market Rules, as
a foreign private issuer, we have elected to rely on home country governance requirements and certain exemptions thereunder rather than
the Nasdaq Stock Market Rules, with respect to the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Composition of the board of directors</I>. Swiss
    law does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore
    may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition,
    we will not be subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors must regularly have scheduled
    meetings at which only independent directors are present.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Quorum</I>.
        In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements
        generally applicable to general meetings of shareholders.&nbsp;Our practice thus varies from the requirement of Nasdaq Listing
        Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not
        be less than one-third of the outstanding voting stock.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
        to Swiss law, for the approval of the management report and the annual financial statements, the Company&rsquo;s auditor must
        be present at such a general meeting of shareholders, unless the general meeting of shareholders waives such attendance by unanimous
        decision.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proxy Solicitations</I>. There are currently three
    types of institutional proxies under Swiss Law: (i) the independent proxy, (ii) the board proxy and (iii) the custodian proxy, all
    which tend to vote in favor of the board&rsquo;s proposals, because the default for the independent proxy is to vote with the board
    and by virtue of law the board and custodian proxies must vote with the board of directors. The Swiss Ordinance against Excessive
    Compensation in Listed Stock Companies, or the Compensation Ordinance, is applicable to companies limited by shares that are listed
    in Switzerland or abroad. According to the Compensation Ordinance, the solicitation of proxies by our board of directors or a custodian
    thereof is not permitted and only independent proxies are permitted. The independent proxy has to be elected by the general meeting
    of shareholders, must only vote pursuant to the specific instructions of the shareholders and must abstain from voting in the absence
    of specific instructions. However, Swiss law does not have a regulatory regime for the solicitation of proxies and company solicitation
    of proxies is prohibited for public companies in Switzerland; thus our practice will vary from the requirement of Nasdaq Listing
    Rule 5620(b), which sets forth certain requirements regarding the solicitation of proxies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share Issuances</I>. Pursuant to Swiss law, prior
    to our initial public offering, we opted out of shareholder approval requirements by way of including authorized and conditional
    share capital for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another
    company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of the Company
    and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally
    requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Compensation,
        Nomination and Governance Committee</I>. The Compensation Ordinance requires that we adopt a compensation committee, so in accordance
        with Nasdaq Listing Rule 5615(a)(3), we will follow home country requirements with respect to the compensation committee. Under
        home country rules, the general meeting of shareholders has the authority to set up the basic principles of the compensation
        committee&rsquo;s responsibilities in a company&rsquo;s articles of association. In addition, the shareholders may decide to
        include in the articles of association a list of concrete responsibilities of the compensation committee. Unless the articles
        of association list concrete responsibilities of the compensation committee, the determination of the concrete responsibilities
        falls within the competence of the board of directors. Furthermore, the general meeting of shareholders must vote on the compensation
        report and the total of the remunerations of the board of directors, management and advisory committee. According to the doctrine,
        the strategic planning of the remuneration system and policy as well as the determination of the remuneration procedure is the
        inalienable task of the board of directors, unless a list of concrete responsibilities is included in the articles of association
        of the Company. Apart from that, the board of directors has the authority to determine whether the compensation committee shall
        have the decision-making power with regard to the individual salaries or whether it shall have only a request right to the board
        of directors.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
        pursuant to Swiss law, both the number of committee members (the minimum and maximum number of compensation committee members)
        and the identity of the compensation committee members is determined by our shareholders. Our home country rules also do not
        require us to authorize a committee of our independent directors or alternatively hold a vote consisting of solely our independent
        directors in order to determine which persons shall be nominated for election by our shareholders. Our practice will therefore
        vary from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities,
        composition and independence of compensation committees, and from the independent director oversight of director nominations
        requirements of Nasdaq Listing Rule 5605(e). Furthermore, we will be subject to the Compensation Ordinance (&ldquo;Say on Pay&rdquo;
        Rule). This means that the compensation of our board of directors and senior management must be presented by the board of directors
        to our shareholders and our shareholders must vote on the proposed compensation. Furthermore, pursuant to the Compensation Ordinance,
        severance, advances, transaction premiums and similar payments to senior management and director are prohibited.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Code of Business Conduct and Ethics</I>. Pursuant
    to Swiss law, we adopted a code of business conduct and ethics applicable to all of our directors, senior management and employees,
    which may not comply with the requirements of Nasdaq Listing Rule 5610.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_067"></A>ITEM
    16H.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINE SAFETY DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_068"></A>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_069"></A>ITEM
    17.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have elected to provide financial statements and related information pursuant to Item 18.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_070"></A>ITEM
    18.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consolidated financial statements and the related notes required by this Item are included in this annual report beginning on page F-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_071"></A>ITEM
    19.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following documents are filed as part of annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit
    Number</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit&nbsp;Description</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 11%; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1</FONT></TD><TD STYLE="width: 1%; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 88%; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390021006237/ea134404ex3-1_nlspharma.htm">Amended
    and Restated Articles of Association of NLS Pharmaceutics Ltd. (filed as Exhibit 3.1 to form 6-K (File No. 001-39957) filed on February
    2, 2021).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex2-1_nlspharma.htm">Description
    of Securities (filed herewith).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex1-1_nlspharma.htm">Representative&rsquo;s
    Warrant (filed as Exhibit 1.1 to form F-1 (File No. 333-236797) filed on January 20, 2021).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex4-2_nlspharma.htm">Warrant
    Agent Agreement (filed as Exhibit 4.2 to form F-1 (File No. 333-236797) filed on November 13, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390020036675/ea129645ex4-3_nlspharma.htm">Form
    of Warrant (filed as Exhibit 4.3 to form F-1 (File No. 333-236797) filed on November 13, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-14_nlspharma.htm">License
    Agreement dated February 2019 between Eurofarma Laboratorios S.A. and the Company (filed as Exhibit 10.14 to form F-1 (File No. 333-236797)
    filed on February 28, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390020005070/ea119052ex10-15_nlspharma.htm">Assignment
    and Transfer Agreement dated August 31, 2015 between NLS-1 AG and NeuroLife Sciences SAS (filed as Exhibit 10.15 to form F-1 (File
    No. 333-236797) filed on February 28, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex4-6_nlspharma.htm">License
    Agreement by and between NLS Pharmaceutics Ltd. and Novartis Pharma AG, dated March 10, 2021 (filed herewith).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex8-1_nlspharma.htm">Listing of Subsidiaries</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.1</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex12-1_nlspharma.htm">Certification
    of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 (filed herewith).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.2</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex12-2_nlspharma.htm">Certification
    of the Interim Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 (filed herewith).</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.1</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex13-1_nlspharma.htm">Certification
    of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.2</FONT></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f20f2020ex13-2_nlspharma.htm">Certification
    of the Interim Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith.</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">101</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following financial information from the
    Registrant&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2020, formatted in XBRL (eXtensible Business Reporting
    Language): (i) Balance Sheets; (ii) Statements of Operations and Comprehensive Loss; (iii) Statements of Changes in Shareholders&rsquo;
    Deficit; (iv) Statements of Cash Flows; and (v) Notes to the financial statements, tagged as blocks of text and in detail.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_072"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on Form 20-F filed on its behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Subhasis
    Roy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subhasis Roy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 300pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
PHARMACEUTICS LTD.<BR>
FINANCIAL STATEMENTS<BR>
YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
PHARMACEUTICS LTD.<BR>
FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 91%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_001">Report
    of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-3</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_002">Balance
    Sheets as of December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_003">Statements
    of Operations and Comprehensive Loss for the Years Ended December 31, 2020, 2019 and 2018</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_004">Statements
    of Changes in Shareholders&rsquo; Deficit for the Years Ended December 31, 2020, 2019 and 2018</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-6</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_005">Statements
    of Cash Flows for the Years Ended December 31, 2020, 2019 and 2018</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-7</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_006">Notes
    to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-8</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_001"></A><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To the Shareholders
and Board of Directors of<BR>
NLS Pharmaceutics Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have audited the accompanying balance sheets of NLS Pharmaceutics Ltd. (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019,
and the related statements of operations and comprehensive loss, changes in shareholders&rsquo; deficit and cash flows for each of the
three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31,
2020 in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Restatement
of Previously Issued Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
discussed in Note 3 to the financial statements, the Company has restated its 2019 and 2018 financial statements to correct an error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Substantial
Doubt about the Company&rsquo;s Ability to Continue as a Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has incurred recurring losses since inception and will need to raise additional funds to meet
its obligations and sustain its operations which raises substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Basis
for Opinion </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ PricewaterhouseCoopers
AG</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Zurich, Switzerland</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;May
14, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have served
as the Company&rsquo;s auditor since 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_002"></A>NLS
PHARMACEUTICS LTD.<BR>
BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,711</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">220,267</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets, including related party of $0 and $13,432 as of December 31, 2020 and 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">103,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">161,479</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">196,711</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">381,746</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">946,912</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">260,211</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    receivables, net &ndash; related party</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">67,954</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54,472</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    assets</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,211,577</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">696,429</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND SHAREHOLDERS&rsquo; DEFICIT</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable, including related party of $454,315 and $34,727, respectively</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,006,473</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,509,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">316,174</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">170,268</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    promissory notes &ndash; related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">591,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">540,071</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    portion of credit facilities, subordinated &ndash; related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    portion of convertible loans, including related party of $113,130, net of discount of $37,362 as of December 31, 2020</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">463,980</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    loan</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">565,650</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    salaries</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">459,195</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">102,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    accrued liabilities, including related party of $40,842 and $12,391 as of December 31, 2020 and 2019, respectively</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">650,753</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">562,465</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,203,918</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,035,104</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    loans, net of discount of $4,248 and $64,788 as of December 31, 2020 and 2019, respectively</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,463</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">152,058</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Swiss
    government loan</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">281,015</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenues</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,499,969</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,499,969</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    pension liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">178,269</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180,248</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,195,634</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,867,379</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies (Note 12)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    deficit:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    shares, CHF 0.02 ($0.02) par value, 10,440,000 authorized, 6,960,000 shares issued and outstanding at December 31, 2020 and 2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,139</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,139</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,649,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,600,871</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29,759,697</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(26,898,262</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    other comprehensive loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,381</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,698</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    shareholders&rsquo; deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,984,057</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,170,950</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities and shareholders&rsquo; deficit</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,211,577</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">696,429</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_003"></A>NLS
PHARMACEUTICS LTD.<BR>
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018<BR>
    (as&nbsp;restated)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development <SUP>1</SUP></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,580</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,455</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative <SUP>1</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,199,790</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,299,251</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,740,406</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,299,370</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,197,039</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,448,861</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,299,370</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,197,039</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,448,861</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    (expense) income, net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(328,365</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(65,445</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,035</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(86,792</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(992</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense on related party loans</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,908</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(818,719</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,084,708</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on conversion of debt</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(364,950</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(629,232</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,861,435</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,146,766</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    comprehensive loss:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Defined
    pension plan adjustments</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(683</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,444</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,261</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Comprehensive
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,862,118</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,454,589</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,148,027</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted net loss per common share</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.41</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.80</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.82</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average common shares used in computing basic and diluted net loss per common share</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,960,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,840,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,240,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Comparative
                                            figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct
                                            the classification of intellectual property expenses from research and development expenses
                                            to general and administrative expenses. For further information, see Note 3 &ldquo;Restatement
                                            of Previously Issued Financial Statements&rdquo; to the financial statements.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_004"></A>NLS
PHARMACEUTICS LTD.<BR>
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; DEFICIT<BR>
FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Shares</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional<BR> Paid in</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated<BR> Other<BR> Comprehensive</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE,
    JANUARY 1, 2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,120,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">128,344</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,468,547</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,304,351</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,993</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,717,453</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common shares for conversion of related party debt to equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">260,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,200</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,042,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,047,752</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
    discount on related party loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Defined
    pension plan adjustments</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,261</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,261</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,146,766</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,146,766</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE, DECEMBER 31,
    2018</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,380,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">133,544</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,515,118</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21,451,117</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,813,709</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common shares for conversion of related party debt to equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,595</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,011,605</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,023,200</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
    discount on related party loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,540</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,540</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    conversion feature on convertible loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,608</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,608</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Defined
    pension plan adjustments</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE, DECEMBER 31,
    2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,960,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,139</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,600,871</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(26,898,262</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,698</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,170,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    conversion feature on convertible loans</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,911</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,911</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    conversion feature on related party convertible loan</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Defined
    pension plan adjustments</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,861,435</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,861,435</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE,
    DECEMBER 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,960,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,139</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,649,882</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29,759,697</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,381</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,984,057</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_005"></A>NLS
PHARMACEUTICS LTD.<BR>
STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Operating Activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,861,435</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447,145</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,146,766</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -9.9pt; padding-left: 13.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Periodic
    pension costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,258</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,085</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,566</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of debt discounts</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">72,188</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">755,555</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,090,411</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on conversion of debt</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">364,950</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">629,232</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in operating assets and liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,477</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,038</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,382</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    receivables, net - related parties</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,482</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(41,101</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,497,123</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,378,545</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">565,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">137,826</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">67,159</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,252</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenues</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,499,969</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 21.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">446,129</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">185,911</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,873</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(729,386</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(190,009</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,732,804</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Financing Activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible loans</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">249,306</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,890</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible loan &ndash; related party</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">113,130</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from Swiss government loan</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">262,137</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from Bridge loan</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">565,650</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible promissory notes &ndash; related parties</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">512,800</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">557,920</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    offering costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(686,701</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260,211</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">503,522</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">407,479</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">557,920</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of exchange rate on cash and cash equivalents</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,308</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,881</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,369</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in cash and cash equivalents</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(126,556</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">213,589</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,176,253</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at the beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">220,267</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,678</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,182,931</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at the end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,711</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">220,267</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,678</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    disclosure of non-cash investing and financing activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common shares for settlement of related party credit facilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,023,200</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,047,752</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
    discount on related party loans</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,540</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,019</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible loans in transit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,956</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these financial statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_006"></A><I>Note
1</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Background:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the &ldquo;Company&rdquo;) is an emerging biopharmaceutical company engaged in the discovery
and development of life-improving drug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic
hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;).
The Company&rsquo;s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 12, 2019, the Company merged NLS-0 Pharma Ltd. and NLS Pharma Ltd. into <FONT STYLE="background-color: white">NLS-1 Pharma Ltd.
(the &ldquo;Merger&rdquo;), the predecessor of the Company,</FONT> retroactively and effective on January 1, 2019 and renamed the Company
NLS Pharmaceutics Ltd. Due to the high degree of common ownership among the three companies and because individual investors&rsquo; ownership
is in substance the same after the transaction, this Merger was deemed to be a non-substantive merger, with no step up in basis of the
assets and liabilities in the Merger. The financial statements presented were prepared as if the Merger occurred on January 1, 2018.
All intercompany transactions and balances were eliminated in the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
February 2, 2021, the Company </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">completed the closing of its initial public
offering (the &ldquo;Initial Public Offering&rdquo;) of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common
share and one Warrant to purchase one common share (the &ldquo;Warrants&rdquo;). The common shares and Warrants were immediately separable
from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021
under the symbols &ldquo;NLSP&rdquo; and &ldquo;NLSPW,&rdquo; respectively. The Company received net proceeds of $17 million, after deducting
underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years
from the date of issuance and have an exercise price of $4.15 per share. In addition, the Company granted the underwriters a 45-day option
to purchase up to an additional 722,891 common shares at the public offering price of $4.14 per common share and/or up to an additional
722,891 Warrants to purchase 722,891 common shares at the public offering price of $0.01 per Warrant, of which the underwriters exercised
their option to purchase Warrants to purchase up to 722,891 common shares. These Warrants were issued in the Company&rsquo;s Initial
Public Offering and therefore have the same exercise price of $4.15 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Liquidity
and Going Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company had an accumulated deficit of approximately $29.8 million and the Company incurred operating losses
since inception, including operating loss for the year ended December 31, 2020 of approximately $2.3 million. To date, the Company has
dedicated most of its financial resources to research and development, clinical studies associated with its ongoing biopharmaceutical
business and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company&rsquo;s cash and cash equivalents were $93,711 and shareholders&rsquo; deficit was $8,984,057. The
Company expects that its existing cash and cash equivalents, including the net proceeds of $17 million from its Initial Public Offering,
will be sufficient to fund operations into the second quarter of 2022. These conditions raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern for one year from the issuance of these financial statements. Additionally, the Company&rsquo;s
operating plans may change as a result of many factors that may currently be unknown to the Company including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the length of the COVID-19
    pandemic and its impact on our planned clinical trials, operations and financial condition;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of
    our pre-clinical studies, clinical trials and other research and development activities; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, prioritization
    and number of our clinical trials and other research and development programs;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any cost that we may incur
    under in- and out-licensing arrangements relating to our product candidate that we may enter into in the future; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of obtaining
    regulatory approval for our product candidates; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
    enforcing and defending patent claims and other intellectual property rights; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of, and timing for,
    strengthening our manufacturing agreements for production of sufficient clinical and commercial quantities of our product candidates;
    </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting
    with third parties to provide marketing and distribution services for us or for building such capacities internally; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring or
    undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates
    and the magnitude of our general and administrative expenses. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result, the Company may require additional capital to finance expenditures related to the manufacture of the Company&rsquo;s product
candidates for use in clinical trials, conducting clinical trials and general and administration costs<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has historically financed its activities primarily with cash from the private placement of equity and debt securities and borrowings
under credit facilities and shareholder loans. The Company intends to raise additional capital through private placements of debt and
equity securities or through loans from third parties, but there can be no assurance that these funds will be available, or if they are
available, their availability will be on terms acceptable to the Company or in an amount sufficient to enable the Company to fully complete
its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop
and implement a plan to further extend payables and indebtedness, reduce overhead, or scale back its current business plan until sufficient
additional capital is raised to support further operations or force the Company to grant rights to develop and commercialize product
candidates that it would otherwise prefer to develop and commercialize on its own. There can be no assurance that such a plan will be
successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accordingly,
the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;), which contemplate continuation of the Company as a going concern for a period within one year from
the issuance of these financial statements and the realization of assets and satisfaction of liabilities in the normal course of business.
The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable
or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
1A</I>&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stock
Split</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 14, 2020, the Company filed an amendment to its Articles of Incorporation and effected a 5,000-for-1 stock split of its issued
and outstanding common shares, whereby 1,392 outstanding common shares with a par value of CHF 100.00 per share were exchanged for 6,960,000
common shares with a par value of CHF 0.02 per share. All per share amounts and number of shares in the financial statements and related
notes have been retroactively restated to reflect the share split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
2</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Summary
of Significant Accounting Policies:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Basis
of Presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance
is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&ldquo;ASC&rdquo;) and Accounting
Standards Updates (&ldquo;ASU&rdquo;) of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial
statements, the Company&rsquo;s significant estimates include (1) pension and other post-employment benefits, including certain asset
values that are based on significant unobservable inputs; (2) the inputs used in determining the fair value of equity per share; (3)
the beneficial conversion feature on the convertible loans and (4) valuation allowance relating to the Company&rsquo;s deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>JOBS
Act Accounting Election </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is an &ldquo;emerging growth company&rdquo; or &ldquo;EGC&rdquo;, as defined in the Jumpstart Our Business Startups Act of 2012
(the &ldquo;JOBS Act&rdquo;). Under the JOBS Act, an EGC has elected to delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Cash
and Cash Equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. The Company
generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Deferred
Offering Costs </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Specific
incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly
be deferred and charged against the gross proceeds of such an offering. As of December 31, 2020 and 2019, there were $946,912 and $260,211,
respectively, of Initial Public Offering costs, primarily consisting of legal, accounting and printing fees, that were capitalized in
other non-current assets on the balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Concentration
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2020 and 2019, substantially
all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions
which are in excess of federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Functional
Currency</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has operations in Switzerland and the United States. The Company&rsquo;s functional currency is the U.S. dollar (&ldquo;USD&rdquo;).
The results of its non-USD based operations are translated to USD at the average exchange rates during the year. The Company&rsquo;s
assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&rsquo; equity is
translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company&rsquo;s
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Revenue
Recognition </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company has not recognized any revenue from its exclusive license agreement (the &ldquo;EF License Agreement&rdquo;),
as the upfront payment the Company received has been deferred. The EF License Agreement is to develop and commercialize its product candidate,
Nolazol, in Latin American countries with Eurofarma Laboratorios S.A. (&ldquo;Eurofarma&rdquo;), a Brazilian pharmaceutical company.
The EF License Agreement is within the scope of ASC 606, &ldquo;<I>Revenue from Contract with Customers</I>&rdquo; (&ldquo;ASC 606&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities
of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the
goods or services are integral to or dependent on other goods or services in the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in
the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that
includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be
received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received
based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the
transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant
reversal in the amount of the cumulative revenue recognized will not occur in a future period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The
Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified
in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations,
which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally,
in determining the stand-alone selling price for material rights, the Company may reference comparable transactions, clinical trial success
probabilities, and develop estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each
performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress at each reporting
period and, if necessary, adjusts the measure of performance and related revenue recognition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within the Company&rsquo;s control or the licensee&rsquo;s control, such
as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting
period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary,
adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect license revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement
of development, regulatory, or commercial milestone revenue resulting from the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting
from any of the Company&rsquo;s license agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
the extent the Company receives payments, including non-refundable payments, in excess of the recognized revenue, such excess is recorded
as deferred revenue until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the Company&rsquo;s right to consideration is unconditional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Costs
for research and development (&ldquo;R&amp;D&rdquo;) of products, including payroll, contractor expenses, and supplies, are expensed
as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where
contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when
the milestone results are probable of being achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
and Administrative Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Fair
Value Measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with ASC 820, &ldquo;<I>Fair Value,&rdquo;</I> which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to
access as of the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity
for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted
as appropriate for liquidity, credit, market and/or other risk factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above.
The carrying values of the Company&rsquo;s accounts payable approximate their fair value due to the short-term nature of these liabilities.
The carrying value of the Company&rsquo;s debt is estimated to approximate its fair value, as the notes are near maturity and the interest
rates on the debts approximates market rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Debt
Issuance Costs and Debt Discount</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount
of that debt liability, consistent with debt discounts, and are amortized to interest expense over the term of the related debt using
the effective interest method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&rsquo;s tax
returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from
future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that
all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax
expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due
to the fact that the Company has a history of generating losses, and expects to generate losses in the foreseeable future, a full valuation
allowance has been recorded as no deferred taxes have been recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Income
Taxes </I><FONT STYLE="background-color: white">(</FONT><I>Accounting for Uncertainty in Income Taxes),&rdquo; </I><FONT STYLE="background-color: white">which
clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position
can be recognized in the financial statements only if the position is &ldquo;more-likely-than-not&rdquo; to be sustained were it to be
challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without
regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the &ldquo;more-likely-than-not&rdquo;
threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority
is recorded. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Employee
Benefits (including Post Retirement Benefits)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company operates the mandatory pension plan for its employees in Switzerland. The plan is generally funded through payments to insurance
companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on
individual savings accounts. However, this plan is classified as a defined benefit plan under ASC 960 <I>&ldquo;Plan Accounting &ndash;
Defined Benefit Pension Plans</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of
plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected
unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&rsquo;
projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating
the terms of the related liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Remeasurements
of the net defined benefit liability, which comprise actuarial gains and losses, and the return on plan assets (excluding interest),
are recognized immediately in Other Comprehensive Loss. Past service costs, including curtailment gains or losses, are recognized immediately
as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses
are recognized in either research and development and/or general and administrative expenses within the operating results. The Company
determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to
measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement
dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period
as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized
in the statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Earnings
per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted-average number of common
shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator
is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period
in which a net loss is reported or if their effect is anti-dilutive. The Company&rsquo;s potential common shares consist of convertible
promissory notes and convertible loans with their potential dilutive effect considered using the &ldquo;if-converted&rdquo; method. For
the years ended December 31, 2020 and 2019, 50,205 and 20,000 shares related to the convertible loans were excluded from the computation,
respectively.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Segment
Reporting</I></B></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company
manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&rsquo;s
singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company&rsquo;s
tangible assets are held in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Accounting
Pronouncements &ndash; Not Yet Adopted</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU No. 2019-12, <I>Income Taxes (Topic 740)</I>: <I>Simplifying the Accounting for Income Taxes</I>.
The FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining
usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology
for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the
amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate
consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes
in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance
will become effective for the Company beginning after December 15, 2021 and interim periods within fiscal years beginning after December
15, 2022. Because the Company&rsquo;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from
the adoption of this standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Accounting
Pronouncements &ndash; Recently Adopted</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU No. 2018-13, <I>Fair Value Measurement (Topic 820): Disclosure Framework &ndash; Changes to the Disclosure
Requirements for Fair Value Measurement</I>, which adds and modifies certain disclosure requirements for fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount and reasons for transfers between Level 1 and Level 2 of
the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public business entities will be required
to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related
changes in unrealized gains and losses included in other comprehensive income. ASU 2018-13 was effective for public and non-public business
entities for fiscal years beginning after December 15, 2019, including interim periods. The adoption of ASU 2018-13 did not have a material
impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
3</I></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Restatement
of Previously Issued Financial Statements</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the audit of the Company&rsquo;s financial statements for the year ended December 31, 2020, the Company identified an error in the presentation
of the intellectual property expenses in 2019 and 2018. The intellectual property expenses should have been classified as general and
administrative expenses instead of research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
resulted in a restatement to correct previously reported amounts in the financial statements of the Company for the years ended December
31, 2019 and 2018. This reclassification of expenses had no impact on total operating expenses, net loss, loss per share or the balance
sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following tables present the impact of the restatement in the financial statements for the years ended December 31, 2019 and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As&nbsp;Previously<BR>
    Reported</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    Restated</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development expenses</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,702,117</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">($</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">804,329</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,788</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,494,922</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">804,329</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,299,251</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,197,039</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,197,039</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As&nbsp;Previously
    Reported</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    Restated</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development expenses</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,437,202</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">($</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,747</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,455</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,011,659</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,747</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,740,406</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,448,861</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,448,861</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note 4</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prepaid
Expenses and Other Current Assets:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s prepaid expenses and other current assets consisted of the following as of December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vendor
    overpayments</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,380</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">37,445</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">VAT
    recoverable and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,207</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">33,579</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    loan funding</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,956</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,413</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,067</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO
    receivable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,432</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    prepaid expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">103,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">161,479</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
balance of the prepaid expenses and other current assets for the years ended December 31, 2020 and 2019, consisted mainly of some vendor
overpayments and value added tax (&ldquo;VAT&rdquo;) recoverable, that were returned to the Company during the following fiscal periods.
Additionally, the Company recorded a receivable from the Chief Executive Officer (&ldquo;CEO&rdquo;) for using Company credit cards for
personal travel expenses. Subsequent to the year ended December 31, 2019, the CEO receivable has been paid in full. The prepaid expenses
and other current assets for the year ended December 31, 2019 also included funding of a convertible loan entered into on December 23,
2019, for which funding was received on January 6, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
5</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Receivables, net &ndash; Related Party:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s majority shareholders are also majority shareholders in Pegasus Advanced Research SAS, formerly NeuroLifeScienses SAS
(&ldquo;Pegasus&rdquo;), and as such Pegasus is considered to be a related party to the Company. In December 2015, Pegasus assigned its
exclusive global license to certain compounds involving mazindol to the Company (the &ldquo;License Agreement&rdquo;). The License Agreement
includes a royalty payment of 1.8% of the annual net sales (including sales made by sub-licensees) of the licensed compounds covered
thereunder; provided, however, that such royalty payment could be further reduced to 0.9% in the event that the U.S. Patent and Trademark
Office were to issue a revised notice of allowance or expand the patent rights of certain licensed compounds or be completely cancelled
in the event that a competing generic product were to reach the market during the term of the patents covering such licensed compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
assigning the License Agreement to the Company, the Company and Pegasus have paid for some operating expenses for each other. The transactions
between the companies are minimal and are not considered to be a funding source for either entity. The Company offsets the related receivables
and payable to/from Pegasus for a combined net other long-term receivable of $67,954 and $54,472 for the years ended December 31, 2020
and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
6</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Convertible
Promissory Notes &ndash; Related Parties:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&rsquo;s convertible promissory notes with related parties as of December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    promissory notes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">591,693</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">540,071</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2019, the Company entered into an agreement with Magnetic Rock Investment AG (&ldquo;MRI&rdquo;), which is owned by certain shareholders
of the Company, to loan the Company CHF 550,000 ($557,920). The loan proceeds were received in advance of the agreement, in two payments,
in each of August and December 2018 in the amount of CHF 500,000 ($507,200) and CHF 50,000 ($50,720), respectively. Management determined
that no separate accounting or bifurcation was required for this conversion feature as it doesn&rsquo;t meet the definition of a derivative
because the net settlement criterion is not met. The note accrues interest at 10% per year and has a conversion feature such that upon
a capital closing (as defined), MRI has the right to require conversion of its note to equity at the same terms as such capital closing.
As of December 31, 2020, such capital closing (as defined) has not occurred, so the note has not converted. The note had an original
maturity date of April 30, 2019 at which time if it wasn&rsquo;t already converted, a new maturity date would be set at the discretion
of MRI. The parties have amended the agreement to extend the maturity date to March 31, 2021. The Company has accrued interest payable
of $42,929 for the note as of December 31, 2020. Additionally, the Company recorded debt discount of $4,019 based on an imputed interest
rate of 12%, the rate readily available to the Company, compared to the 10% annual interest rate stated in the loan agreement. The debt
discount is being amortized to interest expense using the effective interest rate method over the debt term. For the years ended December
31, 2019 and 2018, amortization of $237 and $3,782, respectively, was included in interest expense &ndash; related parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2019, MRI and the Company agreed to convert an aggregate amount of CHF 526,980 ($526,769) of its loan into 40,000 of the Company&rsquo;s
common shares at a conversion price of approximately $13 per share. The common shares had a fair value of CHF 14 ($14) per share and
an aggregate fair value of $550,829, resulting in a $24,060 loss on conversion of the loan. Pursuant to an amendment to this loan, the
maturity date of the remaining loan of CHF 23,020 ($26,043) was extended to March 31, 2021. <FONT STYLE="background-color: white">The
Company determined that the extension of the loan which was past due or near maturity was in substance no different than issuing new
financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2019, the Company entered into four additional convertible promissory notes, on the same terms, with certain Company shareholders.
The promissory notes were for CHF 125,000 ($128,200) each, accrue interest at 10% per year and have original maturity dates of the earlier
of April 30, 2019 or when any investment into the Company of CHF 500,000 ($565,650) or greater occurs. The maturity of these notes was
extended to March 31, 2021. The Company has accrued interest payable of $119,045 for the notes as of December 31, 2020. Additionally,
the Company recorded debt discount of $8,540, based on an imputed interest rate of 12% compared to the 10% interest accrued on the loans.
The debt discount is being amortized to interest expense using the effective interest rate method over the debt term. For the year ended
December 31, 2019 amortization of $8,540 was included in interest expense &ndash; related parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, all of the convertible promissory notes, including accrued interest, were repaid in full.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
7</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Credit
Facilities, Subordinated &ndash; Related Parties:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&rsquo;s credit facilities with related parties as of December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Second
    Credit Facility, net of debt discount of $0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2015, the Company entered into a second credit facility agreement (the &ldquo;Second Credit Facility&rdquo;) with certain shareholders
(the &ldquo;Lenders&rdquo;). The maximum borrowings under the Second Credit Facility were $500,000. The Second Credit Facility had a
maturity date of December 31, 2018 and accrued interest at 0%. As the Second Credit Facility did not accrue interest, management, upon
issuance of the debt, recorded total debt discount and a corresponding increase in additional paid in capital based on an imputed interest
at a rate of 12%. The debt discount was being amortized to interest expense using the effective interest rate method over the debt term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
June 2018, the Company and the Lenders entered into a subordination agreement regarding the Second Credit Facility. The subordination
agreement deferred payments on the Second Credit Facility during the term of the agreement. The agreement was to expire if (i) the Lenders
irrevocably waived the subordinated claims; or (ii) if the claims were converted to share capital or participation capital of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the remaining balance of the Second Credit Facility of $150,000 was outstanding and the parties amended the agreement
covering such credit facility to extend the maturity date to March 31, 2021. Additionally, the accrued interest of $85,737 on an expired
credit facility remained unpaid and the parties amended that credit facility to extend the maturity date to March 31, 2021. <FONT STYLE="background-color: white">The
Company determined that the extension of these credit facilities which were past due or near maturity was in substance no different than
issuing new financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the remaining balance on the Second Credit Facility and the accrued interest on an expired credit facility was paid in
full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
8</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Convertible
Loans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&rsquo;s convertible loans as of December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    loans, net of discount of $41,611</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">383,313</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">152,058</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    loans &ndash; related party</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">113,130</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">496,443</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">152,058</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    current portion</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(463,980</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    loans, long term</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,463</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">152,058</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, the Company entered into two loans for a total of CHF210,000 ($216,846) (the &ldquo;Convertible Loans&rdquo;). <FONT STYLE="background-color: white">In
February, March and June 2020, the Company entered into five additional convertible loans, on terms similar to those in December 2019,
including one with a related party, for a total of CHF 265,606 ($300,480).</FONT> The Convertible Loans accrued interest at 10% and have
a conversion feature such that the lender could choose to convert the loan to equity at any time up to the maturity date of August 31,
2021. The conversion rate of CHF 9 ($11) per common share was at a discount to the CHF 11 ($13) per common share fair value of the Company.
The proceeds from the loans were allocated between the debt instruments and the beneficial conversion feature, with the beneficial conversion
feature valued at CHF 63,537 ($65,608) for the December 2019 convertible loans and CHF 37,779 ($49,011) for the 2020 convertible loans.
On the date of issuance, the beneficial conversion feature value was calculated as the difference between the conversion price and the
fair value per share, multiplied by the number of common shares into which the Convertible Loans are convertible. The embedded conversion
feature was not bifurcated as it did not meet all of the elements of a derivative. For the year ended December 31, 2020, amortization
of $48,088 was included in interest expense and $24,100 was included in interest expense &ndash; related parties. For the year ended
December 31, 2019, amortization of $820 was included in interest expense. The Company has accrued interest payable of $48,634 and $172
for the Convertible Loans as of December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, all of the Convertible Loans, including accrued interest, were repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
9</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Swiss
Government Loan:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April 2020, in response to the COVID 19 pandemic, the Swiss Federal Council issued the COVID-19 Ordinance on Joint and Several Guarantees,
according to which companies domiciled in Switzerland that are economically affected by the COVID-19 pandemic can apply for financial
support in the form of emergency bank loans of up to 10% of their 2019 revenues or a maximum of CHF 20 million (the &ldquo;COVID-19 Loan&rdquo;).
This COVID-19 Loan was secured by the Swiss Confederation. The lending banks received collateral in the form of joint and several guarantees.
The Company received a COVID-19 Loan from its bank for CHF 248,400 ($281,015), which carried a 0% interest rate and was due in 60 months.
The loan could be drawn down over several installments and the Company had drawn down the entire amount. Pursuant to the terms of the
COVID-19 Loan, the Company could not pay any dividends until it repays such loan in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the COVID-19 Loan was repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
10</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Bridge
Loan:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2020, the Company received the first tranche of CHF 300,000 ($309,780) pursuant to a bridge loan (the &ldquo;Bridge Loan&rdquo;).
Pursuant to the Bridge Loan, the Company could borrow up to an aggregate of CHF 500,000 ($516,300), or an additional CHF 200,000 ($206,520),
upon successful filing of its Form F-1, which occurred in August 2020. The total Bridge Loan of CHF 500,000 ($527,650) carried an interest
rate of 10% annually and was initially due September 30, 2020 <FONT STYLE="background-color: white">which was amended to December 31,
2020. </FONT>In January 2021, the Bridge Loan was amended two additional times. The first of the two amendments extended the maturity
date to March 31, 2021, and the second amendment increased the total amount of the Bridge Loan to CHF 600,000 ($633,180).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the Bridge Loan, including accrued interest, was repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
11</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pension
Liability:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company joined a collective pension plan operated by an insurance company as of 2016 which covers the employees in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both
the Company and the participants provide monthly contributions to the pension plan which are based on the covered salary. The respective
saving parts of premiums are credited to employees&rsquo; accounts. In addition, interest is credited to employees&rsquo; accounts at
the rate provided in the plan. The pension plan provides for retirement benefits as well as benefits on long-term disability and death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table provides information on the pension plan for the years ended December 31, 2020, 2019 and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Service
    cost</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,875</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,206</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,617</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    cost</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">832</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,992</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,190</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    return on assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,713</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,249</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,294</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of settlement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28,754</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,810</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Administrative
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,185</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,946</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,053</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    periodic pension cost (benefit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,575</FONT></TD><TD STYLE="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,085</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,566</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
reconciliation of the projected benefit obligation and the changes to the fair value of the plan assets of the pension plan are shown
in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, beginning of period</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">386,064</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">385,448</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Service
    cost</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,875</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,206</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    cost</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">832</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,992</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(169,942</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(40,147</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actuarial
    (gain)/ loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,561</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,765</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -3pt; padding-left: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,800</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">273,675</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">386,064</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan
    assets, beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">205,816</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">226,428</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual
    return on plan assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(620</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,739</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employer
    contributions</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,207</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,867</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Participant
    contributions</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,954</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,608</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(142,931</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49,755</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Administration
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,185</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,946</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,165</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,875</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan
    assets, end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95,406</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">205,816</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    pension liability</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">178,269</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180,248</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, the Company recorded an accrued pension liability of $178,269 and $180,248, respectively, as non-current
liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
pension assets are measured at fair value and are invested in a collective pension foundation with pooled investments. Plan assets mainly
consist of cash and cash equivalents, equity funds, equity securities, corporate bonds, government bonds, and real estate funds classified
as Level 1 and Level 2 under the fair value hierarchy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company records net gains/losses, consisting of actuarial gains/losses, curtailment gains/losses and differences between expected and
actual returns on plan assets, in other comprehensive income/loss. Such net gains/losses are amortized to the statements of operations
to the extent that they exceed 10% of the greater of projected benefit obligations or pension assets. The Company further records prior
service costs/credits from plan amendments in other comprehensive income/loss in the period of the respective plan amendment and amortizes
such amounts to the statement of operations over the future service period of the plan participants. For the years ended December 31,
2020 and 2019, the amortization was $0. As of December 31, 2020 and 2019, the accumulated other comprehensive loss includes unrecognized
pension costs of $19,381 and $18,698, respectively, consisting of net losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table shows the components of unrecognized pension cost in accumulated other comprehensive income/loss that have not yet been
recognized as components of net periodic pension cost:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss,
    beginning of period</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,698</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,254</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    gain/loss during the period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,895</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,634</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of settlement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,212</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,810</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of pension related net loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss, end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,381</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,698</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
    service cost, beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of prior service cost</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
    service cost end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    unrecognized pension cost, end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,381</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,698</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
weighted average of the key assumptions used to compute the benefit obligations were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Discount
    rate</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.15</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.35</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rate
    of increase in compensation level</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    credit rate on savings accounts</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    long-term rate of return on plan assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inflation
    rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
assumption of the expected long-term rate of return on plan assets was based on the long-term historical rates of returns for the different
investment categories which were adjusted, where appropriate, to reflect financial market developments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accumulated benefit obligation as of December 31, 2020 and 2019 amounted to $273,675 and $386,064, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
investment risk is borne by the insurer and the reinsurer respectively, and the investment decision is taken by the board of trustees
of the collective insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
12</I></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Deferred
Revenues:</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2019, the Company entered into the EF License Agreement, to develop and commercialize its product candidate, Nolazol, in Latin
American countries with Eurofarma, a Brazilian pharmaceutical company. The EF License Agreement covers the grant of non-transferable
licenses, without the right to sublicense, to Eurofarma to develop and commercialize Nolazol in Latin America. The EF License Agreement
also specifies the Company&rsquo;s obligation to advance ongoing development activities with respect to Nolazol in the United States.
A joint steering committee will oversee the development and regulatory activities directed towards marketing approval, manufacturing
and commercialization phases. The Company believes its participation in the joint steering committee is not of material significance
to the licenses in the context of the EF License Agreement on the whole and, as such, management has excluded these activities in the
determination of its performance obligation(s) under the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
EF License Agreement provides that the parties shall enter into a separate manufacturing and supply agreement during the term of the
EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the EF License Agreement, the Company received a non-refundable, upfront payment, of $2,500,000 and is further eligible to receive non-refundable
milestone payments of up to $16,000,000, based on the achievement of milestones related to regulatory filings, regulatory approvals and
the commercialization of Nolazol. The achievement and timing of the milestones depend on the success of development, approval and sales
progress, if any, of Nolazol in the future. In addition, the Company is also eligible for tiered royalty payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company identified the licenses granted to Eurofarma and its obligation to advance development activities with respect to Nolazol in
the United States as the material promises under the EF License Agreement. For purposes of identifying the Company&rsquo;s performance
obligations under the EF License Agreement, management believes that while the exclusive licenses were granted to Eurofarma at the outset
of the EF License Agreement, the grant of those licenses does not singularly result in the transfer of the Company&rsquo;s broader obligation
to Eurofarma under the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is obligated under the EF License Agreement to advance its development activities in the United States and those activities precede
Eurofarma&rsquo;s necessary regulatory approvals for commercialization of Nolazol, in Latin American countries. The Company intends to
apply its proprietary know-how to the ongoing development activities in the United States involving its intellectual property relating
to Nolazol. These development activities are specific to the Company and the Company believes they are not capable of being distinct
in the context of the EF License Agreement on the whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
licenses provided to Eurofarma are not transferable and without the right to sublicense therefore Eurofarma is not presently able to
monetize its investment in Nolazol as clinical development in the United States or any Latin American countries has yet to be completed
and Eurofarma has yet to seek or obtain regulatory approval in any Latin American country. The licenses to Eurofarma represent rights
to use the Company&rsquo;s intellectual property with respect to Nolazol for which revenue is recognized at a point in time which is
when Eurofarma is able to use and benefit from the licenses. The licenses are considered of limited value without the Company&rsquo;s
development activities with respect to Nolazol in the United States. As such, the licenses are not capable of being distinct until after
successful clinical development and regulatory approval and alone do not have standalone functionality to Eurofarma. Management has determined
that the licenses, while capable of being distinct, are not distinct as they do not have stand-alone value to Eurofarma without the Company&rsquo;s
planned development activities in the United States and the approval for sale in Latin America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bundled
together with the Company&rsquo;s development activities of Nolazol in the United States, the licenses granted under the EF License Agreement
will enable Eurofarma to seek regulatory approvals and ultimately seek to commercialize Nolazol in Latin America. Therefore, management
believes the licenses bundled together with the Company&rsquo;s development activities in the United States constitute a single distinct
performance obligation under the EF License Agreement for accounting purposes (the &ldquo;License Performance Obligation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has initially estimated a total transaction price of $2,500,000, consisting of the fixed upfront payment determined to be an
advance on the License Performance Obligation. Upon execution of the EF License Agreement and as of December 31, 2020 and 2019, variable
consideration consisting of milestone payments has been constrained and excluded from the transaction price given the significant uncertainty
of achievement of the development and regulatory milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has allocated the transaction price entirely to the single License Performance Obligation and recorded the $2,500,000 as deferred
revenue that is expected to be recognized upon Brazilian or other Latin American market approval or, in the event marketing approval
in the United States and/or Latin America is not achieved, whether by failure in clinical development or otherwise, when the Company&rsquo;s
performance obligations are contractually complete or the EF License Agreement is terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amounts
expected to be recognized as revenues within the 12 months following the balance sheet date are classified as a current portion of deferred
revenues in the accompanying condensed balance sheets. Amounts not expected to be recognized as revenues within the 12 months following
the balance sheet date are classified as deferred revenues, net of current portion. As of December 31, 2020 and 2019, the Company has
long-term deferred revenues of $2,500,000, which will be recognized when the development services of Nolazol are completed and the product
candidate receives applicable regulatory approval in Latin America that allows Eurofarma to commence commercialization of Nolazol in
accordance with the EF License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
13</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Commitments
and Contingencies: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Commitments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, the Company entered into a feasibility development agreement (the &ldquo;Development Agreement&rdquo;) with Adare Pharmaceuticals,
Inc. (&ldquo;Adare&rdquo;), pursuant to which the Company intends to utilize Adare&rsquo;s proprietary modified release technologies
in the development of mazindol for use in the Company&rsquo;s product candidates used for the treatment of narcolepsy and ADHD. The formulation
to be developed by Adare under this Development Agreement is intended to be owned solely by the Company. Upon completion of certain milestones,
as defined in the Development Agreement, the Company is obligated to pay Adare up to $840,000. <FONT STYLE="background-color: white">In
January 2021, the Company and Adare agreed to terminate the Development Agreement, effective as of December 19, 2020. The project was
never started and the Company has no liability to Adare.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Litigation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company may become involved in miscellaneous litigation and legal actions, including product liability, consumer, commercial, tax and
governmental matters, which can arise from time to time in the ordinary course of the Company&rsquo;s business. Litigation and legal
actions are inherently unpredictable, and excessive verdicts can result in such situations. The Company is not currently involved in
any such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>COVID-19</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In
December 2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) emerged in Wuhan, China. Since then, it has spread to several other
countries and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak
of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in the United States, Canada and internationally,
including in Switzerland, have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions,
border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19
outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals,
including unprecedented business, employment and economic disruptions. The continued spread of COVID-19 in the United States, Canada
and globally, including in Switzerland, could have an adverse impact on our business, operations and financial results, including through
disruptions in our cultivation and processing activities, supply chains, as well as a deterioration of general economic conditions including
a possible national or global recession. Shelter-in-place orders and social distancing practices designed to limit the spread of COVID-19
may affect our ability to conduct clinical studies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
Company has not been adversely affected from the effects of the COVID-19 outbreak, neither from any delay in its clinical development
activities nor by its ability to source necessary financing to fund its operations. In view of the continuing uncertainty about the further
development of COVID-19, an adverse development can be expected in 2021, but its financial impact on the Company cannot yet to be adequately
and conclusively assessed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
14</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shareholders&rsquo;
Deficit:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company had 6,960,000 registered and issued common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2019, the Company issued a total of 580,000 of its common shares to creditors in exchange for payment of $5,131,481 of the credit
facilities, $2,000,000 of the interest-free $2 million bridge loan and $529,769 of convertible promissory notes. </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
July 2018, the Company issued 260,000 of its common shares to the creditors in exchange for payment of $3,418,519 due under the $7.1
million credit facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
15</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Income
Taxes</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has Swiss tax loss carryforwards of $15.5 million as of December 31, 2020 (December 31, 2019: $11.5 million) of which $9.7 million
will expire within the next five years, and $5.8 million will expire between 2025 - 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
significant components of net deferred taxes as of December 31, 2020 and 2019 are shown in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    benefit from tax loss carryforwards</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,393,809</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,031,524</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenues</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">224,997</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">224,997</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other,
    net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,951</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,065</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    allowance</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,625,757</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,241,456</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company recorded a valuation allowance in 2020 and 2019 to reduce the net deferred taxes, as the Company deemed it to be more likely
than not that the future deferred tax assets would not be realized in the future based on the lack of sufficient positive evidence in
the jurisdictions related to the realization of the deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
effective tax rate was 0% for the years ended December 31, 2020, 2019 and 2018. The following table shows the income taxes in 2020, 2019
and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current tax</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">$<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            -</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    income tax (benefit)</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(384,301</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(325,572</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(289,462</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(384,301</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(325,572</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(289,462</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">384,301</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">325,572</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">289,462</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total income tax expense</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company files income tax returns in Switzerland. The Company&rsquo;s income tax position in Switzerland is finally assessed up to the
year ended December 31, 2018, so the years ended December 31, 2019 and 2020 are open for examination. Currently the Company does not
have any open tax assessments. The following table shows the reconciliation between expected and effective tax rate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Statutory
    tax rate</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of permanent differences</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2.3</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance on deferred tax assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12.9</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6.7</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5.3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
    tax rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company had generated approximately $9,700,000 of net operating losses (&ldquo;NOLs&rdquo;) prior to the Merger, in which the Company&rsquo;s
preliminary analysis indicates that such NOLs would not be subject to significant limitations pursuant to applicable income tax regulations.
The permanent differences relate to the conversion to U.S. GAAP from Swiss accounting, mainly in the areas of debt, intangible amortization
and deferring financing costs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, there were no unrecognized tax benefits. <FONT STYLE="background-color: white">If such matters were to
arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. </FONT>The Company did
not incur any material interest or penalties in connection with income taxes during the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
16</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Related
party consulting agreements:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company entered into consulting agreements with several of its senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2017, and as subsequently amended in October 2020, the Company entered into a consulting agreement with CHG BioVenture SA, an
entity controlled by Mr. Herv&eacute; Girsault, the Company&rsquo;s current Head of Business Development. Pursuant to the consulting
agreement, the Company agreed to pay CHG BioVenture SA a monthly fee of CHF 17,500, as well as an opportunity to a bonus of up to 15%
of the annual fee, subject to the Company&rsquo;s discretion. In addition, the Company has agreed to pay CHG BioVenture SA a 1% fee tied
to the net proceeds actually received by the Company in certain transactions, such as, but not limited to, an M&amp;A transaction. The
consulting agreement may be terminated by either party for any reason at the end of each calendar quarter with three months&rsquo; prior
written notice, or immediately if Mr. Girsault breaches the confidentiality provision. The consulting agreement also provides for a 24-month
non-competition clause. The consulting agreement also provides for standard confidentiality provisions as well as reimbursement for certain
expenses. For the year ended December 31, 2020, 2019 and 2018, the Company recorded fees to CHG BioVenture SA of $285,859, $285,538 and
$286,206, respectively, included in general and administrative expenses on the statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company provided BioVenture SA and Mr. Girsault notice of the Company&rsquo;s termination of the consulting agreement with CHG BioVenture
SA, pursuant to which Mr. Girsault provides his services to the Company, which will take effect on June 30, 2021. The Company is actively
in discussions with Mr. Girsault on continuing his engagement with the Company in his current role.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2021, the Company entered into a consulting agreement with Mr. Subhasis Roy, the Company&rsquo;s current Interim Chief Financial
Officer, pursuant to which the Company agreed to pay Mr. Roy a daily rate of CHF 2,000 for his services. The consulting agreement may
be terminated by either party upon 30 days&rsquo; written notice or immediately by the Company in the event of a material breach by Mr.
Roy that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the Company entered into a consulting agreement with Mr. Eric Konofal, the Company&rsquo;s current Interim Chief Scientific
Officer, pursuant to which the Company agreed to pay Mr. Konofal a daily rate of CHF 2,000 for his services. The consulting agreement
may be terminated by either party upon 30 days&rsquo; written notice or immediately by the Company in the event of a material breach
by Mr. Konofal that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month
non-solicitation clause as well as reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2021, the Company entered into a consulting agreement with Mr. Carlos Camozzi, the Company&rsquo;s current Interim Medical Director,
pursuant to which the Company agreed to pay Mr. Camozzi an hourly rate of CHF 230 plus 7.7% VAT for his services. The consulting agreement
may be terminated by either party upon 30 days&rsquo; written notice or immediately by us in the event of a material breach by Mr. Camozzi
that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause as well as reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Note
17</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subsequent
Events</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In
January 2021, the loans listed below were further amended such that the maturity date of each instrument were scheduled to be March 31,
2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$85,737 under an old expired
    credit facility;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150,000 under the Second
    Credit Facility;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 500,000 (approximately
    $565,650) under the four convertible promissory notes from January 2019, each of which carried an interest rate of 10% per year;
    </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 23,020 (approximately
    $26,043) under the Convertible Note with MRI, which carried an interest rate of 10% per year; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 100,000 (approximately
    $113,130) under the Convertible loan with a related party, which carried an interest rate of 10% per year, and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 600,000 (approximately
    $678,780) under the Bridge Loan, which carried an interest rate of 10% per year.</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
February 2, 2021, the Company </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">completed the closing of its Initial Public
Offering of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one Warrant. The common shares
and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the
Nasdaq Capital Market on January 29, 2021 under the symbols &ldquo;NLSP&rdquo; and &ldquo;NLSPW,&rdquo; respectively. The Company received
net proceeds of $17 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants
are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share. In addition,
the Company granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase
722,891 common shares, of which the underwriters exercised the option to purchase warrants to purchase up to 722,891 shares of common
shares. These Warrants were issued in the Company&rsquo;s Initial Public Offering and therefore have the same exercise price of $4.15
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the Company repaid all of its various loans and notes, including accrued interest, in full.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, on March 10, 2021, the Company entered into a License Agreement with Novartis Pharma AG (&ldquo;Novartis&rdquo;), whereby the
Company obtained, on an exclusive basis in the U.S., all <FONT STYLE="background-color: white">of the available data referred to and
included in the original NDA for Sanorex&reg; (mazindol) submitted to the FDA in February 1972. The agreement encompasses all preclinical
and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation
data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety
reports from 1973 onwards. Under the Agreement, the Company has obtained the same rights on a non-exclusive basis in all territories
outside of the U.S. except for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed
territories. The Agreement includes the right to sublicense or assign the license to third parties, subject to such third parties meeting
certain obligations. As consideration for the license, the Company agreed to pay Novartis $250,000 upon the signing of the agreement
with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to
be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of
</FONT>Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time
payment upon the Company&rsquo;s product candidate reaching $250 million in cumulative sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>





<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
<!-- Field: /Page -->








</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>f20f2020ex2-1_nlspharma.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
2.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description
of Rights of Each Class of Securities</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
and Class of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, NLS Pharmaceutics Ltd., or the Company, had a share capital of CHF 139,200.00 divided into 6,960,000 registered
shares with a nominal value of CHF 0.02 each, or the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the initial public offering of the Company in February 2021 on Nasdaq, the Company conducted a share capital increase. As of
5 February 2021, the Company has a registered share capital of CHF 235,826.50 divided into 11,791,325 registered shares with a nominal
value of CHF 0.02 each, or the Common Shares. In addition, 277,000 warrants have been exercised whereby the aforementioned share capital
increases to CHF 241,366.50 divided into 12,068,325 Common Shares with a nominal value of CHF 0.02 each. For the avoidance of doubt,
the additional 277,000 Common Shares have been issued, but the share capital has not yet been updated resp. registered in the Commercial
Register of the Canton of Nidwalden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Number and Purposes and Objects of the Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is registered with the Commercial Register of the Canton of Nidwalden, Switzerland, registration number <FONT STYLE="background-color: white">CHE-447.067.367</FONT>.
The purpose of the Company is the research and development of pharmaceutical, chemical, medical-technical, bio-technical and similar
related products, the acquisition, holding and granting of licenses and other intellectual properties as well as to provide various services
in this regard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Articles
of Association </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Ordinary
Capital Increase, Authorized and Conditional Share Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
Swiss law, we may increase our share capital (Aktienkapital) with a resolution of the general meeting of shareholders (ordinary capital
increase) that must be carried out by the board of directors within three months in order to become effective. In the case of subscription
and increase against payment of contributions in cash, a resolution passed by an absolute majority of the shares represented at the general
meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund acquisitions in
kind, when shareholders&rsquo; statutory pre-emptive rights are withdrawn or where transformation of reserves into share capital is involved,
a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal
amount of the shares represented is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Swiss Code of Obligations, or the CO, our shareholders, by a resolution passed by two-thirds of the shares represented at a general
meeting of shareholders and the absolute majority of the nominal amount of the shares represented, may empower our board of directors
to issue shares of a specific aggregate nominal amount up to a maximum of 50% of the share capital in the form of:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorized capital
    (&ldquo;genehmigtes Kapital&rdquo;) to be utilized by the board of directors within a period determined by the shareholders but not
    exceeding two years from the date of the shareholder approval; or</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditional capital (&quot;bedingtes
    Kapital&quot;) for the purpose of issuing shares in connection with, among other things, (i) option and conversion rights granted
    in connection with warrants and convertible bonds of the Company or one of our subsidiaries or (ii) grants of rights to employees,
    members of our board of directors or consultants or our subsidiaries or other persons providing services to the Company or a subsidiary
    to subscribe for new shares (conversion or option rights).</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Our
Authorized Share Capital</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
articles of association authorize our board of directors to increase the share capital (within a period of no more than two years) and
set forth the nominal amount by which the board of directors may increase the share capital (such authorized capital may not exceed one-half
of the existing share capital).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
our current version of the articles of association dated 2 February 2021, our board of directors is authorized until 29 January 2023,
to increase our share capital by a maximum aggregate amount of CHF 117,551.80 through the issuance of not more than 5,877,590&nbsp;common
shares, which would have to be fully paid-in, each with a par value of CHF 0.02 per common share. Increases in partial amounts are permitted.
The board of directors determines the timing, issue price, the type of contributions and the date on which the dividend entitlement commences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
articles of association also explicitly set forth the events for which a restriction or exclusion of the pre-emptive rights from the
current shareholders is permitted.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Within
the limits of Swiss law, a general meeting of shareholders may increase or alter the authorization granted to the board of directors.
</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
affect any capital increase based on our authorized share capital, the Company will have to follow the relevant procedures under Swiss
law. In particular, the Company&rsquo;s board of directors will have to approve a general authorization resolution (&ldquo;Erm&auml;chtigungsbeschluss&rdquo;),
issue a capital increase report (&ldquo;Kapitalerh&ouml;hungsbericht&rdquo;), approve a notarized confirmation resolution (&ldquo;Feststellungsbeschluss&rdquo;)
on the capital increase and the articles of association, and obtain (i) duly executed subscription form(s) covering the subscription
of the relevant number of new shares, (ii) a report of an audit firm relating to the withdrawal of the pre-emptive rights, as well as
(iii) a banking confirmation confirming the payment of the aggregate nominal value of the respective number of new shares to a special
Swiss bank account, all in accordance with Swiss law. The Company&rsquo;s board of directors will subsequently have to file the relevant
documentation accompanied by an application form with the competent commercial register. Any issuance of common shares based on such
filing(s) is subject to the recording of the respective capital increase(s) in the commercial register in accordance with Swiss law and
its publication in the electronic Swiss Official Gazette of Commerce (&ldquo;Schweizerisches Handelsamtsblatt&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Our
Conditional Share Capital</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conditional
Share Capital for Warrants and Convertible Bonds and Advisors</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
per our current version of the articles of association, our nominal share capital may be increased by a maximum aggregate amount of CHF
110,843.36 through the issuance of not more than 5,542,168 common shares, which would have to be fully paid-in, with a nominal value
of CHF 0.02 each, by the exercise of option and conversion rights granted in connection with warrants and convertible bonds of the Company
or one of our subsidiaries. Shareholders will not have pre-emptive subscription rights in such circumstances. The holders of convertible
bonds are entitled to the new shares upon the occurrence of the applicable conversion feature. Warrants that have been exercised in the
meantime are not yet reflected in the articles of association of the Company by means of an increase of the issued share capital and
the respective reduction of the conditional share capital. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">When
issuing convertible bonds, the board of directors is authorized to withdraw or to limit the advance subscription right of shareholders
to subscribe to the convertible bond issuance:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the purpose of financing or
    refinancing the acquisition of enterprises, divisions thereof, or of participations or of newly planned investments of the Company;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the issuance occurs in domestic
    or international capital markets, including private placements.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the advance subscription rights are withdrawn, (i)&nbsp;the convertible bonds are to be issued at market conditions;
(ii)&nbsp;the term to exercise the option or conversion rights may not exceed ten years as of the date of the convertible bond issue
and twenty years for conversion rights; and (iii)&nbsp;the exercise price for the new shares must at least correspond to the market conditions
at the time of the convertible bond issuance.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: 11.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conditional
Share Capital for Equity Incentive Plans</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
nominal share capital may, to the exclusion of the pre-emptive subscription rights of shareholders, be increased out of the condition
share capital of the Company by a maximum aggregate amount of CHF 6,949.40 through the issuance of not more than 347,470 common shares,
which would have to be fully paid-in, with no less than the nominal value of CHF 0.02 each, by the exercise of option or conversion rights
that have been granted to employees, members of the board of directors or consultants of the Company or of one of our subsidiaries, if
any, or other persons providing services to the Company or a subsidiary, if any, through one or more equity incentive plans created by
the board of directors. If this conditional share capital is not sufficient for our future equity incentive plan, then we intend to rely
on the authorized share capital, which we will have to dedicate for that purpose, or, alternatively, if such conditional or authorized
share capital is not sufficient, then we intend to seek shareholder approval for the equity incentive plan(s) that we may seek to implement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Pre-emptive
Rights</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the CO, shareholders have pre-emptive rights (&ldquo;Bezugsrechte&rdquo;) to subscribe for new issuances of shares. With respect to
conditional capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders
have advance subscription rights (&ldquo;Vorwegzeichnungsrechte&rdquo;) for the subscription of conversion rights, convertible bonds
or similar debt instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
previously convened a meeting of our shareholders whereby our shareholders authorized our board of directors to withdraw or limit pre-emptive
rights and/or advance subscription rights in certain circumstances.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our authorized share capital, the board of directors is authorized by our articles of association to withdraw or to limit
the pre-emptive rights of shareholders, and to allocate them to third parties or to us, in the event that the newly issued shares are
used for a purpose set forth in our articles of association.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Uncertificated
Securities</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
shares are uncertificated securities (&ldquo;Wertrechte,&rdquo; within the meaning of the CO) and, when administered by a financial intermediary
(&ldquo;Verwahrungsstelle,&rdquo; within the meaning of the Federal Act on Intermediated Securities, or FISA), qualify as intermediated
securities (&ldquo;Bucheffekten,&rdquo; within the meaning of the FISA). In accordance with art. 973c of the CO, we maintain a non-public
register of uncertificated securities (&ldquo;Wertrechtebuch&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
registered in our share register, a shareholder may at any time request from us a written confirmation with respect to such person&rsquo;s
shares. The Company may issue certificates representing one or several shares at any time. Shareholders are not entitled, however, to
request the printing and delivery of certificates.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Participation
Certificates and Profit-sharing Certificates</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has not issued any non-voting equity securities, such as participation certificates (&ldquo;Partizipationsscheine&rdquo;) or
profit sharing certificates (&ldquo;Genussscheine&rdquo;), nor has it issued any preference shares (&ldquo;Vorzugsaktien&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>No
Additional Capital Contributions</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
Swiss law, shareholders are not obliged to make any capital contribution in excess of the subscription amount, which can be under no
circumstance less than the nominal value per share.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>General
Meeting of Shareholders: Meetings and Powers</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
general meeting of shareholders is our supreme corporate body. Under Swiss law, an annual, ordinary general meeting of shareholders must
be called on an annual basis and we may hold extraordinary general meetings of shareholders in addition to any annual general meeting.
Under Swiss law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation&rsquo;s
financial year. In our case, this means on or before the 30<SUP>th</SUP>&nbsp;day of June.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following powers are vested exclusively in the general meeting of shareholders:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adopting and amending our articles
    of association;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">electing the members of the board of directors, the
    chairman of the board of directors, the members of the compensation, nomination and governance committee, the auditors and the independent
    proxy holder (a person annually elected by the general meeting of shareholders and who may represent our shareholders at a general
    meeting of shareholders as a proxy solicitor);</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the annual report, the
    annual statutory financial statements and the consolidated financial statements, and deciding on the allocation of profits as shown
    on the balance sheet, in particular with regard to dividends and bonus payments to members of the board of directors;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the compensation of members
    of the board of directors and executive management, which under Swiss law is not necessarily limited to the executive officers;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discharging the members of the board
    of directors and executive management from liability with respect to their tenure in the previous financial year;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dissolving the Company with or without
    liquidation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deciding matters reserved to the
    general meeting of shareholders by law or our articles of association or that are presented to it by the board of directors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
extraordinary general meeting of shareholders may be called by a resolution of the board of directors or, under certain circumstances,
by our auditor, liquidator or bondholder (or the representatives of convertible bondholders), if any. In addition, in accordance with
the CO, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at
least one-tenth of our share capital request such general meeting of shareholders in writing. Such request must set forth the items to
be discussed and the proposals to be acted upon. According to the CO, the board of directors must convene an extraordinary general meeting
of shareholders and propose financial restructuring measures if, based on our stand-alone annual statutory balance sheet, half of our
share capital and reserves are not covered by our assets.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Voting
and Quorum Requirements</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Shareholder
resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the absolute majority
of shares represented at the general meeting of shareholders, unless otherwise stipulated by law.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
resolution of the general meeting of the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute
majority of the nominal value of the shares represented is required for:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any amendment of the Company&rsquo;s
    objectives;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the introduction of shares with
    preferential voting rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any restriction on the transferability
    of registered shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating authorized or conditional
    share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a capital increase funded by equity,
    against contributions in kind or for the purpose of funding acquisitions in kind and the granting of special privileges;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any restriction or cancellation
    of the subscription right (i.e., pre-emptive rights);</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a relocation of the seat (registered
    office) of the Company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dissolution of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
same voting requirements apply to resolutions regarding transactions among corporations based on Switzerland&rsquo;s Federal Act on Mergers,
Demergers, Transformations and the Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally
applicable to general meetings of shareholders. Additionally, before a resolution to approve the management report and consolidated accounts
can be passed, our auditor must also be present at such general meeting of the shareholders, unless the general meeting of the shareholders
waives such attendance by unanimous decision of those present. To this extent, our practice varies from the requirement of Nasdaq Listing
Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less
than one-third of the outstanding voting stock.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Notice</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
meetings of shareholders must be convened by the board of directors at least twenty days before the date of the meeting. The general
meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette
of Commerce. Registered shareholders may also be informed by letter, facsimile or electronic mail. The notice of a general meeting of
shareholders must state the items on the agenda, the proposals to be acted upon and, in case of elections, the names of the nominated
candidates. Except in the limited circumstances listed below, a resolution may not be passed at a general meeting without proper notice.
This limitation does not apply to proposals to convene an extraordinary general meeting of shareholders, the initiating of a special
audit or the election of an auditor upon request of a shareholder. No previous notification is required for proposals concerning items
included in the agenda or for debates that do not result in a vote. The notice period for a general meeting of shareholders may be waived
if all shareholders are present or represented at such meeting (&ldquo;Universalversammlung&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Agenda
Requests</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to Swiss law, one or more shareholders whose combined shareholdings represent the lower of (i) one tenth of the share capital or (ii)
an aggregate nominal value of at least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting
of shareholders. To be timely, the shareholder&rsquo;s request must be received by us at least 30 calendar days in advance of the meeting.
The request must be made in writing and contain, for each of the agenda items, the following information:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a brief description of the business
    desired to be brought before the ordinary general meeting of shareholders and the reasons for conducting such business at the ordinary
    general meeting of shareholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name and address, as they appear
    in the share register, of the shareholder proposing such business; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other information required under
    the applicable laws and stock exchange rules.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
accordance with Swiss law, a business report, compensation report (as prepared by our board of directors) and an auditor&rsquo;s report
must be made available for inspection by the shareholders at our registered office no later than 20 days prior to the ordinary general
meeting of shareholders. Shareholders of record are notified of this in writing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
right to vote, and the other rights of share ownership, may only be exercised by shareholders (including any nominees) or usufructuaries
(a person who has the right to enjoy the use and advantages of another&rsquo;s property short of the destruction or waste of its substance),
who are entered in our share register at cut-off date determined by the board of directors, as authorized by our articles of association
and Swiss law. Those entitled to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually
elected by the general meeting of shareholders), another registered shareholder or third person with written authorization to act as
proxy or the shareholder&rsquo;s legal representative. The chairman of the board of directors has the power to decide whether to recognize
a power of attorney.&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Dividends
and Other Distributions</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution.
Dividend payments require a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders.
In addition, our auditor must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles
of association.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
Swiss law, we may only pay dividends if we have sufficient distributable profits brought forward from the previous business years (&ldquo;Gewinnvortrag&rdquo;),
or if we have distributable reserves (&ldquo;frei verf&uuml;gbare Reserven&rdquo;), each as evidenced by our audited stand-alone statutory
balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association
have been deducted. We are not permitted to pay interim dividends out of profit of the current business year.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
our articles of association and in accordance with Swiss law, only our shareholders have the power to approve the payment of any dividends.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Distributable
reserves are generally booked either as &ldquo;free reserves&rdquo; (&ldquo;freie Reserven&rdquo;) or as &ldquo;reserve from capital
contributions&rdquo; (&ldquo;Reserven aus Kapitaleinlagen&rdquo;). Under the CO, if our general reserves (&ldquo;allgemeine Reserven&rdquo;)
amount to less than 20% of our share capital recorded in the commercial register (i.e., 20% of the aggregate nominal value of our issued
capital), then at least 5% of our annual profit must be retained as general reserves. The CO permits us to accrue additional general
reserves. Further, a purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding
to the purchase price of such own shares. Finally, the CO, under certain circumstances, requires the creation of revaluation reserves
which are not distributable.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Distributions
out of issued share capital (i.e. the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a
share capital reduction. Such a capital reduction requires a resolution passed by an absolute majority of the shares represented at a
general meeting of shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must
confirm that claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register.
The share capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital
of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of shareholders of the
capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of
Commerce three times and notify creditors that they may request, within two months of the third publication, satisfaction of or security
for their claims. The reduction of the share capital may be implemented only after expiration of this time limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
board of directors determines the date on which the dividend entitlement starts. Dividends are usually due and payable shortly after
the shareholders have passed the resolution approving the payment; however, the shareholders, upon request of the board of directors,
may resolve at the general meeting of shareholders to defer the due date of the dividend payments (e.g., in quarterly or other installments).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Transfer
of Shares</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Shares
in uncertificated form (&ldquo;Wertrechte&rdquo;) may only be transferred by way of assignment. Shares that constitute intermediated
securities (&ldquo;Bucheffekten&rdquo;) may only be transferred when a credit of the relevant intermediated securities to the acquirer&rsquo;s
securities account is made in accordance with the relevant provisions of the FISA. Article 4 of our articles of association provides
that in the case of securities held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity,
any transfer, grant of a security interest or usufructuary right in such intermediated securities and the appurtenant rights associated
therewith requires the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructuary right
to be valid against us.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Voting
rights may be exercised only after a shareholder has been entered in our share register (&ldquo;Aktienbuch&rdquo;) with his, her or its
name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. Any acquirer of our shares
who is not registered in our share register as a shareholder with voting rights will, assuming the acquirer holds our shares as of the
record date, still be entitled to dividends and other rights with financial value with respect to such shares.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Inspection
of Books and Records</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the CO, a shareholder has a right to inspect our share register with respect to his own shares and otherwise to the extent necessary
to exercise his shareholder rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected
with the express authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding
of our business secrets. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Special
Audit</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
the shareholders&rsquo; inspection rights, as outlined above, prove to be insufficient in the judgment of the shareholder, any shareholder
may propose to the general meeting of shareholders that specific facts be examined by a special audit in a special investigation. If
the general meeting of shareholders approves the proposal, a company or any shareholder may, within 30 calendar days after the general
meeting of shareholders, request a court in Stans, Switzerland, where our registered office is located, to appoint a special auditor.
If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10 percent of the share capital
or holders of shares in an aggregate nominal value of at least CHF 2,000,000 may within three months&rsquo; request that the court appoint
a special auditor. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the
board of directors or our executive management infringed the law or our articles of association and thereby caused damages to the Company
or our shareholders.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Compulsory
Acquisitions; Appraisal Rights</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Business
combinations and other transactions that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain asset
transfers) are binding on all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented
at a general meeting of shareholders and the absolute majority of the nominal value of the shares represented.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
a transaction under the Swiss Merger Act receives all of the necessary consents, there are no appraisal rights and all shareholders are
compelled to participate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Swiss
corporations may be acquired by an acquirer through the direct acquisition of the share capital of the Swiss corporation. The Swiss Merger
Act provides for the possibility of a so-called &ldquo;cash-out&rdquo; or &ldquo;squeeze-out&rdquo; merger if the acquirer controls 90%
of the outstanding shares. In these limited circumstances, minority shareholders of the corporation being acquired may be compensated
in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of
the acquiring corporation or of another corporation). Following a statutory merger or demerger, pursuant to the Merger Act, shareholders
can file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate
compensation payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, under Swiss law, the sale of&thinsp; &ldquo;all or substantially all of our assets&rdquo; (&ldquo;faktische Liquidation&rdquo;)
by us may require the approval of two-thirds of the number of shares represented at a general meeting of shareholders and the absolute
majority of the nominal value of the common shares represented. Whether a shareholder resolution is required depends on the particular
transaction, including whether the following test is satisfied:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a core part of our business is sold
    without which it is economically impracticable or unreasonable to continue to operate the remaining business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assets, after the divestment, are not invested
    in accordance with our statutory business purpose; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proceeds of the divestment are
    not earmarked for reinvestment in accordance with the Company&rsquo;s business purpose but, instead, are intended for distribution
    to our shareholders or for financial investments unrelated to our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Board
of Directors</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to Swiss law and according to our articles of association, the board of directors shall consist of three or more members, none of which
need to be shareholders. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swiss
law requires that any listed company exceeding two of the three thresholds specified in art. 727 para.1 no. 2 of the CO in two successive
financial years shall have each gender represented by at least 30% on the board of directors and 20% on the executive management team.
If a company fails to comply, it must be disclosed in the remuneration report, including an explanation and a designation of measures
to be taken to reconcile the failed compliance. For our board of directors, this rule will apply, subject to meeting the thresholds required
under the CO, from the business year 2026, whereas for the executive management from the business year 2031. The triggering thresholds
are (i) a balance sheet total of 20 million CHF, (ii) sales revenue of 40 million CHF and (iii) an average of 250 full-time per year.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
members of our board of directors are elected by the general meeting of shareholders for a term of one year. A year within the meaning
of this provision is the period between two ordinary general meetings of shareholders. If a member of the board of directors retires
or is replaced, his successor shall continue in office until the end of his predecessor&rsquo;s term. Each member of our board of directors
must be elected individually.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Powers</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
board of directors has the following non-delegable and inalienable powers and duties:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall management of the company
    and the issuing of all necessary directives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of our appropriate management organization,
    including the power to define responsibilities and duties of our corporate bodies as well as our internal hierarchy;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the organization of the accounting,
    financial control and financial planning systems as required for management of the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the appointment and dismissal of persons entrusted
    with managing and representing the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall supervision of the persons
    entrusted with managing the Company, in particular with regard to compliance with the law, articles of association, operational regulations
    and directives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compilation and issuance of an annual report, preparation
    for the general meeting and implementation of its resolutions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">notification to the court in the event that the Company
    is over-indebted.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">According
to Article 17 of our articles of association, the board of directors may assign the preparation and the implementation of its resolutions
or the supervision of business transactions with regard to the non-transferable and inalienable duties to committees or individual members.
In the event that our board of directors assigns duties in accordance with our articles of association and Swiss law, the board of directors
shall design and implement reporting policies describing how such an assignment would be carried out by a committee or individual member.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Based
on Article 18 of our articles of association, our board of directors may completely or partially delegate the power to manage the Company
to one or more of its members (managing directors) or to third persons (managers).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Indemnification
of Executive Management and Directors</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">According
to Swiss Law and our articles of association, the general meeting of shareholders has the authority to grant discharge to the members
of the board of directors from liability. The effect of the resolution of release (discharge) by the general meeting of shareholders
is effective only for disclosed facts and only as against the Company and those shareholders who approved the resolution or who have
since acquired their shares in full knowledge of the resolution. The right of action of other shareholders lapses six months after the
resolution of release.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses
incurred by such employee in the proper execution of their duties under the employment agreement with the employer. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Conflict
of Interest, Management Transactions</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Swiss
law does not provide for a general provision regarding conflicts of interest. However, the CO contains a provision that requires our
directors and executive management to safeguard the Company&rsquo;s interests and imposes a duty of loyalty and duty of care on our directors
and executive management. This rule is generally understood to disqualify directors and executive management from participation in decisions
that directly affect them. Our directors and executive officers are personally liable to us for a breach of these provisions. In addition,
Swiss law contains provisions under which directors and all persons engaged in the Company&rsquo;s management are liable to the Company,
each shareholder and the Company&rsquo;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore,
Swiss law contains a provision under which payments made to any of the Company&rsquo;s shareholders or directors or any person associated
with any such shareholder or director, other than payments made at arm&rsquo;s length, must be repaid to the Company if such shareholder
or director acted in bad faith.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Principles
of the Compensation of the Board of Directors and the Executive Management</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to Swiss law, our shareholders must annually approve the compensation of the board of directors and the persons whom the board of directors
has, fully or partially, entrusted with the management of the Company. The board of directors must issue, on an annual basis, a written
compensation report that must be reviewed together with a report on our business by our auditor. The compensation report must disclose
all compensation, loans and other forms of indebtedness granted by the Company, directly or indirectly, to current or former members
of the board of directors and executive management to the extent related to their former role within the Company or not on customary
market terms.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
disclosure concerning compensation, loans and other forms of indebtedness must include the aggregate amount for the board of directors
and the executive management as well as the particular amount for each member of the board of directors and executive officer, specifying
the name and function of each respective person.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
forms of compensation are prohibited for members of our board of directors and executive management, such as:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severance payments provided for
    either contractually or in the articles of association (compensation due until the termination of a contractual relationship does
    not qualify as severance payment);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incentive fees for the acquisition
    or transfer of corporations or parts thereof by the Company or by companies being, directly or indirectly, controlled by us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loans, other forms of indebtedness, pension benefits
    not based on occupational pension schemes and performance-based compensation not provided for in the articles of association; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity securities and conversion
    and option rights awards not provided for in the articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
to members of the board of directors and executive management for activities in entities that are, directly or indirectly, controlled
by the Company is prohibited if the compensation (i) would have been prohibited if it was paid directly by the Company, (ii) is not provided
for in the articles of association or (iii) has not been approved by the general meeting of shareholders.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general meeting of shareholders votes on the compensation received directly or indirectly by the board of directors, the executive management
and the advisory board (&ldquo;Beirat&rdquo;). The general meeting of shareholders must vote annually on the compensation of its board
of directors, executive management and the advisory board, and accordingly, at such a meeting, the vote of the general meeting of shareholders
shall have a binding effect.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the general meeting of shareholders votes prospectively on the compensation of the executive management, the articles
of association may provide for an additional amount for the compensation of the members of the executive management appointed after the
vote.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional amount may only be used if the total amount of the compensation of the executive management decided by the general meeting
of shareholders is not sufficient for the compensation of the new members until the next vote of the general meeting of the shareholders.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general meeting of shareholders shall not vote on the additional amount of compensation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Borrowing
Powers</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Swiss law nor our articles of association restrict in any way our power to borrow and raise funds. The decision to borrow funds is made
by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Repurchases
of Shares and Purchases of Own Shares and Other Limitations on the Rights to Own Securities</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CO limits our right to purchase and hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (i)
freely disposable equity capital is available in the required amount; and (ii) the combined nominal value of all such shares does not
exceed 10% of the share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in
the articles of association, the foregoing upper limit is 20%. We currently do not have any transfer restriction in our articles of association.
If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled by means of a capital reduction
within a reasonable time.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
held by us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits
applicable to the shares generally, including dividends and pre-emptive rights in the case of share capital increases.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Swiss
law and/or our articles of association do not impose any restrictions on the exercise of voting or any other shareholder rights by shareholders
residing outside of Switzerland.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Notification
and Disclosure of Substantial Share Interests</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
disclosure obligations generally applicable to shareholders of Swiss corporations under the Swiss Financial Market Infrastructure Act
do not apply to us since our shares are not listed on a Swiss exchange. Similarly, the Swiss takeover regime imposes a duty on any person
or group of persons who acquires more than one-third of a company&rsquo;s voting rights to make a mandatory offer for all of the company&rsquo;s
outstanding listed equity securities. However, these protections are applicable only to issuers that list their equity securities in
Switzerland and, because our common shares are listed exclusively on Nasdaq, is not applicable to us.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to Article 663c of the CO, Swiss corporations whose shares are listed on a stock exchange must specify the significant shareholders and
their shareholdings in the notes to the balance sheet, where these are known or ought to be known. Significant shareholders are defined
as shareholders and groups of shareholders linked through voting rights who own more than five percent of all voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
and Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has warrants that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The Company issued 5,542,168
of such warrants in February 2021 in conjunction with its initial public offering. The warrants entitle the registered holder to purchase
common shares at a price equal to $4.15 per share, subject to adjustment as discussed below, immediately following the issuance of such
warrants and terminating at 5:00 p.m., New York City time, five years after their issuance. Warrants that have been exercised in the
meantime are not yet reflected in the articles of association of the Company by means of an increase of the issued share capital and
the respective reduction of the conditional share capital.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of common shares issuable upon exercise of the warrants may be adjusted in certain circumstances, including
in the event of a stock dividend or recapitalization, reorganization, merger or consolidation. Except by virtue of such holder&rsquo;s
ownership of our common shares, the holder of warrants does not have rights or privileges of a shareholder, including any voting rights,
until the holder exercises such warrant.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants were issued in registered form under a warrant agency agreement between a warrant agent, VStock Transfer LLC, and us. The warrants
were initially being represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The
Depository Trust Company, or DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any other securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>3
<FILENAME>f20f2020ex4-6_nlspharma.htm
<DESCRIPTION>LICENSE AGREEMENT BY AND BETWEEN NLS PHARMACEUTICS LTD. AND NOVARTIS PHARMA AG, DATED MARCH 10, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 4.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>by and between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NLS PHARMACEUTICS LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>And</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVARTIS PHARMA AG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>dated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11 March 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This LICENSE AGREEMENT
(this &ldquo;<B>Agreement</B>&rdquo;) is made as of 11 March 2021 (the &ldquo;<B>Effective Date</B>&rdquo;), by and between Novartis Pharma
AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, CH-4056 Basel, Switzerland (&ldquo;Novartis&rdquo;)
and </FONT>NLS Pharmaceutics Ltd.<FONT STYLE="font-size: 10pt">, a company organized under the laws of Switzerland and located at Alter
Postplatz 2, CH-6370 Stans</FONT>, <FONT STYLE="font-size: 10pt">Switzerland (&ldquo;NLS&rdquo;). Novartis and NLS are each referred to
individually as a &ldquo;<B>Party</B>&rdquo; and together as the &ldquo;<B>Parties</B>.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Novartis and/or its
Affiliates own or Control the data relevant to mazindol and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, NLS wishes to obtain
from Novartis, and Novartis wishes to grant to NLS, certain licenses of data relevant to mazindol in the Field with which NLS desires
to research, develop, market, sell, offer for sale, distribute, manufacture and have manufactured Licensed Products in the Field, as set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants and agreements herein contained, the Parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">DEFINITIONS AND INTERPRETATION</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 <B>Definitions</B>.
The capitalized terms used in this Agreement shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Accounting Standards</B>&rdquo;
means, with respect to NLS, IFRS (International Financial Reporting Standards), as consistently applied by NLS and its Affiliates. NLS
shall promptly notify Novartis in the event that it changes the Accounting Standards pursuant to which its records are maintained, it
being understood that NLS may only use internationally recognized accounting principles (i.e., IFRS or US GAAP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to a Party, any Person that directly or indirectly controls, is controlled by, or is under common control with that
Party. For the purpose of this definition, &ldquo;control&rdquo; means: (a) direct or indirect ownership of more than fifty percent (50%)
of the shares of stock entitled to vote for the election of directors, in the case of a corporation; (b) more than fifty percent (50%)
of the equity interest in the case of any other type of legal entity or status as a general partner in any partnership; (c) any other
arrangement whereby the entity or Person controls or has the right to control the board of directors or equivalent governing body of a
corporation or other entity; (d) if a Party has rights to variable returns from its involvement with an entity or Person and has the ability
to affect its returns and cause the direction of the management or policies of such entity or Person through its power over such entity
or Person; or (e) the ability to cause the direction of the management or policies of a corporation or other entity. In the case of entities
organized under the Laws of certain countries, the maximum percentage ownership permitted by Law for a foreign investor may be less than
fifty percent (50%), and in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign
investor has the power to direct the management and policies of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Auditor</B>&rdquo;
is defined in <U>Section 7.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means a day other than (a) a Saturday or a Sunday; (b) a bank or other public holiday in Basel and Stans, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Calendar Quarter</B>&rdquo;
means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Calendar Year</B>&rdquo;
means a period of twelve (12) consecutive calendar months ending on December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>cGCP</B>&rdquo;
means current Good Clinical Practices as defined in 21 C.F.R. &sect; 50, 54, 56, 312 and 314, and applicable ICH standards as each may
be amended from time to time, and further including any analogous set of regulations, guidelines or standards as defined, from time to
time, by any relevant Regulatory Authority having jurisdiction over the Development, use, Manufacture, and/or Commercialization of the
Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>cGLP</B>&rdquo;
means current Good Laboratory Practices as defined in 21 C.F.R. &sect; 58 and applicable FDA then-current laboratory review and inspection
requirements, as each may be amended from time to time, and further including any analogous set of regulations, guidelines or standards
as defined, from time to time, by any relevant Regulatory Authority having jurisdiction over the Development, use, Manufacture, and/or
Commercialization of the Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>cGMP</B>&rdquo;
means current Good Manufacturing Practices pursuant to 21 C.F.R. &sect; 211, et seq., and applicable ICH standards, as each may be amended
from time to time, and further including any analogous set of regulations, guidelines or standards as defined, from time to time, by any
relevant Regulatory Authority having jurisdiction over the Development, use, Manufacture, and/or Commercialization of the Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Change of Control</B>&rdquo;
is defined in Section 15.2(c)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Combination Product</B>&rdquo;
is defined in the definition of &ldquo;Net Sales&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Commercialize</B>&rdquo;
means any and all activities directed toward commercialization of the Licensed Products, including pre-launch, launch and post-launch
marketing, promoting, detailing, distributing, importing, exporting, selling or offering to sell a Licensed Product, including Manufacturing
activities in support of the foregoing. &ldquo;<B>Commercialization</B>&rdquo; and &ldquo;<B>Commercializing</B>&rdquo; shall have a corresponding
meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compliance Standards</B>&rdquo;
is defined in <U>Section 8.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compound</B>&rdquo;
means mazindol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Control</B>&rdquo;
or &ldquo;<B>Controlled</B>&rdquo; means, with respect to any proprietary, trade secret or other data or information, the legal authority
or right (whether by ownership, license or otherwise) of a Party or its Affiliates to grant a license or a sublicense of data to the other
Party or its Affiliates or provide such data or other information to such other Party or its Affiliates without breaching the terms of
any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party or without giving rise
to any financial or other obligation to any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Development</B>&rdquo; means, with respect to the Compound or any Licensed Products, drug research and development activities,
including, without limitation, process development, test method development and stability testing, assay development and audit development,
toxicology, formulation, pharmaceutical development, quality assurance/quality control development, statistical analysis, clinical studies,
process development, packaging development, product validation activities, regulatory affairs, and the preparation, filing and prosecution
of Regulatory Filings with Regulatory Authorities, including, without limitation, the EMA and the FDA, in order to obtain the Regulatory
Approval for any such Licensed Products in a particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective Date</B>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>EMA</B>&rdquo; means
the European Medicines Agency or any successor entity thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA</B>&rdquo; means
the United States Food and Drug Administration or any successor entity thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Field&rdquo;</B>
means autism, attention deficit hyperactivity disorder, narcolepsy type 1 and type 2, idiopathic hypersomnia, Klein-Levine syndrome and
substance abuse disorder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>First Commercial
Sale</B>&rdquo; means, with respect to a Licensed Product, the first arm&rsquo;s length sale to a Third Party (other than an Affiliate
or sublicensee) in a particular country after the Regulatory Approval of such Licensed Product has been obtained in such country, for
use of such Licensed Product in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Force Majeure</B>&rdquo;
means any unavoidable and unforeseeable event which is beyond the reasonable control of the Party affected, including but not limited
to the following events: earthquake, storm, flood, fire or other acts of nature, epidemic, war (whether or not declared), riot, public
disturbance, strike or lockouts, government actions, terrorist attack or the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Entity</B>&rdquo;
means any court, agency, authority, department, legislative or regulatory body or other instrumentality of any government, country, or
national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country, a supranational
organization of which any such government or country is a member, or quasi-governmental authority or self-regulatory organization of competent
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ICH</B>&rdquo; means
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Improvements</B>&rdquo;
is defined in <U>Section 5.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Improvement Patents</B>&rdquo;
is defined in <U>Section 5.3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U STYLE="text-decoration: none">&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IND</B>&rdquo; means
an Investigational New Drug application in the United States filed with the FDA or the corresponding application for the investigation
of Licensed Products in any other country or group of countries, as defined in the applicable Law and filed with the Regulatory Authority
of a given country or group of countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Information</B>&rdquo;
means all proprietary information and data of a financial, commercial, clinical or technical nature, including Know-How, owned or Controlled
by a Party, which has been supplied or otherwise made available to the other Party or its Affiliates, under this Agreement or under the
CDA executed between the Parties on July 22, 2017 and whether made available orally (if and to the extent a written summary of such oral
information is made available within thirty (30) days after the oral information is made available), in writing or in electronic form,
including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvency Event</B>&rdquo;
means, in relation to a Party, any one of the following: (a) such Party is the subject of voluntary or involuntary bankruptcy proceedings
instituted on behalf of or against such Party (except for involuntary bankruptcy proceedings which are dismissed within one-hundred and
twenty (120) days); (b) an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator or similar officer
is appointed for substantially all of the assets of such Party; (c) a resolution to wind up such Party shall have been passed, other than
a resolution for the solvent reconstruction or reorganization of such Party; or (d) a resolution shall have been passed by such Party&rsquo;s
board of directors to make an application for an administration order or to appoint an administrator for substantially all of the assets
of such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Intellectual Property
Rights</B>&rdquo; means all rights in Patents, rights to inventions, copyright and related rights, rights in trademarks, trade names and
domain names, rights in designs, rights in computer software, database rights, rights in Information, Know-How and any other intellectual
property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals
or extensions (for their full term) of, such rights and all similar or equivalent rights or forms of protection which subsist or will
subsist now or in the future in any part of the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intermediaries</B>&rdquo;
is defined in <U>Section 8.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Know-How</B>&rdquo;
means all existing and available technical information, know-how and data, including inventions (whether patentable or not), discoveries,
trade secrets, package specifications, chemical specifications, analytical test methods, stability data, testing data, product specifications,
instructions, processes, formulation information, validation documents, materials (including all biological and chemical materials), drawings,
formulae, reports, and other technology and techniques including all biological, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, clinical safety, safety data, preclinical and clinical data, and expertise and other technology applicable to
compounds, molecules, cell lines, formulations, compositions, products or to their manufacture, development, registration, use or Commercialization
or methods of assaying or testing them or process for their manufacture, formulations containing them, compositions incorporating or comprising
them, expertise and information, regulatory filings and copies thereof, relevant to the development, manufacture, use or Commercialization
of and/or which may be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Knowledge</B>&rdquo;
means to the knowledge of the employees of Novartis listed on Schedule C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Law</B>&rdquo; means
any statute, law, regulation, rule, code, order, ordinance, judgment or requirement of a Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Legal Proceeding</B>&rdquo;
means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate
proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving,
any court or other Governmental Entity or any arbitrator or arbitration panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Licensed Data</B>&rdquo;
means data that is listed on Schedule B and, <U>provided</U>, <U>however</U>, that notwithstanding anything else in this Agreement or
on Schedule B, the documentation listed in Schedule B shall be provided in two stages: (i) within 30 days of the Effective Date for documents
on Schedule B which are in electronic format and readily available/accessible, and (ii) for all other documents on Schedule B, when conditions
related to the COVID-19 pandemic have subsided sufficiently so that Novartis staff has the capability to physically extract documents
from archives which are in paper format and have not yet been digitized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Licensed Know-How</B>&rdquo;
means the Know-How relevant to Compound or Licensed Product, but only to the extent that such Know-How is (a) owned and/or Controlled
by Novartis and/or its Affiliates as of the Effective Date, (b) is necessary to Develop, Manufacture or have Manufactured, and/or Commercialize
any Licensed Products in the Field in the Territory, including to Manufacture or have Manufactured the Compound in the Field in the Territory,
and (c) is provided to NLS pursuant to <U>Article 3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Licensed Product(s)</B>&rdquo;
means one (1) or more pharmaceutical, therapeutic or diagnostic products containing the Compound as an active ingredient alone or in combination
with other active ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Licensed Product
Activities</B>&rdquo; is defined in <U>Section 4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Losses</B>&rdquo;
is defined in <U>Section 9.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Manufacture</B>&rdquo;
or &ldquo;<B>Manufacturing</B>&rdquo; means any and all activities directed to the manufacture, receipt, incoming inspections, storage
and handling of the Compound and/or any Licensed Products, and the manufacture, processing, formulation, fill, finish, packaging, labeling,
warehousing, quality control testing (including in-process, release and stability testing), supplying, shipping, and release thereof,
including manufacturing process development, scale-up, yield and other improvements, and validation and other testing, as well as recordkeeping,
data and database development, management, storage and retention activities relating to any of the foregoing in this definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>mazindol</B>&rdquo;
means the active pharmaceutical ingredient mazindol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Milestone</B>&rdquo;
is defined in <U>Section 6.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&ldquo;<B>Milestone Payments</B>&rdquo;
is defined in <U>Section 6.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Sales</B>&rdquo;
means the net sales recorded by NLS or any of its Affiliates or sublicensees (sublicensees excludes distributors and wholesalers) for
any Licensed Products sold to Third Parties other than sublicensees, as determined in accordance with NLS&rsquo; Accounting Standards
as consistently applied. The deductions booked on an accrual basis by NLS and its Affiliates under its Accounting Standards to calculate
the recorded net sales from gross sales include, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">normal trade and cash discounts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">amounts repaid or credited by reasons of defects, rejections,
recalls or returns;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">rebates and chargebacks to customers and Third Parties (including,
without limitation, Medicare, Medicaid, managed healthcare and similar types of rebates);</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">amounts provided or credited to customers through coupons and other discount programs;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">delayed ship order credits, discounts or payments related to the impact of price increases between purchase
and shipping dates or retroactive price reductions;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">fee for service payments to customers for any non-separable services (including compensation for maintaining
agreed inventory levels and providing information); and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">other reductions or specifically identifiable amounts deducted for reasons similar to these listed above
in accordance with the Accounting Standards.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">With respect to the calculation
of Net Sales:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(w)</TD><TD STYLE="text-align: justify">Net Sales only include the value charged or invoiced on the first arm&rsquo;s length sale to a Third Party.
Sales between or among NLS and its Affiliates and between NLS and its sublicensees shall be disregarded for purposes of calculating Net
Sales;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(x)</TD><TD STYLE="text-align: justify">if a Licensed Product is delivered to the Third Party before being invoiced (or is not invoiced), Net
Sales will be calculated at the time all the revenue recognition criteria under the Accounting Standards are met; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(y)</TD><TD STYLE="text-align: justify">wholesalers and distributors shall not be considered as sublicensees.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                             </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a Licensed
Product is sold in a finished dosage form containing the Compound in combination with one (1) or more other active ingredients (a &ldquo;<B>Combination
Product</B>&rdquo;), Net Sales will be calculated by multiplying the Net Sales of the Combination Product by a fraction, A/(A+B), where
&ldquo;A&rdquo; is the weighted (by sales volume) average sale price in the relevant country of such Licensed Product containing the Compound
as the sole active ingredient in finished dosage form, and &ldquo;B&rdquo; is the weighted average sale price (by sales volume) in that
country of the product(s) containing the other component(s) as the sole active ingredient(s) in finished dosage form. Regarding prices
comprised in the weighting average price when sold separately referred to above, if these are available for different dosages from the
dosages of Compound and other active ingredient components that are included in the Combination Product, then Novartis shall be entitled
to make a proportional adjustment to such prices in calculating the Net Sales of the Combination Product. If the weighted average sale
price cannot be determined for the Product or other product(s) containing the single Compound or component(s), the calculation of Net
Sales for Combination Products will be agreed by the Parties based on the relative value contributed by each component (each Party&rsquo;s
agreement not to be unreasonably withheld or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Sales Milestone
Payment Amount</B>&rdquo; is defined in <U>Section 6.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>NLS</B>&rdquo; is
defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Novartis</B>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Novartis Indemnitees</B>&rdquo;
is defined in <U>Section 11.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Party</B>&rdquo;
and &ldquo;<B>Parties</B>&rdquo; are defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Patents</B>&rdquo;
means any and all (a) granted patents; (b) pending patent applications, including all provisional applications, divisionals, continuations,
substitutions, continuations-in-part and renewals, and all patents granted thereon; (c) patents-of-addition, re-examinations, reissues
and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term
extensions, supplementary protection certificates or the equivalent thereof; (d) inventor&rsquo;s certificates; and (e) other forms of
government-issued rights substantially similar to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Phase 3 Clinical
Trial</B>&rdquo; means a pivotal clinical study with a defined dose or a set of defined does of a pharmaceutical product in patients designed
to ascertain the efficacy and safety of such product for the purpose of enabling the preparation and submission of applications for Regulatory
Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Approval</B>&rdquo;
means, with respect to a Licensed Product, any approval (notwithstanding the indication), registration, license or authorization from
a Regulatory Authority to market and sell such Licensed Product in the Field in one or more countries in the Territory. For clarity, Regulatory
Approval does not include any approvals related to pricing and/or reimbursement of a Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Authority</B>&rdquo;
means, in a particular country or regulatory jurisdiction, any applicable Governmental Entity involved in granting Regulatory Approval
in such country or regulatory jurisdiction, such as the FDA or the EMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Filings</B>&rdquo;
means, with respect to a Licensed Product, any submission to a Regulatory Authority for any appropriate Regulatory Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sales Report</B>&rdquo;
is defined in <U>Section 7.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term</B>&rdquo;
is defined in <U>Section 12.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Territory</B>&rdquo;
means worldwide with the exception of Japan, subject to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third Party</B>&rdquo;
means any Person other than a Party or an Affiliate of a Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Upfront Payment</B>&rdquo;
is defined in <U>Section 6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>US Dollars</B>&rdquo;
or &ldquo;<B>US$</B>&rdquo; or &ldquo;<B>United States Dollars</B>&rdquo; means the lawful currency of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 <B>Interpretation</B>.
In this Agreement unless otherwise specified:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall mean respectively includes and including without
limitation;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">words denoting the singular shall include the plural and vice versa and words denoting any gender shall
include all genders;</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Schedules and other attachments form part of the operative provision of this Agreement and references
to this Agreement shall, unless the context otherwise requires, include references to the Schedules and attachments;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">references to Articles and Sections are to articles and sections of this Agreement unless otherwise specified;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">a reference to an enactment or statutory provision is a reference to it as it may from time to time be
amended, modified, consolidated, repealed or reenacted and shall include any orders, regulations, instruments or other subordinate legislation
made under the relevant statute;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">the headings in this Agreement are for information only and shall not be considered in the interpretation
of this Agreement;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                            </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">any reference to &ldquo;writing&rdquo; or &ldquo;written&rdquo; includes faxes and any legible reproduction
of words delivered in permanent and tangible form (but does not include email);</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">the words &ldquo;hereof&rdquo;, &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of like import
used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">the Parties agree that the terms and conditions of this Agreement are the result of negotiations between
the Parties and that this Agreement shall not be construed in favor of or against any Party by reason of the extent to which any Party
participated in its preparation.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">LICENSE</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <B>License
Grant from Novartis to NLS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms and conditions
of this Agreement, Novartis grants to NLS a non-exclusive (except for the USA), sublicenseable (subject to <U>Section 2.2</U>), assignable
(subject to <U>Section 15.2</U>) license under the Licensed Data to use the Licensed Data solely to Develop, Manufacture or have Manufactured
and/or Commercialize Licensed Products including the right to Manufacture or have Manufactured the Compound in the Field in the Territory.
For the avoidance of doubt, for the USA, such license shall be exclusive; provided, however, that Novartis agrees not to grant such a
license in the future for any other country in the Territory and Novartis acknowledges that with respect to Canada, it may have granted
such license to a company in the past, and it believes such company is now dissolved, and in addition, with respect to France, it may
have granted such license as well. Notwithstanding the foregoing, to the Knowledge of Novartis, other than with respect to the now dissolved
company in Canada and with respect to France, Novartis has not previously licensed the use of such data for the Field in any country in
the Territory, but if such license does exist, NLS shall have no right to make any legal claim of any kind against Novartis based on this
Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.2</TD><TD STYLE="text-align: justify"><B>Sublicensing</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sublicense by NLS will
be subject to a written agreement that (i) requires the sublicensee to comply with all applicable obligations of this Agreement and (ii)
is not in conflict with any term of this Agreement. NLS shall provide Novartis with a copy of such sublicense. NLS shall undertake to
enforce the provisions of any such sublicense and shall remain responsible and jointly and severally liable with the sublicensee to Novartis
for any breach of this Agreement which is caused by any acts or omissions of its sublicensees as if they were the acts or omissions of
NLS under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.3</TD><TD STYLE="text-align: justify"><B>Reservation of Rights by Novartis</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without prejudice to any other
rights that Novartis and/or its Affiliates may have, NLS agrees that Novartis and/or its Affiliates retains or shares full and unencumbered
rights to exploit or have exploited the Compound in the Territory outside the Field. Novartis also retains the right to use and reference
the Licensed Data and the Licensed Know-How to the extent it is necessary or useful for the defense, correspondence or prosecution of
any legal or regulatory proceeding or investigation in which Novartis or any of its Affiliates is involved. NLS acknowledges and agrees
that as between the Parties, Novartis and/or its Affiliates are the sole owner(s) of all right, title and interest in and to Compound
as well as all Licensed Data, and NLS has not acquired, and shall not acquire, any right, title or interest in or to the Compound and
Licensed Data pursuant to this Agreement other than the rights expressly set forth in this Agreement. For the avoidance of doubt, NLS
hereby acknowledges and agrees that it or any of its Affiliates or any Third Party acting on behalf of, or under the authority of or license
from, NLS, shall have no right to practice, and shall not practice, during the Term and at any time thereafter, any Licensed Data for
any purpose other than to Develop, Manufacture or have Manufactured, and/or Commercialize Licensed Products in the Field in the Territory,
including the right to Manufacture or have Manufactured the Compound in the Field in the Territory, in each case as provided for in this
Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">TRANSFER OF LICENSED DATA AND LICENSED KNOW-HOW</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <B>Licensed
Data and Licensed Know-How. </B>The Parties agree and acknowledge that within the time period specified in the definition of &ldquo;Licensed
Data&rdquo;, Novartis shall have provided NLS with the necessary Information, comprising Licensed Data and Licensed Know-How, which NLS
would need to proceed with its Development, Manufacturing and Commercialization of Licensed Product in the Field. For additional information,
at NLS&rsquo;s request, Novartis will try to provide such information where such information is available and it is feasible to do so,
however, only if Novartis has the appropriate resource available to support NLS in collecting such required additional information and
at an agreed upon cost in advance between NLS and Novartis, in Novartis&rsquo; sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <B>Adverse
Event Reporting and Safety Data Exchange</B>.&nbsp; NLS shall be solely responsible for the reporting and handling of safety information
involving or relating to the Compound and/or Licensed Products that are subject to this Agreement to the extent required by applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">DEVELOPMENT, COMMERCIALIZATION AND MANUFACTURING</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <B>NLS
Responsibilities</B>. NLS will Develop or have Developed, Manufacture or have Manufactured, and Commercialize or have Commercialized Licensed
Products in the Field in the Territory (individually and together, the &ldquo;<B>Licensed Product Activities</B>&rdquo;) at its own cost
and expense and to conduct the Development activities as outlined in the Development Plan, NLS shall provide Novartis with an updated
version of such Development Plan in accordance with its reporting obligations as defined in <U>Section 4.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">4.2 <B>Reporting
Obligations</B>. NLS shall provide Novartis with a written summary report on or before the first (1<SUP>st</SUP>) of March of each Calendar
Year, summarizing NLS&rsquo;: (a) Licensed Product Activities for the Compound and/or the Licensed Product(s) in the Field in the Territory
performed in the prior twelve (12)-month period, and (b) anticipated plans for the Licensed Product Activities for the Compound and/or
the Licensed Product(s) in the Field in the Territory for the subsequent twelve (12)-month period. The reporting obligation of NLS to
produce and communicate a written summary report under this article shall immediately cease upon the payment of the Net Sales Milestone
due under as clause 6.4.(a); provided, however, that if at such time or thereafter NLS has any sublicensees or promotion partners in the
United States, such obligation will continue or resume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">INTELLECTUAL PROPERTY</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <B>Ownership</B>.
Subject only to the license rights expressly granted to the other Party under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Each Party shall retain all right, title and interest in and to any Intellectual Property Rights that
are owned, licensed or sublicensed by such Party prior to or independent of this Agreement</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">NLS shall retain all rights, title and interest to the Orphan Drug Designation of mazindol granted to
NLS by the European Commission and by the FDA respectively in 2016 for the treatment of narcolepsy, type 1 and type 2.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">NLS shall be the sole owner of any Patents and Know-How discovered, developed, invented, conceived or
reduced to practice in connection with this Agreement, including in respect of any invention (patentable or not patentable) made using
the Licensed Data and arising from such activities (&ldquo;<B>Improvements</B>&rdquo;).</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">To the extent of any Improvements hereunder, NLS shall have no right to exploit and/or practice, and shall
not exploit and/or practice, any such Improvements outside the Field in the Territory.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <B>No
Diminution of Rights</B>. NLS shall not do or omit to do anything that would substantially diminish or impair the rights of Novartis and/or
its Affiliates in the Licensed Data and Licensed Know-How, provided however, that the foregoing shall not restrict NLS&rsquo; discretion
as to the Development, use, Manufacture and Commercialization of the Compound and/or Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <B>Prosecution
and Defense of Patents</B>. As of the Effective Date, NLS shall be solely responsible for the filing, prosecution and maintenance of any
Patents claiming Improvements. (&ldquo;<B>Improvement Patents</B>&rdquo;). NLS shall be responsible for all costs and expenses incurred
by it relating to such filing, maintenance and prosecution, including attorneys&rsquo; fees and internal costs incurred in connection
therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">FINANCIAL PROVISIONS</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1 <B>Upfront
Payment</B>. As partial consideration for the licenses and rights granted to NLS hereunder, NLS shall pay to Novartis a one-time, non-refundable,
non-creditable upfront payment (the &ldquo;<B>Upfront Payment</B>&rdquo;) of Two Hundred Sixty-Nine Thousand Two Hundred Fifty United
States Dollars (US$269,250.00) due on the Effective Date, without any deduction for any bank charges which shall be paid separately by
NLS, and which is inclusive of Swiss VAT of $19,250.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2 <B>Digitalization
Fees.</B> In addition to the payment in 6.1, NLS shall separately pay Novartis for the costs and expenses of digitalization of NDA volumes
selected by NLS from the NDA Table of Contents in Schedule B, as well as any other documents selected by NLS for digitalization from Schedule
B.&nbsp; Novartis shall bill such amount in one or more invoices and charge 60 USD per volume.&nbsp; NLS will pay such invoices to Novartis
within thirty (30) days from the date of its receipt of the invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3 <B>Milestone
Payments</B>. As partial consideration for the licenses and rights granted to NLS hereunder, NLS shall pay to Novartis upon achievement
of the milestones set forth below (each, a &ldquo;<B>Milestone</B>&rdquo;) by NLS itself or through any of its Affiliates or sublicensees,
the corresponding one-time, non-refundable, non-creditable payments (&ldquo;<B>Milestone Payments</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0; width: 50%; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; width: 1%; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; border-bottom: Black 1.5pt solid; width: 49%; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">End of Phase 2 meeting with the FDA, subject to the FDA accepting the validity
    of the Novartis&rsquo; data submitted for a Licensed Product. The Milestone Payment associated with this Milestone may be reduced,
    in the event that FDA requires any toxicology study(ies) to be repeated, but such reduction shall not apply if NLS does additional
    complementary toxicology studies.&nbsp;&nbsp;The reduction shall be for the actual documented third party costs of the study(ies); <U>provided</U>, <U>however</U>,
    that in no event shall this Milestone be reduced below US$375,000, even if the cost of such toxicology studies exceeds
    US$375,000.</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven Hundred Fifty Thousand United States Dollars (US$750,000.00) (subject to reduction as per Milestone definition in column to the left)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval, received by NLS, its Affiliates or any sublicensee of regulatory dossier by the FDA for any Licensed Product </FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two Million United States Dollars (US$2,000,000.00)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt of any up-front and/or milestones payments, received by NLS or its Affiliates, from its sublicensees and/or promotion partners in the United States</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of amount received </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4 Each
Milestone Payment shall be deemed earned as of the first achievement of the respective Milestone event, and is payable one time only</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5 <B>Net
Sales Milestone</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Net Sales Milestone</B>. As partial consideration for the licenses and
rights granted to NLS hereunder, NLS will make a </FONT>one-time, non-refundable, non-creditable <FONT STYLE="font-size: 10pt">milestone
payment to Novartis on cumulative Net Sales of all Licensed Products as set forth below:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 79%; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cumulative Net Sales of Licensed Products in the Territory</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-right: 0; width: 1%; padding-left: 0; text-indent: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 20%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Sales Milestone Payment Amount</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">Milestone upon NLS, its Affiliates
    or sublicensees cumulative Net Sales of Two Hundred Fifty Million US Dollars ($250,000,000) in the Territory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Million US Dollars ($3,000,000)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.125in; text-indent: 0in">The Net Sales Milestone
Payment Amount shall be deemed earned as of the first achievement of the Net Sales Milestone event. NLS shall pay the Net Sales Milestone
Payment Amount only one-time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.125in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Example for Calculation of Net Sales
Milestone: The example below describes a situation where the milestone is paid during year 3:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.375in; text-indent: 0in"><FONT STYLE="font-weight: normal">Year
1: Total Net Sales reported in all markets equals to 50 mio USD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.375in; text-indent: 0in"><FONT STYLE="font-weight: normal">Year
2: Total Net Sales reported in all markets equals to 120 mio USD corresponding to a cumulative Net Sales of 170 mio USD at the end of
year 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.375in; text-indent: 0in"><FONT STYLE="font-weight: normal">Year
3: Total Net sales reported in all markets equals to 150 mio USD corresponding to a cumulative Net Sales of 320 mio USD; milestone payment
triggered in the course of year 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"><FONT STYLE="font-weight: normal"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">REPORTS AND PAYMENT TERMS</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1 <B>Payment
Terms</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">NLS shall notify Novartis in writing within ten (10) days after achievement of the applicable Milestone
and Novartis shall thereafter issue to NLS an invoice substantially in the form provided by Novartis in respect of the applicable Milestone
Payment. NLS will pay such invoice to Novartis within thirty (30) days from the date of its receipt of the invoice, provided, however,
that the payment terms for the Upfront Payment shall be paid as per the timing specified in Section 6.1(a).</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">All payments from NLS to Novartis shall be made by wire transfer of immediately available funds in US
Dollars to the credit of such bank account or accounts as may be designated by Novartis in writing to NLS from time to time. Any payment
which falls due on a date which is not a Business Day may be made on the next succeeding Business Day.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2 <B>Currency
Exchange Rate</B>. All payments under this Agreement shall be payable in US Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3 <B>Taxes</B>.
In the event any payments to be made by NLS to Novartis hereunder are subject to deduction or withholding of any tax under applicable
Law, NLS shall deduct in full the respective amount from the payment due and pay the full amount withheld or deducted to the relevant
taxing authority. Within sixty (60) days of making such payment to the relevant taxing authority, NLS shall deliver to Novartis proof
of such payment. Each Party agrees to reasonably assist the other Party in lawfully claiming exemptions from and/or minimizing such deductions
or withholdings under double taxation Laws, treaties or similar circumstances. Except for Article 6, Section 6.1 of the Agreement, all
amounts in this Agreement are exclusive of sales taxes and VAT. Novartis (CHE 116.268.023 MWST) and NLS (CHE-447.067.367 MWST) are VAT
registered in Switzerland. Both parties agree that for the supply of services by Novartis, Swiss VAT, charged at the current applicable
ordinary tax rate (2020, currently 7.7%) will be added to the agreed sales price (Art. 3 e and Art. 8 para 1 of the Swiss VAT Law). Novartis
has to issue its invoices according to Art. 26 of the Swiss VAT law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4 <B>Sales
Report</B>. After the First Commercial Sale in the Territory and within thirty (30) days after the end of each Calendar Quarter, NLS will
prepare and provide to Novartis a quarterly written report or reports substantially in the form set forth in Schedule A showing each of:
(a) gross sales for Licensed Products in the Field in the Territory in both USD and local currencies during the reporting period and cumulatively;
(b) Net Sales for Licensed Products in the Field in the Territory both in USD and local currencies during the reporting period and cumulatively;
(c) units sold for the reporting period and cumulatively; (d) date of First Commercial Sale for each Licensed Product in each country.
For the avoidance of doubt, such written report shall also show details on the aforementioned (a) to (c) items for: (i) NLS, its Affiliates
and authorized sublicensees; (ii) last Calendar Quarter and year to date data, for example, up to the last month of the last Calendar
Quarter; and (iii) for each Licensed Product (&ldquo;<B>Sales Report</B>&rdquo;) Sales Reports shall be considered Information of NLS.
The obligation of NLS to produce and communicate the Sales Report under this article shall immediately cease and shall become null and
void once the Net Sales Milestone payment has occurred as per clause 6.4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5 <B>Records
and Audit Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">NLS shall keep complete, true and accurate books and records in accordance with the Accounting Standards
in relation to its obligations under this Agreement, including regarding Net Sales and the Sales Report. NLS will keep such books and
records for at least three (3) years following the Calendar Quarter to which they pertain.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Novartis shall have the right for a period of three (3) years after receiving each Sales Report to appoint
an internationally-recognized independent accounting firm (hereinafter referred to as the &ldquo;<B>Auditor</B>&rdquo;) to inspect the
relevant records of NLS and its Affiliates or its sublicensees to verify such reports, statements, records or books of accounts, as applicable.
NLS&rsquo; agreements with its Affiliates or sublicensees shall permit such audit by Novartis. The Auditor shall have the right to disclose
to Novartis and/or other Affiliates of Novartis its conclusions regarding any payments owed under this Agreement. Novartis shall have
the right to do one audit per calendar year, and can only audit the same period once.</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">NLS and its Affiliates and sublicensees shall make their records available for inspection by the Auditor
during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice
from Novartis, its Affiliate or designated independent accounting firm, to verify the accuracy of the Sales Reports and compliance with
this Agreement. Novartis agrees to, and to cause the Auditor to, hold in confidence all information received and all information learned
in the course of any audit or inspection, except to the extent that such information is not confidential and/or it is necessary to disclose
it to enforce its rights under this Agreement or if disclosure is required by Law.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                            </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Novartis shall pay for such audits, as well as its own expenses associated with enforcing its rights with
respect to any payments hereunder, except that, if an underpayment exists such that the interest amount calculated under section 7.4(e)
below is more than five percent (5%) of a particular milestone amount that was audited, the reasonable fees and expenses charged by or
incurred by the Auditor shall be paid by NLS.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">In the event that the final result of the inspection reveals an undisputed underpayment by NLS, the underpaid
amount shall be settled promptly to Novartis with interest at the rate per annum equal to the lesser of: (i) two (2) times the three (3)-month
USD-LIBOR rate (or if the&nbsp;three (3)-month USD-LIBOR&nbsp;rate is no longer available, its official successor or such other comparable
interbank three-month borrowing rate) as quoted on Bloomberg (or if it no longer exists, a similarly authoritative source); or (ii) the
highest rate permitted by Law, calculated on the number of days such payment is paid after the date such payment is due, and compounded
monthly from the date such underpayment was due until the date that NLS makes the underpayment.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the information provided by NLS pursuant to this <U>Section 7.5</U> shall
be deemed to be Information of NLS for purposes of this Agreement.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">REPRESENTATIONS, WARRANTIES AND COVENANTS</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1 <B>Representations
and Warranties by Each Party</B>. Each Party represents and warrants to the other as of the Effective Date that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">It is a company duly organized, validly existing, and in good
standing under the Laws of its jurisdiction of formation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">It has full corporate power and authority to execute, deliver,
and perform this Agreement, and has taken all corporate action required by Law and its organizational documents to authorize the execution
and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">This Agreement constitutes a valid and binding agreement enforceable
against it in accordance with its terms.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">The execution and delivery of this Agreement and all other instruments
and documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not
and shall not: (i) conflict with or result in a breach of any provision of its organizational documents; (ii) result in a breach of any
agreement to which it is a party that would impair the performance of its obligations hereunder; or (iii) violate any applicable Law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2 <B>Novartis
Representations and Warranties</B>. Novartis represents and warrants to NLS that as of the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">To its knowledge, Novartis and/or its Affiliates is the sole owner of the Licensed Data, free and clear
of all liens, and has the right to grant to NLS the licenses as purported to be granted hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">There is no pending or, to its knowledge, threatened, litigation or other action that alleges, or any
written communication alleging, that Novartis&rsquo;s activities with respect to the Compound or the Licensed Data have infringed or misappropriated
any of the Intellectual Property Rights of any Third Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3 <B>NLS
Representations, Warranties and Covenants</B>. NLS represents, warrants, and covenants to Novartis that, as of the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">NLS shall comply with all applicable Law with respect to the performance
of its obligations hereunder, including complying with cGMP, cGCP and cGLP, where applicable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">(i) Neither NLS, nor, to its knowledge, any employee, agent or
subcontractor of NLS, involved in or who will be involved in the Development, Manufacture and/or Commercialization of the Compound and/or
Licensed Products has been debarred under Subsection (a) or (b) of Section 306 of the Federal Food, Drug and Cosmetic Act (21 U.S.C.
&sect; 335a); (ii) no Person who is known by NLS to have been debarred under Subsection (a) or (b) of Section 306 of said Act will be
employed by NLS in the performance of any activities hereunder; and (iii) to its knowledge, no Person on any of the FDA clinical investigator
enforcement lists (including, but not limited to, the (1) Disqualified/Totally Restricted List, (2) Restricted List, and (3) Adequate
Assurances List will participate in the performance of any activities hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">NLS, together with its Affiliates, contractors, sublicensees and
distributors, has or will have the necessary resources and expertise, including relevant approvals and licenses (or the resources to
acquire the expertise) to carry out its obligations hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">NLS acknowledges that (i) it has been furnished the materials
relating to the Licensed Data and Licensed Know-How that it has requested, ; (ii) it has completed to its satisfaction an independent
investigation of the Licensed Data, Licensed Know-How that it has requested; and (iii) in making its decision to enter into this Agreement,
and to consummate the transactions contemplated hereby, it has relied solely on the results of its own independent investigation and
analysis and the representations and warranties set forth in <U>Sections 8.1</U> and <U>8.2</U>. NLS has no knowledge that any representations
or warranty of Novartis made in this Agreement are not true and correct.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Execution of Data Transfer Agreements.&nbsp;&nbsp;
Upon the request of Novartis, NLS shall enter into appropriate data transfer agreements with Novartis and its Affiliates as needed to
satisfy cross-border transfer obligations relating to personal data, such as the European Commission Standard Contractual Clauses or
other similar agreements.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Prohibited Cross-Border Transfers.</FONT>&nbsp;
NLS shall not, and shall not permit any of its subcontractors to, process personal data in a manner that involves (i) the transfer of
such personal data from one country to any other country (the EU and Switzerland constituting a single country for this purpose), or
(ii) accessing personal data from another country; in each case without the prior written consent of Novartis or as explicitly permitted
in the Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4 <B>NLS
Anti-Corruption Covenants</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">NLS agrees that none of its actions with respect to this Agreement
will violate any anti-corruption Laws, including but not limited to the U.S. Foreign Corrupt Practices Act or any other Law applicable
to bribery, or any applicable standard implementing compliance with such Laws that are adopted by Novartis and/or its Affiliates from
time to time during the Term (the &ldquo;<B>Compliance Standards</B>&rdquo;), or cause Novartis and/or its Affiliates to suffer reputational
harm.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Specifically, with regard to anti-bribery, in addition to the
above, NLS undertakes not to bribe anyone either directly or through intermediaries, such as agents, consultants, advisers, or any other
business partners (&ldquo;<B>Intermediaries</B>&rdquo;). NLS understands that Novartis and its Affiliates do not distinguish between
public officials and private persons so far as bribery is concerned; bribery is not tolerated, regardless of the status of the recipient.
NLS also agrees and undertakes not to make any facilitation payment, directly or through Intermediaries. This applies irrespective of
whether or not local Law permits facilitation payments. For clarity, facilitation payments are payments to public officials to expedite
the performance of duties of a non-discretionary nature. These payments are intended to influence only the timing of the public officials&rsquo;
actions (e.g. payments to expedite visa issue or clearing goods through customs), but not their outcome.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">NLS shall be solely responsible for training its personnel and
sales force and any other employee who is involved with the activities set forth in this Agreement on anti-bribery at its own expense.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5 No Other Warranties</B>.
EXCEPT AS EXPRESSLY STATED IN THIS <U>ARTICLE 8</U>, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF TITLE, NON-INFRINGEMENT, VALIDITY, ENFORCEABILITY,
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE COMPOUND, LICENSED PRODUCT(S), LICENSED IP, LICENSED PLATFORM PATENTS, AND MANUFACTURING
PLATFORM TECHNOLOGY PROVIDED BY NOVARTIS OR ITS AFFILIATES HEREUNDER ARE MADE AVAILABLE TO NLS ON AN &ldquo;AS IS&rdquo; BASIS WITHOUT
WARRANTY WITH RESPECT TO COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR OTHER APPLICABLE LAW OR FITNESS FOR A PARTICULAR PURPOSE
OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify">INDEMNIFICATION</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1 <B>NLS
Indemnification Obligations</B>. NLS shall indemnify and hold Novartis, its Affiliates and their respective officers, directors, agents
and employees (&ldquo;<B>Novartis Indemnitees</B>&rdquo;) harmless from and against any and all costs, charges, claims, damages or expenses
(including attorneys&rsquo; fees and expenses) (&ldquo;<B>Losses</B>&rdquo;) against or incurred by them to the extent arising or resulting
from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any activity by NLS that is outside of the Field;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the negligence, reckless or wanton intentional acts or omissions
of NLS, its Affiliates, subcontractors or sublicensees;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">NLS&rsquo; breach of any representation, warranty or covenant
as set forth in this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">NLS&rsquo; breach of the scope of the licenses set forth in <U>Section
2.1</U>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">any inquiry and/or investigation conducted by a Governmental Entity
in connection with this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">any claim that asserted by a third party arising out of the sale
or use of a product developed by NLS and/or drug substance used in such product that NLS develops as a result of this Agreement, including
but not limited to claims that arise from, relate to or are in connection with injury or death to a human being, whether premised on
allegations of design or manufacturing defect, negligence, failure to warn, breach of warranty, or any other legal theory, or any claims
premised on regulatory action or voluntary action involving such a product or drug substance, such as product recalls; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">any claim that is asserted by a third party for infringement of
any Intellectual Property Rights as a result of this Agreement, or arising out of the development, Commercialization and Manufacture
of Licensed Product in the Field.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2 <B>Indemnification
Procedure</B>. Novartis shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">promptly notify NLS of a Loss;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">permit NLS to participate in or lead the conduct, defense and/or
settlement of such claim, proceeding, inquiry or investigation, provided however, that NLS shall not compromise or otherwise settle the
same without Novartis&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">reasonably assist, at NLS&rsquo; expense, in the investigation
and defense of such claim, proceeding, inquiry or investigation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.</TD><TD STYLE="text-align: justify">Insurance Requirements</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NLS warrants that it has sufficient
insurance to provide for the financial protection related to its liabilities and responsibilities under this Agreement. Further, prior
to the initiation of any clinical trials for the Compound and/or any Licensed Products in any country in the Territory, NLS warrants that
it will secure appropriate clinical trials insurance providing coverage in accordance with the respective rules and regulations in place
by the appropriate Regulatory Authority in such country in the Territory. NLS shall provide to Novartis a written summary of such insurance
policy within sixty (60) days of Novartis&rsquo;s written request. NLS agrees that it shall give Novartis at least thirty (30) days&rsquo;
written notice prior to the cancellation or termination of any such insurance policy, or any material change that restricts the coverage
or reduces the limits afforded by any such insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">LIMITATION ON LIABILITY</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN NO EVENT SHALL NOVARTIS
OR ANY OF ITS AFFILIATES BE LIABLE FOR ANY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY PRODUCT THAT IS DEVELOPED OR COMMERCIALIZED
BY NLS HEREUNDER. IN ADDITION, NEITHER NOVARTIS NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIENCE, BREACH OF STATUTORY
DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS
SUFFERED BY NLS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.</TD><TD STYLE="text-align: justify">TERM AND TERMINATION</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1 <B>Term</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">This Agreement shall come into force on the Effective Date and,
subject only to earlier termination pursuant to this <U>Article 12</U>, shall terminate upon NLS&rsquo;s termination of the Commercialization
of the Licensed Products in the Field in the last country of the Territory in which Commercialization had actually begun (the &ldquo;<B>Term</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Upon the expiration of this Agreement, the license grants to NLS
in <U>Section 2.1</U> shall continue on a non-exclusive, perpetual, royalty-free, fully paid-up basis for the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2 <B>NLS
Termination.</B> Upon written notice to Novartis, NLS may terminate this Agreement for cause due to the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">an Insolvency Event of Novartis occurs; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Novartis materially breaches its obligations hereunder and fails
to cure such breach within a period of sixty (60) days after the occurrence of such material breach; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.3 <B>Novartis
Termination</B>. Upon written notice to NLS, Novartis may terminate this Agreement for cause due to the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">NLS fails to pay any undisputed amount due under <U>Article 6
</U>and NLS fails to remedy such failure within thirty (30) days of receipt of a written notice from Novartis specifying such failure;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">an Insolvency Event occurs; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">NLS materially breaches its obligations hereunder and fails to
cure such breach within a period of sixty (60) days after the occurrence of such material breach.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">NLS is not able to initiate a Phase 3 Clinical Trial in any indications
in the Field in the Territory by December 31, 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.4
<B>Effect of Termination</B>. Except as otherwise specifically provided in this <U>Section 12.5</U>, in the case of termination in accordance
with <U>Section 12.2</U> (NLS Termination), <U>Section 12.3</U> (Novartis Termination):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All the licenses and rights granted to NLS hereunder will cease
and revert to Novartis as of the date of such termination and NLS shall cease all use thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">NLS shall promptly return to Novartis and/or its Affiliates, or,
at Novartis&rsquo;s request, destroy, all material, and documents provided to NLS related to the Compound, or any Licensed Products hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">To the extent permitted by applicable Law, and at Novartis&rsquo;s
request and expense, NLS will promptly assign to Novartis and/or its Affiliates all clinical data, Regulatory Approvals, Regulatory Filings,
regulatory dossiers, and other regulatory materials submitted and controlled by NLS related to the Licensed Data. If NLS is restricted
under applicable Law from transferring ownership of any of the foregoing items to Novartis, NLS shall grant Novartis and/or its Affiliates
(or its or their designee(s)) a right of reference or use to such item (it being understood that NLS shall transfer the same to Novartis
when possible). NLS shall, at Novartis&rsquo;s request and expense, take actions reasonably necessary to effect such transfer or grant
of right of reference or use to Novartis and/or its Affiliates, including by making such filings as may be required with Regulatory Authorities
in the Territory that may be necessary to record such assignment or effect such transfer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Solely in the event of termination by NLS pursuant to <U>Section
12.2(b)</U>, NLS shall be permitted to sell any remaining inventory of Licensed Product(s) in the ordinary course of business until such
inventory of Licensed Product(s) is depleted or for a period of thirty (30) days from the date of such termination by NLS, whichever
period of time is shorter. For the avoidance of doubt, in no event shall NLS be permitted to sell any inventory (including any work in
process).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.5 <B>Accrued
Rights</B>. The early termination or expiration of this Agreement for any reason will be without prejudice to any rights that have accrued
to the benefit of either Party prior to the early termination or expiration of this Agreement, and any and all damages arising from any
breach or default hereunder, including any payments due to Novartis from NLS hereunder. Upon the early termination or expiration of this
Agreement for any reason, the Parties shall have no further obligation to perform any activities under this Agreement other than as provided
for or referenced in this <U>Article 14</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.6 <B>Termination
Not Sole Remedy</B>. Termination is not the sole remedy under this Agreement, and whether or not termination is effected and notwithstanding
anything contained in this Agreement to the contrary, all other remedies under applicable Law will remain available except as otherwise
agreed to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.7 <B>Survival</B>.
Notwithstanding any other provision of this Agreement, the following provisions shall survive the termination or expiration of this Agreement
for any reason, in accordance with their respective terms and conditions, and for the duration stated, and where no duration is stated,
shall survive for so long as required to give effect to the subject matter of the provision: Article 1 (Definitions and Interpretation),
Section 2.2 (Sublicensing) Section 2.3 (Reservation of Rights by Novartis), Section 5.1 (Ownership; Grant-Back to Novartis), Article 6
(Financial Provisions), Article 9 (Indemnification), Article 10 (Insurance), Article 11 (Limitation on Liability), Article 12 (Term and
Termination), Article 13 (Confidentiality), Article 14 (Press Releases and Publications), Article 15 (Miscellaneous).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.</TD><TD STYLE="text-align: justify">CONFIDENTIALITY</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1 <B>Duty
of Confidence</B>. Subject to the other provisions of this <U>Article 13</U>, all Information will be maintained by the Parties in confidence
and otherwise safeguarded by the Parties. Each Party may only use the Information strictly for the purposes of this Agreement and pursuant
to the rights and obligations of such Party under this Agreement. Subject to the other provisions of this <U>Article 13</U>, each Party
shall hold as confidential such Information of the other Party or such Party&rsquo;s Affiliates (in the case of Novartis, where Affiliates
of Novartis disclose Information) in the same manner and with the same protection as such recipient Party maintains its own confidential
information, but in no event less than a reasonable degree of care. Subject to the other provisions of this <U>Article 13</U>, a Party
may only disclose Information to employees, agents, contractors, consultants and advisers of such Party and in the case of Novartis, Novartis
may also disclose to its Affiliates and their employees, agents and contractors, and in the case of NLS, NLS may also disclose to its
sublicensees to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement, provided
that such Persons are bound to maintain the confidentiality of the Information in a manner consistent with the confidentiality provisions
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2 <B>Exceptions</B>.
The obligations under this <U>Article 13</U> shall not apply to any Information to the extent the recipient Party can demonstrate by competent
evidence that such Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">is (at the time of disclosure) or becomes (after the time of disclosure)
known to the public or part of the public domain through no breach of this Agreement by the recipient Party or its Affiliates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">was known to, or was otherwise in the possession of, the recipient
Party or its Affiliates prior to the time of disclosure by the disclosing Party or any of its Affiliates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">is disclosed to the recipient Party or an Affiliate on a non-confidential
basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party or any
of its Affiliates; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">is independently developed by or on behalf of the recipient Party
or its Affiliates, as evidenced by its written records, without reference to the Information disclosed by the disclosing Party or its
Affiliates under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3 <B>Authorized
Disclosures</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">In addition to disclosures allowed under <U>Section 13.2</U>,
NLS may disclose Information belonging to Novartis or its Affiliates to the extent such disclosure is necessary in connection with the
Regulatory Filings for a Licensed Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">In addition to disclosures allowed under <U>Section 13.2</U>,
either Party may disclose Information belonging to the other Party (and/or its Affiliates) to the extent such disclosure is necessary
to: (i) prosecute or defend litigation as permitted by this Agreement, and/or (ii) comply with applicable court orders or governmental
regulations or any securities regulatory organization&rsquo;s disclosure requirements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">In the event the recipient Party is required to disclose Information
of the disclosing Party by Law or in connection with bona fide legal process, such disclosure shall not be a breach of this Agreement,
provided that the recipient Party (i) informs the disclosing Party as soon as reasonably practicable of the required disclosure; (ii)
limits the disclosure to the required purpose; and (iii) at the disclosing Party&rsquo;s request and expense, assists in an attempt to
object to or limit the required disclosure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4 <B>Ongoing
Obligation for Confidentiality</B>. Upon early termination of this Agreement for any reason, each Party and its Affiliates shall immediately
(a) return to the other Party or destroy any Information supplied or disclosed by the other Party together with all hard copies thereof,
except for (i) such copies as must be retained pursuant to applicable Law, and (ii) one copy which may be retained in its confidential
files for archive purposes; (b) destroy all notes and all summaries or extracts in any medium prepared by or on behalf of recipient derived
from this Information; and (c) use all best efforts to procure that all third parties, to which this Information was disclosed, destroy
or erase any Information contained in any materials and documentation recorded in any memory device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5 <B>Termination
of Prior Confidentiality Agreement</B>. This Agreement supersedes and replaces the Confidentiality Agreement between the Parties dated
February 1, 2016 and amended on February 18, 2016. All information exchanged between the Parties under such Confidentiality Agreement
shall be deemed Information hereunder and shall be subject to the terms of this <U>Article 13</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.</TD><TD STYLE="text-align: justify">PRESS RELEASES AND PUBLICATIONS</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither Party shall issue
any press release, trade announcement or make any other public announcement or statement with regard to the transactions contemplated
by this Agreement without the other Party&rsquo;s prior written consent, which shall not be unreasonably withheld. Where consent is forthcoming,
the Parties agree to consult with each other regarding the content of any such press release or other announcement. The aforementioned
restriction shall not apply to announcements required by any Regulatory Authority, security exchanges or Governmental Entity under applicable
Law, provided, that in such event the Parties shall coordinate the wording and NLS shall take into consideration any requests of Novartis.
Each Party hereto acknowledges that NLS and Novartis shall have the right to disclose a brief summary of the transaction, including the
amounts payable by NLS under this Agreement, in its official financial reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify">MISCELLANEOUS</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.1 <B>Governing
Law; Jurisdiction and Venue</B>. This Agreement shall be governed by and construed under the Laws of Switzerland, without giving effect
to the conflicts of Laws provisions thereof, and with the exclusion of the Vienna Convention on the International Sale of Goods. The parties
irrevocably agree that the courts of Basel City, Switzerland shall have exclusive jurisdiction to hear and decide any suit, action or
proceedings, and/or to settle any disputes, which may arise out of or in any way relate to this Agreement or its formation and, for these
purposes, each party irrevocably submits to the jurisdiction of the courts of Basel City, Switzerland. Each Party further irrevocably
and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any
such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2 <B>Assignment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Neither Party may assign its rights and obligations under this
Agreement without the other Party&rsquo;s prior written consent, which consent shall not be unreasonably conditioned, withheld or delayed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Notwithstanding <U>Section 15.2(a)</U>, Novartis may, without
the consent of NLS, assign and/or novate this Agreement or any of its rights or obligations (i) to an Affiliate; (ii) to a successor
to all or substantially all of its business or assets to which this Agreement relates; or (iii) to Novartis Pharma AG or any of its affiliates
at any time, regardless of whether Novartis is, at the time of such assignment and/or novation, an affiliate of Novartis Pharma AG, or
(iv) to an unaffiliated third party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Notwithstanding <U>Section 15.2(a)</U>, NLS may, without the consent
of Novartis, assign and/or novate this Agreement or any of its rights or obligations to an Affiliate, provided however, that such assignment
to an Affiliate shall be subject to a written agreement that (i) requires the assignee to comply with all applicable obligations of this
Agreement, and (ii) is not in conflict with any term of this Agreement. In the event of a Change of Control of NLS:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.125in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Novartis shall have the right to require that NLS, the Third Party
with whom such Change of Control is effected and each of their respective Affiliates, (1) adopt procedures reasonably calculated, as
approved by Novartis which shall not be unreasonably withheld to limit the dissemination of Sensitive Information to only those Persons
employed by or under contract with NLS, in each case having a need to know such Sensitive Information in order for NLS to perform its
obligations and exercise its rights under this Agreement; (2) prohibit and limit the use and disclosure of Sensitive Information for
competitive reasons against Novartis and its Affiliates, including the use of Sensitive Information for the Development, use, Manufacture,
and/or Commercialization of the Compound and/or Licensed Products in the Field; and (3) comply with the restrictions on use of Permitted
sublicensees for purposes of Manufacturing as set forth in <U>Section 2.2(a)</U> and such other related provisions. Without limiting
the foregoing or being limited thereby, at a minimum in such circumstance, no Sensitive Information shall be disclosed to or used by
any Person who is also working on or making decisions regarding any product that is competitive with any Licensed Product at the time
of receipt or use of any Sensitive Information, or within two (2) years following receipt or use of any Sensitive Information. For the
avoidance of doubt, the foregoing applies equally to technical staff as well as senior management.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.125in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">For the purpose of this <U>Section 15.2(c)</U>, &ldquo;<B>Change
of Control</B>&rdquo; means, with respect to NLS: (1) the sale, conveyance, transfer, or lease of all or substantially all of NLS&rsquo;
assets or business relating to this Agreement to any Third Party; (2) a merger, reorganization or consolidation involving NLS in which
the total voting power of the stock of NLS outstanding immediately prior thereto ceases to represent at least fifty percent (50%) of
the combined voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors immediately
after such merger, reorganization or consolidation; or (3) a Person or group of Persons acting in concert becoming the beneficial owner,
directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of NLS normally entitled
to vote in elections of directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.125in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">For the purpose of this <U>Section 15.2(c)</U>, &ldquo;<B>Sensitive
Information</B>&rdquo; means all Information of Novartis disclosed to or otherwise available to NLS or Persons employed by or under contract
with NLS and Information arising from the Parties&rsquo; performance of this Agreement in relation to the Development, use Manufacture,
and/or Commercialization of the Compound and/or Licensed Products in the Field.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.875in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Any permitted assignee shall assume all obligations of the assigning
Party under this Agreement (or the assigned portion in the case of any partial assignment), and no permitted assignment shall relieve
the assignor of liability hereunder. Any attempted assignment in contravention of this <U>Section 15.2</U> will be null and void. Subject
to the terms of this Agreement, this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors
and assigns.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">15.3 <B>Injunctive
Relief</B>. The Parties understand and agree that monetary damages may not be a sufficient remedy for breach of this Agreement and that
each Party will be entitled to seek equitable relief, including injunction and specific performance for any such breach. Nothing contained
in this Agreement shall be construed as limiting a Party&rsquo;s right to any other remedies it may have under this Agreement or in Law,
including, without limitation, the recovery of damages for breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">15.4 <B>Force
Majeure</B>. If and to the extent that either Party is prevented or delayed by Force Majeure from performing any of its obligations under
this Agreement and promptly so notifies the other Party in writing, specifying the matters constituting Force Majeure together with such
evidence in verification thereof as it can reasonably give and specifying the period for which it is estimated that the prevention or
delay will continue, then the Party so affected shall be relieved of liability to the other for failure to perform or for delay in performing
such obligations (as the case may be), but shall nevertheless use its commercially reasonable efforts to resume full performance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">15.5 <B>No
Trial By Jury. </B>THE PARTIES EXPRESSLY WAIVE AND FOREGO ANY RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">15.6 <B>Notices</B>.
All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly
given when: (a) delivered by hand or by express courier service (in both instances with written confirmation of receipt), or (b) when
received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case to the
appropriate addresses set forth below (or to such other addresses as a Party may designate by written notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to NLS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">NLS Pharmaceutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Alter Postplatz 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">6370 Stans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Switzerland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to Novartis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Novartis Pharma AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Lichtstrasse 35, CH-4056 Basel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Head, Alliance Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy at the same address to:<BR>
General Counsel, Novartis Pharma AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each Party may change its address for purposes of this Agreement by written notice to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7 <B>Waiver
and Amendments</B>. The failure of a Party to assert a right hereunder or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by
the other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision
of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.8 <B>Severability</B>.
Without prejudice to any other rights that a Party may have pursuant to this Agreement, every provision of this Agreement is intended
to be severable. If any provision of this Agreement shall be invalid or unenforceable, such invalidity or unenforceability shall not affect
the other provisions of this Agreement, which shall remain in full force and effect. The Parties hereto agree to consult each other and
to agree upon a new stipulation which is permissible under the Law and which comes as close as possible to the original purpose and intent
of the invalid, void or unenforceable provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.9 <B>Entire
Agreement</B>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and
oral, between the Parties with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.10 <B>Relationship
of the Parties</B>. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of
any type between Novartis and NLS, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement,
or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor,
and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.11 <B>Expenses</B>.
Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other
experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.12 <B>Further
Assurances</B>. Novartis and NLS hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge
and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and
purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.13 <B>Headings</B>.
Titles or captions of articles and sections contained in this Agreement are inserted only as a matter of convenience and for reference,
and in no way define, limit, extend, or describe the scope of this Agreement or the intent of any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.14 <B>Compliance
with Law</B>. Each Party shall perform its obligations under this Agreement in accordance with all applicable laws. No Party shall, or
shall be required to, undertake any activity under or in connection with this Agreement which violates or which it believes, in good faith,
may violate any applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.15 <B>No
Third Party Beneficiary Rights.</B> The provisions of this Agreement are for the sole benefit of the Parties and their successors and
permitted assigns, and they shall not be construed as conferring any rights to any third Party (including any third party beneficiary
rights).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.16 <B>English
Language</B>. This Agreement is written and executed in the English language. Any translation into any other language shall not be an
official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation,
the English version shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.17 <B>Cumulative
Remedies.</B> No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any
other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.18 <B>Counterparts</B>.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one (1) and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties intending to be
bound have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOVARTIS PHARMA AG</B></FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NLS PHARMACEUTICS LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="padding-bottom: 0; border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Jean-Marc
Sequter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="padding-bottom: 0; border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Ronald
    Hafner&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jean-Marc Sequter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ronald Hafner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global BDL Head Divestment/Out-Licensing</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman of the Board</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Shusaku
    Iwasaki&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Alex
    Zwyer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Shusaku Iwasaki</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Alex Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Legal Counsel</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>SCHEDULE
A<BR>
</U>SALES REPORT FORM<BR>
<BR>
</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex4-6_001.jpg" ALT="" STYLE="width: 670px; height: 376px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex4-6_002.jpg" ALT="" STYLE="width: 670px; height: 266px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white"><B><U>Schedule
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white"><B>licensed
data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Licensed Data to be provided subject to the time periods
specified in the definition of &ldquo;Licensed Data&rdquo; in this Agreement. Embedded NDA Table of Contents pdf at end of this Schedule
B is provided for reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All available mazindol data referred to and included in
the 1972-02-25 Original NDA 17247.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD>Available as scanned documents: volumes 1 to 52</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD>To be scanned upon request of Licensee: volumes 53 to 418</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All available mazindol data used for the formulation, manufacturing,
including stability and other data, pre-clinical and development of the Licensed Product as stored in the Novartis electronic document
management systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All post-marketing periodic safety reports/updates from
1973-1999 and at any later date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD>PSURs available as scanned documents: PSURs for period 1995-2010. &nbsp;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD>To be checked for availability and scanned if available: PSUR version 1, covering the period from launch till end of 1994</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD>Other safety related scanned documents available, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;<IMG SRC="ex4-6_003.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;<IMG SRC="ex4-6_004.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white"><B><U>SCHEDULE
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white"><B>KNOWLEDGE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Jean Marc
Sequier</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="background-color: white">Head, Divestments
&amp; Outlicensing </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>f20f2020ex8-1_nlspharma.htm
<DESCRIPTION>SUBSIDIARY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 51%; padding-left: 10pt; text-indent: -10pt; border-bottom: Black 1.5pt solid"><B>Subsidiary</B></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 48%; border-bottom: Black 1.5pt solid"><B>Jurisdiction</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">NLS Pharmaceutics Inc.</TD>
    <TD>&nbsp;</TD>
    <TD>Delaware</TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>f20f2020ex12-1_nlspharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 12.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Alexander Zwyer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20&ndash;F of NLS Pharmaceutics Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a&ndash;15(e) and 15d&ndash;15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">b) [paragraph omitted in accordance
with Exchange Act Rule 13a-14(a)];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">d) Disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the period covered by the annual
report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 60%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>f20f2020ex12-2_nlspharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 12.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Subhasis Roy, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20&ndash;F of NLS Pharmaceutics Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a&ndash;15(e) and 15d&ndash;15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">b) [paragraph omitted in accordance
with Exchange Act Rule 13a-14(a)];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">d) Disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the period covered by the annual
report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 60%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Subhasis Roy</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Subhasis Roy</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
</TABLE>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>f20f2020ex13-1_nlspharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 13.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18 U.S.C. Section 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">In connection with the
filing of the Annual Report on Form 20-F for the period ended December 31, 2020 (the &ldquo;Report&rdquo;) by NLS Pharmaceutics
Ltd. (the &ldquo;Company&rdquo;), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to
18 U.S.C. Section 1350, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">(1) the Report fully
complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">(2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>8
<FILENAME>f20f2020ex13-2_nlspharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 13.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18 U.S.C. Section 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">In connection with the
filing of the Annual Report on Form 20-F for the period ended December 31, 2020 (the &ldquo;Report&rdquo;) by NLS Pharmaceutics
Ltd. (the &ldquo;Company&rdquo;), the undersigned, as Interim Chief Financial Officer of the Company, hereby certifies pursuant
to 18 U.S.C. Section 1350, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">(1) the Report fully
complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">(2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Subhasis Roy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Subhasis Roy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>nlsp-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nlsp="http://www.nlspharma.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="nlsp-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c2_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c3_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c5_AsOf31Dec2017_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2017_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2017_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2017_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c10_From1Jan2018To31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c11_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2018To31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2018To31Dec2018_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c14_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c16_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c19_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c23_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c27_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c31_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c35_From30Jan2021To2Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-30</startDate>
      <endDate>2021-02-02</endDate>
    </period>
  </context>
  <context id="c36_AsOf2Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-02-02</instant>
    </period>
  </context>
  <context id="c37_AsOf2Feb2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2021-02-02</instant>
    </period>
  </context>
  <context id="c38_From1Sep2020To14Sep2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2020-09-01</startDate>
      <endDate>2020-09-14</endDate>
    </period>
  </context>
  <context id="c39_From1Jan2019To31Dec2019_ScenarioPreviouslyReportedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c40_From1Jan2019To31Dec2019_RestatementAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c41_From1Jan2019To31Dec2019_RevisionOfPriorPeriodReclassificationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c42_From1Jan2018To31Dec2018_ScenarioPreviouslyReportedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c43_From1Jan2018To31Dec2018_RestatementAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jan2018To31Dec2018_RevisionOfPriorPeriodReclassificationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c45_AsOf31Jan2019_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-01-31</instant>
    </period>
  </context>
  <context id="c46_AsOf31Aug2018_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-31</instant>
    </period>
  </context>
  <context id="c47_AsOf31Dec2018_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c48_AsOf31Dec2019_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c49_From1Jan2019To31Dec2019_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c50_From1Mar2019To31Mar2019_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c51_AsOf31Mar2019_MagneticRockInvestmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nlsp:MagneticRockInvestmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c53_From1Mar2019To31Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c54_AsOf31Aug2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2015-08-31</instant>
    </period>
  </context>
  <context id="c55_From5Aug2015To31Aug2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2015-08-05</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="c56_AsOf31Dec2020_SecondCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nlsp:SecondCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c57_AsOf31Dec2019_SecondCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">nlsp:SecondCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c58_From1Dec2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2019-12-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c59_AsOf31Dec2020_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c60_From1Apr2020To30Apr2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-04-30</endDate>
    </period>
  </context>
  <context id="c61_AsOf30Apr2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2020-04-30</instant>
    </period>
  </context>
  <context id="c62_From1Aug2020To31Aug2020_FirstTrancheMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlsp:FirstTrancheMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c63_AsOf31Aug2020_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c64_AsOf31Aug2020_FirstTrancheMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nlsp:FirstTrancheMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c65_From1Aug2020To31Aug2020_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jul2018To31Jul2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="c67_AsOf31Jul2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2018-07-31</instant>
    </period>
  </context>
  <context id="c68_AsOf31Oct2020_CHGBioVentureSAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nlsp:CHGBioVentureSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-10-31</instant>
    </period>
  </context>
  <context id="c69_AsOf31Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
    </entity>
    <period>
      <instant>2020-10-31</instant>
    </period>
  </context>
  <context id="c70_From1Mar2021To31Mar2021_MrRoyMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nlsp:MrRoyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-03-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c71_From1Feb2021To28Feb2021_MrKonofalMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nlsp:MrKonofalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-01</startDate>
      <endDate>2021-02-28</endDate>
    </period>
  </context>
  <context id="c72_From1Mar2021To31Mar2021_MrCamozziMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nlsp:MrCamozziMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-03-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c73_AsOf31Mar2021_MrKonofalMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nlsp:MrKonofalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c74_From1Jan2021To31Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-31</endDate>
    </period>
  </context>
  <context id="c75_From30Jan2021To2Feb2021_SubsequentEventMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-30</startDate>
      <endDate>2021-02-02</endDate>
    </period>
  </context>
  <context id="c76_From1Mar2021To10Mar2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001783036</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-03-01</startDate>
      <endDate>2021-03-10</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="chfPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:CHF</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="chf">
    <measure>iso4217:CHF</measure>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="_ResearchAndDevelopmentExpense-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_ResearchAndDevelopmentExpense-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">Comparative figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification of intellectual property expenses from research and development expenses to general and administrative expenses. For further information, see Note 3 &#8220;Restatement of Previously Issued Financial Statements&#8221; to the financial statements.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ResearchAndDevelopmentExpense-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ResearchAndDevelopmentExpense-c3_From1Jan2019To31Dec2019_usd" xlink:href="#_ResearchAndDevelopmentExpense-c3_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ResearchAndDevelopmentExpense-c3_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_ResearchAndDevelopmentExpense-c4_From1Jan2018To31Dec2018_usd" xlink:href="#_ResearchAndDevelopmentExpense-c4_From1Jan2018To31Dec2018_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_ResearchAndDevelopmentExpense-c4_From1Jan2018To31Dec2018_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_GeneralAndAdministrativeExpense-c0_From1Jan2020To31Dec2020_usd" xlink:href="#_GeneralAndAdministrativeExpense-c0_From1Jan2020To31Dec2020_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_GeneralAndAdministrativeExpense-c0_From1Jan2020To31Dec2020_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_GeneralAndAdministrativeExpense-c3_From1Jan2019To31Dec2019_usd" xlink:href="#_GeneralAndAdministrativeExpense-c3_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_GeneralAndAdministrativeExpense-c3_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_GeneralAndAdministrativeExpense-c4_From1Jan2018To31Dec2018_usd" xlink:href="#_GeneralAndAdministrativeExpense-c4_From1Jan2018To31Dec2018_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_GeneralAndAdministrativeExpense-c4_From1Jan2018To31Dec2018_usd" xlink:to="ftnt_0" order="1"/>
  </link:footnoteLink>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">V8</dei:EntityIncorporationStateCountryCode>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentAnnualReport contextRef="c0_From1Jan2020To31Dec2020">true</dei:DocumentAnnualReport>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentShellCompanyReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentTransitionReport>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">20-F</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001783036</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-39957</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">NLS Pharmaceutics Ltd.	</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">6960000</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">93711</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">220267</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">103000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">161479</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">0</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">13432</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">196711</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">381746</us-gaap:AssetsCurrent>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">946912</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">260211</us-gaap:DeferredCosts>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">67954</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">54472</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">1211577</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">696429</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">4006473</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">2509350</us-gaap:AccountsPayableCurrent>
  <nlsp:AccountsPayableIncludingRelatedParty unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">454315</nlsp:AccountsPayableIncludingRelatedParty>
  <nlsp:AccountsPayableIncludingRelatedParty unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">34727</nlsp:AccountsPayableIncludingRelatedParty>
  <us-gaap:InterestPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">316174</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">170268</us-gaap:InterestPayableCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">591693</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">540071</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:LinesOfCreditCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">150000</us-gaap:LinesOfCreditCurrent>
  <us-gaap:LinesOfCreditCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">150000</us-gaap:LinesOfCreditCurrent>
  <us-gaap:ConvertibleDebtCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">463980</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:LongTermDebt unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">113130</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">37362</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">565650</us-gaap:BridgeLoan>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">459195</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">102950</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">650753</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">562465</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">40842</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">12391</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">7203918</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">4035104</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleDebtNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">32463</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">152058</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">4248</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">64788</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
  <us-gaap:LongTermLoansFromBank unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">281015</us-gaap:LongTermLoansFromBank>
  <us-gaap:DeferredRevenueNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">2499969</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">2499969</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">178269</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">180248</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">10195634</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">6867379</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">145139</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">145139</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="chfPershares" contextRef="c1_AsOf31Dec2020" decimals="2">0.02</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="chfPershares" contextRef="c2_AsOf31Dec2019" decimals="2">0.02</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">6960000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">6960000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">6960000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">6960000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">10440000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">10440000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">20649882</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">20600871</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">-29759697</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">-26898262</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">-19381</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">-18698</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">-8984057</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">-6170950</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">1211577</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">696429</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense id="_ResearchAndDevelopmentExpense-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">99580</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="_ResearchAndDevelopmentExpense-c3_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">897788</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="_ResearchAndDevelopmentExpense-c4_From1Jan2018To31Dec2018_usd" unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">708455</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="_GeneralAndAdministrativeExpense-c0_From1Jan2020To31Dec2020_usd" unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2199790</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="_GeneralAndAdministrativeExpense-c3_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">3299251</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="_GeneralAndAdministrativeExpense-c4_From1Jan2018To31Dec2018_usd" unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">2740406</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2299370</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">4197039</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">3448861</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-2299370</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-4197039</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-3448861</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-328365</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-65445</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">16035</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestExpenseDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">86792</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">992</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">146908</us-gaap:InterestExpenseOther>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">818719</us-gaap:InterestExpenseOther>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">1084708</us-gaap:InterestExpenseOther>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-364950</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-629232</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-2861435</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-5447145</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-5146766</us-gaap:ProfitLoss>
  <nlsp:DefinedPensionPlanAdjustments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">683</nlsp:DefinedPensionPlanAdjustments>
  <nlsp:DefinedPensionPlanAdjustments unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">7444</nlsp:DefinedPensionPlanAdjustments>
  <nlsp:DefinedPensionPlanAdjustments unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">1261</nlsp:DefinedPensionPlanAdjustments>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-2862118</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-5454589</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-5148027</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-0.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">-0.80</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">-0.82</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">6960000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">6840000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="INF">6240000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c5_AsOf31Dec2017_CommonStockMember" decimals="INF">6120000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c5_AsOf31Dec2017_CommonStockMember" decimals="0">128344</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c6_AsOf31Dec2017_AdditionalPaidInCapitalMember" decimals="0">8468547</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2017_RetainedEarningsMember" decimals="0">-16304351</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2017_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-9993</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2017" decimals="0">-7717453</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c10_From1Jan2018To31Dec2018_CommonStockMember" decimals="INF">260000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_CommonStockMember" decimals="0">5200</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="0">4042552</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">4047752</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="0">4019</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">4019</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c13_From1Jan2018To31Dec2018_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-1261</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-1261</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c12_From1Jan2018To31Dec2018_RetainedEarningsMember" decimals="0">-5146766</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-5146766</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c14_AsOf31Dec2018_CommonStockMember" decimals="INF">6380000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31Dec2018_CommonStockMember" decimals="0">133544</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="0">12515118</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c16_AsOf31Dec2018_RetainedEarningsMember" decimals="0">-21451117</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-11254</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">-8813709</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">580000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_CommonStockMember" decimals="0">11595</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">8011605</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">8023200</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">8540</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">8540</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">65608</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">65608</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-7444</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-7444</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="0">-5447145</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-5447145</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c23_AsOf31Dec2019_CommonStockMember" decimals="INF">6960000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31Dec2019_CommonStockMember" decimals="0">145139</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">20600871</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-26898262</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-18698</us-gaap:StockholdersEquity>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">24911</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24911</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">24100</nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan>
  <nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24100</nlsp:BeneficialConversionFeatureOnRelatedPartyConvertibleLoan>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-683</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-683</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c27_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="0">-2861435</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-2861435</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c31_AsOf31Dec2020_CommonStockMember" decimals="INF">6960000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf31Dec2020_CommonStockMember" decimals="0">145139</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c32_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">20649882</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-29759697</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-19381</us-gaap:StockholdersEquity>
  <nlsp:PeriodicPensionCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">4258</nlsp:PeriodicPensionCosts>
  <nlsp:PeriodicPensionCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-20085</nlsp:PeriodicPensionCosts>
  <nlsp:PeriodicPensionCosts unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-26566</nlsp:PeriodicPensionCosts>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">72188</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">755555</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">1090411</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">3477</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">16038</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-7382</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">13482</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-1000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">41101</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1497123</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">1378545</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">565851</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedTaxesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">137826</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedTaxesPayable unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">67159</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedTaxesPayable unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-5252</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">2499969</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">446129</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">185911</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">140873</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-729386</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-190009</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-2732804</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">249306</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">154890</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">113130</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nlsp:ProceedsFromSwissGovernmentLoan unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">262137</nlsp:ProceedsFromSwissGovernmentLoan>
  <nlsp:ProceedsFromSwissGovernmentLoan unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nlsp:ProceedsFromBridgeLoan unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-565650</nlsp:ProceedsFromBridgeLoan>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">512800</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">557920</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:PaymentsOfFinancingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">686701</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">260211</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">503522</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">407479</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">557920</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">99308</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-3881</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-1369</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-126556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">213589</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-2176253</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">220267</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">6678</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c9_AsOf31Dec2017" decimals="0">2182931</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">93711</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <nlsp:IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nlsp:IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">8023200</nlsp:IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities>
  <nlsp:IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">4047752</nlsp:IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities>
  <nlsp:DebtDiscountOnRelatedPartyLoans unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nlsp:DebtDiscountOnRelatedPartyLoans unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">8540</nlsp:DebtDiscountOnRelatedPartyLoans>
  <nlsp:DebtDiscountOnRelatedPartyLoans unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">4019</nlsp:DebtDiscountOnRelatedPartyLoans>
  <nlsp:DebtDiscountOnConvertibleLoans unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">61956</nlsp:DebtDiscountOnConvertibleLoans>
  <nlsp:BackgroundTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;a name=&quot;b_006&quot;&gt;&lt;/a&gt;&lt;i&gt;Note
1&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Background:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the &amp;#x201c;Company&amp;#x201d;) is an emerging biopharmaceutical company engaged in the discovery
and development of life-improving drug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic
hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder (&amp;#x201c;ADHD&amp;#x201d;).
The Company&amp;#x2019;s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;On
March 12, 2019, the Company merged NLS-0 Pharma Ltd. and NLS Pharma Ltd. into &lt;font&gt;NLS-1 Pharma Ltd.
(the &amp;#x201c;Merger&amp;#x201d;), the predecessor of the Company,&lt;/font&gt; retroactively and effective on January 1, 2019 and renamed the Company
NLS Pharmaceutics Ltd. Due to the high degree of common ownership among the three companies and because individual investors&amp;#x2019; ownership
is in substance the same after the transaction, this Merger was deemed to be a non-substantive merger, with no step up in basis of the
assets and liabilities in the Merger. The financial statements presented were prepared as if the Merger occurred on January 1, 2018.
All intercompany transactions and balances were eliminated in the Merger.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;On
February 2, 2021, the Company &lt;/font&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;completed the closing of its initial public
offering (the &amp;#x201c;Initial Public Offering&amp;#x201d;) of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common
share and one Warrant to purchase one common share (the &amp;#x201c;Warrants&amp;#x201d;). The common shares and Warrants were immediately separable
from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021
under the symbols &amp;#x201c;NLSP&amp;#x201d; and &amp;#x201c;NLSPW,&amp;#x201d; respectively. The Company received net proceeds of $17 million, after deducting
underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years
from the date of issuance and have an exercise price of $4.15 per share. In addition, the Company granted the underwriters a 45-day option
to purchase up to an additional 722,891 common shares at the public offering price of $4.14 per common share and/or up to an additional
722,891 Warrants to purchase 722,891 common shares at the public offering price of $0.01 per Warrant, of which the underwriters exercised
their option to purchase Warrants to purchase up to 722,891 common shares. These Warrants were issued in the Company&amp;#x2019;s Initial
Public Offering and therefore have the same exercise price of $4.15 per share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the Company had an accumulated deficit of approximately $29.8 million and the Company incurred operating losses
since inception, including operating loss for the year ended December 31, 2020 of approximately $2.3 million. To date, the Company has
dedicated most of its financial resources to research and development, clinical studies associated with its ongoing biopharmaceutical
business and general and administrative expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the Company&amp;#x2019;s cash and cash equivalents were $93,711 and shareholders&amp;#x2019; deficit was $8,984,057. The
Company expects that its existing cash and cash equivalents, including the net proceeds of $17 million from its Initial Public Offering,
will be sufficient to fund operations into the second quarter of 2022. These conditions raise substantial doubt about the Company&amp;#x2019;s
ability to continue as a going concern for one year from the issuance of these financial statements. Additionally, the Company&amp;#x2019;s
operating plans may change as a result of many factors that may currently be unknown to the Company including:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the length of the COVID-19
    pandemic and its impact on our planned clinical trials, operations and financial condition;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the progress and costs of
    our pre-clinical studies, clinical trials and other research and development activities; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the scope, prioritization
    and number of our clinical trials and other research and development programs;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;any cost that we may incur
    under in- and out-licensing arrangements relating to our product candidate that we may enter into in the future; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the costs and timing of obtaining
    regulatory approval for our product candidates; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the costs of filing, prosecuting,
    enforcing and defending patent claims and other intellectual property rights; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the costs of, and timing for,
    strengthening our manufacturing agreements for production of sufficient clinical and commercial quantities of our product candidates;
    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the potential costs of contracting
    with third parties to provide marketing and distribution services for us or for building such capacities internally; and &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;the costs of acquiring or
    undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates
    and the magnitude of our general and administrative expenses. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
a result, the Company may require additional capital to finance expenditures related to the manufacture of the Company&amp;#x2019;s product
candidates for use in clinical trials, conducting clinical trials and general and administration costs&lt;font&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has historically financed its activities primarily with cash from the private placement of equity and debt securities and borrowings
under credit facilities and shareholder loans. The Company intends to raise additional capital through private placements of debt and
equity securities or through loans from third parties, but there can be no assurance that these funds will be available, or if they are
available, their availability will be on terms acceptable to the Company or in an amount sufficient to enable the Company to fully complete
its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop
and implement a plan to further extend payables and indebtedness, reduce overhead, or scale back its current business plan until sufficient
additional capital is raised to support further operations or force the Company to grant rights to develop and commercialize product
candidates that it would otherwise prefer to develop and commercialize on its own. There can be no assurance that such a plan will be
successful.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Accordingly,
the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States
of America (&amp;#x201c;U.S. GAAP&amp;#x201d;), which contemplate continuation of the Company as a going concern for a period within one year from
the issuance of these financial statements and the realization of assets and satisfaction of liabilities in the normal course of business.
The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable
or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
1A&lt;/i&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Stock
Split&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;On
September 14, 2020, the Company filed an amendment to its Articles of Incorporation and effected a 5,000-for-1 stock split of its issued
and outstanding common shares, whereby 1,392 outstanding common shares with a par value of CHF 100.00 per share were exchanged for 6,960,000
common shares with a par value of CHF 0.02 per share. All per share amounts and number of shares in the financial statements and related
notes have been retroactively restated to reflect the share split.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</nlsp:BackgroundTextBlock>
  <nlsp:InitialPublicOfferingUnits unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">4819277</nlsp:InitialPublicOfferingUnits>
  <nlsp:PricePerShareUnit unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">4.15</nlsp:PricePerShareUnit>
  <nlsp:GrossProceeds unitRef="usd" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="-6">17000000</nlsp:GrossProceeds>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="2">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <nlsp:AdditionalPurchaseShare unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">722891</nlsp:AdditionalPurchaseShare>
  <nlsp:PublicOfferingPrice unitRef="usdPershares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="2">4.14</nlsp:PublicOfferingPrice>
  <nlsp:AdditionalWarrantsShare unitRef="shares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="INF">722891</nlsp:AdditionalWarrantsShare>
  <nlsp:WarrantPurchaseCommonShare unitRef="shares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="INF">722891</nlsp:WarrantPurchaseCommonShare>
  <nlsp:WarrantOfferingPerShare unitRef="usdPershares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="2">0.01</nlsp:WarrantOfferingPerShare>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">722891</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c37_AsOf2Feb2021" decimals="2">4.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:OtherOperatingIncome unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">2300000</us-gaap:OtherOperatingIncome>
  <nlsp:StockholdersEquity1 unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">8984057</nlsp:StockholdersEquity1>
  <nlsp:GrossProceeds unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-6">17000000</nlsp:GrossProceeds>
  <us-gaap:StockholdersEquityNoteStockSplit contextRef="c38_From1Sep2020To14Sep2020">On September 14, 2020, the Company filed an amendment to its Articles of Incorporation and effected a 5,000-for-1 stock split of its issued and outstanding common shares, whereby 1,392 outstanding common shares with a par value of CHF 100.00 per share were exchanged for 6,960,000 common shares with a par value of CHF 0.02 per share.</us-gaap:StockholdersEquityNoteStockSplit>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
2&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Summary
of Significant Accounting Policies:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
accompanying financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance
is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting
Standards Updates (&amp;#x201c;ASU&amp;#x201d;) of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;).&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial
statements, the Company&amp;#x2019;s significant estimates include (1) pension and other post-employment benefits, including certain asset
values that are based on significant unobservable inputs; (2) the inputs used in determining the fair value of equity per share; (3)
the beneficial conversion feature on the convertible loans and (4) valuation allowance relating to the Company&amp;#x2019;s deferred tax assets.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;JOBS
Act Accounting Election &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company is an &amp;#x201c;emerging growth company&amp;#x201d; or &amp;#x201c;EGC&amp;#x201d;, as defined in the Jumpstart Our Business Startups Act of 2012
(the &amp;#x201c;JOBS Act&amp;#x201d;). Under the JOBS Act, an EGC has elected to delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. The Company
generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding
operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred
Offering Costs &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Specific
incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly
be deferred and charged against the gross proceeds of such an offering. As of December 31, 2020 and 2019, there were $946,912 and $260,211,
respectively, of Initial Public Offering costs, primarily consisting of legal, accounting and printing fees, that were capitalized in
other non-current assets on the balance sheet.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Concentration
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Financial
instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2020 and 2019, substantially
all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions
which are in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Functional
Currency&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has operations in Switzerland and the United States. The Company&amp;#x2019;s functional currency is the U.S. dollar (&amp;#x201c;USD&amp;#x201d;).
The results of its non-USD based operations are translated to USD at the average exchange rates during the year. The Company&amp;#x2019;s
assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&amp;#x2019; equity is
translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company&amp;#x2019;s
results of operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the Company has not recognized any revenue from its exclusive license agreement (the &amp;#x201c;EF License Agreement&amp;#x201d;),
as the upfront payment the Company received has been deferred. The EF License Agreement is to develop and commercialize its product candidate,
Nolazol, in Latin American countries with Eurofarma Laboratorios S.A. (&amp;#x201c;Eurofarma&amp;#x201d;), a Brazilian pharmaceutical company.
The EF License Agreement is within the scope of ASC 606, &amp;#x201c;&lt;i&gt;Revenue from Contract with Customers&lt;/i&gt;&amp;#x201d; (&amp;#x201c;ASC 606&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities
of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the
goods or services are integral to or dependent on other goods or services in the contract.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in
the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that
includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be
received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received
based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the
transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant
reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The
Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified
in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations,
which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally,
in determining the stand-alone selling price for material rights, the Company may reference comparable transactions, clinical trial success
probabilities, and develop estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each
performance obligation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress at each reporting
period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within the Company&amp;#x2019;s control or the licensee&amp;#x2019;s control, such
as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting
period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary,
adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect license revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement
of development, regulatory, or commercial milestone revenue resulting from the EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting
from any of the Company&amp;#x2019;s license agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;To
the extent the Company receives payments, including non-refundable payments, in excess of the recognized revenue, such excess is recorded
as deferred revenue until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the Company&amp;#x2019;s right to consideration is unconditional.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Costs
for research and development (&amp;#x201c;R&amp;amp;D&amp;#x201d;) of products, including payroll, contractor expenses, and supplies, are expensed
as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where
contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when
the milestone results are probable of being achieved.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company measures and discloses fair value in accordance with ASC 820, &amp;#x201c;&lt;i&gt;Fair Value,&amp;#x201d;&lt;/i&gt; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to
access as of the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity
for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted
as appropriate for liquidity, credit, market and/or other risk factors.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company&amp;#x2019;s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above.
The carrying values of the Company&amp;#x2019;s accounts payable approximate their fair value due to the short-term nature of these liabilities.
The carrying value of the Company&amp;#x2019;s debt is estimated to approximate its fair value, as the notes are near maturity and the interest
rates on the debts approximates market rates.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs and Debt Discount&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Debt
issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount
of that debt liability, consistent with debt discounts, and are amortized to interest expense over the term of the related debt using
the effective interest method.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&amp;#x2019;s tax
returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from
future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that
all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax
expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Due
to the fact that the Company has a history of generating losses, and expects to generate losses in the foreseeable future, a full valuation
allowance has been recorded as no deferred taxes have been recognized.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;The
Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, &amp;#x201c;&lt;/font&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Income
Taxes &lt;/i&gt;&lt;font&gt;(&lt;/font&gt;&lt;i&gt;Accounting for Uncertainty in Income Taxes),&amp;#x201d; &lt;/i&gt;&lt;font&gt;which
clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position
can be recognized in the financial statements only if the position is &amp;#x201c;more-likely-than-not&amp;#x201d; to be sustained were it to be
challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without
regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the &amp;#x201c;more-likely-than-not&amp;#x201d;
threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority
is recorded. &lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Employee
Benefits (including Post Retirement Benefits)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company operates the mandatory pension plan for its employees in Switzerland. The plan is generally funded through payments to insurance
companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on
individual savings accounts. However, this plan is classified as a defined benefit plan under ASC 960 &lt;i&gt;&amp;#x201c;Plan Accounting &amp;#x2013;
Defined Benefit Pension Plans&lt;/i&gt;.&amp;#x201d;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of
plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected
unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&amp;#x2019;
projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating
the terms of the related liability.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Remeasurements
of the net defined benefit liability, which comprise actuarial gains and losses, and the return on plan assets (excluding interest),
are recognized immediately in Other Comprehensive Loss. Past service costs, including curtailment gains or losses, are recognized immediately
as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses
are recognized in either research and development and/or general and administrative expenses within the operating results. The Company
determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to
measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement
dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period
as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized
in the statement of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Basic
net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted-average number of common
shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator
is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period
in which a net loss is reported or if their effect is anti-dilutive. The Company&amp;#x2019;s potential common shares consist of convertible
promissory notes and convertible loans with their potential dilutive effect considered using the &amp;#x201c;if-converted&amp;#x201d; method. For
the years ended December 31, 2020 and 2019, 50,205 and 20,000 shares related to the convertible loans were excluded from the computation,
respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The Company
manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&amp;#x2019;s
singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company&amp;#x2019;s
tangible assets are held in Switzerland.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements &amp;#x2013; Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;: &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.
The FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining
usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology
for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the
amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate
consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes
in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance
will become effective for the Company beginning after December 15, 2021 and interim periods within fiscal years beginning after December
15, 2022. Because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from
the adoption of this standard.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements &amp;#x2013; Recently Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
August 2018, the FASB issued ASU No. 2018-13, &lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#x2013; Changes to the Disclosure
Requirements for Fair Value Measurement&lt;/i&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount and reasons for transfers between Level 1 and Level 2 of
the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public business entities will be required
to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related
changes in unrealized gains and losses included in other comprehensive income. ASU 2018-13 was effective for public and non-public business
entities for fiscal years beginning after December 15, 2019, including interim periods. The adoption of ASU 2018-13 did not have a material
impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
accompanying financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance
is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting
Standards Updates (&amp;#x201c;ASU&amp;#x201d;) of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial
statements, the Company&amp;#x2019;s significant estimates include (1) pension and other post-employment benefits, including certain asset
values that are based on significant unobservable inputs; (2) the inputs used in determining the fair value of equity per share; (3)
the beneficial conversion feature on the convertible loans and (4) valuation allowance relating to the Company&amp;#x2019;s deferred tax assets.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;JOBS
Act Accounting Election &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company is an &amp;#x201c;emerging growth company&amp;#x201d; or &amp;#x201c;EGC&amp;#x201d;, as defined in the Jumpstart Our Business Startups Act of 2012
(the &amp;#x201c;JOBS Act&amp;#x201d;). Under the JOBS Act, an EGC has elected to delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. The Company
generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding
operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred
Offering Costs &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Specific
incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly
be deferred and charged against the gross proceeds of such an offering. As of December 31, 2020 and 2019, there were $946,912 and $260,211,
respectively, of Initial Public Offering costs, primarily consisting of legal, accounting and printing fees, that were capitalized in
other non-current assets on the balance sheet.&lt;/font&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">946912</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">260211</us-gaap:DeferredCostsCurrent>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Concentration
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Financial
instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2020 and 2019, substantially
all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions
which are in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Functional
Currency&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has operations in Switzerland and the United States. The Company&amp;#x2019;s functional currency is the U.S. dollar (&amp;#x201c;USD&amp;#x201d;).
The results of its non-USD based operations are translated to USD at the average exchange rates during the year. The Company&amp;#x2019;s
assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&amp;#x2019; equity is
translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company&amp;#x2019;s
results of operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the Company has not recognized any revenue from its exclusive license agreement (the &amp;#x201c;EF License Agreement&amp;#x201d;),
as the upfront payment the Company received has been deferred. The EF License Agreement is to develop and commercialize its product candidate,
Nolazol, in Latin American countries with Eurofarma Laboratorios S.A. (&amp;#x201c;Eurofarma&amp;#x201d;), a Brazilian pharmaceutical company.
The EF License Agreement is within the scope of ASC 606, &amp;#x201c;&lt;i&gt;Revenue from Contract with Customers&lt;/i&gt;&amp;#x201d; (&amp;#x201c;ASC 606&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities
of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the
goods or services are integral to or dependent on other goods or services in the contract.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in
the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that
includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be
received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received
based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the
transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant
reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The
Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified
in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations,
which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally,
in determining the stand-alone selling price for material rights, the Company may reference comparable transactions, clinical trial success
probabilities, and develop estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each
performance obligation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress at each reporting
period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within the Company&amp;#x2019;s control or the licensee&amp;#x2019;s control, such
as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting
period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary,
adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect license revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement
of development, regulatory, or commercial milestone revenue resulting from the EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting
from any of the Company&amp;#x2019;s license agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;To
the extent the Company receives payments, including non-refundable payments, in excess of the recognized revenue, such excess is recorded
as deferred revenue until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the Company&amp;#x2019;s right to consideration is unconditional.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Costs
for research and development (&amp;#x201c;R&amp;amp;D&amp;#x201d;) of products, including payroll, contractor expenses, and supplies, are expensed
as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where
contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when
the milestone results are probable of being achieved.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.&lt;/font&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company measures and discloses fair value in accordance with ASC 820, &amp;#x201c;&lt;i&gt;Fair Value,&amp;#x201d;&lt;/i&gt; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to
access as of the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity
for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted
as appropriate for liquidity, credit, market and/or other risk factors.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company&amp;#x2019;s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above.
The carrying values of the Company&amp;#x2019;s accounts payable approximate their fair value due to the short-term nature of these liabilities.
The carrying value of the Company&amp;#x2019;s debt is estimated to approximate its fair value, as the notes are near maturity and the interest
rates on the debts approximates market rates.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs and Debt Discount&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Debt
issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount
of that debt liability, consistent with debt discounts, and are amortized to interest expense over the term of the related debt using
the effective interest method.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&amp;#x2019;s tax
returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from
future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that
all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax
expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Due
to the fact that the Company has a history of generating losses, and expects to generate losses in the foreseeable future, a full valuation
allowance has been recorded as no deferred taxes have been recognized.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;The
Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, &amp;#x201c;&lt;/font&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Income
Taxes &lt;/i&gt;&lt;font&gt;(&lt;/font&gt;&lt;i&gt;Accounting for Uncertainty in Income Taxes),&amp;#x201d; &lt;/i&gt;&lt;font&gt;which
clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position
can be recognized in the financial statements only if the position is &amp;#x201c;more-likely-than-not&amp;#x201d; to be sustained were it to be
challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without
regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the &amp;#x201c;more-likely-than-not&amp;#x201d;
threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority
is recorded.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <nlsp:TaxBenefitsMoreLikelyToBeRecognizedPercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.50</nlsp:TaxBenefitsMoreLikelyToBeRecognizedPercentage>
  <us-gaap:AssetRetirementObligationsPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Employee
Benefits (including Post Retirement Benefits)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company operates the mandatory pension plan for its employees in Switzerland. The plan is generally funded through payments to insurance
companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on
individual savings accounts. However, this plan is classified as a defined benefit plan under ASC 960 &lt;i&gt;&amp;#x201c;Plan Accounting &amp;#x2013;
Defined Benefit Pension Plans&lt;/i&gt;.&amp;#x201d;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of
plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected
unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&amp;#x2019;
projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating
the terms of the related liability.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Remeasurements
of the net defined benefit liability, which comprise actuarial gains and losses, and the return on plan assets (excluding interest),
are recognized immediately in Other Comprehensive Loss. Past service costs, including curtailment gains or losses, are recognized immediately
as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses
are recognized in either research and development and/or general and administrative expenses within the operating results. The Company
determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to
measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement
dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period
as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized
in the statement of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;</us-gaap:AssetRetirementObligationsPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Basic
net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted-average number of common
shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator
is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period
in which a net loss is reported or if their effect is anti-dilutive. The Company&amp;#x2019;s potential common shares consist of convertible
promissory notes and convertible loans with their potential dilutive effect considered using the &amp;#x201c;if-converted&amp;#x201d; method. For
the years ended December 31, 2020 and 2019, 50,205 and 20,000 shares related to the convertible loans were excluded from the computation,
respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">50205</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The Company
manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&amp;#x2019;s
singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company&amp;#x2019;s
tangible assets are held in Switzerland.&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <nlsp:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements &amp;#x2013; Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;: &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.
The FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining
usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology
for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the
amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate
consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes
in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance
will become effective for the Company beginning after December 15, 2021 and interim periods within fiscal years beginning after December
15, 2022. Because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from
the adoption of this standard.&lt;/font&gt;&lt;/p&gt;</nlsp:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements &amp;#x2013; Recently Adopted&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
August 2018, the FASB issued ASU No. 2018-13, &lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#x2013; Changes to the Disclosure
Requirements for Fair Value Measurement&lt;/i&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount and reasons for transfers between Level 1 and Level 2 of
the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public business entities will be required
to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related
changes in unrealized gains and losses included in other comprehensive income. ASU 2018-13 was effective for public and non-public business
entities for fiscal years beginning after December 15, 2019, including interim periods. The adoption of ASU 2018-13 did not have a material
impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0DW2eoVZ+PEfDrufS76vXk7] CSR-->
  <nlsp:RestatementOfPreviouslyIssuedFinancialStatementsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
3&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Restatement
of Previously Issued Financial Statements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;During
the audit of the Company&amp;#x2019;s financial statements for the year ended December 31, 2020, the Company identified an error in the presentation
of the intellectual property expenses in 2019 and 2018. The intellectual property expenses should have been classified as general and
administrative expenses instead of research and development expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;This
resulted in a restatement to correct previously reported amounts in the financial statements of the Company for the years ended December
31, 2019 and 2018. This reclassification of expenses had no impact on total operating expenses, net loss, loss per share or the balance
sheet.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following tables present the impact of the restatement in the financial statements for the years ended December 31, 2019 and 2018:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
    the Year Ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As&amp;#xa0;Previously&lt;br/&gt;
    Reported&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    Restated&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,702,117&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;($&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;804,329&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;897,788&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,494,922&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;804,329&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,299,251&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,197,039&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,197,039&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
    the Year Ended December 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As&amp;#xa0;Previously
    Reported&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    Restated&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,437,202&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;($&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;728,747&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;708,455&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,011,659&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;728,747&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,740,406&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,448,861&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,448,861&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</nlsp:RestatementOfPreviouslyIssuedFinancialStatementsTextBlock>
  <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
    the Year Ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As&amp;#xa0;Previously&lt;br/&gt;
    Reported&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    Restated&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,702,117&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;($&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;804,329&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;897,788&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,494,922&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;804,329&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,299,251&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,197,039&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;4,197,039&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;For
    the Year Ended December 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As&amp;#xa0;Previously
    Reported&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
    Restated&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Research
    and development expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,437,202&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;($&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;728,747&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;708,455&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;General
    and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,011,659&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;728,747&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,740,406&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif&quot;&gt;
    &lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,448,861&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,448,861&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c39_From1Jan2019To31Dec2019_ScenarioPreviouslyReportedMember" decimals="0">1702117</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c40_From1Jan2019To31Dec2019_RestatementAdjustmentMember" decimals="0">804329</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c41_From1Jan2019To31Dec2019_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">897788</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c39_From1Jan2019To31Dec2019_ScenarioPreviouslyReportedMember" decimals="0">2494922</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c40_From1Jan2019To31Dec2019_RestatementAdjustmentMember" decimals="0">804329</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c41_From1Jan2019To31Dec2019_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">3299251</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c39_From1Jan2019To31Dec2019_ScenarioPreviouslyReportedMember" decimals="0">4197039</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c40_From1Jan2019To31Dec2019_RestatementAdjustmentMember" xs:nil="true"/>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c41_From1Jan2019To31Dec2019_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">4197039</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c42_From1Jan2018To31Dec2018_ScenarioPreviouslyReportedMember" decimals="0">1437202</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c43_From1Jan2018To31Dec2018_RestatementAdjustmentMember" decimals="0">728747</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c44_From1Jan2018To31Dec2018_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">708455</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c42_From1Jan2018To31Dec2018_ScenarioPreviouslyReportedMember" decimals="0">2011659</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c43_From1Jan2018To31Dec2018_RestatementAdjustmentMember" decimals="0">728747</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c44_From1Jan2018To31Dec2018_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">2740406</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c42_From1Jan2018To31Dec2018_ScenarioPreviouslyReportedMember" decimals="0">3448861</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c43_From1Jan2018To31Dec2018_RestatementAdjustmentMember" xs:nil="true"/>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c44_From1Jan2018To31Dec2018_RevisionOfPriorPeriodReclassificationAdjustmentMember" decimals="0">3448861</us-gaap:OperatingExpenses>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note 4&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Prepaid
Expenses and Other Current Assets:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company&amp;#x2019;s prepaid expenses and other current assets consisted of the following as of December 31, 2020 and 2019:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Vendor
    overpayments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,380&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;37,445&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;VAT
    recoverable and other current assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;61,207&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;33,579&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loan funding&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;61,956&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prepaid
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;14,413&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;15,067&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;CEO
    receivable&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;13,432&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    prepaid expenses and other current assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;103,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;161,479&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
balance of the prepaid expenses and other current assets for the years ended December 31, 2020 and 2019, consisted mainly of some vendor
overpayments and value added tax (&amp;#x201c;VAT&amp;#x201d;) recoverable, that were returned to the Company during the following fiscal periods.
Additionally, the Company recorded a receivable from the Chief Executive Officer (&amp;#x201c;CEO&amp;#x201d;) for using Company credit cards for
personal travel expenses. Subsequent to the year ended December 31, 2019, the CEO receivable has been paid in full. The prepaid expenses
and other current assets for the year ended December 31, 2019 also included funding of a convertible loan entered into on December 23,
2019, for which funding was received on January 6, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Vendor
    overpayments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;27,380&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;37,445&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;VAT
    recoverable and other current assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;61,207&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;33,579&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loan funding&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;61,956&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prepaid
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;14,413&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;15,067&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;CEO
    receivable&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;13,432&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    prepaid expenses and other current assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;103,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;161,479&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <nlsp:PrepaidVendorOverpayments unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">27380</nlsp:PrepaidVendorOverpayments>
  <nlsp:PrepaidVendorOverpayments unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">37445</nlsp:PrepaidVendorOverpayments>
  <us-gaap:PrepaidTaxes unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">61207</us-gaap:PrepaidTaxes>
  <us-gaap:PrepaidTaxes unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">33579</us-gaap:PrepaidTaxes>
  <us-gaap:PrepaidInsurance unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PrepaidInsurance unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">61956</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">14413</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">15067</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">13432</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">103000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">161479</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
5&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Other
Receivables, net &amp;#x2013; Related Party:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company&amp;#x2019;s majority shareholders are also majority shareholders in Pegasus Advanced Research SAS, formerly NeuroLifeScienses SAS
(&amp;#x201c;Pegasus&amp;#x201d;), and as such Pegasus is considered to be a related party to the Company. In December 2015, Pegasus assigned its
exclusive global license to certain compounds involving mazindol to the Company (the &amp;#x201c;License Agreement&amp;#x201d;). The License Agreement
includes a royalty payment of 1.8% of the annual net sales (including sales made by sub-licensees) of the licensed compounds covered
thereunder; provided, however, that such royalty payment could be further reduced to 0.9% in the event that the U.S. Patent and Trademark
Office were to issue a revised notice of allowance or expand the patent rights of certain licensed compounds or be completely cancelled
in the event that a competing generic product were to reach the market during the term of the patents covering such licensed compounds.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Since
assigning the License Agreement to the Company, the Company and Pegasus have paid for some operating expenses for each other. The transactions
between the companies are minimal and are not considered to be a funding source for either entity. The Company offsets the related receivables
and payable to/from Pegasus for a combined net other long-term receivable of $67,954 and $54,472 for the years ended December 31, 2020
and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <nlsp:AnnualNetSalesPercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.018</nlsp:AnnualNetSalesPercentage>
  <nlsp:RoyaltyPaymentPercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.009</nlsp:RoyaltyPaymentPercentage>
  <us-gaap:OtherLongTermDebt unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">67954</us-gaap:OtherLongTermDebt>
  <us-gaap:OtherLongTermDebt unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">54472</us-gaap:OtherLongTermDebt>
  <nlsp:ConvertiblePromissoryNotesRelatedPartiesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
6&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Convertible
Promissory Notes &amp;#x2013; Related Parties:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following summarizes the Company&amp;#x2019;s convertible promissory notes with related parties as of December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;591,693&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;540,071&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
January 2019, the Company entered into an agreement with Magnetic Rock Investment AG (&amp;#x201c;MRI&amp;#x201d;), which is owned by certain shareholders
of the Company, to loan the Company CHF 550,000 ($557,920). The loan proceeds were received in advance of the agreement, in two payments,
in each of August and December 2018 in the amount of CHF 500,000 ($507,200) and CHF 50,000 ($50,720), respectively. Management determined
that no separate accounting or bifurcation was required for this conversion feature as it doesn&amp;#x2019;t meet the definition of a derivative
because the net settlement criterion is not met. The note accrues interest at 10% per year and has a conversion feature such that upon
a capital closing (as defined), MRI has the right to require conversion of its note to equity at the same terms as such capital closing.
As of December 31, 2020, such capital closing (as defined) has not occurred, so the note has not converted. The note had an original
maturity date of April 30, 2019 at which time if it wasn&amp;#x2019;t already converted, a new maturity date would be set at the discretion
of MRI. The parties have amended the agreement to extend the maturity date to March 31, 2021. The Company has accrued interest payable
of $42,929 for the note as of December 31, 2020. Additionally, the Company recorded debt discount of $4,019 based on an imputed interest
rate of 12%, the rate readily available to the Company, compared to the 10% annual interest rate stated in the loan agreement. The debt
discount is being amortized to interest expense using the effective interest rate method over the debt term. For the years ended December
31, 2019 and 2018, amortization of $237 and $3,782, respectively, was included in interest expense &amp;#x2013; related parties.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
March 2019, MRI and the Company agreed to convert an aggregate amount of CHF 526,980 ($526,769) of its loan into 40,000 of the Company&amp;#x2019;s
common shares at a conversion price of approximately $13 per share. The common shares had a fair value of CHF 14 ($14) per share and
an aggregate fair value of $550,829, resulting in a $24,060 loss on conversion of the loan. Pursuant to an amendment to this loan, the
maturity date of the remaining loan of CHF 23,020 ($26,043) was extended to March 31, 2021. &lt;font&gt;The
Company determined that the extension of the loan which was past due or near maturity was in substance no different than issuing new
financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
January 2019, the Company entered into four additional convertible promissory notes, on the same terms, with certain Company shareholders.
The promissory notes were for CHF 125,000 ($128,200) each, accrue interest at 10% per year and have original maturity dates of the earlier
of April 30, 2019 or when any investment into the Company of CHF 500,000 ($565,650) or greater occurs. The maturity of these notes was
extended to March 31, 2021. The Company has accrued interest payable of $119,045 for the notes as of December 31, 2020. Additionally,
the Company recorded debt discount of $8,540, based on an imputed interest rate of 12% compared to the 10% interest accrued on the loans.
The debt discount is being amortized to interest expense using the effective interest rate method over the debt term. For the year ended
December 31, 2019 amortization of $8,540 was included in interest expense &amp;#x2013; related parties.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, all of the convertible promissory notes, including accrued interest, were repaid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</nlsp:ConvertiblePromissoryNotesRelatedPartiesTextBlock>
  <us-gaap:DebtInstrumentFaceAmount unitRef="chf" contextRef="c45_AsOf31Jan2019_MagneticRockInvestmentsMember" decimals="0">550000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c45_AsOf31Jan2019_MagneticRockInvestmentsMember" decimals="0">557920</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="chf" contextRef="c46_AsOf31Aug2018_MagneticRockInvestmentsMember" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c46_AsOf31Aug2018_MagneticRockInvestmentsMember" decimals="0">507200</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="chf" contextRef="c18_AsOf31Dec2018" decimals="0">50000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c47_AsOf31Dec2018_MagneticRockInvestmentsMember" decimals="0">50720</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="2">0.10</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
  <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c3_From1Jan2019To31Dec2019">The note had an original maturity date of April 30, 2019 at which time if it wasn&amp;#x2019;t already converted, a new maturity date would be set at the discretion of MRI. The parties have amended the agreement to extend the maturity date to March 31, 2021.</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">42929</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <nlsp:DebtDiscount unitRef="usd" contextRef="c48_AsOf31Dec2019_MagneticRockInvestmentsMember" decimals="0">4019</nlsp:DebtDiscount>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="2">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="2">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:InterestExpenseRelatedParty unitRef="usd" contextRef="c49_From1Jan2019To31Dec2019_MagneticRockInvestmentsMember" decimals="0">237</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">3782</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="chf" contextRef="c50_From1Mar2019To31Mar2019_MagneticRockInvestmentsMember" decimals="0">526980</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c50_From1Mar2019To31Mar2019_MagneticRockInvestmentsMember" decimals="0">526769</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c50_From1Mar2019To31Mar2019_MagneticRockInvestmentsMember" decimals="INF">40000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c51_AsOf31Mar2019_MagneticRockInvestmentsMember" decimals="0">13</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:SharePrice unitRef="chfPershares" contextRef="c52_AsOf31Mar2019" decimals="0">14</us-gaap:SharePrice>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">550829</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:DebtConversionOriginalDebtAmount1 unitRef="usd" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">24060</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="chf" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">23020</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">26043</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:InterestExpenseRelatedParty unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">8540</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;591,693&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;540,071&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:SubordinatedBorrowingsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
7&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Credit
Facilities, Subordinated &amp;#x2013; Related Parties:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following summarizes the Company&amp;#x2019;s credit facilities with related parties as of December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Second
    Credit Facility, net of debt discount of $0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
August 2015, the Company entered into a second credit facility agreement (the &amp;#x201c;Second Credit Facility&amp;#x201d;) with certain shareholders
(the &amp;#x201c;Lenders&amp;#x201d;). The maximum borrowings under the Second Credit Facility were $500,000. The Second Credit Facility had a
maturity date of December 31, 2018 and accrued interest at 0%. As the Second Credit Facility did not accrue interest, management, upon
issuance of the debt, recorded total debt discount and a corresponding increase in additional paid in capital based on an imputed interest
at a rate of 12%. The debt discount was being amortized to interest expense using the effective interest rate method over the debt term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
June 2018, the Company and the Lenders entered into a subordination agreement regarding the Second Credit Facility. The subordination
agreement deferred payments on the Second Credit Facility during the term of the agreement. The agreement was to expire if (i) the Lenders
irrevocably waived the subordinated claims; or (ii) if the claims were converted to share capital or participation capital of the Company.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the remaining balance of the Second Credit Facility of $150,000 was outstanding and the parties amended the agreement
covering such credit facility to extend the maturity date to March 31, 2021. Additionally, the accrued interest of $85,737 on an expired
credit facility remained unpaid and the parties amended that credit facility to extend the maturity date to March 31, 2021. &lt;font&gt;The
Company determined that the extension of these credit facilities which were past due or near maturity was in substance no different than
issuing new financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, the remaining balance on the Second Credit Facility and the accrued interest on an expired credit facility was paid in
full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:SubordinatedBorrowingsDisclosureTextBlock>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity unitRef="usd" contextRef="c54_AsOf31Aug2015" decimals="0">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <nlsp:AccruedInterestPercentage unitRef="pure" contextRef="c55_From5Aug2015To31Aug2015" decimals="2">0.00</nlsp:AccruedInterestPercentage>
  <nlsp:ImputedInterestRate unitRef="pure" contextRef="c18_AsOf31Dec2018" decimals="2">0.12</nlsp:ImputedInterestRate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c0_From1Jan2020To31Dec2020">2021-03-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">150000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <us-gaap:DepositLiabilitiesAccruedInterest unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">85737</us-gaap:DepositLiabilitiesAccruedInterest>
  <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Second
    Credit Facility, net of debt discount of $0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
  <nlsp:SecondCreditFacility unitRef="usd" contextRef="c56_AsOf31Dec2020_SecondCreditFacilityMember" decimals="0">150000</nlsp:SecondCreditFacility>
  <nlsp:SecondCreditFacility unitRef="usd" contextRef="c57_AsOf31Dec2019_SecondCreditFacilityMember" decimals="0">150000</nlsp:SecondCreditFacility>
  <nlsp:DebtDiscount unitRef="usd" contextRef="c56_AsOf31Dec2020_SecondCreditFacilityMember" decimals="0">0</nlsp:DebtDiscount>
  <nlsp:DebtDiscount unitRef="usd" contextRef="c57_AsOf31Dec2019_SecondCreditFacilityMember" decimals="0">0</nlsp:DebtDiscount>
  <us-gaap:DebtDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
8&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Convertible
Loans:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following summarizes the Company&amp;#x2019;s convertible loans as of December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans, net of discount of $41,611&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;383,313&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans &amp;#x2013; related party&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;113,130&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;496,443&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less:
    current portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(463,980&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans, long term&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;32,463&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
December 2019, the Company entered into two loans for a total of CHF210,000 ($216,846) (the &amp;#x201c;Convertible Loans&amp;#x201d;). &lt;font&gt;In
February, March and June 2020, the Company entered into five additional convertible loans, on terms similar to those in December 2019,
including one with a related party, for a total of CHF 265,606 ($300,480).&lt;/font&gt; The Convertible Loans accrued interest at 10% and have
a conversion feature such that the lender could choose to convert the loan to equity at any time up to the maturity date of August 31,
2021. The conversion rate of CHF 9 ($11) per common share was at a discount to the CHF 11 ($13) per common share fair value of the Company.
The proceeds from the loans were allocated between the debt instruments and the beneficial conversion feature, with the beneficial conversion
feature valued at CHF 63,537 ($65,608) for the December 2019 convertible loans and CHF 37,779 ($49,011) for the 2020 convertible loans.
On the date of issuance, the beneficial conversion feature value was calculated as the difference between the conversion price and the
fair value per share, multiplied by the number of common shares into which the Convertible Loans are convertible. The embedded conversion
feature was not bifurcated as it did not meet all of the elements of a derivative. For the year ended December 31, 2020, amortization
of $48,088 was included in interest expense and $24,100 was included in interest expense &amp;#x2013; related parties. For the year ended
December 31, 2019, amortization of $820 was included in interest expense. The Company has accrued interest payable of $48,634 and $172
for the Convertible Loans as of December 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, all of the Convertible Loans, including accrued interest, were repaid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="c58_From1Dec2019To31Dec2019">the Company entered into two loans for a total of CHF210,000 ($216,846) (the &amp;#x201c;Convertible Loans&amp;#x201d;). In February, March and June 2020, the Company entered into five additional convertible loans, on terms similar to those in December 2019, including one with a related party, for a total of CHF 265,606 ($300,480). The Convertible Loans accrued interest at 10% and have a conversion feature such that the lender could choose to convert the loan to equity at any time up to the maturity date of August 31, 2021. The conversion rate of CHF 9 ($11) per common share was at a discount to the CHF 11 ($13) per common share fair value of the Company. The proceeds from the loans were allocated between the debt instruments and the beneficial conversion feature, with the beneficial conversion feature valued at CHF 63,537 ($65,608) for the December 2019 convertible loans and CHF 37,779 ($49,011) for the 2020 convertible loans. On the date of issuance, the beneficial conversion feature value was calculated as the difference between the conversion price and the fair value per share, multiplied by the number of common shares into which the Convertible Loans are convertible. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
  <us-gaap:AdjustmentForAmortization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">48088</us-gaap:AdjustmentForAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24100</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AdjustmentForAmortization unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">820</us-gaap:AdjustmentForAmortization>
  <us-gaap:InterestPayableCurrentAndNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">48634</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">172</us-gaap:InterestPayableCurrentAndNoncurrent>
  <nlsp:ScheduleOfConvertibleLoansTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;December
    31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans, net of discount of $41,611&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;383,313&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans &amp;#x2013; related party&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;113,130&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;496,443&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Less:
    current portion&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(463,980&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Convertible
    loans, long term&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;32,463&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;152,058&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nlsp:ScheduleOfConvertibleLoansTableTextBlock>
  <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">-383313</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
  <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">-152058</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
  <nlsp:DebtDiscount unitRef="usd" contextRef="c59_AsOf31Dec2020_ConvertibleDebtMember" decimals="0">41611</nlsp:DebtDiscount>
  <us-gaap:ConvertibleDebt unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">496443</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">152058</us-gaap:ConvertibleDebt>
  <nlsp:SwissGovernmentLoanDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
9&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Swiss
Government Loan:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
April 2020, in response to the COVID 19 pandemic, the Swiss Federal Council issued the COVID-19 Ordinance on Joint and Several Guarantees,
according to which companies domiciled in Switzerland that are economically affected by the COVID-19 pandemic can apply for financial
support in the form of emergency bank loans of up to 10% of their 2019 revenues or a maximum of CHF 20 million (the &amp;#x201c;COVID-19 Loan&amp;#x201d;).
This COVID-19 Loan was secured by the Swiss Confederation. The lending banks received collateral in the form of joint and several guarantees.
The Company received a COVID-19 Loan from its bank for CHF 248,400 ($281,015), which carried a 0% interest rate and was due in 60 months.
The loan could be drawn down over several installments and the Company had drawn down the entire amount. Pursuant to the terms of the
COVID-19 Loan, the Company could not pay any dividends until it repays such loan in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, the COVID-19 Loan was repaid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</nlsp:SwissGovernmentLoanDisclosureTextBlock>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c60_From1Apr2020To30Apr2020" decimals="2">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <srt:BankLoans unitRef="chf" contextRef="c61_AsOf30Apr2020" decimals="-6">20000000</srt:BankLoans>
  <nlsp:LoanFromBank unitRef="chf" contextRef="c61_AsOf30Apr2020" decimals="0">248400</nlsp:LoanFromBank>
  <nlsp:LoanFromBank unitRef="usd" contextRef="c61_AsOf30Apr2020" decimals="0">281015</nlsp:LoanFromBank>
  <us-gaap:SubordinatedBorrowingInterestRate unitRef="pure" contextRef="c60_From1Apr2020To30Apr2020" decimals="2">0.00</us-gaap:SubordinatedBorrowingInterestRate>
  <nlsp:BridgeLoanTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
10&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Bridge
Loan:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
August 2020, the Company received the first tranche of CHF 300,000 ($309,780) pursuant to a bridge loan (the &amp;#x201c;Bridge Loan&amp;#x201d;).
Pursuant to the Bridge Loan, the Company could borrow up to an aggregate of CHF 500,000 ($516,300), or an additional CHF 200,000 ($206,520),
upon successful filing of its Form F-1, which occurred in August 2020. The total Bridge Loan of CHF 500,000 ($527,650) carried an interest
rate of 10% annually and was initially due September 30, 2020 &lt;font&gt;which was amended to December 31,
2020. &lt;/font&gt;In January 2021, the Bridge Loan was amended two additional times. The first of the two amendments extended the maturity
date to March 31, 2021, and the second amendment increased the total amount of the Bridge Loan to CHF 600,000 ($633,180).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, the Bridge Loan, including accrued interest, was repaid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</nlsp:BridgeLoanTextBlock>
  <us-gaap:ProceedsFromFeesReceived unitRef="chf" contextRef="c62_From1Aug2020To31Aug2020_FirstTrancheMember" decimals="0">300000</us-gaap:ProceedsFromFeesReceived>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c63_AsOf31Aug2020_BridgeLoanMember" decimals="0">309780</us-gaap:BridgeLoan>
  <us-gaap:AdditionalCollateralAggregateFairValue unitRef="chf" contextRef="c64_AsOf31Aug2020_FirstTrancheMember" decimals="0">500000</us-gaap:AdditionalCollateralAggregateFairValue>
  <nlsp:AggregateBorrowings unitRef="usd" contextRef="c65_From1Aug2020To31Aug2020_BridgeLoanMember" decimals="0">-516300</nlsp:AggregateBorrowings>
  <nlsp:AdditionalValue unitRef="chf" contextRef="c62_From1Aug2020To31Aug2020_FirstTrancheMember" decimals="0">200000</nlsp:AdditionalValue>
  <nlsp:AdditionalValue unitRef="usd" contextRef="c65_From1Aug2020To31Aug2020_BridgeLoanMember" decimals="0">-206520</nlsp:AdditionalValue>
  <us-gaap:BridgeLoan unitRef="chf" contextRef="c64_AsOf31Aug2020_FirstTrancheMember" decimals="0">500000</us-gaap:BridgeLoan>
  <nlsp:BridgeLoanValue unitRef="usd" contextRef="c65_From1Aug2020To31Aug2020_BridgeLoanMember" decimals="0">-527650</nlsp:BridgeLoanValue>
  <nlsp:InterestRate unitRef="pure" contextRef="c62_From1Aug2020To31Aug2020_FirstTrancheMember" decimals="2">0.10</nlsp:InterestRate>
  <nlsp:AmendmentShare unitRef="chf" contextRef="c62_From1Aug2020To31Aug2020_FirstTrancheMember" decimals="0">600000</nlsp:AmendmentShare>
  <nlsp:AmendmentPriceValue unitRef="usd" contextRef="c65_From1Aug2020To31Aug2020_BridgeLoanMember" decimals="0">-633180</nlsp:AmendmentPriceValue>
  <nlsp:PensionLiabilityTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
11&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Pension
Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company joined a collective pension plan operated by an insurance company as of 2016 which covers the employees in Switzerland.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Both
the Company and the participants provide monthly contributions to the pension plan which are based on the covered salary. The respective
saving parts of premiums are credited to employees&amp;#x2019; accounts. In addition, interest is credited to employees&amp;#x2019; accounts at
the rate provided in the plan. The pension plan provides for retirement benefits as well as benefits on long-term disability and death.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following table provides information on the pension plan for the years ended December 31, 2020, 2019 and 2018:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Service
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;24,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,617&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;832&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,992&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,190&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    return on assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,713&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(4,249&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,294&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of settlement&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(28,754&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5,810&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Administrative
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,946&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,053&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    periodic pension cost (benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,575&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20,085&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;26,566&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
reconciliation of the projected benefit obligation and the changes to the fair value of the plan assets of the pension plan are shown
in the following table:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Projected
    benefit obligation, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;386,064&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;385,448&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Service
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;24,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;832&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,992&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Transfers-in
    and (-out), net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(169,942&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(40,147&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Actuarial
    (gain)/ loss&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,561&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,765&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -3pt; padding-left: 13.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Currency
    conversion adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;28,285&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,800&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Projected
    benefit obligation, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;273,675&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;386,064&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Plan
    assets, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205,816&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;226,428&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Actual
    return on plan assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(620&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,739&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Employer
    contributions&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;15,207&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,867&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Participant
    contributions&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,954&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,608&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Transfers-in
    and (-out), net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(142,931&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(49,755&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Administration
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,946&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Currency
    conversion adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;12,165&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Plan
    assets, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;95,406&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205,816&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Accrued
    pension liability&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;178,269&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;180,248&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020 and 2019, the Company recorded an accrued pension liability of $178,269 and $180,248, respectively, as non-current
liabilities.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
pension assets are measured at fair value and are invested in a collective pension foundation with pooled investments. Plan assets mainly
consist of cash and cash equivalents, equity funds, equity securities, corporate bonds, government bonds, and real estate funds classified
as Level 1 and Level 2 under the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company records net gains/losses, consisting of actuarial gains/losses, curtailment gains/losses and differences between expected and
actual returns on plan assets, in other comprehensive income/loss. Such net gains/losses are amortized to the statements of operations
to the extent that they exceed 10% of the greater of projected benefit obligations or pension assets. The Company further records prior
service costs/credits from plan amendments in other comprehensive income/loss in the period of the respective plan amendment and amortizes
such amounts to the statement of operations over the future service period of the plan participants. For the years ended December 31,
2020 and 2019, the amortization was $0. As of December 31, 2020 and 2019, the accumulated other comprehensive loss includes unrecognized
pension costs of $19,381 and $18,698, respectively, consisting of net losses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
following table shows the components of unrecognized pension cost in accumulated other comprehensive income/loss that have not yet been
recognized as components of net periodic pension cost:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net loss,
    beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;11,254&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Other
    gain/loss during the period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,895&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,634&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of settlement&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5,212&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,810&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization
    of pension related net loss&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    loss, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;19,381&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prior
    service cost, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization
    of prior service cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prior
    service cost end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    unrecognized pension cost, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;19,381&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
weighted average of the key assumptions used to compute the benefit obligations were as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Discount
    rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.15&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.35&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Rate
    of increase in compensation level&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    credit rate on savings accounts&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    long-term rate of return on plan assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Inflation
    rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.60&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.60&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
assumption of the expected long-term rate of return on plan assets was based on the long-term historical rates of returns for the different
investment categories which were adjusted, where appropriate, to reflect financial market developments.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
accumulated benefit obligation as of December 31, 2020 and 2019 amounted to $273,675 and $386,064, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
investment risk is borne by the insurer and the reinsurer respectively, and the investment decision is taken by the board of trustees
of the collective insurance.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</nlsp:PensionLiabilityTextBlock>
  <nlsp:AccruedPensionLiability unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">178269</nlsp:AccruedPensionLiability>
  <nlsp:AccruedPensionLiability unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">180248</nlsp:AccruedPensionLiability>
  <nlsp:ProjectedBenefitObligationsPercentageRate unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="2">0.10</nlsp:ProjectedBenefitObligationsPercentageRate>
  <nlsp:AmortizationCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">0</nlsp:AmortizationCost>
  <nlsp:AmortizationCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">0</nlsp:AmortizationCost>
  <nlsp:UnrecognizedPensionCosts unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">19381</nlsp:UnrecognizedPensionCosts>
  <nlsp:UnrecognizedPensionCosts unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">18698</nlsp:UnrecognizedPensionCosts>
  <nlsp:AccumulatedBenefitObligation unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">273675</nlsp:AccumulatedBenefitObligation>
  <nlsp:AccumulatedBenefitObligation unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">386064</nlsp:AccumulatedBenefitObligation>
  <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Service
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;24,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,617&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;832&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,992&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,190&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    return on assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,713&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(4,249&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,294&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of settlement&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(28,754&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5,810&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Administrative
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,946&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,053&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    periodic pension cost (benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3,575&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;20,085&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;26,566&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
  <us-gaap:DefinedBenefitPlanServiceCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24875</us-gaap:DefinedBenefitPlanServiceCost>
  <us-gaap:DefinedBenefitPlanServiceCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">25206</us-gaap:DefinedBenefitPlanServiceCost>
  <us-gaap:DefinedBenefitPlanServiceCost unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">25617</us-gaap:DefinedBenefitPlanServiceCost>
  <us-gaap:DefinedBenefitPlanInterestCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">832</us-gaap:DefinedBenefitPlanInterestCost>
  <us-gaap:DefinedBenefitPlanInterestCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">2992</us-gaap:DefinedBenefitPlanInterestCost>
  <us-gaap:DefinedBenefitPlanInterestCost unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">2190</us-gaap:DefinedBenefitPlanInterestCost>
  <nlsp:ExpectedReturnOnAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-1713</nlsp:ExpectedReturnOnAssets>
  <nlsp:ExpectedReturnOnAssets unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-4249</nlsp:ExpectedReturnOnAssets>
  <nlsp:ExpectedReturnOnAssets unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">-3294</nlsp:ExpectedReturnOnAssets>
  <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-28754</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
  <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-5810</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
  <us-gaap:DefinedContributionPlanAdministrativeExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1185</us-gaap:DefinedContributionPlanAdministrativeExpenses>
  <us-gaap:DefinedContributionPlanAdministrativeExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">1946</us-gaap:DefinedContributionPlanAdministrativeExpenses>
  <us-gaap:DefinedContributionPlanAdministrativeExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">2053</us-gaap:DefinedContributionPlanAdministrativeExpenses>
  <nlsp:NetPeriodicPensionCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-3575</nlsp:NetPeriodicPensionCost>
  <nlsp:NetPeriodicPensionCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">20085</nlsp:NetPeriodicPensionCost>
  <nlsp:NetPeriodicPensionCost unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">26566</nlsp:NetPeriodicPensionCost>
  <nlsp:ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Projected
    benefit obligation, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;386,064&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;385,448&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Service
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;24,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;25,206&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;832&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,992&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Transfers-in
    and (-out), net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(169,942&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(40,147&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Actuarial
    (gain)/ loss&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3,561&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,765&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -3pt; padding-left: 13.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Currency
    conversion adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;28,285&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,800&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Projected
    benefit obligation, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;273,675&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;386,064&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Plan
    assets, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205,816&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;226,428&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Actual
    return on plan assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(620&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,739&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Employer
    contributions&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;15,207&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;16,867&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Participant
    contributions&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,954&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9,608&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Transfers-in
    and (-out), net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(142,931&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(49,755&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Administration
    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,185&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,946&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 22.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Currency
    conversion adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;12,165&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2,875&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Plan
    assets, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;95,406&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;205,816&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Accrued
    pension liability&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;178,269&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;180,248&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nlsp:ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock>
  <nlsp:ProjectedBenefitObligationBeginningAndEnding unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">386064</nlsp:ProjectedBenefitObligationBeginningAndEnding>
  <nlsp:ProjectedBenefitObligationBeginningAndEnding unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">385448</nlsp:ProjectedBenefitObligationBeginningAndEnding>
  <nlsp:ProjectedBenefitObligationServiceCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24875</nlsp:ProjectedBenefitObligationServiceCost>
  <nlsp:ProjectedBenefitObligationServiceCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">25206</nlsp:ProjectedBenefitObligationServiceCost>
  <nlsp:ProjectedBenefitObligationInterestCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">832</nlsp:ProjectedBenefitObligationInterestCost>
  <nlsp:ProjectedBenefitObligationInterestCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">2992</nlsp:ProjectedBenefitObligationInterestCost>
  <nlsp:ProjectedBenefitObligationTransfersinAndoutNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-169942</nlsp:ProjectedBenefitObligationTransfersinAndoutNet>
  <nlsp:ProjectedBenefitObligationTransfersinAndoutNet unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-40147</nlsp:ProjectedBenefitObligationTransfersinAndoutNet>
  <nlsp:ProjectedBenefitObligationActuarialgainLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">3561</nlsp:ProjectedBenefitObligationActuarialgainLoss>
  <nlsp:ProjectedBenefitObligationActuarialgainLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">6765</nlsp:ProjectedBenefitObligationActuarialgainLoss>
  <nlsp:ProjectedBenefitObligationCurrencyConversionAdjustments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">28285</nlsp:ProjectedBenefitObligationCurrencyConversionAdjustments>
  <nlsp:ProjectedBenefitObligationCurrencyConversionAdjustments unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">5800</nlsp:ProjectedBenefitObligationCurrencyConversionAdjustments>
  <nlsp:ProjectedBenefitObligationBeginningAndEnding unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">273675</nlsp:ProjectedBenefitObligationBeginningAndEnding>
  <nlsp:PlanAssetsBeginningAndEnding unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">205816</nlsp:PlanAssetsBeginningAndEnding>
  <nlsp:PlanAssetsBeginningAndEnding unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">226428</nlsp:PlanAssetsBeginningAndEnding>
  <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-620</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
  <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">1739</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
  <nlsp:PlanAssetsEmployerContributions unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">15207</nlsp:PlanAssetsEmployerContributions>
  <nlsp:PlanAssetsEmployerContributions unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">16867</nlsp:PlanAssetsEmployerContributions>
  <nlsp:PlanAssetsParticipantContributions unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">6954</nlsp:PlanAssetsParticipantContributions>
  <nlsp:PlanAssetsParticipantContributions unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">9608</nlsp:PlanAssetsParticipantContributions>
  <nlsp:PlanAssetsTransfersinAndoutNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-142931</nlsp:PlanAssetsTransfersinAndoutNet>
  <nlsp:PlanAssetsTransfersinAndoutNet unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-49755</nlsp:PlanAssetsTransfersinAndoutNet>
  <nlsp:PlanAssetsAdministrationExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-1185</nlsp:PlanAssetsAdministrationExpenses>
  <nlsp:PlanAssetsAdministrationExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-1946</nlsp:PlanAssetsAdministrationExpenses>
  <nlsp:PlanAssetsCurrencyConversionAdjustments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">12165</nlsp:PlanAssetsCurrencyConversionAdjustments>
  <nlsp:PlanAssetsCurrencyConversionAdjustments unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">2875</nlsp:PlanAssetsCurrencyConversionAdjustments>
  <nlsp:PlanAssetsBeginningAndEnding unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">95406</nlsp:PlanAssetsBeginningAndEnding>
  <nlsp:ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net loss,
    beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;11,254&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Other
    gain/loss during the period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,895&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,634&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of settlement&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5,212&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;5,810&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization
    of pension related net loss&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    loss, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;19,381&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prior
    service cost, beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amortization
    of prior service cost&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Prior
    service cost end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 1pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total
    unrecognized pension cost, end of period&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;19,381&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;18,698&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nlsp:ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock>
  <nlsp:NetLossinBeginningAndEnding unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">18698</nlsp:NetLossinBeginningAndEnding>
  <nlsp:NetLossinBeginningAndEnding unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">11254</nlsp:NetLossinBeginningAndEnding>
  <nlsp:OtherGainlossDuringThePeriod unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">5895</nlsp:OtherGainlossDuringThePeriod>
  <nlsp:OtherGainlossDuringThePeriod unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">1634</nlsp:OtherGainlossDuringThePeriod>
  <nlsp:EffectOfSettlement unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-5212</nlsp:EffectOfSettlement>
  <nlsp:EffectOfSettlement unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">5810</nlsp:EffectOfSettlement>
  <nlsp:AmortizationOfPensionRelatedNetLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nlsp:AmortizationOfPensionRelatedNetLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nlsp:NetLossinBeginningAndEnding unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">19381</nlsp:NetLossinBeginningAndEnding>
  <nlsp:PriorServiceCostBeginning unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <nlsp:PriorServiceCostBeginning unitRef="usd" contextRef="c18_AsOf31Dec2018" xs:nil="true"/>
  <nlsp:AmortizationOfPriorServiceCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nlsp:AmortizationOfPriorServiceCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nlsp:PriorServiceCostBeginning unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <nlsp:TotalUnrecognizedPensionCostEndOfPeriod unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">19381</nlsp:TotalUnrecognizedPensionCostEndOfPeriod>
  <nlsp:TotalUnrecognizedPensionCostEndOfPeriod unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">18698</nlsp:TotalUnrecognizedPensionCostEndOfPeriod>
  <nlsp:ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Discount
    rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.15&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.35&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Rate
    of increase in compensation level&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Interest
    credit rate on savings accounts&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Expected
    long-term rate of return on plan assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Inflation
    rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.60&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.60&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nlsp:ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock>
  <nlsp:WeightedAverageDiscountRate unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0015</nlsp:WeightedAverageDiscountRate>
  <nlsp:WeightedAverageDiscountRate unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="4">0.0035</nlsp:WeightedAverageDiscountRate>
  <nlsp:RateOfIncreaseInCompensationLevel unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0000</nlsp:RateOfIncreaseInCompensationLevel>
  <nlsp:RateOfIncreaseInCompensationLevel unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="4">0.0000</nlsp:RateOfIncreaseInCompensationLevel>
  <nlsp:InterestCreditRateOnSavingsAccountsinDollars unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0100</nlsp:InterestCreditRateOnSavingsAccountsinDollars>
  <nlsp:InterestCreditRateOnSavingsAccountsinDollars unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="4">0.0100</nlsp:InterestCreditRateOnSavingsAccountsinDollars>
  <nlsp:ExpectedLongtermRateOfReturnOnPlanAssets unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0200</nlsp:ExpectedLongtermRateOfReturnOnPlanAssets>
  <nlsp:ExpectedLongtermRateOfReturnOnPlanAssets unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="4">0.0200</nlsp:ExpectedLongtermRateOfReturnOnPlanAssets>
  <nlsp:WeightedAverageInflationRate unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0060</nlsp:WeightedAverageInflationRate>
  <nlsp:WeightedAverageInflationRate unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="4">0.0060</nlsp:WeightedAverageInflationRate>
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
12&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Deferred
Revenues:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2019, the Company entered into the EF License Agreement, to develop and commercialize its product candidate, Nolazol, in Latin
American countries with Eurofarma, a Brazilian pharmaceutical company. The EF License Agreement covers the grant of non-transferable
licenses, without the right to sublicense, to Eurofarma to develop and commercialize Nolazol in Latin America. The EF License Agreement
also specifies the Company&amp;#x2019;s obligation to advance ongoing development activities with respect to Nolazol in the United States.
A joint steering committee will oversee the development and regulatory activities directed towards marketing approval, manufacturing
and commercialization phases. The Company believes its participation in the joint steering committee is not of material significance
to the licenses in the context of the EF License Agreement on the whole and, as such, management has excluded these activities in the
determination of its performance obligation(s) under the EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
EF License Agreement provides that the parties shall enter into a separate manufacturing and supply agreement during the term of the
EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Under
the EF License Agreement, the Company received a non-refundable, upfront payment, of $2,500,000 and is further eligible to receive non-refundable
milestone payments of up to $16,000,000, based on the achievement of milestones related to regulatory filings, regulatory approvals and
the commercialization of Nolazol. The achievement and timing of the milestones depend on the success of development, approval and sales
progress, if any, of Nolazol in the future. In addition, the Company is also eligible for tiered royalty payments.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company identified the licenses granted to Eurofarma and its obligation to advance development activities with respect to Nolazol in
the United States as the material promises under the EF License Agreement. For purposes of identifying the Company&amp;#x2019;s performance
obligations under the EF License Agreement, management believes that while the exclusive licenses were granted to Eurofarma at the outset
of the EF License Agreement, the grant of those licenses does not singularly result in the transfer of the Company&amp;#x2019;s broader obligation
to Eurofarma under the EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company is obligated under the EF License Agreement to advance its development activities in the United States and those activities precede
Eurofarma&amp;#x2019;s necessary regulatory approvals for commercialization of Nolazol, in Latin American countries. The Company intends to
apply its proprietary know-how to the ongoing development activities in the United States involving its intellectual property relating
to Nolazol. These development activities are specific to the Company and the Company believes they are not capable of being distinct
in the context of the EF License Agreement on the whole.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
licenses provided to Eurofarma are not transferable and without the right to sublicense therefore Eurofarma is not presently able to
monetize its investment in Nolazol as clinical development in the United States or any Latin American countries has yet to be completed
and Eurofarma has yet to seek or obtain regulatory approval in any Latin American country. The licenses to Eurofarma represent rights
to use the Company&amp;#x2019;s intellectual property with respect to Nolazol for which revenue is recognized at a point in time which is
when Eurofarma is able to use and benefit from the licenses. The licenses are considered of limited value without the Company&amp;#x2019;s
development activities with respect to Nolazol in the United States. As such, the licenses are not capable of being distinct until after
successful clinical development and regulatory approval and alone do not have standalone functionality to Eurofarma. Management has determined
that the licenses, while capable of being distinct, are not distinct as they do not have stand-alone value to Eurofarma without the Company&amp;#x2019;s
planned development activities in the United States and the approval for sale in Latin America.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Bundled
together with the Company&amp;#x2019;s development activities of Nolazol in the United States, the licenses granted under the EF License Agreement
will enable Eurofarma to seek regulatory approvals and ultimately seek to commercialize Nolazol in Latin America. Therefore, management
believes the licenses bundled together with the Company&amp;#x2019;s development activities in the United States constitute a single distinct
performance obligation under the EF License Agreement for accounting purposes (the &amp;#x201c;License Performance Obligation&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has initially estimated a total transaction price of $2,500,000, consisting of the fixed upfront payment determined to be an
advance on the License Performance Obligation. Upon execution of the EF License Agreement and as of December 31, 2020 and 2019, variable
consideration consisting of milestone payments has been constrained and excluded from the transaction price given the significant uncertainty
of achievement of the development and regulatory milestones.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has allocated the transaction price entirely to the single License Performance Obligation and recorded the $2,500,000 as deferred
revenue that is expected to be recognized upon Brazilian or other Latin American market approval or, in the event marketing approval
in the United States and/or Latin America is not achieved, whether by failure in clinical development or otherwise, when the Company&amp;#x2019;s
performance obligations are contractually complete or the EF License Agreement is terminated.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Amounts
expected to be recognized as revenues within the 12 months following the balance sheet date are classified as a current portion of deferred
revenues in the accompanying condensed balance sheets. Amounts not expected to be recognized as revenues within the 12 months following
the balance sheet date are classified as deferred revenues, net of current portion. As of December 31, 2020 and 2019, the Company has
long-term deferred revenues of $2,500,000, which will be recognized when the development services of Nolazol are completed and the product
candidate receives applicable regulatory approval in Latin America that allows Eurofarma to commence commercialization of Nolazol in
accordance with the EF License Agreement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <nlsp:NonrefundableUpfrontPayment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2500000</nlsp:NonrefundableUpfrontPayment>
  <nlsp:ReceiveNonrefundableMilestonePayments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">16000000</nlsp:ReceiveNonrefundableMilestonePayments>
  <nlsp:EstimatedTotalTransactionPrice unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2500000</nlsp:EstimatedTotalTransactionPrice>
  <us-gaap:DeferredRevenueRevenueRecognized1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2500000</us-gaap:DeferredRevenueRevenueRecognized1>
  <nlsp:LongTermDeferredRevenue unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">2500000</nlsp:LongTermDeferredRevenue>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
13&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Commitments
and Contingencies: &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Commitments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
December 2019, the Company entered into a feasibility development agreement (the &amp;#x201c;Development Agreement&amp;#x201d;) with Adare Pharmaceuticals,
Inc. (&amp;#x201c;Adare&amp;#x201d;), pursuant to which the Company intends to utilize Adare&amp;#x2019;s proprietary modified release technologies
in the development of mazindol for use in the Company&amp;#x2019;s product candidates used for the treatment of narcolepsy and ADHD. The formulation
to be developed by Adare under this Development Agreement is intended to be owned solely by the Company. Upon completion of certain milestones,
as defined in the Development Agreement, the Company is obligated to pay Adare up to $840,000. &lt;font&gt;In
January 2021, the Company and Adare agreed to terminate the Development Agreement, effective as of December 19, 2020. The project was
never started and the Company has no liability to Adare.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company may become involved in miscellaneous litigation and legal actions, including product liability, consumer, commercial, tax and
governmental matters, which can arise from time to time in the ordinary course of the Company&amp;#x2019;s business. Litigation and legal
actions are inherently unpredictable, and excessive verdicts can result in such situations. The Company is not currently involved in
any such matters.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;&lt;b&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;In
December 2019, a novel strain of coronavirus (&amp;#x201c;COVID-19&amp;#x201d;) emerged in Wuhan, China. Since then, it has spread to several other
countries and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak
of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in the United States, Canada and internationally,
including in Switzerland, have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions,
border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19
outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals,
including unprecedented business, employment and economic disruptions. The continued spread of COVID-19 in the United States, Canada
and globally, including in Switzerland, could have an adverse impact on our business, operations and financial results, including through
disruptions in our cultivation and processing activities, supply chains, as well as a deterioration of general economic conditions including
a possible national or global recession. Shelter-in-place orders and social distancing practices designed to limit the spread of COVID-19
may affect our ability to conduct clinical studies. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;The
Company has not been adversely affected from the effects of the COVID-19 outbreak, neither from any delay in its clinical development
activities nor by its ability to source necessary financing to fund its operations. In view of the continuing uncertainty about the further
development of COVID-19, an adverse development can be expected in 2021, but its financial impact on the Company cannot yet to be adequately
and conclusively assessed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:OtherCommitment unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">840000</us-gaap:OtherCommitment>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
14&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Shareholders&amp;#x2019;
Deficit:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020, the Company had 6,960,000 registered and issued common shares.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
March 2019, the Company issued a total of 580,000 of its common shares to creditors in exchange for payment of $5,131,481 of the credit
facilities, $2,000,000 of the interest-free $2 million bridge loan and $529,769 of convertible promissory notes. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
July 2018, the Company issued 260,000 of its common shares to the creditors in exchange for payment of $3,418,519 due under the $7.1
million credit facility.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <nlsp:CommonSharesRegisteredAndIssued unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">6960000</nlsp:CommonSharesRegisteredAndIssued>
  <nlsp:CommonSharesToCreditors unitRef="shares" contextRef="c53_From1Mar2019To31Mar2019" decimals="INF">580000</nlsp:CommonSharesToCreditors>
  <nlsp:PaymentOfInitialCreditFacility unitRef="usd" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">5131481</nlsp:PaymentOfInitialCreditFacility>
  <us-gaap:LongtermConstructionLoanCurrentAndNoncurrent unitRef="usd" contextRef="c52_AsOf31Mar2019" decimals="0">2000000</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c52_AsOf31Mar2019" decimals="-6">2000000</us-gaap:BridgeLoan>
  <nlsp:ConvertiblePromissoryNote unitRef="usd" contextRef="c53_From1Mar2019To31Mar2019" decimals="0">529769</nlsp:ConvertiblePromissoryNote>
  <nlsp:CommonSharesToCreditors unitRef="shares" contextRef="c66_From1Jul2018To31Jul2018" decimals="INF">260000</nlsp:CommonSharesToCreditors>
  <nlsp:PaymentOfInitialCreditFacility unitRef="usd" contextRef="c66_From1Jul2018To31Jul2018" decimals="0">3418519</nlsp:PaymentOfInitialCreditFacility>
  <us-gaap:LongtermConstructionLoanCurrentAndNoncurrent unitRef="usd" contextRef="c67_AsOf31Jul2018" decimals="-5">7100000</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
15&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company has Swiss tax loss carryforwards of $15.5 million as of December 31, 2020 (December 31, 2019: $11.5 million) of which $9.7 million
will expire within the next five years, and $5.8 million will expire between 2025 - 2026.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
significant components of net deferred taxes as of December 31, 2020 and 2019 are shown in the following table:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    benefit from tax loss carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,393,809&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,031,524&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred
    revenues&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;224,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;224,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Other,
    net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,951&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(15,065&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Valuation
    allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,625,757&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,241,456&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    deferred taxes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company recorded a valuation allowance in 2020 and 2019 to reduce the net deferred taxes, as the Company deemed it to be more likely
than not that the future deferred tax assets would not be realized in the future based on the lack of sufficient positive evidence in
the jurisdictions related to the realization of the deferred tax assets.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
effective tax rate was 0% for the years ended December 31, 2020, 2019 and 2018. The following table shows the income taxes in 2020, 2019
and 2018:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Current tax&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;
                                            -&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred
    income tax (benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Change
    in valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total income tax expense&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company files income tax returns in Switzerland. The Company&amp;#x2019;s income tax position in Switzerland is finally assessed up to the
year ended December 31, 2018, so the years ended December 31, 2019 and 2020 are open for examination. Currently the Company does not
have any open tax assessments. The following table shows the reconciliation between expected and effective tax rate:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Statutory
    tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of permanent differences&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(2.3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3.7&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Change
    in valuation allowance on deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(12.9&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(6.7&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5.3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effective
    tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company had generated approximately $9,700,000 of net operating losses (&amp;#x201c;NOLs&amp;#x201d;) prior to the Merger, in which the Company&amp;#x2019;s
preliminary analysis indicates that such NOLs would not be subject to significant limitations pursuant to applicable income tax regulations.
The permanent differences relate to the conversion to U.S. GAAP from Swiss accounting, mainly in the areas of debt, intangible amortization
and deferring financing costs&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As
of December 31, 2020 and 2019, there were no unrecognized tax benefits. &lt;font&gt;If such matters were to
arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. &lt;/font&gt;The Company did
not incur any material interest or penalties in connection with income taxes during the years ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <nlsp:DescriptionOfIncomeTaxDescription contextRef="c0_From1Jan2020To31Dec2020">The Company has Swiss tax loss carryforwards of $15.5 million as of December 31, 2020 (December 31, 2019: $11.5 million) of which $9.7 million will expire within the next five years, and $5.8 million will expire between 2025 - 2026.</nlsp:DescriptionOfIncomeTaxDescription>
  <nlsp:NetCapitalLossCarryforward unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-5">15500000</nlsp:NetCapitalLossCarryforward>
  <nlsp:NetCapitalLossCarryforward unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-5">11500000</nlsp:NetCapitalLossCarryforward>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <nlsp:NetOperatingLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">9700000</nlsp:NetOperatingLoss>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    benefit from tax loss carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,393,809&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;1,031,524&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred
    revenues&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;224,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;224,997&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Other,
    net&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;6,951&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(15,065&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Valuation
    allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,625,757&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(1,241,456&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Net
    deferred taxes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">1393809</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">1031524</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">224997</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">224997</us-gaap:DeferredRevenueCurrent>
  <nlsp:OtherDeferredTaxNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">6951</nlsp:OtherDeferredTaxNet>
  <nlsp:OtherDeferredTaxNet unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">-15065</nlsp:OtherDeferredTaxNet>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">1625757</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">1241456</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Current tax&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;
                                            -&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Deferred
    income tax (benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Change
    in valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;384,301&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;325,572&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;289,462&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Total income tax expense&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">384301</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">325572</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">289462</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="0">384301</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="0">325572</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c18_AsOf31Dec2018" decimals="0">289462</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">384301</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">325572</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">289462</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Statutory
    tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effect
    of permanent differences&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(2.3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(3.7&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Change
    in valuation allowance on deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(12.9&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(6.7&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;(5.3&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Effective
    tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.090</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="3">0.090</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="3">0.090</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="3">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="3">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">-0.129</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="3">-0.067</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="3">-0.053</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c4_From1Jan2018To31Dec2018" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
16&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Related
party consulting agreements:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company entered into consulting agreements with several of its senior management.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
January 2017, and as subsequently amended in October 2020, the Company entered into a consulting agreement with CHG BioVenture SA, an
entity controlled by Mr. Herv&amp;#xe9; Girsault, the Company&amp;#x2019;s current Head of Business Development. Pursuant to the consulting
agreement, the Company agreed to pay CHG BioVenture SA a monthly fee of CHF 17,500, as well as an opportunity to a bonus of up to 15%
of the annual fee, subject to the Company&amp;#x2019;s discretion. In addition, the Company has agreed to pay CHG BioVenture SA a 1% fee tied
to the net proceeds actually received by the Company in certain transactions, such as, but not limited to, an M&amp;amp;A transaction. The
consulting agreement may be terminated by either party for any reason at the end of each calendar quarter with three months&amp;#x2019; prior
written notice, or immediately if Mr. Girsault breaches the confidentiality provision. The consulting agreement also provides for a 24-month
non-competition clause. The consulting agreement also provides for standard confidentiality provisions as well as reimbursement for certain
expenses. For the year ended December 31, 2020, 2019 and 2018, the Company recorded fees to CHG BioVenture SA of $285,859, $285,538 and
$286,206, respectively, included in general and administrative expenses on the statement of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;The
Company provided BioVenture SA and Mr. Girsault notice of the Company&amp;#x2019;s termination of the consulting agreement with CHG BioVenture
SA, pursuant to which Mr. Girsault provides his services to the Company, which will take effect on June 30, 2021. The Company is actively
in discussions with Mr. Girsault on continuing his engagement with the Company in his current role.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
March 2021, the Company entered into a consulting agreement with Mr. Subhasis Roy, the Company&amp;#x2019;s current Interim Chief Financial
Officer, pursuant to which the Company agreed to pay Mr. Roy a daily rate of CHF 2,000 for his services. The consulting agreement may
be terminated by either party upon 30 days&amp;#x2019; written notice or immediately by the Company in the event of a material breach by Mr.
Roy that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, the Company entered into a consulting agreement with Mr. Eric Konofal, the Company&amp;#x2019;s current Interim Chief Scientific
Officer, pursuant to which the Company agreed to pay Mr. Konofal a daily rate of CHF 2,000 for his services. The consulting agreement
may be terminated by either party upon 30 days&amp;#x2019; written notice or immediately by the Company in the event of a material breach
by Mr. Konofal that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month
non-solicitation clause as well as reimbursement for certain expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
March 2021, the Company entered into a consulting agreement with Mr. Carlos Camozzi, the Company&amp;#x2019;s current Interim Medical Director,
pursuant to which the Company agreed to pay Mr. Camozzi an hourly rate of CHF 230 plus 7.7% VAT for his services. The consulting agreement
may be terminated by either party upon 30 days&amp;#x2019; written notice or immediately by us in the event of a material breach by Mr. Camozzi
that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause as well as reimbursement for certain expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent unitRef="chf" contextRef="c68_AsOf31Oct2020_CHGBioVentureSAMember" decimals="0">17500</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
  <nlsp:BonusAnnualFee unitRef="pure" contextRef="c69_AsOf31Oct2020" decimals="2">0.15</nlsp:BonusAnnualFee>
  <nlsp:OtherTransactionPercentage unitRef="pure" contextRef="c68_AsOf31Oct2020_CHGBioVentureSAMember" decimals="2">0.01</nlsp:OtherTransactionPercentage>
  <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">285859</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">285538</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="0">286206</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
  <us-gaap:SellingExpense unitRef="chf" contextRef="c70_From1Mar2021To31Mar2021_MrRoyMember_SubsequentEventMember" decimals="0">2000</us-gaap:SellingExpense>
  <us-gaap:SellingExpense unitRef="chf" contextRef="c71_From1Feb2021To28Feb2021_MrKonofalMember_SubsequentEventMember" decimals="0">2000</us-gaap:SellingExpense>
  <us-gaap:SellingExpense unitRef="chf" contextRef="c72_From1Mar2021To31Mar2021_MrCamozziMember_SubsequentEventMember" decimals="0">230</us-gaap:SellingExpense>
  <nlsp:VATServicesPercentage unitRef="pure" contextRef="c73_AsOf31Mar2021_MrKonofalMember_SubsequentEventMember" decimals="3">0.077</nlsp:VATServicesPercentage>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;i&gt;Note
17&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&lt;b&gt;Subsequent
Events&lt;/b&gt;:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;In
January 2021, the loans listed below were further amended such that the maturity date of each instrument were scheduled to be March 31,
2021:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$85,737 under an old expired
    credit facility;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$150,000 under the Second
    Credit Facility;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CHF 500,000 (approximately
    $565,650) under the four convertible promissory notes from January 2019, each of which carried an interest rate of 10% per year;
    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CHF 23,020 (approximately
    $26,043) under the Convertible Note with MRI, which carried an interest rate of 10% per year; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CHF 100,000 (approximately
    $113,130) under the Convertible loan with a related party, which carried an interest rate of 10% per year, and &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: left; vertical-align: top&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;CHF 600,000 (approximately
    $678,780) under the Bridge Loan, which carried an interest rate of 10% per year.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; &quot;&gt;On
February 2, 2021, the Company &lt;/font&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;completed the closing of its Initial Public
Offering of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one Warrant. The common shares
and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the
Nasdaq Capital Market on January 29, 2021 under the symbols &amp;#x201c;NLSP&amp;#x201d; and &amp;#x201c;NLSPW,&amp;#x201d; respectively. The Company received
net proceeds of $17 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants
are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share. In addition,
the Company granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase
722,891 common shares, of which the underwriters exercised the option to purchase warrants to purchase up to 722,891 shares of common
shares. These Warrants were issued in the Company&amp;#x2019;s Initial Public Offering and therefore have the same exercise price of $4.15
per share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
February 2021, the Company repaid all of its various loans and notes, including accrued interest, in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
addition, on March 10, 2021, the Company entered into a License Agreement with Novartis Pharma AG (&amp;#x201c;Novartis&amp;#x201d;), whereby the
Company obtained, on an exclusive basis in the U.S., all &lt;font&gt;of the available data referred to and
included in the original NDA for Sanorex&amp;#xae; (mazindol) submitted to the FDA in February 1972. The agreement encompasses all preclinical
and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation
data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety
reports from 1973 onwards. Under the Agreement, the Company has obtained the same rights on a non-exclusive basis in all territories
outside of the U.S. except for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed
territories. The Agreement includes the right to sublicense or assign the license to third parties, subject to such third parties meeting
certain obligations. As consideration for the license, the Company agreed to pay Novartis $250,000 upon the signing of the agreement
with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to
be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of
&lt;/font&gt;Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time
payment upon the Company&amp;#x2019;s product candidate reaching $250 million in cumulative sales.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:DebtInstrumentDescription contextRef="c74_From1Jan2021To31Jan2021_SubsequentEventMember">In January 2021, the loans listed below were further amended such that the maturity date of each instrument were scheduled to be March 31, 2021: &amp;#x25cf; $85,737 under an old expired credit facility; &amp;#x25cf; $150,000 under the Second Credit Facility; &amp;#x25cf; CHF 500,000 (approximately $565,650) under the four convertible promissory notes from January 2019, each of which carried an interest rate of 10% per year; &amp;#x25cf; CHF 23,020 (approximately $26,043) under the Convertible Note with MRI, which carried an interest rate of 10% per year; &amp;#x25cf; CHF 100,000 (approximately $113,130) under the Convertible loan with a related party, which carried an interest rate of 10% per year, and &amp;#x25cf; CHF 600,000 (approximately $678,780) under the Bridge Loan, which carried an interest rate of 10% per year.</us-gaap:DebtInstrumentDescription>
  <nlsp:ClosingValue unitRef="shares" contextRef="c75_From30Jan2021To2Feb2021_SubsequentEventMember_IPOMember" decimals="INF">4819277</nlsp:ClosingValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="2">4.15</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <nlsp:WarrantExpireTerm contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember">P5Y</nlsp:WarrantExpireTerm>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c36_AsOf2Feb2021_SubsequentEventMember" decimals="INF">722891</us-gaap:CommonStockSharesIssued>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">722891</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <nlsp:PurchaseWarrants unitRef="shares" contextRef="c35_From30Jan2021To2Feb2021_SubsequentEventMember" decimals="INF">722891</nlsp:PurchaseWarrants>
  <nlsp:NetSalesOfMilestonePayments unitRef="usd" contextRef="c76_From1Mar2021To10Mar2021_SubsequentEventMember" decimals="-4">4150000</nlsp:NetSalesOfMilestonePayments>
  <us-gaap:SubsequentEventDescription contextRef="c76_From1Mar2021To10Mar2021_SubsequentEventMember">As consideration for the license, the Company agreed to pay Novartis $250,000 upon the signing of the agreement with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company&amp;#x2019;s product candidate reaching $250 million in cumulative sales.</us-gaap:SubsequentEventDescription>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>nlsp-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.nlspharma.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nlsp="http://www.nlspharma.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nlsp-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nlsp-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nlsp-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nlsp-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet" id="nlsp_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nlsp_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConsolidatedIncomeStatement" id="nlsp_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ShareholdersEquityType2or3" id="nlsp_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Statements Of Changes In Shareholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConsolidatedCashFlow" id="nlsp_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/Background" id="nlsp_r_Background">
        <link:definition>006 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies" id="nlsp_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements" id="nlsp_r_RestatementofPreviouslyIssuedFinancialStatements">
        <link:definition>008 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets" id="nlsp_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>009 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty" id="nlsp_r_OtherReceivablesnetRelatedParty">
        <link:definition>010 - Disclosure - Other Receivables, net &#8211; Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties" id="nlsp_r_ConvertiblePromissoryNotesRelatedParties">
        <link:definition>011 - Disclosure - Convertible Promissory Notes &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties" id="nlsp_r_CreditFacilitiesSubordinatedRelatedParties">
        <link:definition>012 - Disclosure - Credit Facilities, Subordinated &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertibleLoans" id="nlsp_r_ConvertibleLoans">
        <link:definition>013 - Disclosure - Convertible Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SwissGovernmentLoan" id="nlsp_r_SwissGovernmentLoan">
        <link:definition>014 - Disclosure - Swiss Government Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/BridgeLoan" id="nlsp_r_BridgeLoan">
        <link:definition>015 - Disclosure - Bridge Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/PensionLiability" id="nlsp_r_PensionLiability">
        <link:definition>016 - Disclosure - Pension Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/DeferredRevenues" id="nlsp_r_DeferredRevenues">
        <link:definition>017 - Disclosure - Deferred Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/CommitmentsandContingencies" id="nlsp_r_CommitmentsandContingencies">
        <link:definition>018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ShareholdersDeficit" id="nlsp_r_ShareholdersDeficit">
        <link:definition>019 - Disclosure - Shareholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/IncomeTaxes" id="nlsp_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/Relatedpartyconsultingagreements" id="nlsp_r_Relatedpartyconsultingagreements">
        <link:definition>021 - Disclosure - Related party consulting agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SubsequentEvents" id="nlsp_r_SubsequentEvents">
        <link:definition>022 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/AccountingPoliciesByPolicy" id="nlsp_r_AccountingPoliciesByPolicy">
        <link:definition>023 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables" id="nlsp_r_RestatementofPreviouslyIssuedFinancialStatementsTables">
        <link:definition>024 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="nlsp_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables" id="nlsp_r_ConvertiblePromissoryNotesRelatedPartiesTables">
        <link:definition>026 - Disclosure - Convertible Promissory Notes &#8211; Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables" id="nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesTables">
        <link:definition>027 - Disclosure - Credit Facilities, Subordinated &#8211; Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertibleLoansTables" id="nlsp_r_ConvertibleLoansTables">
        <link:definition>028 - Disclosure - Convertible Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/PensionLiabilityTables" id="nlsp_r_PensionLiabilityTables">
        <link:definition>029 - Disclosure - Pension Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/IncomeTaxesTables" id="nlsp_r_IncomeTaxesTables">
        <link:definition>030 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/BackgroundDetails" id="nlsp_r_BackgroundDetails">
        <link:definition>031 - Disclosure - Background (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails" id="nlsp_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>032 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable" id="nlsp_r_ScheduleofrestatementinthefinancialstatementsTable">
        <link:definition>033 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of restatement in the financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="nlsp_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>034 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails" id="nlsp_r_OtherReceivablesnetRelatedPartyDetails">
        <link:definition>035 - Disclosure - Other Receivables, net &#8211; Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails" id="nlsp_r_ConvertiblePromissoryNotesRelatedPartiesDetails">
        <link:definition>036 - Disclosure - Convertible Promissory Notes &#8211; Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable" id="nlsp_r_ScheduleofconvertiblepromissorynotesTable">
        <link:definition>037 - Disclosure - Convertible Promissory Notes &#8211; Related Parties (Details) - Schedule of convertible promissory notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails" id="nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesDetails">
        <link:definition>038 - Disclosure - Credit Facilities, Subordinated &#8211; Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable" id="nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable">
        <link:definition>039 - Disclosure - Credit Facilities, Subordinated &#8211; Related Parties (Details) - Schedule of credit facilities with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals" id="nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals">
        <link:definition>040 - Disclosure - Credit Facilities, Subordinated &#8211; Related Parties (Details) - Schedule of credit facilities with related parties (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ConvertibleLoansDetails" id="nlsp_r_ConvertibleLoansDetails">
        <link:definition>041 - Disclosure - Convertible Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0AjDB/GVInRFsMP24O4Wl/l] CSR-->
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable" id="nlsp_r_ScheduleofconvertibleloansTable">
        <link:definition>042 - Disclosure - Convertible Loans (Details) - Schedule of convertible loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals" id="nlsp_r_ScheduleofconvertibleloansTable_Parentheticals">
        <link:definition>043 - Disclosure - Convertible Loans (Details) - Schedule of convertible loans (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SwissGovernmentLoanDetails" id="nlsp_r_SwissGovernmentLoanDetails">
        <link:definition>044 - Disclosure - Swiss Government Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/BridgeLoanDetails" id="nlsp_r_BridgeLoanDetails">
        <link:definition>045 - Disclosure - Bridge Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/PensionLiabilityDetails" id="nlsp_r_PensionLiabilityDetails">
        <link:definition>046 - Disclosure - Pension Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofpensionplanTable" id="nlsp_r_ScheduleofpensionplanTable">
        <link:definition>047 - Disclosure - Pension Liability (Details) - Schedule of pension plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable" id="nlsp_r_ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable">
        <link:definition>048 - Disclosure - Pension Liability (Details) - Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable" id="nlsp_r_ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable">
        <link:definition>049 - Disclosure - Pension Liability (Details) - Schedule of unrecognized pension cost in accumulated other comprehensive income/loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable" id="nlsp_r_ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable">
        <link:definition>050 - Disclosure - Pension Liability (Details) - Schedule of weighted average of the key assumptions used to compute the benefit obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/DeferredRevenuesDetails" id="nlsp_r_DeferredRevenuesDetails">
        <link:definition>051 - Disclosure - Deferred Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/CommitmentsandContingenciesDetails" id="nlsp_r_CommitmentsandContingenciesDetails">
        <link:definition>052 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ShareholdersDeficitDetails" id="nlsp_r_ShareholdersDeficitDetails">
        <link:definition>053 - Disclosure - Shareholders&#8217; Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/IncomeTaxesDetails" id="nlsp_r_IncomeTaxesDetails">
        <link:definition>054 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable" id="nlsp_r_ScheduleofnetdeferredtaxassetsTable">
        <link:definition>055 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable" id="nlsp_r_ScheduleofincometaxprovisionTable">
        <link:definition>056 - Disclosure - Income Taxes (Details) - Schedule of income tax provision</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable" id="nlsp_r_ScheduleofeffectivereconciliationofthefederalincometaxrateTable">
        <link:definition>057 - Disclosure - Income Taxes (Details) - Schedule of effective reconciliation of the federal income tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails" id="nlsp_r_RelatedpartyconsultingagreementsDetails">
        <link:definition>058 - Disclosure - Related party consulting agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/SubsequentEventsDetails" id="nlsp_r_SubsequentEventsDetails">
        <link:definition>059 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nlspharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="BackgroundAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BackgroundAbstract"/>
  <xs:element name="RestatementOfPreviouslyIssuedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfRestatementInTheFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ConvertiblePromissoryNotesRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfConvertiblePromissoryNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract"/>
  <xs:element name="ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfConvertibleLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfConvertibleLoansAbstract"/>
  <xs:element name="SwissGovernmentLoanDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_SwissGovernmentLoanDisclosureAbstract"/>
  <xs:element name="BridgeLoanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BridgeLoanAbstract"/>
  <xs:element name="PensionLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PensionLiabilityAbstract"/>
  <xs:element name="ScheduleOfPensionPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfPensionPlanAbstract"/>
  <xs:element name="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract"/>
  <xs:element name="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfIncomeTaxProvisionAbstract"/>
  <xs:element name="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract"/>
  <xs:element name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_OtherComprehensiveLossAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DeferredTaxAssetsAbstract"/>
  <xs:element name="AccountsPayableIncludingRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AccountsPayableIncludingRelatedParty"/>
  <xs:element name="DefinedPensionPlanAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DefinedPensionPlanAdjustments"/>
  <xs:element name="BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan"/>
  <xs:element name="PeriodicPensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PeriodicPensionCosts"/>
  <xs:element name="ProceedsFromSwissGovernmentLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProceedsFromSwissGovernmentLoan"/>
  <xs:element name="ProceedsFromBridgeLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProceedsFromBridgeLoan"/>
  <xs:element name="IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities"/>
  <xs:element name="DebtDiscountOnRelatedPartyLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DebtDiscountOnRelatedPartyLoans"/>
  <xs:element name="DebtDiscountOnConvertibleLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DebtDiscountOnConvertibleLoans"/>
  <xs:element name="BackgroundTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BackgroundTextBlock"/>
  <xs:element name="RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock"/>
  <xs:element name="ConvertiblePromissoryNotesRelatedPartiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock"/>
  <xs:element name="SwissGovernmentLoanDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_SwissGovernmentLoanDisclosureTextBlock"/>
  <xs:element name="BridgeLoanTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BridgeLoanTextBlock"/>
  <xs:element name="PensionLiabilityTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PensionLiabilityTextBlock"/>
  <xs:element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfConvertibleLoansTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfConvertibleLoansTableTextBlock"/>
  <xs:element name="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock"/>
  <xs:element name="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock"/>
  <xs:element name="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock"/>
  <xs:element name="PrepaidVendorOverpayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PrepaidVendorOverpayments"/>
  <xs:element name="SecondCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_SecondCreditFacility"/>
  <xs:element name="DebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DebtDiscount"/>
  <xs:element name="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable"/>
  <xs:element name="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems"/>
  <xs:element name="ExpectedReturnOnAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ExpectedReturnOnAssets"/>
  <xs:element name="NetPeriodicPensionCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NetPeriodicPensionCost"/>
  <xs:element name="ProjectedBenefitObligationBeginningAndEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationBeginningAndEnding"/>
  <xs:element name="ProjectedBenefitObligationServiceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationServiceCost"/>
  <xs:element name="ProjectedBenefitObligationInterestCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationInterestCost"/>
  <xs:element name="ProjectedBenefitObligationTransfersinAndoutNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationTransfersinAndoutNet"/>
  <xs:element name="ProjectedBenefitObligationActuarialgainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationActuarialgainLoss"/>
  <xs:element name="ProjectedBenefitObligationCurrencyConversionAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments"/>
  <xs:element name="PlanAssetsBeginningAndEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsBeginningAndEnding"/>
  <xs:element name="PlanAssetsEmployerContributions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsEmployerContributions"/>
  <xs:element name="PlanAssetsParticipantContributions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsParticipantContributions"/>
  <xs:element name="PlanAssetsTransfersinAndoutNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsTransfersinAndoutNet"/>
  <xs:element name="PlanAssetsAdministrationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsAdministrationExpenses"/>
  <xs:element name="PlanAssetsCurrencyConversionAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PlanAssetsCurrencyConversionAdjustments"/>
  <xs:element name="AccruedPensionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AccruedPensionLiability"/>
  <xs:element name="NetLossinBeginningAndEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NetLossinBeginningAndEnding"/>
  <xs:element name="OtherGainlossDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_OtherGainlossDuringThePeriod"/>
  <xs:element name="EffectOfSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_EffectOfSettlement"/>
  <xs:element name="AmortizationOfPensionRelatedNetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AmortizationOfPensionRelatedNetLoss"/>
  <xs:element name="PriorServiceCostBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PriorServiceCostBeginning"/>
  <xs:element name="AmortizationOfPriorServiceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AmortizationOfPriorServiceCost"/>
  <xs:element name="TotalUnrecognizedPensionCostEndOfPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_TotalUnrecognizedPensionCostEndOfPeriod"/>
  <xs:element name="WeightedAverageDiscountRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_WeightedAverageDiscountRate"/>
  <xs:element name="RateOfIncreaseInCompensationLevel" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_RateOfIncreaseInCompensationLevel"/>
  <xs:element name="InterestCreditRateOnSavingsAccountsinDollars" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_InterestCreditRateOnSavingsAccountsinDollars"/>
  <xs:element name="ExpectedLongtermRateOfReturnOnPlanAssets" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets"/>
  <xs:element name="WeightedAverageInflationRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_WeightedAverageInflationRate"/>
  <xs:element name="OtherDeferredTaxNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_OtherDeferredTaxNet"/>
  <xs:element name="BackgroundDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_BackgroundDetailsTable"/>
  <xs:element name="BackgroundDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BackgroundDetailsLineItems"/>
  <xs:element name="InitialPublicOfferingUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_InitialPublicOfferingUnits"/>
  <xs:element name="PricePerShareUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PricePerShareUnit"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_GrossProceeds"/>
  <xs:element name="AdditionalPurchaseShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AdditionalPurchaseShare"/>
  <xs:element name="PublicOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PublicOfferingPrice"/>
  <xs:element name="AdditionalWarrantsShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AdditionalWarrantsShare"/>
  <xs:element name="WarrantPurchaseCommonShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_WarrantPurchaseCommonShare"/>
  <xs:element name="WarrantOfferingPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_WarrantOfferingPerShare"/>
  <xs:element name="StockholdersEquity1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_StockholdersEquity1"/>
  <xs:element name="TaxBenefitsMoreLikelyToBeRecognizedPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage"/>
  <xs:element name="AnnualNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AnnualNetSalesPercentage"/>
  <xs:element name="RoyaltyPaymentPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_RoyaltyPaymentPercentage"/>
  <xs:element name="ConvertiblePromissoryNotesRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable"/>
  <xs:element name="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems"/>
  <xs:element name="AccruedInterestPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AccruedInterestPercentage"/>
  <xs:element name="ImputedInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ImputedInterestRate"/>
  <xs:element name="LoanFromBank" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_LoanFromBank"/>
  <xs:element name="BridgeLoanDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_BridgeLoanDetailsTable"/>
  <xs:element name="BridgeLoanDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BridgeLoanDetailsLineItems"/>
  <xs:element name="AggregateBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AggregateBorrowings"/>
  <xs:element name="AdditionalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AdditionalValue"/>
  <xs:element name="BridgeLoanValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BridgeLoanValue"/>
  <xs:element name="InterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_InterestRate"/>
  <xs:element name="AmendmentShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AmendmentShare"/>
  <xs:element name="AmendmentPriceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AmendmentPriceValue"/>
  <xs:element name="ProjectedBenefitObligationsPercentageRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ProjectedBenefitObligationsPercentageRate"/>
  <xs:element name="AmortizationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AmortizationCost"/>
  <xs:element name="UnrecognizedPensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_UnrecognizedPensionCosts"/>
  <xs:element name="AccumulatedBenefitObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_AccumulatedBenefitObligation"/>
  <xs:element name="NonrefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NonrefundableUpfrontPayment"/>
  <xs:element name="ReceiveNonrefundableMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ReceiveNonrefundableMilestonePayments"/>
  <xs:element name="EstimatedTotalTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_EstimatedTotalTransactionPrice"/>
  <xs:element name="LongTermDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_LongTermDeferredRevenue"/>
  <xs:element name="CommonSharesRegisteredAndIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_CommonSharesRegisteredAndIssued"/>
  <xs:element name="CommonSharesToCreditors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_CommonSharesToCreditors"/>
  <xs:element name="PaymentOfInitialCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PaymentOfInitialCreditFacility"/>
  <xs:element name="ConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ConvertiblePromissoryNote"/>
  <xs:element name="DescriptionOfIncomeTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DescriptionOfIncomeTaxDescription"/>
  <xs:element name="NetCapitalLossCarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NetCapitalLossCarryforward"/>
  <xs:element name="NetOperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NetOperatingLoss"/>
  <xs:element name="RelatedpartyconsultingagreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_RelatedpartyconsultingagreementsDetailsTable"/>
  <xs:element name="RelatedpartyconsultingagreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_RelatedpartyconsultingagreementsDetailsLineItems"/>
  <xs:element name="BonusAnnualFee" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_BonusAnnualFee"/>
  <xs:element name="OtherTransactionPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_OtherTransactionPercentage"/>
  <xs:element name="VATServicesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nlsp_VATServicesPercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nlsp_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_SubsequentEventsDetailsLineItems"/>
  <xs:element name="ClosingValue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_ClosingValue"/>
  <xs:element name="WarrantExpireTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_WarrantExpireTerm"/>
  <xs:element name="PurchaseWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_PurchaseWarrants"/>
  <xs:element name="NetSalesOfMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nlsp_NetSalesOfMilestonePayments"/>
  <xs:element name="CHGBioVentureSAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_CHGBioVentureSAMember"/>
  <xs:element name="FirstTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_FirstTrancheMember"/>
  <xs:element name="MagneticRockInvestmentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_MagneticRockInvestmentsMember"/>
  <xs:element name="MrCamozziMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_MrCamozziMember"/>
  <xs:element name="MrKonofalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_MrKonofalMember"/>
  <xs:element name="MrRoyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_MrRoyMember"/>
  <xs:element name="SecondCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_SecondCreditFacilityMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nlsp_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>nlsp-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedBalanceSheet" roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedIncomeStatement" roleURI="http://www.nlspharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedCashFlow" roleURI="http://www.nlspharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BridgeLoan" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLoansFromBank" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0Cs9O15B2LNEmnMIkPMHGJC] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestExpenseDebt" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestExpenseOther" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nlsp_DefinedPensionPlanAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_DefinedPensionPlanAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="nlsp_DefinedPensionPlanAdjustments" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="nlsp_PeriodicPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_PeriodicPensionCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nlsp_PeriodicPensionCosts" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromSwissGovernmentLoan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nlsp_ProceedsFromSwissGovernmentLoan" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromBridgeLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromBridgeLoan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nlsp_ProceedsFromBridgeLoan" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="nlsp_PrepaidVendorOverpayments" xlink:href="nlsp-20201231.xsd#nlsp_PrepaidVendorOverpayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nlsp_PrepaidVendorOverpayments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>nlsp-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedBalanceSheet" roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedIncomeStatement" roleURI="http://www.nlspharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersEquityType2or3" roleURI="http://www.nlspharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedCashFlow" roleURI="http://www.nlspharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_Background" roleURI="http://www.nlspharma.com/role/Background"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RestatementofPreviouslyIssuedFinancialStatements" roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_OtherReceivablesnetRelatedParty" roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedParties" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedParties" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoans" roleURI="http://www.nlspharma.com/role/ConvertibleLoans"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SwissGovernmentLoan" roleURI="http://www.nlspharma.com/role/SwissGovernmentLoan"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BridgeLoan" roleURI="http://www.nlspharma.com/role/BridgeLoan"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiability" roleURI="http://www.nlspharma.com/role/PensionLiability"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_DeferredRevenues" roleURI="http://www.nlspharma.com/role/DeferredRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CommitmentsandContingencies" roleURI="http://www.nlspharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersDeficit" roleURI="http://www.nlspharma.com/role/ShareholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxes" roleURI="http://www.nlspharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_Relatedpartyconsultingagreements" roleURI="http://www.nlspharma.com/role/Relatedpartyconsultingagreements"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SubsequentEvents" roleURI="http://www.nlspharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_AccountingPoliciesByPolicy" roleURI="http://www.nlspharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RestatementofPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedPartiesTables" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesTables" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoansTables" roleURI="http://www.nlspharma.com/role/ConvertibleLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiabilityTables" roleURI="http://www.nlspharma.com/role/PensionLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxesTables" roleURI="http://www.nlspharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofrestatementinthefinancialstatementsTable" roleURI="http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertiblepromissorynotesTable" roleURI="http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable" roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals" roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertibleloansTable" roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertibleloansTable_Parentheticals" roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofpensionplanTable" roleURI="http://www.nlspharma.com/role/ScheduleofpensionplanTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable" roleURI="http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable" roleURI="http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable" roleURI="http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofnetdeferredtaxassetsTable" roleURI="http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofincometaxprovisionTable" roleURI="http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofeffectivereconciliationofthefederalincometaxrateTable" roleURI="http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BackgroundDetails" roleURI="http://www.nlspharma.com/role/BackgroundDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_OtherReceivablesnetRelatedPartyDetails" roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedPartiesDetails" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesDetails" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoansDetails" roleURI="http://www.nlspharma.com/role/ConvertibleLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SwissGovernmentLoanDetails" roleURI="http://www.nlspharma.com/role/SwissGovernmentLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BridgeLoanDetails" roleURI="http://www.nlspharma.com/role/BridgeLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiabilityDetails" roleURI="http://www.nlspharma.com/role/PensionLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_DeferredRevenuesDetails" roleURI="http://www.nlspharma.com/role/DeferredRevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CommitmentsandContingenciesDetails" roleURI="http://www.nlspharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersDeficitDetails" roleURI="http://www.nlspharma.com/role/ShareholdersDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxesDetails" roleURI="http://www.nlspharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RelatedpartyconsultingagreementsDetails" roleURI="http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SubsequentEventsDetails" roleURI="http://www.nlspharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.nlspharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BridgeLoan" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermLoansFromBank" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccountsPayableIncludingRelatedParty" xlink:href="nlsp-20201231.xsd#nlsp_AccountsPayableIncludingRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="nlsp_AccountsPayableIncludingRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DefinedPensionPlanAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_DefinedPensionPlanAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="nlsp_DefinedPensionPlanAdjustments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:href="nlsp-20201231.xsd#nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PeriodicPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_PeriodicPensionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nlsp_PeriodicPensionCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromSwissGovernmentLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nlsp_ProceedsFromSwissGovernmentLoan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromBridgeLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromBridgeLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nlsp_ProceedsFromBridgeLoan" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:href="nlsp-20201231.xsd#nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscountOnRelatedPartyLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnRelatedPartyLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="nlsp_DebtDiscountOnRelatedPartyLoans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscountOnConvertibleLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnConvertibleLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="nlsp_DebtDiscountOnConvertibleLoans" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/Background">
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundAbstract" xlink:to="nlsp_BackgroundTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements">
    <loc xlink:type="locator" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:to="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties">
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SwissGovernmentLoan">
    <loc xlink:type="locator" xlink:label="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_SwissGovernmentLoanDisclosureTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="nlsp_SwissGovernmentLoanDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BridgeLoan">
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanAbstract" xlink:to="nlsp_BridgeLoanTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiability">
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_PensionLiabilityTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DeferredRevenues">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/Relatedpartyconsultingagreements">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetRetirementObligationsPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables">
    <loc xlink:type="locator" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertibleLoansTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="nlsp_ScheduleOfConvertibleLoansTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiabilityTables">
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_PrepaidVendorOverpayments" xlink:href="nlsp-20201231.xsd#nlsp_PrepaidVendorOverpayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="nlsp_PrepaidVendorOverpayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertiblePromissoryNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_SecondCreditFacilityMember" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="nlsp_SecondCreditFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_SecondCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacility"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nlsp_SecondCreditFacility" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0AFdsJJuibxQ5tLkXL5JEqI] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_SecondCreditFacilityMember" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="nlsp_SecondCreditFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="nlsp_DebtDiscount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_LongTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:to="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:to="nlsp_DebtDiscount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofpensionplanTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfPensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPensionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ExpectedReturnOnAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedReturnOnAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="nlsp_ExpectedReturnOnAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetPeriodicPensionCost" xlink:href="nlsp-20201231.xsd#nlsp_NetPeriodicPensionCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="nlsp_NetPeriodicPensionCost" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationBeginningAndEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationBeginningAndEnding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationServiceCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationInterestCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationInterestCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationInterestCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationTransfersinAndoutNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationActuarialgainLoss" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationActuarialgainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationActuarialgainLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsBeginningAndEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsBeginningAndEnding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsEmployerContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsEmployerContributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsEmployerContributions" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsParticipantContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsParticipantContributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsParticipantContributions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsTransfersinAndoutNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsTransfersinAndoutNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsAdministrationExpenses" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsAdministrationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsAdministrationExpenses" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsCurrencyConversionAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_PlanAssetsCurrencyConversionAdjustments" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccruedPensionLiability" xlink:href="nlsp-20201231.xsd#nlsp_AccruedPensionLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_AccruedPensionLiability" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetLossinBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_NetLossinBeginningAndEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_NetLossinBeginningAndEnding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherGainlossDuringThePeriod" xlink:href="nlsp-20201231.xsd#nlsp_OtherGainlossDuringThePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_OtherGainlossDuringThePeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_EffectOfSettlement" xlink:href="nlsp-20201231.xsd#nlsp_EffectOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_EffectOfSettlement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationOfPensionRelatedNetLoss" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPensionRelatedNetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_AmortizationOfPensionRelatedNetLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PriorServiceCostBeginning" xlink:href="nlsp-20201231.xsd#nlsp_PriorServiceCostBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_PriorServiceCostBeginning" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationOfPriorServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPriorServiceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_AmortizationOfPriorServiceCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_TotalUnrecognizedPensionCostEndOfPeriod" xlink:href="nlsp-20201231.xsd#nlsp_TotalUnrecognizedPensionCostEndOfPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_TotalUnrecognizedPensionCostEndOfPeriod" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_WeightedAverageDiscountRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_WeightedAverageDiscountRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_RateOfIncreaseInCompensationLevel" xlink:href="nlsp-20201231.xsd#nlsp_RateOfIncreaseInCompensationLevel"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_RateOfIncreaseInCompensationLevel" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_InterestCreditRateOnSavingsAccountsinDollars" xlink:href="nlsp-20201231.xsd#nlsp_InterestCreditRateOnSavingsAccountsinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_InterestCreditRateOnSavingsAccountsinDollars" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedLongtermRateOfReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_WeightedAverageInflationRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageInflationRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_WeightedAverageInflationRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfNetDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherDeferredTaxNet" xlink:href="nlsp-20201231.xsd#nlsp_OtherDeferredTaxNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="nlsp_OtherDeferredTaxNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfIncomeTaxProvisionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BackgroundDetails">
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_BackgroundDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_BackgroundDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_InitialPublicOfferingUnits" xlink:href="nlsp-20201231.xsd#nlsp_InitialPublicOfferingUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_InitialPublicOfferingUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PricePerShareUnit" xlink:href="nlsp-20201231.xsd#nlsp_PricePerShareUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_PricePerShareUnit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_GrossProceeds" xlink:href="nlsp-20201231.xsd#nlsp_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_GrossProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalPurchaseShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalPurchaseShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_AdditionalPurchaseShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PublicOfferingPrice" xlink:href="nlsp-20201231.xsd#nlsp_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_PublicOfferingPrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalWarrantsShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalWarrantsShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_AdditionalWarrantsShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantPurchaseCommonShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantPurchaseCommonShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_WarrantPurchaseCommonShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantOfferingPerShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantOfferingPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_WarrantOfferingPerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncome" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_StockholdersEquity1" xlink:href="nlsp-20201231.xsd#nlsp_StockholdersEquity1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_StockholdersEquity1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:href="nlsp-20201231.xsd#nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_AnnualNetSalesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AnnualNetSalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="nlsp_AnnualNetSalesPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_RoyaltyPaymentPercentage" xlink:href="nlsp-20201231.xsd#nlsp_RoyaltyPaymentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="nlsp_RoyaltyPaymentPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherLongTermDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_MagneticRockInvestmentsMember" xlink:href="nlsp-20201231.xsd#nlsp_MagneticRockInvestmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nlsp_MagneticRockInvestmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="nlsp_DebtDiscount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccruedInterestPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AccruedInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="nlsp_AccruedInterestPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ImputedInterestRate" xlink:href="nlsp-20201231.xsd#nlsp_ImputedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="nlsp_ImputedInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_AdjustmentForAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SwissGovernmentLoanDetails">
    <loc xlink:type="locator" xlink:label="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BankLoans" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BankLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="srt_BankLoans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_LoanFromBank" xlink:href="nlsp-20201231.xsd#nlsp_LoanFromBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="nlsp_LoanFromBank" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BridgeLoanDetails">
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_BridgeLoanDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_BridgeLoanDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_FirstTrancheMember" xlink:href="nlsp-20201231.xsd#nlsp_FirstTrancheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nlsp_FirstTrancheMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_BridgeLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="us-gaap_BridgeLoan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AggregateBorrowings" xlink:href="nlsp-20201231.xsd#nlsp_AggregateBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_AggregateBorrowings" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalValue" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_AdditionalValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanValue" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_BridgeLoanValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_InterestRate" xlink:href="nlsp-20201231.xsd#nlsp_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_InterestRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmendmentShare" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_AmendmentShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmendmentPriceValue" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentPriceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_AmendmentPriceValue" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiabilityDetails">
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccruedPensionLiability" xlink:href="nlsp-20201231.xsd#nlsp_AccruedPensionLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_AccruedPensionLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationsPercentageRate" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationsPercentageRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_ProjectedBenefitObligationsPercentageRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_AmortizationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_UnrecognizedPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_UnrecognizedPensionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_UnrecognizedPensionCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccumulatedBenefitObligation" xlink:href="nlsp-20201231.xsd#nlsp_AccumulatedBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_AccumulatedBenefitObligation" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DeferredRevenuesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_NonrefundableUpfrontPayment" xlink:href="nlsp-20201231.xsd#nlsp_NonrefundableUpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nlsp_NonrefundableUpfrontPayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ReceiveNonrefundableMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_ReceiveNonrefundableMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nlsp_ReceiveNonrefundableMilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_EstimatedTotalTransactionPrice" xlink:href="nlsp-20201231.xsd#nlsp_EstimatedTotalTransactionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nlsp_EstimatedTotalTransactionPrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_LongTermDeferredRevenue" xlink:href="nlsp-20201231.xsd#nlsp_LongTermDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nlsp_LongTermDeferredRevenue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_CommonSharesRegisteredAndIssued" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesRegisteredAndIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nlsp_CommonSharesRegisteredAndIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_CommonSharesToCreditors" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesToCreditors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nlsp_CommonSharesToCreditors" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PaymentOfInitialCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_PaymentOfInitialCreditFacility"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nlsp_PaymentOfInitialCreditFacility" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_BridgeLoan" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNote" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nlsp_ConvertiblePromissoryNote" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nlsp_DescriptionOfIncomeTaxDescription" xlink:href="nlsp-20201231.xsd#nlsp_DescriptionOfIncomeTaxDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nlsp_DescriptionOfIncomeTaxDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetCapitalLossCarryforward" xlink:href="nlsp-20201231.xsd#nlsp_NetCapitalLossCarryforward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nlsp_NetCapitalLossCarryforward" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetOperatingLoss" xlink:href="nlsp-20201231.xsd#nlsp_NetOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nlsp_NetOperatingLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails">
    <loc xlink:type="locator" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="nlsp_RelatedpartyconsultingagreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_CHGBioVentureSAMember" xlink:href="nlsp-20201231.xsd#nlsp_CHGBioVentureSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nlsp_CHGBioVentureSAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrRoyMember" xlink:href="nlsp-20201231.xsd#nlsp_MrRoyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nlsp_MrRoyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrKonofalMember" xlink:href="nlsp-20201231.xsd#nlsp_MrKonofalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nlsp_MrKonofalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrCamozziMember" xlink:href="nlsp-20201231.xsd#nlsp_MrCamozziMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nlsp_MrCamozziMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_BonusAnnualFee" xlink:href="nlsp-20201231.xsd#nlsp_BonusAnnualFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="nlsp_BonusAnnualFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherTransactionPercentage" xlink:href="nlsp-20201231.xsd#nlsp_OtherTransactionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="nlsp_OtherTransactionPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_SellingExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_VATServicesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_VATServicesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="nlsp_VATServicesPercentage" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="nlsp_SubsequentEventsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nlsp_SubsequentEventsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nlsp_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_ClosingValue" xlink:href="nlsp-20201231.xsd#nlsp_ClosingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_ClosingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_GrossProceeds" xlink:href="nlsp-20201231.xsd#nlsp_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_GrossProceeds" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantExpireTerm" xlink:href="nlsp-20201231.xsd#nlsp_WarrantExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_WarrantExpireTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_PurchaseWarrants" xlink:href="nlsp-20201231.xsd#nlsp_PurchaseWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_PurchaseWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetSalesOfMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_NetSalesOfMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_NetSalesOfMilestonePayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>nlsp-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">BALANCE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">BALANCE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">BALANCE (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">BALANCE (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BackgroundAbstract_lbl" xml:lang="en-US">Background [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundAbstract" xlink:to="nlsp_BackgroundAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract_lbl" xml:lang="en-US">Restatement Of Previously Issued Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:to="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule of restatement in the financial statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract" xlink:to="nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract_lbl" xml:lang="en-US">Convertible Promissory Notes Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertiblePromissoryNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract_lbl" xml:lang="en-US">Schedule of convertible promissory notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract" xlink:to="nlsp_ScheduleOfConvertiblePromissoryNotesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingsAbstract_lbl" xml:lang="en-US">Subordinated Borrowings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of credit facilities with related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:to="nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfConvertibleLoansAbstract_lbl" xml:lang="en-US">Schedule of convertible loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfConvertibleLoansAbstract" xlink:to="nlsp_ScheduleOfConvertibleLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SwissGovernmentLoanDisclosureAbstract_lbl" xml:lang="en-US">Swiss Government Loan Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SwissGovernmentLoanDisclosureAbstract" xlink:to="nlsp_SwissGovernmentLoanDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BridgeLoanAbstract_lbl" xml:lang="en-US">Bridge Loan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanAbstract" xlink:to="nlsp_BridgeLoanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PensionLiabilityAbstract_lbl" xml:lang="en-US">Pension Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PensionLiabilityAbstract" xlink:to="nlsp_PensionLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfPensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPensionPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfPensionPlanAbstract_lbl" xml:lang="en-US">Schedule of pension plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfPensionPlanAbstract" xlink:to="nlsp_ScheduleOfPensionPlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract_lbl" xml:lang="en-US">Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationBeginningAndEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl" xml:lang="en-US">Projected benefit obligation, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:to="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl0" xml:lang="en-US">Projected benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:to="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsBeginningAndEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nlsp_PlanAssetsBeginningAndEnding_lbl" xml:lang="en-US">Plan assets, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsBeginningAndEnding" xlink:to="nlsp_PlanAssetsBeginningAndEnding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nlsp_PlanAssetsBeginningAndEnding_lbl0" xml:lang="en-US">Plan assets, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsBeginningAndEnding" xlink:to="nlsp_PlanAssetsBeginningAndEnding_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Schedule of unrecognized pension cost in accumulated other comprehensive income/loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetLossinBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_NetLossinBeginningAndEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nlsp_NetLossinBeginningAndEnding_lbl" xml:lang="en-US">Net loss, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetLossinBeginningAndEnding" xlink:to="nlsp_NetLossinBeginningAndEnding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nlsp_NetLossinBeginningAndEnding_lbl0" xml:lang="en-US">Net loss, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetLossinBeginningAndEnding" xlink:to="nlsp_NetLossinBeginningAndEnding_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_PriorServiceCostBeginning" xlink:href="nlsp-20201231.xsd#nlsp_PriorServiceCostBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nlsp_PriorServiceCostBeginning_lbl" xml:lang="en-US">Prior service cost, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PriorServiceCostBeginning" xlink:to="nlsp_PriorServiceCostBeginning_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nlsp_PriorServiceCostBeginning_lbl0" xml:lang="en-US">Prior service cost end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PriorServiceCostBeginning" xlink:to="nlsp_PriorServiceCostBeginning_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract_lbl" xml:lang="en-US">Schedule of weighted average of the key assumptions used to compute the benefit obligations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfNetDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of net deferred tax assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="nlsp_ScheduleOfNetDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfIncomeTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfIncomeTaxProvisionAbstract_lbl" xml:lang="en-US">Schedule of income tax provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="nlsp_ScheduleOfIncomeTaxProvisionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract_lbl" xml:lang="en-US">Schedule of effective reconciliation of the federal income tax rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets, including related party of $0 and $13,432 as of December 31, 2020 and 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables, net &#8211; related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable, including related party of $454,315 and $34,727, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccountsPayableIncludingRelatedParty" xlink:href="nlsp-20201231.xsd#nlsp_AccountsPayableIncludingRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AccountsPayableIncludingRelatedParty_lbl" xml:lang="en-US">Accounts payable including related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccountsPayableIncludingRelatedParty" xlink:to="nlsp_AccountsPayableIncludingRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Current portion of credit facilities, subordinated &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Current portion of convertible loans, including related party of $113,130, net of discount of $37,362 as of December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl0" xml:lang="en-US">Less: current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Related party, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Convertible loans &#8211; related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Net of discount, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoan_lbl" xml:lang="en-US">Bridge loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BridgeLoan_lbl0" xml:lang="en-US">Total value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities, including related party of $40,842 and $12,391 as of December 31, 2020 and 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities, including related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible loans, net of discount of $4,248 and $64,788 as of December 31, 2020 and 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl0" xml:lang="en-US">Convertible loans, long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US">Net of discount, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US">Swiss government loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued pension liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; deficit:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common shares, CHF 0.02 ($0.02) par value, 10,440,000 authorized, 6,960,000 shares issued and outstanding at December 31, 2020 and 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in Francs per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Additional common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherComprehensiveLossAbstract" xlink:href="nlsp-20201231.xsd#nlsp_OtherComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_OtherComprehensiveLossAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherComprehensiveLossAbstract" xlink:to="nlsp_OtherComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares used in computing basic and diluted net loss per common share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares for conversion of related party debt to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares for conversion of related party debt to equity (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Debt discount on related party loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax_lbl" xml:lang="en-US">Defined pension plan adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature on convertible loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:href="nlsp-20201231.xsd#nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl" xml:lang="en-US">Beneficial conversion feature on related party convertible loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:to="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Other accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from convertible loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible loan &#8211; related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromSwissGovernmentLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan_lbl" xml:lang="en-US">Proceeds from Swiss government loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromSwissGovernmentLoan" xlink:to="nlsp_ProceedsFromSwissGovernmentLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from convertible promissory notes &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:href="nlsp-20201231.xsd#nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl" xml:lang="en-US">Issuance of common shares for settlement of related party credit facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:to="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscountOnRelatedPartyLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnRelatedPartyLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_DebtDiscountOnRelatedPartyLoans_lbl" xml:lang="en-US">Debt discount on related party loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnRelatedPartyLoans" xlink:to="nlsp_DebtDiscountOnRelatedPartyLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscountOnConvertibleLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnConvertibleLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_DebtDiscountOnConvertibleLoans_lbl" xml:lang="en-US">Proceeds from convertible loans in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnConvertibleLoans" xlink:to="nlsp_DebtDiscountOnConvertibleLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense on related party loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DefinedPensionPlanAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_DefinedPensionPlanAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nlsp_DefinedPensionPlanAdjustments_lbl" xml:lang="en-US">Defined pension plan adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DefinedPensionPlanAdjustments" xlink:to="nlsp_DefinedPensionPlanAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PeriodicPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_PeriodicPensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nlsp_PeriodicPensionCosts_lbl" xml:lang="en-US">Periodic pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PeriodicPensionCosts" xlink:to="nlsp_PeriodicPensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Other receivables, net - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProceedsFromBridgeLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromBridgeLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nlsp_ProceedsFromBridgeLoan_lbl" xml:lang="en-US">Proceeds from Bridge loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromBridgeLoan" xlink:to="nlsp_ProceedsFromBridgeLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_BackgroundTextBlock_lbl" xml:lang="en-US">Background</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundTextBlock" xlink:to="nlsp_BackgroundTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl" xml:lang="en-US">Restatement of Previously Issued Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:to="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of restatement in the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PrepaidVendorOverpayments" xlink:href="nlsp-20201231.xsd#nlsp_PrepaidVendorOverpayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PrepaidVendorOverpayments_lbl" xml:lang="en-US">Vendor overpayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PrepaidVendorOverpayments" xlink:to="nlsp_PrepaidVendorOverpayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">VAT recoverable and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Convertible loan funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">CEO receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Other Receivables, net &#8211; Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock_lbl" xml:lang="en-US">Convertible Promissory Notes &#8211; Related Parties:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl" xml:lang="en-US">Credit Facilities, Subordinated &#8211; Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Schedule of credit facilities with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SecondCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_SecondCreditFacility_lbl" xml:lang="en-US">Second Credit Facility, net of debt discount of $0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SecondCreditFacility" xlink:to="nlsp_SecondCreditFacility_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_DebtDiscount_lbl" xml:lang="en-US">Debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscount" xlink:to="nlsp_DebtDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfConvertibleLoansTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ScheduleOfConvertibleLoansTableTextBlock_lbl" xml:lang="en-US">Schedule of convertible loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfConvertibleLoansTableTextBlock" xlink:to="nlsp_ScheduleOfConvertibleLoansTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Total Convertible loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SwissGovernmentLoanDisclosureTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_SwissGovernmentLoanDisclosureTextBlock_lbl" xml:lang="en-US">Swiss Government Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SwissGovernmentLoanDisclosureTextBlock" xlink:to="nlsp_SwissGovernmentLoanDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_BridgeLoanTextBlock_lbl" xml:lang="en-US">Bridge Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanTextBlock" xlink:to="nlsp_BridgeLoanTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PensionLiabilityTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PensionLiabilityTextBlock_lbl" xml:lang="en-US">Pension Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PensionLiabilityTextBlock" xlink:to="nlsp_PensionLiabilityTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of weighted average of the key assumptions used to compute the benefit obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US">Service cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US">Interest cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ExpectedReturnOnAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedReturnOnAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ExpectedReturnOnAssets_lbl" xml:lang="en-US">Expected return on assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ExpectedReturnOnAssets" xlink:to="nlsp_ExpectedReturnOnAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl" xml:lang="en-US">Effect of settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xml:lang="en-US">Administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetPeriodicPensionCost" xlink:href="nlsp-20201231.xsd#nlsp_NetPeriodicPensionCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NetPeriodicPensionCost_lbl" xml:lang="en-US">Net periodic pension cost (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetPeriodicPensionCost" xlink:to="nlsp_NetPeriodicPensionCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:to="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationServiceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationServiceCost_lbl" xml:lang="en-US">Service cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationServiceCost" xlink:to="nlsp_ProjectedBenefitObligationServiceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationInterestCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationInterestCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationInterestCost_lbl" xml:lang="en-US">Interest cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationInterestCost" xlink:to="nlsp_ProjectedBenefitObligationInterestCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationTransfersinAndoutNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl" xml:lang="en-US">Transfers-in and (-out), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" xlink:to="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationActuarialgainLoss" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationActuarialgainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl" xml:lang="en-US">Actuarial (gain)/ loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationActuarialgainLoss" xlink:to="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl" xml:lang="en-US">Currency conversion adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:to="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl" xml:lang="en-US">Actual return on plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsEmployerContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsEmployerContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PlanAssetsEmployerContributions_lbl" xml:lang="en-US">Employer contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsEmployerContributions" xlink:to="nlsp_PlanAssetsEmployerContributions_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsParticipantContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsParticipantContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PlanAssetsParticipantContributions_lbl" xml:lang="en-US">Participant contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsParticipantContributions" xlink:to="nlsp_PlanAssetsParticipantContributions_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsTransfersinAndoutNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PlanAssetsTransfersinAndoutNet_lbl" xml:lang="en-US">Transfers-in and (-out), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsTransfersinAndoutNet" xlink:to="nlsp_PlanAssetsTransfersinAndoutNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsAdministrationExpenses" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsAdministrationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PlanAssetsAdministrationExpenses_lbl" xml:lang="en-US">Administration expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsAdministrationExpenses" xlink:to="nlsp_PlanAssetsAdministrationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PlanAssetsCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsCurrencyConversionAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PlanAssetsCurrencyConversionAdjustments_lbl" xml:lang="en-US">Currency conversion adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsCurrencyConversionAdjustments" xlink:to="nlsp_PlanAssetsCurrencyConversionAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccruedPensionLiability" xlink:href="nlsp-20201231.xsd#nlsp_AccruedPensionLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AccruedPensionLiability_lbl" xml:lang="en-US">Accrued pension liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedPensionLiability" xlink:to="nlsp_AccruedPensionLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl" xml:lang="en-US">Schedule of unrecognized pension cost in accumulated other comprehensive income/loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:to="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherGainlossDuringThePeriod" xlink:href="nlsp-20201231.xsd#nlsp_OtherGainlossDuringThePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_OtherGainlossDuringThePeriod_lbl" xml:lang="en-US">Other gain/loss during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherGainlossDuringThePeriod" xlink:to="nlsp_OtherGainlossDuringThePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_EffectOfSettlement" xlink:href="nlsp-20201231.xsd#nlsp_EffectOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_EffectOfSettlement_lbl" xml:lang="en-US">Effect of settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_EffectOfSettlement" xlink:to="nlsp_EffectOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationOfPensionRelatedNetLoss" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPensionRelatedNetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AmortizationOfPensionRelatedNetLoss_lbl" xml:lang="en-US">Amortization of pension related net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationOfPensionRelatedNetLoss" xlink:to="nlsp_AmortizationOfPensionRelatedNetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationOfPriorServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPriorServiceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AmortizationOfPriorServiceCost_lbl" xml:lang="en-US">Amortization of prior service cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationOfPriorServiceCost" xlink:to="nlsp_AmortizationOfPriorServiceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_TotalUnrecognizedPensionCostEndOfPeriod" xlink:href="nlsp-20201231.xsd#nlsp_TotalUnrecognizedPensionCostEndOfPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_TotalUnrecognizedPensionCostEndOfPeriod_lbl" xml:lang="en-US">Total unrecognized pension cost, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_TotalUnrecognizedPensionCostEndOfPeriod" xlink:to="nlsp_TotalUnrecognizedPensionCostEndOfPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average of the key assumptions used to compute the benefit obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:to="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_WeightedAverageDiscountRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_WeightedAverageDiscountRate_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WeightedAverageDiscountRate" xlink:to="nlsp_WeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RateOfIncreaseInCompensationLevel" xlink:href="nlsp-20201231.xsd#nlsp_RateOfIncreaseInCompensationLevel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_RateOfIncreaseInCompensationLevel_lbl" xml:lang="en-US">Rate of increase in compensation level</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RateOfIncreaseInCompensationLevel" xlink:to="nlsp_RateOfIncreaseInCompensationLevel_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_InterestCreditRateOnSavingsAccountsinDollars" xlink:href="nlsp-20201231.xsd#nlsp_InterestCreditRateOnSavingsAccountsinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_InterestCreditRateOnSavingsAccountsinDollars_lbl" xml:lang="en-US">Interest credit rate on savings accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InterestCreditRateOnSavingsAccountsinDollars" xlink:to="nlsp_InterestCreditRateOnSavingsAccountsinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedLongtermRateOfReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets_lbl" xml:lang="en-US">Expected long-term rate of return on plan assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets" xlink:to="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_WeightedAverageInflationRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageInflationRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_WeightedAverageInflationRate_lbl" xml:lang="en-US">Inflation rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WeightedAverageInflationRate" xlink:to="nlsp_WeightedAverageInflationRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DeferredTaxAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DeferredTaxAssetsAbstract" xlink:to="nlsp_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net benefit from tax loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherDeferredTaxNet" xlink:href="nlsp-20201231.xsd#nlsp_OtherDeferredTaxNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_OtherDeferredTaxNet_lbl" xml:lang="en-US">Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherDeferredTaxNet" xlink:to="nlsp_OtherDeferredTaxNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective reconciliation of the federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effect of permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance on deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related party consulting agreements:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Convertible loans, net of discount of $41,611</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">As Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US">As Restated [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SecondCreditFacilityMember" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_SecondCreditFacilityMember_lbl" xml:lang="en-US">Second credit facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SecondCreditFacilityMember" xlink:to="nlsp_SecondCreditFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_InitialPublicOfferingUnits" xlink:href="nlsp-20201231.xsd#nlsp_InitialPublicOfferingUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_InitialPublicOfferingUnits_lbl" xml:lang="en-US">Initial public offering unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InitialPublicOfferingUnits" xlink:to="nlsp_InitialPublicOfferingUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PricePerShareUnit" xlink:href="nlsp-20201231.xsd#nlsp_PricePerShareUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PricePerShareUnit_lbl" xml:lang="en-US">Price per share unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PricePerShareUnit" xlink:to="nlsp_PricePerShareUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_GrossProceeds" xlink:href="nlsp-20201231.xsd#nlsp_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_GrossProceeds" xlink:to="nlsp_GrossProceeds_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nlsp_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_GrossProceeds" xlink:to="nlsp_GrossProceeds_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalPurchaseShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalPurchaseShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AdditionalPurchaseShare_lbl" xml:lang="en-US">Additional purchase share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalPurchaseShare" xlink:to="nlsp_AdditionalPurchaseShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PublicOfferingPrice" xlink:href="nlsp-20201231.xsd#nlsp_PublicOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PublicOfferingPrice_lbl" xml:lang="en-US">Public offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PublicOfferingPrice" xlink:to="nlsp_PublicOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalWarrantsShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalWarrantsShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AdditionalWarrantsShare_lbl" xml:lang="en-US">Additional warrants share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalWarrantsShare" xlink:to="nlsp_AdditionalWarrantsShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantPurchaseCommonShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantPurchaseCommonShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_WarrantPurchaseCommonShare_lbl" xml:lang="en-US">Warrant purchase common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantPurchaseCommonShare" xlink:to="nlsp_WarrantPurchaseCommonShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantOfferingPerShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantOfferingPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_WarrantOfferingPerShare_lbl" xml:lang="en-US">Warrant offering per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantOfferingPerShare" xlink:to="nlsp_WarrantOfferingPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Underwriters exercised share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_StockholdersEquity1" xlink:href="nlsp-20201231.xsd#nlsp_StockholdersEquity1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_StockholdersEquity1_lbl" xml:lang="en-US">Shareholders deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_StockholdersEquity1" xlink:to="nlsp_StockholdersEquity1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Stock split of its issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:href="nlsp-20201231.xsd#nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl" xml:lang="en-US">Tax benefits more likely to be recognized, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:to="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Convertible loans were excluded from computation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AnnualNetSalesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AnnualNetSalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AnnualNetSalesPercentage_lbl" xml:lang="en-US">Annual net sales, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AnnualNetSalesPercentage" xlink:to="nlsp_AnnualNetSalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RoyaltyPaymentPercentage" xlink:href="nlsp-20201231.xsd#nlsp_RoyaltyPaymentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_RoyaltyPaymentPercentage_lbl" xml:lang="en-US">Royalty payment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RoyaltyPaymentPercentage" xlink:to="nlsp_RoyaltyPaymentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebt_lbl" xml:lang="en-US">Other long-term receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Accrues interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Maturity date description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate stated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common shares fair value per share (in Francs per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Aggregate fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Loss on conversion loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Remaining loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum borrowing from lenders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccruedInterestPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AccruedInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AccruedInterestPercentage_lbl" xml:lang="en-US">Accrued interest, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedInterestPercentage" xlink:to="nlsp_AccruedInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ImputedInterestRate" xlink:href="nlsp-20201231.xsd#nlsp_ImputedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ImputedInterestRate_lbl" xml:lang="en-US">Imputed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ImputedInterestRate" xlink:to="nlsp_ImputedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl" xml:lang="en-US">Outstanding borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl" xml:lang="en-US">Convertible debt description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Bank loans percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BankLoans" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BankLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BankLoans_lbl" xml:lang="en-US">Loan secured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BankLoans" xlink:to="srt_BankLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_LoanFromBank" xlink:href="nlsp-20201231.xsd#nlsp_LoanFromBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_LoanFromBank_lbl" xml:lang="en-US">Loan from bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_LoanFromBank" xlink:to="nlsp_LoanFromBank_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Company received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCollateralAggregateFairValue" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AggregateBorrowings" xlink:href="nlsp-20201231.xsd#nlsp_AggregateBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AggregateBorrowings_lbl" xml:lang="en-US">Aggregate borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AggregateBorrowings" xlink:to="nlsp_AggregateBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AdditionalValue" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AdditionalValue_lbl" xml:lang="en-US">Additional value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalValue" xlink:to="nlsp_AdditionalValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanValue" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_BridgeLoanValue_lbl" xml:lang="en-US">Bridge loan value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanValue" xlink:to="nlsp_BridgeLoanValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_InterestRate" xlink:href="nlsp-20201231.xsd#nlsp_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_InterestRate_lbl" xml:lang="en-US">interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InterestRate" xlink:to="nlsp_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmendmentShare" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AmendmentShare_lbl" xml:lang="en-US">Amendment share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmendmentShare" xlink:to="nlsp_AmendmentShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmendmentPriceValue" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentPriceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AmendmentPriceValue_lbl" xml:lang="en-US">AmendmentPriceValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmendmentPriceValue" xlink:to="nlsp_AmendmentPriceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ProjectedBenefitObligationsPercentageRate" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationsPercentageRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ProjectedBenefitObligationsPercentageRate_lbl" xml:lang="en-US">Projected benefit obligations percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationsPercentageRate" xlink:to="nlsp_ProjectedBenefitObligationsPercentageRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AmortizationCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AmortizationCost_lbl" xml:lang="en-US">Amortization cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationCost" xlink:to="nlsp_AmortizationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_UnrecognizedPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_UnrecognizedPensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_UnrecognizedPensionCosts_lbl" xml:lang="en-US">Unrecognized pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_UnrecognizedPensionCosts" xlink:to="nlsp_UnrecognizedPensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_AccumulatedBenefitObligation" xlink:href="nlsp-20201231.xsd#nlsp_AccumulatedBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_AccumulatedBenefitObligation_lbl" xml:lang="en-US">Accumulated benefit obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccumulatedBenefitObligation" xlink:to="nlsp_AccumulatedBenefitObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NonrefundableUpfrontPayment" xlink:href="nlsp-20201231.xsd#nlsp_NonrefundableUpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NonrefundableUpfrontPayment_lbl" xml:lang="en-US">Non-refundable upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NonrefundableUpfrontPayment" xlink:to="nlsp_NonrefundableUpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ReceiveNonrefundableMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_ReceiveNonrefundableMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ReceiveNonrefundableMilestonePayments_lbl" xml:lang="en-US">receive non-refundable milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ReceiveNonrefundableMilestonePayments" xlink:to="nlsp_ReceiveNonrefundableMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_EstimatedTotalTransactionPrice" xlink:href="nlsp-20201231.xsd#nlsp_EstimatedTotalTransactionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_EstimatedTotalTransactionPrice_lbl" xml:lang="en-US">Estimated total transaction price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_EstimatedTotalTransactionPrice" xlink:to="nlsp_EstimatedTotalTransactionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_LongTermDeferredRevenue" xlink:href="nlsp-20201231.xsd#nlsp_LongTermDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_LongTermDeferredRevenue_lbl" xml:lang="en-US">Long term deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_LongTermDeferredRevenue" xlink:to="nlsp_LongTermDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Company obligated to pay adare</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0AROZvAXIklSEpvDQA642TS] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_CommonSharesRegisteredAndIssued" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesRegisteredAndIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_CommonSharesRegisteredAndIssued_lbl" xml:lang="en-US">Common shares, registered and issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesRegisteredAndIssued" xlink:to="nlsp_CommonSharesRegisteredAndIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_CommonSharesToCreditors" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesToCreditors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_CommonSharesToCreditors_lbl" xml:lang="en-US">Common shares to creditors (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesToCreditors" xlink:to="nlsp_CommonSharesToCreditors_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PaymentOfInitialCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_PaymentOfInitialCreditFacility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PaymentOfInitialCreditFacility_lbl" xml:lang="en-US">Payment of initial credit facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PaymentOfInitialCreditFacility" xlink:to="nlsp_PaymentOfInitialCreditFacility_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent_lbl" xml:lang="en-US">Credit facilities amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" xlink:to="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNote" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ConvertiblePromissoryNote_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNote" xlink:to="nlsp_ConvertiblePromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_DescriptionOfIncomeTaxDescription" xlink:href="nlsp-20201231.xsd#nlsp_DescriptionOfIncomeTaxDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_DescriptionOfIncomeTaxDescription_lbl" xml:lang="en-US">Income tax expiration, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DescriptionOfIncomeTaxDescription" xlink:to="nlsp_DescriptionOfIncomeTaxDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetCapitalLossCarryforward" xlink:href="nlsp-20201231.xsd#nlsp_NetCapitalLossCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NetCapitalLossCarryforward_lbl" xml:lang="en-US">Net capital loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetCapitalLossCarryforward" xlink:to="nlsp_NetCapitalLossCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetOperatingLoss" xlink:href="nlsp-20201231.xsd#nlsp_NetOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NetOperatingLoss_lbl" xml:lang="en-US">Net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetOperatingLoss" xlink:to="nlsp_NetOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Monthly fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BonusAnnualFee" xlink:href="nlsp-20201231.xsd#nlsp_BonusAnnualFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_BonusAnnualFee_lbl" xml:lang="en-US">Bonus annual fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BonusAnnualFee" xlink:to="nlsp_BonusAnnualFee_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_OtherTransactionPercentage" xlink:href="nlsp-20201231.xsd#nlsp_OtherTransactionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_OtherTransactionPercentage_lbl" xml:lang="en-US">Other transaction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherTransactionPercentage" xlink:to="nlsp_OtherTransactionPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">General and administrative expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Service payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_VATServicesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_VATServicesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_VATServicesPercentage_lbl" xml:lang="en-US">VAT services percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_VATServicesPercentage" xlink:to="nlsp_VATServicesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Description of loan related transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ClosingValue" xlink:href="nlsp-20201231.xsd#nlsp_ClosingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_ClosingValue_lbl" xml:lang="en-US">Closing value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ClosingValue" xlink:to="nlsp_ClosingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Price per unit (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_WarrantExpireTerm" xlink:href="nlsp-20201231.xsd#nlsp_WarrantExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_WarrantExpireTerm_lbl" xml:lang="en-US">Warrant expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantExpireTerm" xlink:to="nlsp_WarrantExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Warrants common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_PurchaseWarrants" xlink:href="nlsp-20201231.xsd#nlsp_PurchaseWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_PurchaseWarrants_lbl" xml:lang="en-US">Purchase warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PurchaseWarrants" xlink:to="nlsp_PurchaseWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NetSalesOfMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_NetSalesOfMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NetSalesOfMilestonePayments_lbl" xml:lang="en-US">Net sales of milestone payments (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetSalesOfMilestonePayments" xlink:to="nlsp_NetSalesOfMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">JOBS Act Accounting Election</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs and Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xml:lang="en-US">Employee Benefits (including Post Retirement Benefits)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationsPolicy" xlink:to="us-gaap_AssetRetirementObligationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements &#8211; Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements &#8211; Recently Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_MagneticRockInvestmentsMember" xlink:href="nlsp-20201231.xsd#nlsp_MagneticRockInvestmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_MagneticRockInvestmentsMember_lbl" xml:lang="en-US">DebtInstrumentFaceAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MagneticRockInvestmentsMember" xlink:to="nlsp_MagneticRockInvestmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_FirstTrancheMember" xlink:href="nlsp-20201231.xsd#nlsp_FirstTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_FirstTrancheMember_lbl" xml:lang="en-US">First tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_FirstTrancheMember" xlink:to="nlsp_FirstTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US">Bridge Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_CHGBioVentureSAMember" xlink:href="nlsp-20201231.xsd#nlsp_CHGBioVentureSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_CHGBioVentureSAMember_lbl" xml:lang="en-US">CHG BioVenture SA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CHGBioVentureSAMember" xlink:to="nlsp_CHGBioVentureSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrRoyMember" xlink:href="nlsp-20201231.xsd#nlsp_MrRoyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_MrRoyMember_lbl" xml:lang="en-US">Mr. Roy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrRoyMember" xlink:to="nlsp_MrRoyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrKonofalMember" xlink:href="nlsp-20201231.xsd#nlsp_MrKonofalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_MrKonofalMember_lbl" xml:lang="en-US">Mr. Konofal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrKonofalMember" xlink:to="nlsp_MrKonofalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_MrCamozziMember" xlink:href="nlsp-20201231.xsd#nlsp_MrCamozziMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nlsp_MrCamozziMember_lbl" xml:lang="en-US">Mr. Camozzi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrCamozziMember" xlink:to="nlsp_MrCamozziMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US">Deferred Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable_lbl" xml:lang="en-US">Convertible Loans (Details) - Schedule of convertible loans (Parentheticals) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:to="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems_lbl" xml:lang="en-US">Convertible Loans (Details) - Schedule of convertible loans (Parentheticals) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:to="nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BackgroundDetailsTable_lbl" xml:lang="en-US">Background (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundDetailsTable" xlink:to="nlsp_BackgroundDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BackgroundDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BackgroundDetailsLineItems_lbl" xml:lang="en-US">Background (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundDetailsLineItems" xlink:to="nlsp_BackgroundDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Convertible Promissory Notes &#8211; Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Convertible Promissory Notes &#8211; Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BridgeLoanDetailsTable_lbl" xml:lang="en-US">Bridge Loan (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanDetailsTable" xlink:to="nlsp_BridgeLoanDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_BridgeLoanDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BridgeLoanDetailsLineItems_lbl" xml:lang="en-US">Bridge Loan (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanDetailsLineItems" xlink:to="nlsp_BridgeLoanDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsTable_lbl" xml:lang="en-US">Related party consulting agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsTable" xlink:to="nlsp_RelatedpartyconsultingagreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RelatedpartyconsultingagreementsDetailsLineItems_lbl" xml:lang="en-US">Related party consulting agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="nlsp_RelatedpartyconsultingagreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SubsequentEventsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SubsequentEventsDetailsTable" xlink:to="nlsp_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nlsp_SubsequentEventsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SubsequentEventsDetailsLineItems" xlink:to="nlsp_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AccountsPayableIncludingRelatedParty_lbl0" xml:lang="en-US">Amount of accounts payable including related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccountsPayableIncludingRelatedParty" xlink:to="nlsp_AccountsPayableIncludingRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AccruedInterestPercentage_lbl0" xml:lang="en-US">Accrued interest, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedInterestPercentage" xlink:to="nlsp_AccruedInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AccruedPensionLiability_lbl0" xml:lang="en-US">Amount of accrued pension liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedPensionLiability" xlink:to="nlsp_AccruedPensionLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AccumulatedBenefitObligation_lbl0" xml:lang="en-US">Amount of accumulated benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccumulatedBenefitObligation" xlink:to="nlsp_AccumulatedBenefitObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AdditionalPurchaseShare_lbl0" xml:lang="en-US">Number of share additional purchase share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalPurchaseShare" xlink:to="nlsp_AdditionalPurchaseShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AdditionalWarrantsShare_lbl0" xml:lang="en-US">Number of share additional warrants share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalWarrantsShare" xlink:to="nlsp_AdditionalWarrantsShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_AnnualNetSalesPercentage_lbl0" xml:lang="en-US">Annual net sales, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AnnualNetSalesPercentage" xlink:to="nlsp_AnnualNetSalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_BackgroundTextBlock_lbl0" xml:lang="en-US">The entire disclosure for background.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundTextBlock" xlink:to="nlsp_BackgroundTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl0" xml:lang="en-US">Beneficial conversion feature on related party convertible loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:to="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_BonusAnnualFee_lbl0" xml:lang="en-US">Amount of bonus annual fee percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BonusAnnualFee" xlink:to="nlsp_BonusAnnualFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_CommonSharesRegisteredAndIssued_lbl0" xml:lang="en-US">Common shares, registered and issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesRegisteredAndIssued" xlink:to="nlsp_CommonSharesRegisteredAndIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_CommonSharesToCreditors_lbl0" xml:lang="en-US">Common shares to creditors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesToCreditors" xlink:to="nlsp_CommonSharesToCreditors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ConvertiblePromissoryNote_lbl0" xml:lang="en-US">Convertible promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNote" xlink:to="nlsp_ConvertiblePromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_DebtDiscount_lbl0" xml:lang="en-US">Amount of debt discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscount" xlink:to="nlsp_DebtDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_DebtDiscountOnConvertibleLoans_lbl0" xml:lang="en-US">Debt discount on convertible loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnConvertibleLoans" xlink:to="nlsp_DebtDiscountOnConvertibleLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_DebtDiscountOnRelatedPartyLoans_lbl0" xml:lang="en-US">Debt discount on related party loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnRelatedPartyLoans" xlink:to="nlsp_DebtDiscountOnRelatedPartyLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_DefinedPensionPlanAdjustments_lbl0" xml:lang="en-US">pension plan adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DefinedPensionPlanAdjustments" xlink:to="nlsp_DefinedPensionPlanAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_GrossProceeds_lbl1" xml:lang="en-US">The amount of gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_GrossProceeds" xlink:to="nlsp_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ImputedInterestRate_lbl0" xml:lang="en-US">Imputed interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ImputedInterestRate" xlink:to="nlsp_ImputedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_InitialPublicOfferingUnits_lbl0" xml:lang="en-US">Number of share Initial public offering unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InitialPublicOfferingUnits" xlink:to="nlsp_InitialPublicOfferingUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl0" xml:lang="en-US">Issuance of common shares for settlement of related party credit facilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:to="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_LoanFromBank_lbl0" xml:lang="en-US">Loan from bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_LoanFromBank" xlink:to="nlsp_LoanFromBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_NetSalesOfMilestonePayments_lbl0" xml:lang="en-US">Net sales of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetSalesOfMilestonePayments" xlink:to="nlsp_NetSalesOfMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for new accounting pronouncements not yet adopted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_OtherDeferredTaxNet_lbl0" xml:lang="en-US">Other deferred tax net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherDeferredTaxNet" xlink:to="nlsp_OtherDeferredTaxNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_OtherTransactionPercentage_lbl0" xml:lang="en-US">Amount of other transaction percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherTransactionPercentage" xlink:to="nlsp_OtherTransactionPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_PaymentOfInitialCreditFacility_lbl0" xml:lang="en-US">Payment of initial credit facility.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PaymentOfInitialCreditFacility" xlink:to="nlsp_PaymentOfInitialCreditFacility_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_PeriodicPensionCosts_lbl0" xml:lang="en-US">Amount of periodic pension costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PeriodicPensionCosts" xlink:to="nlsp_PeriodicPensionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_PrepaidVendorOverpayments_lbl0" xml:lang="en-US">Prepaid vendor overpayments amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PrepaidVendorOverpayments" xlink:to="nlsp_PrepaidVendorOverpayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_PricePerShareUnit_lbl0" xml:lang="en-US">Number of price per share unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PricePerShareUnit" xlink:to="nlsp_PricePerShareUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProceedsFromBridgeLoan_lbl0" xml:lang="en-US">Proceeds from Bridge loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromBridgeLoan" xlink:to="nlsp_ProceedsFromBridgeLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan_lbl0" xml:lang="en-US">Proceeds from Swiss government loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromSwissGovernmentLoan" xlink:to="nlsp_ProceedsFromSwissGovernmentLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl0" xml:lang="en-US">Amount of actuarial (gain)/ loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationActuarialgainLoss" xlink:to="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl1" xml:lang="en-US">Projected benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:to="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl0" xml:lang="en-US">Amount of currency conversion adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:to="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationInterestCost_lbl0" xml:lang="en-US">Amount of Interest cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationInterestCost" xlink:to="nlsp_ProjectedBenefitObligationInterestCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationServiceCost_lbl0" xml:lang="en-US">Amount of service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationServiceCost" xlink:to="nlsp_ProjectedBenefitObligationServiceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl0" xml:lang="en-US">Amount of transfers-in and (-out), net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" xlink:to="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ProjectedBenefitObligationsPercentageRate_lbl0" xml:lang="en-US">Projected benefit obligations percentage rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationsPercentageRate" xlink:to="nlsp_ProjectedBenefitObligationsPercentageRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_PublicOfferingPrice_lbl0" xml:lang="en-US">Number of share public offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PublicOfferingPrice" xlink:to="nlsp_PublicOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_RoyaltyPaymentPercentage_lbl0" xml:lang="en-US">Royalty payment, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RoyaltyPaymentPercentage" xlink:to="nlsp_RoyaltyPaymentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:to="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of unrecognized pension cost in accumulated other comprehensive income/loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:to="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of weighted average of the key assumptions used to compute the benefit obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:to="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_SecondCreditFacility_lbl0" xml:lang="en-US">Second Credit Facility.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SecondCreditFacility" xlink:to="nlsp_SecondCreditFacility_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_StockholdersEquity1_lbl0" xml:lang="en-US">Total of all stockholders&apos; equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity&apos;s stockholders&apos; equity attributable to the parent excludes the amount of stockholders&apos; equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_StockholdersEquity1" xlink:to="nlsp_StockholdersEquity1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl0" xml:lang="en-US">Tax benefits more likely to be recognized, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:to="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_UnrecognizedPensionCosts_lbl0" xml:lang="en-US">Amount of unrecognized pension costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_UnrecognizedPensionCosts" xlink:to="nlsp_UnrecognizedPensionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_VATServicesPercentage_lbl0" xml:lang="en-US">Amount of VAT services percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_VATServicesPercentage" xlink:to="nlsp_VATServicesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_WarrantExpireTerm_lbl0" xml:lang="en-US">Warrant expire term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantExpireTerm" xlink:to="nlsp_WarrantExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_WarrantOfferingPerShare_lbl0" xml:lang="en-US">Number of share warrant offering per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantOfferingPerShare" xlink:to="nlsp_WarrantOfferingPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nlsp_WarrantPurchaseCommonShare_lbl0" xml:lang="en-US">Number of share warrant purchase common share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantPurchaseCommonShare" xlink:to="nlsp_WarrantPurchaseCommonShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsTransfersinAndoutNet_lbl0" xml:lang="en-US">PlanAssetsTransfersinAndoutNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsTransfersinAndoutNet" xlink:to="nlsp_PlanAssetsTransfersinAndoutNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DebtDiscount_lbl1" xml:lang="en-US">DebtDiscount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscount" xlink:to="nlsp_DebtDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AggregateBorrowings_lbl0" xml:lang="en-US">AggregateBorrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AggregateBorrowings" xlink:to="nlsp_AggregateBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DebtDiscountOnConvertibleLoans_lbl1" xml:lang="en-US">DebtDiscountOnConvertibleLoans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnConvertibleLoans" xlink:to="nlsp_DebtDiscountOnConvertibleLoans_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:to="nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_InitialPublicOfferingUnits_lbl1" xml:lang="en-US">InitialPublicOfferingUnits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InitialPublicOfferingUnits" xlink:to="nlsp_InitialPublicOfferingUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1" xml:lang="en-US">NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_OtherDeferredTaxNet_lbl1" xml:lang="en-US">OtherDeferredTaxNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherDeferredTaxNet" xlink:to="nlsp_OtherDeferredTaxNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ExpectedReturnOnAssets_lbl0" xml:lang="en-US">ExpectedReturnOnAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ExpectedReturnOnAssets" xlink:to="nlsp_ExpectedReturnOnAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_VATServicesPercentage_lbl1" xml:lang="en-US">VATServicesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_VATServicesPercentage" xlink:to="nlsp_VATServicesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SecondCreditFacility_lbl1" xml:lang="en-US">SecondCreditFacility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SecondCreditFacility" xlink:to="nlsp_SecondCreditFacility_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfConvertibleLoansTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfConvertibleLoansTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfConvertibleLoansTableTextBlock" xlink:to="nlsp_ScheduleOfConvertibleLoansTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PriorServiceCostBeginning_lbl1" xml:lang="en-US">PriorServiceCostBeginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PriorServiceCostBeginning" xlink:to="nlsp_PriorServiceCostBeginning_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AmortizationOfPriorServiceCost_lbl0" xml:lang="en-US">AmortizationOfPriorServiceCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationOfPriorServiceCost" xlink:to="nlsp_AmortizationOfPriorServiceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertiblePromissoryNote_lbl1" xml:lang="en-US">ConvertiblePromissoryNote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNote" xlink:to="nlsp_ConvertiblePromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl1" xml:lang="en-US">IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:to="nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_MagneticRockInvestmentsMember_lbl0" xml:lang="en-US">MagneticRockInvestmentsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MagneticRockInvestmentsMember" xlink:to="nlsp_MagneticRockInvestmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DescriptionOfIncomeTaxDescription_lbl0" xml:lang="en-US">DescriptionOfIncomeTaxDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DescriptionOfIncomeTaxDescription" xlink:to="nlsp_DescriptionOfIncomeTaxDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ImputedInterestRate_lbl1" xml:lang="en-US">ImputedInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ImputedInterestRate" xlink:to="nlsp_ImputedInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsAdministrationExpenses_lbl0" xml:lang="en-US">PlanAssetsAdministrationExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsAdministrationExpenses" xlink:to="nlsp_PlanAssetsAdministrationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NetLossinBeginningAndEnding_lbl1" xml:lang="en-US">NetLossinBeginningAndEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetLossinBeginningAndEnding" xlink:to="nlsp_NetLossinBeginningAndEnding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsParticipantContributions_lbl0" xml:lang="en-US">PlanAssetsParticipantContributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsParticipantContributions" xlink:to="nlsp_PlanAssetsParticipantContributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NetSalesOfMilestonePayments_lbl1" xml:lang="en-US">NetSalesOfMilestonePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetSalesOfMilestonePayments" xlink:to="nlsp_NetSalesOfMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_GrossProceeds_lbl2" xml:lang="en-US">GrossProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_GrossProceeds" xlink:to="nlsp_GrossProceeds_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_UnrecognizedPensionCosts_lbl1" xml:lang="en-US">UnrecognizedPensionCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_UnrecognizedPensionCosts" xlink:to="nlsp_UnrecognizedPensionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DeferredTaxAssetsAbstract" xlink:to="nlsp_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AmendmentPriceValue_lbl0" xml:lang="en-US">AmendmentPriceValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmendmentPriceValue" xlink:to="nlsp_AmendmentPriceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BridgeLoanValue_lbl0" xml:lang="en-US">BridgeLoanValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanValue" xlink:to="nlsp_BridgeLoanValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BonusAnnualFee_lbl1" xml:lang="en-US">BonusAnnualFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BonusAnnualFee" xlink:to="nlsp_BonusAnnualFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_LoanFromBank_lbl1" xml:lang="en-US">LoanFromBank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_LoanFromBank" xlink:to="nlsp_LoanFromBank_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsBeginningAndEnding_lbl1" xml:lang="en-US">PlanAssetsBeginningAndEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsBeginningAndEnding" xlink:to="nlsp_PlanAssetsBeginningAndEnding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_CommonSharesToCreditors_lbl1" xml:lang="en-US">CommonSharesToCreditors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesToCreditors" xlink:to="nlsp_CommonSharesToCreditors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl1" xml:lang="en-US">BeneficialConversionFeatureOnRelatedPartyConvertibleLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:to="nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_LongTermDeferredRevenue_lbl0" xml:lang="en-US">LongTermDeferredRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_LongTermDeferredRevenue" xlink:to="nlsp_LongTermDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PurchaseWarrants_lbl0" xml:lang="en-US">PurchaseWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PurchaseWarrants" xlink:to="nlsp_PurchaseWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SwissGovernmentLoanDisclosureTextBlock_lbl0" xml:lang="en-US">SwissGovernmentLoanDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SwissGovernmentLoanDisclosureTextBlock" xlink:to="nlsp_SwissGovernmentLoanDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AdditionalWarrantsShare_lbl1" xml:lang="en-US">AdditionalWarrantsShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalWarrantsShare" xlink:to="nlsp_AdditionalWarrantsShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_WarrantOfferingPerShare_lbl1" xml:lang="en-US">WarrantOfferingPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantOfferingPerShare" xlink:to="nlsp_WarrantOfferingPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_WeightedAverageDiscountRate_lbl0" xml:lang="en-US">WeightedAverageDiscountRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WeightedAverageDiscountRate" xlink:to="nlsp_WeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_MrKonofalMember_lbl0" xml:lang="en-US">MrKonofalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrKonofalMember" xlink:to="nlsp_MrKonofalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_InterestCreditRateOnSavingsAccountsinDollars_lbl0" xml:lang="en-US">InterestCreditRateOnSavingsAccountsinDollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InterestCreditRateOnSavingsAccountsinDollars" xlink:to="nlsp_InterestCreditRateOnSavingsAccountsinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsCurrencyConversionAdjustments_lbl0" xml:lang="en-US">PlanAssetsCurrencyConversionAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsCurrencyConversionAdjustments" xlink:to="nlsp_PlanAssetsCurrencyConversionAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AccruedPensionLiability_lbl1" xml:lang="en-US">AccruedPensionLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedPensionLiability" xlink:to="nlsp_AccruedPensionLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl1" xml:lang="en-US">ProjectedBenefitObligationTransfersinAndoutNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationTransfersinAndoutNet" xlink:to="nlsp_ProjectedBenefitObligationTransfersinAndoutNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_MrCamozziMember_lbl0" xml:lang="en-US">MrCamozziMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrCamozziMember" xlink:to="nlsp_MrCamozziMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProceedsFromBridgeLoan_lbl1" xml:lang="en-US">ProceedsFromBridgeLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromBridgeLoan" xlink:to="nlsp_ProceedsFromBridgeLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationInterestCost_lbl1" xml:lang="en-US">ProjectedBenefitObligationInterestCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationInterestCost" xlink:to="nlsp_ProjectedBenefitObligationInterestCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_OtherComprehensiveLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherComprehensiveLossAbstract" xlink:to="nlsp_OtherComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_SecondCreditFacilityMember_lbl0" xml:lang="en-US">SecondCreditFacilityMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_SecondCreditFacilityMember" xlink:to="nlsp_SecondCreditFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_CHGBioVentureSAMember_lbl0" xml:lang="en-US">CHGBioVentureSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CHGBioVentureSAMember" xlink:to="nlsp_CHGBioVentureSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl0" xml:lang="en-US">RestatementOfPreviouslyIssuedFinancialStatementsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:to="nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NetCapitalLossCarryforward_lbl0" xml:lang="en-US">NetCapitalLossCarryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetCapitalLossCarryforward" xlink:to="nlsp_NetCapitalLossCarryforward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AmendmentShare_lbl0" xml:lang="en-US">AmendmentShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmendmentShare" xlink:to="nlsp_AmendmentShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_EstimatedTotalTransactionPrice_lbl0" xml:lang="en-US">EstimatedTotalTransactionPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_EstimatedTotalTransactionPrice" xlink:to="nlsp_EstimatedTotalTransactionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DefinedPensionPlanAdjustments_lbl1" xml:lang="en-US">DefinedPensionPlanAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DefinedPensionPlanAdjustments" xlink:to="nlsp_DefinedPensionPlanAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AnnualNetSalesPercentage_lbl1" xml:lang="en-US">AnnualNetSalesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AnnualNetSalesPercentage" xlink:to="nlsp_AnnualNetSalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PricePerShareUnit_lbl1" xml:lang="en-US">PricePerShareUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PricePerShareUnit" xlink:to="nlsp_PricePerShareUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_DebtDiscountOnRelatedPartyLoans_lbl1" xml:lang="en-US">DebtDiscountOnRelatedPartyLoans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_DebtDiscountOnRelatedPartyLoans" xlink:to="nlsp_DebtDiscountOnRelatedPartyLoans_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AccruedInterestPercentage_lbl1" xml:lang="en-US">AccruedInterestPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccruedInterestPercentage" xlink:to="nlsp_AccruedInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PeriodicPensionCosts_lbl1" xml:lang="en-US">PeriodicPensionCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PeriodicPensionCosts" xlink:to="nlsp_PeriodicPensionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_WarrantExpireTerm_lbl1" xml:lang="en-US">WarrantExpireTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantExpireTerm" xlink:to="nlsp_WarrantExpireTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_TotalUnrecognizedPensionCostEndOfPeriod_lbl0" xml:lang="en-US">TotalUnrecognizedPensionCostEndOfPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_TotalUnrecognizedPensionCostEndOfPeriod" xlink:to="nlsp_TotalUnrecognizedPensionCostEndOfPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationsPercentageRate_lbl1" xml:lang="en-US">ProjectedBenefitObligationsPercentageRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationsPercentageRate" xlink:to="nlsp_ProjectedBenefitObligationsPercentageRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock_lbl0" xml:lang="en-US">ConvertiblePromissoryNotesRelatedPartiesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock" xlink:to="nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:to="nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:to="nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl2" xml:lang="en-US">ProjectedBenefitObligationBeginningAndEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationBeginningAndEnding" xlink:to="nlsp_ProjectedBenefitObligationBeginningAndEnding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProceedsFromSwissGovernmentLoan_lbl1" xml:lang="en-US">ProceedsFromSwissGovernmentLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProceedsFromSwissGovernmentLoan" xlink:to="nlsp_ProceedsFromSwissGovernmentLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_OtherGainlossDuringThePeriod_lbl0" xml:lang="en-US">OtherGainlossDuringThePeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherGainlossDuringThePeriod" xlink:to="nlsp_OtherGainlossDuringThePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets_lbl0" xml:lang="en-US">ExpectedLongtermRateOfReturnOnPlanAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets" xlink:to="nlsp_ExpectedLongtermRateOfReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_FirstTrancheMember_lbl0" xml:lang="en-US">FirstTrancheMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_FirstTrancheMember" xlink:to="nlsp_FirstTrancheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NetPeriodicPensionCost_lbl0" xml:lang="en-US">NetPeriodicPensionCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetPeriodicPensionCost" xlink:to="nlsp_NetPeriodicPensionCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AmortizationOfPensionRelatedNetLoss_lbl0" xml:lang="en-US">AmortizationOfPensionRelatedNetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationOfPensionRelatedNetLoss" xlink:to="nlsp_AmortizationOfPensionRelatedNetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NonrefundableUpfrontPayment_lbl0" xml:lang="en-US">NonrefundableUpfrontPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NonrefundableUpfrontPayment" xlink:to="nlsp_NonrefundableUpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_WeightedAverageInflationRate_lbl0" xml:lang="en-US">WeightedAverageInflationRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WeightedAverageInflationRate" xlink:to="nlsp_WeightedAverageInflationRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_OtherTransactionPercentage_lbl1" xml:lang="en-US">OtherTransactionPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_OtherTransactionPercentage" xlink:to="nlsp_OtherTransactionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_NetOperatingLoss_lbl0" xml:lang="en-US">NetOperatingLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_NetOperatingLoss" xlink:to="nlsp_NetOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl1" xml:lang="en-US">ProjectedBenefitObligationCurrencyConversionAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:to="nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_WarrantPurchaseCommonShare_lbl1" xml:lang="en-US">WarrantPurchaseCommonShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_WarrantPurchaseCommonShare" xlink:to="nlsp_WarrantPurchaseCommonShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ReceiveNonrefundableMilestonePayments_lbl0" xml:lang="en-US">ReceiveNonrefundableMilestonePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ReceiveNonrefundableMilestonePayments" xlink:to="nlsp_ReceiveNonrefundableMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BackgroundTextBlock_lbl1" xml:lang="en-US">BackgroundTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BackgroundTextBlock" xlink:to="nlsp_BackgroundTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AdditionalValue_lbl0" xml:lang="en-US">AdditionalValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalValue" xlink:to="nlsp_AdditionalValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_CommonSharesRegisteredAndIssued_lbl1" xml:lang="en-US">CommonSharesRegisteredAndIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_CommonSharesRegisteredAndIssued" xlink:to="nlsp_CommonSharesRegisteredAndIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RoyaltyPaymentPercentage_lbl1" xml:lang="en-US">RoyaltyPaymentPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RoyaltyPaymentPercentage" xlink:to="nlsp_RoyaltyPaymentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PlanAssetsEmployerContributions_lbl0" xml:lang="en-US">PlanAssetsEmployerContributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PlanAssetsEmployerContributions" xlink:to="nlsp_PlanAssetsEmployerContributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PublicOfferingPrice_lbl1" xml:lang="en-US">PublicOfferingPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PublicOfferingPrice" xlink:to="nlsp_PublicOfferingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_RateOfIncreaseInCompensationLevel_lbl0" xml:lang="en-US">RateOfIncreaseInCompensationLevel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_RateOfIncreaseInCompensationLevel" xlink:to="nlsp_RateOfIncreaseInCompensationLevel_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl1" xml:lang="en-US">ProjectedBenefitObligationActuarialgainLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationActuarialgainLoss" xlink:to="nlsp_ProjectedBenefitObligationActuarialgainLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PaymentOfInitialCreditFacility_lbl1" xml:lang="en-US">PaymentOfInitialCreditFacility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PaymentOfInitialCreditFacility" xlink:to="nlsp_PaymentOfInitialCreditFacility_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ClosingValue_lbl0" xml:lang="en-US">ClosingValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ClosingValue" xlink:to="nlsp_ClosingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AccountsPayableIncludingRelatedParty_lbl1" xml:lang="en-US">AccountsPayableIncludingRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccountsPayableIncludingRelatedParty" xlink:to="nlsp_AccountsPayableIncludingRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_InterestRate_lbl0" xml:lang="en-US">InterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_InterestRate" xlink:to="nlsp_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PrepaidVendorOverpayments_lbl1" xml:lang="en-US">PrepaidVendorOverpayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PrepaidVendorOverpayments" xlink:to="nlsp_PrepaidVendorOverpayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_BridgeLoanTextBlock_lbl0" xml:lang="en-US">BridgeLoanTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_BridgeLoanTextBlock" xlink:to="nlsp_BridgeLoanTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_MrRoyMember_lbl0" xml:lang="en-US">MrRoyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_MrRoyMember" xlink:to="nlsp_MrRoyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_StockholdersEquity1_lbl1" xml:lang="en-US">StockholdersEquity1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_StockholdersEquity1" xlink:to="nlsp_StockholdersEquity1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AmortizationCost_lbl0" xml:lang="en-US">AmortizationCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AmortizationCost" xlink:to="nlsp_AmortizationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_EffectOfSettlement_lbl0" xml:lang="en-US">EffectOfSettlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_EffectOfSettlement" xlink:to="nlsp_EffectOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl1" xml:lang="en-US">TaxBenefitsMoreLikelyToBeRecognizedPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:to="nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_ProjectedBenefitObligationServiceCost_lbl1" xml:lang="en-US">ProjectedBenefitObligationServiceCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_ProjectedBenefitObligationServiceCost" xlink:to="nlsp_ProjectedBenefitObligationServiceCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_PensionLiabilityTextBlock_lbl0" xml:lang="en-US">PensionLiabilityTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_PensionLiabilityTextBlock" xlink:to="nlsp_PensionLiabilityTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AdditionalPurchaseShare_lbl1" xml:lang="en-US">AdditionalPurchaseShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AdditionalPurchaseShare" xlink:to="nlsp_AdditionalPurchaseShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nlsp_AccumulatedBenefitObligation_lbl1" xml:lang="en-US">AccumulatedBenefitObligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nlsp_AccumulatedBenefitObligation" xlink:to="nlsp_AccumulatedBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl0" xml:lang="en-US">Interest Expense, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl1" xml:lang="en-US">Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl0" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl0" xml:lang="en-US">Line of Credit, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl0" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue_lbl0" xml:lang="en-US">Additional Collateral, Aggregate Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCollateralAggregateFairValue" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl0" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl0" xml:lang="en-US">Defined Benefit Plan, Service Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncome_lbl0" xml:lang="en-US">Other Operating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl0" xml:lang="en-US">Subordinated Borrowings Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl0" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax_lbl0" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl0" xml:lang="en-US">Defined Benefit Plan, Interest Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoanMember_lbl0" xml:lang="en-US">Bridge Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl0" xml:lang="en-US">Defined Contribution Plan, Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Interest Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BankLoans_lbl0" xml:lang="en-US">Broker-Dealer, Bank Loan, Short-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BankLoans" xlink:to="srt_BankLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl0" xml:lang="en-US">Deposit Liabilities, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl0" xml:lang="en-US">Asset Retirement Obligation [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationsPolicy" xlink:to="us-gaap_AssetRetirementObligationsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl0" xml:lang="en-US">Prepaid Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl1" xml:lang="en-US">Convertible Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl0" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl0" xml:lang="en-US">Other Commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl1" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent_lbl0" xml:lang="en-US">Long-term Construction Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" xlink:to="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansFromBank_lbl0" xml:lang="en-US">Loans Payable to Bank, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl0" xml:lang="en-US">Subordinated Borrowing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl0" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl0" xml:lang="en-US">Other Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoan_lbl1" xml:lang="en-US">Bridge Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl0" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Payment for Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl0" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Revenue Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl1" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>nlsp-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:12:40 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedBalanceSheet" roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedIncomeStatement" roleURI="http://www.nlspharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersEquityType2or3" roleURI="http://www.nlspharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConsolidatedCashFlow" roleURI="http://www.nlspharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_Background" roleURI="http://www.nlspharma.com/role/Background"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RestatementofPreviouslyIssuedFinancialStatements" roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_OtherReceivablesnetRelatedParty" roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedParties" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedParties" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoans" roleURI="http://www.nlspharma.com/role/ConvertibleLoans"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SwissGovernmentLoan" roleURI="http://www.nlspharma.com/role/SwissGovernmentLoan"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BridgeLoan" roleURI="http://www.nlspharma.com/role/BridgeLoan"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiability" roleURI="http://www.nlspharma.com/role/PensionLiability"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_DeferredRevenues" roleURI="http://www.nlspharma.com/role/DeferredRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CommitmentsandContingencies" roleURI="http://www.nlspharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersDeficit" roleURI="http://www.nlspharma.com/role/ShareholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxes" roleURI="http://www.nlspharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_Relatedpartyconsultingagreements" roleURI="http://www.nlspharma.com/role/Relatedpartyconsultingagreements"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SubsequentEvents" roleURI="http://www.nlspharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_AccountingPoliciesByPolicy" roleURI="http://www.nlspharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RestatementofPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedPartiesTables" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesTables" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoansTables" roleURI="http://www.nlspharma.com/role/ConvertibleLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiabilityTables" roleURI="http://www.nlspharma.com/role/PensionLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxesTables" roleURI="http://www.nlspharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofrestatementinthefinancialstatementsTable" roleURI="http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertiblepromissorynotesTable" roleURI="http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable" roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals" roleURI="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertibleloansTable" roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofconvertibleloansTable_Parentheticals" roleURI="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofpensionplanTable" roleURI="http://www.nlspharma.com/role/ScheduleofpensionplanTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable" roleURI="http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable" roleURI="http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable" roleURI="http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofnetdeferredtaxassetsTable" roleURI="http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofincometaxprovisionTable" roleURI="http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ScheduleofeffectivereconciliationofthefederalincometaxrateTable" roleURI="http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BackgroundDetails" roleURI="http://www.nlspharma.com/role/BackgroundDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_OtherReceivablesnetRelatedPartyDetails" roleURI="http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertiblePromissoryNotesRelatedPartiesDetails" roleURI="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CreditFacilitiesSubordinatedRelatedPartiesDetails" roleURI="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ConvertibleLoansDetails" roleURI="http://www.nlspharma.com/role/ConvertibleLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SwissGovernmentLoanDetails" roleURI="http://www.nlspharma.com/role/SwissGovernmentLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_BridgeLoanDetails" roleURI="http://www.nlspharma.com/role/BridgeLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_PensionLiabilityDetails" roleURI="http://www.nlspharma.com/role/PensionLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_DeferredRevenuesDetails" roleURI="http://www.nlspharma.com/role/DeferredRevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_CommitmentsandContingenciesDetails" roleURI="http://www.nlspharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_ShareholdersDeficitDetails" roleURI="http://www.nlspharma.com/role/ShareholdersDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_IncomeTaxesDetails" roleURI="http://www.nlspharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_RelatedpartyconsultingagreementsDetails" roleURI="http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#nlsp_r_SubsequentEventsDetails" roleURI="http://www.nlspharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nlsp-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.nlspharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BridgeLoan" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermLoansFromBank" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableIncludingRelatedParty" xlink:href="nlsp-20201231.xsd#nlsp_AccountsPayableIncludingRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="AccountsPayableIncludingRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseOther" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DefinedPensionPlanAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_DefinedPensionPlanAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="DefinedPensionPlanAdjustments" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" xlink:href="nlsp-20201231.xsd#nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="BeneficialConversionFeatureOnRelatedPartyConvertibleLoan" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodicPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_PeriodicPensionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PeriodicPensionCosts" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSwissGovernmentLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromSwissGovernmentLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSwissGovernmentLoan" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromBridgeLoan" xlink:href="nlsp-20201231.xsd#nlsp_ProceedsFromBridgeLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromBridgeLoan" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" xlink:href="nlsp-20201231.xsd#nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountOnRelatedPartyLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnRelatedPartyLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="DebtDiscountOnRelatedPartyLoans" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountOnConvertibleLoans" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscountOnConvertibleLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="DebtDiscountOnConvertibleLoans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/Background">
    <loc xlink:type="locator" xlink:label="BackgroundAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundAbstract"/>
    <loc xlink:type="locator" xlink:label="BackgroundTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundAbstract" xlink:to="BackgroundTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements">
    <loc xlink:type="locator" xlink:label="RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:to="RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties">
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="ConvertiblePromissoryNotesRelatedPartiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SwissGovernmentLoan">
    <loc xlink:type="locator" xlink:label="SwissGovernmentLoanDisclosureAbstract" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SwissGovernmentLoanDisclosureTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SwissGovernmentLoanDisclosureAbstract" xlink:to="SwissGovernmentLoanDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BridgeLoan">
    <loc xlink:type="locator" xlink:label="BridgeLoanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="BridgeLoanTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanAbstract" xlink:to="BridgeLoanTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiability">
    <loc xlink:type="locator" xlink:label="PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="PensionLiabilityTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="PensionLiabilityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DeferredRevenues">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/Relatedpartyconsultingagreements">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetRetirementObligationsPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables">
    <loc xlink:type="locator" xlink:label="RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestatementOfPreviouslyIssuedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleLoansTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ScheduleOfConvertibleLoansTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiabilityTables">
    <loc xlink:type="locator" xlink:label="PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestatementInTheFinancialStatementsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfRestatementInTheFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestatementInTheFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidVendorOverpayments" xlink:href="nlsp-20201231.xsd#nlsp_PrepaidVendorOverpayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidVendorOverpayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePromissoryNotesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertiblePromissoryNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePromissoryNotesAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SecondCreditFacilityMember" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="SecondCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="SecondCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacility"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="SecondCreditFacility" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbkFwByFeAd1CbiLVeE/yzKbfnXGxt3NdGPWTzZARBRRSXHKdu0EOd9Wiveoa6fgONjezZcvQr4rTn/glV1bXlQheLUcNGX+YVCvk4DG1z+BRYQzar3rXvbB9tfBd1k0rmkxpFsHFIMQ4MMX/M+74YP7fe8dZUky/rws4lEB8X3p9n5l/DccxcESE+jmeJ+R0DMI668ciWZYkPoF34nCPND] CSR-->
    <loc xlink:type="locator" xlink:label="ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCreditFacilitiesWithRelatedPartiesAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SecondCreditFacilityMember" xlink:href="nlsp-20201231.xsd#nlsp_SecondCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="SecondCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="DebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleLoansAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_LongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleLoansAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfConvertibleLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleLoansAbstract" xlink:to="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsTable" xlink:to="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems" xlink:to="DebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofpensionplanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfPensionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanServiceCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanInterestCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedReturnOnAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedReturnOnAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="ExpectedReturnOnAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetPeriodicPensionCost" xlink:href="nlsp-20201231.xsd#nlsp_NetPeriodicPensionCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPensionPlanAbstract" xlink:to="NetPeriodicPensionCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationBeginningAndEnding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationServiceCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationInterestCost" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationInterestCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationInterestCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationTransfersinAndoutNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationTransfersinAndoutNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationActuarialgainLoss" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationActuarialgainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationActuarialgainLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationCurrencyConversionAdjustments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationBeginningAndEnding_0" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="ProjectedBenefitObligationBeginningAndEnding_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsBeginningAndEnding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsEmployerContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsEmployerContributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsEmployerContributions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsParticipantContributions" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsParticipantContributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsParticipantContributions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsTransfersinAndoutNet" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsTransfersinAndoutNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsTransfersinAndoutNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsAdministrationExpenses" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsAdministrationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsAdministrationExpenses" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsCurrencyConversionAdjustments" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsCurrencyConversionAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsCurrencyConversionAdjustments" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanAssetsBeginningAndEnding_0" xlink:href="nlsp-20201231.xsd#nlsp_PlanAssetsBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="PlanAssetsBeginningAndEnding_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedPensionLiability" xlink:href="nlsp-20201231.xsd#nlsp_AccruedPensionLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract" xlink:to="AccruedPensionLiability" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossinBeginningAndEnding" xlink:href="nlsp-20201231.xsd#nlsp_NetLossinBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="NetLossinBeginningAndEnding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="OtherGainlossDuringThePeriod" xlink:href="nlsp-20201231.xsd#nlsp_OtherGainlossDuringThePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="OtherGainlossDuringThePeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfSettlement" xlink:href="nlsp-20201231.xsd#nlsp_EffectOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="EffectOfSettlement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfPensionRelatedNetLoss" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPensionRelatedNetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="AmortizationOfPensionRelatedNetLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossinBeginningAndEnding_0" xlink:href="nlsp-20201231.xsd#nlsp_NetLossinBeginningAndEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="NetLossinBeginningAndEnding_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="PriorServiceCostBeginning" xlink:href="nlsp-20201231.xsd#nlsp_PriorServiceCostBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="PriorServiceCostBeginning" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfPriorServiceCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationOfPriorServiceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="AmortizationOfPriorServiceCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PriorServiceCostBeginning_0" xlink:href="nlsp-20201231.xsd#nlsp_PriorServiceCostBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="PriorServiceCostBeginning_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="TotalUnrecognizedPensionCostEndOfPeriod" xlink:href="nlsp-20201231.xsd#nlsp_TotalUnrecognizedPensionCostEndOfPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="TotalUnrecognizedPensionCostEndOfPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="WeightedAverageDiscountRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RateOfIncreaseInCompensationLevel" xlink:href="nlsp-20201231.xsd#nlsp_RateOfIncreaseInCompensationLevel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="RateOfIncreaseInCompensationLevel" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestCreditRateOnSavingsAccountsinDollars" xlink:href="nlsp-20201231.xsd#nlsp_InterestCreditRateOnSavingsAccountsinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="InterestCreditRateOnSavingsAccountsinDollars" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedLongtermRateOfReturnOnPlanAssets" xlink:href="nlsp-20201231.xsd#nlsp_ExpectedLongtermRateOfReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="ExpectedLongtermRateOfReturnOnPlanAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageInflationRate" xlink:href="nlsp-20201231.xsd#nlsp_WeightedAverageInflationRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract" xlink:to="WeightedAverageInflationRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfNetDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDeferredTaxNet" xlink:href="nlsp-20201231.xsd#nlsp_OtherDeferredTaxNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="OtherDeferredTaxNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxProvisionAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfIncomeTaxProvisionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BackgroundDetails">
    <loc xlink:type="locator" xlink:label="BackgroundAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundAbstract"/>
    <loc xlink:type="locator" xlink:label="BackgroundDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BackgroundDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BackgroundDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundAbstract" xlink:to="BackgroundDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsTable" xlink:to="BackgroundDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingUnits" xlink:href="nlsp-20201231.xsd#nlsp_InitialPublicOfferingUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="InitialPublicOfferingUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShareUnit" xlink:href="nlsp-20201231.xsd#nlsp_PricePerShareUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="PricePerShareUnit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="nlsp-20201231.xsd#nlsp_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="GrossProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPurchaseShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalPurchaseShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="AdditionalPurchaseShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="nlsp-20201231.xsd#nlsp_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="PublicOfferingPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalWarrantsShare" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalWarrantsShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="AdditionalWarrantsShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantPurchaseCommonShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantPurchaseCommonShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="WarrantPurchaseCommonShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantOfferingPerShare" xlink:href="nlsp-20201231.xsd#nlsp_WarrantOfferingPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="WarrantOfferingPerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncome" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquity1" xlink:href="nlsp-20201231.xsd#nlsp_StockholdersEquity1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="StockholdersEquity1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitsMoreLikelyToBeRecognizedPercentage" xlink:href="nlsp-20201231.xsd#nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TaxBenefitsMoreLikelyToBeRecognizedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AnnualNetSalesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AnnualNetSalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="AnnualNetSalesPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentPercentage" xlink:href="nlsp-20201231.xsd#nlsp_RoyaltyPaymentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="RoyaltyPaymentPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesAbstract" xlink:to="ConvertiblePromissoryNotesRelatedPartiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MagneticRockInvestmentsMember" xlink:href="nlsp-20201231.xsd#nlsp_MagneticRockInvestmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="MagneticRockInvestmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsTable" xlink:to="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscount" xlink:href="nlsp-20201231.xsd#nlsp_DebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="DebtDiscount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_SharePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterestPercentage" xlink:href="nlsp-20201231.xsd#nlsp_AccruedInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="AccruedInterestPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImputedInterestRate" xlink:href="nlsp-20201231.xsd#nlsp_ImputedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="ImputedInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ConvertibleLoansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_AdjustmentForAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SwissGovernmentLoanDetails">
    <loc xlink:type="locator" xlink:label="SwissGovernmentLoanDisclosureAbstract" xlink:href="nlsp-20201231.xsd#nlsp_SwissGovernmentLoanDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SwissGovernmentLoanDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_BankLoans" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BankLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SwissGovernmentLoanDisclosureAbstract" xlink:to="srt_BankLoans" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanFromBank" xlink:href="nlsp-20201231.xsd#nlsp_LoanFromBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SwissGovernmentLoanDisclosureAbstract" xlink:to="LoanFromBank" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SwissGovernmentLoanDisclosureAbstract" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/BridgeLoanDetails">
    <loc xlink:type="locator" xlink:label="BridgeLoanAbstract" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="BridgeLoanDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BridgeLoanDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanAbstract" xlink:to="BridgeLoanDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FirstTrancheMember" xlink:href="nlsp-20201231.xsd#nlsp_FirstTrancheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="FirstTrancheMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_BridgeLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsTable" xlink:to="BridgeLoanDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="us-gaap_BridgeLoan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateBorrowings" xlink:href="nlsp-20201231.xsd#nlsp_AggregateBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="AggregateBorrowings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalValue" xlink:href="nlsp-20201231.xsd#nlsp_AdditionalValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="AdditionalValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BridgeLoanValue" xlink:href="nlsp-20201231.xsd#nlsp_BridgeLoanValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="BridgeLoanValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="nlsp-20201231.xsd#nlsp_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="InterestRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmendmentShare" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="AmendmentShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmendmentPriceValue" xlink:href="nlsp-20201231.xsd#nlsp_AmendmentPriceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BridgeLoanDetailsLineItems" xlink:to="AmendmentPriceValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/PensionLiabilityDetails">
    <loc xlink:type="locator" xlink:label="PensionLiabilityAbstract" xlink:href="nlsp-20201231.xsd#nlsp_PensionLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedPensionLiability" xlink:href="nlsp-20201231.xsd#nlsp_AccruedPensionLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="AccruedPensionLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectedBenefitObligationsPercentageRate" xlink:href="nlsp-20201231.xsd#nlsp_ProjectedBenefitObligationsPercentageRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="ProjectedBenefitObligationsPercentageRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationCost" xlink:href="nlsp-20201231.xsd#nlsp_AmortizationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="AmortizationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedPensionCosts" xlink:href="nlsp-20201231.xsd#nlsp_UnrecognizedPensionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="UnrecognizedPensionCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedBenefitObligation" xlink:href="nlsp-20201231.xsd#nlsp_AccumulatedBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionLiabilityAbstract" xlink:to="AccumulatedBenefitObligation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DeferredRevenuesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="NonrefundableUpfrontPayment" xlink:href="nlsp-20201231.xsd#nlsp_NonrefundableUpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="NonrefundableUpfrontPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiveNonrefundableMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_ReceiveNonrefundableMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ReceiveNonrefundableMilestonePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedTotalTransactionPrice" xlink:href="nlsp-20201231.xsd#nlsp_EstimatedTotalTransactionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="EstimatedTotalTransactionPrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDeferredRevenue" xlink:href="nlsp-20201231.xsd#nlsp_LongTermDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LongTermDeferredRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/ShareholdersDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonSharesRegisteredAndIssued" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesRegisteredAndIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="CommonSharesRegisteredAndIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesToCreditors" xlink:href="nlsp-20201231.xsd#nlsp_CommonSharesToCreditors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="CommonSharesToCreditors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfInitialCreditFacility" xlink:href="nlsp-20201231.xsd#nlsp_PaymentOfInitialCreditFacility"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="PaymentOfInitialCreditFacility" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_LongtermConstructionLoanCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_BridgeLoan" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNote" xlink:href="nlsp-20201231.xsd#nlsp_ConvertiblePromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ConvertiblePromissoryNote" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfIncomeTaxDescription" xlink:href="nlsp-20201231.xsd#nlsp_DescriptionOfIncomeTaxDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="DescriptionOfIncomeTaxDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetCapitalLossCarryforward" xlink:href="nlsp-20201231.xsd#nlsp_NetCapitalLossCarryforward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="NetCapitalLossCarryforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLoss" xlink:href="nlsp-20201231.xsd#nlsp_NetOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="NetOperatingLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedpartyconsultingagreementsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedpartyconsultingagreementsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_RelatedpartyconsultingagreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedpartyconsultingagreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CHGBioVentureSAMember" xlink:href="nlsp-20201231.xsd#nlsp_CHGBioVentureSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CHGBioVentureSAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrRoyMember" xlink:href="nlsp-20201231.xsd#nlsp_MrRoyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrRoyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrKonofalMember" xlink:href="nlsp-20201231.xsd#nlsp_MrKonofalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrKonofalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrCamozziMember" xlink:href="nlsp-20201231.xsd#nlsp_MrCamozziMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrCamozziMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsTable" xlink:to="RelatedpartyconsultingagreementsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAnnualFee" xlink:href="nlsp-20201231.xsd#nlsp_BonusAnnualFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="BonusAnnualFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherTransactionPercentage" xlink:href="nlsp-20201231.xsd#nlsp_OtherTransactionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="OtherTransactionPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="us-gaap_SellingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VATServicesPercentage" xlink:href="nlsp-20201231.xsd#nlsp_VATServicesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartyconsultingagreementsDetailsLineItems" xlink:to="VATServicesPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="nlsp-20201231.xsd#nlsp_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClosingValue" xlink:href="nlsp-20201231.xsd#nlsp_ClosingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ClosingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="nlsp-20201231.xsd#nlsp_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="GrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpireTerm" xlink:href="nlsp-20201231.xsd#nlsp_WarrantExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="WarrantExpireTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseWarrants" xlink:href="nlsp-20201231.xsd#nlsp_PurchaseWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PurchaseWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesOfMilestonePayments" xlink:href="nlsp-20201231.xsd#nlsp_NetSalesOfMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NetSalesOfMilestonePayments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nlspharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nlsp-20201231.xsd#nlsp_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex4-6_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &@ S$# 2(  A$! Q$!_\0
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M*DXX!//<T'_@OU^P'"NUM1^*C,.0I\#6[2,I^8/D:^04P<;B1T]J_FO^$_\
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M%@L+B:]/%2XBEE=-U<'7GA,70IT\9D>']I5P6+C'#XETW4=.O4A0FHU%R/\
MJ7_X?\?L#!"[:C\4!@X*?\(+;"0\XX4>(B#C_>_^NG_#_?\ 8!S(BW_Q5>2(
MX>)/!,!D4?W\'Q !L'J#T[5_+/\ $/\ X)W_ !8\'_#;Q?\ %OPGXS^&WQC\
M._#G[2/'$'PZU&2_F\,_82RW@U/S45T^S&-Q(T:R ;#M)XKK/"?_  3/^(7B
M+X8?";XK:_\ &KX-?#_0?C>UG'\.;?Q7J%U:7VLWM^B26FDQS0V[+-<3!T50
MQ126'S5"\0/$^O&$L%E^!E"5&.(YI99A7"I0J3JTZ5>E-Y]R3HSGA\3!582E
M3E.A6BIN5*HH9Q\&?HV?4<-B,=Q#Q1D]>=7%TYTJN:XK'UIK#T8XJ]2C1X=J
MUL*J>#E]:_?4:2J8:7UB+E1BZI_3B?\ @OA^P(0"FH?%:7(5L1>";9RL; 'S
M#_Q4 Q& <ENN.<4T_P#!?;]@(;@-3^*)5!\[GP+;NJAONEF_X2 9#9RO&,8S
M7\NFH_\ !/'XE^#_ (P^(_@9\2_B9\(_A!XYTB338-"3Q-J5Y'#XQM=9:)+/
M^Q0EO.LD%RLZ_93(Z.59,@&J'[4/[ /C/]E"/6=/^(GQH^$]]XMT2WM+M/AO
MHUU./%&J6%Q"DMM=1I):F/:T#HX#2@E>:P7B-XDT8NMBL/E7LE)TXN&!P-WB
M.6<U22_UANY\E.K)TTG+EA)\K49-=F&\#/HZ5ZN#HX;/.,<VJYIA(XS 4:>)
MS/!QKX"K7CA8YMAL54X6A0KX*&)<<-]8I5IT'7J*E[95%R']3L?_  7O_8%E
M4,NJ_$\\E2I\"VP*D+N 93X@P,KRO4=.E)'_ ,%]_P!@EHUECO\ XIX<$A?^
M$#M5DVJ2"Q7_ (2/.._7D?A7\>W[-_[,7Q7_ &I/%^I>%OAO86ZKX>L/[=\3
M^)-3:.+1_#>FH@C,VHS!(HTB1CAF#%AC. !FO3_BI^P7\4OA]\+=3^,VA>+/
M 7Q>\ >&+ZXTKQ=K?PPU*:^G\/36LK"5[^.1 (HX9T,4S^64^\2=G-*?BAXE
M2P=3&PRJE*%.FZU*I3RJG!3I0J0IU*E.I3S3$RE3IN;52I3H5X0?NS<+MQ]:
MI]''P#P&.65UL?Q/+&UJM+#S57BN*67XC$P=3#4<9)Y-R82MB4E'#4<54P];
M$.<%1I5>:-_ZN!_P7^_8%9EV:O\ $YXV.TS+X%MQ$C=Q(S>( 5P>#A2 >YIK
M?\%_OV!@IW:G\4#EBFT^ [?#9P W_(P?ZML]3C(.>E?RB?LC?L%?'3]M2]\0
MGX86MEIVA:*XLM6\1ZW"(M+GF\LR&STX)''YE\$#%\!L ,V<"OE3Q;X6U/P3
MXFU_PQK+6TVH>'-;U7P]?S6DB-93-HTDT+/M:$RHDK0;6<)E0Q/:N;'>+WB#
M@\+@L16P=&A'&3A"C*M24(UFYTXS5)5'257EY]5&23U3G'64+ROZ,_@OF.9Y
MCE]#'<08FKE4:=3,J%'BJ&(G@:-9UE2GC*5'):DJ,:BH5U&-3EE4]E4BHWM?
M^V<?\%]_V",+_I?Q,^9<X_X0:U4 CHISX@&&/&T<Y)QFHA_P7Y_8(W$?:_B2
MN.Y\#6PSSVQKY.>_/'O7\PWPE_X)P?%/XSZ3X._L;XK?!?3_ !K\1/#\GBCP
MI\,M5U>2/Q7J<*63ZC:Q6\$2!29K>/S0DDD;E0<)NPI\S^$O["OQT^*WB_XM
M^'8XO#O@.T^#$-[)\4/%GC25H/#WAB&P#F[:XEC3,+1K'(^$$C[5^Z3Q7H1\
M2_$:45..64)0EM..4T''5)_$L]<5HT_>:T=]CR*7@+]'WVO$5'$YKFE"IDJ@
MXTZV9XRC47MY2AA6H5>'J<YK$S488=PA45>;4*+J2E&,OZR_^'_G[ ZM&CZC
M\4$$B[O,/@BW,,9(R$8IXA)#=L8X/>E7_@OW^P4RNRWWQ4.QB"O_  @T&\KG
M D4?\)&?W;<D-UP/NU_)O\6?V&OB[\%M;^$NCWESX7\1^'/C9=65E\/_ (BZ
M#=>?X-U9]095LVEN[I05,VX,"PBSR<"O0M>_X)P_%;3O _CWQYX4^(?PQ^)0
M^%EE+?\ CGP[X(U%KW5]"MH+>2\O#J 90J):VT,\TAC+HJQ/SQ@SA_$OQ0J4
M\Q4LMY:N6P5;%4GAI0GA</47/0K5Z7O2H4:M.5.=*<G*G.G.$J=6K!QJ24_
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MZ/\ B.?'/_/[AO\ \-%?_P"5A_Q*1X2_S<5_^),__G*?W'?\/^_V!?\ G_\
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M ,(2V_\ FAH_X?\ ?[ O_/\ _%;_ ,(2V_\ FAK^'';/_>F_[[B_^1Z-L_\
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M .;#SG)]#^G^-&3Z']/\:]&_X4G\:/\ HE?C?_PD==_QH_X4G\:/^B5^-_\
MPD==_P :/[ XC_Z%<_\ P"?_ ,B'^M_#G_0QX*_\23#_ /S8><Y/H?T_QHR?
M0_I_C7HW_"D_C1_T2OQO_P"$CKO^-'_"D_C1_P!$K\;_ /A(Z[_C1_8'$?\
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M?QH_Z)7XW_\ "1UW_&C_ (4G\:/^B5^-_P#PD==_QH_L#B/_ *%<_P#P"?\
M\B'^M_#G_0QX*_\ $DP__P V'G.3Z']/\:,GT/Z?XUZ-_P *3^-'_1*_&_\
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MKT;_ (4G\:/^B5^-_P#PD==_QH_X4G\:/^B5^-__  D==_QH_L#B/_H5S_\
M )__ "(?ZW\.?]#'@K_Q),/_ /-AYSD^A_3_ !HR?0_I_C7HW_"D_C1_T2OQ
MO_X2.N_XT?\ "D_C1_T2OQO_ .$CKO\ C1_8'$?_ $*Y_P#@$_\ Y$/];^'/
M^ACP5_XDF'_^;#SG)]#^G^-&3Z']/\:]&_X4G\:/^B5^-_\ PD==_P :/^%)
M_&C_ *)7XW_\)'7?\:/[ XC_ .A7/_P"?_R(?ZW\.?\ 0QX*_P#$DP__ ,V'
MG.3Z']/\:,GT/Z?XUZ-_PI/XT?\ 1*_&_P#X2.N_XT?\*3^-'_1*_&__ (2.
MN_XT?V!Q'_T*Y_\ @$__ )$/];^'/^ACP5_XDF'_ /FP\YR?0_I_C1D^A_3_
M !KT;_A2?QH_Z)7XW_\ "1UW_&C_ (4G\:/^B5^-_P#PD==_QH_L#B/_ *%<
M_P#P"?\ \B'^M_#G_0QX*_\ $DP__P V'G.3Z']/\:,GT/Z?XUZ-_P *3^-'
M_1*_&_\ X2.N_P"-'_"D_C1_T2OQO_X2.N_XT?V!Q'_T*Y_^ 3_^1#_6_AS_
M *&/!7_B28?_ .;#SG)]#^G^-&3Z']/\:]&_X4G\:/\ HE?C?_PD==_QH_X4
MG\:/^B5^-_\ PD==_P :/[ XC_Z%<_\ P"?_ ,B'^M_#G_0QX*_\23#_ /S8
M><Y/H?T_QHR?0_I_C7HW_"D_C1_T2OQO_P"$CKO^-'_"D_C1_P!$K\;_ /A(
MZ[_C1_8'$?\ T*Y_^ 3_ /D0_P!;^'/^ACP5_P"))A__ )L/.<GT/Z?XT9/H
M?T_QKT;_ (4G\:/^B5^-_P#PD==_QH_X4G\:/^B5^-__  D==_QH_L#B/_H5
MS_\  )__ "(?ZW\.?]#'@K_Q),/_ /-AYC=Y-K<  Y\I\#@Y..@ )/Z5_HI?
M\$R6(_86_9M&,8^'-FIR.<C5M8R"#W&>1[CI7^?M<?!7XT+;W&/A5XV9VBQ&
M#X5\00N7WH?W3HZGS H8J.1@$XX&/] __@F_:7VE?L1?LZ:;J%E>Z=?VO@-(
M-0TZ^AEAO[2Z&KZH66\CN29D/J&(;D$YXK]O\"LIS;#<18^>+H2P\5A87@U)
M*UI)/5+XK_AH?Q_]+[B3*,RX5X;P6$KY76DN((3YLKQM/'8:T\OQB:]M"K5_
M>)I<\+^ZW'17/N78/1OS7_&BF[&]/U'^-%?UKS2[O^OD?YX_5J?\[^]%][6V
MD5U>W@99%".&BC(=5SM5@5.X+DE0<@$\52&B:2H(73K, ]0+:$ _4!.>IZ^M
M:E%<3I4I-RE2IRE)<LI2ITY2E'^64I4VY1_NR<H_W3NC5JP34*M2"=KJ%2I%
M.VBNHU(IVZ73MTL9O]D:9L\O[#:[,YV>1%LSC&=NS&<<9QTI%T;2TSLL+1,\
MG;;Q+DCH3A!6G14/#X=[X?#O;>A0>VV]%[=.W2Q7MZ^J]M6L]6O;5K-]VO:V
M;\VF4$TO34Y6PL\Y)W&V@+<XS\Q3/.!WJ;['9X*_9;;#8##R(L,!T!&S!QVS
MTJS13]A0T_<4--%^YHZ+LOW.B\E9>0G6K/>K5=MKU:KMZ7J.Q2.G6!&/L5J/
M=;>)3],A <>U1_V3IN[=]BMMPY#>3'N!]<[<_K6C12>'P[=WA\.VFFFZ%!M-
M;--T6TUT=[KHT'MJW_/ZK_X-J_\ RTSSI.G'.;.W.>#F&,Y'H?EYI!I.FJ$4
M65L%CSL AC 3/78 N%SWQBM&BG]7H)MJA03>[5"BF_5^QN_FV'MJVWMJMNWM
M:MMK?\_>S:]&UL[%/^SM/+!S8V;.%V[VMH2^WTW%,X[XSC-1MI6FN26LK4D]
M?W$6/RV5H44>PH6M["A9VNO8T;.VUU[*SM=VNG:[M:[N>VK?\_JVFW[VKIZ?
MO="FFG6$8PEG:@9S_J(NN /[GH*<;&Q8Y:SM6/J;>$G\RGL*M45/U;#:_P"S
M8;7?_9\/KZ_N-?G</:U;W]K5OW]K5O\ ?[2_XF?+I6F3+LDT^R==P?#6L!&Y
M>C<Q]1V/44/I6G/MWV=N^PY3?#&VP^JY4[3P.F*T**%AL,K6PV&5M5;#X=6;
MW:M05F[*[5F[*][#]M6T_?5M+M?OJNE][?O=+];6OUN9G]C:7G=]@M,^OV>+
M/Y[,T'1M+)!-A:$CH3;Q$CZ'9Q6G16GLJ3M^[I^Z[Q_=T_=?>/[OW7YQL_,/
M;U_^?];M_&K;=OXNWD9G]C:5_P ^%I_X#Q?7^YZ\T?V+I6)!_9]IB4;91]GA
MQ(HX"R#9AP!QALBM.BH>'P\OBP]"6M_>H4):WO?WJ+UOK?>^M[ZA[>O_ ,_Z
M_P#X.K=&FO\ E[T:379I-6:36<FDZ;&H2.RMD11@*D,:J!C& JJ !CC '3BI
M(]-L(SE+.V!'0^1%QZD?)P3WQC/>KM%/V%#3]S1TV_<T=-;Z?NM-4GI;5)[I
M,3K5G>]:J[[WJU7?UO5=]WO?<IMI]@PP;.U&22<01 Y)R3D)GD\GU[U"-(TP
M8Q8VHQTQ!$,?3"5I44I8;#334\/AYIZM2P]"2?752H23UUU3U#VU;_G]6_\
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MB'PY/#;ZI9&"X16(MY9E3S5+)(?F0XX'KD\ABAED4 LJ,4#?=+XP@8C!"EB
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M_P#VS+>Z%HFB>38^(8M6MTDTXH8RDI6O ]6_X(Z?M-_L_P!Y^SAX]_9=\5_
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MKY*_XFB"26'H?\:=3%ZO]?ZFGU,&W%-ZO7\V:2T?R7Y(****H04444 %%%%
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M\3LL4:%UCE#^5&0N/)0JI96DQND8E&M75 D<<2*059+=8X4&\X+J&4D%0 2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHI#R#]#0#V?HQ:"0.I ^M1JI!R>,
M?KUJ(@$8_P YINU]'?S%3O-:KE>O]:V+-%-0851[4ZD,**** "BBB@ HHHH
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MK^T+^P!\3_$WQ?\ $.MZYX_^(4G@KX@:%XYTBW\,+H6@:S?:G'H^JIX>DO\
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M&VIV)^'/@TZQI:7'V>7P19>(_AXVK6UY=Z>]S9OK5U)]J6QFBB7YI^"_QO\
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MW?!OQ+IC3^&D\(P:19^#;2.*WBMGETR.Q$DU]#-(3.L;K\K_ !-\>?'3PO\
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M-6^&WC[P1KOA2*Y\=>(IO!MEJZ^ K#^S]?N[/2M4$NBC6F>Z65KD);#;[?\
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MUJ%[X?\ #5[J-T9)KB71=.LB[2O[8_6S[0/[TWUVC_#'Z4];L  ;IN/0+_\
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M\,P/O/VL^EQ_WRG^%'VL^EP/P3_XFG[*I_*_P_S*]W_GY1_\'T/_ )<> O\
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M+"2S3&8PPH;MISY.\W9FP+>)5P!BO=OM?KYX^H7_ .)I/MB[<EIEXR0WEJ0
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M?\]B.YS'P/7&.G2M.2K.4Y-7G4G.K4UC?GJRE4G?WK7<IMNVE]@O'_GY1_\
M!]!?^YCP9O@/"\*6S^*;WR(;LWEND=I81&&00I#$6:.V5KAX0':.6X,DH,CC
M?M(%3S?! SHD<OC#5I%B39"7\AGBW'=<;',9=4N6$;2Q!O+W1J0N<Y]S>\";
M<-,Y<';L"OSZ-A01]3Q^&:07F1AA.I_VE'3U^[C';')_G64GR?$I?*$Y?^DP
MD+VB46E5I<C>K5>C:[3LFO;7U2?3H>$/\#4>\%\WBW4A<)Y+0M&884BEM[=[
M6)A'%&D;1B&1P]NZM;RR.\LD;2L6IZ_ R'<KS>*M4G8)$DC2-'NG$('E1SL$
M#36D;!6BL)"UG%M"1PJG%>Y"X7GYY3]5'Z8'7_/&*D%R. &F( Y("XR.W3.?
M;\Z(OG3<5*T5=WC*-NGVXQOKVN_(B#I2;<*M&3DD[*K2O:RDM'471I];;.SN
MCPM_@>)#<._BW4VENA&)F*6XA#1RRS&:"U$7V:UNG>9E>ZMXHYS D%L9#;V\
M,:0M\!K5YX[B7Q-J$SQK(JK*D$D.9 ?WGD-&8A*KR7$@E""3,[J6*J@'O'VY
M,E2\P8?PD+GGG^[Z<_2A;QF!)6Y7YL#*KDKQAA\N,'/KVJU"37,DVKI??V6[
M]4FEU94)TZG-R5:4N23C+]]23C)2<6FG53TDFKI-:;M6;\'3X#6<8M577V"6
M"+%8H-,TH+;0_,\D6/LG[U9IW>XE,V\O*Q+$@ "POP06,&./Q=K*6S!3)9B8
M&U:5E_TB18"#'']ID+2LD:JD;L1$J XKW+[4/[TWM\HY]ON_Y]J#=*>-\O\
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MJ,7",I37M:=U&$%4DVE-Z*#4FU?MOH>"?\,^Z;_T,%Y_WZM__C='_#/NF_\
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M8_6T?(S*,[3N;=VW'MSSGOCGC]/Y /\ @Y"$B_&3]G0[?O\ @_QW(-PP=O\
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M&_>-O_!II7^-'_$2'\(/^C?O&W_@TTK_ !K^2(F< DKP.O3C]::7E'4 9Z9
M_P :A^-7&45>3HQ5[7E**5]K7=9*]]+7O?2Q<?HD^$L_@X<QLM.;W<PE+W6K
MI^[&6EM;[6UO;4_K>_XB0_A'D;?@#XW5#G<O]K:6 WIP 0<9[TT_\''WP?VL
M(_V??'!;@G&L:4I(##(S@<'K@>OUK^20^=P2G7H2HYIT9<!\J!P.2/\ :&><
M_3BN?$>-_&U)TU%TN64HJ3^RKM6YFIM*Z=]9+1JUTS"7T4/"1XBA%<.XQJG"
M3369-ZIR?NNVEFFFEJG>]NG]C/AK_@O]\+?$G@?XF?$!/@?XQLX/AK:>'[F^
MTW^T=)>>^3Q!XETCPU"8I]I3='<ZO#,P)XC1^*\_'_!R)\(SG_BP'COC&<ZO
MHI'/KA 2/7!S7\W7PR=A^SU^U>?E_P"0'\,\=/\ HK/@;'ZCN?;GK7S/YKA7
M/RCF/^[SR,?7Z<G\Z]/$>,?&E+V"C*D_:8>%9J,D])RFKZ5/A]W?;I=GG95]
M%?PGQLLQ<N'L:G1S"K14?[2E&T(4:+4N6U[-MWELVF[K4_K@_P"(D/X0?]&_
M>-O_  ::5_C1_P 1(?P@_P"C?O&W_@TTK_&OY'_-D]5_3_&E$DK#( (Z< =?
M2N1>-7&35TZ+5[74HM75[K2L]59W6ZL^QZZ^B5X2R5X\.XR2[QS&36F^JBUI
MZG];_P#Q$A_"#_HW[QM_X--*_P :/^(D/X0?]&_>-O\ P::5_C7\D.Z;^[^@
MHW3_ -W]!_C3_P"(T\9_].OO79/_ )^]FGZ-/9IM?\2E^$=^7_5[%\W\O]I/
MF^ZU_P #^M[_ (B0_A!_T;]XV_\ !II7^-'_ !$A_!_O^S]XV_\ !KI0_P :
M_DAWS>GZ#_&FM)(!EMH&1R<8R3@=3W)Q^-'_ !&?C1Z)4V^R>O\ Z=?Y%2^B
M3X3P7,^&\<DE>[Q\UT3W<+;23]&GLTW_ %P_\1(GP>_Z-]\;_P#@VTG_  H_
MXB1/@_V_9]\;_P#@VTG_  K^2!A,@!:, ,=JDJ.206 'J2 3]!FD_>G^ ?BH
M_P _ES0_&?C5;JFO65OSJ(YW]%7PAY7+^P,59:-_VHK)W:2;V3<DXI-W<DU:
MZ:/ZWC_P<B?"+O\ L_>-B1ZZMI?^']*U_#7_  <0?"GQ?XBT'PO;_ +QG;7?
MB+6M%T2%YM5TF2)?[8NY+.5G('RQQM]F)&06#DCA&Q_(5^]Z[!^0_E_C^%>D
M?!IF'Q>^&)(7_D?/!V0,9XUN ?7/XX^HYK/#>-/&U;&PP\O9JG-I1E=J,KO[
M,G/E=_)O0X\P^BOX3T,!/%PX=QLI0BW)?7W)1LG\22=K;ZV?ST?]6'B3_@XC
M^$WA+Q!K?A>?X">,KF;P]JVH:-+/%J>E)'(^G74MJ610  @,6%QU !YSFL7_
M (B1/A#_ -&^^-?_  ;:5_A7\LOQ?9_^%K?$@ +_ ,CQXHP, G_D,WGOFO.P
M922H52P&2,#(!Z''OBMJ_C/QE1JU8N5%1A5J4U)SBE>,Y1M=U4KZ;7OY&N#^
MBQX1U\)AJ_\ 8&*?M*-"4FLR32G4I0ERMZI2;>D6U)]C^MT_\'(?PB/ _9]\
M=="<QZQHZ_F'')],>O;K7H7PW_X. /A;\2=8UO1;+X'>.-.N-$\'ZSXRE:XU
M+1[E+FQT66QAN;1$B4L)I/MZNAR.(V&.:_C@!DW!2H!96VC&"<8W8Y&<9&>>
M,U],?LL,K>/OB"KK$Y7X"_$/#,>89!<^'<2H1TD4Y"CL"WX].#\8^,Y2;;HW
MFKQ3=W+3>/[Q\WK%/RU,<T^BSX486A&HN'\P2Y93J/\ M*2C3IQG%2G/W+0I
MIRBI3FXP3DDY+FC?^E#2O^#BGX6ZO-=+H_[,_P 2M1>U$<EREA=V$ZPP2MMB
MGGCCC;R0YQD.H*YP>E:EY_P<.> =/M[6]O\ ]ESXHZ=IUZ9DM;^_EL[6SFFA
MEE@D1;B:%(B5:)R5!SL D^Z03_+?^S+XT\7^$?BY\-'\-^+?%GAP:IXZ\)65
M^^B:LUHU]:RZG#&T5UY$JW"VTBN8W"E0R,R-\K$']L?VH/AQ;_M-?\%/?&/P
M*^(GQ!\31_![2_AEH7CAO"%EK!6TUK6M$\-"X.FZ4#)YMI=W\\DC7"6ACGE^
M=AD@$?297Q]QMFV58W&4L[I9=6H9@L+]6CAU7G/FH0J^U=E.<=9<BBH[)RM<
M_-.*O [PHX8SK"9?5X5Q\\/B>&LRSJ4UCJCM6PF+P%"G22Y%!NI#$5917.IN
M4'9.*G*/V#_Q$??"51;;_P!GCQVIN!<M&#JFF ,MM)Y;.."55R1) Q $T7[Q
M,J<TC?\ !Q[\)]K%/V>?'D:IL>25M5TU42-^59F"@*KC#*3P00>G3X?^!'[,
MO[.JZS^RC\?8/ J^&;KQ3\>O&OPFUKX3>,/$&HZU8>)=.\/&XBL?%EO:>(;N
MZ$J:=:FWM+Z)%,<=RRQR*'.*^?\ 5?@1X5^)?[1O[5FOVGP?\&:1\&_@IXTF
MT[Q1J.H^+O&>CZ?8Q:EKNH0QWOA_3[/5;>YN9[E4/^BV:/IUK(!;V\4<:JH]
M&?&''5.GE+_M>GF;Q6(K0JT_J\J7U>$*,:D:M1VA[L[RC%5.7X;J[O;CP_AA
MX+/-<SI3X3Q]+!Y5B\31E6GF"IPJI9YF^4T:=.HXQC5E.&"P\X2HRJPE&I"<
M9<E6E.?[%:#_ ,' ?@[Q7IOB/7O#?[*OQ5\0:3X1M8+WQ-JVBR65_I^AP7&[
MR7UB\@CDALU=%WIYK(2A#=#7/V__  <=?"B]N+:SM/V=_'MU<W3PPV=O;ZKI
M<TUT\JL5-O'&K-(B!29&4,(^-V,UX/=?LY_#?]FGX=?M[>'?A/JM_P#\(1X\
M_94^$'Q&TNPN+R[EBT.[UT:RET9;B_D>[N/MMS;330"YDDF2&1+<G$05?@'_
M ()A:5I*_"+]L+Q]X<MXK_\ :"\'?#/39OA?#!:_VCXATVSE6\MM3U+P[I,Z
M30B]589IQ<6=N+[:BNTGEK%M=;C?C2EG5'+<-B\![2>$Q5?EJXC#J*="E";2
MYL2KR:DN5/5R;5NAY^"\*?"C%\)YMQA2X1S&-'!XKAC#2POUJLJW-GV59=BG
M4J4G152$*>)Q-:,ZCI<L5"2<E).WZ]:C_P '%GP[TDQC5/V9/B;IZ>?<0^=>
MSVEO YM]IE:.:6)4*('0LY;;B13D!@:H1_\ !R+\&MK2W'[/OCU+<"-S+'J^
MD(%$Y;R0S2*4_>!&8#AB@##Y3S\)>"/V8M8^-/@S]C&3XS_&_P 8_&WX4?'7
MQSXRE;PYXJMY-.\;>%]8T.QT_3=?@M_$MY'#K=O9R:AIHVV<5VL.T*R1@9SX
MEI7[/G[(WB2/]JOXB>'OA+XHM]._9@>Y\*VOPXU7QIJVJWGB;Q<OB/5M-U#Q
M1=ZW;ZA)JL.EW5A:Z>B61NELH,8DC!*US0XR\3*\JZ=7+J;BI>R<Z]"$I6O*
M\;UTI-+9)RT=DG8]2?A=X)T[R?#>9PC2K8N%>M@<>ZU:A['BS,\B@Z45"4O:
M.EA*<H.4$G&7M)-0G%O]9A_P<>_!=F94_9U^*#A71"Z:GHK1D2V\5S!('";3
M%<Q3*;>0';,5D$9)1L!_X.//@P(Q(W[.WQ/B5A(P:74]%C"QH2IG?<@VP%@=
MLK81\?*37YOZK^Q#^QOX+^)6D)XR\8P^"_#'C_\ 9Z\ _$OPGX.\:>)+^'P=
MX7^(GBZ"Y:7PUXH\1W5T+JP@M_)@F\/P/>1336\X:V!0BJ=O^Q5^S1X9^)_C
M;PO\8X?!_P /+U/!?@N]^%>IZAX]\13_  K\<^)/$EDMQ%KL_C&+5FU&PCO/
M,BB@T6'4HHF*@I!B3)'Q3XI1O?%9?:-^;_:J'17L_P!_HVD[;7]0AX=> M1+
MER_CSWHJ<;N?O1YN64TEA9.4*;_BM7Y%J^:+3?Z0K_P<??".:>W6#X"_$D0-
M=06M]-#K.B,;,W"0R0S7**F8;>9)4>.=@(Y V0>#7H'Q*_X.!?A-\-/%]QX.
MU7X&^.-2O;+1/#6LR3IK.BXMSXH\/Z9XBLX!*!B8K8ZI;"21"RJY93AE(K^8
M_P#;$^#,OP'^.\O@5]"M/#,NCP>'M0TVST[Q%>>++.ZM+JTL3+J^A:SJ=YJ%
M_9Z5.X8KHTURKV6"GE1G@8/[7,7E_'OQ(@C+!?!WP="L-SJ1_P *G\%X*LV6
M<8'#,69N&)R<GY^MXL\7X:_[R@N5V?[R.FZ:;53ONGZ]C[3#_1O\)LRPN65<
M-/'<M=*2=ZCC*,^649).E&[:VDFK*ZMKI_3%9?\ !PSX!U"">ZTW]F?XJZO:
MQRF&2;3I;2\BCN%4-+'OMX73>"PX')/3-0ZO_P '#GPQT1$37?V9/B?HYFCM
MKU%O[BPMI9(K@E4G6.6-6,(92LTF"(F5@Q!4BOQF_P""27CWQG8?M9>'/ \/
MBWQ';^$+_2/%&J2>%XM6OCX?GFBMY 9GT]9OLEO=?:$>12(T>5V\[)+EC?\
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M:_XEUJ]L/'VF+JUB->L;[SKUS:'Q#:_:([2#3C#!/YR@HR$@]=^UA^SUX/\
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M[F.>)$9H6@6W=)@ZKLDVQG#,HKQO]C[]F/X,_"OX]?LL_&7X6VZV"_$;P_\
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MXTEQUQAA\TP&%Q/%5)P;E"LW@4HJ5.//.,GRQ7-&FO:5(MQ<(:R48^\?,?\
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MC&N'>-:^35\M56AE\ZN&]JKN4UA^&,RSYN,>6TG?+(JW.F]]+:_S1=>1R/\
M/>C_ #^A_EU_#FOU9\,?L_\ P>^('CSXU:QX&^#>E^%O@G^S]K-OX5\>:C\5
M?B+XD43Z_-XMO-.MVTW2]"U3^T+J35;6W\ZT6:%[ RVZ/.-Z0D?3WB#_ ()]
M?LR>"?B#^U)?7VC^(/$G@GX?_LU_#/XW^"=,MO%^N6ITO5?&5]XLM=6M)KF.
M]2Y-I,-*MELQ>.3':EX\#=BO.CX?YO\ 5:=>566(O1QDE5;;O'!95GF9))OI
M%Y,[:K6VFIU8_P 9>%:.8U,+B:><8>LY9>Y4<"YJA%YAF>1Y<E)4Y**K2CG2
M<UJVG&[V3_ 9R-K>ZD],G&"<@#)/'3UZ"NFU_P  ^-O!UAX>U/Q9X-UG1++Q
M+8C4O#>IZWI$L-IJVF$X%WHYDA5)SW#(6.<=,U^WNL?\$]?V;+778OB3_9?B
M6;P''^QAX,_:"D^#UCXGUF75;SQ3JUSXCTORK3Q&MV;H:,JZ=%++IL=WLB8R
M2O$-V3X3_P %0[O3]0^!?[ 5WH>C/X6T^]^!VJSV6A27+S'2[;^V,+9_VE(S
M2Z@RJOW)992>HZ\]M;@3%97@L=C\5BGA7A<;0P5-/W>=5J&#K2U;5N5XQ;7U
M=CERCQAPF:Y]PY@N'\-F.*AF]>I@L9+'N;=.=2CFU>@J*ES.2G'*9^T2Y4FH
MRU:LOR:>QU.'R[U[#46M;HA+:1[>1!(6!"$ IC>>/D&2#D8ILMK=64C6U[')
M#<QD&2.92DB>8!(@96 ()C=",@<$8&#7]3'P]A^''CG]E_\ X)X? #QS;6%E
MJ?Q+TG4/%7@KQ'<".--/\:^!/%JS64+N<*LFIZ??2V[H3_S#H@1]T5\V_M2?
MLX:-XY_;1_:I^(_Q$\+>"+GX1>$_B'\*?"FI>*==USQ!H\T&N:O\/?!\=W8Z
M;:>'+B"2\U6=Y1<17,J.J"5(]ZB/ [LP\,<=1I96\!BI8FIF=? NI!:VIXRM
MAL/.32DW92Q<(W:LT[WZ'B9-XZ7S;&8+.<+'!T/99W7IMROSU<JSJ&4T4GR0
M@YU8NK:*DW&:4-?B?\^M)GL2,_Y[9K]T/%/[!?[.OPV\9?ML1:CX>UOQ7X6^
M"/@;X:^// >F2>(=;T][5?&D5S=W^D7FJ-=17-T\DB_:X);J9Y?(N8HMVV)5
M'5W7[ W[+^J?$WPQ\-M+\$>)],F^*'[(4_[0>DZK>^)M4U >$-7CLI)5TC3(
M[ZZEAU$1O$\ES!()51)86"@2Y;A7 69Q>&H67MZ]+"8F*ZWJ3X@F^E]5P[)K
MRLSTUXZ<,U(RK3<TH1<D^3HHTI.[YM.55HI]I0J1WA=_@*#Z'\O3M_(_E1V/
MNKX]^#7[1+^R+^R'\(?A'^SSXE^+^KZWK</QG\%:CJ\WBO3+/Q9<ZY9:M!))
M'IVAZ'H7AI&TJ>73IVF-[I\ML\DS7"N48-D_CEXDL++2/$WB72-,,\&D:;K^
MMVVE7&L6L^EZG_90NI#I%F^GWZ0W.GW>H6A2XNM-6*)EE8EX@:\+,N'\1D=>
MGA\5\=*K"%NM\$X:VUM=<0IW\VM&FE]UPUQOEO%N'QRP;;C2PM>2DXM0E:&)
MIVC)VO*,Z3YHV32<):PG%OVOXK_\D6_9=_[)SX[_ /5K^.J^?Z^@/BO_ ,D6
M_9=_[)SX[_\ 5K^.J^?Z\K,M_N_*)])DO^Y+UE_Z6RB_WF_WC_,U^O?[%$S6
MG[$'[85Y\*(KG_AH*W:U\B\T6&X;Q?IO@BXTNUBN+WP]-$/-B43)=!I;4@B9
M) QWJ:_)*M[PKXE\4>#M:76_"7B/Q'X:U5(CLO?"]Y+IEX,9 $]W"\3.,#Y=
MTAVJ0!TP?2X:SE9=CL71:34\-*+5[:RI63]4W?;ITNFOG^.,@EQ+EN#R6$G"
M6%Q5'&W2;35.O&O*$DG%\M1-PE9WU3U2<9?JG^S)\'_%WQK\.^*_%W[4VD^,
M/'FI_!CX%7WBGX#>"?&USJIU3QS%;OJ%I<13/%(NJZUI<5S92W L=TZ1WDMR
MXC#,2?J7X=_L0?LS>+?%/P8UC6? RZ-K/Q<_9>O_ (F:E\)+J[U$1Z)XLL-#
MGN[:Z@^T2F^L8]\<1M].G=!%(&(B5V)K\)I?BW\5[WQ'9^-9?B/X\_X36R1K
M:P\43^*M5FU:RM1,\WDVVJK=,E@/->23894&]V;'S9J%OBA\4W\4+X[D^(7C
MV3QWN>-?%TOB76T\0(BCYGDU%+KSA$5XBNEDV2$?*Y(S7U&$XLR6CAX4\3P]
M#%UZ<K5<3*G&3K2>7<2/G<G3E>RE&"NVK078_,<R\/>+JF*G+ <:5,KP<G36
M&P-.K.G#"0A3ITW24(UX6YIPG6G**A)SJ2:=I'[E?L]?L*?LV>++;]C>V\>?
M"]+FY^*'P?\ B/XD\:V]_=ZG#-J>M^%-"N;W1?M<;RKM%I/"C1;P"XPO(QCH
MOV=O@;\ H?$'_!/#X]^&?ACX6\,:K\9OB9\1/ GB3P[/<7=[X;G;PSJFH6-A
MJK0W$LENVMJMO&\43J6,VU0I.*_"F\^._P ;M2U"RUS4/BU\4]8U'3K:\M--
MU&X\9:[JEW9V=XABU.S^VW=Y*(K2\B+17$/F /&=NT\UR \;_$""PT33X/''
MBY=)\+7\VK>'5;Q#>BST[5+R9KF:]TT1W :"^BG=G26$+(L@R#G%:RXQR9./
MLLDAAHJGAW[/V<5>7U7")R:Y$VY-7U\]]6[J^%?'>)FJLN,*^,ISA4O5^L5[
M1C5RGB/*(44_K#LJ./XCRC'*SB^;*H5/=<*;I_M1=?"WX#ZM??\ !17XQ?%/
M]F_2&U/]G_XA:M<^%_"=I-J'ANSU-+?5YI(]0N[OS;6(Q3X\T!7QM;Y< @&7
MX!_LF_LV?M3?#?X;_M'^'O!.A> O"7PX\5>+9_VE_"UMK]TUE%H6BB[U33K=
M9;J[;40+JU2 *%D!VN!R.GXWZI\8/BAKD>MVVM_%+X@ZO:ZQ;+;:ZFM>+?$$
M]WJ]N%VBVUO?>,;FQ"_(B/N'EX %>M> OVIO&7PY_9\^*W[-_A72])TC1_BY
MXDMAXD\9M=:D=??3U$0_LZ.</YGE31*(>#C:>N,U='B/*<=4Y?JM/#RIT:W*
MG"/[R4DI6>D6TG!1:;?NR:V=FL?P#QI@\/'^R^(,37SJKB\L@W3Q-:,Z&18;
M+,LRCB)P:J3Y75K9=CLPYU%7K8N$Y.4ESGAWC+5O#VO^*O$>L^$]'7P[X4U7
M6M2O_#NBI)-*NDZ+=W<LVFZ>LUPS7$@M+1XX0\SF5MF9"6)KF\ ?=;</7W[C
M\#Q^&*9%L$48C@-J@10MMN>0P#'$.^0F1O+&$W.=QQDY/5]?EM=J=?'U(6Y'
MBI6LM+MU'I_P%V/WO#9?0P6$R_ZIC?K&%6#H0A#F<K8A4Z/UR5W*5VJ\9J3=
MY-MMMMLJ770?3^HKZ4^//_(L?LT_]D \*_\ HBRKYKNN@^G]17TI\>?^18_9
MI_[(!X5_]$65=>#_ -RQ7^&/_I<#S<5_R-,'_C?_ *;J'SM37V[&W\I@[@>,
MKWY^E.J.8A8I"4W@(QV=-W!^7/OTKE>S][ET?O?R_P![_MW?Y'L*]U9<SNK1
M_F=U:/\ V\[+YFGIVC:M?(7TG0]9OD7@OIT,LRKGH,QAN<X"Y/T]*9)HFL0W
M8T^;1KVVU!N5TMM)E,[9/IY)89[DCN?3-?M-^QYJ.EZ%_P $R/VM_$&I>-O$
MOP\6V^)OA''B[P-)+;>)=,5M6M 3;36Q$P('RG:1\A(-'[/VJI<?L:_MK?&W
MX1>*/$/Q&^/^@:EI&@:/\1/$MLUW\3]*^'%Y>P0Z_=Z6LR-J%C!!IS32_:K=
M8Q%M\P."N:_28<#<U:E@/[4_B<*RXF?O=L-*OHN;5VCOIU>RU_#ZWBQC,%2S
MNJ\J?[KBZ/"D+<R3]IB8892DW"T8IU&FES;1C?FFK?BT^F:K:7\6E'2;VPUJ
M928M.6WE6YG7&&(@VAE)'4!1@\<&FW6EZII,A75=,U#3PWS&/489(YBQ&XNG
MF!3L)Y0+P,_3/ZU_LI?M#_$WP9'JOQ5_:1\!_$OQKX*@^$NJ>#?#7QXL/#5S
MK'Q(^'6E>*G@TVR\8:5JIM9KC4(K"6YC=M0N));B0D%Y">3C_MY^ [[3_@#\
M)OB=X8_:(\1_&[X*>(M>U>]\&_\ "RM-ELOB%HUQ>Z9?-=7+7E]!#J36YD8+
M#&KF"&/<L*JG \O,N%?9\+T,P4O:/W*K=K2:DJ4E-WW4^?F]URLVKI7;-\!X
MH8VEQK1X<G3E16)ITZ,)<TI4I\U*3E3@XQ;A.DHJ+C65/F2E*$GRQC+\H T;
M$F-BR\<'^'.>/:AON-]!_P"A+3(D5%&W+*RJXE^\LV\9WK+UE/\ >)8D$C."
M>7M]QOH/_0EKX+$.^%JO_IY37_@,:<?T/VQ4YTL11A/X_92E+UJ*=3\IH^B_
MAI_R;S^U=_V _AC_ .K:\#U\S. $8$D<Q\^GS+CGGO\ EZU],_#3_DWG]J[_
M + ?PQ_]6UX'KYG<1[6$S%8MT7FLI((C#*&8$<@A<_,.1P0.*]VJ[/"/^;)J
M$;>3JX@\/*)^RKXY_P#03F]?#?\ E&@__;Q "Q"J"S$X"@$DGT ')/TK?U#2
M]9T\1G5].U*P+A3$;VWDAB<,NY2&=%&"N".>1S[U^AW_  2=\(^ ?&W[7&BV
MOCW2](U:[TSP?XLUCP-I.O6EM=:?J?C2STYSHT#O<HR&9R7*#.X,,CD U]/_
M  8U'7OC-\"/^"A5M^U+<76O^&_ DD6K^#KOQC>2RW/@WQZ][K6GV6E>%=3O
MWW:/E#;VT4%A+"'B*Q!2K8KZ7+.$*F,R:EBJ6DYNM42Y?^HC+<.N9Z6YGF'*
MO771V?Y_Q/XE5.&N(,UR=0<J.5T\!7JOGY7;'XB='W(N+4_9JFYS5UHK1U39
M^((&.#MRHYV'*_4'G@_ESV%+7[VW_P#P3S_9Y;XH>/\ PS8:)KC:-HG[#UW\
M<M*C36=9CBG\9PVEC,+RXEMYUBU:QD+,+;2+AIM+6XQ,T ?YJY7X*_L ?##Q
M5X+\5>%_C/X6TKP-\0KC]G#Q-\8/ 4WA[Q)XKEU^8Z!):W&AWVO0Q73>&+47
MZR7*?8H%C>()EXUW*3T5_"[/)-WJNA13Q7[Q-I*6&SG-<HC%OW;<W]F67?ET
M/+I^//",\&ZN)IXVMB(5,-'V.#B_K4O;5Z="4HQIN<I0I\\O;6^'F@Y63T_#
M.X#Y4J>%W9'Y>V><$=1C!_"QI-EJ&N:II>BZ/IUSJFLZI>PV.DZ=9VKW=]J&
MH7!\F&VL(E1B]R2Y=-H)"(_8U^^?@?\ 80_9;U?4OV4?AW>>$-9'BGX\? /X
MH>,-;\:_\)+K+0Z5XJ\!P++IUQ:62W?V>::YCO;E9K&&-EF(6>2-FME9<[4_
M!/PA@_9S_86T9/A793:_XE_:3UCX<W'C?POJVJZ=X@LH=&U80G69]6LIXI[W
M498U)73[J:3[.H>9(U:'*Y4O"_,Z<U4GF;4:?ORUD[J_+:_,[?$M7ITW9CCO
M'/)8XK#0P>69]>4JR@\5[18>+I9EQ/E:E6C+24/^,?<'%6=^5_#%M?AIXD\,
M^(/!'B/5?"_C#2;_ ,/^*-'E@L]6T;7=.DMM8@DNHVN8))1)&IB4I"P4\;@<
M"LG'_P!;_#\/\\'-?T??M!?"SX2_##]FO]NR_E^'$7Q*U#P)\</ -A!X@\6Z
MQJNI>,);/4=.E:7S?%SW$FIV<-BP,D%H+Q(A(JH4R0#\YV?[%O[,WB'PIX>_
M:HTFSU2P_9I@_9O\5>(_$FCW7BC6)+F'XX:;?Z+I>G:'%<27;/*;^35WE2U=
MBLR0J"A!.<<9X?XJ$*E19BY*G2J59*[>D(SFT];/2"3:2C[QKE7C9DU3!U:.
M,R^-.I6QKPU-M1]^J\HX:S>#BGK&4I<0MPIMRFW"3V]Y?B;7>_!O_DK_ ,,O
M^Q]\'?\ I[AK@[F6UEO9)K2WN+2VN;B]GTV.\8O]BTKC_1F#$[6 (&".V>M=
MY\&RI^+WPR*XVGQ[X.*XZ;?[;AQCVQC%?)8;^+E?^*/Y(_9,8O\ A%S;_!+\
MF2_%E)9OBO\ $6.,7$SGQQXG588H]Q.=9O,!<*2WT&>^.^//[BTNH)'AN[:X
MLVB19GAN$9)F1B0IVN P1BI"Y&,J2.*^D_#ZK-^V7X>&%>5/VC;-7>3 6&U/
MBF]#*N>Q)/H"3UK['_X**Z!X<N/^"FNH67C%)XO!%_KGPGL]:FO9KK3],_L:
M^CMXKLSWJF.W@MI5\U3F15G*NC@A0!]73X:_M3+\;7M=QS&N[)+9UZKO?IKI
MY]S\XQ/&TLCQ>19#_9BG#&\(YEQ"ZMG[T\G=.BG;DL^:,93YG*ZM:UG<_+*/
M1M<>Q_M6WT75ETS8P-U;V\DD;!<9:1@F-H!RIS@Y;FO>?V63&/'OQ!6/!$GP
M$^(CL7_UH9;OP\""#SU)S^!/6OT5_;\\;?'SX;_M=ZK\*O@8/$-G\(]/^$^D
M6O@7P1X<TR6\\%ZC\/-0T(3ZKK]OH5O$^FWNZ^+QW>O&WDF@Q'FX7?S^>'[,
M D7QK\1EN$2WG'P7^*N84<*B$W'A!I!&H;$VV5GW]?LS?NQL#8/#B<&L!FN&
MPBO^YIP6JLKRIPGM=Z:_D=F2\53XRX5QN:RI*A]>X3QF(5)2;<%+$93I*\8K
MF=DW9-7;UT/FW1]3O-'FTW5M.N9;._TZXLKRRNX)3;SVMU 6EM[B&8%3%)%*
ML<B.""K*#U%>@:M\8/BAK'CV'XGZC\1?$VI?%"TA@CT?QQ+K<UYXI@$ "_9;
M?78YF>VM8(@H$1G4(O\ ",5YM9X^P6IQU\COWV.,_P!:N-T/T/\ *O-J9CC<
M'BL;3PV,>&A/$<\H*3CS34%'F:4DGHE&]NA]GC,JR3,94IYG@HXFM1H0HTYR
MA&3C2LIN";B[)S;;6SOJF>J>)?CO\;O&FL>&_$'B?XM?$#5M=\(74FH>%M6O
M=?UB5?#%_<$->W.D7D5P8?[0U)E5Y9D8R.5&X\#&ZG[5O[2FG:Y=^)(/CA\1
M[37=9C33=;U*7Q'J4$^I6=E&+FTAU6?[0L5YY*7!6-)]\@YXSG'S_7[+_L>Z
MY^SI?_L\:/\ "ZV^(7AK]F_]ICQ5XXN=8B^*7Q%\$0:WHWCW0+%A9:9H.E^(
M=1T^ZTA-,CNII+"^L8;A9X[E)3(@=B3[>1X;.^(J]:-+B*6#>!C"NX^VE'ZQ
M[64J2I_Q$FURMZWM=][/XKBFMPEPI3RW%5>%:>;8/%XZ.$QF'G0O1HT72K2C
MC*U3#8;&X^E#!S_?1>"RS'-SY?;1PU**KK\V]6_:=^/OB@Z__;?Q>^(>NVOB
M?1+33O$0U/7+N9-8TR":X;2]#GM9YB[65O)-=2V\;H8RDWF1KM=2>+\$>*OB
M#X"U9?%OP[\0>*O".MZ.89+KQ!X>O-3T,VL0,LMU%J%[9O!;SP;K@QK;W#M]
MTG: XK]4/B7^QAXRUOX[?%67X]^ M.AT+0[;X<6.N?$SX1>(_#O@SX>1Q:QI
MUK'ILL,GB"ZL;:6[U* P:W+HNGYW37\A6 F3GZZ\,?L66_PC^%O[<G[.FB^*
MXM;@\17/P8O?#_BS5%$LEOI7CO3E$45W:0 QI)IL=H29[=1:2"1)%8NTA/TF
M&X+S_%YBZ[K3M1PN*:Q_O-MPI)QA>^U5KE;YM--&?#9AXI>&^09/A,'E].EB
M:=661TY1J86CBJ6:QQF5X"%26'AAHX]XV.41BZJJ9I0RG%4XM2IX53G.$/PW
MUK]J']H;7=<\-^(]1^,GQ!U'5O! O)/!4\NO7LT^A7&LR2S7&HZ-;O<-$O\
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M<3)'#=B17DEEMV5FD+%CDUX?]H:U:.YC$;R0RQND3',LQW@&*VC',D\@RL8
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M/&OB"Y^+7CN]UGQ]I*:7\0+I=<UE;SQ=I+)Y7]C75R;@"^TV%/W?V=&>,HN
MG(J#P)\=OC;\*-)NO#'PQ^)OC?PKH3W(U2YTO1M2U>SLK>0QA);Q+=I5^R++
M@O\ :(51V# [B>:^\%_9)_9-\1^)_A+I6@_M0>%?"=SXQ\77GA7QQH]U\1?
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M^GM^/MCZ'UKC]D[X8#(_Y+'XPS[_ /$FU;IQVYS2P\ZU?#8R5;6K["KRWO\
M%RNWXE9K&GA\5EE+#+W:.)H/2WV9_=L?/$P!BD!4L"C94*7)&TC 3JQ/91U/
MN:[+Q+\0?B)XNL_#FB^)O&6OZ[I'@:RMH?!.FW^LR/8^%=)M]C63V=EYQ:W$
M+K$5"(",5R-%<6'Q>+PNEY*]KZM7[72WUUZ_+<[*V4X',VI8N,923;BY1C)I
MR5FXMIM/ET=FFUH[K0]1\>?M!?&SXD>&!X6\>_%[QYXE\+R3VG]JV&N^(=6O
M=/NA:SQ6UG)<V27+LLUO(T;PRSI^[958%<9&XG[4_P"T6;G0+V'XT?$>?5?!
M\4%KX:U5_$6KW4FB000FV@TVTNOM+2;(K1GA6TD?:%^1D&,5]*_\$_\ QQ^S
MGX+\2_$G4_C[:Z9HMT?"UUH?PJ^*VL^%CXI\(?##QEKL1M;75-55[2[MK>X$
MTWR33*JASG.TFOJ[XV_LB?%SXE7/P.MF3P5^TU\-?%UQKCZ-\2/@[!H7@3Q)
MKFB6]C=:E=P>,KZU73;&2WT*&V^U/+K3&0M;*9"6%?H-')\^QV3X+%83-9MJ
MHM(SDVFI75USWZW3LU?3=GXKF7&7!60\68[*<9PK3BG1J>_.A",'&7#6(4G&
M<J+BW=1A*'/&;7O.+IQN_P U8?VJ?VH]0U[0M0L?C5\4+O5/#\6HKH$MIXCU
M>\U'3+?4K6:UO39Z?!<OY45YI\UW'>(L0"1NX<8KS/P5X^^(7P\\4/XZ\">,
M=>\)^-Y9[Z!]=T'4+S2]6GMM6CF74H9[^:2.1DO8GE^W0*^')(92<5_0K^QM
M^QC\/_A-^T#^SM\6O!OB>?6=%^+'A#XU:!XBL-2U32_%,FCZMI'P]\3:K.BZ
MQI,MW8R2W4FFM:R10SL\;/L< L ?EC6_^"??[/GA33_ 7BC]HCXY:5X"D^/]
MGXU\7Z5XBN/$_@_P]IGA"QE-U)HVG76EZU<V^JZS8R2F*RU"'2XIX5BG,-RN
M^15/=BN$N(:T\'B*N;2C4JRPO,Y3DHY?*CG>%4:BGS^[+-I25E9<SBD^=.R\
M[+?&'P_PV99_ED>'Z#I85YA3C"/#M/$U<?.ODN,C.@U]0<JJR1156%9U)QGS
MR<>246Y?DC;_ !6^)UKX)\1?#RR\=>+H?A[XMU1]5\2^%;#4;^/2-=U>.Z2_
M2^U#3[:53=7<6HPPW(N?+?#H6WY(KJ[O]I_]H?4O"LO@^\^,_CN]\,7.F2:+
M?Z7>:QJ%Y'=6"P%$TJ%I99+FS2",;TCW)O\ *$>"6P?T9^$/_!/GX:?$_P"%
M^G^,O!_C/5/C3XHOM0\6MJ_ACP!XR\'6&K>"]%T+3-0N[.XM=$DO8M2URYU!
MK6"2>"U@N&DMRQ (6OR)U33QI>M:KIHM;^VCT_4[^TC@U,-:2VSVT[0M&VF3
M;!!J8&1=2VT2[H_-W$H3GY+,5Q-ET*>(EF-2C0GAZ35#GDHX5VGS82W,E%T'
MHXV33GK%7N_T/AK,> .)L1F^#PF74:V*HRE>M]1A@IXF\4HXKZO[*E)+$)75
M9PM65*\:D^7W>YUWXN_%'QAX2TWP/XQ\=^,O$'A7P]!9KI.B^)=9U'4[73(H
M9HVLDL].GGEDME\U4"N46) -S$*#7&^&_P#D9O#7_8S^'_\ TX150_\ K5?\
M-_\ (S>&O^QG\/\ _IPBKP,/B,3B:_M,5BGBIN2M)R<N57UC=M[O7IL?7/"8
M;!90\/A<+'"4H*=HQ@H*;<K\UDDNKN^K;;;;N>L?M*_\G$?%?_L;8?\ TV:?
M7BR?='X_S->T_M*_\G$?%?\ [&V'_P!-FGUXLGW1^/\ ,TL9&]>_:3?XM&^4
MW6"P\EM%Q;].5H%DFBEB:V>6*ZCEAF@F@&R:,02"1YEG&"K1,L;##<$=N:[K
MQ/\ %CXE>,?$VB>+/$?Q \5:OXC\.6ME%X;\0WNNZA->>';+1)$DM[C3+RUN
M/,L)+0X@3+QY$^1D UP]59KN&V=1+Y,9\MI(9GC#N)4DB41+P2%D21V?'9!G
MM7;@LQJT:V'A1K>PJ.O1BJB=N6]6":NFMT[7[-BQ>49)B<93S''X.ECJ>'C4
M=;#U(SDJE*5-QJ-*G&4N:,.:<>>]'GC'V_[GG/7?&G[07QI^(4'AN/QC\5?B
M-X@B\,ZTNMZ0-7\4ZQ>-INH@Q3VNLZ=/%=LL%S&+)W25B)0H;YNH.U;_ +4_
M[1ESKX\8V_QQ^(8\30V-QHUQK,?BC5+C4=1T*;RI7%[=M=-E&CM#IP%PQ!2Z
M9%Y85]F_L#>+/V:_#/P\^+'AWXG:QH7PJ^*GC6;3=&^'?QX\0^#+?Q-X3\.0
MW%S'J-[8SO?V-WI=I?2C3DNHY;K8 EG*@8EP*]:^-W[('Q3UOXK^&X_B%H_A
M7XH^$HO@S<^+5^+OP8N?"O@#0O$'AO1]01H/%?C:>=M-T2&Y$&IO9V2@J\LU
MT(HPSR '[:AD?$=?"8/$T,TFZ56EE<I\LYOEC+ 9JI<WO:>Y?>ZL]&K.WXW5
MX]X$P'$#P&8\)Q5>C7ITZRQ&%PU3%5E"E[3,O9T:5&>3XG#O'2RV%6E27UY\
MMG2=25)2_.:[_:?_ &I/$-S+<Q_&;XJ:E?3>$[KPO>7$/B'5]4QX5UBX:35/
M#MQ%'/+&-.F2RM&FA8>2RJ0PQ7EG@CXE_$'X>KXDD\ ^*=?\*+XDT^;P[XA?
MP_J3Z9_;NFW9_P")A8:L5DC(B<@%D?"G'(XK^B_]GW]CKPE^SEXT^+D7A#7[
MOQ-X3^,G[!WB_P 6Z-#?7NF2R:+JT.M:19^1%K"O]CN5:35@@-O,V\C<ASM(
M^*_B-_P3_P#V=?A#I7_"-?%/XYVOACXE:E\'H/B1I&NWWB7PY#;:CXDN0FHZ
M;X4L?"D=R+]H);;S+34-<CL]R?(KW"EQE9CP9Q%#"1Q>,S.I[9PI>UYIM6QS
MJ?\ "M[W-O\ V5=RV]U6=D<F3^+W $\;1RC"Y51KQHY;PW1C./"\9RQ\:T,Y
M<\S<%@&V\FE/E3]]KV7,G'I^59^+/Q2_X0G3OAT/'_BQ_!&BZXGB31O"3:Q<
M2:59>);618H-32R6<_8+B-=0=H[I$C$Q);>P->@>(OVF/V@O%NACPQXI^,?C
MWQ!HADLQ/I5SKUW>P7LFG*GV!;BR@F:68Z5(@:W<H=@"D$'K]]R?\$_/AU>_
M ZP^*?P[\0>)?CA)/\/=0\:>+-2^''C'PM<:;X5U:RE6"UL=0\"K>G5-5BTV
MX^TO+>'3YGAC5Y3(I(-?DJ006!*EE9U;:\KY=6(<L9LR+)N!\R-L"*0O$H"H
MH'SN:5>(\EJTJ&)S6:ISA'D]^5G!I<J7OM.T7#;:[5D]#[[AK%\!<6QKU,'E
ME"I.E6J0FU1A&7.IU+R</9QG!SE3<ES1C=6<7**C([WQY\4_B-\4;?2+3XD>
M-]=\:P^'(XX=.?Q)JLURT$,*JELEN]U*UPL-O'B&*Q9ML6QF$8\PD\#E9&:7
M"EWP#(MF;7<B\(N[8BS!,MAP2?FY/(I:*^=KU)UJU2K4J>UG4DY2J7OSMI>]
M>[O>RZ]#[RCAZ&$I4\-A::I8>A%4Z-)*RA3C=QBDDDDN:6EEN(/]?9?]?]E_
MZ4QU_IF?LV?\F^_!+_LE'@+_ -1VRK_,VB_X^+/_ *_K+_TJBK_3(_9K_P"3
M?O@G_P!DI\!?^HY8U_2'T?G_ +3C_5_DV?PE]-'X^!O\69_@J+/;J***_JL_
M@@T****YP*Y RPP,!OZ"OY ?^#D;_DL?[.'_ &(OCO\ 76O"'^?8\CFOZ_C]
MY_\ >/\ (5_(#_P<C?\ )9/V</\ L1?'?_IZ\'U^/>,__)O^(?\ L*PW_IRD
M?OOT8]?&+A>^O^P\5;Z_\TMG!_/I\./BI\2_A%K%SXC^%WC7Q!X'UV^TZZTB
M\U'PWJ5YI-]=:7<RMY]C/=64D4LEI/M'F6[L8FV@LO%=EJ/[27[0&MZ]X:\4
M:Q\8_B%?>(O!<-Y;^$=5F\4:P;_PO!J(VW\.B7+7/FZ='>J MPMLT8E"@/D<
M5XE&#L7#,O,GW6*_\M9/2G@8[L?=B2?UK^/'C,92;ITL7BJ5-<EJ=/$XBG!<
MLL-B(VA"O""Y:]&C75HJU>E2K*U6G3JP_P!7L7D^48C%3Q%?*<KKXB7*Y5ZV
M6Y?6KR<L)'#R<JU7 U*LG+#U:M"3E5;="K5HMNE4J4Y^H^#_ (Y_&'X;ZGXF
MUWP)\1O%_AG5_&LT4WBV_P!'UW4;&Y\1SQ3/<Q7&LRVTZ/J$T5Q))-'+<^8Z
M22.X(9B:V-6_:7^/WB'4O$>LZW\7_'FHZOXO\/67A+Q1?7GB359KKQ%X8TZZ
MN+ZP\/ZQ/).SW^D65Y=7-S;V-P7MX9II9$0-(Q/BK+N&,D<_PD@_F"#1M&,$
MDCT8D_\ Z_QS3CFN/IQ5-9AC8Q7/:"QN+44JM.K2J)06)44JE*O7I32C:=.M
M6IR4H5:L*F$N',EKS=:>5Y5[1^S3D\NR_G?L9TZE)N3P7,_9U*-&I3O)\E2C
M2G#EG2ISI^QVO[1/QULM=T?Q/:_%CQO;^(O#_A^+PGH>M1^)M574M)\,0F0Q
M:!878G$UMI$9FF*6$3K;KYDF(QN.>?\ B-\8_BE\7#HQ^*'Q \2>.CX>L9--
MT$^(=3O=8_L?3YI3--9Z=]LDF^R6TDI,CPPA(W<[F!)S7GFQ/[J_]\C_  I>
M>Q8?0D5-;,<;BHN%7'8RM3<E.5.KC,56A*:48QG*%3$3BYJ,(14G%R4802DE
M&*CI0R/*<#4IU<-EN6TJU*7/1JT,OP-&K0DE4BI4:E+"4ZE*5JU9<U*=.5JM
M57M4J*?HDGQP^+LEIX!L)/B5XLDLOA5+<3?#6VDUJ_,7@66ZD6:YE\+QF;;H
MLMQ*B2S-8B%I)%#.2P!KK;#]J']HBPUGQ1XCLOC3\05U[QO>V>H^,-4'B?6!
M?>(=0TZWAM+"]UBY%SYFH7-G:V\$-O-<-(\4<2(A"J /#-F?XG_[Z-. (& S
M#_@1R?K3_M/,H\CCF.81=/E5-QQ^-BZ?)*,X*FXXI.').$)0Y.50E",H\LHQ
M:SGP[D>)E^\R?*')>U?.\KRUR_?352LN9X!RM6J?O:JYOWM1*I4]I-<YZ]JO
M[0GQPUZ[\;7^L_%GQOK%Y\2+'2]*\?W.H^(M5N)O%VFZ(9#H^G>(GENB=6L]
M,,TC6,%X9H[8RR>4%W&IU_:3^/5IK5CXDB^+WCN+7M.\)GP)I^KQ^)-6_M&T
M\&^481X7M[O[29H-"6)FC&FHZVNQBOEXXKQDJIZ@,?5@"?S-&Q<@@8QG[O&?
MKC&?:E_:>8N49/,,>Y12C"3QV-<HQC[91C&3Q/-&*6)Q"45**2Q%=))5JWM<
MUPGP[23E'),ELMX_V1E7*[Z6<?[.Y7\XO9=DUZ_X,_:-^/'P^T2'PMX2^+?C
M31- M[J\U'3M&T[Q#J=CI>G76HA5OY[2TAG2"WGNUCC$[QHK2;%W$X%>3WU[
M>ZCJ6H:KJMS)?ZGJUS<7U]?2NTLUW>7)9YKJXE8EY9Y7):21V+.Q)8GM J*,
MCE@>H<[AGU&<X/TH"J <#'RO_P"@FIEB,1B*L)8C$5\1+G3<J]>M6DW*5+F?
M-6JU7>7LJ7,[^][*G>_LX<FRR[+\#AL3]2P&!P7-0K<WU/!83"WO2J7O]6PV
M'O?K>]SZ"^*__)%OV7?^R<^._P#U:_CJOG^OH#XK_P#)%OV7?^R<^.__ %:_
MCJOG^HS+?[ORB3DO^Y+UE_Z6PID@!1P1G'E@9[ N0P^A!Y]:?2$9!!Z-C/\
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MNYU.ZU,%TCO+J]+B=P[A9+RX=Y2TLLFXD;F))4FOO/\ :<\??!KP3\4?C/\
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MLE=GZ;F$W]1C1;O*C@,"Y7;;<JM*M4<FVW=RLKMW;LKMV5O6/VE?^3B/BO\
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M;O@QXV_:,'_!0O\ :.^'GQ2\8:)?_#6/X,_"GQQ\,_!_AZ.[^Q>%]/U_Q/\
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M+;DVE5;>JBXNI]+_ ,1ZM%\W^J*551YXJCF:BU&I3JIV6*7+:="&J2T4X/\
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M%MCXS^(7A7X[_%3PU-JWAZP>Q\/PZ7I.O/;66D:-8+%$$T>PM-T$%M/#'.
M/*W'%?'7Q1^)/QM^!/QS\03^&_V@/&7QS\<^$_"?QR^*_P 8OA^+B]3X6^ _
MACX=^'7BOQ%\/M$ET>WS8:;XT;Q99>'=/TF.&)=;UF*6=!%):-<L+K> O!5#
M&QC+-<\=-X:%3V2I.4;RIQFFVL,I\UG=I:)W6UF<^&^F%XE353G?"$E&<HJ3
MPN-5[2DM+55I[ME=/=7/PW'_  0O_;[=)##X5\$2M&LX&WQGHA\R>")Y7A2(
M7YF#941*2F'DD3;\N2 ?\$+/V_RL4G_"+>!Y(KA)!Y:^+=+AGMI$=%4S?:+R
M..1&+%BD!>41H[[=JDC]M/A]XE_:0BU[P-\/;7]I;Q/IU[^U!^R]XK^+>L>.
M_%MY_;NG?!O7_#.M:#'KFK^$A>R366A:/:>$=3UV"STZV>"TL=8;3M4N%A2P
M::+8\&^-/VFK_P#9>_;3\6_ WXO>(/%VA^"M&U>;X#?&7XVRZGKOB&\'A/PY
MK&I?$K5](U"X6ZUG5=#NFL8U\(SE7TXF3S+*0V\4CHZ?@%P?-8>M+%YW5PN(
MYYNG*BX\W)4J03F_91E'^':-FN;E6[;#_B;OQ+<H5/:<'QE-24+X7&W2NUI^
M]_-/2_D?D3X2_P""-?[;?A?X5_&GP'K/AOP@/$7Q0L?"&F^&H[?Q1IAM9+SP
MWXV\.^+-1\^XDO D,"Z+H>HR([LN^=8HUR7 /E$/_!"+_@H%*/G\*>!%8G?M
M7QQH)RB89",ZCU8@#'OQVK^H#4?B%\1%_8C\ ?%"X\7:A_PL6?X36.M:AXIB
MDDMKN?4FL2UW.D(*A)[J0LJLP4B%G!(/!_)#_ALW]IQ59G^,/BI'EM+41'[9
M*<;9A)*Q*N3_ *J-P3CN,\ D<<?!;A+&8JM3EF>?4*>$F\+1HK#^[&G!*:2;
MPSD[2J25VV]-;D+Z5_B5@:,Y0GP?2GB*TL1*^&QEYRDE#GLZTDE)05MM.B9^
M>Y_X(3?\% !U\)^!Q]?&V@C_ -R--_X<4_\ !0#MX2\$'_N== /Y9U&OT)'[
M:?[2_&/C9XI'7_E^E_J^#^/0Y]>5_P"&UOVFO^BU^)OQO)L_C\]:0\"^#U4J
MQEF^>M)1LI4-%K).S^J-Z];E2^EYXDJG2G.IP=4;<K?[/CTTU:[?+6C>^FZ/
MSU'_  0I_;]P2_A/P5$!U=_&>A%/P*ZB3C/]1S2+_P $*?V_B-P\+^!)E/"F
M'QIHA.[C(8'4,\9'0<]J_2?1OV[?VF-)N8I#\6)]1?ADM]6^S7"S>JL2[R9/
M3]Z V.O4&OK?X0?\%0O$=GJEMI?QHT&UU/1IY5CF\2Z-'!9RZ:TS)'!]JCF\
MI9(F8-M> 2-]XL. :J7@1P7>\,TSWF=KM46GY[X1QM\KOIJ0OIA^)*3L^#^9
M7M;#8]IK72SK;OIJD?A$?^"%'[?H:!/^$7\#%I[A(&(\8Z-LM%=)'^T7/^GY
M$*F,1DID^9)& ,&JS_\ !#']OF*-)F\,^!GAD:8O,OB_288[&W@=(GN+[S[Y
M&5&:3SD,0;-O#/(<!,C^U'4O%>K>./AAJFO_  :U+0;K7=5\.W%SX+U/5'EN
M=&&J/ &A7419)-/)';,0SPQH[M*(R%.#C\8=!^)O[9/Q-_82^$\6FWOQ0^)?
MQ?\ $W[26L>#?B3XF^"^KIX0\6:1X(T,^)K_ %671-6U2[TB72](CGTW3=$-
M_-- $_M)(68-,JM4/ C@]2BY9MGK5]?W5U;WM=,(O+3LWV+A],+Q,FXJ_"$'
M)I*^$QE]5=O^._3>Z=E9WN?BB/\ @A=^WT W_%+>")R^!;-:^--"EA<' 29Y
MQJ!C6&8L&B.X-LCE+8VBH8_^"&?[?SIO_P"$0\$''F[VC\;^'Y4A>W9%EMYC
M'J3;+F4RQFU3@N"S$87-?O;J7C/XY^(_@IX\^(/[.WC'XR^-(O!W@3Q%\$M8
M^$NJ^([GQ;\9M*^-]YXW^'"R:A-XD:[NHYK[0/ ]WXHN[>_BU"2UMA<EH9Q+
ML!R-/_;#T/\ 9T^ 'C_P'XH\<>/O"?[30U/0?#EEX<_:F^)MAXIU#1/%GC;P
MKKU[H'B)?$>HZS?Z-;Z NG>%/%NL_P!E07XF270387%NEU=VL,NM3P#X%GJ\
MRSF<E:RE3E&+?F_JR]V]K[-IRUB[,TE]+;Q)DXOVG"+<G&W^RX]6UWE_M"2U
ML_M;:IW/PJ/_  0Q_;[+S"+PSX!N4A>WC\R+QQH*"1W(:[15EU%6#V,4L+RA
M@-Y\X1;]G'5^!O\ @B-^W7X/\<^%?&&J^'_ K:-X:\0:/XAO6@\8:0TXTS2-
M1BO96V&^_P!<88+QB@[+#C.\U^GGP:_:%^-7[1WA+X$> 8OVC_$*ZW8_LL_M
M&_&SQK\0OAKXC^RWWBGQ[X&\9:+X:\*PW<^E7(N[7PSIL&K7<XTR]$6GW4<N
MGC:[&(5^R/[*'Q&\3_&#]E+X<^/_ !3<^?KWB#P;>QZQ>3KB:YOM(FU'1+B\
MNP!]_4#I9O)2N06NR2<DYUGX"Y%&,*]+%PA&@DZ;YIM0MJK-U)=M+W\R:OTM
MO$QJIA9U.$:BK+EJP6%Q=YJ6DKVJQ:2;;;BU9'\F'C;_ ((B?MV^,O&GBOQ7
MHOAGP6VC>(M<U37=*-QXPT6.YN8-4OY;V*-E^W^7:[+:=9#-=&.%R0B.7R*Y
M6T_X(6_M[RP2RQZ!X"E6 GS_ "?%>G3%'$DBXA6.\9[R.15$23VJRPK<PW2N
MX5%-?V(_M%>/M5^%W[-?Q'^)&DV]O>:GX-\!C6;*.5'-NMW;0A=.NIU12)[>
MPO&BNYK9P5D@B974@C/RG\+_ (0?%+1](^"_[0&K?M:^.[>^\96&C:[\1O#/
MC+5HS\(?$D/C/2+75;;3M T"^N?[&T+4[-VCMM,N-(A2^O(G>.4?Z.0N#\#>
M#JMZE;-<Z5:I+GJ>SI<U-U)MRG[.7U?X')RY/B]WENWNXE]+OQ5P[HX>C@N#
ME2I0A2A_LV/UITXJ$6_]HDV^6*V:WV1_,]#_ ,$+?V_+E9"OACP-#E7_ -'F
M\7:5Y\:@ J9)$O3;F1^28(W::!=IG1-Z9]1^#G_!&S]MKX8>(_$NM>*?#7A
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MQ-I2+;1^%M(LM*T2\TLPW(DMDCMX$M[YUV2M+"9$!B=7/F/[-G_!,K_@I?\
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M3_@A)_P4 CD6X/A;P,T=O?6LMT@\8:0LW[N<SR>0K7P#KM/RDY'N:]9^-_\
MP1J_;3^*_P 2-2\:>%/#WA%M(O="\":$&N_%FC1O'J/A+P3H'AC6%(%[S%'J
M&D7*(PX.T\FOZU?V:O$.M^+/V=?@1XGU[4VUG6O$?P7^&OB/5;^1762]U76/
M!^EZE?7+LX'^NFNGP6(+-DD<FO1O!8NQX=C;9Y.;W6MT! /E;M9OB<D9#2#.
MUF!PS X8C!KFK^!_"V#OAY8W.JC=](TE):;)M4=':^C>CNNAM3^EQXDUI_7)
M4N$IRBURS^JXVVJNVK8B*MHM;*RMHV]/XCXO^"%?[?@5O^*;\ _O<M\WC+2
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M^7?VJ?VC=#^ /PWU35[NZMY/$VHV$J>%]&D*&:_N94*K/) ?G^RVS'=/E=^
M0@9C@=&/\,,IJ82GEU3/\XP^%A3I4883 Q@\-"E2BX4XTV\'4J/E@VM<0VVW
M=JY\CA_'3.X/$+&Y!P1BZV*>"EBL3B,-F4JM66 I4:6#FZD,P@Z;HTJ%*-Z"
MI<[IQE552:<I?RS_  #_ ."6'_!3_P#9RUN_\1^#/"O@&ZL-:\-WWA3Q=X7U
M?Q)I-UI'BOP\&FLSIFI6JW<OVI;^T =)BCRYFX(&*]7U+]@S_@J,L_PPT+0_
MAI\%- ^'7PGUB\D\+?#32]?T6;P=?WNNEKK4[[5DN;@+=V-Q+=2_:)PLD$)9
MOG7;7L_[-'[5'[6WCW_@H1\(_ 7C7XM(_P %=>\!_$J2U\.RI()IM5MO#5QJ
M'V[5FND2S>STZYEV:>/,=XUAC$@0C%>D_M/_ !1_:-^ ^HS^!/&7QS^,7BGQ
M#\-/@%K_ ,1[#5/A"WB&Y(\>S^)]8N-&U?XVC2XVETGP'9Z4;"W:Y\1+;^#!
M;0L3=_9LM2I>$F186E2H4N).)8494Z2Y?8PMRT,0\31WP4G:%>U1:M-NSYDN
M5^]5^DQQ+FN*Q6/QN4< 8K&.5.G4Q-3 8^56:IX>5&ES2^L1YI0HRE!2DI34
M&U[1<VGR%/\ \$^O^"E5AX'\6> ?AK\(O@G\'/#OC[5H-0^(%M\//$.G1WFO
M+9&,PZ9($G5K32[@Q*8+/3Q]GNH&41J\;J3ZYXI_9;_X*S^(?$.L?$*P^&GP
M \%?%'5_"-KX!O\ XIZ%KND-KT'ABTLTL4MM.V2^78;M.1;.RFM629XO+D'7
M->TZ/^U?\8O&WBSQ!\3O$GC[XA>"O _PO^*O@GP#KWCGPG=:?;_ &QTZ)M-M
M]>TS7_#\MU%<>*%\3R&Y>/Q%!IMX^A&[$3SVYM<)UES^VAXO_:7_ &V=3^$_
MP/\ VBO!7A+X?>,?@Y\6_!'P\T;2O$6EW7B:[^)OA2+6K&/QWJ^DVMS)<6?V
M6]LP-#MY8DO3816HDA6<E!Z$?"O*G[U//^(Z^M*552H4W;V%%X:BVOJ*7N46
MZ=XM*SNTY/G7F5?'_-\3.O-Y!P JSHUZ?M(X/,H7ABH4Z&(@U#&0C)5J-.G3
MDI0FG"FE9)6?R#\+_P#@E5^V+\(?V7_CEX/T/1/#VI?'/]HC4CIGBJ^G\6Z4
M++PYX0FD!GMKC5'O@MYJ>J)NDDB:22(33%I#MW$?"$/_  0X_;M-JDL>B?#Y
MQ,(W@NHO%^ER6$L$S VTT<Z7I0P3HRQVR!O.#.GFJHSC^A7XK^ _C$G[2/[,
MGPN\/_M'?%[2_&]S9:?\3OCK=:1XYUVT^'6G^!O!!1M92+PM-=0VUFGC:^T^
M?14ENK2)[C[=YUQB1V->3Z-_P4:\/^)OV]+*Z'[07P[T3]ESPO\ #?XQ-!X4
M3QEH<NK>(O%/@6?6H/$GBW6M(%\;VSM[6;3[L:!:S0)(8$MCY8?@>+F7@KP]
MFV(A.IF&=SM%Q4O8))W3=VXT+-N^K\K1ND>SDOTG_$#*Z>,E0I\'PJ8G$K&5
M9/#XQSE6I8>&#IN/-6=N3"1]A!15O9WYI-R;/Q07_@A)^W],8,>&_ :S?:8V
M,!\7Z23 @<,WG3"^\AG"@G$+N,]37K-__P $8/VW+WX"^!?AS;:!X);Q7H'Q
M#\2>)-6LV\7Z-L@T[4+"_MK653]O!*R//%@G@[N"<U^VG_!/K]K_ ,7_ +2O
M[3_[3]MJOQ>\(>)/!5WX9^'_ (S^%GPZ\->(='UB7P!X6U[1M/DA34X;"ZGG
MM]7E-R@UC<HA34GEB5RX"U^L-K#-%X\U2<NV]]!LXF! VN%EB(8+_>!')'XU
MQOP1X4R[]S/%9VG7?LXS]DTX\RY5*[H-))]7%K;3H>I4^EIXEXQJM/\ U2K/
M"I54UA<79.G9VTKQNTWZ:-W>E_XE1_P0F_;^_B\*^!6'<?\ "8Z. P[@_P"G
M]".#4EA_P0O_ ."AFF7FGZC9:%X+@U'2[ZSU&SO$\9:,)8;JQE26"1#]OX8,
M@!(/N,$5_<WYDWK_ .."CS)O7_QP5-#P/X4PU7V]#-<ZIU7]M*+?W2P,E^ J
MWTP?$K$4_95J7"52FMHO"8Q+3SCBHO\ $_FM^*W[$7[;5G^T'\/OVOO@9X(\
M'6?QNU7X>/X7^+'A_6M9LGT:RU"[T*31K^^L=02=UGGNDFE>3?)CYF*D@5Y=
MX7_93_X*\^&?%_P+\4P>#_@H^H_ /PSXL\,^$HYM=TO9=6&O:'J6FWYO'28O
MB2WNY4A4$PRL0K$@Y/\ 3[KFF:V-%U!M"GTZ;6H+*]DT5]1B*6,6HFWE^QR7
M4,"L98XYBC. K$@' )(S^/7P0\1_M;>+/@G\7?$?CKXV12_$#X$?M5_$77/'
M=SH.G7J:/K_P\^&^LW.IWOP\T*R-LES_ &9+IMB^GV\#P(&W!&7:37U+\-J-
M>FJ&%S6I0IIQE%)W2E',:6;*7[SGU_M*C3Q3UM[2*@TJ3=$^'P_C9G']GO#Y
MEDG V,4,NAE-/VU#-H5/[-I8*OE]'"1E0S"C+V-'!8FMA8RDW5Y)N7M)5/WI
M^-'PR_X)+_\ !2GX4_&C0_COX9\)_"V3QOHGB&ZUJSM+KQ7HS:9:WOB-YH+D
MO;F])MX(1=NT81 H0$CY06KTGQO_ ,$U?^"C/B_QNOQ3T_X&? ;X=?%3_A+K
M'Q@/B%X1\::''K@U>TU2VO/E%Q?1PI!K'EO97C(PD,5R\>"'Q7Z ?LK?'3XX
M_$[5?AW?:G\4/BGX \4_M/?!OQSKG@2T^)5K%J_@O5?%=MH.J:I;:_X&\.1R
M7>J>$-/\&6]E+J=ZVJZ=IEMKT=H2&N)-@/9_#/Q/X@2;]KGX9_$CX[_'_2/
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M+?@[2?&WPK\%?%_XI^*?M_P<^%?Q!\1^,/']CK-CXR\->//$GC[_ (13XE>
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M47FDZ';#6K32+=[57F-O:EXHFR">'#.ZU2[]>N_4Z)+F=_=7_<*CT5EO1?\
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M)HK9()8D*?+=LJF,N67/QO\ "']IK]K3Q9XA^"#W'BCPCXF;]L'X6?$#Q;X
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MW2 &-F#5<Z^+JQ=.6,K\L]';V*:NT]/W%EJK]F]TV"J--/DHZ._\"AT]*/\
M6VQ^\'PP_8J\!_#_ %IO$7B?Q+K_ ,6=<_X1>;P5X<N?'MVFN+X=\"V+,MKX
M7TY+F2YW:=:HY,J1@B*2665\&7+6/AU^Q%\%_AS\/?C3\-_#&D1Z3X;^.'B?
M6O%OC&*TVQPQZAXGAB2\BT:9,(FD6R1QKIT6Y1"N^-DC(P/S#\.?M=_M'?\
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MN[Z7XR^.-2\9^)X;ZZW6R7.I:#IFC3)&A<X3R])@7*#>!(Q (%?.-M_P3_\
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M!,\NE:_I]SIE\D 4$F9K:YD$0[O@9KY,_9J_9'O_ (/^.;_XA^-OBCK/Q/\
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M;HZ[#]&!!Z_[PQUS7PI_P4.\$V/BC]FWQ+=N%^T^$+BRUFR88W*@/V60 _>
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M3Q5K?AV/4[>98VN+7PO<Z=I^E:Y;Q) 78ZC<H\2[!G#U_P#X. ?'6C:=XI^
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MH=?\(ZW=7W@?P-J_Q@\6ZYH5OX2\?ZU%:?9M-UWPU%I7VV>Q9F2\A+W 9HY
MS:[_ +?OQOT:V^*EK-X9\&>/M1_9FU+Q'H_Q^UWP)J#:AH&HVVH>"M.\4>!K
M[1H]/ADNK-9;V]N=/OQ]G633T@6[D58M0A>2/;4:M-S4Y)*ZLX2?POR7D8^T
MCW[].W]7/HOP5_P3Y\&ZKXDDU[]H[5=+_:$DT_P)H_PM\$6'B/PGH^D:=X5\
M">&[Z2_L%%M;S.=8U6>2:P\W6 CL%M+:,2$QX''^&?\ @F=X<^&'PW\0> O@
MOX[NOAK/KOQP\0?%K^T=,\.VVK:%>6NN:/8:0?"WB#P_<EK75(M#&G_;]&O[
MP!K6^F"6YP\I7A?A1^WE\6I-2\7_  _\>>%?"WQ/^)C?LZ>&_P!I;P-X>^#E
M[/<WESX>\27T]CI/@366OX+!K37-,>R,]U?28@N(&NML[R1.@ZB[_;G^,2?\
M$[+/]K:P^"%UKWQ/U*;Q-#?_  \\/:C;7VD^'1IWB37=!N=0\0Z@DWD-IVBV
M^E06^L*KNT>H^8-C99J*>)@H1LIM<JL^66JUUV8Z=14W)ZOG;\K77SN?;?[/
MOP1\/? #X<:%\._#VI/K4=BOB75=2U>:-4GU;5]>U6YU/4]9GMK4R6>EW6H7
MTURD]ND@5UM888]QLI5B]M\"?\BQ8_\ 7;4/_3KJ%<)\*O$FJ>,?A=\.?&&K
M6MO:7_B_X>^$?$]]86A5K?2[[6O#EAJ%U;VKKC=8RR7&;3&5_=2D8)-=[X$_
MY%NV_P"NFH?^G._KD]NI8YI1>M*"N[I_:Z-'1&'^QSDG>]66EK;Z]SK****[
MSA+%%%%!T%<C(;Z$_P"?SS7 6,@C\4>)@Q5&?3]#*N954D!M:'0G<.>/_K5W
MLA*JP'N/YG^8KP/Q!QXNUAFE,43V6AK+.I),0SK1$1B7EBQR0W/!]J\+.\=/
M+H4\7%Q4')4_>=GS;:KMINWV/2RC"RQ"E2NDY)M/HK2OVZ_CLKO0]PBNX%0
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MZF$IM6UK4H\\M?Y;*R:N[M)I71^G.AW<:^(/%OS0X-UIN-LRY;_B2Z:0!\P
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M?]YO\>O%8+B_$1E%U\#2A!R23;?Q=%[RMLGYCCP_4?,KQ7NO5I+MU/=I+J(
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M>S)LPQO!-Y:.Y"_.>N,FO.?'/[.OQ=MO%/[8'CWX+_$GPOX2\?\ QX\!^$]
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MW>Y+X=JJG4C>G>M)..KUTC%W=O=VVM+HSY#^-?P^NOA7^Q5IGPXO]6M]4OO
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M 1WDDDA8_P 2P)_=K^5CPAXA\2?!7XL:?J@2:#6?AYXBFM=1AE!,MQ:P[(I
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MI.V-E51@#HN!@5_-SX9_X*U_'?QK^R_\+OC-\.?V/+'XJ_%3XN^/?%>D>$/
MGPC^*V@>.?ASIGASPYX3U?Q?XA\1?$/XMZ/J-SX6\$36/A[1-2FM-#UO4[.X
MGU*.WLX8VGE1&_4#]D/]I;1_VO?V;_ ?[06BZ-J?A2'QQINJ27_A?49DFFT*
M_P!(2XAU.P6[@DE%ZEG>0MY-U&62Z0 1E@V:RQF?8RG@L0WA/9N,DK4U>]X/
M5_#JMEI>W;8TP^64*N+I3C-2C"+3E!1E9\ZE9ZI6:L]U9/[ONWP?=Q1^'M-A
M:6#:(451YR\8N\ #GMD8Q78?:[<<>=#_ -_4_J<_Y[5\R>'9G&A:0ROG-NY!
M)(SY4P>,D'!ZX)!Y(X/I71/+(6)WMR<\,V.>>.:\*CQ?B:>&@U@YU)<[C:I%
MI))-W34GK=;66AVXO)$ZSE"[3O\ \NU=)O;1O1;7OOT/>?MEO_SVA_[_ "?X
MT?;+?_GM#_W^3_&O!/,D_P">C_\ ?3?XT>9)_P ]'_[Z;_&G_KKB_P#H6Q_'
M_,YO[#G_ "O_ ,%GO?VRW_Y[0_\ ?Y/\:1KRWP<30C_ML@_7-> RS2)&TIE=
M4C*&0Y9B%>18AA0<L=\B\#)P"<8!KP7]J']HCPC^RS\#?'7QV\?IKT_ASP1I
MTEQ_97AW2KW7];UV_.P65E::;813W:K=7#Q02S"(K:P22W4I6.!V6X\9XQRC
M;+%K)*^MM6EW\R7DSAK)-):M^S5DEJWJULDV_),^\7NXF1U6:)F96"@7,8))
M!  .[@D\ ]CS7'^,;+6]<\*>(-)\,:X_AO7-4T>ZMM-\46<,=\=!U!$ BN6A
M#;YY8F.5"J2,.>NW/XK_  D_X*7^*?BOX-_8E^)6A?L\^*'\$?M66OQAUKQ=
MK\5S>S67P/T/X6Z+J.KV5YXME2 B.?Q(U@UO:V\H#K,#&H9B!7R!^S[_ ,%Z
MM.^,?A?]J7XG:E\&_"^D_#+]G&T\0'2X-!^+7A_7_BUXT\1MXTTKP/X6M?\
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M^G2Q,N(:BC=PLGHGIJVM+:;ZH^B]O_31/^^7_P *=L)9E ;*\DE&VD=?E/\
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M=;Q5F>$;8?\ GX3_ +XD_P#B:-L/_/PG_?$G_P 37N_]D67_ #[0_P#?(_\
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M]O3:LW9RI>]UT;3*K9GA95(NAA)4VE*TVT[)K5-WU;V6FJ[-7/Q\_P""3_\
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MPF.FF1?]]N/Y9H_X5GX3/73(O^^W/\\4_P#57.?^?Z^Y?_)$_P"LE.W\./\
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M6.W@O_$/AW4=,M'GD@26:*$3W*&62&*65$W-'&[@*?AC]F/X8_&3QM\>-/\
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M.G^)[;6AJ=I>ZA9S6EP)H5M9Q&'?^B[0->\/^)M#TK7?#FI:=KF@^(+"SO\
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MR_@XU5]-:-6G_P"#81CT]$!^)7B+PAXO_:L\!^,OC)JY^+]A\:YKGX>7-O\
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M:#<:>GB'45\0:G-;:?I)M=+>'5Y[F.TTN:XN;B"-^B=3VDG/O9?<K ?DE/\
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M3A_96,_Y]R^Y_P"1Z;=R>7;3NRM(%B<F,*9"^%/RA,_,3TQWK\1O^"@WQ/\
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M*/\ A,]3_P"?:U_[^#_XJC_A,]3_ .?:U_[^#_XJE_KED?\ T_\ NG_F<O\
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MDU??9ZGJV3ZG\S1D^I_,UY1_PF>I_P#/M:_]_!_\51_PF>I_\^UK_P!_!_\
M%5K_ *Y9'_T_^Z?^9G_8N*[/_P #_P#M3U?)]3^9HW'^\?SKRC_A,]3_ .?:
MU_[^#_XJC_A,M3/'V:T'UD7MSZG^5-<99'=?QMUTF^O:XO[$Q3TL]?[_ /\
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M?!SX@_%WX5?\% _CIKEGHGBC5_%>J3S_  "U7P;H&M:!H[QV7P^TW2_'%_X
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MK?\ B#1/#WB"2V:TDBE^PK)ITS7*+(%:,\'YBMO@;^V_^PIX7_9%_9>\(_M
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MOGK<,YF\5ATYK=Z>RI?R2[0_JYI0SG!K#5Y7B^51=K/7WXI:VTU,G _NQ_\
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M<YJ5<=+ZA"-L;45G%+_EW3=]3JQ&>X6'LE:,KT8N]E_--6^5OUZGGVX^D?\
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M9\)/I_A=;+2-"T[2'L]#T_2+:W32M.M42\EN8[&TMI#;N^62(?-'&FTJH 7
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M'#RTBOX:NEIRR7QJ1R?7:"A*-23C2=^=IM/EZI;-636S3\[G\<-M\ +OPO\
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M4?\ "&^-?^>7AW_P8ZC_ /*JO&_LW-_^A5_Y*_\ (];Z[EW_ $-5_P" TO\
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MJKQ;OI]W_!/8Q&,RZ->4%FD5&*:24:;2?-W=*][;]#.P/^>:_FO_ ,71@?\
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M,Z_9W1UE)KK4-1TZTM+Z^M)H+>*&YDE=IU@>.0^R_#;]H;]MW6M"\7Z!\/\
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M ,6/$G@"0IXITGX8ZK>:/-##+/<V1%N5U&_MH(E:6:ZM[0BYLXD3 >S=B5)
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MCXM\-6FOWW@[5K;Q-X6EO]V--UVUC2[MKNV>*= 9865,-+:. 5&00*\WT/\
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M;9:6IQMIUMT1<8*G@H4X>["G>$4NJYJDKO?5NH]5;2WF=;1116GL8_S3^_\
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M]GZ/\F5S_JS_ +R_^A+7'>$O^/[Q)_V%9*[$_P"K/^\O_H2UQWA+_C^\2?\
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MO:MXJM+VTU1]9MYM'M-1U"UFM+V["VSZE/Y19=L:XVE3ES8A8;57I*:J6O\
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ME1'=23)Y#AA\F_#G]GS0?#/AKX'?M':O^U)X^\-^//&>GZ;<>*=<U?6K+4?
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M6OM@ALHK$7MRRZ;%;RQ@3)-$(/J?Q-JVB+!IABOO,6'6[0QJP&V$M'=-*(\
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MN?SL].NIZF.GXM_,TM8(\0:: ,W<0) /(/\ $,Y^\.#GBC_A(M,_Y_(?R/\
M\57;]>P2T>+P]U_T]B<GL:RT]C4TTTB[:=C>HK"_X2'2^]Y#_P!\D_\ LXH_
MX2'2_P#G]B_[Y/\ \74O,< G9XS#)_\ 7V)2H5VKJC5_\ 9N-T/T/\JKGH>G
M0]3@?B>P]ZR7\0::48)?0!BIVEE(4''5COX'J:RF\5Z;^Z/V^R"W2EH59VW[
M5&&\E,'[6S-DA 83CC/&2XYA@93HTXXJA*5><Z=/EJ1:YZ=+VLDW?3W-5O=Z
M%+"XE[4*KM;_ )=RZ_+^EJ?DC^TIXT_:2^&7QR\,/X1_:%DUOQAX^^,G@'3_
M (3?LU^%/#^GS>#C\+VFTR#QI=?$W6;R:Y\00I#I_P!OUJX\80'2]+BB8QV5
MA>748M&RO'/BG]JOPM^T./@OI/QYU&Z\>_&+PE\6=2T=M>\)66D_"GP+<#0=
M6U3X86'PWUEA<7VK^+M)<Z4FOV.HWMY%J+Q7%U;6]JLR6J>]R?L:WEG^T1XR
M_:)\-_M+^+M!N/B%K&G7>J>$]0\*^'-<M+'1K"TM[&/PAH&K7D<=]X<\/SV\
M 6YL[59)))I993,6?%=/X7_8Z\(>'_B?X<\7>)/BEXX\>>#_ (=Z[JOB7X5_
M#GQ'JEG<:7X \2ZY'+:ZGJ*ZXBKK^M1P6\TCZ7:W=Y&MJJPK(EPB%"O[1P/U
M>&)^LTO95*7MHWDE+D]I[*]N_/I9-^M]#-TJZDX_5\1=;_NI6WMO\ONU1\J6
M_P ;OBKX._:.UZ;XY^,/VE_"GP>\!ZU\)O!^G^,_#>C?#JQ^"_BWQ5J>B:*F
MH:EXNEOWU#QUK&CZWKTTT5W/X>TJP>V2=E$-F4V)XS\7/^"F_CW3_P!H3XEZ
M[\.?'WP_F_9_^&_[.GQUUCPAH$NIZ7?:UX^^*7PUL->#>(-?M++49->MM 75
M-,-M::=9Z0+YUV7<S)&7C'Z'^/OV0_"_Q"\7W6O^(OC#XXN?A=K'BS0?&OBK
MX17$EC>>&-:U[PV;:[LK^VN'5-5TK3+Z\M8]5O\ 3]-E$1:22. 6\15%S?'?
M_!/G]D;QG\2X_B)J'@7P[H$EQ\./'/PKU'3?#]E8:7IVJZ+\0K:_L=:O9O(M
MWN5U@V^I7"?; UNZS$2NSOEB3S' TXTIRQ-+EJZPM--V6NJNK:+N73HUY2M]
M7K[2_P"74M;+7:_?L>:_L+_&#XB^)OB-?:'\1?B%\4[N7QE\+=,\>:;X.^-'
MA?POHFN/=S7UK9:EXB^&ESX8U2Y9/AW]JEDL=-TGQ-86WB&!G@>]8O&ZG]--
M.$G_  G6HG<C1_V/;G!_UX<LF3*.F3G VX')XZU\F_ /]FOP[\*_&DWQ$\6_
M%KQ7\8/%VF^%(_ '@;6?&$&E6=SX/\!6E]'?'0K*#2K.W6[>74(([J?4KN:2
M2>0,4@B5MJ_4%GK.G+XOU*47,'RZ; OF[2)9063_ %QW[6ZY!5$&>W7'+C,P
MP4Z^&DL502]M3O>I%;-ZO\_Z5]L-A\1R5U]7K+W)IMTY66V[Z>NO=Z'J-%<[
M_P )%8?\_D/Y?_94?\)%8?\ /Y#^7_V5=OU[!?\ 09AO_!T?\C/ZKB/^?4ON
M?^1T5%8'_"0Z;_S^Q?E_]>C_ (2'3?\ G]B_+_Z]+Z_@?^@S#?\ @V/^9/U>
MO_SYJ?\ @$O\BGXL;61HFN#0((KG7#I5['HEM=MLLKC4Y;29;);N1")$M%NC
M$USL(E,:L8F5MN?RA_9V^(7QV^*?[.7[1FL_M*_&N7X=>*/A3\<?B[;ZQXN^
M"<>G6L7A[P3X GDOX-(MSXKTK58GM[72K6X-Z;BVEGNBGDPS>9(H/ZKWOB/3
M=P1;N D;9FWK<HH\@^<K;XX)$D"^7ED5PQ *GKBOC&\_96^'%Y\*/CW\+K3Q
M;XB@T7]HKQAXS\7^)]8M-0M;74M/7QM?07NJ0:7=/I#V=M9>5#):I;7>FWCO
M',8Y+A@S&LYYI@*:K2EBJ35!X95.6:?^]NU%QUU3^T].5=Q*AB&[+#UWOK[*
M5M/.VOD?G[X/U+_@H/X8_9&NOVC=,^+7B'Q^]YX&^+_C*P\%^,[71]3\5V>A
MZGI%['\/'CM/#N@:+!JVM>'XB=5;2H3IZ75[%:1BZ*;XY-#X&?M7?''Q#?\
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M 5UVMN4 9[59^R7?_/M-_P!\?_7H^R7?_/M-_P!\?_7I<G_4-C__  3B>O\
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M?BK1=/ET#2=?O9-/9+NXAT>:\U:;2ECO7GB33I=0O9;8?N)+B1T+M^2^L?\
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M+_5I[;PY9W%Q9:)IEO>Q)<6&CVUW<1KA8S<(%R?E:W_X)"?"KQEX)^./P_\
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M ,2&K_\ ,X?\2B9C_P!'%PO_ (0U3^__ /M_PI_T$-(_\#8/_BJ/^$@\+_\
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M^9P_XE$S'_HXN%_\(:I_H"?\)!X6[:EI&.W^FP__ !RC_A(/"_\ T$M(_P#
MV'_XY7\  ^*OQ3  'Q0\=* .%/BK7R0/0D:@ 3]!CTI?^%K?%/\ Z*EXY_\
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MW=<_UXTJ?2TPV&<4N'<-^]C[1\J2?O>[K96^SYR[[(\.A]%[BNMQ"\NIYA?
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MG&[MDX R3GI7&>(O$?A^[L[)(?$.G2-_;%O)D/;J%18K@$G<RJJ+D9=B!D@
MU_!O_P +4^*3(ZGXG>.G#;1\OBK75QR>NZ_/X=NN:[/PAXV^)NNIXSTMOB+X
MZFD?P#K4MJS^+-:#6UQ'>Z4%N8B;_B6*-Y-I'.&8CVTA]+?#XESB^',,^6S4
MI5EC(Z6>E>I33GV:2BH_#KRW?D9K]%',<LP.*SBCQ7/,,TRUQ65X6C1JTZ&:
M.<5*2J153EC[.<Y4FYTW?EOM8_O#M?$/AM;>)7\0:1,"NP 7=H5<J,E2T<S
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M0UY8*3MX( ,@)(/! &<\8S56X\7^'8SM?Q'I:L4+8$UL_P HY.=K$ @9)!Y
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MF$5?_B)&&:73ZC4?YR_0_P!  ^(?#&"6U+2"%Y.+V#CD 'B0GJ0/QIA\1>&
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M09#GY?.QVQ;D_P LCK7]Z_\ PRC^S-DY^#/@(GU_X1C2_P#Y#))]Z7_AE?\
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M .O7]Z__  RM^S2_RGX,?#_'7_D6-+[?2T%'_#*'[,W_ $1CX?\ _A,:9_\
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M3/\ Y&I?^&4OV9_^B,^ /_"9TW_Y&K#_ (E/SG_HL,E_\,LO_E1?_$VF3?\
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M^<<0^-/!_$&)GC,=PIQ'2ISBH5(T,]I\T%*I=U:2O&:K7FHMJJH..C@[7?\
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MG-/93B:Z>*:/_63')ZY_MR_X90_9F_Z(Q\/_ /PF-,_^1J8/V3?V;4 Q\(/
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M(9Z_[1P[P[I?VY2Y$I)J4D[J49R3]Z4:J327NW2:_G8;_@IQ\*[N7X0>(/\
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<EV/)/O\ F**L9'J/S%%?N/U+S1^'>W7>?X'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex4-6_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_$"L/_T%2_\  5_F?TN?\-@?"?\ Z*1X$_\ !_:__%T?\-@?"?\ Z*1X$_\
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M?\*/]?*__/I?>'_$"L/_ -!4O_ 5_F?TN?\ #8'PG_Z*1X$_\']K_P#%T?\
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M_B!6'_Z"I?\ @*_S/Z7/^&P/A/\ ]%(\"?\ @_M?_BZ/^&P/A/\ ]%(\"?\
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M .BD>!/_  ?VO_Q=?S1_9E_NQ_\ ?"_X4?9E_NQ_]\+_ (4?Z^5_^?2^\/\
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M:_\ Q=!_;!^%.?\ DHW@/_P?6O\ \77\T?V9?[L?_?"_X4?9U_NQ_P#?M?\
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M_%4?\0\Q/\Z_'_(/^(X97_SXG^'_ ,D?SS;_ *_I1O\ K^E?T,_\.F?V=O\
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M\Z_'_(/^(X97_P ^)_A_\D?SS;_K^E&_Z_I7]#/_  Z9_9V_Z)5X7_[]-_\
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M ,D?SS;_ *_I1O\ K^E?T,_\.F?V=O\ HE7A?_OTW_Q5'_#IG]G;_HE7A?\
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M_P @_P"(X97_ ,^)_A_\D?SS;_K^E&_Z_I7]#/\ PZ9_9V_Z)5X7_P"_3?\
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M'\3? 7B75)K.S\)^(+Y?&7B;PHGPRALY/^$DBM-,L+ZXMM3,Z7&=L[VUOE3
MJ;+R/:X926747F?IE]LBVY\R/![[A_GL?RJ16#+D'(]17X]_LF?MK>-/CK^W
MK#XHUCXV> ;&'6/V<+;Q'=30P-%X=\&W]QK$<C+=V3WP$DT*LT3N\D3G*!@N
M1G]?=-=9+"%E8.I4$,"?F'KR2>?<YK6I3<'RLE,E$RD_>7TZT@N(V!_>)\O7
MYNE?''_!7*_AO/ WPZ\+^(?B3XB^#OP]\:>)SIWBSQEHNJ+I5UIL,5C>7%M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5XM^/'AOP9XWM_#
MNH7T,6M7D;36MH77SKI$";S&F=S[?,3. <;AZUVM?&_[97P \?>)OVZ/AO\
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M>*E\/6OB[QC=>)+>WLKZZ3^T+>XU1KJ2$R-;L=/D-N0ADM@Y9C@\*"4^(?\
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M_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\
MA>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_
M]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>
MA^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H
M ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__
M 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]
M8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ
M/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%
MW_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8
M_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:
M\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?
M_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\
MA>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_
M]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>
MA^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H
M ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__
M 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%W_\ WX:C_A"]
M8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8_P"@7?\ _?AJ
M/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:\O\ ^$+UC_H%
MW_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?_?FO+_\ A"]8
M_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\ A>>A^MW_ -^:
M\O\ ^$+UC_H%W_\ WX:C_A"]8_Z!=_\ ]^&H ]0_X7GH?K=_]^:/^%YZ'ZW?
M_?FO+_\ A"]8_P"@7?\ _?AJ/^$+UC_H%W__ 'X:@#U#_A>>A^MW_P!^:/\
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M5RDNSW;\Z-GNWYU%YC_WDH\Q_P"\E5S1[H.4EV>[?G1L]V_.HO,?^\E'F/\
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M]T'*2[/=OSHV>[?G47F/_>2CS'_O)1S1[H.4EV>[?G1L]V_.H_-?^]'399I
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M[0P_Y=?!/_@Z;_XU2^HY]_)/[R?[<X0_Z<_^ K_(\9_X>,_'?_HK/C3_ ,&
M_P#B:/\ AXS\=_\ HK/C3_P8#_XFO9O^'"O[0O\ S[>"?_!VW_QJC_APK^T+
M_P ^W@G_ ,';?_&J?]GY]_)/[P_MSA#_ *<_^ K_ "/&?^'C/QW_ .BL^-/_
M  8#_P")H_X>,_'?_HK/C3_P8#_XFO9O^'"O[0O_ #[>"?\ P=M_\:H_X<*_
MM"_\^W@G_P ';?\ QJC^S\^_DG]X?VYPA_TY_P# 5_D>,_\ #QGX[_\ 16?&
MG_@P'_Q-'_#QGX[_ /16?&G_ (,!_P#$U[-_PX5_:%_Y]O!/_@[;_P"-4?\
M#A7]H7_GV\$_^#MO_C5']GY]_)/[P_MSA#_IS_X"O\CQG_AXS\=_^BL^-/\
MP8#_ .)H_P"'C/QW_P"BL^-/_!@/_B:]F_X<*_M"_P#/MX)_\';?_&J/^'"O
M[0O_ #[>"?\ P=M_\:H_L_/OY)_>']N<(?\ 3G_P%?Y'C/\ P\9^._\ T5GQ
MI_X,!_\ $T?\/&?CO_T5GQI_X,!_\37LW_#A7]H7_GV\$_\ @[;_ .-4?\.%
M?VA?^?;P3_X.V_\ C5']GY]_)/[P_MSA#_IS_P" K_(\9_X>,_'?_HK/C3_P
M8#_XFC_AXS\=_P#HK/C3_P & _\ B:]F_P"'"O[0O_/MX)_\';?_ !JC_APK
M^T+_ ,^W@G_P=M_\:H_L_/OY)_>']N<(?].?_ 5_D>,_\/&?CO\ ]%:\:?\
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MZ\?\+8\;?AJ _P#B:]F_X<*?M"_\^O@K_P '3?\ QJC_ (<*?M!_\^O@G/\
MV&F_^-55/ Y[S+F4TO)_\$FIG'",XN,/8I^B7_MK-;Q;\8_B]I_A+5K71_VC
MO&6I>,O".GV6I>)+&Y'V/3["WNFA5O*N"6\UK=YX#(=H#)(2A)!4\;^U=^U#
M\<OV:_B[)X5A^-WC36O)L+2\>\%UY*S&:%9#M4C(7YN,XZ]*]^\2_P#!//\
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M/^'C/QW_ .BL^-/_  8#_P")KV;_ (<*_M"_\^W@G_P=M_\ &J/^'"O[0O\
MS[>"?_!VW_QJC^S\^_DG]X?VYPA_TY_\!7^1XT/^"C'QW/\ S5GQG_X,!_\
M$T?\/&/CO_T5GQG_ .# ?_$U[+_PX4_:%_Y]O!/_ (.F_P#C5'_#A3]H7_GU
M\%?^#IO_ (U4_4<^_DG]X?VYPA_TY^Y?Y'#_  /_ &R_CW\9?B38Z&WQH\8:
M;921RW=_?2WGF?8[2")YYY @7+,(HY"J\9; RN<CV?P1\6?&GQ&\0Z/-8_M2
M?$AM%\56QCTB%=(?^U[B^27RYH7C4F-(X 4EDEW@%#D9VL:SOAE_P1;_ &FO
MA'XUL?$&BKX&M]1L&<+OU42QRQNC))&Z-"0R,C,I!'(8].M>P7?[&?[7]]!Y
M<F@?!.&-M'DT#RXK@QI%8RG,L4>V,;0^%!(PQ"@%FQ7T.!PV8*BO:^TOZO\
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MMZF@#V?_ (7=X;_Y^I?^_#?X4?\ "[O#?_/U+_WX;_"O&-[>IHWMZF@#V?\
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M_1IK)6Z[CVZT?8(_]K\Z^*_AM_P5DN)+Z.'Q=X96.V+8>YTN0M(@]1&Y^;Z
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M_P!M;X(Z]XLOK=M6^*FEWC>-CX"BOIDU=K.^U!9(HXY!<Q;X8[5Y9XECFE9
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M[Q[\U%=_LW:'?SS22:AXH:2:,1/G7KME90,;2ID*D=3@C&6;^\<Z/]O^//\
MH7_"G_@^N?\ Y#I/[>\=G_F7_"G_ (/KG_Y#H_<=OS)]I5_F,K_AE[PVLRR+
M=>)(Y$38CIK=TK("22%(?Y5.X_*,+W !YI+3]EWPY8"W\FZ\31_8V+0;=<NE
M$.>NT!\#.:UO[=\=_P#0O^$__!]<?_(=']N^._\ H7_"G_@^N/\ Y#H_<=OS
M'[2IW*-K^SGHNGSS30ZAXIAFN6W32KKET&F/3+?/S_\ 7JQ_PHS3_P#H->+O
M_!]=?_%U-_;OCO\ Z%_PI_X/KC_Y#H_MWQW_ -"_X3_\'UQ_\AT?[/U7YD.5
M1_:(?^%&:?\ ]!KQ=_X/KK_XNC_A1FG_ /0:\7?^#ZZ_^+J;^W?'?_0O^%/_
M  ?7'_R'1_;OCO\ Z%_PI_X/KC_Y#I_[/V_,7-4_F(?^%&:?_P!!KQ=_X/KK
M_P"+H_X49I__ $&O%W_@^NO_ (NIO[=\=_\ 0O\ A3_P?7'_ ,AT?V[X[_Z%
M_P *?^#ZX_\ D.C_ &?M^8<U3^8A_P"%&:?_ -!KQ=_X/KK_ .+H_P"%&:?_
M -!KQ=_X/KK_ .+J;^W?'?\ T+_A3_P?7'_R'1_;OCO_ *%_PI_X/KC_ .0Z
M/]G[?F'-4_F(?^%&:?\ ]!KQ=_X/KK_XN@? O3S_ ,QKQ?\ ^#ZZ_P#BZF_M
M[QW_ -"_X3_\'US_ /(=!UKQXW_,!\++]-=G_K:"E_L_;\PYJG\Q"/@99[O^
M0UXPV_\ 8P7?_P 778+IJVVGI"KR,$18PSL68XXR3Z^]<F-6\>[O^0#X5_'7
MY_\ Y#KJH'N#:QM,JB1@NY VX*<<X/&<'UKHH\J7NA4N]V>*^,_V7M6^)/[3
MB^+-2\6:Q;^#8]%CM$\.V-U);^?>^8Y:XED0J554*!54YR7)., =&G[*OAEL
MDW'B9N>/^)_>?_'/K72ZSJWBJ+5'_LO1-!NK7&!)=ZG-;2''^R+9_P#T(U!'
MKGCO''A[PG_X/;C_ .0ZYI4Z46]]0IQE&.AA?\,J>&/^>_B;_P 'UY_\<H_X
M94\,?\]_$W_@^O/_ (Y6]_;GCS_H7_"?_@^N/_D.C^W/'G_0O^$__!]<?_(=
M+EH]W^)5Y&#_ ,,J>&/^>_B;_P 'UY_\<H_X94\,?\]_$W_@^O/_ (Y6]_;G
MCS_H7_"?_@^N/_D.C^W/'G_0O^$__!]<?_(='+1[O\0O(\L^/'PFTWX1?"S6
MM>T?PUXZ\::IIT0:UT?3_$5Q'-?R%U0('>4*@!;<S'(50QP<8KYE\*_MP> ?
M%_Q^3X9V7AOQ/)XTMM-U#49]-@\=.UU?O92:DABTV-Y8S?;VTQ@)%**OVF$G
M($H3ZU^/WPL\2?M'?"77O!.O:+IMOHOB*'[->/I7BZ^T^Z:+<"Z+-%:AU#!=
MI"D;E9AWKP_PC_P2L\-?#Z'PZ^F^$9+:[\*Z(V@65VOQ)UAKE[<17$4#2N(
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MP?[?NOE_\?K\U?VLO$W_  G'QRUQ8=1UJ[TW3+M[#3TNM5EN"!&0I(+L3\S
MGK7Z8G6?'9'_ " ?"W_@]F_^1:YS6O VH:O(TU]\._AK?2,0[-<7Q9B0<@Y-
MD3P>]2XT&_\ ARXU:BV>IY1^R_\ \$]/".A?#C2=4\1VNJ:CXDO8EN99&U">
M-;8.H81*@8+A0>I!.2><8 ]6N?V1?!][ 8YH=5EC/.R349F4?@6P/PJMKO[1
MMQX19H]2N/ACIS1'#1R>+F5E/IM-J#7 ^*O^"CVD>%HV&[PEJ4BN4\O3]7O;
M@\>ZV.#]02#1*%'HG^(+VK^*QXM^W]^Q+X<^#OAK3_%'A?\ M.QMY+K[+?6Q
MOYI(P74E74,QQG##\1C%+_P2_P!(CUWQ+XHT&74_$4-O)!'?QK:ZO<6ZJX)1
MB0C@'(*]?[M8/[3_ /P4 OOVA/AY-X9C\&V>FQ274<WVJ35VF*A"3\J"W4Y)
MX^8]&-3?\$R[[Q!:?'#5QIUCI%S(^C2%DGOW@4XDCQR(&/<^GXU=.GAW>Z?X
MA-UH_"U;Y'VU>?!K3K*REN)-<\7"&&,R.S>(+LX &>\GH":_,SXOZ_=?M$?%
MEKVSE\27BWUPMII-I)JDTTZHQ"Q(I9\;W)YSW/4=:^_OVI?B%XT\)_L^^,+N
M;1?#MO$VF/;+-'K,TCQF4"+(4VP!/SG!SFOB#]B_P]JGB7]ISPW;V]C8SR6_
MVBZ :_>#E87 ;<(B006R".A'%91IX9RU3_$I>W2YK_D:7[+S^&OA[X)TIOB!
M\)?B+:^.[SQAHWA>Z0:BUQ'H!U06[0R74BN([?RHKJ(NAWL7<*C,#N7MM?\
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M_!]<?_(=/_9^WYF'-4_F(?\ A1FG_P#0:\7?^#ZZ_P#BZ!\"]//_ #&O%_\
MX/KK_P"+J;^W?'?_ $+_ (4_\'UQ_P#(=']N^._^A?\ "G_@^N/_ )#I?[/V
M_,.:I_,0_P#"C+'MK7C#_P ']U_\77@G[8WQEB_9&7PK=3>'?B=XKT7Q!J=M
MIMW?Z;XCF5=/:XO;6R@14:3?-,\MT&6-0 8X)WWC8%;Z!_MWQY_T+WA/_P '
MUQ_\AUXU^T/^R7J'[3GCWP-XC\0V-YI^I_#^[>_TS^P/B#JFDPM+* KM*L%L
MJR90%#N_@ED7HV#/+3;3UL:Q<UJK7/+O@I^U#=?M#^*_B-X;TKX?^/M0U'X;
MZA<:5JL=MX_2:VGNELX[B*T\TRJ%E>20P.#\J/&XW.N37G>C?\%-/ >M?$?X
M5>%SX:\?6&O_ !0L8TT<3^,G$8EDN+VVBBB,<ADEMS+IK++.$_<"YM69,RD#
MW_X9?L#Z/\,/ GC_ ,/V/@71[RS^)HV:_+J?C74;ZYGB53'!;QS2VQ>.WA0X
MBC0A(@<* *S-"_X)K>&O#LO@AH_ >EW!^'UK>QZ1]H\<ZE,&N;MY'FO9PUL1
M/>EYIG%U(#*&E<[LL2=(^P[?F/VF(ZO\BY^R)XMN/VR/V>M:\3:?:^*?!\TE
M]JNE:)=CQ;=WEG?_ &:1X!J$3;8R]NT^_9\AW*@;^+%>D?!+]ES4O!/P[TK2
M_%7Q \<>,O$%NA>\U6YU6:V:X=NN(XBJA1T4')YK2^$'@?7_ (%?"KPWX+\-
M>$?"ECX?\)Z9;Z1IT)\0W,C1V\$:Q1@L;/+-M498\L<D\FNF&K^.D.?^$?\
M"O\ X/)OZ6AJ7'#\RE;\S%.JI<[>I&/@58 ?\AGQ?_X/[K_XNC_A1>G@_P#(
M:\7_ /@^NO\ XNIO[=\=_P#0O^%/_!]<?_(=']N^._\ H7_"?_@^N/\ Y#I_
MN.J_,?-4_F(?^%&:?_T&O%W_ (/KK_XNC_A1FG_]!KQ=_P"#ZZ_^+J;^W?'?
M_0O^%/\ P?7'_P AT?V[X[_Z%_PI_P"#ZX_^0Z/]G[?F+FJ?S$/_  HS3_\
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M]N\77MS<37D9D9;BYDDM2\\IDF>5GD+%I,N26 -:<M%-Z,KGK-*]CY)\;_\
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MD>I"91_$U.%PG]['X5Y9_P -H_!W_HI_P\_\'EM_\71_PVC\'?\ HI_P\_\
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MPH_\*VP_^.TC?M[_  -'_-9_A/[Y\76'_P =I\H]3UC;[?K1M]OUKR4?M]?
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MG,_[O_@3#_B+.0]I_P#@*_S/Q3Q_N_\ ?(_PHQ_N_P#?(_PK]K/^(>;X(_\
M02\>?^#./_XS1_Q#S?!'_H)>//\ P9Q__&:/]2<S_N_^!,/^(LY#VG_X"O\
M,_%/'^[_ -\C_"C'^[_WR/\ "OVL_P"(>7X)?]!+QU_X,H__ (S0?^#>;X)#
MKJ7CK_P9Q_\ QFC_ %)S/^[_ .!,/^(LY#VG_P" H_%/'^[_ -\C_"C'^[_W
MR/\ "OVL_P"(>;X(_P#02\=_^#./_P",T?\ $/+\$_\ H)>.O_!E'_\ &:/]
M2<S_ +O_ ($P_P"(L9#VG_X"O\S\4\?[O_?(_P *,?[O_?(_PK]K/^(>;X(_
M]!+QY_X,X_\ XS1_Q#S?!'_H)>//_!G'_P#&:/\ 4G,_[O\ X$P_XBSD/:?_
M ("O\S\4\?[O_?(_PHQ_N_\ ?(_PK]K/^(>;X(_]!+QY_P"#./\ ^,T?\0\W
MP1_Z"7CS_P &<?\ \9H_U)S/^[_X$P_XBSD/:?\ X"O\S\4^G]W_ +Y'^%&?
MI_WR/\*_:S_B'E^"/_02\>?^#*/_ .,T?\0\OP3[:EXZ_'4H_P#XS1_J1F7]
MW_P)B_XBQD/:?_@*_P S\2-2XL9ON\JP^Z/\*_J/\$IGPCI2_P /V2+C_MFM
M?$4__!O)\$Y4:,ZAXYVMU_XF,7_QFONG3M-70]+CAC61Q;Q+&BG)SM4*O/OC
M]:^PX2R3$Y>YK$]=NI^7>(W%F!SIT'@4UR7O=6W/YQO^#DM-G_!5[Q*HSA?#
MFCX_&%JY'_@GC\*?@_X@_9?^+WC#XK_V+:Q^%=:\.P65_J&A7FM>5'<->^?$
MEO;7,!!D$2#S&)"':37[6_ME_P#!#GX+?MV?'2Z^(?C>;QG:>(;RSALI3I>J
MI!!)'%N$?R20OA@IQP:\M'_!KQ^S6(V7^UOB@JL0Q4:];X)'(/\ Q[=NU?:K
M3<_,S\K;>+X Q_LL_$7XH:9\)_MS^'_&)\)^$])O[^X^R2V%]NN;>ZO@DA=Y
M[:&&Z@!1]H$BE@Q0DY_Q/_8N\%W/_!,FR^/7A^WU[3=6U+5A]HLEO8DT:T\V
M]NXOL%M'+&)I9(HUB.4EF;.]GCB %?K W_!KM^S48?+_ +6^*)C5@X7^WK?:
M",X./LW49/YFFO\ \&O7[-KQ+&VJ?%!HU&%4Z[;D*/8?9O<_G4:I-A'?4_,7
MQ1_P30\)Q^&? =KX=C^)&N:WXJ\-7FH6NM0-92:#XIU :%)J$-KIZK^_+Q72
M_9I(\.696 ,;$*/5/$7_  2:^"GPI^!0UOQA>_%JU\10Z7)?WEI:7MBJVDEK
MX=L-5NH&1K9F#M--/ OS'9P6#>6]?<R_\&NW[-9,.=4^* ^S_P"J_P")];_N
M^"/E_P!&XX)''8GUJ:;_ (-?OV;[@?/K/Q4DV]-VOP-CI_T[?[*_D/2J6X(_
M/CQ1_P $C?A_?^ -4\3^&;KQ[?:1H]KXJO-59[VUD_L;[)H\6H:5!.4B&UY&
MD978[?-"9C"#+#L?B-_P2?\ @[X.LM:\=ZII_BC3?#MIXUMK."QL=5@CTN6Q
M.L66G26JCRI3&P2X>5FEN8W W!8W0B4?; _X-??V;\2?\3CXK?O@/,_XG\/[
MS P,_P"C\\<4DG_!K_\ LX3*8VUGXJLK AE.OP8.>O\ R[=\#\J(@</\-/V;
M/AKX&\'^&O#_ )S> M.T.PN=8U.PU'48!>6>G1ZCJ$4K,S $NHCM%4D8VR?Q
M'FOAS_@M!^R%X%^%7@/PW\4O#>N:IJ&J>-+BU21I99I=,OXFL-[/;2"T2']R
MT:1L4N)LM+\WED"-OT;F_P"#7K]G"<,LFL?%5_,0QL&\00'<N02I_P!&Z9 .
M/4"HC_P:X_LTA(U_M/XH;8<^6/[=M\)G@X_T;C/?'6IE%O8:/RG_ ."!.Q/^
M"N/P>9%C7S)=49F4#+?\2N\'7W 'Y5_2I\58ED^&VO\ J-.N&'M^[:OD']E#
M_@@?\$?V-OV@?#WQ&\)WGCV;Q!X9:<V8U#4XKBV(FBDB?<JP*>$D.#NK[2U[
M2(];TBZLY@YBN8FAD ZLK @C\B:FI%RIM+>UBXR49QGV:9_++I<>S3X0/[@Z
M@'L*L8_W?^^1_A7[46__  ;Q_!&--J:AXZ2-3\JG4T) ZXR8B>.GX5)_Q#R_
M!/\ Z"7CK_P91_\ QFOR.MP7F4YN2M_X$S^E,-XJY%3I1@U+1+[*/Q3,C0E9
M(SMDC(=64#*$'(/X=?PKZV^"?[2.D^/O#EG;:AJ-O9Z]MQ/%,1&MP1T=">.>
MI'N:^^'_ .#>?X'E,-?^/#T/.IQ8S]/)J&7_ (-Y?@G(.-0\<]<Y.HQG_P!H
MUZV39'F^72;34D^ESYGB?C#AK.Z/+/GA)/1\J_&Q\,>*?V9?"/CG4I-0FLFC
MN+H[Y9;.8KO;Z<C\164_P*^&_P ,)/[0O5L8Y(UV"34KD;5]MN1G\J_1#3O^
M"#/PJTRV6*'Q-\38(UX"Q:V$4#Z"*JE]_P &^?P7U2?S;C5OB!<2]WEU5';\
MS#7O2P552]I##PY_-_Y'QN'SG#1_<U<94=/MRO\ S1X9XH;1=/TWQ%JW_"(Q
MV/PWT/1]/N],\5Q:@6?7)IGM%,:DLR%6628$A!L**25VLI\Y_P""HG@GPS!#
M?:3X;73=/MX;"QUB"R2\#%7,)9A\Q))RWKSZ5]>6W_! #X/Z5930V^N_$:&&
MXC,,L46L(JRH2I*L!#RN54X/'RCTJE-_P;U_!.YDWR7OCR1L ;GU2(G & .8
M?2JQ%/-:U"5*4(Z_WGH:X7%Y!0Q4,3"K.\7?X=_6\F?BL$!7E5Z#L/K7I_[/
M?[1<WPIFBTG4%6;P_)*6<A-TEMGJ5'<9^8CZU^I?B/\ X-^/@SIN@7\UO=>/
M&E@MGEC4:G%\SJ,@']R.I '';-?)GP0_8J^$OC7Q[H6AZ_IOBJVBUJ]BLWO(
M->CC6$OP&*F ]R!C/O[U\CEW"^<X2O[6G)>EV?H^;>(?"V8X5X6O&5K:M0UO
M;I9F)<^/O 7Q9TL0W%]H>H6C'<L5RR1O&?HV&'X&L^PM?AA\*KG^T+>3P_I\
MV<B9+A7D& ?NX9B.O08S[]OO#_B'O^!,^&&H>/23P&.J0GW_ .>'I36_X-[?
M@?&X_P")CXZ..?\ D)PY_P#1-?55(YHX\TZ--3[K<_-J>*X?@^2GBZZI]N5/
M]3\^=#_:CB\8_%O3=!T6#=IMQ)*)+N3=YDBK$6!P>GS#\JN?MAS[/@Q,JG;N
MO[?;CN3OY_2OJG]H[_@FC\$?V.[.VU7PWJWBF\\9K,8+6SN]2AFCB#*#(TJ"
M-3]QLC/KQ3/V9_V%=#_;>O=8TGQ6VL6_AO28H;D2Z;(L$C7FX[5W,K97:7.!
MQ]VM'@\PK9=4HXAKGEM;H<U3-,EPN;8?$X%25*.LKI.3?>VQ^59P!SP.^%%>
MH_L[_M#M\+[J+2]4$EQX?D8G*)N>VSW4#DKURH]<]J_5R+_@WG^":M\VI>.O
MPU./_P",T2_\&\OP/9,?VAX\_'4HO_C-?'Y?POG.#K>UHRCIW;/U'.O$3AC,
ML,\)B(SL]GRQ/B34[?P;\=-$CAGFTG7+1&+H5<+(A('(Z,IQ@8-<_'^QUX)B
MDW&SU!D7I&;@A<?]\_UK[\M?^#>OX+V-SYUOJGCR&3^^FJ1JWY^36E)_P0B^
M%SQ[6\4_%)E]#KPQ_P"BJ^P^J8BL^?$T(.7=,_,(YIA<(W3R_&5(P?2S_1V/
MD'X&R^ ?"GCO2_#M]=:7:PS0SBSTS[6$DU*Z2"1H(-V[)+S+&N"P+%L Y-.U
MS]G/Q%\:O%?A%O$7P3TNR7[)<7>K6KW]S=0:'I\5T&6Y2WAE+27ES&KHL8+;
M&C7Y5^;/U1/_ ,&\_P $Y69O[4\>%GY8MJ<9)[_\\:M2?\$!/@[)"(Y-=^)$
MBB1I0IUA,!VQN;!BZG:N3U.!Z5.,P^8XBDJ4J<8I=FS;"YADV'J?6859NH]V
MX_\ VQ^*.N6<=CKVH6\5K<6,5O=2Q);7.&FMU5R CG)RR@ 'W!JOC_=_[Y'^
M%?M8_P#P;W?!)VR=2\?-[G4HL_\ HFC_ (AY_@B?^8EX[_'4X_\ XS7P\N"\
MSE-NZ^;:/U7#^*V1P@HRYM%_*OU9^*>/]W_OD?X48_W?^^1_A7[6?\0\WP2_
MZ"7CK\-3C_\ C-'_ !#S?!'_ *"7CS_P9Q__ !FC_4G,_P"[_P"!,W_XBQD/
M:?\ X"O\S\4\_3_OD?X4#D_P_D!^M?M9_P 0\OP1_P"@EX\_\&4?_P 9H?\
MX-YO@F$/_$P\='CI_:4?/_D&C_4C,K_9_P# F+_B+&0OI/\ \!7^9\#_ +.W
MBC2[#X':+%-J6GVTT<3@B2X16'SD\@D8ZFOF_P",]Y%J'Q>\2S0RQS1R7[LK
MH0ZD<8P<FOV ;_@WE^"+C_CZ\<M['48O_C-2P_\ !O-\$SNS?>.TYR?^)G'S
M_P"0:^BS+)<VQF$IX:48)0ZJ3NSXS)>*.'LNS*MF$93?M.G*M/Q/Q6Q_N_\
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M?_QFC_4G,_[O_@3#_B+.0]I_^ K_ #/Q3Q_N_P#?(_PHQ_N_]\C_  K]K/\
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M6<DB\LBEAGVYJ:H-3_Y!\_\ US;^1H \N?\ :"OA(VVQM6&2!\["C_AH._\
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M%EX?BOO%EKJT,=E=WZW4+$S3[)&C5%/ERRJ%567@$9S]I#^9%*,[_"SG)?\
M@GQXKM_"L>@VUUX4L;2'3]/BU"XCN[Q&\4R6HTZ-4ND$8%I"8[/RB;=]S*P8
MCD@=E\6?V&Y/BY\(M%TF:33M%UYM5:XU74["620PP,ZN((6F5FN&BB2VBBF?
MRID6/>)3\R-YI\.O@S\1/#GB.*&3XF>"M+L_[.M[2;5Y=97499,VVG0SH)1<
M1W4FX6]R 2B")I?,0N6Q5[6_V>M6M/@9X9T[2O&WA5?%,FG/;ZM=Q>+)(8(K
MV*.VAM+])))7EE6VAA^9 3)(TQZ[V(/:0O926URO8SM>SWL=7XZ_8X\5Z_XQ
M\>WUCIOPUFL_$'B6ZU?3K6]>:6(17&E#3GDG4P$"YBVI,A&X$R/\V>#]?_LV
M:1_PCVJ:7I_G/<-8V MWE8Y\YDC1-YSSN(49R!_.OC'XA>&O$VM>'OB9I,$G
MP[NO^$@OKJ7P_J37^FIJ-L9FNVEDF87.V58@R")QMFC#.!$1S7U[^S-XHTN\
M\66-C#KFEZE?QV9646^HQW+2,J(&8 '=@GG)&3U.#D4_:1O9.Y+A-*[6A]"Q
M_=HHA_U?YT51(K=*YSQ]X0?Q?H&J6-MJ$NB7M_:26\.HVL<37-E(R[5F19%:
M-F7@@.C#@=N*Z-JY3Q'X#U+6M8EN;?Q=XBTN&3&VVM8K)HH\ #@R6[OSC)RQ
MY)Q@8 SJVY=5<J&][GY6?#__ (*8>-/V(_#7CJ\\?^)=?^,S2?$+Q7X7TFY\
M23V&AVMHF@J&M[6![+3]LVH:@)ML2.!&\D>1LY!]?O/^"QUO\/\ XV0_#_Q3
MHO@"Q\3:YX_C\/VVCG76M[[3=+D?3(D>0O"T<ETGV]I6A5QNC5BHV*6K[:;X
M%7#Q[6\8^))-TPGDWVNF_O)!SOP+4*&)Q\P /7&,YITOP.O)I(Y&\:>)9)HY
M#-YCV>EL[,=H))^Q]<*HR,' QT  QC:^M/\ $T]I=[GY\VG[:7Q#U/\ X)?_
M  G\6:UXX3P_<>-_%^LZ/XM^(JV]A"WABT@O]2CMF!F7[)!YSVMM9B>8>5&)
MB[$'YA3^&?\ P6/U[X6_!JSAOO"]O\0%\,^!?^$IUCQ%=:E%9W.H1?\ "1W.
MAQ2&.TM[BVD@V0QSR7,)VO"9)(X\N%K]$)_@-=7%E-:GQCXD%G,6+6XM--\O
MYFW'"_9,>O7)Y-$?P(N(E"KXR\2(OE^256VT[:8\8\OFUX0=E&,$D]Z-+_PO
MQ"4[[R/D?PO_ ,%<=-UOXC_"W3)O#_P_GT/XD:KJ.CVFK:5XT2^^VSVT\D4-
MS8VZ0">ZL)#"6>\V"./YM^$7>=CX2?\ !0P_M/?L/_%;QUHMQX*\!^*/ +ZA
MI=SJ$<S>*-!TRZB@#I<BXMHP+JW43(6\C=LY#8(9!]/VGP&GLY[9X_&7B/-F
MI6%19:6JQ ]<;;0$9'&!QCH!3['X'7MA9^3'XV\3!-S,=MKIJ9+#G[MH!W;G
M_:-3RW5G3_$F,NJG^!^;G[/7_!9__A7'P:^$>D^(KB/XG:[XS\?7/A"75[^^
MM-/EO;4ZC;6:W]A-;1-;:C!%)>QYFC6W9U3<8XP#CJ_A/_P61\0O\4_"_P +
M=0^&<>MZM#\-;+Q3?>+M3\3:=H]MJ4K:)'J37)@D =;9I#]G:XC4I&[N=N %
MK[T@^ 5Q;6T4:^-?$H6W4K%_H>EXCRV[@?8\#YL'  'RBI$^!=U'MV^-/$VX
M1>07^R:9N,><[,_9,A>O QCC&,53;_Y]_B',K6<SR_\ X)S?MD:+^WS^SU;>
M.K'1K#3V_M*[TN[M[:X^VVL4]NP1S#<[5CFC.Y 'C+*V>#P0/H)-+M3]VUA_
M[Y!KD;'X)ZAID$45MXZ\5V\,1)$<5MIBH<]L?9.!GGY<<_4YL/\ "?56^]X]
M\7?]^M.'_MK4N*?_ "[_ !)]9LZ?^RK?_GUA_P"_8_PI?[*M?^?.'_O@5RO_
M  J34_\ H??%_P#W[T__ .1:/^%2:G_T/OB__OWI_P#\BU*I_P#3O\2N9?SG
M4G2;4C_CTA_[X'^%)_8]K_SZQ?\ ?%<O_P *EU/_ *'SQA_W[T__ .1:/^%2
M:G_T/OB__OWI_P#\BU7*_P#GW^(N9?SG4?V3;?\ /K#_ -\"E_LJWQ_QZQ_]
M\"N6_P"%2ZG_ -#YXP_[]Z?_ /(M'_"I-3_Z'WQ?_P!^]/\ _D6I]G_T[_$?
M,OY_P.H_LF _\N\7_? _PH_LFW_Y]HO^_8_PKE_^%2ZG_P!#[XP_[]Z?_P#(
MM'_"I-3_ .A]\8?]^]/_ /D6J]G?_EW^(<R_G.H_LBW_ .?6+_O@?X4?V1;_
M //K%_WP/\*Y?_A4FI_]#YXP_P"_>G__ "+1_P *DU/_ *'SQA_W[T__ .1:
MGV?_ $[_ !)T_G.H_LBW_P"?6+_O@?X4?V1;_P#/K%_WP/\ "N7_ .%2:G_T
M/GC#_OWI_P#\BT?\*DU/_H?/&'_?O3__ )%H]G_T[_$-/YSJETFU'_+K'_WP
M/\*FD;9"B*NW/R@$A<X]/P]*XX?"O50<?\)UXMQZ^5I__P BUV,.G-#;1QF>
M21HU"F0G#/@8R<8'Z5TT[-6M8<E;K<Y!O@9X<G^+DWCJ72;6;Q1-I,6C"\D3
M+16R2RR[$)&5#/*Q8CDX4=A71QZ+'&N!%#U_YY?Y[5E>)/A]>ZUJS74'BCQ!
MI:L OD6JVIC&._[R%S^M4&^%&J.?^1[\7#Z1Z?\ _(M82IP3M&%V$?=5^:QT
MW]DQ_P#/*+_OW1_9,?\ SRB_[]UR_P#PJ75!_P S[XN_[]Z?_P#(M'_"IM4_
MZ'[Q=_WQI_\ \BTN1_\ /O\ $KVG]_\  Z@Z2G_/&+_OW7QI^W]^TMJOP4_;
M4^ OA?2?&UWH_P#PDVK007?A6/PS'=Q^)+:>Z2VED6Z<;A);F2.0Q1%'2/S)
MRS+$8W^H_P#A4VJ?]#]XN_[]Z?\ _(M0W7P7OKLH[>-O%'VB$MY4YM].:2'<
MA4E2UJ<'G/'7 !R,@OD_Z=_B-5+?;_ ^4;SX]?%3X?\ P.\6?$:\AU#QUJ/P
M\\9:_HMSX3\*Z";QM81KJ.WLD141I_+LPYE=E1I'5)<*6*J?D?X=?\%)?CM>
M:CX%U+_A*-.\1:O?> -9U7_A#)=+BTS4-0N;2+7FFO)K"6%;@HLUA:) (7VJ
MJ.DH#2QLWZS_ /"FM065F3QQXLB5F9PD<6GJ%)]Q:Y./]HG/?-,7X(7B31R)
MXT\3+-"#Y4GV;3@T9)))&+4=<]#E?E'&<Y/<O\']6L4JKZ3_  /SA\#?M/>/
M/'W_  2S\0?&#6/C%XVL8O!-SJ>BQZEH.EZ.LWBZ]34D2SDMKB:T>WE@D:3R
M!-'!'N!Y0/&^[O\ ]LWXV_'3]C?X9:\I\5:3KFJ:#\)4U&"[BT99;W^TXKS2
M;*]U:Y4+Y;!!<7$JQQQI&HC);)8D?;H^!-TELEN/&7B/[''M_P!&^RZ=Y)VD
MD9'V7/4ELY^]SV&))O@I?W083>.O%DRR#:^Z+3P67(RN1:@A3M (!Y YS5:?
M\^_Q)=25K>T_ \Y_X)M_$76/C%^Q_P"#?$GB34$U[4+IKN*'6C;)!_;-K%>S
MPVM\$4!0)X$BD 4!?WF0!FO?M0"R1*I957=@@_Q>W]?PKD?#WPGU#P]<VI7Q
MEXDGMK9T;[-)#8+$ZJ?]6=MLI"D<?*00,8(ZUUU] US RJ[1L0<,H!93@\C(
M(JHV2?NV,Y1ULY7.+^"?[/?A/]GGX>6?A;PKH5GI>CV)9DBC0$R.QRTCMC+.
MQY)//X8KK/[)MO\ GUA_[X%<JOPFU1R3_P )WXN3)Z!+# _.V)IW_"I-3_Z'
MWQ?_ -^]/_\ D6L?8KI3_$?NK3F.H_LBW_Y]8O\ O@?X4?V1;_\ /K%_WP/\
M*Y?_ (5)J?\ T/GC#_OWI_\ \BT?\*DU/_H?/&'_ '[T_P#^1:/9_P#3O\1:
M?SG4?V1;_P#/K%_WP/\ "C^R+?\ Y]8O^^!_A7+_ /"I-3_Z'SQA_P!^]/\
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M.F+"?"/5 H#>/_&#L!RQCT[YO?BU _( 4Y1NK.DC&7O:2G<ZK^R+;)_T6/\
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MC]FC_@H!\:OVD[_X6_"VV\4:RMWXEMO%FC#XF1>$OM^E^(M0B&K1:==V]S%
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MM-\86MA###"FEQR:C>6MGJ\FT73QO:W%Q=S'3UN8(TC+?9)([;#N*POVR_\
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M (@_Y\2_#_,_33SI/\BCSI/\BOS+_P"(E;PO_P!$G\5?^!UK_C1_Q$K>%_\
MHD_BK_P.M?\ &C_6C+O^?OX!_P 0_P"(/^?$OP_S/TT\Z3_(I?.D]/TK\RO^
M(E;PO_T2?Q5_X'6O^-'_ !$K>%_^B3^*O_ ZU_QH_P!9\N_Y^_@'_$/^(/\
MGQ+\/\S].4D9A3E8L_WOPK\PF_X.5/"L,;2'X4^*AC_J(6H_]G_I7Z6:'K"Z
MW86MP8V7[1&DJ!AG&5##\LG\J]+!9EA\5KAYWL>-FF18_+&HXZGR7VOU-7;1
ML%?G9_P4'_X. _#7_!/;]J+4OAGJ?PU\3>)KS3]/M+YKZTU&"")EG4LJA7&[
MC'K7E_A'_@Z0L_B(+AO#O[-_Q5\0K9[1<'3+J.[%ONSMW^6AVYP<9QG!]*]
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M^A]9'@'/Y1YHT)6^7^9^FGG2?Y%'G2?Y%?F7_P 1*WA?_HD_BK_P.M?\:/\
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MT-7;Q2;!7X_6/_!V[X*%NN/@MXS8'!'_ !.;5< C('W1VQUYJ7_B+?\ !?\
MT17QG_X.K7_"NHXS]?-@HV"OR#_XBW_!?_1%?&?_ (.K7_"D?_@[@\%J,_\
M"E/&G_@[M?\ "@#]?=@HV"ORKNO^#FR:RT--4G_9>^,4.FR!&2[8@6[B1@J$
M/Y>WYF90.>2P ZBF1?\ !S9)<>(9=)3]E_XQMJ\,2W$E@&'VE(F.!(8_+W!"
M>C8Q0!^JY0$4@B5>U?D_K/\ P=$6WAJVOY]2_9M^+&GP:5)'%>R75PD*6;R
M%%D+( C,"" V"<C%9^N_\'7WAOPMK$VGZI\!?B!INH6V!-:W6J00S19 (W(R
M@C((/(Z&BX>1^N C4=J78*_(/_B+?\%_]$5\9_\ @ZM?\*/^(M_P7_T17QG_
M .#JU_PH\@/U[6-13@,5^07_ !%O^"_^B*^,_P#P=6O^%>Y?\$[O^"^GAO\
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M8H_M:U_Y^(/^^Q7]/?\ PS[X'_Z%+PY_X+H?_B:/^&?/ _\ T*7AS_P70_\
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MI>'/_!=#_P#$T?\ $.Y?\_OP#_B,]'_H$_%?Y'\PG]K6O_/Q!_WV*/[6M?\
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MBOZ?#^S]X'/_ #*/AS_P70__ !-(/V?? Y_YE/PY_P""Z'_XFO-CX=SMK6_
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ME_X9\\#_ /0I>'?_  70_P#Q-+_B'<_^?WX#_P"(ST?^@3\5_D?S!_VM:_\
M/Q!_WV*/[6M?^?B#_OL5_3W_ ,,^>!_^A2\.?^"Z'_XFC_AGSP/_ -"EX<_\
M%T/_ ,33_P"(=R_Y_?@'_$9Z/_0)^*_R/YA/[6M?^?B#_OL4V35[41M_I4(X
MZAUR/I[U_3]_PS[X'_Z%+P[_ ."Z'_XFA?V?O Z]/"7AT'L1IT61_P".TO\
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M^>!_^A2\.?\ @NA_^)H'[/O@?_H4O#G_ (+H?_B:%X=R_P"?WX!_Q&>C_P!
MGXK_ "/QX_X-VG#_ +:OB#H6_P"$3N ._/VNU/\ B?PK]D/BE\GPT\2DMA3I
M5UU[?N6I_ACX/^&?!FK/?Z3H>EZ;>R1F)IK6TCA=DR#@E5'' _*MVXLXYHF2
M11(CY5E;E6!!!!'<>U?;9%E<\!A_J\I<VK?WGY3Q9Q LXS!XZ$.2Z2M>^Q_%
M_::G;Q0JKS0QL ,AG (.!D$=L'C\*D_M:U_Y^K?_ +^"O["H_P!F;X<PIM'@
M/P<![:+;_P#Q'/U-._X9K^'?_0A^#_\ P36__P 17M'S)_'G_:UK_P _5O\
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MK_S]6_\ W\%?V&-^S;\.W8L? G@\LQR3_8UOR?\ OBC_ (9K^'?_ $(?@_\
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MR#C]: .;\;_M.>-_#7QH\(^';%M*U+3_ ! 6^T)]LE&J0QJ&,DXC6$Q)#'A
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MI_X,H_\ "E]:I^8O9S\CJ]]&^N5_X2KQ(?\ F5T_\&4?^%-/BOQ(/O>&(_\
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M_P"A73_P91_X4?68=F/V4^MCJM]&^N4_X2OQ)_T*Z?\ @RC_ ,*/^$K\2?\
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M#4^TP_\ 3/\ .C[3#_TS_.LO_A6?A_\ Z NE_P#@*G^%'_"L_#__ $!=+_\
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MPT\/_P#0&TO_ ,!8_P#"@_#/P^?^8-IG_@*G^%%ZQ/)2N?!_["W_  39U/\
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M  H_X5GX>_Z FE_^ J?X4.55N]K#]SH:GVF'_IG^='VF'_IG^=9?_"L_#_\
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MM9?+O+"WGB2$SA\-&Q1D0"OT9_X5EX?_ .@+I7_@(G^%+_PK3P__ - 72_\
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1=2LC4C&U?2BB-=B8HK4D_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex4-6_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G GP# 2(  A$! Q$!_\0
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M=:>-X<S#,<'0JK&X6O2>%K5XXE1C&LZ:I3A*7O%%?/?P\_:C^"_Q5^-'Q<^
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M&WPO\76UQXLLM0'BAK3Q1I?AR\LX-%,BZ?>/^ZGCGX3?"OXGG3C\2OAG\/\
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MX4_"G_@FUX4\)_LH_M22>,?@ZEKX'^('P6\=VOQ)TWX)Z3\04\7_  YB\?\
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MWPCX(U+3;31-:\4^!]'\0WNG^$[6;5=!&O:O+X7D.H?5W[4O@3]KC]HSXO\
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MFZM*-:,/JJE%WHK!QQ]*CSX>4G2A+,J5+*IXOWY5*%3$XZ<K8JA%+YZ\'?\
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MR?&"'QWXW^'7B'XI^"KE[JS^+MU\)9_"?B?P?X;OKJU\3V'Q2O-.TN\=-/\
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M$\+_ !-\-QW$MQIU[:_V=?>(/">G0:U;P6D$MQIDUY;V5Q83R0W,'QI\;?\
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MP]\,QZA=^"X/!VE:;X2UO4X[S5?L3W;>);KQ'>R1W<,.C_\ !,C]G?2_AO\
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MX_AYX?U34]%@TZ3^W3XU\3RZWIUIX:\%:K?F\L[3.O/^";W@[6?!FM67B?\
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MW6"/\GOB5^U?^U?\*Y/^"ANG^,_B?X(>+X/^/_V:-)\#^.?"OPC>'P[^S_\
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M)K/Q=\6=1_9X\4?%70O!'PX\4O/<+!I/P^ET&TU;Q5JVE-,^HW/B3P_X?BU
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MZG=:WXCFM_#]QX<F&L:A-IO-%P4Z'MU.@I8F='%TG[]7!WRG$8A4JCA3C)O
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M7"[I'=R6.A_PG=U_T('Q _\ !5H__P OJ_)GPE^W[^TM)^T:=+\6:1\ +_\
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M?M$>(]"L+_3?!&H^'K.SM/%$^D+<:G::K/JT$]OI)\'R#Q./$<>AG^V IXK
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M\0/_  5:/_\ +ZC_ (3NZ_Z$#X@?^"K1_P#Y?5^//[2?_!2?XV_";]LOXE_
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M[;G[0?QF_9V^#?ASXH?"?P'\/O&$4GQ$^$7ASQY>>//$VN:3!X7\+_$'XH>
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M_P OJQOCIXJ^(W@?X2^._%OPF\)^%O&WC[P_X>U#5=!\.^-/%5[X,\,W<UG
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MIW[('Q.UOPSX@^&WP=_:*^%O[0GBWQ=9:]\,/CAXD^*'AWQC\'KGX3G3- \
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M^H_X3NZ_Z$#X@?\ @JT?_P"7U>@44?6LN_Z%$/\ PZ9E_P#(!]5S#_H;S_\
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M2<(.G2]FZ5#EBJ-%J-)0ISE&?UO'^2^+O!4LEX7\2. ^*^#ITLMAC<CR'B3
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M/2O%G@'X:_$CX4:_JWQ-^+GQG^-GACQ9X3^+?PWUCP5X\73?AU\0/BK?^$/
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M)\B?LR?L#?!GX-_$3XT_M#ZM\/\ P7JWQY^/OQ/^(OQ.O?B)JGP^\+:=\5_
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M3A=:_P"":'Q1T_0M'F^%O[4&D>$_B+XE^%?QZ^%/QX\6^*O@;8>--$\>Z?\
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M[U+XBPZ/\#=9\0V.AW$&I7=UX0^)$D*7\3VC17-A%<2?I%_PA>I?]%%\>?\
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MN _Z&]+_ ,-V:?Y!]:QW_0IJ_P#AQRS_ #.\HK@_^$+U+_HHOCS_ +^^$_\
MYDJ/^$+U+_HHOCS_ +^^$_\ YDJ/JN _Z&]+_P -V:?Y!]:QW_0IJ_\ AQRS
M_,[RBN#_ .$+U+_HHOCS_O[X3_\ F2H_X0O4O^BB^//^_OA/_P"9*CZK@/\
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MHUJ^"QN.INM.OBFZ'XV_LK>&_#W@+]@[_@H1X-ELO"GP\^(VDZ[^T]JGQC^
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M(KX:4J:C6A2J4%0PU3'TW_:6%C44<JJQA1<ZG\X_[77Q^_;0^*<OQ1\1:?\
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M3POJ6H6=G M@\WSQ\9?A;=?ML?MU_M,M^SS\&_AA\4)?'OPR_P""?/CWX?\
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M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+X2^(IG7PSJ<]MHNIBQ%O<7,9G.'XQ_X*4_$WX=^&/B-X9\=?LG+X?\ VH_
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M\(XNI>>^IZ>L6YKVV$O\_&K?LN_&+X,?M$_L):#X8_9=^ NK?%N5/VX?'/\
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M]+UWQ9K-S;;="\.746L3026TL/F_0_AKX\_ WQGXZU?X7>#_ (S?"CQ7\3-
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MVOCPUJVLWE];7%E:Z98:G<7T]U!-;Q0/+$Z+^*'[7GP,_:6^&O[(7[)/[/\
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MJMU-Y#^S<GCZ_P#VOO%OBZ2U^,?PJU*Y_:A_X*3^?\;/%'[0WB_Q]\-?VD?
M_P /]<^*_AVR_9N\,_!RZ\=ZWH?PP\6_#J\OO"?C[PO)/X/\*W<_A3X0^);W
MPO?7EJFH6LN,G*$<5[6,8U,#@<3B\7&%2-:BJE'+*>:TZ.$Q<%]5QT*F'K4X
MNO0JOGFU/ T,QHXC RQ=3H2C"K--.,<8L)07+-3K.&;X_):\ZE/E=3#<N+R^
MHZ2G&I#DJP^O5LNE0QRPG]2%%?S._L>>%=0\)?\ !,:U^/OBOP)\:_V<OB3;
M_#;X _%[PE\8_&'[5'CK]H2Z_:&^)6F6=MK?AB^A\$#XG>,;O0=+^(WB2]L]
M$U?X=7.DZ2^MV_C&.QFTBX?2ECM_NKX)^-_$WC7_ ()Q?M-?'_6_%OB&T^.'
MQ)^'_P"T+XP^)VB/K?B6RE^ OQ2\.^#/$&AW/P?\-:?JUS'J/@Z#X3SZ-;:=
M:S06NF7>K7B/XPPZ:Q9S56.O@5G"E:I+)<+#$8I1DHJI*O3E+#4Z*M*JE*=#
M%PQ3KTJ=; >SPCQ6&A/,\#1J%"@Z^88' J2BLQS>OE5"M9RC%X7,I9=7Q%6,
M6TJ;4L/6PSI5*M+&2EC,+0Q$L1EF,Y?UXHK^6W]E7X[^._V/_P!G'XA_M=^#
MO@Y^U5'\!K7]EC]FC2+OP%^T7KWQ/UCQ#\8?VR?'OBW1_"DOQ!^&EC\4_&'C
MGQC;_#W5+'QIX8&OZGH%[9:-XFFC,7A?0)-8M]US]V?#S]OG]L#XAZ_^SO\
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M#8[#Q''J5K<VWB73;^^EM;&YTZ>P%W^K_P"QK^T3\0_CWX7^,FE_%_P9X/\
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M6,K W>#PS-^S7\"?V>-;^"WQ9^,&CZ_^TK_P31_:0\<?'WP7XB^-GQ.^(_\
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M=44Y0A*W-&,N6C4PT>:,9<N'JT7AZM!)II4:E"4J,Z22A*E)P<>5LCVD_?\
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M&Y*A P4>'?"/]@/]CSX$^$O'?@7X5_ ?PEX8\+?$SPK=^!?&VF/<^(-?;6?
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex4-6_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !N *4# 2(  A$! Q$!_\0
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M9]EQ%K6E?"RQE%PK,PFC\KQYXB\P2*_ELIFMUC$",JNTTFSDT_X. OA0/O\
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MVC?L_:+?6<-G:VJ7-A\&_#^L:]I'@**4P,SZ/9ZO?"28R:A-*+B]FC3^H?\
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MM\-_AU\5]5\?S>+?!WQA_LMO@[_PICP9X_\ VA/%OQ@BUC0IO%5G=?";X<?
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MM \5_'_P3\)-"N[2_9K'4Y;NWTBXMKX:BME<>O\ @;]ABUT_XC_#SXH_'?\
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M\7/!&M?#T^/?A)\;];\*0^ M7N/ 5EXQ^&?C#X<ZGX1U/P))KOA#4/"7Q2\
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DT2&VVVV[MMR;>K;E*4I-OJY2E*3>[<I-ZMA1110(**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #X E@# 2(  A$! Q$!_\0
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MXZ\.2_$KPMKF@-XC_9=\1?#S1+SP1H/B&31(I?%*>/;/XJZ=JQU&TMTET/\
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M^?!?_@I7\9/B1XJ^(]IX.\$?\)3\0OB5\=_AE\#OAE\&/B#XJL?A3X<^#/Q
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M[9OQ0\'>%_%NH-\./$G[,/AOX;?"SP<V@Z=<VOAS]JWXU0^/8_@EXRTZYM-
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MMQX3FTWQ*Z74.@:SI^JZ7K.@ZO)XLO[O2[;Q7?\ A70+O3+X _?*BOQ+L?\
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M.2,#=E0&;"D$A0>"QP O7YB.#BI*CEQY;9SVQA'D(;<-C;4!<[7PV5QM W9
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MS7VKWOB73-4\/GXV:;&IFN+S4/&*6/\ 95IXU&S5]8:SL+83W%U#&_R#K_\
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M7[('P\\8_",?%30]/^(/B_X.?![6/BOKWQ2\:?$GQ+\.?&]MH\FF:JWCO1/
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MA?W]AJFNZW:W<?\ ;]C<RZIXF^(-Q\5]9U.^-KK!M/$-[=_$UV\;Z:+^"?\
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M3LD*22%1^T!\'KSX5>,OC-8^,8+GX7^"-5\<Z3XK\4:?I6OW T_4/AOXCO\
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MD:4 _9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DF=AP,YP#ZA20&8
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M,L8!D8. P5XRR>6 Q(Z"B@ HHHH **** "BBB@!C]."005/RC<V-P)&,$X<
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M-U31=>TR?4K.Y:TU>"&#Q':ZMK^DZUHFI3_>% !1110 4444 %%%% !1110
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MXN&G[#BWC6FNM3*GIYQY'_Z41G2_<8-VZRAM_>A*/]>>YKT445^D'A!1110
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M)NE:I;>!-4*:[X@\,Z=I>IP>#-0\0:3'<K+XWT_6+62,V>C3;=#XK?M<>.O
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M&/E(8$L>B;U],P6=[8W9F^Q3V]QY%U+;71M65A%>QJ3,DQ4\.!@'=GYB 6)
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M,5"'NM74;S\ENG;=>=M.^K/TV1>"7*_*62,@?\LV^8)QTQMV^F%%()$\Q4
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M1X1L_P"T[V:YO-TD4$AAC,PCM9O3;#X"?LOZ'8^'8]$^'OPJT&S\&>+M,O=
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M.O+J34_%/CGQ[=:7J&J7*EKZ:RT.!M66:5C@K%K&N>(_$'B.'@<:RN23T_6
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M6VH77AZ6^#OI/PVT#Q!+$=5D\(^"=&DAT:QC$\2RZIIVK:Y\XUEU3Q3]M/\
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MXP_9;_;&T;QUHOP_\,_%K1[?X7^//%6@:=K'@V]FCGT_X?\ Q3L[^SGF>Y\
M^((0=)FUG20&@\7^")I1=Z#J)\^ 2PPYA_1"(*74'DHY7:Y:0K*8B28Y'.X*
M8V;G X8J @)4_%YI"E0JQPM'+U1A2E*-Y5/:S]V4H^T=5J,9<J248TZ<.79W
M=[>;B%[%NGR\M^^[Z:<MUO?K;OW+M><?%?X8>#OC'X'O_A_X^T[^U_"FJ:QX
M0U;4M):X^RPZG+X0\8Z#XSTK3[N3RY"UA>ZQH%A;ZC;HJ27=C+<6D<T$DRSQ
M^CT5P'&?F=XA_P""7/[*7BG7I_%EQHOBK199Y]9N=-T?PWJEIH&A:);ZVEU<
MWFCZ5H^EZ+826%G9ZSJVJ:IIF@I(;&#4DL-/N=/N?#7AWP[X8T3FO#W_  2H
M_9H\.IK$4_\ PF.IZ?;Z#HGAWP5,NI06NL> [/P_>S7=S-I6I>1+H\6K>(-3
MN;&6YU33O#>BPZ9H'AG1_"6IO<:)HUQ#<_JM10!^2WA'_@D+^RSX;TIM&N+W
MXE>(=)L)KZ+P[8ZAKFE6E[INA:CI^CQ:IX9U74=-T6R_X2ZUU37M-@UV2[\3
MM--=-&NE12-X7DO+>[],^+/_  3;_9P^--AX8'Q%L/&6L:UX:\,:+X;MO&%E
MXOET*]N-(T'3]5ALHM8ATB(:7=Z-;7?B+4-9L_#]Y:R^'[#5M%T_4=.@MKZU
MLIV_1VB@#\R/^'5G[+=QI]W97,?Q#N8;BPTGPQIUWJ'B:VN;_P /^"](7Q#8
MVO@G0Y;O09HH?#%U:^*O$$$MO-YTS6^K2+'*LFTM]J_!_P"$O@;X'^%+?X?_
M  \TJ72/#MKJ&I:@FGEGGAL;S5GCU#48XIK?3K:T599W@D42.I<M)L)=71O8
MJ* (G*JN7QL4$-D9&TC!)'/RCDL2,!03]T$U\->#/!WQC^'?[7'Q&&B>';$_
ML^?%OPU9_$3Q5XAEU 6__"._%[2M'T[PGJIT*Q=F+2>++*PTK5-0,F%5-*GF
M948!1]U4P@#)XW>^<8/'('MQG%50JO#^W:4)?6(2IVG?E3DERR2OK.+BI1?1
MW:W?,GJFNZ:^]6/A#]M[]EJ\_:2\"Z3;^%?^$7T[XD^%-;M[_P /ZSXACU""
MS&G7J&VUS0I-3T@_VE:"\>:TU>S>(;9=3TRPAG"VT]U(/HKX9:'=?#'X2>!_
M#_C'Q4FL:CX+\%Z#IOB?Q5JEXZK>76GZ79P7][+=WS&\$%X\;30.Q5F:U03$
M.9$KUNZN[2UVM=31PJY5=\IVIF1E2,$D@#>Y5%YY<@8R>//OBSX,N?B'\/\
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MI3C-]/=IRY[-;.UM+WV^[ZQ^)&DS7V@1ZG:_\A7PS?1:[;8Z>5%/$UU]X_\
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MI\2#6;+QL;272]$B\.&YOM$L=1^&WQ,TKQ%J#,(- USP;X@L+_RX(P&T;?\
M;E_9_P!0@U&]T+4/'/BS2K"_T/0+#7/#/PS\=:MI_C7Q3K^@Z/XJTKPMX(U"
MR\,QZ?XN\8S>&O$:>(]5\+:.LESIFFV^J:AJ,5M8V-VXY+XG_LF? +5-?^"O
MA33-<O\ X4:S%XBU&[TRS\+^+?%?A[QCXH\'^&?#GQ=U#6O"?AW6]+\00WN@
M+INO?&7Q#XHU2\M&?S]->^TV1WL[MW3V(_LF_!"+P2/ &C^%+K0/"UOXLT;Q
M]I%OX5\2^,_#VK>$O&'AOPUH_@_2M6\ >)-'\5:5KO@O5-/T3PYI6CV!TJ\@
MALM..O:-=12:=XDU"UG //;[]OO]EFSTB35+WX@21"SBN+C4+"7PIXNT_5;6
MVL]$M-6O%UK1]3T#^TK,?VAJEIX-N()(!>1_$F\N_ATZMX@L->@@\ZO_ -K?
MX":OXG^#B?"KP=<>-/$WQ"^+'@.7Q#KM]X&U'2(_ASJ?C.XU[X,W'B7QIXAN
M-"2'P[\2[+3/!_B7P5H6B3W$<>HZ99#3XF.AZAX>:Y]L?]B_]F8Z5<:-)\+M
M'N[6]^&:_!^2X?4_$(U,^#(O'-]\3+>R&MVNI3:Q;ZS=>/;N]\47/C(:I!X@
MC\7VUKJ-C<_;FA4W;']D'X'6FL^#/%#Z7XPO-4\&3^&=5@U35?BG\0M3N-=U
M+P3<>(]7\&^(/&5QJ/B=I?&NJ>&K[QEXAN+#6/%0O=4@N;Y)))'MXHL '%_%
M+]MCX<?##XI:7X$U :B= TK6O$FC_&#XCWGAOQ%)X*^'-SX>^$.L?%!/#Y\0
MV%E/HVN^.YK:Y\)7%WX2T475]'IOB?SBHN(S'%;E_;I_9[M]5@T+4[SX@:+J
M32:A;>*M/U_X3^-[&Y^&WD:KX>T33HOBE9S>'C?>"K+7[WQ9H4?AJ]UN".QU
M2UU^W6.=3<1%>P\9_LD_ GXA^*=7\9^,_!M_JNHZ^=3N]?TB/Q3XST_PKJ.O
M:YX6MO!4GB'_ (0VPUUO#:>,!X12TTA?&VD10:M:W.FP:C#?07ULMS;^5']@
M+X/3_$K3_%=W)XHU?PI;>#]2T[Q'X:U7QU\1;_4_B%XXUCQCX7\80^,?'OBS
M4?%D^K>/(K67PCH2:1IOB/4M9L=%U'3-,O[&*VO+".6$ U-0_;Q_9YTO3[S6
M-4O_ (A12Z/K_C31=;M6^%OCMM?\(0_#V/PGK/B+6?&&D1Z!!=6/A/2-%\>^
M%M:L->D&;WP_XB^SC=K$>O6\1'^W-\(CJ3P/8^,Y89I-,\/+H</@CQ=+\2T\
M<7VO^-/#6J>#]7^'L?AWSH-4T>/P)JNI7IED#1:-9B[*2VX0/TOA[]AS]F[P
MW8^)=)TGP9JITSQ9H_B70]5BO_'/C748)M$\8Z+X)T+Q3!:O+XE9;2/5](\#
M>#;.0! Q3PU;F/\ =G<_:1?LM?!&Q\8S?$.#PA)'XP/BC_A.3J0\1>)?.7Q#
M'=^)M0N;]%GUX6D;OJ/C7Q%?A_*C2&356DB13'$4 .?^'?[9/[/OQ7^(&D?#
MCP1XOO-4\6Z[X9@\3Z1&?#_B6+398+_POX;\=KI<^LW>DQ6%IK]GX3\4>'O$
M-_X=EN8Y;#3[XM<1F6!HX_6])^,7PG\2WVH:/X9^)G@?Q3JVDVM[JFI:9X:\
M3Z1XCU+3(-+G6"_GN]+\/W$URJV-[M^TQ7"B?*38C!C;9Y[\,_V4_@E\)O%5
MGXL^'7A_5O#EY:>'M#\.)IEKXO\ %J>%);/P_P"$].\$:/J%YX1?67\.ZWKB
M^$=)TO0WUR]L[J>6'3(+I91?1>>_ODOA_1Q!>QQZ?;6AO(I8KJXLXY+2Z,$Z
M-'<M;W=C+;7EI<&!I!#=6MQ'<6\I6:)C(@4@'QMIW_!03]F'4[#X779\5:YI
MEE\7K&2_\*I>^$/$L$R:-<>(Y?!NCZ_J-O9VT]UHFB^(/$49T+1]16-U?4;^
MQ,Y@B,DR2:?^WM\ 9[71=6GO/B79:-X@TG3_ !A'JNJ_"WXBZ=I^B^!M9N;"
MPT/XA^(?.\.F7P_\-O$^IS"R\,^*-1=M/OM7MO$&D&6W31[V*+;TK]AS]G70
M+G1+W1?"_B+3]4T/4/%&I3:Q#\2/B"-8\07/C'6['Q)XAC\6ZS;^*[;7/%]B
M=8TW39X=-UR]DLK8PQ,D$@4Q'7U[]DKX$>)U\"1:KX3OXX_AWX0\.?#O2]-L
MO&7BO3=&U'X?^"+BRU3P[X0^(.EVFK:/:_$/PEX<URTCU*STCQ1#K<$UW-'J
M<Y/]JSR@ X;2/V]/@3/I7]K7J_%#08?[6\<17\&H_"'QJKZ)X=\$>,)_"WB/
MXFZW;:?H,Q\/?#N?Q \FBP^+-?=(EU>TU72[N.+5] \3Q017/[>/P3D2>?2M
M4UE--T+4G@UNYU[P=XXT2/4?"VFZ9\7KB_\ $?P\BMO#3WOC&TDU+X.>+=(M
M]1T^)?#UU/I2QVMT)F17WM3_ &)/V>[R2>YF\*^(TBO]9\33WUG#\4?B;#IM
MQHOC/Q2_B_Q5X%N-)@\21Z?>?#O5O&K)XFG^%K#_ (14:U=:E-I=DEP(D;HK
MK]CS]GG4K:UL9_A]$ME#I&J:)!;VOB#Q38V4>BZK=?$&YN])CLCJTMLVGW,O
MQ;^(4T-NR[=+_MW^SH#$BP% #TGX-_&;P=\:M)U76_!X\26\?A_7%\.ZWIOB
MWPSK/A7Q)I&JW'AW0_%%G;ZAHNM:797=K:ZOX9U_P_XEM;DE8YTU6V <L_DK
M[/7G?@GX?>$? %UKS^%M,_LZ7Q7J&FZMKC"\O;PWVH:!X1\-^ +"=FN"V#8>
M&?!OA[2QG&1"I)#%1)Z)0 4444 %-;[I_#^8IU1R9V$ <G X[98 GMT!)]\&
MFMUZHF;:A)K=1;7JEH9^HVD5Y8W5I/&LT%Q$]O/ PRLT$RM'-$1N7B2,LA^8
M?>ZU\-_"7]ED?"OXWOKWAR""P^&FAZ9JESX>@;5)=5U63Q#XC$Z:K8743_O;
M2TMX[Z6YMQEUPD09F1B3]F^(_%'A[PI9IJ7B/6M*T.RFN+6QBOM4NHK.*6YN
M9H[:W@^T3,D8>:YEBAC4M\\LB*OS.JE^ISR'1[K4+-&O98K&XNK2WA#W(O)8
MXFEMXH4M_P![-'=.$1DC#":.0J/E8D]$'4Y5%MPA.7*Y;)\T4G=M623?O/[*
M3>R:."KA,)B,TISK).O#"R=-]8MK1Z:[JZ6UT>,?'[PM^SYX@\)7<OQ]TKX>
M7VAZ5!/?M>^-[71I)=/@M5^T-<VDMTIU"(VWE>>HM2)B\2$K@#'PY_P3Z^!W
M@/5/%WQ&_:?T'P1I7@_PMKWB?Q#X;^!GAK3[1H;70O!NBI%X6U+Q,N[>(]8\
M8R6$\^H_O6=+NXUZ-O,$Q<:=U^R7\,8OV>_$OQL^,G@:Q\>_M"3_  J\3_$S
MQ+XO\;_VAK.I:7XPO?">I^)DT/2TO+AH['1/"-^RZ7IFBI$B6*Z1;3^6)HXI
MS]>?LE>&[;PO^RU\"]#A6!([;X4>#I;N(H;:VDU*_P!$LM3U:80J2RV\NK75
M^7A)"S1.48-&Y!]6EC*F#R;$X3#8_$3AB<2L)5@YR5"<)J4I.$5-W<Y1C2FY
MQ4W&T=G-/Z"<_88"4%)OFC*+3Z7CJEUT2=];>6IWWQ]@\,W7P5^*4/C 6A\*
MO\/O%P\0?;462V&E+H-\;QI$? W+;[GC/5) C+EE /YP_P#!,;X$?#O4/@I_
MPM3Q3X8T/Q#XX\3:WXAT:6Z\06%OKMSX<T;16BT$Z+I]S.I^Q6VKRZ7)XCF5
M"A>/61"S88AO;OVI/$4_QT\7:3^QUX!BNM1.J:GX9\0?M%>)[5-VF> _A7!>
MV^N/X4U._56^R>,?B:MC'8:%I05&CT?[3>2*D*J%XO\ X)^Z_I7PZU[XW?LK
MZIJ"CQ/\-/B?XNU;PU]NNE>\\3>"+^6S6UU*)2HWW^G(U@VHA6+B+5D;8R*[
M1U0E7H\.8O#JJXSKUZ%:<$WS*BG*@IM+93FU=:.2A%M.&KJ#<<NG*^RE.RW4
M4M?RMY;&/^T3\&M3_97\27?[7?[/<$&A:5H"6%S\</A7IXAM?#OC'P1:7<<>
MK:M96\2*MMJ.FV=Q+J9,:J";194"X=!^EWAWQ!IGB?P_HGB/1K@7>D^(= TK
M6-*FC=$6;3]2LH]1M)HF&UT-Y:W"2!@RKFU!+@9 I?$WPQ'XX^'WC;P;,8/*
M\5^%=>\-RFX#F 1ZYI5UIDAG2,AI8=ER3)".)TWPGB0U^2_['?P(^*WCGX$^
M"&\/?M6_$KP)\/-774M+\:_#K1M"\,W'B3PSXJ\.ZY?^'_%OAWPCX^N8[C6/
M!NE:I?65QJ$-C;6TEQIGF)<0$;I"G.Y_VM@XX[$55*MESC@X2E&<ISA^\4(R
MG%-MQ]G*%*55^]%*GS7BFW%*OAXU'HZ;6W5**:O;OTOUN?H3X.^ OA;P[=>+
M?#,J:3XB^%?B+7I/'>D_#3Q!X:%UI7@3Q?J>HPZ[K,WA&&8/%:^']:\0W6H^
M*+KP_+&H\,^(+I+NR,<6J,B?25I$D$44$444,4*)#"D!9X$BBCV+%"G MTC5
M44( %P @SP1\\?!O]F/X3_!'4UUCP+IWBB+Q!>6$FG:YKWB+Q_XZ\3ZEXBB4
MF1KK7XM;\2W&DZCJDMR4G;4O['D=&79"T0$,H^E*\NI\7R1PU?BWOHM;6"BB
MBLS,**** "BBB@ HHHH *@N03!(-YC^1AY@7<4RI&\+W*YW8QCCGBDNQFVES
M@J%WR(5B82Q(0\L#"?\ =;+B)7@=G("K(6W*0&'GGA'XI?#[QM%>S^%?'/A?
MQ1#H^M>(/"]_<Z'K>GZA'#KOA34X] \4:?J/V<'[)=Z-XA1M*NH58A;@QJX*
MNM T[-/LT_N/G7]K[X6_$3XG:-X7L/ 6F6FKO::AJ"7UI-JMCILEA-=I!%8Z
MY&;]?LLG]G7/EW4R_/<I"C/; W)BKT^V^.?PY\/>/8/A#XB\6V^F>-M-\*:7
MX@U&77K?5](T*\@U%[73K.?3O%>M11:-J4]P\%XL<%K=R-/<;(F\BY=HV]BG
M\2Z!";G=K&E+):/:QW*S:C##%;2W<\=I9I+(RL(UN;N>"V#%2<S+L5FPAY'0
M/&7PO^)&CVNL>&_$_@?QGX?\06,]O::OI6KZ+K>FZG8G^T4EC@O8GE34UG&F
M:C+/"DC11II5Q,PQ;EI.FIC)5L-1PK4>3#\W+:W->;;?,[M_E=ZRNTF<E'"J
MC7K5UO633WZG$^!O#WA7PY\=OB;J.@Z5I=G=_$SPAX#\;:EJMC!IT5WK>IZ1
M=>*?"FI2WLUN!->1II]IX9>.905WD[F&"#]$5Y1X7\-_"'0_$,FN^$+#P;I6
MOZ]8&)Y]$DTRUN]3LI<7\C-!;,KR>6FFO.61,"."4O@(Y7IO$?C;P?X3T>]U
MKQ/XGT/1=$T^POM4O-4U+5+:VMH--TBUFU+5+FZFE/EI;6MC:W$UPS-@Q1NK
M;6/',=1V-%<EI'BWPUX@L+37-"UW2-8T>^TBUUZUU*QO].N(+K0M1A-W9:LD
MZ2E?[*DMV8P3L%\QB-S;=SM8'B/PW,;>)/$&BF2_B7[%C4]-::\BF.Q%@0N?
M,42.FP1K(KL  &.Y: .EHKE7\5^%8(;BZ;Q#H$%O;LYNIWUC2XK:&;RY+J0W
M,YFVQ*D5I+))(Y'[I)9"&$19>8\%?%OX8_$+2SK?@CQ]X1\7:0#)$=6T+7K#
M5M.E2WTW3]5G6WU&URMY)!I>I6&H3K&S"*/4%9WP % /4:*IVEQ;7<,%S:SQ
MW%M/$LUM/#*)(YX& *L""0P&]<,,G[N2"2M7* "O,?C' ]Q\./$Z)U2TAN3Q
MTCM+VUNI/PV0MGUKTZJ.I6EMJ%A=V5VHDM;J"2"=&^Z\4JF.1#@@X920<$$9
MX(/3R<[P5;,<FS7+Z#4:^-R['82C)NR57$X:K2IMOHE.<;LZ,'66&QF$Q$ES
M1P^)H5I+NJ56$VOFHL\5\-S1W?A[09XPYMYM-TZ:((^QA(L.Y<..F"!N&<L
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M5HTUY)"J7%[+8V4%H]_/^\/E"X-@74#(+O@LP5379R*C#[ZAB<H60L ^05.
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M(Z[SM Z]R0!]17EGC'XG_"SP?XH\(^#?&GB_PSH?BSQE<RW/@S0M=N;:UO\
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MP_91OIE_)%>:U%:1&>$-;;Y98E?&\-^/_@A\=_C-X._X1O[)XU/PQ\%/\6O
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M!IVAMKMOK.LQ:7H[*D<-UXGU2#2)M?UG:TU]9^%?"EMYGE0C=Z?110 4444
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MD.<<8SD=>F,C/Z9I:* (VE19(XB?GDW;1_NJ6/Z _P"34E%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5[E0T+[L[%PYV^9NPC!B L0+N<
MXC7_ %O$9!5CFQ44P!C93T.#PQ4Y##'((."<9 ZC(PV=I+M:QMS?9OM?I?YA
M=K6/Q+5>JV_&QX)X:_9^^$WA?XN>,/COH7ADV?Q)\;:':Z!XAUV*[U%)+G3;
M!8H8HX])G?[/8DG2XMERJ*9F7*M\U<#H^O?M,S_M9^)=!U3PKX8@_9=A^'6F
M7GA_Q:EZ6\1W/CJX=%O;>.W:1F1(K@ZH)D<",:5_94RQB5V#:?@K]J7P1XT_
M:/\ B/\ LV:9HGB.W\7?#7PSIOB?5]6N[ CP_=6^JRVOEKIUZ-VZ7_B;1AF;
M;O!"@#@'Z@*+O5ACD9)Y !Y[9)_3I71*K5PRD\6KSK4^2+DG*WM+J#CJVI76
MC;5G?NT^?'8?%5I8:IS-.G4IU==VH24K?X=+-;_=I\G>//A]^T/JW[2OPO\
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M3X3?M'S?$[XV_&SX0CX:^+_#$/P;N](L5\9ZW D6D^*VU2!9\Z4P7=L0,TB
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M,M#\4:)#\3?"?Q>'AR>YU'XJZ-\5O#-UI>CZQ=>([<:==IJ'PS2+?\0?"_\
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M]C2+HWQ)V9MG!7P]IC%C>0-<J-HU\GY4#;^N&/RY'(5?^"J/[.88;M'^)H4
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MG^>W^E.5]S !@2<\8(S@$@9VU^:?_#U+]G#_ * _Q/\ _"6TO_Y?UZ/\)?\
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MIK=QX^NK&34OB'9:9>6&A:OI&E:/IM@\'A1;KPX^GH/^)/K^HVIF\5QW4O\
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M:O/!I\K7-Q;35MVO[,G[/4,&F:EJ?C3Q+<Z7<W?A4:)':>._".[XBZ7J]_\
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M4;MH-/\ B1;FQ\.Z?KUE&EK=>!_%.D>((+>&VV1FTBD@2_)D_AVZ<]RW&0Q
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M% !1110 =:^1/VZ_^33OC;_V*'_N2TVOKK/RY]L_I7R+^W7_ ,FF_&W_ +%
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MC:(F@Z;K=IX;Q]EDO+&WBU!ETZ2Z<#Z[VU2;OUL]>FN]KWU3:TN>55H9+E^
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MK4C86%JY?4K?]KHWM]>ZE9_&A]3T_6= TJ^OGTG68S:>(+C6[S4?"-Q;.?\
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MJ5UH4^H(W]FW/B6VMA++JVH:'X7"W4EGIMO=:O')?W]KI]G+=C#ZKA>R_P#
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MN#4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #O G # 2(  A$! Q$!_\0
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M\I/W8MQ6NS>^YY=XM^$OASQEXIC\6ZI>ZW!J47PY\<?#%8+"YL(K$Z!X_N=
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M234':\5:WNZ:*UETM=WUN[6Z-MM=VVVV[)7;;;;=VV]6PHHKC/B/XN_X5_\
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M4BO-0349E=?WMZ+Z[-R^Z5[B9W9SZY5K5)[#DDFTG=)V377S/%_^&;_V=_\
MH@OP7_\ #6^!_P#Y14?\,W_L[_\ 1!?@O_X:WP/_ /**O:**8CQ?_AF_]G?_
M *(+\%__  UO@?\ ^45'_#-_[.__ $07X+_^&M\#_P#RBKVBB@#Q?_AF_P#9
MW_Z(+\%__#6^!_\ Y15Q?BG]E7X,ZIKGPWOM$^#7P7T[3?#GC2^UKQ?9_P#"
MO/"MI_;WAV?X>>//#UMI/V>T\.R6^J>3XLU[PQKGV#4W@L8_[&_M..4ZEIVG
MP3?3E?F/\3_V=_CGJ'CCQKJW@W2T?1--\3:OIWPY%MXHTG2XKCPG^T397.G?
M'35[G39+RSBM[GP7>WEMKUDM[&NI7RZ+ /#D%_?JT6J)MK97UU[J*3;:BM9.
MR:23OS..DN:R3;Z*[>B=U9-Z+F5^9IMI/D3:7-)V47?[0_X9O_9W_P"B"_!?
M_P -;X'_ /E%1_PS?^SO_P!$%^"__AK? _\ \HJ\?^%O@7XK> ]4^,WA_7/#
M=]JGPNU&'QOJ?PPT3PKK_AW0KW9<:K?(^@:A?G7+/7+?Q5XKL9=/N?"GBB'7
M-$T30M/AN-.U:Q\*ZWIPU[Q5TW[*'@77/ W@;Q OB'X>W?PFU'Q%XON_$'_"
MM8+GP?-X0\&6TVDZ186VC>"/^$,\5>*;"YTR.*P6?7-?U Z#K'B_QA-XB\57
M?AK0XM7MM/@B$JDHQ<X*#;DI)2<DK+>+Y8OE;NDYJ,G;X5=-U9:V=[7MIO9I
M=;>O5=F[Z=U_PS?^SO\ ]$%^"_\ X:WP/_\ **C_ (9O_9W_ .B"_!?_ ,-;
MX'_^45>T45H(\7_X9O\ V=_^B"_!?_PUO@?_ .45'_#-_P"SO_T07X+_ /AK
M? __ ,HJ]HHH \7_ .&;_P!G?_H@OP7_ /#6^!__ )14?\,W_L[_ /1!?@O_
M .&M\#__ "BKVBN<\8>'+3QAX3\3^$[\*;/Q-H&L:#<[U1PL.K:?<6+OMDCE
M0M&)_,4M'( RAMC8P6M6EMJM>WG\MWY7$]$W:]DW96N[)Z*]E=[*[2NU=I7:
M\&O_ -E7X,S_ !$\+>(;7X-?!>'PGI?@SQ[HVMZ'_P *\\*Q_P!H^(=>UOX<
M7OA?5?[,C\.G3;O^QM-\.>+K3[==SQWVG?V]]GT^*:#5-3>#M/\ AF_]G?\
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M7P]X1U6[\+Z%;QP:9H@L[*VCL+3W:M5_GT:V;6SUUM?Y]K >+_\ #-_[._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME%?RA_\ #]7]K?\ Z)W^SG_X2/Q,_P#GNT?\/U?VM_\ HG?[.?\ X2/Q,_\
MGNT?\0NXM_Y\Y;_X=*'_ ,SA_P 3;^#/_0?Q1_XB6/\ _GF?U>45_*'_ ,/U
M?VM_^B=_LY_^$C\3/_GNT?\ #]7]K?\ Z)W^SG_X2/Q,_P#GNT?\0NXM_P"?
M.6_^'2A_\SA_Q-OX,_\ 0?Q1_P"(EC__ )YG]7E%?RA_\/U?VM_^B=_LY_\
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MC_#S_LXOPC_ZK3XN5_*%7]*^%W_))4?^QEFG_I_#G^5_TM_^3S8__LE^$O\
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MB@#_ $78_P#5Q_[B_P#H(I],C_U<?^XO_H(I]?Q.?[SK9>B_)!1110,****
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M#_B9_(/^B1SW_P .>2?_ "H_K?HK^2#_ (:2_:)_Z+Y\:?\ PZ?CG_Y>T?\
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M,W4BFKVTF[W23>ST"BBBF4>+_'K_ )$?0O\ LM'[-_\ ZT1\+:]HKQ?X]?\
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M_M :A_9/_"1^/?&?@CQQ9>.$^'7P_P#^$S_M'^S/AO\ $'0=3\*7.@O\/O\
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M&WO]+U72[^WN+'4=.OK>"\LKR":VN88IHG1?H#]ES]D7X^?MB?$33OAU\"_
M>K>(YY=5TG3O$_C*>QU*#X>?#>SU>+5+JWU[XD>+[:PO;#PMI+6&A:[>6,,Z
MSZYXEETBZT7P?HWB/Q)+8Z+=_P"CI\3O@1\#_C9_8G_"YO@U\*?BY_PC/]I?
M\(W_ ,+.^'?A#Q[_ ,(__;/V#^V/[$_X2K1]6_LK^U?[*TO^TOL'V?[=_9MA
M]J\W[';^7Z!H.@Z'X5T/1O#'AC1M)\.>&O#FE:=H/A[P]H.G6>CZ'H.AZ19P
MZ?I.C:-I.GPV]AI>E:786]O8Z=IUC;P6=E9P0VUM#%#$B* ?-'[%7[)?@?\
M8G_9W\%? /P1>_V^=!_M#6/%_C>XT/2-!U?X@>.->NFO=?\ %6L6FD1?]>GA
M_P -V^J:AKVKZ%X'T'PKX6O?$>O?V#%J=Q]6T44 %%%% !1110!XO\>O^1'T
M+_LM'[-__K1'PMKVBO%_CU_R(^A?]EH_9O\ _6B/A;7M% !1110 4444 %%%
M% 'X$?\ !QE_R9'\+O\ LZ?P1_ZJ7XWU_%M7]I/_  <9?\F1_"[_ +.G\$?^
MJE^-]?Q;5^W<!_\ ).TO^PW'_P#IVB 4445]D 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '^I['_JX_P#<7_T$4^F1_P"K
MC_W%_P#013Z_E\ HHHH **** "BBB@ HHHH *_GR_P""L'_)Q/@S_LBWAW_U
M.?B-7]!M%7"7)+FM?1JU[;GP_B)P9_K[PS5X=_M'^RO:X_+L;]<^J?7>7ZA6
MKU?9>P^L8:_M?;<O/[5<G+?EE>R_BWHK^TBBM?;_ -W_ ,F_X!^!_P#$KO\
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M?%GX >"_&>I:UX]T[XA^![CP3\:-!U[55\:>'M8D^!WPE\#Z27N])L].T?\
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M.IS3<ZLN7VU.?/6J5L2I8:G3A7E0JXGF****]L04444 %%%% !1110 4444
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MJ7[*_P#X6_Q;_P#G'T?ZT<._]#C!?^!U?_F8#\!Z*_?C_B',_;<_Z*E^RO\
M^%O\6_\ YQ]'_$.9^VY_T5+]E?\ \+?XM_\ SCZ/]:.'?^AQ@O\ P.K_ /,P
M'X#T5^_'_$.9^VY_T5+]E?\ \+?XM_\ SCZ/^(<S]MS_ **E^RO_ .%O\6__
M )Q]'^M'#O\ T.,%_P"!U?\ YF _ >BOWX_XAS/VW/\ HJ7[*_\ X6_Q;_\
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MZ*E^RO\ ^%O\6_\ YQ]'_$.9^VY_T5+]E?\ \+?XM_\ SCZ/]:.'?^AQ@O\
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MB.PMCJ/A+^RK%TB?R_X(_MQ_M"#]H7XJ^#M+\>_";]H_0?C+\;/ 'P_^$GQ
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MHK\;?V^?B3)X5_:U^!'ACQ!\3_#_ ((^'VK_  *^*>LW^C>/_P!NOXQ_L)>
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MD;]MOXV_ 'X:-I.HS67BG]J*\_:#^(/@O]HS_A<OCW0H_A?X'\3Z7H%]XC\
MZ'\-8?B=\:/V=_ /PW^%OQ9\/PZ1+\*;VQ\4S3VVE)JUU?\ ASXJ?$"WU&UU
M!2;3II1<N?F;:3M!1NDV^5I\S5DDUK\37NJ:C)2=1:ITVD[K1ITXU+I[72FE
MROWG\27+=K]]:*_/KX%_M-_'3XB_M%:[\"_'/@#P9X7/@?PW??$/QK?Z4;_4
M_)\%^-]'\#7_ ,%=-TC5[7Q1JFA7FMS:EJ?Q&T/Q;KEE+JVBZQ=?#N[N=!L=
M'M;V)Q\_?M&?&C7?A?\ MV>&I+'XA^.O&AD\*Z5::'^SMX)^(_B_P7K5OJ5K
MX"^*'B2YU>_^$>O^%]3^&_QQ^%_C2:RTFT\2?$'PQJ&F^,OA!XI\/Z/8'7!;
MZGJ.@7C?VK6DU9I1::E>S]V2;BURM2O?5645)RAS%]8I>\I-QYHN,HQ>MN;6
M^LER-)-QE\:@E)Q_8:BOPH\)?\%+_C_XA^%GAOQIXBA_9M^&6DZ_XMU6PE^-
MGBN]T;Q=\+-!33?A;=^.8OAQXL\&?!;]I;XJ>*/!_P 1-6\50P^ ]$D\2>,M
M/\4:I)(M[!\&5\3S1> 1ZKJ__!0/XNV7Q;G\)6EA\()Y%\5P^%8O@&_AKXG6
MWQ\'@Z?X+0_$AOVDY=1US5?#A@^#UEKDKV%UI.K_  BT*:/2K>6RO?'>E^,!
M-X?MFDVTE9MR4%JFN9W5FU?9JS>RZV33(JU(482J3;Y8PJ5'RQE)\M*$JD]$
MMU&#LFTV]%K>W[!45^(.@?\ !1']HR#P/8ZKXW7]G[3+WQ;\(/V3?BY;^/U\
M#_$/1?AU\&M"_:#\7ZUX4\7:M\2]+NOBQKFI>*_#?@./1QK*:W9^*/AK9B.\
M2TUN?3K*VN-?7R#X??\ !17XB_#/P3X!MIOBAX.^*_B'Q[^TM\7[?4[C7O#6
MK:UH?BOX:3_M+V_PYL]4^%WQ \2_M&^'9/"GA_PYI6K/=^'_  CH'ACX^W^E
MZ -)GFLM.\+VTFN7&,ZT(-7N_?K0E:,FX.CA_K,_=47*3Y'%14(R<I2BE=OE
M+<DI<KTE>*L]%>2NM6TMM7:[\M';^AVBOQZT7]MO]JF7Q/X-T[4/"?P:U;1_
MCI\9/B7\'/@TV@^%?'5G=^&-;^$_QU3P?XDD^(=]>?$;4+7Q$;WX-:?XN^(%
MD-%L?!T-KJOA6_MFFO[5EMQ4_;Y^)$GA7]K+X$>&?$/Q.\/>"/A_J_P,^*6L
M:AH_C_\ ;K^,?["7@#5/$VG>-? =II>I2^//A#::G?\ B7Q18Z=>ZI!I?AO4
MM.^S7&GW.IWGVV!K!(Y=K:R6SBFVGOI-PMY7:;5]XVDKI^[#JQM0:U5>5.,=
M8WC[2A+$1<XW;BW3C'W7:7OQTM\7[(45^0,'[;GQPT;XGW>AZ5I?PI\7?";2
M?VBM1_9S\-Z#HUAX[U_XB>([*S_9JB^-'AWQ9!\6]2^(^I:7X@NKS5(&T5_M
M'P\N)_$]A?6VJ'5]/OUF:]^2-(_X*%_&]/&WBSXFV_QF^ WB0Z[\.OV-M%O]
M$LM.^(DOP6^!.K?&'XR^,?#7CRP\8>#+KXPI>GXF_#W3;B&R\8:W-K?@&\U
MZ-90ZYX7\.6UJENF52I&G=-/FC.C&4;-22K.IRR:>]HTJDG%7E>/+92:O/MZ
M?LX5/>49QA*/NN[52HJ4'O97F^K5H^\]#^C6BOQ(\2?\%'OC#I7@/0=?'B']
MFKP_"^E_'[4] ^*GB3PK\2;CX6_M/ZG\(O&NG^&?!G@7]G[3K+XAV6HZ/XE^
M*VF7<FLZ++-XK^*UTRHC^%O#?CC2P^J5PVO?M^?M)Z#\4OVEM(\'^%_AUX-@
M^'OPU\>_'76/#WQ5T_XR?$77X+CX??"K]G;Q--\.H+2?XU^&= \#7$\OQ%U[
M1M1G\)^'M'\/V.I6%MKTG@O4=6GUU]9T5Y*Z5[34'NK-N:OMJDX._EKM;FOG
M3J1II-RDJEM&OX:BY;I)Z25FG;1V;Z?OA17YY_L4?%OXE_$KXF_M<6/Q(^(/
MAS6ET#XG^$+WP/\ #JUL7M/$7@+P+XJ^%_@_Q#HTKN_BS4S/X5U26^O+/3+A
MO"^CR7_B+1O%6J/JEX+Y=#\.?H92C*,XQE%WC*,9QE9KFC.$)Q=G9J\:D79I
M-7LTFFE:UC&6MI14DFFFKN2LTTG]E]%HT[*]@HHHI@%%%% !1110 4444 %%
M%% !117R?^V'X1_:Y\9_#/2=+_8R^*7@3X2_%"'QEH][K'B/X@Z?9:EHUUX*
MA@OUUK2((+_X=?$V%=1N[B33WMY5T&VD5()0NJ6H)28_K\OZ^3 ^L*\_UKX7
M>"/$7C[P=\3=;TN\U+QAX L]:L_!US<>(?$AT70CXAMFLM7U*U\()JZ^#Y/$
M-SI[S:8GB>YT&?Q'::5=7FEV6JV^GWMW;3=M8I=1V5HE]*DUZEK;I>31 ".6
MZ6)!<2Q@1Q )),'9 (H@%( C3[H_-#XG>%/VSD_;#\!_$K1_A]\*_'W@C1I?
M'^@_#"UNOCS\5_!7A[PSX6OO *#4;OXE:'HW[-WCO0-%\8^)_$:'[-XIDU7Q
M66L++1?"GAZUT$-XDO\ Q*XJ_6VC?G\+;6C731ZZWM9DU&HVNE)>TC&ZL[-R
M:A))Q;?O)--*+BGS.4;:_IS17YO?'7XC?MG>#/'C1^ _"NKZ_P"'[#1?#/Q*
MO=,\-^%(?&6@ZB-4L;7X:^(/@OHWBZ+P=I^L7$^@>.-6L_BU;:S=:)I_B74_
M"^GZE]J&C^'+2_LK3YF^)'Q:_P""DG@KXA^._"_AY=9\4:KI.CS:/X/MY_AQ
M\0]0^'OB/3+?X<V,S>/X-1^'G[!7C+P7:?$.[\2Q:MKMK9:I^US!X>AO$C\*
MR?!2[U&32O#VKS>U[Z)=7:SU:NFF]$[7O9VDI6LI6'*SU4[6;ORNWNVNK)RE
M?7W;P7-9\I^V%]96FI65YIVH6T-Y8:A:W%E>VEQ&LMO=6EU$\%S;3Q."LD,\
M,CQ2QL"KHS*0037AGP9_9@^"7[/]WJ^H?"OPGJ.B7VM:3HOAVYO-;\<_$#QY
M=6/A?PVUVWAWPAX>G^('BGQ1)X4\%Z"U]=G1?!WA=M'\,:4;B3[#I,&ZOR_\
M->./VR_%#_#+Q9JFG?$/7/\ A"?'7BW3]=\9W7PR^*%O\6_#WPPU[3/ S^,M
M0TO1/B!^P9^RCX1\9^*X84OH/ FEZ3\#)]-O+%-6@FUSQ3XNT>VT74?T]^*G
MQ(UN_P#A;\;)?@?+>:W\2_AW;W6@RV5CX;NM3U?1O$C:)HOB&X&C:!K,.GV?
MBOQ!IOA;7K;7-#T:&2]T_6=9^Q:#.+BXDN]/$1GSNLG'W:-1);RNU!3YK."C
M&7->,$I2D^52O!OE522C[UN9J";Y8IR2;DDM%=[MVNMWIK>7T!17XX>&_$OQ
MAT>?Q_K]KX__ &Q[/X;>,/C;IR>(?CK'^Q]./VC[[0M&^!?ANR\.1P_!34/V
M9;N,^&;GQI87?AG5_&FB_LQLD%OI&EVT\>CMJ5_XN?K_  )\<_VG_$.@:)\-
M?B'X)^-C?$/6?'LLFOZK-^SYKNC^#I?@=J'P!N;ZPGU;QI9^#A\/])\1ZM\1
M&M%USPOI7B.;QSX<\57=WX<GL['0K00QN,[QJ2<6O9SE"R3;DHSC'FC=1O=2
MYK=D[-VN9SGRQJ-1E+V=.K/:RDZ=/VBBGJVYNT(\L9/FOH[6?ZP45^&GPR7]
MHK4-:_98TS1+'X_?$?0_A9;Z!J-W%\;_ -GG4/@C8?#/XG6G[/WQL\,KX&T&
M=OAQ\.KO6_AHMQ_PBVE7OBK7=9\?6VFZM=Z1:1?%C6K[Q!):6'OG[&GQ6_;<
M\5^([O2/BKH%MXDTA(?#MSXWO?BI#\:/A;X@\%W]T]U#X@3X6_;_ /@G#^SO
M\//'VCVLL)CLO" \>>/=3MF6.^N/C+?Z3<65SJ%RM&VMTW%=-Y2E%==O=3<O
M.UMKZ:>=_>OH[>[)1T?6]VUHKQ5UH?J?17X,:YIWQ[O=!T_X;^'+/]H[QAI=
ME\>9?$WCCX<>,/V:M1\*?#KX>:;IG[6WA?Q5X1\0_#+Q[)\+M)U/XCMK.D7F
MM:UXB!^(OQ-T8^&WU#Q%=Z7\/;+2K?3+GW/PV_[:%G\*_#'B'PIJ_P 0O!6J
M_#CX/_LIRZ-\#-,^"/PN\.> _'7BSQ5K-UI?Q9\.^(]/N/A*GBKPY9^'M(BL
MO[1TGX=>(/ D/P_M\WMU!:6>V%+E!1BY\R:3J)[72@UJDFVTT[Z+NE>S8H/G
MHT:K3C*K*,>2WP-X:GB6VW9\JYW2YG&*=2#CI+W5^NE%?E]^S+XX\3V/Q2\6
M^/\ XN>*?C_KUMJ?PK^!G@:]\0_&S]G+6/@Z=$^*?B+Q[XPM-6^''@^+1OA1
M\/\ 2_$_A32/$'B+3$T_Q!;6OC&UTZVU43:G\4/%.F"'5;:#X]?$KXWZA^T%
M\1?A=X)\1_%75=&LO#?@BRLOACX9^"UKXB^&>K^'_&G@_P ;-\1M5\=_%VV^
M'&M7_A77]'M;+3-1\!Z!+\1?!5WKNNF/2[#3?&<&H3:9I,4DZKDK<BC-*\GR
MIQ:H^][R5K.JXM7LI0:YKWMCB:ZP]/GY)U&XU7"$(N3E.E0J5^2T4Y>\H*-X
MQDX\SDXM1:?ZD45^)WA?XF?MHZ5XJN_!_A+1OCQIW@OPW\#7T5-)\1_"A&TS
MPEXF\/\ @[P0FGZMX'BOOV3_  YINO:L]E:>,=5\,6)_:;^.#ZYKD-MX7\6_
M#CP=KVH:5X6CT/$WQE_;/L/$WPTM?AWX@^.WB?X<SZWJD>F>//B]^S9XT^'O
MB+QW(GBS18)=+^+G@'X7_L/_ !@\2Z3X<TW2[B^L-%\0WWA_]B*76[;[3JBW
MVIZ?I:>)]1GF7/.%I^[5C24G"2C-R;7/%V=X1M[\MH?WDTWHIII>[*[@IZ*Z
MVOR\UU%SWTOK9ZWW_:&BOQ3^'/BK]I3P5X9U3PMI&M_M2Z+X(TWQ%J ^)-__
M ,,NI=>*O@I9:G\7_%DMFW[.&CW_ , ]1NOCA;>(O#$]AJ?B6]DTS]H23PW:
M7@U>UMM,G<>'+7[#E\:_M>2?L]Z)K&F>#-+NO$EU\.M9OM?\8ZM?WNA?&_2[
MZ#5;^'0M9TC]GQ/A)K'A#7/&6H>"HM.\3ZCX6U+Q9X6;3O&-U=>&;?P%?BUB
MT.ZTG'EE)734>JUNO?M:S=W[FJ3=FXJ[YD12J^TH4ZSIS@YTXS=-PES1;C2<
MHI-1<K.HU%\L7-0E)1C9I?=-%?D]\*OB?^TMJ/Q<T'2?^$U_:G\9>#C\0=!T
MOP:GQ6_9)TSX4^'/B#\&[NWU*3XB^.OBWXJ3X+>"KWP'X]\$ZPM]I/@?29V^
M!=QXMTS1/#%[!\)_&-KXHE\3W/&^/Y?VSV^&?B*\U'XB_M(:E?ZEJ'@GQ_;Q
M>&_@[X'77/ XTC]I'6M'NO!/A+0O!WP1.L^)=#F^&=MH6L:]H?C"R^(&OZMI
MMJFLM<Q:#J6H6=W,K12DW=.I"DK)M\T^:S:W4+P:<W[JT_FC>XS4IJ"4DW2E
M5YI1<8I1G"#BV_MMSNE_+&4GHFU^R=%?F%XO\4_M7>#](^!UC#XU^.GB/Q1J
MOPY\,^(3-IGP)\&>(=-^(GQDUSQ-I4WB7X;?'&^\,_!\Z7\$OAUX9\.7K0:/
MK23_  LU&.W_ +1DUGXB:[K^@-9ZQ\D7]Q^U[\&].OKGX6>%/B9X,M/$6OV<
M7B37]/\ AUX\U;50^FR?$J]\.6)TCP_^R+^U]X@O/#=[=ZAYWB&;2?A7IDJ(
M-&M?^%@^$GU:U;4KY%[.I-RLZ<H1Y4N9R<IQ@Y))W<(\W,Y)27*I/9:Y5*\H
M8BA15*4XUJ=:HZBNE#V4%.,-8\KG4ORI2J0M*RUNVOWTHK\H?"'C[XJ+^T'X
M=^(7QUU+XOV^F?#GPG\8-8\8Z/'\!?%6E_ 'X?>')O"O@J7PWK_P^^(TWP9\
M.^+?%VK>,;6'5K[6_#&M^,O&/B/1=0MKC1[OPEX&U#36TN__ %;BE2:*.:)M
MT<L:2QM@KN210R-A@&&5(.& (Z$ \5STZCG*LG"4%3J*FG)2CS^YS2DE)+12
MO%-.2:<977,HKI:M;6^BU6R;N[?=KKKOV'T45\H_M1^$?VM_%;_!L_LI_%'P
M+\,TT7XJ:)JWQI'C;3[*_/B[X3P%?[<\,>'OMGP[^('V;7+P;A;7%N?#$R9&
MWQ#:=M)/EC*23DXPE)1C9RFXQE)0BFTG.;7+!-Q3E**<HIMJ9.UO=E*\HQ]V
MVBD[.3NU[L=Y-7:6R;T/JZBBOS%UGPE\-X/COXRU#XH_LT_$OXF?M!7'QET#
M7?@S\5M!^&?C>Y33/ARB>'AX>B\,_M,:'I\7A+X/>%O!]K;^)D\:?#KQ'\1_
M!3>*KF/Q+#<>%O$MO\1+2W\1*<N6$I=DWK>VBD_><5*23Y;7C";NTN75*0W:
M459^]S:[VLHM+U=^K2M&3Z'Z=5Y_K7PN\$>(O'W@[XFZWI=YJ7C#P!9ZU9^#
MKFX\0^)#HNA'Q#;-9:OJ5KX035U\'R>(;G3WFTQ/$]SH,_B.TTJZO-+LM5M]
M/O;NVF_*2VO_ -JKX+?"?6M.TK5OV@;FTUVT?6/#=CX7^$6D37'PFU6^^-OQ
M AGTG2WT']EC]HGQU<:+K7A2+1]0\1W.M_"/XZ>(H9]8LM:T/2O!OA2^GU/0
M=OPGX_\ VYU\,Z+\2_%/B3XG:??>'?!WP_T_6_AGXH^&7P]T3P)K&MWO@+XH
MWOCOQAXW\3W?P8\(^,;-M'\3:+X.:\U?P_K'PZ\%Z1YB7-[X6M--UR'3(9G5
MC"596JM4'54Y1IR:?LW1B^6WQ\_UB/(H.2DHUM5[.1E3J>UCAN:'++$1I347
M[RI2EAHXJU1N*<'"[IJ3C&7M4DE%NQ^P%%?@WJ7[2/[7NJ>'=1C^$_Q&^.'C
MW1]%\:>'K75O&GBC]GW5O!?Q+T1M<^$6B^+M/T36/ 'P_P#V"_COXDOO ^H^
M*M2U<P>(K;]G[P^FK:%8:!'I?Q/LK;4;7Q-XI^[?VKO!/Q$^*OP1^""^7K5Q
MXCLO'7P\\;>-?#O@_P "Z7XJT#6-2T'PIK7B/[-K7A/XG_#KQ#J47ABR\:V6
MDSV46K^'O#WB#3[Y=+-R=*UZ"U6USIXF%6C.O"-3EA/DLX-2D_W6L4N>\?WT
M4VKV<9IKW6S2HW34FTVH4Y5'RJ_NPC4G)))\TIJ--M04>:3E",6Y2LOKKQ5\
M,? _C;Q-\//&'B?1/[3\1_"G7=4\3> =1_M+5[+^P=;UGP]J7A74KW[)I^H6
MECJGVG0=7U&P^S:U:ZC:0_:/M5O;Q7L4%Q%WM?DW_P )E^V/X9U7PCI%SXS^
M/GB_Q;/X.\$:K;:/=_L_>"I/ASXHT[Q%X)U;7OBAKOCKQWX6^#.EZ=X%\>_#
MGQ7*_A_P%\/#XM\*:EJ=IH?AFQU7PK\2=2\1:QK47:?#$_MB:7XP\!W7CCXJ
M?%WQGH@UWX.-XET36/@]\+/#N@:E9?$WX=ZWJ?Q(M-6N_#OPFTCQ!IVD?"[Q
M9I.EP>'7TOQ'I.J>';G5[O2_B/K7C5KK2HM/Z:GN4YU97<:=U)1]Z=HRBO=A
M?FDG*I[O*FFN:2]U-DJ<%65%)J4X^U4N22IRE*+YKS47'VBC17-S.-^6$4Y2
MY8GZ845^7OQ/UKXQ^!_VM/'>L^ H_CY-:^(+'X2M'X0\(?!.W\3?"CX@>'-&
M\,>-%\>W^K_%;5OAQJFF^'/&W@ZU_L^7P5H/_"U? -OKOB2YL-'O-*\7Q:C/
M;:5\TP?'']NH?"[7]4FU?]H9-1M_B=9GPLUU\$?'9^(/BGP?/X$\^;2DU/2_
M^"3]]:>&K&R\9VMY;7UIXQ_9>T1)[B2"/3OCJVAG3M0UM5/W;II)S]I*,5R+
MFY.9)N535*$(MV;<K[>[K8FC5]K&;<)4W3<[J2E[RA4K13A[O-.\:2D^6-DY
MJ"YW9R_=BBOQ-\;>-OVS_'WC?XR^ O%7AKQNO@74=)NETSP)<?#[X@ZK81Z1
M:'PCJGA>^\(^)?"G['ND_#^3Q;/=">3Q7;:C^V-\0(Y1+K=EH_@'0[[3H+.P
M]"\+:C^V?H[7&N>'IO'^EZ=X?U"TT+P[\%(_@S\.O"WPV\03>(8?C3J6I^(]
M<OK?X46OC:R:WUFR\ LU_H'C+0-#LIKN.\UZRU:7Q#(9V[+#2Q+<DHM\U+D?
MMDE*,-*2;G*7-)>[&_N^\I-;1]8?UY8-TIJ]/GC7L_9749R:E*W+%6C97ES.
M3Y7"-DY?KA17YN_LH>.OVD_'?P3^-DGQJ7Q%KGB*QT6X3PA:>,_AUX[TCQ9+
MJE[X.OI-8T.[TKQO^QQ^R'X9\5:*FLI:PZ%9^&/ 'CVU*W-]I6N>-_$9:SW6
MOV:[G]IR+QSX4N_B%K_Q%_X036(_%'AI_AEJOPI\ >#/ ?P_TGPK\//AG>>%
M=3T>[T#X8^&_&5C>:KXDN_%VGQIK?C&_\-31+/HNC>'[.;1$DA4FHT?;._+S
M48\J3=3]_P"S4;P^+W95$JFEJ:4W)VBV6JU\1'#\DTY4:E53<7R+V<W!P<M8
MJ4E:4%>\D]E9V_1BBOR&^+'BSX\0?''QAXCAD_:9U/4/ &D_'>U\.>'?"/P"
M2[^'W@;0=4L_!FE_#;Q5\,_B./V?_%T?C_Q3XETQK[7?%6A/>?'O4M)N].U.
MQTGX6'4=-L?"?B5G@?XX_M?^&_AOX#U[QOJ'B74O$OQ/\3?$OX'>%= ^(G@R
MPTG7[?Q_K&I?V[\"_B7+;3? 7]FGQ-JWA^/PI'XA'C>*\^#W@M;/2M&TLWW@
MO3/$%EXEN;SGCB$YU(RIU(1A-QYY4YJ/*J2FZD[I*,>:\(M2GS/E>G-&+VEI
M=+WFDG:+3<G)2:C&U]^5*\N6-W=M14I'Z^45^-?@?1_VK]+U/1_"MCXT^.4G
MB"^^('C3PCXO^-GBSX%^![[QKHGAS4_V@Y3,_AWQ'KGP:MO#=SX6F^'SV?B/
MP_=-9^(_ VGSW9NX8;[3= AT73IO&/C7]O7P;\.I-1L?%'QA\8:MK>F^$Y]=
MU"?X3^'-(UGP#;Z5\1_%WA#5KKP3IWPY_9(^->N7>L^*?#>D^$O$?B;3M6^#
M'QDF@_MW4_$/A3P]X.\*26<6B=->U"$9RO.,I0@E37M)*4YR@DX0;:2<7*4O
MAC'WF[6OC1K*M4K4N64)T93B^>,E":@J;<H3<>62;JJ*7-=R4N5.,927['45
MXO\ L[ZYX_\ $OP4^'>N?%%XY?'NH:"LGB*9="\7^&9;BXCN[J&UN;[0O'GP
MX^$'BK3=5N=/BM)]7M]3^%W@)?[4DO)-/\+Z3ICV5JGM%#5FUO9[K9^AJG=)
MV:ND[/1JZ3L[-JZO9V;5T[-JS91112&%%%% !17RC^U'XN_:W\*'X.?\,I_"
M[P+\3!K7Q3T32?C0?&^H65@?"/PGG(_MSQ/X>^V?$3X?_:=<LAN-M;P#Q/,^
M!M\/7?0_5PZ#/7O2O[W+9WY5.]GRV<I1MS;<Z<6W'=1<9/22)4N;FTDN63B^
M9-7:497C?XH^\DI+1R4EO%GG_A?X7>"/!WBSQWXZT+2[V/Q;\2KS2[SQCKFJ
M>(?$GB&\U!=#M9K31=-L!XBU?58?#OA[28;F[;3?#'AJ+2/#EE<WVH7MMI<=
MYJ%[//Z!7YB:WX[^%R?';QG!\6?V@/BYX(^/6B?&/0-+^$GP:\%_%?Q;HEYX
MF^&LL?AX>'?^$4_9RBOY_ _QG\)>)[>Z\1W?C[QWJ/PW\9ZKX>"^*XXO%GAF
M?P#IMUX=\@MOVN_C;\'?A1K=]XW^('PM\N\M9-<^''B7Q=X6N]5O-(AO?C7X
M^\'2:%\1O%/Q,_:9^"7@#7;K4M-T&*70-8UOXC?!#PYX9D:T\+"[\8:DVC0:
MPIU(0NYR22G2I*]W+FJNI""<;.44W2:C*5XR6J:2N9QJQYXP4;<U*=:_NQ22
MKTZ+33Y4Y2G64I6>C<E*\VE/]FJ*_(CP+^VQ^T?XIT;PS\0I-)^$][X5_P"$
M7^'$&O\ P]T[X?\ BRW^(/B+QWXV\$_$W7[U="\4VOQJ\2^&?"=GIVM>"-,T
M^'PN_A_XBW,[WVI:>/&DC6UKJMQ0NOV_/B?9? [XE?$'2_&?[.7Q0G\(_$?X
M4^#K?XI?#32M-M/A7H&F>/O#%OXAUZ\\66/Q-_:D\!>$%U'PGJLP\#7D>H_M
M%>"K"/79K::_NK/56F\(0XRQ5&,HPDYJ<HTIJ/LJMU&M&I.FY>Y:+E&E-N+?
M/%).45%\RUIOVD%4AK%RJ05[)WI5)TIZ7VYZ<U%Z\R2:WL?L-17YB_%CXN?%
MKXE?LJ?L\?$[1/$?AKP+J_C#Q_X6U7QQ%X1\17?B'2/%&AZ%9^+==?3/#GCG
MX"_'B.UTS2/%-SX6L+VZB\/?%3Q[I<6GWLOAC5]0\4646JQZGRH_;,^.OA[5
M?".D>+?$'[/E[XIU?P=X)\2+\+-*\#>.-!\>_$#2_'O@K5_&E]\0OAX=1^,6
MO/#\/?@_Y=MH/C>:X\/>(SKT_AOQ+J=QKGPYDU30-#'1'WJDZ:^*$J47VYJL
M9R@D[6^&$FV[*UM;OE,Y5H0C4E.\53H/$R7+)R=&/.G)12;YE*G./)?FO%WL
MK-_I)K?PN\$>(_'W@[XF:YI=YJ7B_P"']GK-GX.N;CQ#XD.BZ$WB"V:RU;4[
M7P@FKIX/D\0W.GR3:8GB>ZT&?Q'::5=7FEV6J6^GWMW;3>@5^9_PR_:-_:>U
M+QAX#L_B%?\ P&NO#VMZY\';77].\&_#CX@Z3K,UC\<_AYKGB_1K/2/$&M_&
M'7+'3;OX?ZAX>GM=3U>]\,:Q#\0++4X3:Z'\.Y],=]4S_B?^TUXM^$O[6?CK
MPI'\3_AV^@75A\)FC^"GB;3/%/B'XF:MI&H>&?&EWXL\>?"NSTGQ]IR66A>
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9OJ4%%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $7 FL# 2(  A$! Q$!_\0
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M7O"_1=W_ )GA+Q&C_*G\Y(_TH?\ A=OPB_Z*7\//_"W\(^W_ %,'M^I]:/\
MA=OPB_Z*7\//_"W\(^W_ %,'M^I]:_S7O^$J^ 7_ $174O\ PL-8_P */^$J
M^ 7_ $174O\ PL-8_P *V_XEEQG_ $5-/_P2O_D@_P"(CQ_E7_@4S_2A_P"%
MW?"/_HI7P[_\+GPE_P#+_P!OY^IH_P"%W?"/_HI7PZ_\+GPE_P#+_P!OY^IK
M_->_X2KX!?\ 1%=2_P#"PUC_  H_X2KX!?\ 1%=2_P#"PUC_  K'_B6;&_\
M150_\%K_ ##_ (B-#^1??+_(_P!*'_A=OPB_Z*7\//\ PM_"/M_U,'M^I]:/
M^%V_"+_HI?P\_P#"W\(^W_4P>WZGUK_->_X2KX!?]$5U+_PL-8_PH_X2KX!?
M]$5U+_PL-8_PK;_B67&?]%33_P#!*_\ D@_XB/'^5?\ @4S_ $H?^%W?"/\
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M_A2:U1_Q*[BO^BKC_P" K_,/^(YXK_H4_F?W6?\ "W?AE_T/G@#_ ,*[1?\
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M(KJ?_A2:U3_XE=Q7_15Q_P# 5_F5_P 1SQ/_ $*OQ9_=;_PMCX9?]#[X+_\
M"GT?_&C_ (6Q\,O^A]\%_P#A3Z/_ (U_"E_PF_[/7_1%=3_\*36J/^$W_9Z_
MZ(KJ?_A2:U1_Q*[BO^BJC_X"@_XCGB?^A5^+/[K?^%L?#+_H??!?_A3Z/_C1
M_P +8^&7_0^^"_\ PI]'_P :_A2_X3?]GK_HBNI_^%)K5'_";_L]?]$5U/\
M\*36J/\ B5W%?]%7'_P%?YA_Q'/$_P#0J_%G]UO_  MCX9?]#[X+_P#"GT?_
M !H_X6Q\,O\ H??!?_A3Z/\ XU_"E_PF_P"SU_T174__  I-:H_X3?\ 9Z_Z
M(KJ?_A2:U1_Q*[BO^BKC_P" K_,/^(YXG_H5?BS^ZW_A;'PR_P"A]\%_^%/H
M_P#C1_PMCX9?]#[X+_\ "GT?_&OX4O\ A-_V>O\ HBNI_P#A2:U1_P )O^SU
M_P!$5U/_ ,*36J/^)7<5_P!%7'_P%?YA_P 1SQ/_ $*OQ9_=K_PMOX9?]%#\
M%_\ A1Z/_C1_PMOX9?\ 10_!?_A1:/\ XU_"5_PF_P"SU_T174__  I-:H_X
M3?\ 9Z_Z(KJ?_A2:U1_Q*Y/_ **Q?^"U_P#)#_XCHO\ H3O[W_D?W5GXM?#,
M]?B+X)/U\8:(>_\ V'SWYKH-,\7>%?$4,TVA>(]$UNW7BY&D:OI&H*!C&&PS
M?@&//0>W\&?_  FW[/?_ $0_4O\ PI-;_P :Y^+Q5X TV^@U7X=:K\4?@YX@
MM;S[;::MX3\8:SIOV#H>GA_CC/-<^)^BMC5A&\'Q5&36RY.5NVO+\3?O/3HM
M3?#>->$>+_VS*G9JVG1-6OVT7ZG^@M" <G )Y[XSG'X?C5@!2/NX]1W'X]:_
MBW^"O_!6S]LO]F^6P/B_Q):_M9_"&V!&K_\ "1WNCZ=\2K#3/71/&VX9\1 @
M?\4OXL/B\@9 (YK^GW]DG]LCX!?MH_#N#Q[\#_%UOJ%O:@6GB3PM=E=-\;^!
M=5)V_P!B:[H>XR: ZA0<D;2I&&R#M_ N+?#?B/@K%/\ M?*Y.-[*JDY1ZI/F
M2:5U9^]9:[WT/U'ASB[*.(,,OJ<DF_LMI/7735-]MF?:M%5_-'EY[XQ[8_\
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M$>"/%_[1?[7^A? C]F[QQ?ZGXV\'W?[0GA?P7X<^//BRSUGQ)XF^&FJ>.?\
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MC?!^^\<?L]_";XL_&#]G3PWI?@OX*?&+QM>^,=,\3>$_#&A?\B-HNN:'X?\
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M^"GA/PGX[/PF%_X7T/P5H/CO7/&?C?7?#_\ PEF?$0\.ZYH?ACP3X6X\&?\
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M)!X0NO#OQCO+*T\;G1M3\2V.ICQEH']NZ/KFM^'P/#&O?\(IXC/_ ",XW?\
M"9]02:Q[/]K/PK9ZIXN\*P? +PY:_L\>,/AQIGPR\2?!W2?$NLZ;XFU#2]#U
MK^W=#\9ZYXX_Y&;Q!\0_"GB(X'B@YP?^*''S &O-OCC\=_#GQ3\(_"'P!X.^
M&=O\+_!_P3TGQ1H_ANT/C'6/$FIZ[I>N:SH&N_VSK>N>(/#7'B'_ (2/!\;=
M?^0_U-=.29;QH\XRK^V'6E&SM)U$H:TIJ+G!*[ES.,6W)-OWW[MXG/F68Y/]
M4?U-*[ZVUW[_ -?B?<WP-_X7K#^PE\.9_@3\;_!7P5UFY_:#^)UGXBU;QO\
M$?1_AS_;FEY8:%HHUO7P?[>/A0]?"^>0%],UR/QJ@\#_ !K\=_LP_#+XC?$V
MV^+7Q?T/PEXHLOCK\5_@1X;'C;4_'6I%1KO@7P7H8\/>&AX8\?\ B$^'L^&?
M^$G_ .$//@WP822<%@!\,:O\4I]7^ G@CX(S^'+:V/@_XC^)?']GXL-[_:6I
MWVI^.-&T/0O[%&AXX/\ Q)B#U[8]];]GCXUS_ 3X@CQQ8^';?Q7I]SX1\3>
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M"WA7XZ>$]?\ @EX/U3Q-H_Q-^*VK^#3\,_BP? N3KNBZ)HF@-_PD_@#Q#XK
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M<8#?>)Z_-/PQ^/WA7PK\#M1_9\^)OPSUSQ]\/[SQV/B!I%UX3^)&L_#?4_\
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MBN7\8?\ (N:A_P!>(_E7DYG_ +AF_P#AJ?\ I,C;"?[ZO5?^E(_LD_X-3_\
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MLZ?&CP?_ ,*]\>?&/XM?$SQWX#\#>-%U_7?&?CC7/'Y/ACP_\1#X<UP^*/\
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M=Y5OY_V;[3Q]L^R?Y_/%6*_7XN\8MZ-QBVNS:3:^]GRKW?J_S"BBBF 4444
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MX;SK_P"7<>N2:EX5\5:#8:?JFN>#O%NB:?JG]J?V/JWB'PUK.FZ9?ZIH6?\
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M?0_C'X;U#X(WGP:UK5[3X@_$CX-ZEXF^)?A?QUXT\/Z#KNBZY\#_  _GQ/\
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M]KGB36=0\1^*M5U/6_$&JWGVW6/$.K7G]I:G?ZI_T&M<UPY_X2'KCKGI7/\
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MK6OZ#H6B^!_C?X?_ .$M^&/B#X=^$_[#UOQ1_P )3_PB (R? _..=?4OV/\
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M?C'_ .H-X@K_ #&?AY_R3[PM_P!@?2__ $R&O].;]NK_ ),T_:N_[-Q^,?\
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MCQGX/\/_  Q\!Z-X:\#W_B?QU_Q(==UKQQHH\-CPSK_B/Q7X<SX8\;'Q8?\
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M0?%8(\9\_P#""$9&?F#^P?$4VEZAJL'ASQ)<Z/I=Y]CUC5O['UDZ9H6J9_Y
MNN:X/^*8\/\ B(=_"W/\B?E\/PYX;9OSX/!22=_?:E:2EOHYMI)M/9.#?,[2
M:;AU_6.)<+_O:;6MK*36NFZ5M+]SZ>@_:X\<0>#I_#L_@'X7W/C#4_@K_P ,
M_P#B/XK_ /".:U_PG&N_#'^Q3H.AZ*=<'B0>&- \0^%/#C$GQ/X5W>,O&AT
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M4=JGT'PY_;UAXOOO[5TW3?\ A&-(.M&TU:RUG^TM=U3^VO[!_L;1/^$?.?\
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MMKM\CW?_ (:5OH;_ ,/P:5\%_@[HOP_TKPAXH\&_\*H/A#6=1\-:[IGCG6M
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MY/K7T=\"/AC\ [S]G[X__'WXW^'?B/XV@^&'COX.>#/#?A3X?>.]&^''V_\
MX3G^WA_;.N:WK_ASQ;SX4)ZY['CGCJ?$G[)FA_%/2_@AX_\ V0_^$MU/P/\
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M F@?"V]\1W7_  KC0]7U/6=(\)VEIHVG:9_:FMDXUK7-;\/G_A)M?\1 D_\
M(UX_X0S.3R,UQ&?WN/(MKFX_Z>[/_CPQZ?YZ?E7H83@>2P>;X'&9LX_VW-^S
MY7?DC&HI1M?2+E)3E*R5G4:4FXQD<N(SQ76,P>5*_P!IM^6K2OTV7DC]3OC]
M\>/^%A3?M^:'JOQ,MO%G@^YN?A@/@IX>NM8_M+PS_P 2+QEH/]NZSX(T3 _X
MJ+_A'O[;_P"$U'A, <+T(P/%_P!GO5];F_9_\8>!_@]\4_#?PF^,%K\=O"_C
M/Q'>:MXPT?X;ZEKOPPT+1LZ'_8FN>(/^0_X>\*>(O[;\4>-O"X'_ #'B,C(!
M^&N/^6$'_'K_ ,>?7V_^M^GM5;R8)O\ 706US_R^6?\ H7^?3W[UUOPVPF$R
MAX/^V)>]*,VY/F]Z*4;V;2O))-RWYK23;44N9<18MXM8OE3MI9)?=:U_+;_,
M_8_]I7]HJPTC2?&\_P .?BGIMP?%'[;^D:UXON_A]K&C?VGX[^&&A_#'P#_;
MH'_"/\Z_\//%7B'0]<4],<C)&:34/^%9^$?%G[4_Q&\5>,?A?X]\ ?&WXS_L
MZ>,O G@CPKXDT?Q)XF\=^!="^)GA_7M=SX)T$?\ "3Z%_P 4[G_BF,')Y/7G
M\><^3_J(/LW^A^^/Y9ST^O>K%G-/IM_I]]I4_P#9NH6MYI=[9W=I_P 2W4['
M5-"_YC6B>G\J\S#^%\L)@O\ 8\XE_#<)+2//>*5_=E%P:M:/*WRQ?*K<L9+T
MO]9(O%_6\9E::O\ \'9]7Z'ZS_&N\\;7G[.W[;^J^+_C?X3^+/A?7_CGX%O?
MAOI/A[QA_P )'J6@:7KGC37!H8.@Y_XM^Q\.G0_#'_"+XZ: ?^*)&<'RW]F_
MQ3XCE^$7PBTKX/?&'PE\)O%/@[]HW4_&?QV_X2'QWHWPXU/7? >N?V$=$\9Z
MV?$'_(_>'?"OAW1=:\+_ /"+DX;^W0.BBODGXC_'WXQ?%/0K?P[X_P#&/]M:
M/_:_]LWEI::/HWAPZ]XG&BC_ (K/6_\ A'_#?A$^(/$.0/\ BI_%? Q[UXQY
M,$W^O@^TY_TW_2[/G^A/X]?Y\N7^'V-EE,L'C:BBW5=1.*NE*W+>2YHJHVG*
M3<M=8)W<(L,3Q)@UBUC,'E*M:S3^_:WZ6>O<_=;0OC!X U'4/%7_  K/5?"9
MU_2_VOOB_P#$#QWJMU^T$?@%INH>&-<UK0=<\#>--<(\.>+O^%@?#L>'3K?A
M@^%R!_T(Y\$D>+,CYX\(?&SX.7MC\0/B9JVJ>$M.\7_LL?$GXQ>-/V<O#]I:
M#^S/'>F?%4:_H.AZ-X(T/7_#@\3GP]X5^(O_ !4V?%7@\G)R.,FORH\F":+]
M_!;?]O=I_GZD^OH:L9_X]Y_^/FX';/T&>N>?ZU6%\)</'FBLZJ)2^S>S5VG)
M/WKV:]Q*RY(N7*[V:,1Q9'3&?V3'IVM?;:R2U^][G[6_#SXP^ (?A7\(/$>E
M7OA2X\(^#?V?_$_AGXPVWBOX\:SX;TRP^)^NZ-K_ /PG.C:Y^SKH'AKQ;XE^
M(/B#Q9XBUL^)_!?B<#=XRSX:P,^%%W<#-X\TG7O E]X.^"_Q,\-^$_C?KW[,
MG[,>B^&_$%WX\T?PWJ0TSP-K>O'XJ_#+0_&Y_P"1>\1 ZWH9\;>%_P#A+_!Q
M\9^PR:_(CR8/-\_R/M-Q_P _?<X_QST_IT/)@FB\CC[/=7G_ !Z?8A[_ .>.
MG/-="\++*2><-\SOJ]-)2DKISM)^]9MI.5HMIM*Q_K8K7_LB"TZ6ZKND?MMJ
M^L>(O'?PX_:%L/@]\4_"6F?&'2OAO^QYX+^*?Q8M/'FC>"M,\=_%#0M;U_0?
M'/\ 8?CG7\X\0[3HGA<>*<X\9?V%M!'2O-_BS\=['1O!WQNG^&7Q3TZV^)^I
M^*_V3]$\8>-_!&L_V=J7Q*\4>!_!VNZ%\5?&6AZV3GQ!X?'B+^Q!XU\4CCQB
M 1QD9_+FS\2>([+PGXG\$6.J_P#%'^,KOPO>>)/#WV/1?[,U[4]#UK^WM#UK
M/3_BD\#/]#7/_N/*^T8MO7.><8],]:YL/X2R^M\V-SB2C"S@TVFHQM)1;YDK
M-Q6BLHJ,>570WQ8OJC6$RE-N]TTGW[J_?^K'['>*OVA/ ^O?%C]JW_A9GQ&T
MWQI\(-,^,W[,'B;P)X3^VC4?#5[X8T+QEH!\<ZQX(T/U_P"$=_MOQ/XV_P"$
M3!_X3/\ XJ?C -=QX]^+?A5O$^D3^+];\ W'A_Q3^U'\,?&7@/5KS]I#6?BO
MJ@\,Z%XS&NZYXS\$:%_PC9\,_"#X?#P[_P 4QXV\+^*CX/&"?!&2/":D_ASY
M/D_\L/LWV7O]B_X\/?MC]/6J_D08_<0?9A=?].?'/'7_ ">E=6+\+<,GE7U3
M.I))^^GHW;23OS1Y922?,TG=-15E&*%A^+,4T_\ A)6M[.R=MUU3V?Y>9^LO
M@S]I#[9K>I:WX^^,-UJ4_AC_ (*->!/$_@^ZU7Q(-2U+0?AAKAUW0M<70P?E
M\/\ P]/APZ+_ ,)K_P (K_Q1@&1T)K\\_CG%JI^,GQ//B/6]-\6W]UX[\3WP
M\0:3XE_X233+[2M=UG^WM"UG0];R?[?_ .*<_L/C&!^E>3>2,_ZBV^S8^Q9[
M^OTS_G-3G'E?Z@6WKC\>G^?3%>WD?!&%RC.98["3OS)W5DM;Q=[I\SUB[I[W
MN]4K^;F6=8K%X3ZGBTM[Z)7M>Z6VEMGZ"T445^@'C>]_=_$****'L_1_DSJ&
M?L;_ /*7W_@GE_V7?4?_ %67CVO](U_O'\/Y"O\ -R_8W_Y2^_\ !/+_ ++O
MJ/\ ZK+Q[7^D:_WC^'\A7^>/C5_R7F9?U]N1_67A;_R((?\ ;OYL^4OVZ_\
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M$_M3_"N'X0?#_P" /C_PYX^MO!%U^S)XH_9^^*?BSPG9:-J7B70-5UWXS_\
M"V? OC3P/H>O_P#(P>'?"GB/(\;^%_%G_"'XST.,'X@F^&7Q&A\4'P=/X \;
M6OC#_A)-+\%WGA^[T?6?[3_X2C7,Z_H7@O\ L/'_ ",7BSPY_P RL>W:N7O(
M9[.6XL;Z"YMM0M;S5+*\M+O_ )"=AJFA?\AW1?\ Z_\ +I7GOA+AMJSG>R?O
M.:<E>_O7=];ZQ=K)I):1273_ &SC%]FW_;K_ $C_ %^)^AWCS]JWX$_\*O\
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M&_\ @MW_ ,I-=&_[-Q\,_P#IZUZON3_@U/\ ^4;7C#_L[+X[_P#IXT*OAO\
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MW\0-8\;7>CZQJ6F7_A?P-K>-=UO1-#T CQ-CQ5G)[X! !/%>H0_LO:5J6J>
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M3X(:IH_PRT7PW\*-*\8ZSX<U/P)I7PKT;7]#\#ZSH?CC0/\ BISXBSK>M_\
M";?\)6?^*R_M[CC(/R'_ !L?2U_=<5*ZC;E]V[@U%-NUWIHIMQ=[*_I7X<V;
MCK?9O?6_7O<L:C^R/X<\(6'C_P 5?$7XWZ+X<^%_@W_A3U]I'CCP_P"#M9\1
MZGX[\+_%31]?USP-K.B:&>?#Y)T,_P#":^%_%8*^#1_PDY!P0:[#Q'^RQ\.?
M GPP^/\ #XQ\?6O_  L[P)\:?@[X-\'^+;71]9_X1J_\,?%;P8NNZ%K.N:W_
M ,R__P )9X<UP^)_&_;P9_8(/U\8^)O[3GB/XF^%_&_@Z]\'>'/#?A_Q1=?!
MQ?#EGX?O-9_LSP)X8^%.CZ]H7@;P;HG_  D'_(?(\.ZW_P 5MXI\5_* <;2
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M_:L/[,$/QHUC_AD6?Q7<_ @:/X8_L?\ X34ZU_:(U3^QC_;G]A_\)#_Q4_\
MPCW_  D1&?\ A+.X\4 #%?--%?TAB\K>+SC*L<LWG%1C.#A%VIOFMK*"A[TH
M<MH2<ERJ4E:7->/YA]9^JX3ZI97;3O:[\US>=]=?R/TV_91G^'$/[$/[8_\
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MJ_;N?JM-\*_A7XV^$NL?&+2OA+IOA/4/B-^P[\+_ (G:Q\/?A-J^L^&_#/\
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MI_V8/"/QK^&_QN^!/B?XM?$CX\WEGXRU+Q-I_CW0CX]_MU=#USP^?^$8\/\
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MA7+^,/\ D7-0_P"O$?RKJ*Y?QA_R+FH?]>(_E7DYG_N.;>D_R9MA/]]7JO\
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MOVDO".J?$3Q3\)O#GP=M?VE]+T7X*W6/!VG:G?\ A?7=%U_0="T3X(:WX?\
MFT#X??\ ".?V(/&W_"6')_XIH#G)K\=?BA#XQA^(_P 08/'_ -I_X2__ (3#
MQ1_PDGVO^QL?VG_;0Q_R "?#/3'/A,]L\GBOH^&^-L?FV</"2RA1@Z<9)OGY
MDY-WOS0A%147&VTN92O%)I+GS')<'A,+I*[]4]O-2;OI?MV.&HHHK]"?7Y_J
M>,,_8W_Y2^_\$\O^R[ZC_P"JR\>U_I&O]X_A_(5_FY?L;_\ *7W_ ()Y?]EW
MU'_U67CVO](U_O'\/Y"O\\?&K_DO,R_K[<C^LO"W_D00_P"W?S9\F?MT_P#)
MF?[5_P#V;A\8_P#U"-?K_,@^'G_)/O"W_8'TO_TR&O\ 3?\ VZ?^3,_VK_\
MLW#XQ_\ J$:_7^9!\//^2?>%O^P/I?\ Z9#7Z+]'?XLZ_P"W/_39Y/B-M\O_
M &YG84445_5-EV6FVBT]-#\K"BBB@ HHHH **** "BBBBR[+[D 4444679?<
MO\@"BBB@ HHHHLENDNUTE]VWX %%%%&F^GKI^?\ P0"BBBBWEMMIM^ M/+\
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MOBWXY^.+O]J8?M WGV3P)K/AO^SM*&C>(-"/@S0]$)'_  D/B+Q7X<UO6_\
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M'7/!FO:#KI^*>B_\)(/#'Q ^,G_"1:X?$_\ PE/A/P=X/_Y 'B4X_P"*LY\
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M^3,_VK_^S</C'_ZA&OU_F0?#S_DGWA;_ + ^E_\ ID-?Z;_[=/\ R9G^U?\
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M3%_[H];7U[_.WF?28;%1Q6BLT]K-;)75K/RZ)A1115F@4444 %%%% !1110
M4444 %%%% !7+^,/^1<U#_KQ'\JZBN7\8?\ (N:A_P!>(_E7E9G_ +CFWI/\
MF;83_?5ZK_TI']D?_!J?_P HV_%__9V/QX_]/.@U\.?\%N_^4FNC?]FX^&?_
M $]:]7W'_P &I_\ RC;\7_\ 9V/QX_\ 3SH-?#G_  6[_P"4FNC?]FX^&?\
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M^V/@S-\1O^$RN!\,M5N?#?BC_A&_%%[>7?VS^S?^)7H6B?V]KNBXS_U N/\
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M_8&O?VSTS_R,?]A_T-'@GQ5/IO\ P39^+&E?V5]IT_\ X7!IFBWEW]L&;_\
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M_P"(O%29VLP\L^$2L;'<=M?M7J/[-_[/>L:!_P (WJOP7^%NI: ;/[$=*N_
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MDV^5RBE>[=FTDMW>UG9,_=?]@K7Y]&^,GB""WGTVWM[KX<>)_MEU=WG]F_\
M$ST/1O[=T+1OH/$1)^G'>K/[$/B2^@^/OC"^QIMM_;W@_P >7MY=W=Y_9O\
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M_P +2\#_ /0TZ'_X&'_&C_A:7@?_ *&G0_\ P,/^-=/^N'#=O^1O#_P*G_\
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M'L=;YZ\_7 ZU[#J7[5%CXW\4?\)QXXGUNY\475[I=[>7EWH_]I:9J&IZ%_R
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MS_T-.A_^!HKT?]<.&4O^1Q3LO[\.G_;WD?2KAG.-/^$AVTTY7M]Q[117B_\
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M%%;4,?BGI[:IHGM.HMKVVJ(X_8T_Y5]T?_D1_P#PR!^RM_T;=\!__#7>"_\
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M ,&5/_E@?4<-_P ^H_='S_NA_P ,N?LT?]$"^#/_ (;3P;_\H*/^&7/V:/\
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M )]1^Z/G_=$_X9<_9I_Z('\&?_#:>#/?_J7OI^OIR?\ #+G[-/\ T0/X,_\
MAM/!GO\ ]2]]/U].2BMUC<7I_M%;I_R]J>7]\/J.&_Y]1_\  8^?]T0?LM_L
MU=_@/\'/_#;>#?\ YGAT_'H?;/HNA> O ?@V#=X:\%>&/!R'&3H?AW1])S]5
MT14."" 1SWZ]RBL<1C,3HG7J37:4YR6J71SMU["^I89-6I16[T45MZ11W]'_
9 "R_S_=HHKG>N^OKJ="26RMZ%BBBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 EH# 2(  A$! Q$!_\0
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M7SM11_8^4?\ 0L7_ ($O_D@_UIXE_P"AE+_P&7^1]$_\-=?M7?\ 1Q?QC_\
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MIXOW_M.5O\$[??RV_$^B?^&NOVKO^CB_C'_X7>L?X4?\-=?M7?\ 1Q?QC_\
M"[UC_"OG:BC^QLH>BRQ-]E)-_=</]:N);7>9R];2M]^Q]$_\-=?M7?\ 1Q?Q
MC_\ "[UC_"C_ (:Z_:N_Z.+^,?\ X7>L?X5\[44_[&RG_H5_C_P1?ZU\1_\
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MV@/VW?$EUJ%CHGQM^.5S<:9H_BGQ->?\5UK&F_8?"^B:/_PD&NZR?^$@&/\
MBE/#QW$8)+$$@FOLCPK_ ,%0M)LO%%_XP\>_"OQKXLU_7?A9X$^'_B2[M/'>
MC:;IFO:KX'T?Q\QUK6]#'AP>&,>+/[<;Q.00?^$+R#TR&X^3_@H-X5L?#?@G
MPWI7@#XLZD/!WPY\>_#.S'BOXCZ-XC&NZIX\T;^PAXSUS_BG#XG'B+PIG+'/
M_"%^#?!I;P3X# +8KYC_ &FROE%.]M;*FTG;I>S:OILGY;H_4W'A_%-_4N/J
MCL[I.,[M7>C23L_E;T/DC_AK+]K3SK9O^%^_'/-SS96I\1^,3]NZ=#V[<_\
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MF&^BOXARO9QE9M-IQE9ZZ>ZY:].Y_.C17]%'_#@ZR_Z.G\2?^&KT3_YIJ/\
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M?VI_$@/H?A=H(S]#_P )/4'_  X0L>W[4_B,^G_%K-#Y_P#+GKYS_6/(&O\
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MK>*OA[\7_!_C3PQ\-?"GQO\ C'_PJ7P-J^@:VGAY!\7/^*E(;QLOAC_A%?\
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M%>,]<\=:!XE/AKQ_XB^*_B1CXH7PKXL.WP3XS/\ P@J_\(7T'[X_\*,\*_\
M/]K?_@<?_B:/^%)^%?\ G]UO_P #3_A1?"=W^/\ F!^)_P +/B]_P5/^*D?P
M.\(3ZY=?#;_A._B/X^L?'GQ8\6?LRZW_ &CX#\+Z'\%_#^OG1M=T'Q!X<\(^
M%CXC'Q&76_"_@;Q7X5'_  AOC(:^P4^,1X3;_A,_LK]C;XF_M2>+_B[^U#X3
M_:+TSQ(/"/@OQCI4GP>\6WOPN?X4>"-;\-/KOB(IH^A#Q __  E/B'Q#X5\/
MZ)HL?C7Q(#XO\$NG_",^,_ 'C?R_%P2ON;_A2?A7_G]UO_P-/^%'_"C/"O\
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MWM&;T@8R.O)S^1P.#FMJN/\ ^$<L/36O_"CUK_YHZ/\ A'+#TUK_ ,*/6O\
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M ,(Y8>FM?^%'K7_S1T?\(Y8>FM?^%'K7_P T= '845Q__".6'IK7_A1ZU_\
M-'1_PCEAZ:U_X4>M?_-'0!V%?C)\?O#'[66F?'O]OKQ-\"-,\:'4]=_8H^&6
MC_ '5+B\'_",W?QCT?6OB"VMZ3X,77V/AI?B#)H.KZ0%8YW2#PT.<.1^M?\
MPCEAZ:U_X4>M?_-'4<NA:7#&;B6;5+8?\?=U<MXCUI5R.2<_\)!E1Q@$%D..
M.N* /Q'_ &4H?CSIO[*6K_LW?'7]G#]HWQ[X2U/2OC#?>!/'&L7C>"_B[XM\
M*^!=(\/>.]*T7XX)X=^):>)O /Q#^*_Q"UO7?"O@9_"WC!AXN\(Z&CLGA#&U
MOMS_ ()V? OQG\ _V6/ GAOXCRZY-\3_ !3>:K\3/B':ZKXDUSQ(="\3>.3_
M &T/!?\ ;GB3Q!XK\0+H7A301HGA9%,DFX:"CD[6VGV+X5^,=+^)-S<-<>%_
M&_@\W?ASPQX]\.?VOXDUA5USP-XY?78]$UE3H>OJVA>(@VAM_P )CX8*[?"(
M?PPP^5D*^_?\(Y8>FM?^%'K7_P T= '845Q__".6'IK7_A1ZU_\ -'1_PCEA
MZ:U_X4>M?_-'0!/KW_( \0_]@;4__3-57PS_ ,BYX?\ ^P)I7_I!;UC^(_#F
ME_V#X@YU/']D:IU\1:U_T"&'.?$(_AQU'W<'./G;I/"4(_X17PST_P"1?T;N
M?^@=;4 ?(?B32O _Q(\,:1X7^(OP>M_BAH'ACQ\/&NDVGB+2#J>E6/B?P-XS
MUW7-#\9Z&A\.@#Q%X3\1*N-NW# MSN=7]J_X6_K?_1-_$OY:S_\ ,W7F?CW4
M_COH'PW\,3_L^^"/!7C[Q==_$;2[35]+^(7B;6?#&E:;\+=8\:ZX?'6L:+K>
M@>'R6\2>%O#SNW@KPRB!2@$<N,1E_L6@#XC\5IXHUGQ=IWCCP[#XV\%>(;3P
M]_PC.KB[\.#Q)X9U[PR=7_MS0AKNA @/XA\)^(2Q\$>)_"WC!@#X@\3,!XQV
MKM\BU'X2_P!L77_$]_X3;7-'_P"$E_X33[)_PA_@S3=3O_'FN_V!_;NM:YKG
M_"-_\B[XL_L,9\+>NO\ 0?\ "(^"Z[WXRZOI<7Q>M])\;_$WQK\./!MI\%=4
MUFRN_"WB/7/!)OO$Z>,\!M$_L'+>)/$?]@KD>&,^+@RD,O@EB S\=H/QS_:*
MT'P-X=\4>./AMINNOI=WX'\ :OHUXVK^"/B;X@\=>.?!WA[_ (0C7/[! _X1
MG01XF\2>.M \*>-O"^ ?!);Q+XW9@?"A\&'=?5;?#=_/?YK\OU EF^&/_%1^
M(-5TN#Q_HIU3^U-:O+6U\-Z+J7V_5-=^)W_">:%K6N]!X@_X1/Q'_P B1_S.
MF=?\3_\ %<8KE3\)?$FIZ]XP^VGQ9HF@77B72O&G@^\\/Z-HY\2_\)-_PAFO
M:%KVL_VW_P (Z/\ A'V\)^(=;UP#PODX/S?\)L>5/T%\1/B1\7_#NNZ/IGA3
MPUX'N+<:9\-%\8W6IWOC'5(_[5^*GCB3P'NT3^P40?V!X5?_ (JF4^*!D>$M
MR,_A (7/ED_[5?Q,LV$=]X \-_VG9V6KV%WX)M?^$S/CC7=2T7P9KGB!_B9H
M2CPX ?AV?$?A_6O"XSDJ<;?''_"=9\$EZ]G;IO\ Y 8]I\%X;/1O[%O3X_U#
M0KJRU>QU:TM?#FD:??WV?&OCSQYH)T76 WBOQ+H)\)^(_&VM^%^3XP;QEGPV
M$<!F+6K/X26 U34-<UNQ\6>(M?U3P)JOP_O;O_A#M&\-#_A!-?T;0="_XD>A
M^'O#8\,#Q'X4\/:)DGG/]OGC_A!/"7@OP8*WQ"^/'Q,\4>)S9?#/7?#=UX0U
M/6/#&C>!"='UC4AXL\3Z%\:/A'H6O:S_ &[X?VKX@\.+X;UW7!XW\+^%,9\%
M#Q,6.037VU\/_$/B37_#,-WXGBM-/\16M_XFT76K72 ?[*NM2T#6]7T)]4T=
MM=?<-#D32&EA!QNW@D% "Z>G3^ON YW_ (6UKO\ T('B3]?_ )FZF_X6SKO_
M $(/B3_Q_P#^9VO>MB_Y/^?\GZ8-B^_Y_P"?\D^V)>(H?\^E_P"!/_Y #P;_
M (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)?S?_ .9RO>/E_NG\C_GL/S]S1\O]
MT_D?\]A^?N:Q^LX?^5??+_Y$#P?_ (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)
M?S?_ .9RO>/E_NG\C_GL/S]S1\O]T_D?\]A^?N:/K.'_ )5]\O\ Y$#P?_A;
M.N?]"!XE_-__ )G*/^%LZY_T('B7\W_^9RO>/E_NG\C_ )[#\_<T?+_=/Y'_
M #V'Y^YH^LX?^5??+_Y$#P?_ (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)?S?_
M .9RO>/E_NG\C_GL/S]S1\O]T_D?\]A^?N:/K.'_ )5]\O\ Y$#P?_A;.N?]
M"!XE_-__ )G*/^%LZY_T('B7\W_^9RO>/E_NG\C_ )[#\_<T?+_=/Y'_ #V'
MY^YH^LX?^5??+_Y$#P?_ (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)?S?_ .9R
MO>/E_NG\C_GL/S]S1\O]T_D?\]A^?N:/K.'_ )5]\O\ Y$#P?_A;.N?]"!XE
M_-__ )G*/^%LZY_T('B7\W_^9RO>/E_NG\C_ )[#\_<T?+_=/Y'_ #V'Y^YH
M^LX?^5??+_Y$#P?_ (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)?S?_ .9RO>/E
M_NG\C_GL/S]S1\O]T_D?\]A^?N:/K.'_ )5]\O\ Y$#P?_A;.N?]"!XE_-__
M )G*/^%LZY_T('B7\W_^9RO>/E_NG\C_ )[#\_<T?+_=/Y'_ #V'Y^YH^LX?
M^5??+_Y$#P?_ (6SKG_0@>)?S?\ ^9RC_A;.N?\ 0@>)?S?_ .9RO>/E_NG\
MC_GL/S]S1\O]T_D?\]A^?N:/K.'_ )5]\O\ Y$#P?_A;.N?]"!XE_-__ )G*
M/^%LZY_T('B7\W_^9RO>/E_NG\C_ )[#\_<T?*.BGCIP>W_ZA^?UI_6</_*O
MOE_\B#O8\'/Q8U<_\R3XD_)_Z>'1_GTJM-\4M8E/D?\ "O/$>3_LN>QYP?#^
M.OISWSGFO?*IW?\ J)_7:,>O0UT4&E..CUDNK6G-'_,Y,7I@9O?W*C];*>A^
M 7[.'[)?AS0?V]-8^.%C\?O!/B/6-4\>?&3Q/=_"?2?['_X2:P/CHZ__ &[H
MNNX\2YQX3.N\G_A#QGG\/W<O+]89]O\ 96M7! .3:6A*XZ Y)   Y/Y9[U_+
M)^Q%Y'_#X;XH^3]F^T?\)[^T_P!/3^V]?Q[=?QQ[9K^KS#>86S\NW&.>W7ZG
M/;VZ5[?%3?UO+5S6_=QZZN\-5OUT^X_*_"EX7$97G7_"9R-<3U6V[JZ4I6?1
MVNKM[>9D?VY=?]"KXE_[ZT3_ .:&C^W+K_H5?$O_ 'UHG_S15U0Z#MP*6OG#
M]?.._P"$DOO^A5\2_P#?.B__ #25Y'#X3U'_ (6#_P )]?7/C76]8_L?4=&T
M>TO+3P;IVGZ!X8UQM UW7]&T0Z OA/Q(!+K^A:'E?%7BSQ=M;?M8EP\?T;7Y
M6WOBOXCFQ^%UOJFN?%"V\;W/A#P'>_"W2;;^V]-TSQ;X[/Q,/_"<Z-XWXQXB
M_P"+=_V",^+#CP7X*_X2CQUG(_X3*@#])_[<NO\ H5?$O_?6B?\ S14?VY=?
M]"KXE_[ZT3_YHJZNB@#E/[<NO^A5\2_]]:)_\T5']N77_0J^)?\ OK1/_FBK
MJZ* .4_MRZ_Z%7Q+_P!]:)_\T5']N77_ $*OB7_OK1/_ )HJZNB@#E/[<NO^
MA5\2_P#?6B?_ #14?VY=?]"KXE_[ZT3_ .:*NKJK/_JF_?\ D<#_ $@;?ZG'
MTR<<#&>E '@E[X8L;SQ5JWC.PL_%VG>(M2\-Z;X*%U:VNC;=!TK1=<US7V.B
M+KZXSXH\0:V%\9G&?&8T+PV&/_%*LQY;P+\.[/X>ZG?:C9OX]UFS&C:=X7T<
M>(;W1!_PB'@G1O[9UKP]X-T+^PHO";'0?"?]N2HC>*I/%GC(B8JWC&9O"@>/
MXTU_XDPZO\'/C!?_  X^(OC^[N/^%DBQ^"FD:KXP^,?_  G.=#T?P_H(;0R6
M7Q-X@\0>*?$6B:[XH\%^%?%>?!A&O>&?^$Z'_""^+MK?1'BGQ/=:C^T!\$+?
MPMKVO,-4O_%+^.M)L]<\9C/A?0])\=Z-H9;P3@?#,>'D\2Z(\?C+Q("?%I\7
M#PQ'X()5E5 #[&_MRZ_Z%7Q+_P!]:)_\T5']N77_ $*OB7_OK1/_ )HJZNB@
M#E/[<NO^A5\2_P#?6B?_ #14?VY=?]"KXE_[ZT3_ .:*NKHH ^7?!^L7/_"Y
M/C?_ ,4YK?-I\,.?LNC<#_A#M>Q@_P#"1'.5SQQSA,G.\>[_ -N77_0J^)?^
M^M$_^:*O.O!'_):OCA_UY_"[_P!,FOU[A0!RG]N77_0J^)?^^M$_^:*C^W+K
M_H5?$O\ WUHG_P T5=710!RG]N77_0J^)?\ OK1/_FBKROQSX>C\:V^@"9O'
MOAK5M U<^)O!_B#PY9Z)_:6AZP^C:]HCR.FO1^*_#*/_ ,(]KFM>&B/%7A0A
MO-<N/N,/?Z^3_P!H[7?"_A#X7^(?$GBR7QM:VT-SIUAI*>%=9\:^']1U#Q-K
M,C:#H&D'6_A^?^$@\-[M??)\3;#X1\);U\;-A;8T >F>#]+LO!?A?P_X0T/P
M[XE.D>&-&T[1;*ZO+S1]0U%M,T7&-^M?\)(-Q&W!Y&"3@#@#N?[<NO\ H5?$
MO_?6B?\ S15S?@"2>^\"^!;BY\16OB^:Z\'^&!>^*;5$?3]>==+C;5]>#$G
M\2$,X+ D$AQM9<5Z?0!RG]N77_0J^)?^^M$_^:*C^W+K_H5?$O\ WUHG_P T
M5=710!RG]N77_0J^)?\ OK1/_FBH_MRZ_P"A5\2_]]:)_P#-%75T4 <I_;EU
M_P!"KXE_[ZT3_P":*C^W+K_H5?$O_?6B?_-%75T4 <=_PDE]_P!"KXE_[YT7
M_P":2D.OW4L?[[PGXB(QWM=&&?H!XA/ZGTXKLJ^4?VCW^)]O\)];M_@]]C'B
M"YM=8^TZO:ZRNE^)M$\.G1?$!DUGP0$\.^*]_B0XTCP[X+3RRI?7/-.UHU)
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M[QP3@;JUO#'_ "+7A[_L!Z3_ .D%O6GKW_( \0_]@;4__3-57PS_ ,BYX?\
M^P)I7_I!;T >$:!\/[B\T@ZG_P )OJ.FVUSK'BG%I:;AIMB-<\9ZX<X/B(#
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M<_+1?_FDH_X7GX6_Y\=<_+1?_FDHMBNR_P# 5_D!G?\ "H=1_P"A^\0_F_\
M\T5'_"H=1_Z'[Q#^;_\ S15H_P#"\_"W_/CKGY:+_P#-)1_PO/PM_P ^.N?E
MHO\ \TE%L5V7_@*_R SO^%0ZC_T/WB'\W_\ FBH_X5#J/_0_>(?S?_YHJT?^
M%Y^%O^?'7/RT7_YI*/\ A>?A;_GQUS\M%_\ FDHMBNR_\!7^0&=_PJ'4?^A^
M\0_F_P#\T5'_  J'4?\ H?O$/YO_ /-%6C_PO/PM_P ^.N?EHO\ \TE'_"\_
M"W_/CKGY:+_\TE%L5V7_ ("O\@,[_A4.H_\ 0_>(?S?_ .:*C_A4.H_]#]XA
M_-__ )HJT?\ A>?A;_GQUS\M%_\ FDH_X7GX6_Y\=<_+1?\ YI*+8KLO_ 5_
MD!G?\*AU'_H?O$/YO_\ -%1_PJ'4?^A^\0_F_P#\T5:/_"\_"W_/CKGY:+_\
MTE'_  O/PM_SXZY^6B__ #246Q79?^ K_(#._P"%0ZC_ -#]XA_-_P#YHJ/^
M%0ZC_P!#]XA_-_\ YHJT?^%Y^%O^?'7/RT7_ .:2C_A>?A;_ )\=<_+1?_FD
MHMBNR_\  5_D!G?\*AU'_H?O$/YO_P#-%1_PJ'4?^A^\0_F__P T5:/_  O/
MPM_SXZY^6B__ #24G_"\O#I_Y<=;_P# 71?_ )I*+8KLO_ 5_D!FGX0ZN/\
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MXE_[YT3_ .9VO+O"GBNR\9:AXGT32+WQ6I\':L-&U;5KR[T4A-5(&-%(1_\
MA)2%W<CQ3X3((W!7.03Z1_PE%A_SRUS_ ,)O7/\ YG:\'TGPO<V/Q:U;XC:K
M,+B?4]'&C:5I.D?"O5_#FI?V3_;)UUCXVUTOXJ/C_P 0QG0U;P4Q3P?_ ,(8
MA\3!5W^+_E /H'^P[K_H:O$O_?.B?_,[1_8=U_T-7B7_ +YT3_YG:K?\)18?
M\\M<_P#";US_ .9VC_A*+#_GEKG_ (3>N?\ S.T 6?[#NO\ H:O$O_?.B?\
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M.@%F ;;[$-1Y(SG!(XYQ@9...<5[7%?^]Y9I_P NX]OY?ZVU/RGPJTPF=?\
M"J\Y_P",HJ)ZVY%>>CN]H[6M;W=CLAT'T%+7+C3O$.!_Q4=UT_Z!.C?XU5_L
MSQ#_ -#E<?\ @FT;_"OG3]A.RK\*OV.?V\_BQ\:?VY?C]\$/B'9?8_"VEWGQ
M0LOAKX(T>TT?^T/@OIGP0\;^'O ^O-\<E_X1S_A)-"\2?%M]<'BCP2[>+SX/
M/@S0VV>"E,C%OVK_ +-\0_\ 0T7'_@HT:O+?#.JV6OZQKT&B:GK@UC2[I](\
M1:N?"/\ 9GVW4@?W>BOKDGAI/#FO/X61LM_PB?BQO+(D1F)"EP#WRBN-_LSQ
M#_T.5Q_X)M&_PH_LSQ#_ -#E<?\ @FT;_"@#LJ*XW^S/$/\ T.5Q_P"";1O\
M*/[,\0_]#E<?^";1O\* .RHKC?[,\0_]#E<?^";1O\*/[,\0_P#0Y7'_ ()M
M&_PH [*O._&U[+IO@GQ?K-E.#J&E>&O$]W8^^IZ-HVM\GT!8#KTV@XYK2_LS
MQ#_T.5Q_X)M&_P *G.D:Y)_S-+'G_H#:2V?R4_Y_0 _G(^(/_!0S]KSPU^P9
M^Q7\3_#ECXLN?''Q:\._!WQG\;/CQ9_" ^)/#2:9KWQ.T#P(WPQT,^'_  Z?
M"P^(?BX:WK)P%7_BC= 9_ F?'GB_P=7<?M]_\%'OB)X0^)'@^W_9@^)FBV_A
M?0]&\4V5MI-]X#'B74OCQ^T7X&^/W@'P%KO[,97Q!X:_X27P_P"(O"OAS6]<
M\3X\)@>,B?X>3G]K_P"T_#O]@8_X2^Q_L?\ X2W_ (5_]C_X1S1?[._X2G^V
MO[!_L/\ L7_A'OO_ /"1\;MVWOO[U9F_LJR\4:/X/G\5:;_PE.J#5/$^CZ3_
M ,(YH_\ :6%)&NZUSG!_XGG)QG/&3R  >P0DF)9YH/(N#:'=; @XZD@8Z<_+
MCDC/-:5<;_9GB'_H<KC_ ,$VC?X4?V9XA_Z'*X_\$VC?X4 =E17&_P!F>(?^
MARN/_!-HW^%']F>(?^ARN/\ P3:-_A0!P/@C_DM7QP_Z\_A=_P"F37Z]PKYC
M\'Z;KG_"X_C>?^$C/-K\+_\ F$:3P?\ A#]>Z^V>0#A0N5!\O)KVK^S/$/\
MT.5Q_P"";1O\* .RHKC?[,\0_P#0Y7'_ ()M&_PH_LSQ#_T.5Q_X)M&_PH [
M*OSC_P""B7Q:\1_ []FCQ]\3="_:#'[/5[X74WMGXDM? O@SXD>)_%7B?^QM
M<.@_##P_H/C\?\(PWB#Q;XB&B,[%N/!W_"1 #PB/^*TA^ZO[,\0_]#E<?^";
M1O\ "N8\7BPLM U#6_&&N:;_ ,(_I5G]MN[O5_#FCZGIE@.#_;.3G@#Z_2@#
MSO\ 9E\=WGQ0_9Q^"'C_ %[Q3X0\6^(/%'PN\+:WXP\6?#Z[W^!M>\5?V0/^
M$U?1-9 (.@+XF76"IZH0"&&*^G:\]L]"U6TMA!8ZXMM;VXQ9VMII&C#3K$ 9
MP,>@)[C;GZUH?V9XA_Z'*X_\$VC?X4 =E17&_P!F>(?^ARN/_!-HW^%']F>(
M?^ARN/\ P3:-_A0!V5%<;_9GB'_H<KC_ ,$VC?X4?V9XA_Z'*X_\$VC?X4 =
ME17&_P!F>(?^ARN/_!-HW^%']F>(?^ARN/\ P3:-_A0!V5?C5_P5;_:R^.O[
M+_PFT:\^"'AWQ9_:&J>(["_\2?%^V\'-XU\.^!?#6@^-O#^A'P@#_P (YXK\
M,CX@>*O[=<>#%\61E9!HOB0;E\;CP<K_ *Q_V9XA_P"ARN/_  3:-_A7FGCK
M7[+PMH5MJOC/6=:NM" U5KP6/@;6/$VWKK:_VUHF@>&_%;9\,+HK;2$4$!U9
MA@!@#\3_ /@H?_P4C\8>!M1\$0_LM_&&PT2Z\,Z5\=[WXIV=[X2T;^T['QW\
M*M9^$97X:;?'OAS9KOB+_BM-9;QC\+_"8_X3;QDN#X$Q)X4D%?OMH]Y_;.C:
M7? 70_M71]-O#]JM-7TR_+.FXEDR&T+)R0!SEBQ^7#'S+7=9\.VE_P" H-=\
M7^'+:?XA^)5L/ 1N])T?4CX@\3G1-=UX-HF<;2?#^B-XE&2>026!)"^I?V9X
MA_Z'*X_\$VC?X4 =E17&_P!F>(?^ARN/_!-HW^%']F>(?^ARN/\ P3:-_A0!
M9U[_ ) 'B'_L#:G_ .F:JOAG_D7/#_\ V!-*_P#2"WK'\1Z9XB_X1SQ%CQ3<
M?\@?5/\ F#Z/_P! =CW Q@Y/&>I[8)O^&/\ D6O#W_8#TG_T@MZ /DGXA^&_
MAS\8/!/A_P $>(OB/\4? !\+_%/_ (6 -6^%'B36/!.IZAJG@7QIK^O_ -BZ
M[KGA\9\0>'?%?_,[>%AD>,P3D9(Q]/\ _"V? W_05N?_  !U;_XBOBC]JCXS
M7_[-_P "/"'C[PKX6\%>(_$&O?M"?"_X?WFD^++(?V9_97Q7_:!T#P%KNLD>
M'^OB+PIX<UPD$<#&">Q^3OB1_P %0O"WA;PO\7[[P3^RU\0+G6/ 7A#]I[6_
MAOJWBFS^&B^!O'NJ?LG^--!\!_%<?\4_XE;Q3X>\->%&US0?%)7_ (1#/C7P
M6"O@1F\<DH0#[P\;+I6O?$R?XCZ'XK&G7.E_"W5/!OART;5_&?AS3+[Q1_:W
M]N:$/&G_  CY_P")[X=XR>N07& 7W#YQT+PIXD\.%?&5[?D>+[32/%&BG5O#
MOCOQCXD\3:'X6T+XFZ#X[T+1-#T,^&O^$8U_Q%XL\.G7/#/_  BPP25\, GQ
ME_PEY%>6>!/^"H/PS.I'P5\8O@_XNMO'/@+P:;OX[>*O _PYTE? G@/QWH7P
M8'QZU[1'T'_A)O%_B/0?#Y\/*/"_@;Q9XL\6?\(=XQ\9%U4X9B>NT+]NZX\3
M^)OV3]$T?]C[Q=H4/[4%OXY\3^'+SQAXO^!&FBP\ ^'O"6@>/M&\9:"OA_Q1
MXJ;]YX;\;Z-XF3PSXL/@_P 88T'Q(Q\"3^-5$3NS[/[G_D!=^"FL?$>;01/I
M.NZUX:U#7CI=EX]N_%OB/QF=-T'Q.1X"U[7?&GPIT/Q ?%OB?Q^2=#UOPQXW
M\+^+1X/'_"9CQ0N/^$$.X?2W[/<MS\.-!UZQ\<^,=9UK6-3O-,-Y>W7B_6/&
MNG:YJFA:.NA:YXRT-?$/AKPHN@?\);X@SXFD\,*_B\Y&5 ##9\3>"/\ @JI\
M)YO#OPPU7QC\']<UO^T_ ?P>\:?%[Q7X)\.>#-/\,?";2_CO\3M>^$_PF+:%
MX@\1)XIU_P#X2GQ)H;+XU7PB_C$>"X_O,6(*=79_\%0_@]./&'_&+/QMSI?@
M/X[^-/ ?V+P=X,\2:G\6M,_9M^)_A_X3?%C_ (0?0M \1MQX5\1ZYH:M_P )
M8?!YP<@J?F!9]G]S_P @/U0_X6IX!_Z#A_\  /6:/^%J> ?^@X?_  #UFOBG
MQ%^V/\*]#_9=\!_M2V/PXM_$OA[XB-IG_"/>%-*\2_"&-[[5M=&M-'HD6MMX
MC_X1;Q'KQ31=<#^&?!TGC#Q?YJO&$+F58_GB+_@JE\!)[GP?>V_P&^*5Q\/=
M?T?]E_6O&7Q+_L;X;GPU\-O^&L=(\0'X6Z+K>C?\)2/%FO>(CXAT0^%?& \'
M^$O%WD,<XD14C77_ &7L[V[K?[OZ]0/UC_X6SX&_Z"MS_P" .K?_ !%0_P#"
MU/ /_0</_@'K-?F;^RS^W'9?M8?':W\#:)\%CX'^#&O_ +,>E?'3X<^(?&G_
M  A^I^.O%NE-\3M?\ Z'K(T7P[XD\6>&_#OAT>'-$)'AKQ5L\:H0'. "#X[:
M?\%6?AGH_A.WU;QA\ _&_B/^R]&\4>,_'GC?X?>'?".G>&? ?@+1/VG]>_9K
MT;6O["U_Q0OB;Q"3XAT+0UB\,>$_^$Q/BTY*@H3&<0/V4_X6IX!_Z#A_\ ]9
MH_X6IX!_Z#A_\ ]9K\5;;_@J2_A;7/BU;_%C]F_6IKL_M!?&;X2?!#X?_#_P
MSH^J^-M=\,_LWZ'H.N_%76]?UK7_ !-'X:\1:^K:YH3>"?"GA#PG&[8P)/&
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M?]!6Y_\  '5O_B*ZG_A%?#G_ $+FA_\ @FTG_"C_ (17PY_T+FA_^";2?\*
M.6_X6SX&_P"@K<_^ .K?_$4?\+9\#?\ 05N?_ '5O_B*ZG_A%?#G_0N:'_X)
MM)_PH_X17PY_T+FA_P#@FTG_  H Y;_A;/@;_H*W/_@#JW_Q%'_"V? W_05N
M?_ '5O\ XBNI_P"$5\.?]"YH?_@FTG_"C_A%?#G_ $+FA_\ @FTG_"@#EO\
MA;/@;_H*W/\ X ZM_P#$4?\ "V? W_05N?\ P!U;_P"(KJ?^$5\.?]"YH?\
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M\?'Q2-=UY?')\5^#_!D?@WQ?H3IX)_X3*+YE /V-_P"$Q\*_]![3O_ PT?\
M"8^%?^@]IW_@8:ZFB@#EO^$Q\*_]![3O_ PT?\)CX5_Z#VG?^!AKJ:* .6_X
M3'PK_P!![3O_  ,-'_"8^%?^@]IW_@8:ZFB@#EO^$Q\*_P#0>T[_ ,##1_PF
M/A7_ *#VG?\ @8:ZFN$\7ZC-X?\ "_BC6[#[,;_2_#NJZY9B[W'3LZ-I!;DC
M&%R?I@G=@ Y /$8O#6EG2O[(_P"$W\-$'X[GXM8)R/[+_P"$S_X3O^Q#P?\
MBH"."1VXQ@5Y6WPX\9?\+S@^*=K\4/#NF0:HWAP:K:Z3XG\5KJ=]X4\&R^.-
M%T3P@VAC6'\+Z]HOB%->TN/Q9XD\5>#I?%WA/QDOB4^#Y7EE\&R^"?RI^(/_
M  59_:8\-_L]?L=?%7PYH?PPN_%'Q0_9S\4_M&?&NTO='UO4M+T_2M"\8^ /
M#_RY\2>$AX ^'7_%;:X?^$J'_"8^,PVA>' / ^6;/TO^V+_P4\TOX$?%;X0>
M%? 7_"(_$'X97?\ :GQ _:0^(FDZMHWB(^$OA?H/C;0O NL^#/!&A#Q-X2_X
M2#XC+XBUS0CXV\+JWB[QIX-\'Y9? WBTD*H!^R?_  F/A7_H/:=_X&&C_A,?
M"O\ T'M._P# PUO0SK/%!/"!MN &S[8)S^&#5N@#EO\ A,?"O_0>T[_P,-'_
M  F/A7_H/:=_X&&NIHH ^9?!/BKPY_PN7X[S?VYIN!9?# 9%Y@<:+KN,]...
MP^F*]Q_X3'PK_P!![3O_  ,-><>"/^2U?'#_ *\_A=_Z9-?KW"@#EO\ A,?"
MO_0>T[_P,-'_  F/A7_H/:=_X&&NIHH Y;_A,?"O_0>T[_P,->>_$RWTKQI\
M/O%'@ZQ\4:)IUUXHT?4K"UOKNZ74=.LR,#<<$9 !SM., $*.F?:Z^ /V\?B[
M\1_@'^S;XX^,_P //&'@GPAK_@$?VS8V_C;P1KOCG3?'FI:U(WA_0?AEHFD:
M#XE\'2CQ+XNU_6/#OAKP=XF*>,%5V93X,N,,Y /M8>,/"H ']O:=P,?\?AH_
MX3'PK_T'M._\##7E'P1G^*,WPG\ 7'QE_P"$9MOBO/X=TZ\^):^$;,Z9X8TW
MQ6^CI+X@T718AXE\6_\ $C\+^()#X=5CXL+,-#W[@K_O/H"@#EO^$Q\*_P#0
M>T[_ ,##1_PF/A7_ *#VG?\ @8:ZFB@#EO\ A,?"O_0>T[_P,-'_  F/A7_H
M/:=_X&&NIHH Y;_A,?"O_0>T[_P,-'_"8^%?^@]IW_@8:ZFB@#EO^$Q\*_\
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M_H/:=_X&&OR9_9K_ &W?$'Q^_9W\83^+?B+\'/@W^U=X'NO'.B>.[7Q;H_\
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MI]MHWCWPS9VA\&:0!8:7\5=<_P"$X^*VC$E<8\7^)=#T/Q1XR)P)?&(,D6]
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M^(]T/ NCK_PGOA?0UT-?[$UU1X<&[PYC0]&(5@5W>'O##8W1@BE)K'CWQ?\
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M5L7_ "K_ ,!3_P#;0//?L/QO_P"@]HW_ 'UI'_S.4?8?C?\ ]![1O^^M(_\
MF<KT+_A8_@;_ *&C3/\ P*'_ ,3]?\G@_P"%C^!O^AHTO_P*'_Q/U_R>-N7$
M_P#/O_RF_P#(#S[[%\;_ /H.Z+^>C_\ S-T?8OC?_P!!W1?ST?\ ^9NO0?\
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MGH__ ,S=>@_\+&\"_P#0TZ9_X$C_  H_X6-X%_Z&G3/_  )'^% /9^C_ ".
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M=;O]HV'_ #^VO_@9_P#7H_M&P_Y_;7_P,_\ KT 87V/QA_T%?#7_ (*-9_\
MFCH^Q^,/^@KX:_\ !1K/_P T=;O]HV'_ #^VO_@9_P#7H_M&P_Y_;7_P,_\
MKT 87V/QA_T%?#7_ (*-9_\ FCH^Q^,/^@KX:_\ !1K/_P T=;O]HV'_ #^V
MO_@9_P#7H_M&P_Y_;7_P,_\ KT 87V/QA_T%?#7_ (*-9_\ FCJE<:9KFIVE
MS97USX=N(;D&SN[6YT75FT^]!/(4'Q"PP2N,%6)/&<@$=5_:-A_S^VO_ (&?
M_7H_M&P_Y_;7_P #/_KT ?'UW\*/V;/$&L^#_A5JOP^_9HUK4/A-I/VSP%\/
MKSX:^#=2U/X;:64\S/@C0AD^'0/^)(I_X1<(=ZE<<H6@T;X2_LV?$B_9=+\
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M )HZW?[1L/\ G]M?_ S_ .O1_:-A_P _MK_X&?\ UZ /G;P5#XH_X7+\;_\
M3]$\\'X7X_XDVK;2?^$-UPCKXC)SD  @]^?FV$>V?8_&'_05\-?^"C6?_FCK
MS3P3>6/_  NGXW_Z;;'_ $+X7<?; ,?\277^V0/UXZ= ,^T?VC8?\_MK_P"!
MG_UZ ,+['XP_Z"OAK_P4:S_\T='V/QA_T%?#7_@HUG_YHZW?[1L/^?VU_P#
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M_@HUG_YHZ/L?C#_H*^&O_!1K/_S1UN_VC8?\_MK_ .!G_P!>C^T;#_G]M?\
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M\8?]!7PU_P""C6?_ )HZ/L?C#_H*^&O_  4:S_\ -'6[_:-A_P _MK_X&?\
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M1Z4OPJ\8_P#"37NJ?%C^W]!\"/H>AZ$K^)_$#>*1H>N8R#XQ))+(> (?!_\
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MH\%?\*F\"ZWH>B:!XD'_  CX\)_#G/A?_A%P2!R"<C@^?X@>O_LO?%7]GO\
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MZ%H/ASQ#KA\.Z=<_V'I&IZW]C^QZ2!??V&O]N *?]Y<GH03NX8KGH_.\5?\
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M$94J#GYB\!^*?VFO#?AW3]*UR;4[8:%X"\,>&+3PI9^$/[1U+/\ PA?@(_\
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MQ5M?BW!:Z3X\O?!_A3P1=:SJ7B3Q8O@71M!U_7=$T,'P]_PC/_"/;-<T)/\
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M+3O^%S^;#]DSP5XXLO\ @K'XA\27_@[Q=;>'[GXP?M07UGXANO#6M:=X:O\
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MX1+0O^@7_P"3FK_XT =E17&_\(EH7_0+_P#)S5_\:/\ A$M"_P"@7_Y.:O\
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M\8_C?_H)S]D^%X_X_=7XSX.UY0,Y''(]\=MQ /N'_"):%_T"_P#R<U?_ !H
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M'C1O T>D-K7FCPT0OB'$;^*%.[PAX..0L*'%>@?LB_M$> ?VM/A]XI\;Z3X
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MA?#_ ,./"/A@$^(M#T3Q0/\ A$_"/@_QH#H(SNQ@^7^&_P#@F-\,?"$.G_\
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MH<WPPUGP?:^/?#'@FR\;7GA#QCIWALZ5K?PRT'QV/BAKA'B9CH'AUO$.M_\
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M\/V^)&KZEX&T_P =^.OAH?@/KOQ,T/0]>\,KXE_X6'XH^')V#_A+?&!\&_\
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M_P#F;H_X65X^_P"B8ZE_Y6/_ )FZ]XHH \'_ .%E>/O^B8ZE_P"5C_YFZ/\
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M XW^V=7_ .A7U3_P<:%_\T-']LZO_P!"OJG_ (.-"_\ FAKLJ* .-_MG5_\
MH5]4_P#!QH7_ ,T-']LZO_T*^J?^#C0O_FAKLJ* /SC\5_L2?!SQA\0?C/\
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M"_\ FAKLJ* .-_MG5_\ H5]4_P#!QH7_ ,T-']LZO_T*^J?^#C0O_FAKLJ*
M.-_MG5_^A7U3_P '&A?_ #0UX+;?!_POIOQN\>?'^'P]XO'C?XF?#GPM\,?$
M?VGQ'HK>&G\,>"-9\0ZWH:Z/H0U]BNO@Z[K+EU*G*G<5C#!_JROG+X^Z#?\
MB+X<ZEIECH;:YKNI7FGZ+X:0+K/]FZ%XGUW6ET+0_&>N?V%E_P#A'_";ZV_B
M?QEL94*:'@!@$( /!_"'['_PS^'O@OX8^!_"S?&[3?"7P;^''Q/^&WA#2E^*
M+C2K_P -_%8 Z[_PFV@+XE_X1KQ#K_A5AGP3XD\5^$V/@W)4DY('I'[-_P $
MOA]^RG\)?#_P8^$W@#4O#W@C0VU.^_TS5M(U+4M<U76RSZSK>NZRWB5AK?B7
MQ5XA89<JK'"CC"*+7]G7V@^._@CH/A6'QM_PB/@.T\=>&_$MUJ_]L$WHT7P;
MH6@Z%K.N:WKV/^$@!(('BCDM@C<<<?6= '&_VSJ__0KZI_X.-"_^:&C^V=7_
M .A7U3_P<:%_\T-=E10!YIXCU+5?^$=\0_\ %+ZK_P @?5./[6T;_H#GJ?\
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MGTS5/["A^.OP_M=:^&'@8ZPND#XD^#SJ/@/X6_V/H)&NG1!XA_XI[P\?#/\
M89/BA@ /"'_",1AV!5VLZ1X]_9F\1W^D>'/"?[4/@#Q+XAUW5]3T7PUX=\/?
M%_P?J6I:]JNAG&MZ+HFBKXB;^W_$.1\QP2@.YE"]?S&\0_\ !,SP%XHUS]H#
M4]6^)OC6Z_X: \-?&0:K>:O\+?"&J>)_ GCKXY^"AX#\<^-/!>O-XD\)^&O#
M_A_Q9SXG;PP?"+EO^1)_X3G_ (03PGM7U?1_V!O@[H7Q.T[XDZ&^O:)?Z3\=
M?V8OCGH]EX=^'7@XK9']G+X9I\)F\&Z+K6@>(_\ D7OBKL'B?QDP;Y?&3R*!
MXR!%;?[5;I_Y+Y_U]P'V%\4?BO\ L]_!OQE\./ASXY^,%W:?$#XG^//"OP^\
M'^!]*U?1]1\<'4_'>KC0]"UO6M#T #Q1H'AP'1"I\4LJ>#@5.5 X.CX#\>_L
M]^/;7P?/H?QBMK;4/'GAO_A-/"'A/Q!XD\':;XYO_"__ !/_ .W-;&AX'B<^
M',:'R>@.@8SD''Q[\3/V)?"WQ!_:E_X:3LOB!\4O"=MJ?Q4^!/Q;\1?#V\^'
M'@SQ)_;WB?\ 9QT;7]!T)=#\;:[XB7Q+X>\.>*?#FMA?&GA;!;_A,A_PG+,6
M+%O)]'_X)F_#S37\ Z3<?$SXGVWAOPO^S9XZ_9Q\6VWA+P+X.\-^*?B9X:\=
MZ-\0=!D77M9_X2'Q<J^&O"*^-]8\4^!?#(\*.W@[QKH3@^-4'BM?!LN%^[U^
M0'Z0/X__ &7Y/!9\<V_[3'PWN_!-KXD7PL/&UG\8/"!\,'Q5HFC?VYK6BG74
M\0OX:77_ /A'CK?BA_#.TK&FZ1P%4FN0U'XP_LP:1\6_AQ\#_P#A=]KK7Q(^
M*%KXIN](\.^'O$ND>)/[ TK0?!1\>C7/&Y\/J!X!\/'PWHD?B?P3XH\5X'C(
ME_G8K@_"WA7_ ()E_#33'\+WOCWQ5XL^*.HZ;\>?@[\3O&.E>(_@K\-_#O@?
MQUX8^!OPQ\0_";P+X+UOP1X?(\-,%\/ZZ/$_C7Q-N\6CQEXQT A/!*;52K6N
M_P#!-_X<^(_BW\0?&-QX_P#BCIOPW\>>(_COXGO/A/I/PX\&Z;J>A?\ #2'P
M6_X5+X[T70_BG@>)AX>\)^'3HGB?P1X6\5^#SX+\%C0!X&SSA2_G^* _0^?Q
M]^R]_P (X/&*_M,_#C_A#KN]U/PP?%I^,'@X>&;W4]#!_MO1O[</B/\ X1G_
M (2+PGX= 4@ ,N<L,#-=OX<L/@[XTUG7]#\$_&'3?%>O^#;K3+3Q/I?A3QCH
MWB/4/#^I:WC^Q/[=T7P^,>'C@[ESMR Q)7!%?F#\,O\ @F]\)/"%]\(+WX@7
MUU\6;;X8_$<_$#6?#WB#X0>#AX:^)8T/X8_\*DT+_A-]%U_Q+XM;7_$GA+PW
M_8?BC_A*E(8'0/#!7P/X,QD_4O[-'P2TS]G?XO?M)_%G3];\9ZWHWQX\9#Q-
M8_"BQ\(Z1X;\#^!=2_MG7=?UW7=$'A_Q%XL.N>)/%<FN,/&WB=7\)#QD/#R.
M/!>XE4YOK6*OOU[(#[E_X49I?_0R>)?_  +/^-'_  HS2_\ H9/$O_@6?\:3
M_A=T/_0G>)/_  "/^-'_  NZ'_H3O$G_ (!'_&NGV^,[O_R4!?\ A1FE_P#0
MR>)?_ L_XT?\*,TO_H9/$O\ X%G_ !I/^%W0_P#0G>)/_ (_XT?\+NA_Z$[Q
M)_X!'_&CV^,[_P#I("_\*,TO_H9/$O\ X%G_ !H_X49I?_0R>)?_  +/^-)_
MPNZ'_H3O$G_@$?\ &C_A=T/_ $)WB3_P"/\ C1[?&=__ $D!?^%&:7_T,GB7
M_P "S_C1_P *,TO_ *&3Q+_X%G_&D_X7=#_T)WB3_P  C_C1_P +NA_Z$[Q)
M_P" 1_QH]OC._P#Z2 O_  HS2_\ H9/$O_@6?\:/^%&:7_T,GB7_ ,"S_C2?
M\+NA_P"A.\2?^ 1_QH_X7=#_ -"=XD_\ C_C1[?&=_\ TD!?^%&:7_T,GB7_
M ,"S_C1_PHS2_P#H9/$O_@6?\:3_ (7=#_T)WB3_ , C_C1_PNZ'_H3O$G_@
M$?\ &CV^,[_^D@+_ ,*,TO\ Z&3Q+_X%G_&C_A1FE_\ 0R>)?_ L_P"-)_PN
MZ'_H3O$G_@$?\:/^%W0_]"=XD_\  (_XT>WQG?\ ]) 7_A1FE_\ 0R>)?_ L
M_P"-'_"C=+_Z&3Q+_P"!9_QI/^%W0_\ 0G>)/_ (_P"-'_"[H?\ H3O$G_@$
M?\:/]K\OP![!_P *-TK_ *&7Q)_X%G_&DF^#.E0QF;_A(_$F< @?;/RX/;(^
MM!^-D)_YD_Q*.O2R/?\ 'MVI9OB_8S0W'_%*^).,=;0\_P"3^%=,?K?-'_%'
M^7O$Y,9S?4*EM^2IR^O+4M^-C\9?V;/VU/&/B_\ ;[UK]GR_^'/@#3/#VE^.
MOC+X9M/%FD_VN/$][I7@8:__ &'KC%FV8\4_V'ELG& <9X%?N_>:1!.XN/MV
MHVQ9?^775CIXY&3G&/?'(_+FOP@_9L_8RUSPA^WYK7[0EQ\4OAOJFG:KX[^,
MOB;_ (0;21JQ\3V/_"=#7\:)AOD_X2/PI_;G_%;;N/4 9-?O#=ZO]G46_P#9
M>MW& /\ CUM"?;J>3SZG\!TKT^([?6H=^6._;DCT];[(_,O#)YM]6SC^UK65
M:=K6_FE;K?FVOU^9-_PC</\ T$/$/_A1ZS_C1_PC</\ T$/$/_A1ZS_C3O[>
M'_0%\1_^"@?_ !-']O#_ * OB/\ \% _^)KYP_6%L<IXC_L+PUH6O^)+V\UD
M6'AG2-4UV^:T\1ZR&&FZ&O\ ;>M'GQ#RQ0;&R0R#"<@BOSH\7_\ !3+]F#P?
MX-^"'C?7+?XV_P#"+?M _#?3/C/9G2](UC4=3^%'P<US6?#V@_\ "S_BD%\2
M'_A'_#A\2>.-%\+D^%?^$O((X4J01^B'BO[/XH\.>(?"MQI?B2V'BG1M3T6\
MN[;23_Q+QKFBG0R<DGU/H  !G &/RW\;?\$L/@[XV\ _ GX;W_C?XYZ'8?!S
MX+:9^SGJMUX>M_!VG:K\:_@R/&?AWQT_@[QRI\,@^'=OB3P3H?B7_A*/"7_"
M(^,\?\)&Q8%RJ@'ZTV^@V,T0N(-5\1F"Z'VT'_A(]9 P<$XR2<9 XSGCV!J_
M_P (W#_T$/$/_A1ZS_C5&#5[>RM8(+?0_$=M;VUH+.TM/['/90!QD]@JD# .
M"<=16A_;P_Z OB/_ ,% _P#B: &_\(W#_P!!#Q#_ .%'K/\ C1_PC</_ $$/
M$/\ X4>L_P"-._MX?] 7Q'_X*!_\31_;P_Z OB/_ ,% _P#B: &_\(W#_P!!
M#Q#_ .%'K/\ C1_PC</_ $$/$/\ X4>L_P"-._MX?] 7Q'_X*!_\31_;P_Z
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M9&UO=O\ A&X?^@AXA_\ "CUG_&O$/!^L?\7C^.'_ !*];_X]/A?_ ,PD\_\
M%':]QUZ@\8Z _)T)KW'^WA_T!?$?_@H'_P 30 W_ (1N'_H(>(?_  H]9_QH
M_P"$;A_Z"'B'_P */6?\:=_;P_Z OB/_ ,% _P#B:/[>'_0%\1_^"@?_ !-
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M24?\*Q\4_P#15-<_/6O_ )I*/8>OW/\ ^1 ]XHKP?_A6/BG_ **IKGYZU_\
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M-7B/_P  ]&_^9NC^R=5_Z&KQ'_X!Z-_\S= '8T5QW]DZK_T-7B/_ , ]&_\
MF;H_LG5?^AJ\1_\ @'HW_P S= '8T5QW]DZK_P!#5XC_ / /1O\ YFZ/[)U7
M_H:O$?\ X!Z-_P#,W0!\*_%/7?C]_P *F\?S> ;;6K2^TOXD?$]KKQ!9W[?\
M)/8^&M$\9O\ V+HG@I-?\-A6_P"$K4CPQ_PE.]QX.\',S^ U#1JW@_?U7QE>
M:M\?-.M]-\8>)/[9M?'/AC0_#?P^LFUL>"M;^%[Z)KZ^/-:UC2$*>&]=;PIX
MAT371_PE:,K^"O&F@>&/!*LO_"6Y\8_0.I^,="TOQIH'@B_\1^/+7Q#XIO-2
ML-(O#X0_XEVH:EH6C-KNL@ZX/#7_  C'.@:*P4$D EB#EB!G>"_B'X6^(][?
MP>%/%_BRY;3;/2KW-YX<?2_[0TC6VUT:)K6B/K_A=AX@\/\ BK^Q]>*>)/"I
M <Z">5&\J ?1E%<=_9.J_P#0U>(__ /1O_F;H_LG5?\ H:O$?_@'HW_S-T =
MC17'?V3JO_0U>(__  #T;_YFZ/[)U7_H:O$?_@'HW_S-T <!X(_Y+5\</^O/
MX7?^F37Z]PKYE\'Z=>CXR?'#_BHM;_X]?A?_ ,NFB]1X.U\=?^$=]3GKGMC=
MA3[3_9.J_P#0U>(__ /1O_F;H [&BN._LG5?^AJ\1_\ @'HW_P S=']DZK_T
M-7B/_P  ]&_^9N@#L:^6?VCKB6+X?B;3_'^F?#K_ (J+PU=GQ%JOB36/#VG:
M]IL4@UO7?!?]O: !XFT!?$WA_16!_P"$5_>9!*AFR3[K_9.J_P#0U>(__ /1
MO_F;KG_$E[;^$-!U#Q'KGC'6M-TC0;3[;J]T;/13]ATQ>3_S+9Z=^X(]LT .
M^'OB&;Q7X/\ "'B&?2M1\-SZYX:\-:W=>'M9(&JZ)_;6C0M_9.LD,"=<C+A)
M"RA@P4,#P7]/KCO[*U4_\S5XC_\  /1O_F;H_LG5?^AJ\1_^ >C?_,W0!V-%
M<=_9.J_]#5XC_P# /1O_ )FZ/[)U7_H:O$?_ (!Z-_\ ,W0!V-%<=_9.J_\
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M:BWBGP-XVUW7="9M<\/^(/"CZ_X>7Q"IV^%@0#N*LI^1T^H?^%X^#O[NM?\
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MM_X!?_6I7PO:7WL#R[_A>/@[^[K7_@":/^%X^#O[NM?^ )KTK^S+#_H$VO\
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M?_@GUO\ ^9^C_A+]&_Y[7?\ X)];_P#F?KM:* .*_P"$OT;_ )[7?_@GUO\
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MLKQE<7FE>$/!6H^&;+5=$\%MH7@CQBNN:!X>7PUGP?X:C/AOP7XHVC_A#/!
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M9:OXWN?AMX-;Q+J']MZ*=!UT:YK_ /PC8\2:\3X<_P"*67>R@^#.,D]#PO\
MLPZ%X!ET:;P/X%^#O@JZ\,ZUJ6L>&;KPE\.=#\-MH6JZ]HQT#7];T'^P?#R_
MV!_PD_AH'PW(!\VQ3M#L E?3/_"T? __ $'1_P" 6J__ !OZ_P"3P?\ "T?
M_P#T'1_X!:K_ /&_K_D\'^U]O_)0/!_"GP.OO!6O^)_%7@:W\ >$_$'CR[^W
M>,?$7A/P?HNF:GXKU3 UX:SKNMGPX&U\MXA;7".,?\3[!VG;GT#_ (17XQ?]
M#QIO_@&?_F;KN/\ A:/@?_H._P#DEJO_ ,11_P +1\#_ /0=_P#)+5?_ (BI
M][M^ '#_ /"*_&+_ *'C3?\ P#/_ ,S='_"*_&+_ *'C3?\ P#/_ ,S==Q_P
MM'P/_P!!W_R2U7_XBC_A:/@?_H._^26J_P#Q%97Q@'#_ /"*_&+_ *'C3?\
MP#/_ ,S='_"*_&+_ *'C3?\ P#/_ ,S==Q_PM'P/_P!!W_R2U7_XW]?\G@_X
M6CX'_P"@Z/\ P"U7_P"-_7_)XVOB^WX(#A_^$5^,7_0\:;_X!G_YFZ/^$5^,
M7_0\:;_X!G_YFZ[C_A:/@?\ Z#H_\ M5_P#C?U_R>#_A:/@?_H.C_P  M5_^
M-_7_ ">'_M?;_P E_P" !P__  BOQB_Z'C3?_ ,__,W1_P (K\8O^AXTW_P#
M/_S-UW'_  M'P/\ ]!T?^ 6J_P#QOZ_Y/!_PM'P/_P!!T?\ @%JO_P ;^O\
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M!S1/_!MI(_K4W_"1Z%_T'-&_\&^E_P#Q5?.G["]WZO\ ,H_8O%?_ $,>F?\
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M3^S?$4T7DSZKIEQ;G -K=>&R<XYY(\1CUZ\]\>M7_P#A(]"_Z#FC?^#?2_\
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M'IG_ (3)_P#FCJ]_PD>A?]!S1O\ P;Z7_P#%4?\ "1Z%_P!!S1O_  ;Z7_\
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M/Q4-!\0?\5'IO_((U7_F7#S_ ,2;G/\ Q4@[8/ID\'')ZOPEYW_"*^&?N_\
M(OZ-Z?\ 0.MJPM?\2:'_ &#X@']NZ+_R"-3Q_P 3C2<9_L@GUZ=LCY<8)^3
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M_P""H7[/L.G_ !(G^.OPUUSX-P>#?$O[3]IX-\77O@]?$O@7XD^&/V;O&/\
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M?$?[.GQ8T3PA\!OC3XE^#%YXA'A'P=_9OCW5=#T9]=UW^Q$\0^(_"077SC7
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M:7\:?C5H.E2LVK!B3H.A?$'3="&2<X73E Z 8XJ]_P ,H?!C_GV^)O\ X?\
M^/W_ ,\VBB@ _P"&4/@Q_P ^WQ-_\/\ _'[_ .>;1_PRA\&/^?;XF_\ A_\
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M?_#_ /Q^_P#GFT?\,H?!C_GV^)O_ (?_ ./W_P \VBB@ _X90^#'_/M\3?\
MP_\ \?O_ )YM'_#*'P8_Y]OB;_X?_P"/W_SS:** #_AE#X,?\^WQ-_\ #_\
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M10 ?\,H?!C_GV^)O_A__ (_?_/-H_P"&4/@Q_P ^WQ-_\/\ _'[_ .>;110
M?\,H?!C_ )]OB;_X?_X_?_/-H_X90^#'_/M\3?\ P_\ \?O_ )YM%% !_P ,
MH?!C_GV^)O\ X?\ ^/W_ ,\VC_AE#X,?\^WQ-_\ #_\ Q^_^>;110!R-K^Q[
M\!XY3JZ:3\0UU+7/[,_M:\'QX^/7G7W(_P!<3\3"O_?"K77?\,H?!C_GV^)O
M_A__ (_?_/-HHH /^&4/@Q_S[?$W_P /_P#'[_YYM'_#*'P8_P"?;XF_^'_^
M/W_SS:** #_AE#X,?\^WQ-_\/_\ '[_YYM'_  RA\&/^?;XF_P#A_P#X_?\
MSS:** #_ (90^#'_ #[?$W_P_P#\?O\ YYM'_#*'P8_Y]OB;_P"'_P#C]_\
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GE?\ 'I_T7[X_>I_ZJ=7M=OHNE"" "Q@P(8Q]TGHB]R<G\:** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "U F # 2(  A$! Q$!_\0
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MPHHKXT^ /[6_[/?[3.K^/--^!'Q4T[XC7WP]?2%\2C2])U^P5=*UI]9B\/\
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MQO\ $[P#\.+GP@?&WC'1?#4_CSQSI7PQ\'6NK78SXL\>:\=?_L+P;HBLH/\
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MEFKIZ=M/^'/[=/M$'J?_  );_&E\Z#UC_P# EL=_]CV_4>M?Q!_\/(?VX/\
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M!?#-8_&W_""_\)EX-KY3^(/_  27_;3\8_M3?%+QWX:T/X;_  X\;^*O&/\
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M8\<>-(-5M;GX)_!;]G+PS9_$#P!^T!\./#(_9J/PJT3XMZ-\5O!K+XA_9O\
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MON1WW[-7_!,/X[_!3_@HQ\+OVK?[#\%Z-8ZG^TW_ ,%8O&O[0?C?2/'6M?\
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M1C_IA^O_ -:OS>_X>B_LS_\ /]XW_P#"$UKW_P#K?KZ<G_#T7]F?_G^\;_\
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M ,(36O?_ .M^OIR?\/1?V9_^?[QO_P"$)K7O_P#6_7TY/J^,_IH7_$1N#_\
MHJ8>EX_=^A^E (/3Z4$X],=R3C^G]:_-W_AZ)^S/VO?&P^G@36?_ (DU]+_
M;]H'P!^T7X<UCQ5\.YM1:PT+Q&/#%[_:NCG3=0_M3^Q-!U\Y5F/7P_KVBGIG
ME58D**'AY+5_Y_DK;^9Z>6\6\/9OBOJF!S:$Y65DI)W>_1R=OZL?2E%(. !Z
M 4M<Y],%%%% !11D9QD9].]% !1110 5X?XW^($?A&XT_1;?2/$7B_Q5K_\
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MZK>][]^CT71);;GZH:%^Q/\ "74OAKX^L;'7/$?B2_MO$O@/X@>'/[)\-_\
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M\(>,=6N/&VB>$/['\>?$#P)X>O-7^)G_ !(M4\#:SH&@Z]K?]AZ!X;\7>&/
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MAZ[XU/VFT^!7C.[TGQMH_@W4M,/A?XX:-KRZ'HQ/A_PW_P 3_P 1>$VT-O\
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M/HK[;^(/[-O@V8Z./A/J&HVEA=^)/%&BZQXV\1>+_!_C/P,?#&A>#=?\<_\
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M7_!-,_MB_$OP]\3?^%P'X?GPQX"/@PZ2/ @\2+>G^V==UW^V/[;/B;PEM/\
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M^%/$.AKX7"CQ:H\9,"V22-N#!^W)<0WVKWMQ\.;FZ_M/QA^UAXHR?&&?L/\
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MQZ/^'"%Q_P!'37/_ (9W2O\ YXU4L\X%O?FG]TO+7UTW]>[&_#WQSM\"_P#
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M*^<?&V3W>W5[/K=GZAA? GC!8.SB[JRM;MIV[K8_&JBOV5_X=)C_ *+==_\
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M&SN/^9*QC-0?\*(^._\ T1?XH_\ A!^,?_F;JS_PH?X[?]$6^+7_ (06L_\
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MR/W&_P"%V?"7_HIO@C_PI-$H_P"%V?"7_HIO@C_PI-$K\.?)'_3M^9H\D?\
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M0>EO^:^_^?Q^N#[-!Z6_YK_G_P#7]<6?)/O^8H\D^_YBNCG?\XO[-P?\L?\
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MF^:QDTM%&$6Y/T44]=++3??2Y_07S[?E]??Z?KZ\'/\ D?\ U_I_D\?QO?\
M#X7]N;_H<? '_AN=(_\ FDH_X>^?MV_]#OX _P##;Z+_ /-'7TO^H.;MV]W>
MWQ>=NY^-?\3)\)K_ )D_$^G7V;MIU^#;KZ']D$4@//\ +^7/UY'T(-6."..G
MMQ7\K_['/_!3#]K7XK?M0_!7X9_$#6_!&I^$/&'B75-&\16FE> _[-U-=-_X
M0GQ!KF5US_A)#@_\)#HNBJ2,':2.A-?H7^VQ\?OCQ\%/VH_V=]:^&DFM>(OA
M5X1_9S_:A^,W[1_PBT32#JFJ_$?X6^'_ (G?LE^!M9\;>"=%T +XEU_XA_L_
M>&O'&M_%'P7X4\*QOXR\9>$-"\3> %9_''C#P<7^;SG)<7D.+^IXMII]4TUK
MV:O^>A^N<%\:95QKE/\ :V4J2=[.,TT_/1I:]'UO<_9ZBOYEO@/_ ,%)OC[K
M'P-\'ZH?&_PE\;:/I8^ _P )/$FK>(O$>M:E^T)\6O%'[5O@S_A// O[07PK
M_P"$?'_"+CX>>$O#FNZ$?^$6_P"$0\8GQI_P@'QVQXX\&CX1'_A,9?@S_P %
M3/B8?#G[,_A7Q7\7?@8WA_QE\%M)\'>.OC'\3?"'C)3\/_C+X#_84\/_ +2W
MCGXF_%+QUKWQ(^$/AKX@+X4\2 GQS\+/A3X1;?X*\1>&_&K?'#P=XV;_ (0@
M><?:'],E%?SB:[_P4I_:\^&'PNUCQO\ $7PY^SUX:U#P%^S-\9?VW[S0/'/A
MWXE_"CQ1\:OV=/ _C;0=#\#_  Q\#^"/$7Q(\8>*/A]^T-XM\.,WB7QLOBSQ
M?XO'P4\8_%WX%^ _'/@7QAXZ\6^,?^$+_6']A;Q7XQ\;?L\VVM^-_$ESXV\0
MVWQL_:A\+WGB#50/[1OM+\#?M.?%[P)H6CL/^I3\.Z!HGA8'(^;0,4 ?;5%%
M% !@>@_SG_$_F:,#T_S_ ))_.BB@ HHHH **** "BBB@ HHHH \8A^%GPYTO
M6H?$D'@_0[;6;?QWJ?Q!%];V4>X^.]>T63P-KGC [67/B'Q-X;/_  C/()*,
M<;G+N9I?AIX ;P[XO\$#PAHP\'_$>Z\6WOCOP]]A1M.\7:CX[9_^$X;6]%5?
M+UU?%@UK6CXP+MB1=PD1I 67V&B@#Y4U[]ES]GSQ+XMN?B9XB^"_@'6?'-W>
M[KKQ'=^$-%;4\#1%\!_VR1C \0_\*Y!\*GQ0I_X34^"?^*(##P,Q\&B/QA^R
M]\ OB''<6/B_X.^ /$&F77_",65W:ZOX.T;4"=,\$Z+KNAZ#I WH N@KH&O:
M[X5V,"&\%^(O$_@@L? _BQHU^KZ* /E&?]E/]F^XUJ\U7_A1WPP&H:GX<7P!
MJ%U_PB&BH;WPL=#'@,:*0?#A5Q_PKG1=$\+,N67_ (0GP_X;\#HX\$1HK:WB
M#X!_ _Q$_B+4->^&G@K6;KQ1J_B?6/$IU31-)<Z[JOCOP2GPF\=:SK#F,^:W
MBOX=:+HOA;QG\A#^#]#$>PN"I^F** /C!_V/OV9YKO4X+7X)^$S:ZOK9\37U
ML]KK2:8GB8^+V\>IKNA*1_Q(?$I\4MK'B$>(O"[0OEWD!(\4[6ZG1?V8OV?/
M"FJ>%]5T/X'_  VT6X\":/J&B^$+S2/!^B:;8:%IO_%?AM(TC1%41@%/BE\4
M02H7_D??%0C)/BWQ>#]344 ?,'A7]FOX ^!/LT7@GX/_  X\+JE]XEN@=,\-
M:.FYM?T5- UO.0J?O?#FC:)X3V8<'P=H2^!EV>"4*+[7H'AK0_#6A:1X=T2P
MMM&T#0+'2]&T;2[0J-.L=+T1O^)*BC VJ-L8 S\WR[B6&YNTHH **** "BBB
M@ HHHH _'[]M>>"'XYCSY_LV? 7A?_E[(S_Q.M?SP>GJ>.OMS7R?]LL?^?\
MMO\ P-_^M7] UYX<\.:F_G7FA:+J4^/^/N]TC2;\G\2N[UYX]N:7_A$/"G_0
MJ^'?_!)I7_Q- '\_'VRQ_P"?^V_\#?\ ZU'VRQ_Y_P"V_P# W_ZU?T#_ /"(
M>%/^A5\._P#@DTK_ .)H_P"$0\*?]"KX=_\ !)I7_P 30!_/Q]LL?^?^V_\
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M-*_^)H_X1#PI_P!"KX=_\$FE?_$T ?S\?;+'_G_MO_ W_P"M1]LL?^?^V_\
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M'A3_ *%7P[_X)-*_^)H_X1#PI_T*OAW_ ,$FE?\ Q- '\_'VRQ_Y_P"V_P#
MW_ZU'VRQ_P"?^V_\#?\ ZU?T#_\ "(>%/^A5\._^"32O_B:/^$0\*?\ 0J^'
M?_!)I7_Q- '\_'VRQ_Y_[;_P-_\ K4?;+'_G_MO_  -_^M7] _\ PB'A3_H5
M?#O_ ()-*_\ B:/^$0\*?]"KX=_\$FE?_$T ?S\?;+'_ )_[;_P-_P#K4?;+
M'_G_ +;_ ,#?_K5_0/\ \(AX4_Z%7P[_ ."32O\ XFC_ (1#PI_T*OAW_P $
MFE?_ !- '\_'VRQ_Y_[;_P #?_K5]<?L4S03?&F?R)_M/_%">*.EX3Q_;6@_
MI[].YK]3_P#A$/"G_0J^'?\ P2:5_P#$T6>@:%IC^=9:'HVFS]/M=EI&DZ>P
M[]5RY_SS0!T/;D8]1UKY7^)7[,GP$^+^O?\ "4?$_P"#7PD^(_B"VTK3-%?6
M/&W@#PAXSU*QTC1VDUJ+0HW\0^'G T-?[=U<D@_,VO$A(Q*/+^J?^67^?[M?
MD7^VW^T#\6OAI\7]!\.>!_B)=>$-&N/ASI6M75I:V/@^_;4-3;QAX\T3(7Q'
MX8\6$'_B3:(K8S@@JQWAE&^'Q&*PCOA&T[./,I.+MZIIVZO778\W,LLP>;83
MZGCHQDEJU*,9+_R:,E?U1]4_\,)_L:_]&K_LW?\ AB?AI[_]2R/7]!Z4O_#"
MG[&W_1K'[./_ (93X9^__4M>_P"@]*_)'_ALW]H7_HN&I?\ @G\&?_,U1_PV
M;^T+_P!%PU+_ ,$_@S_YFJZ_[1S;_H:27DI3^[XWZ'A?ZD<'VM_9$&[6MR1U
M=K6U@]W^9^P'A?\ 9 _9@\!:]HWBKP7^SK\%/"?B_0@;K1?$/A[X4^"_#OB/
M06(^4Z/KFA>'EET,@]0C@L,@]"1[+:Z1HD^MZ=XBN=+T0^)-/TC6/#-EJUSH
MX/B+3=)UW5]"UW7=&T?66E;Q)H,?B==#T'Q)-X55MKR:%X8<(C>%%(_'G]G;
M]JCX[>,/CG\,/"NN?%/4M;\/ZKXCU2QUGP]=Z-X-)O\ _B2^(-> SH'AO_A)
MNNB'&>,DG/)JG_P4J^,O[2W@CX[:1X)_9R^)7QCT7QD?V*_VF_BW\(OAA\*O
MACH_Q'TOXL_M/>!_B=\ - ^!_@SXG'Q!\-/&+>'OAUXH\0>-]?\ "_C11XK\
M%*_A#7?$^_QSX*/A8S'FQ.)Q>+L\8W)[)RFY-_>WIIITZ6ZOW,KRS*<IPOU/
M Y5')8](QBDGY^ZOM>E]=7V_6+3/@/\ !""\\)^(]*^#GPGM=1\!^#]2^'_@
M#6M-^''@U=3\)^ =<*OK7@_P3K/]@QOH/AKQ,'"7'A;PP\7A&5861@X9-W,Z
ME^R]^S=K4NHS:[^SU\#=9'B+1]-\&ZM::M\(O!6H'7/"6@Z$N@:#X-UL/X86
M37O#7A3PX=;\,>#?"TBGPC#X2<H-\6UJ_!ZS^('[:/PE^)OPI^&GP>\+?M$>
M"O!^F_M.:1XGU>S;P?\ VGX$^)/@/XY?\%;/B[H/QS"Z#_PS?XN\3>(/^$3_
M &===T3Q7XX\5^+?VC_@\_@SP;X@^&'CGP'X)\9KXK\7^,U3_A>'_!0 ?#KX
M?7I\>_M4W6M:I>?"^]_;7N_&_P 'E^''AO\ 9W^,>N^#?CTWCSX9?LY>.? '
M[)?[17BCQ!\.Q\2-"\">&6/_  J#XQ>#/!G@T?# _P#"\"WQ;\95S'I_CYG[
MQZ#^RS^R[X/M?#]CX'_9T^ 7AG3?!GCN7XH>&_#OA[X0?#;3=/\ "GQ1722/
M^$VT'1="\.K_ ,(]\04&AZ(6\3^%HSXN/]BQ;)!&N6]O\->%?#OANRCT_0-%
MTS1;*VO=:U!+/2[&+3;!-2UW6_[>UQT + #Q+X@E&ONRAB[."QVO\_\ ,-X<
M\5?\%+/A]HW[0'C'X:0?&O4?VUO'FL:C\3[OX)7?P)T;2_V:/'K?\.R?A$1\
M3#KFO^&Q_P (_P#$/_AHW0]!\+?\(K_PN'P>'\::$W@,^!?^$!/_  F;?KS^
MP1XQ^*OBN+X_6?B#QQ\:_BA\'/#WCOPQ9? KXM?M"> 1\-?BWXMTS6?AEX"U
MSQWI!T1/AU\)QKGAOPM\1)M<\.1^))OA)X18>,&\3^!B/&#^#W90#]0:***
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MT ?3_P#PBW[0O_17_ '_ (:#5O\ YY5'_"+?M"_]%?\  '_AH-6_^>57O=%
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M 7P;^%?PX\;:[\+_  3\,?"OPA<^,OC1XA_X3K_BD? 7A)O%_C+]?: /!/\
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M0UW1M:^*<?PC\0>*OA=H7Q#\3^)(=8\3>+I?A4P\%NDGAX[5\='QAO /H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M_C_X#_6H_(B_NT44 -_Y:_Y_O4[R(O[M%% $U%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $_ ?D# 2(  A$! Q$!_\0
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M@[^VO$<G@/P?$WA3P<OA/YV_9-_X(_?%NZ\:^,?B7^W#X_\ %NM^*+/XE?\
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MO@3Q7X,D'L'BK_@L'X,T'XI^*?A/I?[(7[7WCK4=!_:_U/\ 88TCQ7X(T_\
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M@WX1>'/A5XR_9SU_P[H/A7Q#X";X7-\"_!'BSP*2/%SQ>+=#\N8>*O [/X-
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M_BG7CX3BUS1?#/\ PBGA?QCX,\%^-/!_A_PKX!\?^"?&7@/PH?!Z 'QCI_\
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M$._V1D@^&-GX7\>_M/\ P^G^&%G\4O#.K:_X)^*NC>"/%?Q:^%_Q3_: UO\
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MGC6]#R64Y5>HP-R@9.0*.H]BHHHH YX?\AV^_P"O+3/_ '/UT-<\/^0[??\
M7EIG_N?KH: "BBB@ HHHH **** "LC3?^09I_P#UY:7_ .RUKUD:;_R#-/\
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MO#OQW\'?'SQ1X#U71/@UX 7QKHOC?QS\/V/A@MXL^(O_  F_Q,\%>%?^$O\
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M4 ='1110 4444 %%%% !1110!BZ9_P ?^O\ _863_P!,>A5M5BZ9_P ?^O\
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M<:$Q]^50CG/7)K\D_CCX*@^&/CRX\'V^K:EK>GVFCZ9>V=WJW_(3T_2]=/\
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M<9@_[6PF,NGH[ZI[WUV9^6/_  4F^.>A_"[P!IOPX\1_ [Q=\:K7Q/I/Q/\
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MO'?V8:^\Z^#/^"B?_)OOA?\ [/+_ .":O_KQW]F&@#[SHHHH **** *H^60
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MO#!>A\%? ;X6> M7_P"$I\&^%[K3-9-G]A%Z?$GC#4F.F=0 /$'B%EY'!X.
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MA$;C>_X*<S^";3]C+XCW'Q*\5VG@KPC;^+O@/?7GBK7/#FD^)O 7AW4S\?\
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M=???AO\ L]?M&>%?VK_'GQB\3_$_^T?AGXEGUECX<3Q=I#^*/^$9T!/$!^%
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M %9&F_\ (,T__KRTO_V6M>LC3?\ D&:?_P!>6E_^RT :]%%% !1110 4444
M%<YJ'_'SHW_7_?\ _IIURNCKG-0_X^=&_P"O^_\ _33KE '1T444 %%%% !1
M110 4444 8NF?\?^O_\ 863_ -,>A5M5BZ9_Q_Z__P!A9/\ TQZ%6U0 4444
M %%%% !1110!BZE_R!]1_P"O/4OYR5M5BZE_R!]1_P"O/4OYR5M4 %%%% !1
M110 4444 %<]+_R&+'_L$:O_ .A:%70USTO_ "&+'_L$:O\ ^A:%0!T-%%%
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M\+)X)T;Q'X.\,^%?&8\%1G6SXU\=1>+AX6\)+X-_2FL66TMYC;^? /\ 1?\
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MH **** "N>E_Y#%C_P!@C5__ $+0JZ&N>E_Y#%C_ -@C5_\ T+0J .AHHHH
MQ;S_ (]Y_P#KS'\S7\Q_AN\UVS_;>\07VB>&[GQ'K5K\=OC)]C\.VNKZ-X>^
MW'_A,O'V<ZWKV/[!_P"*=_XJ@A>3_8&!@G-?TXW>?LD__7L?_0CC_/TK^97P
M@U[!^V]XH\1-HGB/6](\'?'?XH:SXCL_"?A#QAXVU/1--_X3+Q^VAZQK6B>
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M7_[/+_X)J_\ KQW]F&OO.O@S_@HG_P F^^%_^SR_^":O_KQW]F&@#[SHHHH
M**** "BBB@ HHHH YX?\AV^_Z\M,_P#<_70USP_Y#M]_UY:9_P"Y^NAH KUF
M3PF:/'^OX_/W]O;IZ'G%:=%-.ST_RZI^78YL3AEBTXNW*U9K=6>CTVVOTU/P
M#_:)_9-^,'[(_P 1K_\ :\_8+%W;6%R6O?C5^SY;6)O_  UK^F(S:TQT'06
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M_@V^_ME+WP\W]FZ=\35PH.C:\A \,IXE;06*)XD\5F3P9XT0)X'^(#CP._\
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M7.:A_P ?.C?]?]__ .FG7*Z.N=U$CSM&Y_YC&H_KHNO8_.@#HJ*** "BBB@
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M% &+J7_('U'_ *\]2_G)6U6+J7_('U'_ *\]2_G)6U0 4444 %%%% !1110
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M6&DKXDUH!M0:&0)K<C ,ZGP_X5368Y?&,C?\4?X,C,>XQX"CQ+]K_P#X)_\
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MIQQQCOP?88   _#\$/VWOV([CX;S:Q\6?@_I7VGP1_Q,[WQ=X4M+0?\ %#<
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M;SG_ (1S?_PD';_68YQCFO3: .>'_(=OO^O+3/\ W/UT-<\/^0[??]>6F?\
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MUM_]L>G_ *Q\8?\ 1*O[W_F?ME_;,/\ SVM_R/\ C1_;$!_Y;6_Y'_&OQ/\
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M (CW\-/_ )FZ/^'8'_!.;_HQC]DS_P 1[^&G_P S= 'WS17P-_P[ _X)S?\
M1C'[)G_B/?PT_P#F;H_X=@?\$YO^C&/V3/\ Q'OX:?\ S-T ?;$/_(5O_P#K
MPTS^>O5T-? W_#L#_@G-_P!&,?LF?^(]_#3_ .9NC_AV!_P3F_Z,8_9,_P#$
M>_AI_P#,W0!]\T5\#?\ #L#_ ()S?]&,?LF?^(]_#3_YFZ/^'8'_  3F_P"C
M&/V3/_$>_AI_\S= 'WS17P-_P[ _X)S?]&,?LF?^(]_#3_YFZ/\ AV!_P3F_
MZ,8_9,_\1[^&G_S-T ??-%? W_#L#_@G-_T8Q^R9_P"(]_#3_P"9NC_AV!_P
M3F_Z,8_9,_\ $>_AI_\ ,W0!]\UCZ?\ \>&G_P#7GI?]:^'O^'8'_!.;_HQC
M]DS_ ,1[^&G_ ,S='_#L#_@G-_T8Q^R9_P"(]_#3_P"9N@#[YHKX&_X=@?\
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M7_AV/_P3H_Z,8_94_P###?#7_P"9SZ_Y'*?\.Q_^"='_ $8S^RI_X8;X:_\
MS.?7_(YW^L8KEY+OEO\ #S.WW<UNBZ?F[\?]EX'ZY]>Y(\W\WLX<W??EYO\
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M?@GXR\>,/&?C"AX>_:J_:#32/!_A/6_BDMQ;77B/PO??&K]IOP_K?PU;X(>
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MA^UQ\?M2^,W@CXI>"+[QE\"O@1XH'AWQ9XE\&>)O W@(CXH_M,Z-H7@GP/\
M\('\2/&.$_X1S^Q%\:^)E'_%7^,-!\2^-_' \%+XK\%>#%_6VBB@ HHHH **
M** "BBB@#X1_;%TWP]KWPU\#6GB_XD6_PW\"_P#"WO U[X]U3QM\.=6\;^!/
M$.DZ*=:\0?\ "(?%,IKWA/P[X!^'WB;Q#H6BQ^,O%'BIE\$LCMX'E#-XNC>/
MI/V1M6U[6/V?_ -]JGA'PWX*"OXGL+'P_P"$_".L_#;PWJ'AG1?&OB'0_ WC
M/1? VM*G_" ^&_BIX7TC1?B>OA5RQ\&C71X++>+&0SG[*HH **** "BBB@ H
MHHH *_$_QNOB _MB^,[[Q)]E\4>*;3]H_P#9D\-? GP/=:/\3Q\2]1_9XUSX
M:^ =$^*OC3P1XV\/^)O"OASP]\/_  C\1=:^-7B?XT>&AX.\9^#O&"^ 1X(^
M.06/Q?X*3P=^V%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*_[1WQXT#]F
M/X.^/OC?XN\->(O$?A[X=V6CZQXCTGPE8:-J/B=='UG6=#T/6]9/]O\ B+PE
MX96+PI_;;>)O&6_Q>B+X,T%RCEF16^J*\2^.OPQT'XT?!WXL_![Q!.(= ^+G
MPX\4_#/6=MMNQIGCC0M<T!L 9Z+K1)Z8VDG;N; !\/7O_!3?X$V?COXY_#JT
M\+_$_6O&'P2^+_P*^!1MM'T?PAJ ^+/CCXY^-CX$T'_A53#Q0/[=T#PG\0CK
MOA;QQ)XJ_P"$-/@QM \3,.$"U])6?[9?[+%Z/B=-8_M%_"6X@^"5YGXIX\=:
M)CP</[9.@_\ $\&2-P\0Y\*@C>/^$V)\#[3XY! ^#_AK_P $H_#WA/Q%^PQX
MIO/C!J'BWQ#^R?JGQ8U[XG7EUX#:R'[37CGQAXZ\1>-;CQQK:#XC(/ >N^#/
MC=XV\;_$OPDZ-XR2&;7I+=W#H6/AGAO_ ((J^%=!^'OQ!\ P_''0;MKS2/ _
M@[X.Z^GP6UJQ\3>$]&\ _M(>'OC+HVC?&O6X_C09?C(Z^+]&\/\ @MX_"4?P
M?\%CP[HZ>*1X,;X@LGC,@'Z+ZC^WO^S7IGBWP?;_ /">:;<>!/'GP>\<_&BQ
M^-UGJ^B-\-=.TOP/XX\!_"E]!UW5T\0'Q&GQ \5>(_'$?A7P3X:3P@S/XST#
MQ/X(=E\>Q)X0/M&A_M/?L]>)_BCXB^"/A[XR>"-;^+WA>WU4>(_AEI?B?2[_
M ,3V T:705UT+H9#2M)X3_M_0T\9(A*>#VUV(>-Q%N7;^6NJ_P#!(OPK=+\-
M;I_C9H/AKXH? "P^(GBOPQXK\%_"'6/"_AOPQ^T[\2OC5X$^.GPX^->F^!9/
MB1XJ.L^&]!\1^!7\->*/A?XP\8^,#\0O!.M3GQGXVE\=Q'QHWT7\.?V&O&/P
M[_:XU?\ :8B^/^G6?A?7]8\=^*=8^#_P]^%^J_#C3/'GC?Q]HOA_P_K-Q\4_
M[#^)8^&7Q B\+>*'UCQ!X%\4CX.^$/C1YWB-(_'7QM\9Q_\ "8OXR /U?HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 2P# 2(  A$! Q$!_\0
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MVD?7];UO7=9UUG;7?$/BGQ%K>O>)?&4A="\^NR8CB4*#\,:7_P $DO@)X8^
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MT[QEX;U71M8N_#W_  4)^ ?AOQ-8Z9KVB_V%_P 2/7#XE_XD'B$?V[QXH^X
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M%?$GPK\?^&[KP?8ZMX5U+[3\1OAOX7^+?@^T\/ ^)-3O_A?XZ_Y 6M?\4_\
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M6226B;6BLOP/[I^B?BY8S@:\G)Z[N4GWZMMZ7[]#1HHHK\X/ZJ"BBB@#X/\
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M9H4445^;G]5!1110!\'_ +='_(F^!_\ L</_ '":_7YCU^G'[='_ ")O@?\
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M_P )+XYWKY^*^WM2@^T6D\$,]QIT]U9_8[2[M%_XF5CW! ))&&PV<G!]3@T
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MBBB@3V?H_P F?H1_P2O_ .3\?@-_W4__ -5CX_K^TC_EE_G^[7\6_P#P2O\
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M3_UZ:G_,5_6O^SG_ ,D.^$'_ &3?P%_ZAVAU6)_W67]=6?$?1O\ ][S7Y?\
MMI[U7X,_\%)]4^+GP_\ $FC>+SJ_C[PG\)]3;X8^&;3Q7I7_  423]DO3+WX
MG%_B R>!M \#Q? _XJ^)O$&O>)?#6NKXC\8GPIXLW^-(_#J-*7D\(L[?O-7X
M7?\ !9A_@>_PC^$,/Q3U'XN:=X@/Q'\37OPYU3X.ZIX/TSQ"-2T'X+_$/7-=
MT35S\0?#7BSPQKNA>+= T$^&/!_A+POX1D\<^+_&NN^&$\#( WBYSQG]>GWG
M^PMJ>K:E^R[\,=4UKQ%J7B74-47Q3?\ ]KZO\>-(_:DU.^T__A,]>"@?&[0/
M#?A!?'XVJ3@>%$_X0PM_P@Y7/A7>/MZOSE_X)V#1;S]E#X?'0H/%6G2#Q'\8
M+'Q@?&/C'PG\1/$_B'XH>'_C/X^T?XM:YK/C3X?>'/"?PSU[_A+OB5%K_B<^
M(/"'A+PIX,>+75'@CP5X25MB?HU0 5Y_\1L_\()XYQC_ )$_Q1G/I_8>N_K7
MH%>?_$;/_"">.<8_Y$_Q1G/I_8>N_K0!Z!1110!\:_MV?\F<?M4?]F]_&3_U
M6.OU_#37]RW[=G_)G'[5'_9O?QD_]5CK]?PTU^[^$W_,S_P+]3_/KZ7G_(WR
MOY?DPHHHK]A/X<>[]7^;"BBB@ HHHH$]GZ/\F?H1_P $K_\ D_'X#?\ =3__
M %6/C^O[2/\ EE_G^[7\6_\ P2O_ .3\?@-_W4__ -5CX_K^TC_EE_G^[7\X
M>)__ "4?R_\ DC_3[Z)__)O'_B_5FA1117YL?U6%%%% 'S+\?O@UJGQET'P_
MI>EZ[INB?V%K/]L7EW=V1U+[>?[(V+Q[LPP0.1@]*^7_ /AA?QA_T4;P[_X)
M6_PK].J* /S%_P"&%_&'_11O#O\ X)6_PH_X87\8?]%&\._^"5O\*_3JB@#\
MQ?\ AA?QA_T4;P[_ ."5O\*/^&%_&'_11O#O_@E;_"OTZHH _,7_ (87\8?]
M%&\._P#@E;_"C_AA?QA_T4;P[_X)6_PK].J* /F/X!?!R]^">B^(M+U/7+77
M&US6-,O5N;.T_LW[$=HT0*.Q)&",9XS@]<_3E%% !1110!F/T;_<?^0K^8G]
MNC_D[+XO_P"YX6_]0K0*_IV?HW^X_P#(5_,%^WA_R=?\5\?]2K_ZA6@5U4-G
M_B?Y(_ ?'Q7X<RM)7O4V6O1=%?\ $^/IO^/4_P#7IJ?\Q7]:G[.;'_A2GPB]
MOAQX$[_]2=H@_IFOY+)O(\KM_P >8SZ__K]?>OZV_P!GE1%\$OA23@X^''@0
M#''_ #)^B' [=_U/%5B?]UE?RM][/@OH\X?%K-<WYKQ5EHU9V3N]';H>ZU^2
M?_!4/P_^T;J7PF^%_P#PSIH?AO4M?\*^/]6^*'B/5=?\'?!SXB:EX2/@?X8_
M$'7O VMZ)H/Q_8^%]#'_  L630_"[>*?"N?&7@N37O#,@"^!1XQ"?K8.0#ZU
M_/7^WQ^R9\?_ (P_M)7_ ,1_#O[)?@C]ISPM_P (W^S%9>&O$7C;XO>$/ [>
M$=)^%'Q1^('CSXX_"[1=!\2.\G]@_M ^&M;T+PIX\+$>#6\'JQ*>+B3&O&?U
MV?HQ_P $_P ^/+C]D?X3S^/[+4M#UBYM?$S6=IJG@;P=\--4/@;_ (3;Q O@
M/66\#_#UE\,> 1XM^'2Z'XF_X13PL=O@UM?V$$BOORO@G]@7X9>/_@O^S#X0
M\!_$3P+IWPM\0VGB[XQZU;?#/2?$.C>)O#7PV\*>-_BCX^\>>!_!.A:UX=_X
MI]O#_A'PUKNC>%X@@*YT3HY8"OO:@ KS_P"(V?\ A!/'.,?\B?XHSGT_L/7?
MUKT"O/\ XC9_X03QSC'_ ")_BC.?3^P]=_6@#T"BBB@#XU_;L_Y,X_:H_P"S
M>_C)_P"JQU^OX::_N6_;L_Y,X_:H_P"S>_C)_P"JQU^OX::_=_";_F9_X%^I
M_GU]+S_D;Y7\OR84445^PG\./=^K_-A1110 4444">S]'^3/T(_X)7_\GX_
M;_NI_P#ZK'Q_7]I'_++_ #_=K^+?_@E?_P GX_ ;_NI__JL?']?VD?\ ++_/
M]VOYP\3_ /DH_E_\D?Z??1/_ .3>/_%^K-"BBBOS8_JL**** "BBB@ HHHH
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MHENM[)+\D>)X6X;ZIQ!FEK*\(-*R2::6UK+KVUW/=*_)G_@I'\9?C1\,M'^
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M (03QSC'_(G^*,Y]/[#UW]:] KS_ .(V?^$$\<XQ_P B?XHSGT_L/7?UH ]
MHHHH ^-?V[/^3./VJ/\ LWOXR?\ JL=?K^&FO[EOV[/^3./VJ/\ LWOXR?\
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MDAGW?7U !7G_ ,1L_P#"">.<8_Y$_P 49SZ?V'KOZUZ!7G_Q&S_P@GCG&/\
MD3_%&<^G]AZ[^M 'H%%%% 'QK^W9_P F<?M4?]F]_&3_ -5CK]?PTU_<M^W9
M_P F<?M4?]F]_&3_ -5CK]?PTU^[^$W_ #,_\"_4_P ^OI>?\C?*_E^3"BBB
MOV$_AQ[OU?YL**** "BBB@3V?H_R9^A'_!*__D_'X#?]U/\ _58^/Z_M(_Y9
M?Y_NU_%O_P $K_\ D_'X#?\ =3__ %6/C^O[2/\ EE_G^[7\X>)__)1_+_Y(
M_P!/OHG_ /)O'_B_5FA1117YL?U6%%%% !1110 4444 %%%% !1110 4444
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MF[0/$7BI/?:'SCWKKJ** /C7]NS_ ),X_:H_[-[^,G_JL=?K^&FO[EOV[/\
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M/_DAWP@_[)OX"_\ 4.T.OY*)O^/4_P#7IJ?\Q7]9_P"SY_R17X/?]DW\!?\
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M?_R?C\!O^ZG_ /JL?']?VD?\LO\ /]VOYP\3_P#DH_E_\D?Z??1/_P"3>/\
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M]>FI_P Q7]:_[.?_ "0[X0?]DW\!?^H=H=?R43?\>I_Z]-3_ )BOZU_V<_\
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M_2O&Q.)Q>+Q3Q>*TZ66GELM/E;\3ZO)\LP>5X58/")65[\ROY;M-Z(G"J.@
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2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $K G # 2(  A$! Q$!_\0
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M7B'X(3_#+Q/\./BB?V<O@S^T]9>'O%0\('4_%G@7XKMKN@ZPN/#<GBMO[?\
MA1XGT)/#'CP%A$R:_P"'/^$(/B^)V*_<T5I82Q& V=M_I%I]B/\ HF!?:7@8
M'N".<,3C(/IC\,OV)_V-O'/P!_;C^']E'#K.L_!_]D'_ ()8_![]B_2OB;XC
MLFTAOBO\3=<^)VA^/-<&A L^[P_X1\.>!=!!\,[EC\&CQYX:\&(0A5:_>^'_
M %(^A_E0!B?8H?\ GRM_^//[)_QZ#_D&?] ;_P"M]W_9JO\ V?!!+Y\-A;"<
M69^RDVBC:H!_XE!P< $CO@CDX %=510 W^#_ (#_ $IU%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%9T\T$,<\\^,6W4\XY&0/Q_E0!HU7\_V_3_Z
M]?'GQ'_:^\ >$!<6'A8#QMX@ML6;#2KM/^$:LC@9+ZZ,H2 !D@=1P< "OA+Q
MW^T5\6_B%]H@OO%5SHFGW7_,O>$_^);IG'_4</\ Q4_O^7;B@#]5?%7QD^&7
M@@"#Q%XPT33KE00NEVUZ=3U4Y_A.C:%O?Z\'(KYQUW]M?P/IH\CPYH?B3Q(;
M;_E[NSH_AS3 3Z$]NW;'/K7YD>3G_P!+;S[7D_\ $T_^MGZ\^U'_ $\?K^G_
M -;K[^] 'V[K7[<7C&>,0Z'X!T;2R#UU75]6U,\^^A)X3V@_[..GXTO@_P#:
MY^*GC#QOX0\+7VE>"=-L-?\ $>E65X;2TUDZD-+US)! /B0J,$Y)"\D#.<5\
M0UZ1\)?^2J?#_P#[&3PM_P"GHUU8:SG%/K)+Y.45^K./&OZI@,WDG[RIS<&^
MC4)M-:]';9ZGQM\6?^"O/[4'P\^,GQ8\#Z3X5^"6HZ=X-\>^*?!FCC5?#?C(
MZI_9FAZW_8>B?VY_PC_B3'+$GZGTQ6QX/_X+I_%NS-O;^.?@AX*URV/2Z\$^
M)-8\. =NFOCQ:?S)/ZU^4'[2W_)QO[07_9;/BC_ZFFOUX?7]&97P1PYB\FAC
M,7%7M&UEU:71;ZM]S_+#B?QT\1<IXESC!8+-VHJK))-RT49R2M=VT26W8_J$
M^'/_  7 ^ FM#R/B!X(^(WPWN./MEU:V.D>-M*L![CP](/$YXSP?!_\ C7Z-
M?!C]K_\ 9S^.(MK?X<_&+PEXEU'&/^$?.L?V;XF/4Y.A:\!XF).,YV@CVZU_
M##5?R3YMO/!_Q\6MY]ML[O\ Y!GV#5?^PYW_ #]>:\;,_"_*L4KX&3B]UI?S
M6CM?IK=>I]GPU]*KB+*G'^VO^%Q:<R6F_+S?JOD?Z(T7E'A2!T_Y>R?U''OU
M^O&#6@20!CGU/^?7]*_B0^!W_!1C]J[X'76GPZ5X_N?'WABTQ]K\$_$R]/B/
M3;_&<#0]=S_PD^@CU4Y4YY'-?O+^S+_P5L^!'QKDT[PAX_-W\&_B!J5TUE::
M3XJ!/AK7]3*XQH7C=5/AL]!A/$Y0EAQGI7YOG?!6;Y5JX\R5]HO97Z:]%W^>
MY_5/!/TA>$.->7".2R.;Y5:<DDV[*R;DEK)V[_(_9(8$GJ .>O\ >[?TY^E6
M0<C([USMEJ]O>Q">'!AN!D'N >,@G.,CCZ\^PVXB1",#KGGTZ?SKXMJ2=I)I
M^::U^:76Y^Z87%X3%QYL)-2C9>\M4[VL]VG??T?R+%%%&0.IQ2.L**** "BB
MN,UV+5+O1M1M-#U4:)J]U9?9-)UB[LQJ*V&I= W]BG .%&3DX ^B[@#LZ*^)
M?^%,_ME>7_R>QH>?7_AF+P=G.,]?^%CXQ^/OC%6/^%/?MD?]'GZ'_P"(P^#?
M_GC4 ?:5%?%O_"GOVR/^CS]#_P#$8?!O_P \:C_A3W[9'_1Y^A_^(P^#?_GC
M4 ?:5%?%O_"GOVR/^CS]#_\ $8?!O_SQJ/\ A3W[9'_1Y^A_^(P^#?\ YXU
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M_$8?!O\ \\:@#[2HKXM_X4]^V1_T>?H?_B,/@W_YXU'_  I[]LC_ *//T/\
M\1A\&_\ SQJ /M*BOBW_ (4]^V1_T>?H?_B,/@W_ .>-1_PI[]LC_H\_0_\
MQ&'P;_\ /&H ^TJ*^+?^%/?MD?\ 1Y^A_P#B,/@W_P">-1_PI[]LC_H\_0__
M !&'P;_\\:@#[2HKXM_X4]^V1_T>?H?_ (C#X-_^>-1_PI[]LC_H\_0__$8?
M!O\ \\:@#[2HKXM_X4]^V1_T>?H?_B,/@W_YXU'_  I[]LC_ *//T/\ \1A\
M&_\ SQJ /M*BOBW_ (4]^V1_T>?H?_B,/@W_ .>-1_PI[]LC_H\_0_\ Q&'P
M;_\ /&H ^TJ*^+?^%/?MD?\ 1Y^A_P#B,/@W_P">-2'X-?MBR_\ -Z&AX]OV
M8_!Y_P#0?B*?;_&@#[+\V'U_4_XU8KY)\"?#[]IO0?$^FZKX]_:6T?X@^'[?
M)U?PK9_ ?1?!!O01WUK1/$_BIT+#(P,E1GH>*^MJ "BBB@ IO\'_  '^E.KY
ML^-WQP\*?"?3 ;C&I^)]3M-3.C>'F&?MQ ?YM9.<KH'S?>YRHP,9) !V/Q!^
M)W@WX6:-_:OBB_%M.;0_V1I-F0=3U C"D:+HG.2" ,GD;<'C K\L/BG^T'X_
M^*<MS8S3W/AOP>3_ *'X=TF])%_P!_Q.]<SC7A@#@ #.6QDDUY1XP\8>*O'F
MNW&N>*KVYU+4+J\_[AEAI8_Y@NA_] #PYCKDDYKGZ "BBB@ HHHH$]GZ/\F%
M>C?"?_DJ7PZ_['KPS_Z>37G->C?"?_DJ7PZ_['KPS_Z>351_WZ/^)?\ I2/,
MS?\ Y$M7SA._G[LS^>C]I;_DY+X__P#9:_B?_P"IGK]>,5[/^TM_R<E\?_\
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M;GPI_P %;/\ @HAXP_9YU!M"T/X&7/QAM/V@_ACX+L_%EYI/P=TWQ+KWPO\
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M\+_!_P"UA^R]^RM??L6^([36C^V?X]U/]I#P9X#U\?$S0M:/B;;X>\.^%/\
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MZ!EQXHW_ /")AV($@B 0 'M%%>4R_$?P1:1_OOB!X4M1!X='CC-WXAT4'_A
M^ ?&!SKP_P"*=QR?%+$>$AZC''#^-?CI\%? G@H?$WQ/\1_!.F>"%TC5=:TK
MQ$/&&DG3M>TW0HQK>M#P8X<#Q$571@=OAKS WRN "@=0#Z.HKX'_ &;?VY_V
M<_VNKN:R^#'B/Q'JE\/A[\+?C3I]GX@\&Z]X=U1OAC\<='UO6? OC71O[?\
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M&F\"?%C6M<\$Z!X<4:!XC/B)-$4>*%+-XP.A(SIM(!^NO^&I]5\V?_BA]/\
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M63X(\2>+G\8>.77Q[XI/CCQM(59:_H+_ .&I]<_UW_"&Z=]FZ_\ (9;'Y_\
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M_P !_&WQ-T,$@GP\?B1X(UL1_P"UH! 8$X/Y;ZQ_P1J_:G\>?"2#P/!^R_\
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MS=*?VJ-5S_R(^F9_Y<_^)QK/J?\ J6_7K^M8?V;B^WX@?BQXF_X)-?&SQ_\
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M*/\ _!NC_AJ>^_Z$?3O_  H__P &Z/[-Q3_X<#[>"D'.?K[_ %YI]?(W@_\
M:$U7Q?XGTCP[-X5M]..IW9Q=6FL_VD;''..?#@7<>@)(^HYKZYKD>&^JZ2O=
MJ^]_ZU *_-7]LOXFB:ZM_A;I0_T>T_LS6?%YM+O!O@Q!T31/7YF )]\9!Q7W
M=XP\4V7@GPGX@\5ZJ6.G^&M*U*_O!QB\"#/'J"5(/?YN" ":_"O7M>OO%7B/
M6/%6JSW/]H>*-8U2]O#^/_(%X_K@G-,#'HHHH **** "BBB@ HHHH$]GZ/\
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MGCBPA\1^ ?AO\4/A?K'QCUGQ?X(\66>C?\)-H/ACX&:R/ FN^-/[<\/^&_\
MA&!X=_X1S0S_ ,4M_P )A_PFG@SP7KXQG/''B,.^C_'U\_T^0'Y$?\/C/VMA
M^S7K/BK6]#_9PT3XW_\ ">:79?"KQ#I6C#QKX'\6?V[\&M>^+&N?#'71X?\
M$I^&/A[Q%X3!T3POX)_X2WQA_P )GXS.OG'@@^.\>#*]W\.?\%/?VHO&'B;P
M_P",;&Q_9PTWX,:7XN_X)T^&O'G@C^Q]:U+QS?ZI^W-\&M!\=:Z-#\;_ /"2
M?\4_X=^%'B+6\^"/^$L_Y'/D=N/T!E_;\_X)M6?PYTGQ_-\</@7;?#?7?&'B
M?_A'+S_A#P?^*\\#'0->\<_\2,>&_P#A)_\ A(?"?AW7-#\4#Q2/"'_"9_\
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M_P YSG\O3VZ?G^I'_"G?A9_T(GAW_P %"_\ Q%'_  IWX6?]")X=_P#!0O\
M\11_:GE+\ /RW_[;_P"C8S]DP,?X8[^M'^N_[>?^/O\ Z?\ \L_TZ=^:_4G_
M (4]\*_^A"\.?^"@?_$T?\*>^%?_ $(7AS_P4#_XFL/[27;_ -)_S _+7R?.
ME_U_^1Z>W7'ZFEK]1_\ A3?PM_Z$7PY_X*5IO_"F_A7_ -")X<_\$X_PK?\
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M^T\+_++[U_F!_)C\#/\ @D78_!GQ;;^*KCX[_P#"7:A:>)?VG=;O+2T^&_\
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M]"%X<_\ !0/_ (FC^VGV8'Y;\>MM_P" 9_QI*_4G_A3WPK_Z$+PY_P""@?\
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M,NB>)\C#9T-=R@<C\V+'_@D]X;C_ .%7V.N?&/Q=J/A_PQ^QIXJ_9P^)"FS
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M'T/\J )Z*** "BBB@ K\_P#Q5^UA%\/OVA_ 7P&\2_"3X@VV@_$3Q-IWP_\
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MU]XP\*^&_&GA?Q-X/\5VXN/#_C+P[XF\,ZU9_;#I_P!O\,Z]I']A:X 0,\:
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M>-=+;P_H>L^']"T'0/BD?B1_PM/P[X;\,^'-=U[P\OA;PMXP\*^# /$/BO\
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M75K1;]].U#^RM;R-96+6-#QXACW*<,8V7.1N;H4^:O@Q^QW\ _@!X2T[X?\
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M/04UC7O&_P 0=?\ &'BS7_$#:!H.@>'%'B3Q>LO_  B<4:JSQHZ$ ^D****
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M7+3PM9:)X4\1:SJ_B?3?"6G:%HO]BYTC6/$"^*O$NN_\).Q0^,_%/BERY #
MK@D\OX]_9K^"_P 1_BAX8^-/C/P$-;\?>"K.PL]*N5UKQA_9=]INA:UK?B#P
M^-?\$Z!XA7POX^;PIKVN:WXH\$+XN\)^+E\%^,G'CCP(/"7CO$B 'PM^W-^W
MO>_ OX]_LP_ 7P/XO^''AS6?&'QU^ ]E\?KCX@7PTS4M.^#7Q3\:+X%T31/
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MYXP0,8"C S0!U=%5/W'F^3W_ ./OMC[V,_GSC'2K= !1110 4444 %%%<?\
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ME:C\6KW]H+6O!OPVC\;ZWI:? 77_ (KZ+\&M:SX8'PSPOB/0]&\5^+\^#?\
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M/PYJ7@_PCJ]K9#3SH/AO61&=:T?15 &W02 A"JO\((ZC/LU% !1110 4444
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M]5TW1=!T+2=2UG5]5U2Z_L_3M.TO13_Q.G?621L"_>);&0A(Y.T '>T5\?\
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MX?\ !&O_ -B:'X@\.^$AX 'BSXBC6?# \4^+1X/'C+QEH/B7QMX!/C!<^,B
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M:PVZ?:/@<3POQ/A?]\R:HM6M*<]'?5:0)Z*@\ZW]_P#P%_\ KUU_AOP'X_\
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MOB-^U+\'OAA\8/'_ (?\'>#O$Z>%/ 6NGQT-=;1M'^(7AGQAX:\/OXJ_L/1
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M@[K:Z]\ _@=KO]N^&3X \3?%%=#;XJQ>*?%R")O!WA[_ (0;P1X*\7>.<S1
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M%U,4A#'PK_A#_P!M_P#Z+3\ /_#)^,O_ )Y-'_"'_MO_ /1:?@!_X9/QE_\
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M_P#HM/P _P##)^,O_GDT?\(?^V__ -%I^ '_ (9/QE_\\F@#['HKXX_X0_\
M;?\ ^BT_ #_PR?C+_P">31_PA_[;_P#T6GX ?^&3\9?_ #R: /L>O,1X*\*S
M>(E\8WG@SPY-XRTVR;2;+Q5=Z)HS>)-/TO@MH>B:\GAW_A(O[ +-T\W#-N9=
MX5F'@W_"'_MO_P#1:?@!_P"&3\9?_/)H_P"$/_;?_P"BT_ #_P ,GXR_^>30
M![?;?#SP5%K.D^,X_!'A.W\1>%]'_L/PSKY\,Z0GB70?"A"O_86B:S_8!\0:
M'H>,AO#D>U"<K@!"M>L5\<?\(?\ MO\ _1:?@!_X9/QE_P#/)H_X0_\ ;?\
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M^,O_ )Y- 'V/17QQ_P (?^V__P!%I^ '_AD_&7_SR:C_ .$/_;A_Z+?\ O\
MPRGC'_YY- 'V717RUX)\._M06OB/2)OB)\3?@[K7A"RLV35]*\%?#7QKIGB+
M4-4*9R-:\0?$KQ6NAH!@?+G!R 5ZU]2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Y E@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#PSP%\9OA7\3-=\;^%?AS\1O#?C;7_ (7>
M)#X*\>:3I&K'4M3\)>*-#(_MO1=;QPOB!0<'*]!N)4+S[G7X8?\ !*3_ ).F
M_P""J'_9Z_Q0_P#<#7[GT %%%% !1110 44$@=2!]:* "BBB@ HHHH ****
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M^' ,Z'K992X& $.,G(!^M=%?./PP^+/@#XJ>"?A)\0?"6N6=MX?^-O@7PO\
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M&^\3@M_8Q$8YW*&*[E   /1J*^9/C]\=OA1^SC\*OB!\8/BWXIMO#?@WX=>
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M3P5\2_%OA,^"/@^OB'PWXU?QIX3C\7>$/&%?%VF_\$Z/VN[W]F+]AKPI\?\
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M1^S)\0?%?PW/@?PQ_P +\\5CPAXQ\&GP"/!"^-BP&W]!_P!HCX#_ !P\2?\
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MT']ICP"_CEGDVNFN_$!O#>AE3XK\6D^-?C+_ ,(^_C@CQAX%V>-/&?L/Q?\
M$7[1O_!/?]OO_@H+\3[[_@GO\?\ ]O3X8?\ !0NQ^#GB3X6>(OV</"&C>-OL
M'BGX4?#'0/A.?V?OVC%UX#Q)X ^'Q*CQ/_PE07QAX+'@SQ!XH \#^, ?&@\'
M?U)44 ?R"?ME_L]_$#Q9\4/A?XY_:@_X)I^+?BQ\'O$__!*@?LL_"#]ES]GK
MX:Z)^T?\,OV,?VV->UH:_K>C:%H9/A7PO\(MWAH>!_"?@O\ :C\)_P#"'>#O
M!?\ P@)\$IXW3,;5Y)\</^";OQ;^).E_'.Z_:H_9S\1_M,?&[X3?\&W7PT^"
MW@/QKJ_@;5_C4;[]MS0?^%]?V[HOPM\:[O%I\??M"^%/$6C:'L\5^%@/C&W]
MO$1L?^%KN?&']JU% '\,_P"VG^S#\;_%7AO]J.]_:2_8:_:7_;&^*_Q__P""
M7_[)W@S]A+QOX2^"6K_%W4_V7?C+\)O@UKR?M)>"M>\:L3XD^ /Q"\3_ !'U
MK1?B=AE4_&9F\4>!/ S>,_'>/!7C$_:,_8@^._B_0?\ @K+JFN?L6>/OBD-5
M\%?\$$O&7PKTF^^!#^-M3\=M^SEX,.@_M'#X(:)_PCP_M_XB>$/AWKGCCX9^
M-/"OA/\ XK(>#=?\3>!FROBP(?[F** /XM_BS^RM\:O$@_;OUOX8_LK_ !:'
M[,.J_MO?\$K/CGXD_9GM/@_K'PWU/]H?]A+X&?LS?",_%C]G[X6_"SQ ?"(U
M\^%/[$T/PN?@*-H_X3/P%_PH\#_A/<^##5U[]@_QQ\6]!^','A3]B?XD>"/V
M$?B?_P %POV7OC/\+OV./B#\'I-+7X:_LQ^!O@QKO@;XZ?$SQK^SJ0O_  H/
MX,_%7XS?VWXF;X8^*T\'#_A#=>;_ (3KP1_Q5IW?VI44 ?PS^-_V"OB)I?P#
M^.?@[7?@5^U#\-OA]\'/^"T/[:WC_P#9C\$_#+]AWX9_MB?L]V/P)\=Z-H'A
M_P ":SKG[#_Q \2>$!\0?@T[Z[XX'P2\4?"?P?XP_P"%-'_A)_' _P"$._Y'
M.OZ.O^"2^G_&C1O^">_[-7AOX\? ?1?V;OB?:^$=7L1\'?#Y\7Z7I7@7PF/&
M6NMX(TDZ!XA\3>+_ !1\/M>_X5X=#\1M\+CXMW^"F/\ P@X3P:GA/_A#_!_Z
MO44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M6'>WL&FVEQ>7\\%K!:VGVN[NKIL:=9!<9.200.IX;)&"#EL$ W**\PTSQ7X5
MUG6?$'AO2]<T;4=>\+76F_\ "1:/9:MINHZKH']LYUG1O[?T?.=#W;@8LHI<
M#S4,G#)Z?0!^&'_!*3_DZ;_@JA_V>O\ %#_W U^Y]?AA_P $I/\ DZ;_ (*H
M?]GK_%#_ -P-?N?0 4'@$^E%!X!H Y6[O8-.M;B^O;BVM[:U)N[R[NN0-,7.
M=V,X]/0'@G)K^6_]N3X_^'?B-H?QN_:F^)GQ-USX7_"_]G36-6\&?LR:3X>\
M2?V;XE\6?&/00<?$[0SP/$'A[Q9X=UP!0?X03SBOW>_;*\*_&KQA\ _&'@_X
M V_AN?QQXRN],T6__P"$B)T_33X%UT_V'XY(<\_V\/#K2;00#\PP%'%?Q@?\
M%EOA7\13\7_V"?V0[;P[HNBVVA-X8T?P?X4TK6-8U+[?_8(UY?[:UL #@!1S
MR>O)K]U\".%,%Q!Q)".-S2,%!NI.[I.:HT%&K5Y83YKQJ**HRG&-Z492D[.2
M8\(T\9'"8K:3CRZZ-MVCKIL];=78P-3/QV_X*S?"KP]\*]$\ Z)H@MM8TKQ_
M^U]\8M5U?P=IWB;Q9JFAC_BA!H07Q&3SX<'4\#'UKEOC]^Q1\+=7_8=U#XF?
ML]Z'<>$OVA?V&_'8UKQ=X?\ #N!JFN^!=<UO_B1^,B/#_)!70]RGL%;=QC/H
M/BOX/_!?X9?M\?#CPWXH_9U_X1OP#:Z+IFB_%+X::5XC\8Z=J7BWQ2=%T#^P
M3HF@CQ*@\1 $\@8R!P03FOW8O?@GX&_91^ WBCP1\'O@]X2M?VA_VT+WQ/HW
M@_2KJ\UG41_P@F@K_P 2+_A./4?"CPWKO8D'H3GI^ZS\=?[+XARKACA&:614
M>*Z3JTH2@HJE"]+%0KSYITI4)TI591BXTZ=-TJ3IR5HR/T_CWPX7#W#F49QB
MXV>?0O%M)7<HWAR:*7,FHM65FGNW=&;_ ,$3_P!L7]FGXVV-CI7PS^&FL^&_
M&_C+P)I7BCXH_$%1I \-:[\4%QH6N>#&(89\1;NJ\ C@GDU_2&<&+!/0@^G;
MC]1C%?P*_P#!/P^,/^"?'[0WQO\ V-?'&AZGXC'P)\1_\-4_"JUTFSQJGQ*T
MK1,:"-%T,'_D8">..YXZ5_</\)OBIX5^,/P^\/\ C_PAJMMJ6CZ]:+>9M+_2
M-0^PZIDC6M%^4C!\*L0I ^\>"2 %K\4^DAP9A<JXMAQ+DSG4X0XB3K1JRJ.L
MO:55&M93<5*$6ZK=.*7(H14(N\6C\?R=<N%>$Q5DXMI)*SLG)+SOHKON[L][
M'0?04M(. !Z 4M?@"V5MNGIT/0"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OS;_X*2Z;X/\ &'[%7QXT3QS\0- ^''@"Y\-I>>)O%OBO1=:\2>'!
MI6@^,M!U_P#L/7M$\/D>)_$'AWQ6^AM\,O&OAGPF!XR*^(BHC!^=OTDK\^_^
M"C$'@;4/V-/CE8_$3QAXO\$>#SX;TK[9X@^'OAW2/$OQ)&IKXR\/+H6B^ ]!
M\0$KKGQ#\6>(_P"P_"W@E5";O&NO>&GP222 ?G!_P2]T'X6R?M#?$KXD>&_B
MKKOQ!^,/BGX*?;OC7JEW^RM^TK\ CX\^)_CK]H+QY\6?'/C+6M<^,/PW\'^%
M_$'A[PK_ ,)OX(^&'P1\,>%V_P"$S7P;H7B<E@@ ']$=?B5^P-\2?CO<?%[Q
M_P##K]HOQ[^U5;>-]+^&_ACQIX;^#G[3/PX_9F\,&_\ #6OZW_8(^)G@;QQ^
MS$WBQ?$!\+R:&/"OC?PMXL8'P9+XA7/!8C]M: /P._X).ZE8ZE^TW_P5/OM*
MO]-U*W'[;'Q0L_M>DWG]H_\ ,9T'D^Q!/X_C7[XU_/\ ?\$>O"'AOP%^T/\
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MG(!@A_9Q_:/.G?\ "(7WQ@\$W7AE3_8PU9O!^M'QS?>&!@YUK6V\2[5\1?\
M".\EE4'<<DY.3_+&-R=9M0G-75I2G'ET:O4J36EU9NZ=_P#@(_H?(_%Y<$\6
M\6IQISYJLHR53524.6FDKQES<L(2A&-M&W:2U/Y<O^%>?M"WG[0?P?\ '&J_
M'#Q\-&_:"\-CX8_$B[\5^$/[2\#>$O$^N?\ 0D:%X@ \,#'3_A*!VQTS@<Y\
M)?V?/C!^R/\ \%/OB=^PM;_&YO"?PH_;'\!&^'C>[\!Z)J6G:[JFA>"^1H>A
MAMOA_P 1#^W,MXGW8) /+*,?T;_\%(O@;X=\+?LG6?@_P1H6I:WJ^E_V18^
MKNTNS_:5AXH7(T/6MW?!R2#CAACCD_SY_M?ZGXJ^,'P-_9H_;ZOO&)M?B?\
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M2.',)D7$3>"7NSDVET:DV].GVK:=3U < #T I:!R ?6BOQD_/PHHHH ****
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M)(P&P-#_ (-:SX6UC]B;Q_XPL?#EOIOB>Z^._CO1]9U8<:EKQT/1? 6O#/\
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MW(%?"/\ P5N_91'[8?[#WQN^%=A!;7'BZZ\(:GJ_@Z[NSQ8>*-$QKN@G'J"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#^T)\'M)%M^T/^S]>Z7XU\-:MI-G_P 334-+T+603HP/UT3&#R"#V(Q]+?\
M!%#_ (*$0_MX?LF^&-5\4WIMOB]X# \&?$C2KJ[!U._U703M'C+'7;XKSO[8
MYQZ5^H<?8>?&W#N5<>8!U/:9.HX;BF"CS^SJ>\J=5PC>48-VYYO1ITV^72]<
M18EYN_[8T?>W6]K_ #WLO71G[> Y /J,T4@Z>GMZ>U+D>HK\2NK7NK=[V^^]
MK?.Q\R%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<4\*L5)+=O[FF[W5]KZ'I=%%%?.W6UUZ75_SN2%%%%, HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHH) ZD#ZT %%&0>AS10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?"7[>G_"TS^RC\7YO@OX5'C?XE6ECX6O_  WX?7P%HWQ8U0?V+XTT%M>U
MO0_ GB#/AOQY\0?"OAY-<\4>"/"SM\WC;P_X9!SM&?NVOR2_X*D_#+X):_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?IMW\2=<\5?#C]C/X%?";Q+9:=K7A[X9?L]?!SP;\%/CEX@']KJ="^)?QO\
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M>#O!R#0V)\$^,SXL5/!WW'_P3"^.G[6WQG^)O_!2VP_:!\5>"?%?A#X)?\%
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M?QCI>I>(-4P2-8UG^P?$8!.%/&< #YL8K] ?E7/)/M^A]!]?H/2J?D^_^?\
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MO6M:'C9>/^$T77RK[A)M'WW10!\":'^P'^Q/X/\ "6H?#SP=^R)^SQH/P_\
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M/X#'-?S'Z;_P=/\ _!/02V]OXCL/C%X<N!_Q]B\^&VL\?SX/;I]"*^AO _\
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M-+_Y_K7_ ,#!_C7YC?\ #F'_ ()[_P#1*?&__A^?CW_\\BC_ (<P_P#!/?\
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M (()?\$Q?B%_KO@]X;\)_P"A_8\^"+O1O#F?R( QST]O2OHG_AS'_P $\_\
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M@?K-SK5U9?8KS5=5^-?QFU+4;[3,'(W'XD9*YZ,4'';.!74_\.:/^"?GF_\
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MKGQ.<^"RL\)PQQ3&_>LVE=6TO))I='NTD[W=UZ'U=[V7?9>O8^=]'_X./O\
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MF[\<_$WX0^,?!O@G0/%?[.>D>(?$/QT^&>N:W(A"_$3P=X<T36O%/C(;G\%
M93_A-/\ A.HU\&$L!^LM%?!7[.W[:/PD_:6O[[2O!\'Q'\)>(/\ A$_#'Q T
M;P]\3OASKGPYU'Q;\&O'3Z^? GQI\#CQ" OB#X>^+3H6M;=V/&<;:%M\<^"O
M!_ ;[UH **** "BBBE9+9)>B2_) %)@>@_*EHI@&!Z?Y_P @?E1@>@_S_P#J
M'Y444 %%%% !1112LNR^Y?Y &!Z?Y_R!^5&!Z#_/_P"H?E113 **** "BBB@
M HHHH **** "BBBE9=E]R_R , =!1@'J,T44[+LON7^0!1110 4444 %%%%
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MF7_A-MP!?]PZ* /PY^'_ /P2LN?AKXFTCQ.OQ>L=4N="_:F^#'[3=UX>\$?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'K 9@# 2(  A$! Q$!_\0
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MG?M3_&KQ%\/_ !AX>^,'A+X\^(OB7X\TK0](\-Q#1O@;K?PB\/\ B?POX?\
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M1M>L/ VB>%_'&N:]KWPLSI'B/Q)XM\2KXAD^'A\/^*/&*MXJ\R+Q;KLD<?\
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M/_7P;0#( ^SD<_:AC/ZD8]>3Q_*SC_/VS_[&@#0HHHH **** "BBB@ HHHH
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M:Z\&^,/VS;?]E1?V:?$?@G]N;Q-I_C7QEJ'QY\2?$GP]XB^!?CK_ (4MX ^
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M?[*G_B/?P<_^9J@#ZWHKY(_X87_8?_Z,S_94_P#$>_@Y_P#,U1_PPO\ L/\
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M &5/_$>_@Y_\S5'_  PO^P__ -&9_LJ?^(]_!S_YFJ /K>BODC_AA?\ 8?\
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M\-]9^&WARQTO"H-*_L/Q!\2?BUXC_M]1DMCQ:8RQ!7#+M;VZ@ HHHH ****
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M%?761ZC\_P#/J/SH 6BC(/0YI,@]"#^- "T444 %%%% !1110 4444 %%%%
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MQ\5_^L*_MKU]=U\B?M%_\EE_8(_[.Q\5_P#K"O[:] 'UW1110 4444 %%%%
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M\.^/_BW\4/'VC6OP4\3ZU9Z3XL\>>,?&NF6&J?\ ":^ =!T/6L^(/$OBT?\
M"1?\(YEFZG&OGW-<F>>'6:91@7CL6DDM=&KV6KOJDSZS@KZ2N2\:\1Y3DN"B
ME+.G:+TTMIM;3RT/ZD:***_.#^H0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KY&^ ?\ R5_]N?\ [.I\*?\ K#7[(M?7-?(WP#_Y*_\
MMS_]G4^%/_6&OV1: /KFBBB@ HHHH **** "BBB@ HHHH **** *_P"XF]_T
MS_G\.OO5:&\@GB\^#'_Z_4_Y'OT-?SD_M6_LK?$WQA^VQ^T[^U/\7/\ @FU^
MR9^VK\"O!_[-'P"\+_"^^_:,^(W@M/'#^&/A2_QZ^*OQVTK]G7X5^(?V</C!
MX9?X@>*M=^*&C>&I(_BMXR_9R\*>,O%GA_PN$\;'P5XL\7#P;Q6D^ _V?O\
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M4-.O?$2?LD?M<NHUP>(M<\+OH>@OH0UKQ"?$WA+_ (2[QFOBO0_#W@T^#O\
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MYFD5IYWVV_KJ>5_Q.)@K764NUK[WTM?KKMV^9_H8R:IIPP5FA..H!'\N3_\
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M?3)/N-]*:W7JOS1,_@G_ ()_^DR/XJ_^"IG_ "?A\</I\+O_ %67@*OSVK]
M?^"J'_)^'QX^GPP_]5EX!K\_J_K/A"_^K>4ZO97U?^9_C=XN+_C8_%SMUGT_
MO2\@HHHKZ2Q^5=- KZ%_94X_:A_9K/I^T#\'?_5F:!7SU7T+^RIS^U#^S6/7
M]H'X._\ JS- KQ.)/^2=S>^Z7W>Z]C[/P]>)7'O"-W9>UA:VUO:0_IG]Y-E_
MJ?\ @*_TJU_RR_S_ ':JV7^I_P" K_,5:_Y9?Y_NU_(DOBE_BE_Z5(_VJP>F
M7TWL_9PUZWY(%BBBBI.L**** "OYZO"O[6O_  4/^,_Q \!:W\,;C]DWP1X)
M_:8^"?[1OQ!_97\ >+/"'QC\3^*O#Y^!GC?X"Z+H&M_M%>.=#^)'A1<?%/P]
MX[UUO&/A/PKX.\'I\$O&>O\ A?P)XZ\;>,O'/A+:?Z%:_B]\*C_@F?\ %234
MO&W[2G[)7_!17X6_&[7_ !/X]L_C1\/_ -GKX#_\%0OAQ^S5XZ\4:]XQC7Q[
MXST/P-\'_$'BWPU_PC?Q7.@_\)5XS$C>%/&7C3P<SGQWX&'CHE* /ZCOV4?C
MS9?M+?LW_ C]H.Q\.7'ARP^-WPJ\"?%"S\/W6M:+J/\ 8 \=Z/\ V[K.B-K>
M@LWAO7SX6^90RJ0VQR2K$*/K2OF[X-ZMX/UOX2^ /$?P\\.ZAX4^']UX(\+G
MPAX)U3P/KGPRU3PCX5.D:$_AS0M8\#^(?#_A3Q-X";PKH BA/A7Q7X3B\7>$
M@S !4 @;Z1H **** "OD3]HO_DLO[!'_ &=CXK_]85_;7KZ[KY$_:+_Y++^P
M1_V=CXK_ /6%?VUZ /KNBBB@ HHHH *0]#CT-+10!4 )4<D')R>_4\5DZE 9
MK;R,GFSS[#C' ]??CG'6M_Y5]L_4]/S]:@./*Y[\=/\ 9Z?_ %JFA7^K-2MK
M&7,M-G]U]&D<F,PBQN#G@Y/2I%P;VNI*4?OM)]3^*[_AUE^WG#U^ 1./3XC?
M!PY]O^2C^OX=,T#_ ();?MZ-T^ -T<_]5'^#7_SR/:O[3?+0#_4J?J?7UY'3
MT':H\#OBW]\ _P"/7IWZ5^D8?Q0XCPN%482C9)*S5Y;)+:2TLET/YQQ?T6>!
M,=C9X[&:RE*4G:V\G)OUUDS^([6?^";G[9.CZAX8TG5?@O\ V;J/C'6-1\,^
M&[.Z^)'P<SKNJ:+H_B'QTNBZ&/\ A8Y(!\/:%KOB@D_=_P"$?8L0!QT/_#K7
M]NW_ *(1<_\ AR/@Y_\ /*K^IW]H&W!^+W[#(Q_Q[?M5>+ ??/[#'[7I//H2
M2<=02??/UQY,'_//_P >_P#K53\4.(NK7S?EYR/-E]$[@5W7O6=]+7WOTZ;]
MC^*D?\$LOV[",CX!-C_LHWP<'Z'XBYK])O\ @E[^Q=^TS^SY^T-XG^('QA^&
M?_"%^%;GX0^*/#5IJH\7^#O$IU'Q1K7C/P'KRJFB^'_$_BOQ*K#0-!UKYF++
M@;"!O##^BGRT$6=B_D/[N:18U^:(*%]1CK[X Z<?_7[UYN9\>YOF^$>#QGPO
M1?-VUUL[Z6T1]+PI]'/A#A/.<ISG!.7/DK;BNK=V_5VNFGZ&H,8&.F./I11T
MHKXD_H8**** "BBB@ HHHH **** "BBB@ HHHH **** "F-_JS_N'_T&GTR3
M[C?2A;DR^&7^&7_I,C^.[_@I+\+O%/C#]M;XR:YI>I_#"TL;RZ\!V=FOBSXU
M?!SP5J:ZJOPP\ DAM$\>_$CPIXD7'0 >$F4GA&;K7Q%_PS[X_P"O]O? K_Q)
MS]FK^7_"R,U])?\ !5 Y_;O^.V.EJ/A>?]+_ .R9> LXZYS[?CUKX&K^H.$\
M-F[X=RKZG**BUHFE=7W=W/LV]D?Y)>+>8Y1A>/.+/KL;VG*]M?MRNDDK]7^9
M[>W[/_CU>OB/X&?\!_::_9K;_P!!^(YJO_PS[XWB'_(Q_ OC'_'Y^TU^S6.O
M7&?B.#Q[9]:\8_3[+_9?OT_G^'KWKZ(_:5^ -Q^SKXL\'^#H/%7_  EO_"9_
M#CP'\0+.[_L?_A&]4L/[<_M__B3?\C)W_L/< >?7'(KTGB<9A<7]2>;1YWM=
M1WTTM>V[MN?$8;+,+B\$\XP>4MY0D[NS;;M_A;W_ #,?_AGOX@XS_;GP3_\
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M9Y^&_P"U]X6\1_&.Q^+]WX_O/@SX*_:6_9;\=?\ "9^.AH/@WP-X(\?^'?\
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MT'^?_P!0_*BJ^?\ IO\ I_\ 7HS_ --_T_\ KT ?)G[1?_)9?V"/^SL?%?\
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M_D_#X_?3X7_^JR\!5^?U?H3_ ,%4/^3\/C?_ -??PN_]5EX"K\]J_K/A%_\
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M;<9_X1CP;X,+#6MNW&6;])?(]_U_^M7R9^T7_P EE_8(_P"SL?%?_K"O[:]
M'TG]E\1?]!73?_!-K/\ \TM'V7Q%_P!!73?_  3:S_\ -+7444 <O]E\1?\
M05TW_P $VL__ #2T?9?$7_05TW_P3:S_ /-+7444 <O]E\1?]!73?_!-K/\
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M\\;MX,_9=\$?LN?LWWW[/?[._@3P#XAUO0M'^&7QQU[QVG_"S!XC\(QZ$O\
MPNOQ+X7\9_"!?"H:6'P+X$\%1J9!^B'[>_[8WA[]B_0/@%\3/&WB33/!'PQ\
M9?M->%?AG\7?$5YHVM^)ET_POKWPP^+NO*=&T/P]X=\5^)W\0CQ/H/@C>B^%
M!E  64/FOR1^)/QX_P"#:CXM?%/7_BY\3-$^ ?C;QMXPU<ZWXQU7Q#^RQ\>M
M27X@:KH8_MX:SXXT-OAK_P (WX_*?VV"#XK\(^+5^< [\$* ?N=^R;\6M?\
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MW^)7KY-^ 8'_  MW]NWC_FZCPE_ZPU^R+7UU7R-\ _\ DK_[<_\ V=3X4_\
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M1YT&?)SVQC''7U^O- %FOD3]HO\ Y++^P1_V=CXK_P#6%?VUZ^NZ^1/VB_\
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M ,T% '5T5RG_  B]G_S]Z[_X5_B__P":"C_A%[/_ )^]=_\ "O\ %_\ \T%
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M'X/_ +[6SGX6?#/KXDUOMX,T''3Q#WXY]_E,G!8 ^A**Y3_A%[/_ )^]=_\
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M^$8_X2KQ7X0+9T#Q,0?!I\)>,C7]*$.EV\/*PVX^S6OV6TQ:'_0N  ">?EP
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M/B+Q9X:US1/%$:^+.6\&Z]@$LXQ_3%^T;\:O$GP$^'L7C7PI\ ?C]^T;J/\
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M[)440@A_:5^!?^C<'_B\7@D\#L?^*FY';@D>WK_"[_J9?W'VFV_Z]+S^S?\
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M_P \=9_\)O7/_E!1_:]I_P \=9_\)O7/_E!0!TM%<U_:]I_SQUG_ ,)O7/\
MY04?VO:?\\=9_P#";US_ .4% '2T5S7]KVG_ #QUG_PF]<_^4%']KVG_ #QU
MG_PF]<_^4% '2T5S7]KVG_/'6?\ PF]<_P#E!1_:]I_SQUG_ ,)O7/\ Y04
M]GZ/\C<_Y9CZ'_T%:S[O_57/T'\Q66=<LS_RRUKO_P RWKG]/#X_STQ5>\UN
MT\F?]SK?0_\ ,MZYSD=?^0 ?KDECW#9^8=%!^\E_>CV_FB<>-_Y%];_KU5U_
M[<JG\)?[5'_)TO[3/_9P?QD_]6=K]>$5[S^U1_R=#^TO_P!G!_&/_P!6=X@S
M^E>#5_6G#;PW]C93=N[BKZZ/17W>Q_BMQRW_ *Y<7J[NZE3J]?WM3[^G</\
MEMC_ );_ //G^..G7I_C1_RUQ_SZC_3+3&/L''!_I7V-^R;^R/\ $7]H+Q9X
M'\16/PZ/C7X0:9\8=,\,?$B\_P"$O\':<NG>%]!UCP'X@UW1G(\1^$?$VNI_
MPC>M'YO"OA!5) 4,&90=G]J']B[XQ?!KQ'\4?&/_  KFZ\-? _2OB1XH_P"$
M#N[7QAX-U,Z?X7U[QF-"\##0\>)?%_B8_P#"69T+)\5^#R/!9R,Y!%/^W,J^
MO/)];W^+I>_P_?\ U<R_U)S;_5M<2V7+;RU5NW:Q\05^A'_!*_\ Y/Q^ W_=
M3_\ U6/C^OSWK] /^"6TW_&>'[/_ $Z?%#'V2SP/^28^/@<XSQTR<''?TKEX
MN?\ QC>:J_V=%?RZ79]-X-O_ (V-PGK]I=?[\?,_M<B_U:?[HJ.N<76+/ _<
MZQT_Z%K6_P#YGF_F?K3SK%ID_N=9_P#"<US_ .40_D*_DU[OU?YL_P!D<,[0
MC_AC_P"DP.G'0?04M<T-7M,#]SK/3_H6]<_^4!_F?K1_:]I_SQUG_P )O7/_
M )04BSI:*YK^U[3_ )XZS_X3>N?_ "@H_M>T_P">.L_^$WKG_P H* .EHKFO
M[7M/^>.L_P#A-ZY_\H*/[7M/^>.L_P#A-ZY_\H* .EHKFO[7M/\ GCK/_A-Z
MY_\ *"C^U[3_ )XZS_X3>N?_ "@H Z6BN:_M>T_YXZS_ .$WKG_R@H_M>T_Y
MXZS_ .$WKG_R@H Z6BN:_M>T_P">.L_^$WKG_P H*=::C#J8/D"Z!M^#]IL]
M7TW!Z9RX /'J#[#% '1T444 %%%% 'P_^U!^R=\*/VP_AYI_PL^-NA>(]4\*
M:3XOL?B#X<U3P1X^\9_#OQWX&\>Z,OB-M!\::#KG@7Q%X3\1Z#K_ (7&O@Q/
MN\5CQ5)K83QQX,91M3\Y?%7['?\ P4C^!GQ@^&_QV^#'[1?AW]O+1O@WX/\
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M'W3WQC'7GWKYN'PR\$D9/[2_P-!]#X;_ &DL_I^SF1^M?9W_  3@\">#]/\
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MJL44 5_WO^=U%6** "BBB@ HHHH **** "BBB@ HHHH *^1/VB_^2R_L$?\
M9V/BO_UA7]M>OKNOD3]HO_DLO[!'_9V/BO\ ]85_;7H ^NZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I#P"?0&EI#T/T-#V?H_R8%8?ZL_YZ!J
MH3?ZJ?Z?U-7U_P!4?\_WJH3?ZJ?Z?U-/#?$N]UZ[HY,9_N%3_!/_ -)F?P@_
MM6Y_X:@_:9_[.#^,>/3/_"S=?KYVKZ(_:O\ ^3I/VE_^SA/C+_ZLW7Z^=Z_K
M'A+#)Y/E6+:5K+1I;66]_P#(_P 7?$+%R?&'%V#3E?\ UHG?66D>:?G=1O\
M+8****^E?U+7:^O;?7]3X9N6JO*VO67=^85^@'_!*[/_  W?\#_][XG_ %_Y
M)EX]_P#K5^?]?H!_P2P_Y/Q^ W_=3_\ U6/C^ODN)<,EPYFSLK6=M%M9[?\
M 9^J^$F*D_$;A+!OFMSPU;E:ZE'HVUKV5S^UV/[B_2HJEC^XOTJ*?M^']:_E
M9[OU?YL_V/A\$/\ !#_TF)8HHHI%!1110 4444 %%%% !1110 4444 %%%%
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M67]@C_L['Q7_ .L*_MKT ?27_$[_ .@3HG_@Y/\ \S='_$[_ .@3HG_@Y/\
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M* .6_P")W_T"=$_\')_^9NC_ (G?_0)T3_P<G_YFZZFB@#EO^)W_ - G1/\
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M^VO0!]=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]G8^*_\ UA7]M>OK.ODS]HO_ )++^P1_V=CXK_\ 6%?VUZ /KNBBB@ HHHH
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M]?\  /TTHKY&_P"&,OA'_P!#G^U7_P")W_MP_P#T2-'_  QE\(_^AS_:K_\
M$[_VX?\ Z)&D>D?7-%?(W_#&7PC_ .AS_:K_ /$[_P!N'_Z)&C_AC+X1_P#0
MY_M5_P#B=_[</_T2- 'US17R-_PQE\(_^AS_ &J__$[_ -N'_P"B1H_X8R^$
M?_0Y_M5_^)W_ +</_P!$C0!]<T5\C?\ #&7PC_Z'/]JO_P 3O_;A_P#HD:/^
M&,OA'_T.?[5?_B=_[</_ -$C0!]<T5\C?\,9?"/_ *'/]JO_ ,3O_;A_^B1H
M_P"&,OA'_P!#G^U7_P")W_MP_P#T2-#V?H_R8'U@)C@9Z\\_GZGWJOY\,HXF
MMS^(S^I4?SSSTYKY4;]CGX1Y_P"1P_:LZ?\ 1^'[<)_+_C(QL_X]J\'^&?[.
M'@#Q)X\_:'T'6_&7[49L/ ?Q?\+^#?#AMOVY/VX!_P 2K6O@#\(O'3]?VC<8
M_P"$C\<:YC &>,$9#*4-K^OZ=_(YO;I8E)/3:W1=/S\C]-!T&?2BOD;_ (8R
M^$?_ $.?[5?_ (G?^W#_ /1(T?\ #&7PC_Z'/]JO_P 3O_;A_P#HD:#I/KFJ
M_FP^OZG_ !KY._X8R^$?_0Y_M5_^)W_MP_\ T2-=-\.?@WX=^%,^I3^$]4^+
M>I-JOV"2[7XF_&KXT?&D631?VS$!H[_%_P"(?B]?#H;)4+X6'A.61,2^- XC
MP@!])T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\K?$S]
MI3X2?!OQ1X0\$>,-1\<7OBSQ]HWB36/!_A+X>?!SXQ?%GQ+J6E>!1H1\0,VB
M?"'X<>+O$&AIX7_X2'069O$L49)UXJ6; 1/JFOR3_:5TKXC:I_P4!_9!MOAI
MXT\ >#/&)_9^_:C-EK/Q"\ ZK\2/#6G::->^ AUD#0M ^(_PE\1E_$N%16;Q
M><M&&;+9H ^T_A!\:/AQ\9=$O_%'@'5M2UO3O"WB'4_!7B6RUCPUXR\%>*_"
M/BC0A_Q//!OCCP5\0/#OA#Q5X"\0J'T3Q&/#'BCPAX39_!\GACQP"O@7Q7X0
M:3Z/\Z'S/(\X>?CISGZ8Z>^,_P"%?S]WWC3Q'X#\5_M3> _B->>/_'WQI^(?
M[4_P<\-GQ#^QWJVC_ 1OCQXHU[]GT:_X)^"XUCQW\2?^$E^ .@^%?#/PKT9?
M&WBOPA\8#XU'@QO#.WQLZNRMQG@;Q%\;O$OBW]IS]G72?C/H'@@^%_VH_P!F
M;1K'X<^(/VWOC[XA3Q:-:^&FM:YX[^"WPM_;)\1>&?"/[3/ASQ+XK\2>!U\3
M>,/"OA/PMXN\7^$_&.@_%'P9&)HO%7C&2, _9;]JC0]5\5_LV?M$>%/#>EZA
MKOB'Q-\%?B?H>D>';,!M4UK5M=\$^(-#T/1=%.\%2^OLNT8XWJ?F5JZK5_BY
MX(^'?B7X;^#?%>MM8>(OBSXCU3P=X&LX]&U;4/[=\3:'X/UWQWK.C2:UH'A]
MO#F@N/#&@Z[XGW>*F\(I(()L+O:.(_BA_P +L^*GBJ+X+_LY^%8/C%X)UBZ_
M:$^*'P^^-G@CXW?M::SX;U/0?'FA?!?P#\6M"^"^A_MP?!_PW\7/B?X@\.Y\
M<?\ "4>"/^$K_P"+T>-?[ _X0;Q[_P (;X#_ .*+K8TRQ^*.B_M!_LJ>$OBC
M\0_!GBXZ)^VYX_LO ?A#PK\>-9_:.\1?#'2=:_9-^(2:UX-^*/Q2^(/PZ^%/
MBG7?$7A;7=;U<>#/^$K\*>,/%\G@W7/^$.\=^,/%,GA?PFA?0YOJZ^M].]_+
M?>WZV/W/\*^,;3QCH.G>(]*A\26-AJMHUW:6?B/PAXQ\$>)+([6V'6?#_C_P
M[X4\3Z .-WE^*/"L+D LW0 ^@^;#Z_J?\:_G3_8NL_'/[1_B/X ^'/B9\;OV
MB;G0+O\ X)Q?"[X@WG_"/_'KXR^"M2\0?%'7OC-\6] 'C36O''A[Q)X4\4:[
MKY\.@*__ !5RCQE_8'AR7QZ/&7_"(^#'\'Y/P6^+/[1?[3U_^S]X-U[5+3Q>
MH_8U\*_%"TTCQ)^U-\9/V3/$WQ,\5:W\3_'W@7QOXU7QQ\ /AOXM\3>/V\(:
M!X&T#PSXU\,$>$/^$*/CP>.?'8\8MXN\%MX+1TG](7G0_P#/;_QX_P"%6*^,
M_P!D"]\8ZG^S_P##_P#X69\3/!7QC^( L_%-C>?$/X>^.M'^(_AGQ9I>A^-/
M$.A:&5\<Z!X9\(?\)%XB\*^'5T/POXY\3KX0\(_\5J/$C;<-NK[,H **** "
MBBB@#P?XR?%KP7\#OAYX@^*GQ+URXT7P5X5&E/K&K6>B:WXD-G_;>MZ#X?T=
M(]"\/Z#XI\2:X\OB#7=$$#>%_"Y$;.))%(B8-YEX0_:T^$'CGQ;9> [/4/'O
MA;QSKECJ>I>&/"?Q6^"?QD^">I^.UT!= .O#P0/C'\//!\?CV3PLNMZ0/&GA
M_P (GQ3XN\'%RLT8\M?,\\_X*;\_L1?&@^?C_3/A?Q:]L_&?P!G(]LCOP?7'
M/(_MI2W&J^(_V0/"VE3BY^(.I_MD?!WQCX.LM,NQ_P )2OACP.-=U[XKZQH>
MC_\ %*#_ (1SPI\.=:UOPQXZ\4%7W>#-?7P3EO'7BU P!^CEV!-#-"#W^R<$
M]2#G\\GU_P /FW]E'0M5\+?LW_ #PGXCTFZT/Q!X5^"OPM\,ZSI6K6H&J:#X
MFT'P5X?T/7-(UO:Q8:^77858+N*M\I3!?\7_ !9\7O&;>(OV7OC'\./$7QIT
M/PG\3OVX_AA\/[#XG_&;]J;6;'Q)\9O#?COXF>(? /CGP;X&_8Z\/GQ7\#-
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %B D # 2(  A$! Q$!_\0
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M;Q'^UJ+G7;GX(G4(;'Q>L>OZ)X>N)M"N-.N-.7_A!-%GTO3Y=0L6DL)#)-/
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M?_PZ7@?_ .7M?YD:W<SJKI<RLC ,K"5R&4C((.[D$<@]Q3OM%Q_SWF_[^O\
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M5;>[AOKJZENG_;C_ (5-\*_^B:?#_P#\(WPY_P#*VC_A4WPK_P"B:?#_ /\
M"-\.?_*VOC3]TN_Z2/PKG_8S^ TLT=U+_P %2?#NJ7<NC6NAZO-K_P 4M'U<
M:_I^EP:C=Z-8:\\_QO%[J^CZ=XHU.\\20Z)>WSV$-U=W1MD@N6@N[?0@_93^
M&TD=K-JG_!7BWOM16TELKV?_ (6SHXM6MW@U*&*'3+.7XX3+HSV0U$I9ZAI[
M0ZO#! L0U#]X['[C^,W[4G[(_P #?BEX[^$WBOX)7VH:]\-O@CK/Q]\7:IH/
MPG\$2Z!9>!=&TO7M5D_L^ZU?4=&U#7]1FC\.7]FYT#3-2TG2M2GTRPU_5M(F
MU& &>3]KS_@G+;6>D:U?>)/@=IOA76/#]_KD'B_4=!\(6F@6MQIGBK3_  9=
M^&]0:6U&J6?B9-?U*WLTTV73 DAQLN2\]HER!=_TE_D?'7B?]G#X3>*_#?PC
MT'5?^"J'AB^O/A;\7?'_ ,5_^$CUCXD^&=:U?6KSQ7-IS^'K2-;GXQ16VEW/
M@ZUL[W3-,OFCU*WM['6=0;1]-T2]EEO)^+'[+WAK0-/O9/#/_!8"+5]1LM/B
MD\,Z9XD^.MI;:3;ZS9Z1KT,37%_'\7=<N(X[_7M4@UJ;4+_2_$DNESBY-EIL
M\2VEK#^MGPY\8_L<_%WQ/XF\%_#.X^!OC7Q9X.L[#4/$_A[0=$\*WFJZ/9:D
M=EM=75H-.67R4N,V-Z\0D&FZD&TO4OLFH*UL/9_^%3?"O_HFGP__ /"-\.?_
M "MH"[_I+_(_".;]D+X9S2:7=Q_\%8/"%A<:7KW]OP06?C[PPD1.KSWFI^-]
M+N;J#XR67VR#QKK%XMQXCO38V[ZS:6-I:WMF5,N?V)\)_M!_LS^%_"?AKPXO
M[2'P,O(O#F@Z+X?%[_PM7X?6Z7)TG3;>P6;R4\1-' TZVQF$".PC#%%+*N:]
M3_X5-\*_^B:?#_\ \(WPY_\ *VODV^^&OPY'[=/AG2Q\/_ XTUOV3?'5^]B/
M"6@"T>]C^,'P[MX[MX!I_EM<1P220QS,I=(Y9$1@LCA@5[FA<ZA_P3IO/A7K
M?P.NO%/[)%Q\'O$FKWNO^(/AK+XV^%K^#=:UK4O%:^.M1U35-".L_8;V^OO&
M*+XEO+BXBDDN=8'VV8O-ECX_\/?#'['^B_M$_'7]J/XH_M0_LX_%?XJ_&CP'
MH'P3M?,\2_#/PYX2\"?L^^&KC4]1M?A3I/A^Z\<^*I];C\2:[K.H:]\0/$'B
M#5KQ_%%ZNF65II6@Z%I-II _0+_A4WPK_P"B:?#_ /\ "-\.?_*VO%OVA]?_
M &>/V9O@]XR^-OQ"^%.A7WA'P1;Z;<:K:^%/AOX;UG6Y1JVLZ?H5F+>UEM[&
MR@@6^U.V>_U/5-0T[2-)L%N=2U34+.QM9ITZHXW%PC7A'$5;8B,HUFYRE*<9
MSHSJ+GE*4XNK+#X?VTH2C*M&A1A4G*%.$5RRP6$G*C*6'I7P[BZ*4(QC!PC6
MA3]R,8PDJ4<17]C&491I.O6E3A"=2<G\JZ3^SM_P1CT#P/XO^&FA_#[_ ()^
MZ1X!^(%EX>T[QOX3TV;X)V6B^++3PGXAN_%?AF/7[2WOHUU1M!\17UWJVDSW
M9EGL;J9C;RI&%1>2U/X"_P#!/>\^)'[/.HZ-\:/V2O /P$_9C^(VO_'GX9_L
MZ_#:^^%'@SPW/^T3K=AJ.FVGQ5\5:YI_C5X-03PO%K.KZMX:\+:%X8\,VL?B
MB[M]=U[4O$ TO2["T]"TS]M+]@VZD\=:;K?@_P ,^"O%O@+P%I_Q'OO WC'P
M-\/M+\3:WX<OOA[:?$R9O#!M]1O] UJYTSPU>*]^(-=6T\V"ZGL;N]TN!]2K
MT7_AIW_@G"%NW?XB_LUQ)8>+8O E\\UCX5ACL_%LDEW%)H=U)+I:1P75B]C<
M?VL\C+;:,@AEU6>SBNK5YM8YIF47*7U[%R<U44G5Q%>MK4HRP\ZB5:M54:KH
M3G1C64?;0ISG"%2"DS.66Y?-13P6%BHN#2IT*-*ZIU8UXPDZ5*FY4_;0A5E2
M<O93J0A.I";BC@OB%\'O^"1'Q9GO;KXF>'_V&?'-SJ7Q,U;XR:E<>)M;^$.K
M3ZC\4->TW2=&UWQMJ$MUJSR7NMZUI.A:+INKS732QZE8Z5I]K>Q30VD*)[UX
MR^(G[#7Q T_0-+\7_%7]FW6;'PK('\-0/\4O %F="0VBV$MGI<VG^([2>STR
M[L$CL+_2H9$TS4;&.*SOK2XMHXXE]\'PG^%9 (^&GP^((R"/!OAP@@]"#_9O
M(-'_  J;X5_]$T^'_P#X1OAS_P"5M82Q>+G[-3Q6)DJ+DZ*EB*\E2<XQC)TE
M*K)4^:,(1ER*'-&,8RO&,4MXX7"Q]IRX;#Q]K;VO+0HQ=3EE*<?:.-).?+*<
MI1YW*TI2DK2E)OAU_::_9CMX8[6+]H3X$VL,<$<4$47Q9^'\*PP",+"L*+KZ
MK'&L>WR@BA%0+M&W%?*(MOV694MENOVX]$9HX]1DEDM?VA/ %LT5_=7 :QET
MY1J[PV%KIUE+>:>+>.)I9X98V%S 497[G]C[X;_#K4_AY\0Y]0^'W@6\FB_:
M6_:@M(I)_"'AUVCM+3X[^.X;2UC)TWY+>T@5+>UA7$=O;1Q6\*I#%'&OU;_P
MJ;X5_P#1-/A__P"$;X<_^5M<YO;IT/B%8OV5([*""/\ ;ATG[1:F01/_ ,-%
M?#^.TDMOM5E-;Z?<6D>IC-E#:V9T]HX98FF@NKB20M(8]G6S>)?V3)-2-]%^
MU9\&K>-D=RB>-?V>WOUOI9KLW-ZNK3:;)=R&[M+I;2[@NQ=1SI9VC,=HNHKK
MRSXU?ML_L&_ +XK_ !)^"?Q$\#Z58_$?X;^$/A_XU?0K7X8>$I/^$VTKXAZ]
MI^@6-E\/[NYEL[;Q#K^AS:G::EXBT&22PU*UT0W&JZ=!JEM8WS6WK&L_M&?\
M$[O#T?C"76/'O[-UF/ /B2W\(>+8_L/A2>XTCQ%<OJ\:::;6UTR:YO6CD\/>
M(4N[C3H;RSL6\/Z\+VXM_P"Q=3^R@K(S+;6/V3(;>.WD_:M^"4L4Z%-9MX_%
M'[.5K9ZHZZ/<:9;WJPVVEQS6&I6MU)#JT%U#=/%'=QS11VL=K<"&&4ZS^R)-
M.TM]^U/\%[PQW#7=E-)XS_9Y6^L[F?2VL+J1KL:8POPUP(=1@&I07;1W"S17
M,E[:SB&+V7X?ZQ^R=\5]<\8^'/AI;_!?QSJ_@";1K?QC!X8\/>&-7@T*X\0:
M7#K>C076H6>FR:=)-?:3<6VH1Q6MW.Z6MS;RS+&L\)?U7_A4WPK_ .B:?#__
M ,(WPY_\K: LOZ_K?SW/E'1/%'[+.AZEI>N67[5WP6:]TN7PTTROXO\ @"NF
MRQ:0\$E];0);VL&HZ1'K,\5Q>1C3]7@;2[^YDGLB8HTMAG>([G]BGQ1K6H^(
M-3_:9^&/]IZA>WVHE;?XY?#^+3H;ZYNI;JVNTT\:R8_M6GO($M;M)([M8T 6
M='PZW?BG\-?AS!^UM^R780_#_P #Q66H>$OVE7OK2/PEH"VUV]GHGPR>T>XA
M&GB.5[9Y96@=U+1&6785$C[OK+_A4WPK_P"B:?#_ /\ "-\.?_*V@9\0V>D?
ML1P0J+K]JCP)<W@%P)+V+X^?#^R:;S640O-!%JK13SVD2F**YN1/.XEG,TD@
ME*C4T#_AC+PTUQ_9/[6/@F%;J22:X:3X]?#:25I'8[8T!O1:1642;52SCLPB
MM#:LK*+9%KZ%^+UK\"?@I\*_B+\7_%WPN\)W'A;X8^"_$?COQ%!H?@+PO?:S
M-HWA?2KK6-1BTNSGM[*"ZOY+6TE6TMYKNVCEF*(\\2DN/COP!^W9_P $WOB'
MIVK^(-/N/AIH/A'0_ GPW\<ZEXO\5^"O">B:+:M\3K_Q7IFD^"IHWBGUF#XA
M:'>^"]?C\6>%)])BO-#AM/MSR3Z>)+J, ]GE\:?LK2Z>EH_[7W@$74*-';ZF
MGQK^%2W05+F\N+5KJ(W#6E[/%'=+9W=S+;B;4K2UMHKQG"$F_9_$+]E6RUNP
MUV+]K/X<23VFJ-J-WI]Q\:/A9-H^JPR6MW ^E7NG_:U TQ9KO[=;6\$L36EY
M;VK02+%"(CD:O^T5_P $[M"NO&%GJGC_ /9JMY_ 6CZ;KWBH);>#[J+3M*U>
M?0[6PN8+BTT^>WU9YKKQ/X<MI+31I=0O+6XU[1X+JW@EU*T2;Z=TWX;_  ?U
M?3K#5M.^'?P]NM/U2RM=1L+E/!?A]4N;*]@CN;6=5DTM)%6:"6.15D1' 8!E
M5@0 #SX?M ?LBJS.OQL_9Q#O*;AV'Q(^&09YVR6F9AK.6E)))D)+G)RW-:%M
M^TE^RWIZ%;/X]_ &QCG/F$6WQ2^'=LDS+^[\PB+7460J$\O?R1MVYXP.^_X5
M-\*_^B:?#_\ \(WPY_\ *VOE+X"?#?X=7GQL_;0M;KX?>!9[?3?C5X#MM/@D
M\'^'6BLK>3]G?X/SR06R?V;MABDN));F2.,*KW4]Q<N#/<322 'R/^T3\9/C
M-KWQ!O[KX"?M4?L6:9X$'FRV-MX\\9_"+7+Z/4%NKNXM+VTF7Q787,2I)+%+
M(;P2W"2F9HBTDKO7ST_C/]KB]O=/?5_VIO\ @G;?Z:NGP:7J-JFM?"Z*5+$:
MK'JUU!IB-\09-/2-[JULKB%+BSVM>6L4EWYT2A*_8WX]:C^S[^SI\'_'OQM\
M>_"WPS<^#_AUHO\ ;VOP>'/A_P"%M2UN2R%Y:V173K&XAL(;F?SKN(^7)>6Z
M[ [;\@*?FJ7]K_\ 8FAUO]J?P^_PSMO[1_9#\/:SXB^)T9^%_@R,ZI%X?T&]
M\1ZQIG@N&6[CN]6UFUTRPN+F&QU2VT/^T;1?[4TN2]T97U%/R+$^$.&Q6+QN
M,EQ_XFTY8W%XS%RHT>*8TZ&'>,Q%6N\/A(+ )T<+AU55#"T6YJEAZ5&FY5'#
MG?W]#C^I0H8>A_JCP-66'P]##JK5X?\ WU=4*4*2K8F<,7%5L15Y%4KU7%.K
M5E.HTG)H^)-.^)G[816*36?VN_V!#>QSVD2SZ5J_P;5(]($=ZM[IX:\\<-.2
M\DE@]N\30Q)%'>PO$3<)(KH_B+^T_P#9K6\F_:3_ &!GU6:?2X]>L$\6_ _^
MS[VR-PD>OR6&IMK0OX;NYME2ZT^&_M;Z".:".TN9)$;[2GZR:CKG[/5A:_!.
M6/X5>'-1U#X_:CI%EX!T*P\ >$Y=:-GJ'ABX\9ZIK^LVLD<4>G:!X4\-6LVH
M>)=16>Y6RF>RTZV2\U'4].MKKF/BM\4/V3_@K\2/"GPT^(W@7PGH-_XM^'GQ
M ^)MMXA?X=^';GPOIGAKX;ZCX3TO7QJUY;VDFHQ:E/=^,M'72K*RTJ^:]479
M9X3"JR\C\%\,Y.3\2/%G5ZQ7&"46GJX667WY6]79IWN[W;;Z%XCU4K+@OP^C
MI;3AI7W3O=XUM-6LFK:-Z:L_,W_A:?[6]Q9)I>H_M:_L)7]J+*Q0R2^*?@T;
M7SK:^$5Q:2:++XLGM9;2302+;3Y(KBT?3[V%-T=Q:.53N-,^+GQNU'PK=^&O
M'W[4?[+6HV]\NJ:7J%AX8^*_P/T;1+O0KIY8;=+:VF\2R7>FWCV;AK@Q3RQ0
MW8WP%TR#]I1?M-?\$XIY[VWB^(O[-+/IW@B3XD7LAL_":VT'@B+PO9>-7\0-
M>-IBVC6J^%-0M->\E)VO#ITC3K;$0SB.U=_M%?\ !/.PTWQ'J]]XR_9]L].\
M(VG@^\\2W%UH&@V_]C+X_L$U7P?:WD,NB).FJZ[I+KJUIHJQ/K":5NU*YL8+
M)'G7"KX'X6K9KQ-\8*,HUJ=>,J/&O(U.G4A546I994A4I2E"$9TJL*E.=)2I
M2C[.I4C+2/B74BIJ7 OAO5C.G*G)5.%DWRR4DW&4,QI3A47,W&K"<:D)6E&2
M:37E?P0^/&G^%O$.BZ=XN^/?[-^G^"Q?^)-9\3W-G\9?A1)J&NZMJ^G2_9KF
MYAMO&.IO"T.IQ6TS#3FM+>1[B=C;06\44"_9?_#47[,W_1Q7P*_\.YX _P#F
M@KSGX<_$O]B3XN^-M;^''PQU?X">.?&_AZPN=5U?P[X;T?PKJ5[;Z;9W&G6M
MY?1-#IIMKVUM)]7TE;F>PGN8X%U339)62*^M7E]WF^$_PL6*4CX:?#_(C<C/
M@SPX1D*2,@Z:0?H00>]?J60Y)5R.AC:5;/<\X@K8['U,?4QF?8G"5\11=2AA
M<.L)A(8#+\LPF%P-*.%C4I8:CA4E6K8FM.I.=:37P^:9C3S&IAYTLKRO*:>&
MPL<+'#Y50Q%&E5Y:U>N\1B98K&8ZOB,7.6(<)UZE>[I4J%-0C&DK_D[^T/\
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MP[_\(+PC_P#*:C_A7_P\_P"B=?#O_P (+PC_ /*:M?[<H?\ 1,<*?^&[,?\
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MB>UG19H)(Y%#"Z?VQ?\ @HN22;'_ ())$DDDG]L#7B23R22=<R23U-;&B_\
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M&X^R"Y)G\GS27K]2?^%?_#S_ *)U\.__  @O"/\ \IJ/^%?_  \_Z)U\._\
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M87DQ5&E0K86G2JPCP]"'LX8:O6P\8TX4%[&I*F[P45!N^,<!T [  @#V "X
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MRD>3X<?$=I'=V_X:>_:I^9V+'GX^^/F/+$GEF9CZLQ)Y)-?6] 'Y#_%?6?\
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M)=(L+---\2VND:MJ&F:MKNGQVVH^)K.ZFC\23ZJTCNW[5T4 ?BC>^&?^"/\
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M=S?) \"EUW_!"^K2_P"@>M;NJ]&UKM7O[.W*VM&[)GH'_#;/[*W_ $6+2O\
MPE_B#_\ ,A1_PVS^RM_T6+2O_"7^(/\ \R%>7C_@HAX2M;36]7U'P/\ $!]
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M;2_".J?:+76)=/1=6%S>:A;#4+_0=4T2'S=$-PFJVQCEMDMI(KI][PO^W?\
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M^&%X(UNH-(L;:;5/%%R?"9?PGJNFMJT7@\GQ6^G:L=0D;0;4/YAM:K:IX_\
MV3?$7@J;Q1K4IN/!?[3']I>'KC4[WPEXTAL]4LO XG\(ZE+>0G1%D^'F@Z3>
M:Y?6\^OWL'A_3)M8\1ZAJ<E_->ZU=74QK_,OP[Z?Y%)0BU?"XA*]OXDVY<R]
MZ-URIWASRLDKM:Z-GE-U^W-\,+&X\4:IXA^#^H2>&O#AL-,\)7VFV/@#6-1D
M\;RPV_A[Q5X,N+F#7;O2;;R[DQVNG>--#NY? ^H^%;7%SK;JL%K6Y=_MF?!K
MPY+--'\(]7T+3H)_+>['AGP):76N6>F^'Y-9U6STJTTW5EFT[4=!U4Z%I,Q\
M3C3M+CDN)M3AN?[.TR6_A]-L_P!H_P#9.N=)CM6O=#L/#C^'VECBUCX0^)-'
M\/-H1T34;[3=*$>I>"K;2VE\2^&=&U6^\'>&=IOO&6@Z?<S>&]-U.S5=T7A[
M]I;]G;5?"]GK5[I \-7,NN^(O!]GX+O/ACJUWXO;6=+U2U\/CP[9^%M,\*S:
MK+KFO6.JZ'/!X6MK!M6%IK":3>V?VC3]2@MCYK[OZ[JPG&/_ $"8A6:37M9Z
MZ::6^*\9-O5)Z^[;7R3P5^W%X"UJZL/#>L?"NTL_&5SXBM-)UBST+6_AC=>'
M])TW4O%WC'PQ%>SZU_PD$\%Y>Z-I^B6\E_IT4C2^(IM?@'A3[=8:I8FZ^IOV
M?OB[X0^-OPUT_P ;^!?#.I^$?#+7UUI>F:'JFG:1I4D5I;PVE[97EG8Z%<7.
MFVUAJ%CJ-K=16T;17%E.]S8WMM!=VLRFY\/YOA!X^T[5=2\'>!-"M[#P[XDU
M/P3=/J?PKM_"3KJ_@K58XKJUTZVU?P_IT]WI^BZU9H+*\LXFL[35; _9V@OK
M(B+T_3=)TC18)+31=(TK1;26YN+V6TT?3+'2K66]NY#+=WLMMI\%O#)>7<I,
MMU=.C7%S(3)-([G--)[MI_+]3*K*EK&-*=.5U?FJ.26[:Y=>CCRZMQ6EW<XW
MX&?\G?\ [0__ &07]F3_ -2K]HBONJOA7X&?\G?_ +0__9!?V9/_ %*OVB*^
MZJQ>[]7^;/L\L_W#"?\ 7E?^E5 HHHI'<?Y<OQ"DED\>^-':VEA9_%?B%FBD
M:-GB9M7O&:)VC9D9HR2C%&92P)4D8-<?F3_GDWYK_C7H/CVPU"^\?_$)K#3[
M^_6P\1^*;^_:QLKJ]6PL(-:NQ/?WQMHI19V,!91/>7)BMH2R^9*NX9XNZT_4
M+%+22^T^_L8[^V2]T^2]LKFTCU"QE9DCOK![F*);VRD='2.\M3+;.ZLJREE(
M']%9=1K/+\!;&UE? X)J*HX)V3P>&:2YJ3DTELW=M+F?5G^8G$^-P4>).).;
MA[!U.7B'/E*M+&Y_'G<<[S6$JDO9XN-*+G-.Z@U",Y.$$K1@J69/^>3?FO\
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MKEDDY7_:C_AH+X^_]&/?&7_PY?[.?_SVJ/\ AH+X^_\ 1CWQE_\ #E_LY_\
MSVJ^O:*_&S^XSY"_X:"^/O\ T8]\9?\ PY?[.?\ \]JC_AH+X^_]&/?&7_PY
M?[.?_P ]JOKVH?M-OT\^'/G?9O\ 6I_Q\8SY'WO]=CGROOXYVXH ^2/^&@OC
M[_T8]\9?_#E_LY__ #VJ/^&@OC[_ -&/?&7_ ,.7^SG_ //:KZ]HH ^0O^&@
MOC[_ -&/?&7_ ,.7^SG_ //:KY?O/C?\:C^VGX;U@_L>_%A=83]ESQKIR>&#
M\0?@.=0FTZ7XL^ KF77$O1\3#HRV=K<P06$MM)J2ZD\U[#+#8R6L=Q/'^KM?
M(5]_R?OX7_[-"\>?^KF^'% !_P -!?'W_HQ[XR_^'+_9S_\ GM4?\-!?'W_H
MQ[XR_P#AR_V<_P#Y[5?7M% 'R%_PT%\??^C'OC+_ .'+_9S_ /GM4?\ #07Q
M]_Z,>^,O_AR_V<__ )[5?7321HT:.Z*\K%8E9E5I&5&D98U)!=E1&<A02$5F
M(P"01R1RH'BD25"64/&ZNA9&*. RD@E'5D89RK*5.""* /D7_AH+X^_]&/?&
M7_PY?[.?_P ]JE'[07Q]) _X8?\ C*,GK_PLO]G3CW_Y*U7UY10!^4W[*'QO
M^-6E> ?'D&E?L=_%K7X)_P!HG]I*_GNK/XA_ :UCL[Z_^-GC6[OM&E35/B7I
MT\EWHEU-+I-[<V\,NGW5W9SW&G75U9203/\ 3G_#07Q]_P"C'OC+_P"'+_9S
M_P#GM4_]B_\ Y)M\1_\ LY[]JC_U??CVOKJ@#Y"_X:"^/O\ T8]\9?\ PY?[
M.?\ \]JC_AH+X^_]&/?&7_PY?[.?_P ]JOKVHA<0'9B>$^9+)!'B1/GGB,@E
MA3YOFEC,4HDC7+H8I-P&QL 'R/\ \-!?'W_HQ[XR_P#AR_V<_P#Y[5'_  T%
M\??^C'OC+_X<O]G/_P">U7U[10!^47Q+^-_QJN?VI?V7-2N?V/OBQ8:EIOA7
M]HF/3= F^(/P'EO=>2^T;X=+?3V5U;?$R?3+:/1TMX'NEU.^L9;@7T L$NVB
MN4B^H/\ AH+X^_\ 1CWQE_\ #E_LY_\ SVJ/BQ_R>#^R!_V*'[3W_IB^%]?7
MM 'R%_PT%\??^C'OC+_X<O\ 9S_^>U1_PT%\??\ HQ[XR_\ AR_V<_\ Y[5?
M7M,>2./:9'2,.ZQIO95W2.<(B[B-SN>%499CP 30!\B_\-!?'W_HQ[XR_P#A
MR_V<_P#Y[5'_  T%\??^C'OC+_X<O]G/_P">U7UTDD<F_P N1)/+=HY-CJVR
M1<;HWVD[77(W(<,,C(&:?0!\A?\ #07Q]_Z,>^,O_AR_V<__ )[5?,?P0^-_
MQJL?C%^U]=V/['?Q:U2[U7XP^"+K5=-M_B'\!H9_#MU#\ _A391:=?37OQ+M
M+.[GNK2UM]8BFTFYU"TCL]3M;::XCOX+N"/]6:^1?V>_^2Y_MN_]EP\ ?^LY
M?!R@!G_#07Q]_P"C'OC+_P"'+_9S_P#GM4?\-!?'W_HQ[XR_^'+_ &<__GM5
M]>T4 ?(7_#07Q]_Z,>^,O_AR_P!G/_Y[5'_#07Q]_P"C'OC+_P"'+_9S_P#G
MM5]>U&TT*,RO+$C+$TS*TBJRPJ<-*P)!$2GAI" H/!(H ^1O^&@OC[_T8]\9
M?_#E_LY__/:H_P"&@OC[_P!&/?&7_P .7^SG_P#/:KZ\5E=5=&5T90RLI#*R
ML,JRL,@J00002"#D<4M 'R%_PT%\??\ HQ[XR_\ AR_V<_\ Y[5,D_:!^/C1
MR _L/?&;!1P<?$O]G3."IX&/BRQR>@PK<]CTK[ J*?\ U$W_ %RD_P#0&H _
M#[]E#XQ?%S3/V:?@CI^F_LE_%;Q%86?@'38+37=/\?\ P2L['5H5N;PK>6MI
MJGCNTU*WAD)*K'>VMO<*5.Z, J3]!?\ "\/C3_T9C\8O_#D? /\ ^>'5C]C4
M$_LI_  #DGX<:4 /4FZOJ]:O?BC\+]-6=]2^)?P[TY+:2QBN6O\ QQX6LEMI
M=4AFN-,BN#<ZK$(9-2M[>XN-/27:U[;V\\]L)8H9'79;+5K[CX&M*+KUTJ"D
M_;5MI5V_XM17M%O=ZZ)*[TZ'CO\ PO#XT_\ 1F/QB_\ #D? /_YX=,E^.OQD
M@BEGF_8U^+\,$$4D\\TOQ+^ 4<4,,*-+--+(_P 1 D<44:M))(Y"(BL[$*"1
M]$GQ!X?"7<IU_0O*T\Z4+^7^V=-,=C_;J12Z%]MD%ULM/[<CG@DT7[08_P"U
MHYX7T_[0LL9:MHWBWPGXACM)_#_BGPQXA@U 7YL9-%U_1M:@U!=,>"+51:-8
M7=U%>IISW5M%J:P^:MFUU;QW@B-Q$KNWF_P,N:._L(V[\]>W??FLM._KL?)%
M[^V%J^FV<&I:C^S_ *YI^FW6DV.O6VHWW[0/[+=I87&A:I<R6>EZW#>7'Q8C
MMI='U2\AFL]-U-)&LK^[@FMK6>6:*1%T-*_:K\7:[J4&C:%^S3XOUS6;K1;;
MQ):Z/HWQR_9FU75KGPY>!&L_$-OIMA\4[B]GT*[26)[;5XX&T^=)8GBN'21&
M;YC\8?\ !+72]0^'7QH\%>!/$/@OPIJ7Q,_:F\$?'/PW?W/A7Q)<V/@[X<^!
M;]=;\._ V*.QUR+4[+1-/\0:AXHU;2AX:N=+TG3+GQ+=366DK,JM7=?"3]E^
MV^ OQYG_ &G/$WQB^"N@^#-4^&.D?#;Q)8:9I\NEV?BCQGH^BZ'X1L=>N/'W
MQ \5ZLFCW&D0>&KW2TL?"\^DW7B.#R[/Q997=]HK7;K7^GMJ[_A9_,ZG'!<D
MG"7--*7+!JLG*25-PC[LI:R<ZD='O2;TC*+/HS_A>'QI_P"C,?C%_P"'(^ ?
M_P \.C_A>'QI_P"C,?C%_P"'(^ ?_P \.OIN!DNH(+JU=+JUN88[BVNK9UN+
M:YMY8Q-%<6UQ"7AGMY8F66*:%WBDB99$=D8,3*^<EMN7[3)')-';;E^T20PN
MD<TR09\UX89)8HY950QQO+&CLK2(&=O-G)SP_P"?,/\ P96_^3/F3_A>'QI_
MZ,Q^,7_AR/@'_P#/#KYY\:?&'XMS?M1?L[:C+^R9\5K74+#X8_M,6]CX?E\?
M?!.2_P!;@U!O@L;^_LKN'QV^F6UOH0M+7[=%J%W;75U_:EJ=-ANA;WOD?H6_
MB#P_'KL/A>37M$C\3W.FR:S;^&GU?3D\17&CPS?9YM6M]#:Y&J3:7#/^YEU"
M*T>TCE!C>97! ^>_'G_)W7[,/_9)OVKO_0O@-2:T>KZ?FC2G*"<OW,5^YK/6
M=;5>S?>6S[KMH[K1/^%X?&G_ *,Q^,7_ (<CX!__ #PZY'QCXT\=>/[/2['Q
MA^PO\7M9@T/6[3Q)HK_\+5^"^F7FDZY8Q7-M;ZCI^I:-\4=.U*UE:TO+VPNH
MXKM;;4-.O+O3M0@NK&YGMWT?&'[3>H> O%GC0^(_#GA=_AMX,^).E_#&ZNM+
M\1ZA/\4KG4-1^&NG?$:;Q%I_@Z?2X](U?1=+MKV:WU&QL]9AU*UTVSN=>DD-
MK:W$"I>_MD_#>;Q9IW@7PU8ZWJ?B;4/$GA_18SJ4%E8:++:7_P 1?"_P_P!?
MN;:^LM2U*]^W:*_BFTU6QMK[3+&RUN&.6*SU!I+>\2W-.[*4)JTHX=;<RE&I
M6T5DVW)5%:T9*ZZ)]=;>8:3X>L=#2>/2O^"<?Q!M4N9?-E5OB;\&[OY$OM!U
M&WL8C>_%>Y:WT?3[SPOX??2=!MS%HFC1:7#::3I]E9RW5O/CV?P_\.6%S)>6
MW_!-SXD?:9;>QM'EN?B[\+KXM;:7;M::7;[;_P",=RBQ:;9L;.P155;.SQ:V
MXC@58QW/B_\ ;*UCP)XN\5V'B;X-:U9_#3P7\8_$7P^UWXQ0ZY;7?A>+PMX:
M\(7FOW^HV^F0V_\ ;5S\1AJUE-8)X#2V%BV@!?$P\1;773JU[G]MCP;?:%!K
MW@WX>?%#Q)%::YX!TKQ19W7A_2]$OM"?QQ?W$2Z+':ZAXBBEU'QA:Z+;/XDL
M[*V#>%M0TEXG3Q8L\J6Y7N]]O+\M"[8BR:I2:E;58BLUJDTI-5[)V:?+*SVN
MD]_._$'A=M=TKQ;I\'[ 'Q7\/W_C'3]1L]0\2:%\3O@?#KMI=:A>V^JC6+"6
M[^)EW9IJ=GK5G9:Q:O-:2P"]LX?-A>$R1/SND^ ?$5MX8^#/A#Q+^Q]\?_'6
M@_!"'Q/#X9T[Q#\3O@!;6&HQ>(I-,DLK'6;#1OB)80WFB>$ETBP@\-Z%>-?:
M>(+6U_MA-5N+6&X7W"/]N7X*W4T\.GV?CV_%KJ,-G>7EMX=TZ73].T^\L/#%
M[8>)]2N(O$$DUOX=N'\8:%92^5;7'B&PO9+R"_\ #ULUE*35LOVYOA;>0V\4
M/A'XIZEK#7.EV-WI6A^%]*NYH;K6(/ PTR[A34O$ND7CZ#K&J?$7POI.@ZS=
M65E%JTMY-?QPQZ397=_"]._Z_I\^HU]82M["=D^;6I6NGR.%TY5>:/N-QTDE
M;Y,X[4-&@U:[L+W4_P#@G/\ $*_GTSPK;>";);GXF?!J2TB\-6.DWV@Z;92:
M?_PM4:?=7FDZ)J>I:1H^OW=K/XCT?3K^[M=,U>TBGD4\^/A_X>'(_P""</Q0
M\X69LTN_^%S_  W.H1,=4MM:.J0:D?C1_:$'B0ZK965XWBV*Y3Q47L[6(ZR;
M>"*%?J/6_P!I+X>^'?A_X.^)NK6'C&W\)^/M9TCP]X2N(M @N[[5M8\2Z6NH
M^$+%+"TU2:2WF\87+KX?\.Q7+Q37/B-H]+O(K'SH+B7QV/\ ;N^&<WB**SBT
M/Q(WATQWNFRSK;6EQXJ?QG8:YXET-_#&GZ/I^H7N@7Z:E<Z/I(T76!XI@TNY
M.NH;R[L8[.X9"R[[^GK<F/MVGRT9V5T[5L1:\79K^-:Z;::[W3ZFYX6\=?$#
MP2FM1>%?V&_C!H\7B+7+KQ)K,4?Q5^"]Y'>Z[?I&E_J>S4OBC>+:W%^T2W%\
M+(6T-Y>O/J%S%+?W5S<S=3_PO#XT_P#1F/QB_P##D? /_P">'7G/AK]NWX=Z
MEI^CIX@\(>-](\3SV^B7OB71M.M= U:Q\+:=K5IXVU*34KK5!XCB-Q;^'].\
M"ZL^OV:6ZZN+HPKH6GZY9W-G>7'3^"OVQ? _Q,\6?##POX$\+>-KA?'MY(NL
MZGXHT:'PU!X/T^X\,^/O$'AYKF*34;J?5=3\4+X"OI])ATF&_P!)_L25M0O-
M8L[S[/I\YI:Z;)E3J+F<L+M=RDZE5JT4VWS>UU5HNSZV25]#OOV3/%7B?Q=^
MU/\ M':CXK^&/B7X5:A%\$_V:;6+0/%.N>#]>O[JUC\3?M!.FIQ7?@O6=<TR
M.VG>22%()[J.\1[>1I(%C>)F_26OA7X&?\G?_M#_ /9!?V9/_4J_:(K[JK)[
MOU?YGV.6M/ X5I**=)62;:7O5-+R;;^;N%%%%([3^ C]AO\ :\\ ?L8_M!_M
M7_$7QWHC>*9?%GP>^*OP^\$^$KG0Y==\.>+O&FI>.=%U;3O"_C1(I%_LWPEK
MEGI%]I^KZK+#=P6D<RF6SNE8P2?<'B#]N7_@DA\2O%OP\N/''P%\4_\ "$?#
M[]G?X8_#+P;X9\9_#?5/B3IGP[LM%\>>+_$?Q)^%GAS2K7QQX>/]L:KX=UO1
M]"\#_%P7]_8>''T[SAIR*K6\_P#/Y\0KB"?QYXTFBE#1R^*_$,D;%77<DFKW
MCHVUE# ,K X8 C." <BN/WQ_\]%_\>_PK]QHX#)L51P>+JYA*ABI9=@*,Y8?
M-8X9Q5/+L-AU'DC47+.,5).32G>4XN7(_9K_ #]QW$7'>48_.\FPO#-+,,HH
M\4<18VA2S/A*KFD*DL5Q-FV8NI[:K0;J4:E65*I&FG*@XTZ%6-/VR6*E^T/@
MK]I__@E3%;? A_&?[&RQ7B^-=2T_X]+9Z-<:FFF?#CP0?'2_";7?#\3:O%;>
M)?%/C*77/!%Y\:K:VFA;Q#'X/O;&>&YBO+>.\X#]N;]I;]COXC?!?P1\(?V3
M_#6K^#=&\,_M,>)/C'>^'$\(ZOX8\(0:;XD^%7@SPOJNH>&;?5[RYGTU=1\6
M:)JUXOAI8[>.QCN'GM+>SL9;:V7\G=\?_/1?_'O\*-\?_/1?_'O\*[Z>%RBG
MB*.)6:5)RH5)5(4ZV<*M0YY2K23E2JUII\BKSA!IQ<8<L>9VO+Y_$9QQMB<L
MQN52X/PE&EC\/3PM?%8+@GZCCU1A3P<)PIXO!X.A.*Q$\#0KXA2C.%2O[2?L
MXJ2C3_II^+?_  61_91\>:S^U/I%G\"[:YT7XC_!GP_X+\-_%.3PE>:=\0_C
M=+X9C\/76A?#7XDV#R2_\(KX9T^XOOB)I-SKUU?ZE:ZAI]WX>D6RM4LG@N,'
MXZ?\%+OV*?VA;.U\&?%?QC\;_B-\*_%_[0'PD^+<7@KQ+\#O">AVO[+_ (!^
M%UG'?ZU\+? E[X7U%M2\=M\1[_38?!U]J"N;;3_#GB#5+V6X;[*\.H?S:;X_
M^>B_^/?X4;X_^>B_^/?X5PT\DX<I.G*ECO9RI<KISCFE%SC*%)48U(2J.I*G
M.R4KTG25U[-16';P[][$<?>*.+CBH8O(/K-+&.JL11J<)8N%&K2K8V6-J8>K
M2P\<+3Q-!RG.ER8R&,ER2^L.K/,E',H_K-_P4T_;1_9[_;LM?A9\5O!7ACQS
MX"^./@[4_&/@+Q3X?\3Z5HT^G:_\(+C4[OQ%\/\ 5(?$OAF.TT8:AX4O;R\T
M"UT:>T?5FTS49+C4+J>:V\^Y_)NF[X_^>B_^/?X4;X_^>B_^/?X5[."GE>7X
M:GA,/C</["CS*E&ICJ%65.$I.?LXSE44G"$I2Y%*[BI./,U:WPF?T>+^)<UQ
M.=9GD&8_VAC51>+J87(<;A:>(K4:,:#Q,Z-.A.FL16A3I>WG3Y(U)TH3]G&7
M.YNHIN^/_GHO_CW^%&^/_GHO_CW^%=?U_ _]!N#_ /"K#_\ RT\?_5SB'_H0
MYU_X:LP_^91U?UQ_\&TW_))/VKO^RK^ O_4$:OY&M\?_ #T7_P >_P *_IX_
MX-_?VC?@K\#_ (8?M*Z?\4_'=GX2O/$'Q,\&7^CV]QI7B#47O;.S\&&TN+A&
MT;2-1CC2.X/E%9GBD)!8(4*L?C..\5AJV1*%'$X>K/\ M#"2Y*5>E4ERI8F[
MY83D[*ZN[65U=ZG[K]'?*,VP/B#4KXW*\QP='_5O.:?ML5@<7AZ7M)U,K<(>
MTK4*<.>7++ECS<TN65D[.W]:5%?''_#P']D#_HL^F?\ A,>._P#YEJ/^'@/[
M('_19],_\)CQW_\ ,M7XX?W$?8]?FIX\_8Z^-%UXK\6^,_A5\3_#/@W5/&WQ
MWUCXJ:_8ZU!K.NZ0!8> 9O#WPW\8:':2VTEMH7Q$\,ZM'9Z=KUM!:3>'?%7A
M$6XU*236M T>9O9/^'@/[('_ $6?3/\ PF/'?_S+4?\ #P']D#_HL^F?^$QX
M[_\ F6H ]5_9[\(?%#P3\/CHGQ8\2?\ "1^(#XBUV^TL2>)]1\=7F@>&+VZ6
M71O#>H>/=8\/^%=7\:WNG+]HDDU_4O#VEW)CNHM-$,T&FPW=Q[E7QQ_P\!_9
M _Z+/IG_ (3'CO\ ^9:C_AX#^R!_T6?3/_"8\=__ #+4 ?8]?(5]_P G[^%_
M^S0O'G_JYOAQ57_AX#^R!_T6?3/_  F/'?\ \RU?+]Y^VY^RTW[:7ASQ@OQ;
MTP^'H/V7O&GAR;4!X>\9XCUF[^+'@+4[:R: ^&Q<EIK*QNYUD6$PJ(2KR*[Q
M*X!^L]%?''_#P']D#_HL^F?^$QX[_P#F6H_X> _L@?\ 19],_P#"8\=__,M0
M!W'[0GP,OOC;=?"7['XCN/";?#GQWJGCNV\2:7=W-KXDT'78_A]XR\.^%M:\
M.I'%)8ZC<Z9XBU_3[C5-&UP_V'K?A\:OI.IP7EM>/9S>#_L]_ /]J?X:^-_!
M=YX]^)_A/4_!NFV'B>X\6Z'X.U?Q!9^%;^_\2W/BG6+[1]$^'6J>&C;VTUQX
MXUVT\;P^/KSQC)KVFZ9!-\/$TB\TD+K$OH'_  \!_9 _Z+/IG_A,>.__ )EJ
M/^'@/[('_19],_\ "8\=_P#S+4 ?8]%?''_#P']D#_HL^F?^$QX[_P#F6H_X
M> _L@?\ 19],_P#"8\=#^?A:@"[^Q?\ \DV^(_\ V<]^U1_ZOOQ[7UU7Y.?L
MH?MN?LL^%O 7CRQUOXNZ79W-]^T1^TCKMK'_ ,([XUF\W2=>^-?C75M(O 8O
M#+A4OM-N[6\CC?;-&DRQW$<-PDL,?TY_P\!_9 _Z+/IG_A,>._\ YEJ /L>O
MS)\5_L<?'2SUG5_$'PA^*GAWPA<>)_C#\;OBYK^EZK-KM[:67BCQAI7Q%T3X
M?>+O!-ZVF7Q\)>)G\.^,K7PO\0;2/3;_ $.<6>G^+='@F\0Z"Z>)?;_^'@/[
M('_19],_\)CQW_\ ,M1_P\!_9 _Z+/IG_A,>._\ YEJ /:?@7X8^(?@_X:Z/
MH/Q0\0#Q'XKMK[Q!.UTVN7WBN?3=#OM?U*]\,^';WQCJFD>']3\97_AOP_<:
M;HM[XLU'0M(O=>N;*2_N;))96>3UZOCC_AX#^R!_T6?3/_"8\=__ #+4?\/
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MX3'CO_YEJ/\ AX#^R!_T6?3/_"8\=_\ S+4 ?8]?%'[2?[-'CGXN^,9_B!X
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M/^.=7T9]/CM[+P9XFUO0Y[+1-2:^:XN#>Z9-):117@:/0G_8*^-,/[+?P_\
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M_P!%E^%/_AQ/"'_RXH_X7O\  _\ Z++\*?\ PXGA#_Y<5^+G]VG9^,/%F@>
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M\+1Z<WB+7[V[\1:YX:\/:7I.E3:UHEB\VHZY;3WFI:SIMAIMM>W$[I%CZ_\
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M#_\ HLOPI_\ #B>$/_EQ4<WQV^![12J/C+\*<M&X'_%Q/" Y*D#DZP .>Y(
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M-*?4AX5UG5I/!OB^.]\#ZY-K?PZ\5IIOB[0-'O/#&L:C8I;>)+(( >2_%'X
M? :T_:Q_90TFU^"7PBM]+U;PG^TE)JFFP?#7P9%8:C)IVB_#633Y+ZTCT5;>
M[DL7N;EK1YXY&MC<3F$H99-WU;_PS3^SE_T0#X)_^&J\"?\ RAKR[XL?\G@_
ML@?]BA^T]_Z8OA?7G7QU_;@A^!_QCN_ &J>$X[_PY;W7PC\)G6'U&PTRYM?%
MWQ?L/BKK&DZM=G4]3LS>^&+&+X:V7AN&ST*PU+5+_P 4>*H5OKG0])TRXOW
M/I;_ (9I_9R_Z(!\$_\ PU7@3_Y0UXY\>O@I\._!GPVOM8^$7[+7[/\ XK^(
M%SXD\ ^'-$TW7/@_H5_H5G#XM\>>&_"^L^(]<M?#/A]M<ET;PEH6KZEXGU,6
M+0E+/29GGN;6V6:XB^48?^"JR2:!!J]U\!_%>E:;>6&FC3O&5QXB\&WVBW^J
MZG=>/M%L%/A6R\2_\)196NI^)?A;XVTV.*YF,FFVD6BZC>W+Q:DRP=#\"O\
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MVVLZI)X@\'^ =$TGXL:%>:/X_P#$&B6OA;QGKNFZ[X5T;48[ZRBN;D ^P/\
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M  :6:1Y&  +$ 5]%?\*"^ O_ $0SX-?^&N\#?_**N#_8V_Y-2^ /_9.-*_\
M2J^KZ5K=)66B^Y?Y'Y]7G/V]?WY_QZWVY_\ /ZK_ 'SR;_A07P%_Z(9\&O\
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M4WBEA>-IX:<\+BH9=C9^UAA:E.<J&,Q5/!8FHO:.%?$QHU*C]M^\\1
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MX1G6_BKX 7P_:7$FF:AJ,NHW=G\#-0_X5_?ZG?W%W\0=/MS;Z61/I&RY^B?
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M.1H4G[/FN_#WP-XD^+5Q\,;#XIPW\TOAG6OB%<#Q[:6&FW7V[P5X4BUGQ!J
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M^3Q[_P"&._9]_P#F%IDGP*_::6.0G]N3Q[@(Q/\ Q8W]GQN I)^4^!@#QV)
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MK,6M:9#H&H31:LC:Y-J)U>^T/P_#J:G3[>\M[GS+QU^S'\6?&?Q)\::_X?\
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M1S-@$3?5/\/\R)PH-I4JBCNFI*M-MN5E:U%=+)K6\GIT1[I\#/\ D[_]H?\
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M!./4@ $]3@>@K^1NOZX_^#:;_DDG[5W_ &5?P%_Z@C5\1Q^W_8"U?_(QP?\
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MZ0/AK>CQGXDU!$GUI].GM+?1=4M;"UN+F2?XP?L<6UAH::M\%(M/T;QWH?\
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MZLNO^.K32+'3TL!:16VFW6LZOJ>FPWNDV=\G_#:WPG_Z$S]H_P#\1:_:#_\
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M[=Q=KQ<I.+L[JZ=5IV>JNG9ZK74^GZ*^8/\ AKKX5?\ 0L?M _\ B-/QP_\
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M8_'/]MT%B0/CAX P"2<?\8X_!L<9Z< #Z #H!7US7R+^SW_R7/\ ;=_[+AX
M_P#6<O@Y0!]=4444 %?%G_#:/AKPYKOBK2?BSX'\1?"^S\)_$6P^$,NLW<K>
M*X/$GQ'U32Y/&=G8>#K#POIU]JFK^&+;X6SZ)\0M<\6W]GHUKH=KK(T.[L6U
M72]56T^TZ\L\4?!'X3^-$O4\3^!=#U8ZCXRT[XA7DTL,T%W+XUTK0K'PO8^)
M!>6DUO=Q:I%X:TZS\/R30S1BYT6)M,NEFLIIX9 #3^&?Q.\(?%WPLOC+P/>7
MM]H#ZOKNB1W.H:1J>B7#W_AS5[O1-47^S]8M;*_CCBU"RN(XY);>/S53<H&2
M!Z!7&>!?AYX*^&>C7'A_P'X<T_PSI%YK&K>(;RST]9<7FN:[=O?:OJMY-/)-
M<75]J%TYEN+BXFDD8!(P5BCC1>SH *CF)$,I!((CD((.""%)!!'((/0U)44_
M^HF_ZY2?^@-0!^9?[&LLH_92^  $D@ ^'&E  .P 'VJ^X SQ7TKYTO\ SUD_
M[[;_ !KYF_8V_P"34O@#_P!DXTK_ -*KZOI6MULC\\KI>WKZ+^/6Z+_G]5\B
M3SI?^>LG_?;?XT>=+_SUD_[[;_&HZ?&H:2-6^ZSHK<XX+ 'GMP>M,QLNR^Y?
MY"^=+_SUD_[[;_&CSI?^>LG_ 'VW^-?B99?MQ?MQP?$BW\(W'[/1\2>'=6^/
MW[3_ (:\ ^*-&\*:A:6/CGP3\'/"GC]_"_PW\0><WG>"?&FH^,="\*3:)XU9
M?['\=^&=9N!I[I?V[A_HK]@_]I#]H'XYZ_XYTSXL0Z3XE\,Z1\/_ (>>*X/'
M.C?!?Q]\#[?PA\3_ !/-J<?C?X!7>C>/IYKKQA?^ 8K6UN9?%NF!86$IAO&>
M2YMMJYE>VOW'74P56G"523H\L8QD^6I"3M)I*R2WN[.+Y974DDY1:7Z4^=+_
M ,]9/^^V_P :/.E_YZR?]]M_C4=%,Y++LON7^1)YTO\ SUD_[[;_ !KYD\>2
MR_\ #7?[,)\R3/\ PJ7]JX9WMG!;X#9'7H<#/KBOI>OF3QY_R=U^S#_V2;]J
M[_T+X#4GL_E^:-:25YZ+^%6Z+_GV_(]N\3?$?PCX,U+1-*\6>)K'PY-XALO$
M6HZ;=ZU>)IFC"R\*0Z9/KD^H:Y>R0:5I26R:QIJP_P!H7=O]LEN5@M?-E5D"
M3_$SX?VL[6UU\2/ UM<H-&9[>X\;^'()T'B.(W'ATM#+JJ2*/$%N#<:%E1_;
M%N//T[[3%\]<C\3_ (+>#_BY?>#[[Q8^I-_PA5Y=7FG65H]@=/OVN]8\)ZW-
M!K%I?Z??1WMJUWX-TN/R5\D&WEO8V+-+$\'DWAC]C+X3>&([?3Q<^(-=\-VF
MK7>OVGAGQ!!X2O+2WUO4OAYJOPRU34$U>'PO:^)I/M'AS59)=/LYM:DL?#6J
MVUM=>&;?285>V<U\OZ[A&-!Q3E*:G9WBJ<9)ZNUI-K6UM&K;ZJVOT*/B=\/&
MAEN5^)7@-K:"P?59[A?'/AIH(=+CU(Z-)J<TPU8QQ:='K"G2'OG9;5-4!TYI
M1>?N:S_%'QA^&_@W3+W5_$/Q \-6EKIVOZ5X4NXH/$&FWVHQ^*=;NK.TTOPT
MNEV=Y-J$FOW3W]M.NC1V[:DMBTFH-:BSAEF3Y$C_ ."=GP>@TFST2V\7_$2W
ML+#PSJ/A6UB1/  $-EJ6IZ5JLFI(H\#JB^(XKS0- NHO$.PZH-2T:RU;[0-0
M5IFUK_\ 8E^!.B:O-KEQXQ\0^&[[Q-X_;6K:?4M6\!Q7&JZMK^O6WB:_\(VM
M]K_AJ6_UFXUW7;!;JQG6YN?&>FVYN],\.:M8Z=<WEM*KR[+[_P"NIIR86_\
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MU7Q%XGU#Q5>!9_#JKR_[)_P,^,&J^ ?'L^F_MA_&C0(8/VB?VDK":UL/!/P
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M3GLG>Y>;Z??]G7XVRHT<O[;?QREC<%7CE^'_ .S5+&ZGJKQR?!-D8>S*1WH
M^6U\9?M-^%O">C>(/#>A?M,>)_C/I1FNOB]X>^('@Z+6_A;>>*'\#>/+2:R^
M'FF:'=^&M/U3P<OCU]&N=('@?Q$MM#X<A\.W=_/=ZNMW97OJ7PY_:!_:T\2_
M$/P5H_BWX%3^'O!NN>,].TWQ)J"?#_QG:3:#X;U'X567B":Z.M:WXCL[%'\/
M_$--4\.Z_JEUI:V<UK-HD/AFV\0WC:RVF>J?\,\_''_H]_X[?^$'^S;_ /.5
MH_X9Y^./_1[_ ,=O_"#_ &;?_G*T >&^+_C7^TWX=BUWP=X2^%_Q3\4Z]<?'
M+XM:/J>NZC\-=<ETO3/A3J^O:S'\/M9\#^,[2]L-&+:-I=[H]YILLNE>)H7A
ML)K'6$TZ13=R><Z?\9OV]M;\->#_  AJOPJU;3;'4?",%OJGQ0M/!7BCPKXV
MU;4]/UG3[34-5?0[_5]?L_AMJ%E:03QW=GXO9AXSL[J_\2>&9M'BCM-)7ZX_
MX9Y^./\ T>_\=O\ P@_V;?\ YRM(?V>/C>P*M^V]\=65@596\ _LV,K*1@JR
MGX*$,I'!!!!'!&* /4_V>?$OB/Q?\'/!GB'Q5<37VJW\.LI#JUQ"MO<:_H-C
MXBU?3_"GB:XA2*&-9_$_A:TT;Q!,8X8HWDU)GCC1&51Y;^SW_P ES_;=_P"R
MX> /_6<O@Y2+^SO\;D543]MWXZ(B@*B)X _9K1$51A51%^"@5%4 !54!5
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M.W_A!_LV_P#SE:9)^SU\<%CD8_MO_'; 1R<> OV;2<!3R,?!93D=OF7GN.M
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MF?''_P (;]G[_P"=91_PHOXO_P#1YGQQ_P#"&_9^_P#G64:]OQ%R0_Y_0_\
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M4[*WTUCH&I2I]NU\=_\ #?/[*/\ T4O4O_#8?%S_ .8.C_AOG]E'_HI>I?\
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M((^*>I AVD!'P]^+@(=AAG!_X0?[[#AFZD<$D4S_ (;;_9F)!/Q/O\J<J?\
MA77Q:RI*A20?^$&R"5 7(YV@#H!1_P!O?U]Q4H2?PX&<=4[_ +^6B:;6JMJD
MXO39O2YY_J_QL^._C3X.76K^$/ B^ /B;<?%?X1^$=)L()9-8LY?"OQ$3PGK
M5QJ$NH>,O!,UII5UI6D^(KC2/$NHWOA;5],T'4],O9(VF*@Q<#I?[57QW^'$
M5AX<^,?PZT;QCK[?$$>&KKQ;X.L?&>C:/=Z(?&_B/P;JM_;:=#X,O[#3O[".
MAQ^(--GO=3>'7?"=PM_Y@U.6&R/OI_;:_9F)R?B??$X9<GX<_%HG:Y)=<_\
M"#='))8=&)).<FG+^V[^S0GW/BCJ"\;?E^'?Q;7Y<!<<>!AQ@ 8Z8 '04>?-
MT_K0%&:33P+<7)R7NU5*-[62G9RY5;9WNVVV<;\%_P!JCQE\4_B!X)\%:O\
M!Z?PA8^*/ .K>*;WQ+<:EK9L;;7--UGQ-I4NEZ"FJ^'=)B\0:)8MX=BBU#7%
MN[,RSZUI-[IUO/I-U%</Z)^S3\1=7^)'ASX@7^J>+;CQI:Z#\5O%GAGPSK6I
M^#/^$#U^?PMI2:?;V<NMZ!%IFE6*?:]8BUZZ\.W=I;&6]\(/X?N]4EDU*>XD
MDS6_;<_9H<,K_%'4'5V#NK?#OXML'=0 K,#X&(9E  #')   -))^VW^S/,0T
MWQ0OY65=JF3X=?%IRJCHH+>!B0H]!Q37K<F5.;4E'"5(7Y;6C4ERN,I-M.47
M+WE)1=FE:*T=[KU_X&?\G?\ [0__ &07]F3_ -2K]HBONJOS7_9)^*/@/XL?
MM3?M'^(/A]KLFOZ/:_!3]FK2[B[ET3Q%H+1W\'B7]H&>: 6GB72='OI D5S
MWGQ6SVS;]J3,Z.J_I16+W?J_S/L<N3C@<+&2<6J233333YJFC3U3"BBBD=I_
MG5?LHZ#^SQXH_;V\+Z'^U7J.EZ=\#[WXA>/?^$F;Q#J=SHGA>_UB*W\0R^#M
M(\6ZW:%9M'\,:KXK72;36=1+Q01V[^3>30V4]Q*GZ46W[%W[-?[2?Q'\86OQ
MJU;]DC]C.[\,^ A#X6TG]D_]IWX5Z]X3U^]UK6/&<'AGQ5XO@\6/JEO=ZQ;+
MHNC6-YI.CZMH+OH^H0:SK+:7<WMAIR?G/^QU\!O ?[3G_!0CP;\"_B=#K=QX
M$\>^/?BE;^(8?#FI/H^LO!HGAKQOXEM?L>I1P7,EL%U#1K1[DI"YDM%GA^7S
M-Z_H?X__ .",/PO^*'Q5L-)_9@^(VM>#?A]=?L^_#SXYG4/$OA?Q!\;? >N?
M\)7XB\1Z)XAT/X6?%?P]:>%4\7>);"WTC3)]$\#:CH5AXA\175Y/'!+IL-M<
M+:?M5?%8>C_9T*F;8[+:W]@8"<:M.A*MA:$%2P]ZD?WZIQKUOX=2%3!XESA&
M#ISH\LV?PA@,HS+'/B>MAN#<@XJP?_$2.(Z%3"XG'PP.:X^O+&9DEAZMLNEB
M9X# Z8C#U<-G65QHUZM>.(HXYU*$3D/VI/@?^PFGPA\.:+X?^(/P"^#/B1_B
MO\!M)\2_%#P:C?%'5=(T-OV/4U[QQ WA;X>ZUJVNZMH6N?&*$VNLZGIUO+9:
M?XMN@VH7L;I+"V%\./V3?^"??CKX2_ W7/B1\>(-'NM/\%Z%I'B*[^%GBGX:
M>"/%OCC7O'W[6OB3X9VGB_QCHWQ"CU#5K"+PS\/+W0O&=]9:E:V&LZ!X!L6N
M;^-XH5EK\0M1T^#3-4U.QAANHQI^HZCIR_VCI;Z-J@2TO9H-NI:1,\MQI%^6
MBW7^DSS33:==^;9S2RRP-(U(PPLQ8Q1EFR68QJ6)9=C$DC)W)\AR>5^4\<5[
MD<JQ,</"E#.LPC*-6=;VR]DYOVL.5Q3FZLDK-<JE.I"-ER4XRYIR_/:O&655
M,QKXROP+PW5A/"4,$\'-XN.'B\)7=2-64*$,'2E-SC)5)PH8>M6NU7Q%:DJ=
M"'ZW_LH_L,_LR_&CQ]^UGX+^)W[26D>"],^#7C/7O!/PD\7+\3_A;X2LO'2P
M3>,[?PYXM^P>+4N(O%^BZA-H&BQW<_AW5M'TJ!-7\T:HQN;18_=%_P"">O\
MP3TOM;\.>';?]KC7-,U+2?%/A[PUX[34?BO\"/[.\=7_ (F_9VE^+-EIGPM\
M31PQZ1X7@MO'B1_#G4?%_C(:IH.FZR\^DW!_M!;2:?\ !MX(7"J\,3A!M0/&
MC!%XX4$$*.!P,#@>E)]G@QM\B'&TICRTQL9MS+C;C:S?,5Z%N2,\U=7+\PJ5
M9U(9[CJ,)0IJ%*G2PW)"<*,*4YWE&3E[6495G%VC"K-N#]R".?!\3\.87!T,
M-5\/N'\;6IUL3.MC,3C<U]M7HUL=6QE"@XTJE.%+ZI2G2P,*L>>=;"X=0KQ?
MMJ\G]W?\%'?"7P9\"?M5Z]X7^ %IX3L/AKIWPU^#?V:T\$^)/#WB[18O$TWP
M]T>7QB)_$OA.ZO/#NL:]_P ) ;P>(K[29A:7&K"YFBBA214'PQD^I_,TQ$2-
M0D:+&@R0B*%4$G)(50 ,GD\<FG5Z.&ISP^'H4)5JE>5&E"FZU24O:57!-.I/
MWY>])N[]Z735GRV;8REF>9YAF-/!8;+Z>.Q=;%0P.%A!8;!PJRBXX>@E1I)4
MJ2BHPM2IJS?N1V%R?4_F:,GU/YFDHK>[[O[W_F>?RQ_EC_X#'_Y$7)]3^9K^
MN/\ X-IB?^%2?M7#)Q_PMCP&<9XR? 9!./4A5!/4@#/05_(W7]<?_!M-_P D
MD_:N_P"RK^ O_4$:OB>/VWD"NV_^%'![MO[.*[MG[]]&U)>(U2R2_P",9SO9
M)?\ +S*>R1_3+1117XH?WH%%%?FUXZ_;MUGX7^+?%>E>// ]E9^%;'XZZO\
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M/B.TCO(W_#3W[5/S.S,>?C[X^<\L2>79F/JS,QY)-?6]?(O[%_\ R3;XC_\
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M'5_7'_P;3?\ ))/VKO\ LJ_@+_U!&K^1K+_W8_\ OIZ_I[_X-^I_VBXOA?\
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MS_U<WPXJ/[9^WY_T+G['W_A:_&G_ .8&OE^]N_VV/^&TO#C-X?\ V5_^$O\
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M8+^<QO$R&:^@O;R&\E(WW,5W<QS,Z3RJ_P G_;/V_/\ H7/V/O\ PM?C3_\
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M\[:B@)I_AWPYI$[76D>'/#ND7;V=OIS7>DZ%I.F7;:;9@"STUKJQL[><Z=:
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MO6=/7Q%?^*M.T"#1(]0NM$OM/N9]!TO4M"CU#6-(>ZA&JA;1$EC: DY'V_\
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M!1110 5_7'_P;3?\DD_:N_[*OX"_]01J_D<K^N/_ (-IO^22?M7?]E7\!?\
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M+3?B,\-UX:\%_$+5;RULX;"[%K;:E=:-9>$;S7HKP:UHDEWK-A9^'YI;NRD
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M\7W=G<:C!J6K>&=)@T62]TH:F]O>0^']4\KG_;(_9F\2>!M>^.H\!Q:M8_\
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M^(+^>WMC+Y*'5-5\2:]<:P@3RM8BU6]LM42[L9C;5YQ_PQC\)_\ H;_VE/\
MQ+C]I[_Y[-'_  QC\)_^AO\ VE/_ !+C]I[_ .>S0!]9       8 '  '0 =
M@*^1OV?%8?'/]MTE2 ?CAX P2",_\8X_!L\9Z\$'Z$'H14__  QC\)_^AO\
MVE/_ !+C]I[_ .>S63I_["?P*TF_UW5-+UC]H+3M2\3W]OJGB._LOVJ_VEK:
M[UW4K33;/1K74-6N(?BJDM_>6^DZ?8:;#<7+22QV-G:VJ,(8(T4 ^R**^3?^
M&,?A/_T-_P"TI_XEQ^T]_P#/9H_X8Q^$_P#T-_[2G_B7'[3W_P ]F@#ZRHKY
M-_X8Q^$__0W_ +2G_B7'[3W_ ,]FC_AC'X3_ /0W_M*?^)<?M/?_ #V: /K*
MBODW_AC'X3_]#?\ M*?^)<?M/?\ SV:/^&,?A/\ ]#?^TI_XEQ^T]_\ /9H
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M748@R2R)*KHQ6O!H?V$?V5;:WU.RLOA8NGV&M:1HWA_5=.T[QCX_T_3K_1-
MN]-O],TNYL+/Q5#:2V<5_I5I?S1M"3>7YNKZ[:>\OKV>< Y35?VR/V4?A?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 F\# 2(  A$! Q$!_\0
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M\SD?^'UW_!4#_HM/P*_\1Q/_ ,\FC_A]?_P4Y_Z+'\"O_$93_P#/(KYWT?\
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M\/>).#G*_J=\5_V=(M<MOB_XP^$D'@GX?_'[XL^ ]-^'NK?%?7_"'_"2B_\
M"VA,Q71=>T,:^G]NA(]:UI5P0N79&+L$D?Y8\1_\$RO!EQ^P[\!OV*/!GC(:
M?X=^$OQ)^#OC[6/$6O>'-'U7_A.W\!^.!XY\>#7=#3(!^*KC7EDSG8==.2,-
MCT/K&$LKQN]$]NVO1_*[OYH#Y)^+7_!1/]J'X&W_ ,</@1XC'@GXH_%?P?\
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M=XQL+[1+;4/C#\$]+_9]\=Z3_8Y/AG7O >A^#/\ A!=#SHG?Q%X3\.X/_"4
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M-;Z3>VOBRT\#>+6_9]^&WAAM;;0]<UCXI_%#0P7T'7F"-_PAGAE%_P"*N.U
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M]H>A#6]<\0=/#OA3P[K6M$^%O^ASUWM7GW_"PO O_0Q:=_X":S_\S=?V_?\
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M8'-HREV3BV^VS;N]]C[^HHHKQ3[8**** "BBB@ HHHH **** "BBB@ HHHH
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M^V9X$'C[X+^*;;4Q:6G_ !47A.[_ .)?XY\):J!N_L;7=#(RI&" <E<XY)(
M_A"_;!_9T\.?LZ^//A_I?@[5=;UOP_\ $;X0:9\3;/\ X2RS_P")GH(US6M>
MT'7=%'_(H_\ "0?\@3/_ ")^/^)_WKS?]G#QM\=_AQ\5-'\8?LVZWK7ASXCZ
M8/MIU72KP:;IECI7(QXY!_XIC_A'#_U-GO7S6=<(X3/L*\;@5R3>K2TN^ETK
M==+I<UNKL<F*Q>"P."EC<;-1C&[;;BK)7;U;26B?5=S_ $S%XZ-D>G3USC/^
M?6GY/'R_7D<<_P"37XM_L>?\%2?AU\<8=!^%OQBU;P[X2^-XL--LKW5K+S--
M^&GCS4U!.N?\(+K6N[FW<MGPOXH D)"@!B%"_LC!/#=0@P$KZC)P1Z=1]/?'
M..17Y=B\KQN58AX7%Q:4=%)IV\M;6LU;KZGC9-Q+P[Q!?^Q\VC-J5FHRBW=-
MW37,WT?^9N457JP2!U('UKSCZ3YW"BBB@ HHHH **** "D/0_0TM5_-'EY[X
MQ[8__5V_7-)[/T?Y <[K7_(,O_\ KW7^M?Q!:5_R#(?^OWQ1_P"GKQ!7]L7B
MG7?#F@Z3?'5-<T;3<6Q)%Y>Z3IY Y'/F$-[C(('10>M?Q*^'+R#4_#UA?6-Q
M:W.GZH=5O;.[M/\ D&W^EZ[K7B Z%K7O[Y K]1\.5>=2Z3UCJTG]A]T_ZL?R
M9]*!M97E5F[\VMGK\2WL[FO115BOUAVN]MWV[L_C-.5EK+9=9=EYE?\ Z>/U
M_3_ZW7W]Z^GX/V5_&,]K\ ;[^V]-%M^T#>_8;/[)9C_BA<Z+_;V=; ).!X=)
M\3<X.>Q7!/S!-^^BN(/^?D_Y!Z^M?:\/[4^EZ;JOQ=,'AW4O[ UWX;Z7HOPM
ML[N[SJ?@7Q1H7@O7_ FA^,_0?\4[KFMY."2 <8)!'C9E];6N#2TZ)*S^_MO\
MK'U7#DN'[/\ M>33MH^9Z;^?>WEW/F";X;^/X?!UQ\18/!VMW/@"T)O;/Q6+
M/_B67^EC6O[!T/6LX_Y%WC/_  E)_P *]'U[]GOXCQ>,?$'@[P/X<\2>-KCP
MQ9^&/^$DN]*T<:=]@\3ZYH^@Z[KFC<$Y\0^%!K>1W]1D5W%U\=_ *C^U;'1/
M&[>(?%'PY^&7P9\7Z3>WNC'P/X3\">"&T(ZZ/ YX_P"$@\0^*O[%PF.0NN^)
M1DXS7<67[4WP^FUFP\9>(_#?C7_A,?#'Q'^,/Q \.:7X>N]%TWPWJ&I>-QG0
M-8UT]3XA\(^'=%T7PP <@%B<#)SYV'Q&;]OO7Z\OE^/H>VZ'#OO)9M*VMM]M
M;:7[/\%W/E@_"7XF_P!@V_BJ#P/K=SX?N=9.BVEW:?\ $R_XFFN:S_81T4_]
M3$/$?4?SKL-'^ /CC_A*/^$<\<:5K?@&WM? GB;X@7FK:M9_VE_Q*_ VB_V]
MKO;MC_A%_H">QKU#PY\>/ASX0F^$'_"*V'C[^S_!S:I?>/-)N[/1M-_M_P =
MZ[HVOZ#KOQ,_MS_F8/$/A/\ MS_BBA_S)GMS6/>_'CP?:?#^_P#AGX-TOQ:-
M.M/ NJ^&O#OB'Q8,^)M1\3^.O&6A:[XYUC6^1M(\/:(/#)\+Y/ (Q\V:Z/K&
M;=5U7V5WUW2V.?\ L_A["X3ZVLWN[[<SU=W9)7OJ[+;J=1\,?@;X \2?"_P_
MKFJV5UJ5_P")[/2[W[9:7FL_VG_Q/=:T#^W?[#S_ ,4Q_P 4H-;_ .*V_P"$
MLY[UX]\/O@U_PFOAKXO^+I]5N;;PQ\)QIMH+OP]9G4M4\6^)];UK7=!T/H,?
M\(]G11XG(..?$'MFO*+/Q)XCTW2Y]#L?$>MZ;I]UC[9I-IK']FZ9?_7OC\#_
M %KT#X;_ !.@\!^'?&%C_95SJ6H:]XN^#OC/1_M?_(,_XM5XSU_7==T;7,_]
M#9_DUU8E9M]4_P!EY?.Z5[:7OI?N<N&Q7#V+Q?U3%N25M))M>CW6FS,^\^!O
MQBT>Z\/V.J_#GQ);7_B>\^QZ/:&SXO\ 5/\ D/?V+_V,7/\ R*W;TQ@5CGX>
M^,;+QOI_PYO]#N=-\8:IK&EZ+_9-X,ZG8:IKN?3T/H/6OJ?3OVC_ (<^$/%%
MSJOA?2?B/J=OXI^-*_&7QX/%MWHW]I:#J9T;7SHFB^"">H;Q%K>M >*,?+X+
M'AG).[ \ ^$'Q!L?AE\0KCXC:K977B/4-+TCQ1?>$+2[_P")GIO_  D^NG=H
M6LZY_P!2[X3.N#OG'0BN7#_7;/2^CT=]6O562O>W4ZL10X>6BS=^G,^^B^+T
M7W'7ZG^S??Z/\6;[X5ZMXWT7[!IG@74OB9_PL&TT?6=2TV^\,:'H_P#;NN_V
M)HF=OB#:/^*9/.<# !. 2S_9PO?$EUX?OO!_C+3/%O@[QEX2^)WC'PWXLM-'
MUG3-4OM5\#Z-_;NN>#-<T,D>)O#_ (BR0!U)X !/%>@>'/VD/!\Y\#S^-_ Z
MZ9J'A;P-\3OAI>7?PRL?[-TW4/"_CK1O^)*-$T/7R,^(O"OB'^W .F#\Q!Y%
M8_ASX^^#?AQ_PA_ASX=:5XWMO!_@WPC\8;2U\0ZO>:*WCC7O'?Q4T;^PQXS"
MZ!QX>\.^$SH9YX/ /) QS?6,WU26NR]U?)[>AWK#\.63<TU;6TM]/\7K^IP_
M@[X!:KKUCX(U3Q%>W7@K3O'9^,(!U;PUK U+0M+^%>C:#KNNZT-$SGQ"?%.T
M'P5P.",$G(KD/&O@.#PWX7\(>/O"GC+3?B!\/_&%[JFBVGB&TT?6?#FIZ?XH
MT//]N:-KFA^(/^1?\1$ZV<=CTSG->S^%?VD(1I?PPTOXJ7'C_P 6_P#"&GXZ
M6?B/Q!]K_M+4AX6^*O@PZ%H9T/\ M\_\RJ./KSGK7D_CSQAX(F\'>$?AG\,K
M+Q+_ ,(?X9\1ZEXTO=5\;WFB?\)+XL\3ZWHVA:#D:'X?'_"->'_#WA3PYHN#
MDD#:, $L:Z<+_:WUK_:UIINE:VNW3MYG/F4N'/[)?U.3ND_M:W5_.]WKY?*Q
MY15?][_G=117T+V?H_R9^<K%N^C>_P#-+OY,(._X_P!*_5__ ((\_P#)=OCK
M_P!DX\"_^GKQ!7Y05^K_ /P1\_Y+A\=_^R4?#;_U,/'U?+\7?\D^_E_Z4C]I
M\%)-\;-.3:L]Y-KX;[-M']'-%%%?@!_HP%%%% !1110 4444 %%%% !1110
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M_P#"':"4)#JP%FS^ /Q&FT87T_\ 8FB:Q=6GBC6M&^'OB'6!IGCG7M,\"_\
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M/!/@G3]+L_#&BZ/I/A/P?_9NF:%I>B>,_P#A.]$.B<^+N?\ A(\_C]*V+/\
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M_&#]B?7=!M=0\5? B]U+XD>%[7_3;SP1JW_)7_"6EGO_ -5 \.D?\S3X3/\
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M .W?@O\ V'X@\-^+O$X\1>+/[<T/_H3O!?C3C_BN..?R7HKH_L[#=Y?^!/\
MS _5?1_VNOV5_L'A^>^^'-OHGB'QEX;\4?\ "[/LGPWT;4M,L-4T(^']!^%&
MB^!_^I>\6>'/[<\4>-Q_T.GOT\0_:$_:6\#_ !@\1?!_Q5;SZE;:A\.?CO\
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MBUJFK)ZJY_9T#DD8/&><<<<4'W]?7TYSSCTR?ZU\Y? +]H_X5_M'^$K;QO\
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MZ7Q/XQ\0M?:5HDNN:OI.'\1^)?$P !UMSO+IN'*$?(!]<A0.G7W]/TICLX/
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M0_\ F7_\\4 >_P#[1_[9?Q&_:$NKC2<W/A/X7_; +3P3I-V,Z@.?^)UKFN
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MO*W_  YT'Q(^)&N?%/Q';^(_$<&B:;_9?AO2_!?AKP]X>L_[-\,^$O"^A_\
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MJGB?1;;3OC%X8^&*_#>YL[$CQ+X!\=> M&UP:%XR&M8R/^*A<%55>5Z8X%>
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MP/KYAXV\!ZYX#\27'@[Q'8VUMJ%K9:7>_P"B7G]I:9?Z7KNB_P!O:%K6A_\
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M>,++_A(_AS<W8L_#GQ6TFT_XEM\,D#1M='7P_P"(25.UN0VTE217R#_U[_\
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MG@C0O$"K_;_AP8 5@223R!W^5O!__!+[7)_#WQ?\'^./B'X=\)^!_B?\-G\
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M7/\ BJ>G_$_S[UX_10!] 0_M1?%O38KB"QG\-Z;J&J7FEWMYJUIH_P#Q,_\
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MN]>6S[]D]?RZGM&@_L$6/BG1O^$JTOXT6W_"'ZGH^E_\('JVK>#_ .S=3O\
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MD%%%% PHHHH , ]1FC '08HHH%9=E]R_R"BBB@84444 %%%% !1110 4444
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M=6UQ:_\ +W^/^>OOZ5Y/X\^#^E>,)+C5?"O]F^&_%%U_IMYI/_(-\,Z]J?\
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MN#K7A]% 'TQ9_M7>,=-BUC[#X5\-_P!LZI>:7>V>K7=YK.I:98:IH/\ 8/\
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M22^U$"?2?BC_ ()(_LI>,/'OB'QA?-\4-/\ #'COQYIGQ.\>_!+2/B1K6F_
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M #^7M_+VKQ[X/?$*P^)GPN^'_CRWGM?L_BCPYI>LW04!0NJ<_P!MA>R[=?!
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M%A_$#_H<M;_\##_C1_PL/X@?]#EK?_@8?\:XZBG_ ,1+XQV_UNXJ_P# Y_\
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M%BBBBK **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHI/9^C_)@(/ZG^9JLTH/)SP/\]ZLC^I_F:R)
MO]5_VZ_X5YN*<HX.<HIN2C-Q2O=M1DXKYM)?,<?BC=V5U=]DVDW\DV?)MG^U
MK\)+SPO\1_'$-QK5S8?";6=4T7Q?:"R8:I8:F-9_L+;_ &*",\C.2!E<Y&<D
M_1]EK]A<0V'^G" ZG9_;+6TN[O\ XF1R,D 9/ R,\D ]>AK\2O&'[/7QBL_A
MUXX\8^#O WB3_A*/$_CWQYX8\>>$O^$;_P")GXM\!Z[XT.O:%K6A:'_U*8)'
MN">Q-=M\3/A!\3=8^,GB&;5;'XD6W]IWW@2]^''C;PI\./\ A-_[!TW1-&S_
M ,AS_A)?"7_"OAX5\1L#XU!.?&:L,#H*_!L/XF<<X7&RCB^%)N*E**=I6<5-
MQ35HO5Q47KU9]UB<EX>:C]4S9;7:>]^177;XF_DK;O3]C_[3L3Y_^GVQ^S?Z
M)='[41C4ACKD\'IV!R>!\I%/&IZ4;@6/VZV^TXS]D-V<_7'7DU^/WCSP?\38
M9OCQX)@^&7Q(UJX\8_M'^ _B;X<\0:5I&LZEX8OO#&AZU\/SKN=<'&0-"US_
M (I;G ).<=>GO?@EXWU+0OVO];TOP?K6G?$G7O'FJ6?A#5;L#3=3\0>!%T;P
M]_;FC^!];.3CQ5X=T/6_#!*_=;:<\"O9_P"(G9UB<4L)_JI-6U;Y9[[O7E5T
MO6WR/.>2X/ZJW_:L;WT^&]KI)[W22;Z7TMOH?JS::E8W<68+ZUN3]KZVEY_:
M(]<$]0,\GCOD>Y#J5C-;>?!>VUS;]S:WA_G_ #[GK7X_2_#?XCZQ8?%"?X,?
M"OQ]\)?"-W\+/#.BW?A+56UGPYJ?BSQ/H6N#7=;_ +"T/_A(E/\ PD1\-_VW
MX8/BC!_X3(MC<P"D]AK'@FXUCX5ZC!\+/@'\4? &@?\ "=^!+WXC>$M6L_\
MA&]3^)7A;0S_ ,3[1M#T+_A)!XE; VXRG@__ (3(Y^8AJZ?^(FYSLLGE_P"
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M>UUCPO9>,+2TT?6=2U/0?[=UK^P="T7^W/\ F8/$7BPZ'KG7_D2_7!->;_\
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MW>CVU/Z!O^"?GPW/PX_9P\,3W\'V75_'8U+QIJ_VKO\ V\<Z'GL1_P (X-#
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M_P!/QP7X>ZOJWP2^)'ASX(_ KXM?"_XGW?PZ\"67B+5M57_A'-,\6:GH>LZ
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M(0 #_P AX\BN O/@'JFD:6M]?>(],MO[#L]3O?B-:Y7^T_AMG13K^AZ+K7S
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MS=G63JEAJ@_X1_\ L31=;Z$^(?%1UX>)_!+8 Y&<9%>$>%=8@T?Q'I]]??\
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M#C_/^,OROZ7U^]^A]IEV(EBL(L7BURR=M&FK;*UM&]?+IY%NBBBL#T@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHHL@,__ ):_Y_O57,,'^D?Y_K_+IVSS6Q5?RH?3]#_A7+]5A_+#_P !C_\
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M[/[8\ ^&GE/#TLXE&TL[U:<;26O7F2DM^J0_M^_QTY]/T[=>GX]ZKS0_Y/\
MG\CCU!%6/];_ )QC'Y^OOU_*Q7*?T(TGHTFO-7_.YF%(3GWS_=]_?W'Y>]3B
MW3/WOPR?\/<?E]:GVKZG\C_A['_(Y JYZG/T(_I['_(.7KYG-[#"](Q^_P#X
M!3P/,QCC_P"RQGZ^]+Y/[K/?_P"MTZYZ?_JS6A12']6CV7W+_P"1,[ ]!^0J
M?R!_=_\ 0:=133M_P[7Y"^K1[1^Y?_(E?R/?]?\ ZU'D>_Z__6JQ^Z_SMHK;
MVOG+\ ^K1[1^Y?\ R(>1[_K_ /6JOY'O^O\ ]:M"BL#ILNR^Y?Y%?R/?]?\
MZU6*** LMK*W:RM]UK!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(=X!_P#!,O\ \=HHKLLNR^Y''_8V4_\ 0NPG_@B'^0W_ (8>_92_Z(=X!_\
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3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530197622792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NLS Pharmaceutics Ltd.	<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">6,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001783036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199797160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,711<span></span>
</td>
<td class="nump">$ 220,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets, including related party of $0 and $13,432 as of December 31, 2020 and 2019</a></td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">161,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">196,711<span></span>
</td>
<td class="nump">381,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">946,912<span></span>
</td>
<td class="nump">260,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, net &#8211; related party</a></td>
<td class="nump">67,954<span></span>
</td>
<td class="nump">54,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,211,577<span></span>
</td>
<td class="nump">696,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, including related party of $454,315 and $34,727, respectively</a></td>
<td class="nump">4,006,473<span></span>
</td>
<td class="nump">2,509,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">316,174<span></span>
</td>
<td class="nump">170,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes &#8211; related parties</a></td>
<td class="nump">591,693<span></span>
</td>
<td class="nump">540,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of credit facilities, subordinated &#8211; related parties</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current portion of convertible loans, including related party of $113,130, net of discount of $37,362 as of December 31, 2020</a></td>
<td class="nump">463,980<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge loan</a></td>
<td class="nump">565,650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued salaries</a></td>
<td class="nump">459,195<span></span>
</td>
<td class="nump">102,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities, including related party of $40,842 and $12,391 as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">650,753<span></span>
</td>
<td class="nump">562,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,203,918<span></span>
</td>
<td class="nump">4,035,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible loans, net of discount of $4,248 and $64,788 as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">32,463<span></span>
</td>
<td class="nump">152,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Swiss government loan</a></td>
<td class="nump">281,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">2,499,969<span></span>
</td>
<td class="nump">2,499,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Accrued pension liability</a></td>
<td class="nump">178,269<span></span>
</td>
<td class="nump">180,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,195,634<span></span>
</td>
<td class="nump">6,867,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, CHF 0.02 ($0.02) par value, 10,440,000 authorized, 6,960,000 shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="nump">145,139<span></span>
</td>
<td class="nump">145,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">20,649,882<span></span>
</td>
<td class="nump">20,600,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,759,697)<span></span>
</td>
<td class="num">(26,898,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(19,381)<span></span>
</td>
<td class="num">(18,698)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; deficit</a></td>
<td class="num">(8,984,057)<span></span>
</td>
<td class="num">(6,170,950)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; deficit</a></td>
<td class="nump">$ 1,211,577<span></span>
</td>
<td class="nump">$ 696,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199761608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Other current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AccountsPayableIncludingRelatedParty', window );">Accounts payable including related party</a></td>
<td class="nump">454,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Related party, net of discount</a></td>
<td class="nump">113,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Net of discount, current</a></td>
<td class="nump">37,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities, including related party</a></td>
<td class="nump">40,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Net of discount, noncurrent</a></td>
<td class="nump">$ 4,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in Francs per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in Shares) | shares</a></td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in Shares) | shares</a></td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in Shares) | shares</a></td>
<td class="nump">10,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AccountsPayableIncludingRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable including related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AccountsPayableIncludingRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530204415208">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 99,580<span></span>
</td>
<td class="nump">$ 897,788<span></span>
</td>
<td class="nump">$ 708,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,199,790<span></span>
</td>
<td class="nump">3,299,251<span></span>
</td>
<td class="nump">2,740,406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,299,370<span></span>
</td>
<td class="nump">4,197,039<span></span>
</td>
<td class="nump">3,448,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,299,370)<span></span>
</td>
<td class="num">(4,197,039)<span></span>
</td>
<td class="num">(3,448,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(328,365)<span></span>
</td>
<td class="num">(65,445)<span></span>
</td>
<td class="nump">16,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(86,792)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense on related party loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(146,908)<span></span>
</td>
<td class="num">(818,719)<span></span>
</td>
<td class="num">(1,084,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(364,950)<span></span>
</td>
<td class="num">(629,232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,861,435)<span></span>
</td>
<td class="num">(5,447,145)<span></span>
</td>
<td class="num">(5,146,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DefinedPensionPlanAdjustments', window );">Defined pension plan adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(683)<span></span>
</td>
<td class="num">(7,444)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,862,118)<span></span>
</td>
<td class="num">$ (5,454,589)<span></span>
</td>
<td class="num">$ (5,148,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used in computing basic and diluted net loss per common share (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,960,000<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="nump">6,240,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Comparative figures for the years ended December 31, 2019 and December 31, 2018 were restated to correct the classification of intellectual property expenses from research and development expenses to general and administrative expenses. For further information, see Note 3 &#8220;Restatement of Previously Issued Financial Statements&#8221; to the financial statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DefinedPensionPlanAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>pension plan adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DefinedPensionPlanAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199731048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements Of Changes In Shareholders&#8217; Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2017</a></td>
<td class="nump">$ 128,344<span></span>
</td>
<td class="nump">$ 8,468,547<span></span>
</td>
<td class="num">$ (16,304,351)<span></span>
</td>
<td class="num">$ (9,993)<span></span>
</td>
<td class="num">$ (7,717,453)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in Shares) at Dec. 31, 2017</a></td>
<td class="nump">6,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares for conversion of related party debt to equity</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">4,042,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,047,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares for conversion of related party debt to equity (in Shares)</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Debt discount on related party loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,019<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax', window );">Defined pension plan adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,146,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,146,766)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2018</a></td>
<td class="nump">$ 133,544<span></span>
</td>
<td class="nump">12,515,118<span></span>
</td>
<td class="num">(21,451,117)<span></span>
</td>
<td class="num">(11,254)<span></span>
</td>
<td class="num">(8,813,709)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">6,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares for conversion of related party debt to equity</a></td>
<td class="nump">$ 11,595<span></span>
</td>
<td class="nump">8,011,605<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,023,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares for conversion of related party debt to equity (in Shares)</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Debt discount on related party loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature on convertible loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65,608<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax', window );">Defined pension plan adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,444)<span></span>
</td>
<td class="num">(7,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,447,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,447,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2019</a></td>
<td class="nump">$ 145,139<span></span>
</td>
<td class="nump">20,600,871<span></span>
</td>
<td class="num">(26,898,262)<span></span>
</td>
<td class="num">(18,698)<span></span>
</td>
<td class="num">(6,170,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature on convertible loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,911<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan', window );">Beneficial conversion feature on related party convertible loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax', window );">Defined pension plan adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,861,435)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,861,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2020</a></td>
<td class="nump">$ 145,139<span></span>
</td>
<td class="nump">$ 20,649,882<span></span>
</td>
<td class="num">$ (29,759,697)<span></span>
</td>
<td class="num">$ (19,381)<span></span>
</td>
<td class="num">$ (8,984,057)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial conversion feature on related party convertible loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BeneficialConversionFeatureOnRelatedPartyConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530197333336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,861,435)<span></span>
</td>
<td class="num">$ (5,447,145)<span></span>
</td>
<td class="num">$ (5,146,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PeriodicPensionCosts', window );">Periodic pension costs</a></td>
<td class="num">(4,258)<span></span>
</td>
<td class="nump">20,085<span></span>
</td>
<td class="nump">26,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="nump">72,188<span></span>
</td>
<td class="nump">755,555<span></span>
</td>
<td class="nump">1,090,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on conversion of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">364,950<span></span>
</td>
<td class="nump">629,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,477)<span></span>
</td>
<td class="num">(16,038)<span></span>
</td>
<td class="nump">7,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Other receivables, net - related parties</a></td>
<td class="num">(13,482)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(41,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,497,123<span></span>
</td>
<td class="nump">1,378,545<span></span>
</td>
<td class="nump">565,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Interest payable</a></td>
<td class="nump">137,826<span></span>
</td>
<td class="nump">67,159<span></span>
</td>
<td class="num">(5,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,499,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">446,129<span></span>
</td>
<td class="nump">185,911<span></span>
</td>
<td class="nump">140,873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(729,386)<span></span>
</td>
<td class="num">(190,009)<span></span>
</td>
<td class="num">(2,732,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from convertible loans</a></td>
<td class="nump">249,306<span></span>
</td>
<td class="nump">154,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible loan &#8211; related party</a></td>
<td class="nump">113,130<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProceedsFromSwissGovernmentLoan', window );">Proceeds from Swiss government loan</a></td>
<td class="nump">262,137<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProceedsFromBridgeLoan', window );">Proceeds from Bridge loan</a></td>
<td class="nump">565,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from convertible promissory notes &#8211; related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">512,800<span></span>
</td>
<td class="nump">557,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred offering costs</a></td>
<td class="num">(686,701)<span></span>
</td>
<td class="num">(260,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">503,522<span></span>
</td>
<td class="nump">407,479<span></span>
</td>
<td class="nump">557,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="nump">99,308<span></span>
</td>
<td class="num">(3,881)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="num">(126,556)<span></span>
</td>
<td class="nump">213,589<span></span>
</td>
<td class="num">(2,176,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">220,267<span></span>
</td>
<td class="nump">6,678<span></span>
</td>
<td class="nump">2,182,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="nump">93,711<span></span>
</td>
<td class="nump">220,267<span></span>
</td>
<td class="nump">6,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities', window );">Issuance of common shares for settlement of related party credit facilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,023,200<span></span>
</td>
<td class="nump">4,047,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DebtDiscountOnRelatedPartyLoans', window );">Debt discount on related party loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,540<span></span>
</td>
<td class="nump">$ 4,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DebtDiscountOnConvertibleLoans', window );">Proceeds from convertible loans in transit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DebtDiscountOnConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt discount on convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DebtDiscountOnConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DebtDiscountOnRelatedPartyLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt discount on related party loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DebtDiscountOnRelatedPartyLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for settlement of related party credit facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_IssuanceOfCommonSharesForSettlementOfRelatedPartyCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PeriodicPensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PeriodicPensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProceedsFromBridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Bridge loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProceedsFromBridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProceedsFromSwissGovernmentLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Swiss government loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProceedsFromSwissGovernmentLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530200226536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BackgroundAbstract', window );"><strong>Background [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BackgroundTextBlock', window );">Background</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><a name="b_006"></a><i>Note
1</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Background:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the &#x201c;Company&#x201d;) is an emerging biopharmaceutical company engaged in the discovery
and development of life-improving drug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic
hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder (&#x201c;ADHD&#x201d;).
The Company&#x2019;s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">On
March 12, 2019, the Company merged NLS-0 Pharma Ltd. and NLS Pharma Ltd. into <font>NLS-1 Pharma Ltd.
(the &#x201c;Merger&#x201d;), the predecessor of the Company,</font> retroactively and effective on January 1, 2019 and renamed the Company
NLS Pharmaceutics Ltd. Due to the high degree of common ownership among the three companies and because individual investors&#x2019; ownership
is in substance the same after the transaction, this Merger was deemed to be a non-substantive merger, with no step up in basis of the
assets and liabilities in the Merger. The financial statements presented were prepared as if the Merger occurred on January 1, 2018.
All intercompany transactions and balances were eliminated in the Merger.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">On
February 2, 2021, the Company </font><font style="font-family: Times New Roman, Times, Serif">completed the closing of its initial public
offering (the &#x201c;Initial Public Offering&#x201d;) of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common
share and one Warrant to purchase one common share (the &#x201c;Warrants&#x201d;). The common shares and Warrants were immediately separable
from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021
under the symbols &#x201c;NLSP&#x201d; and &#x201c;NLSPW,&#x201d; respectively. The Company received net proceeds of $17 million, after deducting
underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years
from the date of issuance and have an exercise price of $4.15 per share. In addition, the Company granted the underwriters a 45-day option
to purchase up to an additional 722,891 common shares at the public offering price of $4.14 per common share and/or up to an additional
722,891 Warrants to purchase 722,891 common shares at the public offering price of $0.01 per Warrant, of which the underwriters exercised
their option to purchase Warrants to purchase up to 722,891 common shares. These Warrants were issued in the Company&#x2019;s Initial
Public Offering and therefore have the same exercise price of $4.15 per share.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company had an accumulated deficit of approximately $29.8 million and the Company incurred operating losses
since inception, including operating loss for the year ended December 31, 2020 of approximately $2.3 million. To date, the Company has
dedicated most of its financial resources to research and development, clinical studies associated with its ongoing biopharmaceutical
business and general and administrative expenses.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company&#x2019;s cash and cash equivalents were $93,711 and shareholders&#x2019; deficit was $8,984,057. The
Company expects that its existing cash and cash equivalents, including the net proceeds of $17 million from its Initial Public Offering,
will be sufficient to fund operations into the second quarter of 2022. These conditions raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern for one year from the issuance of these financial statements. Additionally, the Company&#x2019;s
operating plans may change as a result of many factors that may currently be unknown to the Company including:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the length of the COVID-19
    pandemic and its impact on our planned clinical trials, operations and financial condition;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of
    our pre-clinical studies, clinical trials and other research and development activities; </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, prioritization
    and number of our clinical trials and other research and development programs;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any cost that we may incur
    under in- and out-licensing arrangements relating to our product candidate that we may enter into in the future; </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of obtaining
    regulatory approval for our product candidates; </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
    enforcing and defending patent claims and other intellectual property rights; </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of, and timing for,
    strengthening our manufacturing agreements for production of sufficient clinical and commercial quantities of our product candidates;
    </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting
    with third parties to provide marketing and distribution services for us or for building such capacities internally; and </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring or
    undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates
    and the magnitude of our general and administrative expenses. </font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
a result, the Company may require additional capital to finance expenditures related to the manufacture of the Company&#x2019;s product
candidates for use in clinical trials, conducting clinical trials and general and administration costs<font>.</font></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has historically financed its activities primarily with cash from the private placement of equity and debt securities and borrowings
under credit facilities and shareholder loans. The Company intends to raise additional capital through private placements of debt and
equity securities or through loans from third parties, but there can be no assurance that these funds will be available, or if they are
available, their availability will be on terms acceptable to the Company or in an amount sufficient to enable the Company to fully complete
its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop
and implement a plan to further extend payables and indebtedness, reduce overhead, or scale back its current business plan until sufficient
additional capital is raised to support further operations or force the Company to grant rights to develop and commercialize product
candidates that it would otherwise prefer to develop and commercialize on its own. There can be no assurance that such a plan will be
successful.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accordingly,
the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;), which contemplate continuation of the Company as a going concern for a period within one year from
the issuance of these financial statements and the realization of assets and satisfaction of liabilities in the normal course of business.
The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable
or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><i>Note
1A</i>&#xa0;</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b>Stock
Split</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">On
September 14, 2020, the Company filed an amendment to its Articles of Incorporation and effected a 5,000-for-1 stock split of its issued
and outstanding common shares, whereby 1,392 outstanding common shares with a par value of CHF 100.00 per share were exchanged for 6,960,000
common shares with a par value of CHF 0.02 per share. All per share amounts and number of shares in the financial statements and related
notes have been retroactively restated to reflect the share split.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BackgroundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BackgroundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BackgroundTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for background.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BackgroundTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201313416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
2</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Summary
of Significant Accounting Policies:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
accompanying financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance
is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting
Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&#xa0;</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial
statements, the Company&#x2019;s significant estimates include (1) pension and other post-employment benefits, including certain asset
values that are based on significant unobservable inputs; (2) the inputs used in determining the fair value of equity per share; (3)
the beneficial conversion feature on the convertible loans and (4) valuation allowance relating to the Company&#x2019;s deferred tax assets.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>JOBS
Act Accounting Election </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company is an &#x201c;emerging growth company&#x201d; or &#x201c;EGC&#x201d;, as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, an EGC has elected to delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. The Company
generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding
operations.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Deferred
Offering Costs </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Specific
incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly
be deferred and charged against the gross proceeds of such an offering. As of December 31, 2020 and 2019, there were $946,912 and $260,211,
respectively, of Initial Public Offering costs, primarily consisting of legal, accounting and printing fees, that were capitalized in
other non-current assets on the balance sheet.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Concentration
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2020 and 2019, substantially
all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions
which are in excess of federally insured limits.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Functional
Currency</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has operations in Switzerland and the United States. The Company&#x2019;s functional currency is the U.S. dollar (&#x201c;USD&#x201d;).
The results of its non-USD based operations are translated to USD at the average exchange rates during the year. The Company&#x2019;s
assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#x2019; equity is
translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company&#x2019;s
results of operations.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company has not recognized any revenue from its exclusive license agreement (the &#x201c;EF License Agreement&#x201d;),
as the upfront payment the Company received has been deferred. The EF License Agreement is to develop and commercialize its product candidate,
Nolazol, in Latin American countries with Eurofarma Laboratorios S.A. (&#x201c;Eurofarma&#x201d;), a Brazilian pharmaceutical company.
The EF License Agreement is within the scope of ASC 606, &#x201c;<i>Revenue from Contract with Customers</i>&#x201d; (&#x201c;ASC 606&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities
of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the
goods or services are integral to or dependent on other goods or services in the contract.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in
the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that
includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be
received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received
based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the
transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant
reversal in the amount of the cumulative revenue recognized will not occur in a future period.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The
Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified
in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations,
which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally,
in determining the stand-alone selling price for material rights, the Company may reference comparable transactions, clinical trial success
probabilities, and develop estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each
performance obligation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress at each reporting
period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such
as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting
period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary,
adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect license revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement
of development, regulatory, or commercial milestone revenue resulting from the EF License Agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting
from any of the Company&#x2019;s license agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">To
the extent the Company receives payments, including non-refundable payments, in excess of the recognized revenue, such excess is recorded
as deferred revenue until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Costs
for research and development (&#x201c;R&amp;D&#x201d;) of products, including payroll, contractor expenses, and supplies, are expensed
as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where
contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when
the milestone results are probable of being achieved.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with ASC 820, &#x201c;<i>Fair Value,&#x201d;</i> which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to
access as of the measurement date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity
for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted
as appropriate for liquidity, credit, market and/or other risk factors.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company&#x2019;s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above.
The carrying values of the Company&#x2019;s accounts payable approximate their fair value due to the short-term nature of these liabilities.
The carrying value of the Company&#x2019;s debt is estimated to approximate its fair value, as the notes are near maturity and the interest
rates on the debts approximates market rates.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs and Debt Discount</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Debt
issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount
of that debt liability, consistent with debt discounts, and are amortized to interest expense over the term of the related debt using
the effective interest method.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from
future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that
all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax
expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Due
to the fact that the Company has a history of generating losses, and expects to generate losses in the foreseeable future, a full valuation
allowance has been recorded as no deferred taxes have been recognized.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">The
Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, &#x201c;</font><font style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes </i><font>(</font><i>Accounting for Uncertainty in Income Taxes),&#x201d; </i><font>which
clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position
can be recognized in the financial statements only if the position is &#x201c;more-likely-than-not&#x201d; to be sustained were it to be
challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without
regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the &#x201c;more-likely-than-not&#x201d;
threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority
is recorded. </font></font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Benefits (including Post Retirement Benefits)</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company operates the mandatory pension plan for its employees in Switzerland. The plan is generally funded through payments to insurance
companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on
individual savings accounts. However, this plan is classified as a defined benefit plan under ASC 960 <i>&#x201c;Plan Accounting &#x2013;
Defined Benefit Pension Plans</i>.&#x201d;</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of
plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected
unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#x2019;
projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating
the terms of the related liability.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Remeasurements
of the net defined benefit liability, which comprise actuarial gains and losses, and the return on plan assets (excluding interest),
are recognized immediately in Other Comprehensive Loss. Past service costs, including curtailment gains or losses, are recognized immediately
as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses
are recognized in either research and development and/or general and administrative expenses within the operating results. The Company
determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to
measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement
dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period
as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized
in the statement of operations and comprehensive loss.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Earnings
per Share</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted-average number of common
shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator
is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period
in which a net loss is reported or if their effect is anti-dilutive. The Company&#x2019;s potential common shares consist of convertible
promissory notes and convertible loans with their potential dilutive effect considered using the &#x201c;if-converted&#x201d; method. For
the years ended December 31, 2020 and 2019, 50,205 and 20,000 shares related to the convertible loans were excluded from the computation,
respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></font></p><br/><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">The Company
manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s
singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company&#x2019;s
tangible assets are held in Switzerland.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements &#x2013; Not Yet Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic 740)</i>: <i>Simplifying the Accounting for Income Taxes</i>.
The FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining
usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology
for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the
amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate
consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes
in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance
will become effective for the Company beginning after December 15, 2021 and interim periods within fiscal years beginning after December
15, 2022. Because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from
the adoption of this standard.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements &#x2013; Recently Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU No. 2018-13, <i>Fair Value Measurement (Topic 820): Disclosure Framework &#x2013; Changes to the Disclosure
Requirements for Fair Value Measurement</i>, which adds and modifies certain disclosure requirements for fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount and reasons for transfers between Level 1 and Level 2 of
the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public business entities will be required
to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related
changes in unrealized gains and losses included in other comprehensive income. ASU 2018-13 was effective for public and non-public business
entities for fiscal years beginning after December 15, 2019, including interim periods. The adoption of ASU 2018-13 did not have a material
impact on the Company&#x2019;s financial statements.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530204331336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract', window );"><strong>Restatement Of Previously Issued Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock', window );">Restatement of Previously Issued Financial Statements</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><i>Note
3</i></font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b>Restatement
of Previously Issued Financial Statements</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">During
the audit of the Company&#x2019;s financial statements for the year ended December 31, 2020, the Company identified an error in the presentation
of the intellectual property expenses in 2019 and 2018. The intellectual property expenses should have been classified as general and
administrative expenses instead of research and development expenses.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">This
resulted in a restatement to correct previously reported amounts in the financial statements of the Company for the years ended December
31, 2019 and 2018. This reclassification of expenses had no impact on total operating expenses, net loss, loss per share or the balance
sheet.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
following tables present the impact of the restatement in the financial statements for the years ended December 31, 2019 and 2018:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As&#xa0;Previously<br/>
    Reported</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Adjustments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As
    Restated</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,702,117</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">($</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">804,329</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">897,788</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,494,922</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">804,329</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,299,251</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,197,039</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,197,039</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2018</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As&#xa0;Previously
    Reported</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Adjustments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As
    Restated</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,437,202</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">($</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">728,747</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">708,455</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,011,659</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">728,747</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,740,406</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,448,861</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,448,861</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201229224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><i>Note 4</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Prepaid
Expenses and Other Current Assets:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company&#x2019;s prepaid expenses and other current assets consisted of the following as of December 31, 2020 and 2019:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Vendor
    overpayments</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">27,380</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">37,445</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">VAT
    recoverable and other current assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">61,207</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">33,579</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loan funding</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">61,956</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">14,413</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">15,067</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">CEO
    receivable</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">13,432</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Total
    prepaid expenses and other current assets</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">103,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">161,479</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
balance of the prepaid expenses and other current assets for the years ended December 31, 2020 and 2019, consisted mainly of some vendor
overpayments and value added tax (&#x201c;VAT&#x201d;) recoverable, that were returned to the Company during the following fiscal periods.
Additionally, the Company recorded a receivable from the Chief Executive Officer (&#x201c;CEO&#x201d;) for using Company credit cards for
personal travel expenses. Subsequent to the year ended December 31, 2019, the CEO receivable has been paid in full. The prepaid expenses
and other current assets for the year ended December 31, 2019 also included funding of a convertible loan entered into on December 23,
2019, for which funding was received on January 6, 2020.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530273894088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables, net &#8211; Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Receivables, net &#8211; Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
5</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Other
Receivables, net &#x2013; Related Party:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company&#x2019;s majority shareholders are also majority shareholders in Pegasus Advanced Research SAS, formerly NeuroLifeScienses SAS
(&#x201c;Pegasus&#x201d;), and as such Pegasus is considered to be a related party to the Company. In December 2015, Pegasus assigned its
exclusive global license to certain compounds involving mazindol to the Company (the &#x201c;License Agreement&#x201d;). The License Agreement
includes a royalty payment of 1.8% of the annual net sales (including sales made by sub-licensees) of the licensed compounds covered
thereunder; provided, however, that such royalty payment could be further reduced to 0.9% in the event that the U.S. Patent and Trademark
Office were to issue a revised notice of allowance or expand the patent rights of certain licensed compounds or be completely cancelled
in the event that a competing generic product were to reach the market during the term of the patents covering such licensed compounds.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Since
assigning the License Agreement to the Company, the Company and Pegasus have paid for some operating expenses for each other. The transactions
between the companies are minimal and are not considered to be a funding source for either entity. The Company offsets the related receivables
and payable to/from Pegasus for a combined net other long-term receivable of $67,954 and $54,472 for the years ended December 31, 2020
and 2019, respectively.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530286414936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract', window );"><strong>Convertible Promissory Notes Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock', window );">Convertible Promissory Notes &#8211; Related Parties:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
6</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Convertible
Promissory Notes &#x2013; Related Parties:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&#x2019;s convertible promissory notes with related parties as of December 31, 2020 and 2019.</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    promissory notes</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">591,693</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">540,071</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
January 2019, the Company entered into an agreement with Magnetic Rock Investment AG (&#x201c;MRI&#x201d;), which is owned by certain shareholders
of the Company, to loan the Company CHF 550,000 ($557,920). The loan proceeds were received in advance of the agreement, in two payments,
in each of August and December 2018 in the amount of CHF 500,000 ($507,200) and CHF 50,000 ($50,720), respectively. Management determined
that no separate accounting or bifurcation was required for this conversion feature as it doesn&#x2019;t meet the definition of a derivative
because the net settlement criterion is not met. The note accrues interest at 10% per year and has a conversion feature such that upon
a capital closing (as defined), MRI has the right to require conversion of its note to equity at the same terms as such capital closing.
As of December 31, 2020, such capital closing (as defined) has not occurred, so the note has not converted. The note had an original
maturity date of April 30, 2019 at which time if it wasn&#x2019;t already converted, a new maturity date would be set at the discretion
of MRI. The parties have amended the agreement to extend the maturity date to March 31, 2021. The Company has accrued interest payable
of $42,929 for the note as of December 31, 2020. Additionally, the Company recorded debt discount of $4,019 based on an imputed interest
rate of 12%, the rate readily available to the Company, compared to the 10% annual interest rate stated in the loan agreement. The debt
discount is being amortized to interest expense using the effective interest rate method over the debt term. For the years ended December
31, 2019 and 2018, amortization of $237 and $3,782, respectively, was included in interest expense &#x2013; related parties.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
March 2019, MRI and the Company agreed to convert an aggregate amount of CHF 526,980 ($526,769) of its loan into 40,000 of the Company&#x2019;s
common shares at a conversion price of approximately $13 per share. The common shares had a fair value of CHF 14 ($14) per share and
an aggregate fair value of $550,829, resulting in a $24,060 loss on conversion of the loan. Pursuant to an amendment to this loan, the
maturity date of the remaining loan of CHF 23,020 ($26,043) was extended to March 31, 2021. <font>The
Company determined that the extension of the loan which was past due or near maturity was in substance no different than issuing new
financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.</font></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
January 2019, the Company entered into four additional convertible promissory notes, on the same terms, with certain Company shareholders.
The promissory notes were for CHF 125,000 ($128,200) each, accrue interest at 10% per year and have original maturity dates of the earlier
of April 30, 2019 or when any investment into the Company of CHF 500,000 ($565,650) or greater occurs. The maturity of these notes was
extended to March 31, 2021. The Company has accrued interest payable of $119,045 for the notes as of December 31, 2020. Additionally,
the Company recorded debt discount of $8,540, based on an imputed interest rate of 12% compared to the 10% interest accrued on the loans.
The debt discount is being amortized to interest expense using the effective interest rate method over the debt term. For the year ended
December 31, 2019 amortization of $8,540 was included in interest expense &#x2013; related parties.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, all of the convertible promissory notes, including accrued interest, were repaid in full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertiblePromissoryNotesRelatedPartiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530205246920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facilities, Subordinated &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsAbstract', window );"><strong>Subordinated Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsDisclosureTextBlock', window );">Credit Facilities, Subordinated &#8211; Related Parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
7</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Credit
Facilities, Subordinated &#x2013; Related Parties:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&#x2019;s credit facilities with related parties as of December 31, 2020 and 2019.</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Second
    Credit Facility, net of debt discount of $0</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">150,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">150,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
August 2015, the Company entered into a second credit facility agreement (the &#x201c;Second Credit Facility&#x201d;) with certain shareholders
(the &#x201c;Lenders&#x201d;). The maximum borrowings under the Second Credit Facility were $500,000. The Second Credit Facility had a
maturity date of December 31, 2018 and accrued interest at 0%. As the Second Credit Facility did not accrue interest, management, upon
issuance of the debt, recorded total debt discount and a corresponding increase in additional paid in capital based on an imputed interest
at a rate of 12%. The debt discount was being amortized to interest expense using the effective interest rate method over the debt term.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
June 2018, the Company and the Lenders entered into a subordination agreement regarding the Second Credit Facility. The subordination
agreement deferred payments on the Second Credit Facility during the term of the agreement. The agreement was to expire if (i) the Lenders
irrevocably waived the subordinated claims; or (ii) if the claims were converted to share capital or participation capital of the Company.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the remaining balance of the Second Credit Facility of $150,000 was outstanding and the parties amended the agreement
covering such credit facility to extend the maturity date to March 31, 2021. Additionally, the accrued interest of $85,737 on an expired
credit facility remained unpaid and the parties amended that credit facility to extend the maturity date to March 31, 2021. <font>The
Company determined that the extension of these credit facilities which were past due or near maturity was in substance no different than
issuing new financial instruments and accordingly, the Company did not recognize a gain or loss in connection with the extension.</font></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, the remaining balance on the Second Credit Facility and the accrued interest on an expired credit facility was paid in
full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC's uniform net capital rule, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6479118&amp;loc=d3e64650-112822<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272228856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Loans</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
8</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Convertible
Loans:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The
following summarizes the Company&#x2019;s convertible loans as of December 31, 2020 and 2019.</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans, net of discount of $41,611</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">383,313</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans &#x2013; related party</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">113,130</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">496,443</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Less:
    current portion</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(463,980</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans, long term</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">32,463</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
December 2019, the Company entered into two loans for a total of CHF210,000 ($216,846) (the &#x201c;Convertible Loans&#x201d;). <font>In
February, March and June 2020, the Company entered into five additional convertible loans, on terms similar to those in December 2019,
including one with a related party, for a total of CHF 265,606 ($300,480).</font> The Convertible Loans accrued interest at 10% and have
a conversion feature such that the lender could choose to convert the loan to equity at any time up to the maturity date of August 31,
2021. The conversion rate of CHF 9 ($11) per common share was at a discount to the CHF 11 ($13) per common share fair value of the Company.
The proceeds from the loans were allocated between the debt instruments and the beneficial conversion feature, with the beneficial conversion
feature valued at CHF 63,537 ($65,608) for the December 2019 convertible loans and CHF 37,779 ($49,011) for the 2020 convertible loans.
On the date of issuance, the beneficial conversion feature value was calculated as the difference between the conversion price and the
fair value per share, multiplied by the number of common shares into which the Convertible Loans are convertible. The embedded conversion
feature was not bifurcated as it did not meet all of the elements of a derivative. For the year ended December 31, 2020, amortization
of $48,088 was included in interest expense and $24,100 was included in interest expense &#x2013; related parties. For the year ended
December 31, 2019, amortization of $820 was included in interest expense. The Company has accrued interest payable of $48,634 and $172
for the Convertible Loans as of December 31, 2020 and 2019, respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, all of the Convertible Loans, including accrued interest, were repaid in full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272144648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Swiss Government Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SwissGovernmentLoanDisclosureAbstract', window );"><strong>Swiss Government Loan Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SwissGovernmentLoanDisclosureTextBlock', window );">Swiss Government Loan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
9</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Swiss
Government Loan:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
April 2020, in response to the COVID 19 pandemic, the Swiss Federal Council issued the COVID-19 Ordinance on Joint and Several Guarantees,
according to which companies domiciled in Switzerland that are economically affected by the COVID-19 pandemic can apply for financial
support in the form of emergency bank loans of up to 10% of their 2019 revenues or a maximum of CHF 20 million (the &#x201c;COVID-19 Loan&#x201d;).
This COVID-19 Loan was secured by the Swiss Confederation. The lending banks received collateral in the form of joint and several guarantees.
The Company received a COVID-19 Loan from its bank for CHF 248,400 ($281,015), which carried a 0% interest rate and was due in 60 months.
The loan could be drawn down over several installments and the Company had drawn down the entire amount. Pursuant to the terms of the
COVID-19 Loan, the Company could not pay any dividends until it repays such loan in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, the COVID-19 Loan was repaid in full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_SwissGovernmentLoanDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_SwissGovernmentLoanDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_SwissGovernmentLoanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_SwissGovernmentLoanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201145688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bridge Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BridgeLoanAbstract', window );"><strong>Bridge Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BridgeLoanTextBlock', window );">Bridge Loan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
10</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Bridge
Loan:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
August 2020, the Company received the first tranche of CHF 300,000 ($309,780) pursuant to a bridge loan (the &#x201c;Bridge Loan&#x201d;).
Pursuant to the Bridge Loan, the Company could borrow up to an aggregate of CHF 500,000 ($516,300), or an additional CHF 200,000 ($206,520),
upon successful filing of its Form F-1, which occurred in August 2020. The total Bridge Loan of CHF 500,000 ($527,650) carried an interest
rate of 10% annually and was initially due September 30, 2020 <font>which was amended to December 31,
2020. </font>In January 2021, the Bridge Loan was amended two additional times. The first of the two amendments extended the maturity
date to March 31, 2021, and the second amendment increased the total amount of the Bridge Loan to CHF 600,000 ($633,180).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, the Bridge Loan, including accrued interest, was repaid in full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BridgeLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BridgeLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BridgeLoanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BridgeLoanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201311432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PensionLiabilityAbstract', window );"><strong>Pension Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PensionLiabilityTextBlock', window );">Pension Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
11</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Pension
Liability:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company joined a collective pension plan operated by an insurance company as of 2016 which covers the employees in Switzerland.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Both
the Company and the participants provide monthly contributions to the pension plan which are based on the covered salary. The respective
saving parts of premiums are credited to employees&#x2019; accounts. In addition, interest is credited to employees&#x2019; accounts at
the rate provided in the plan. The pension plan provides for retirement benefits as well as benefits on long-term disability and death.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
following table provides information on the pension plan for the years ended December 31, 2020, 2019 and 2018:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Service
    cost</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">24,875</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,206</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,617</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,992</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,190</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Expected
    return on assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,713</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(4,249</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3,294</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of settlement</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,754</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5,810</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,185</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,946</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,053</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    periodic pension cost (benefit)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3,575</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">20,085</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">26,566</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
reconciliation of the projected benefit obligation and the changes to the fair value of the plan assets of the pension plan are shown
in the following table:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, beginning of period</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">386,064</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">385,448</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Service
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">24,875</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,206</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,992</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(169,942</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(40,147</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Actuarial
    (gain)/ loss</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,561</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,765</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -3pt; padding-left: 13.5pt"><font style="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">28,285</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,800</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">273,675</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">386,064</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Plan
    assets, beginning of period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">205,816</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">226,428</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Actual
    return on plan assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(620</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,739</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Employer
    contributions</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">15,207</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">16,867</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Participant
    contributions</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,954</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9,608</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(142,931</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(49,755</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Administration
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,185</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,946</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">12,165</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,875</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Plan
    assets, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">95,406</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">205,816</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    pension liability</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">178,269</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,248</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, the Company recorded an accrued pension liability of $178,269 and $180,248, respectively, as non-current
liabilities.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
pension assets are measured at fair value and are invested in a collective pension foundation with pooled investments. Plan assets mainly
consist of cash and cash equivalents, equity funds, equity securities, corporate bonds, government bonds, and real estate funds classified
as Level 1 and Level 2 under the fair value hierarchy.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company records net gains/losses, consisting of actuarial gains/losses, curtailment gains/losses and differences between expected and
actual returns on plan assets, in other comprehensive income/loss. Such net gains/losses are amortized to the statements of operations
to the extent that they exceed 10% of the greater of projected benefit obligations or pension assets. The Company further records prior
service costs/credits from plan amendments in other comprehensive income/loss in the period of the respective plan amendment and amortizes
such amounts to the statement of operations over the future service period of the plan participants. For the years ended December 31,
2020 and 2019, the amortization was $0. As of December 31, 2020 and 2019, the accumulated other comprehensive loss includes unrecognized
pension costs of $19,381 and $18,698, respectively, consisting of net losses.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
following table shows the components of unrecognized pension cost in accumulated other comprehensive income/loss that have not yet been
recognized as components of net periodic pension cost:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Net loss,
    beginning of period</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">11,254</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Other
    gain/loss during the period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,895</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,634</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of settlement</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5,212</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,810</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Amortization
    of pension related net loss</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Net
    loss, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">19,381</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Prior
    service cost, beginning of period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Amortization
    of prior service cost</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Prior
    service cost end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total
    unrecognized pension cost, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">19,381</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The
weighted average of the key assumptions used to compute the benefit obligations were as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Discount
    rate</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.15</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.35</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Rate
    of increase in compensation level</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    credit rate on savings accounts</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Expected
    long-term rate of return on plan assets</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Inflation
    rate</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.60</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.60</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
assumption of the expected long-term rate of return on plan assets was based on the long-term historical rates of returns for the different
investment categories which were adjusted, where appropriate, to reflect financial market developments.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
accumulated benefit obligation as of December 31, 2020 and 2019 amounted to $273,675 and $386,064, respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
investment risk is borne by the insurer and the reinsurer respectively, and the investment decision is taken by the board of trustees
of the collective insurance.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PensionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PensionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PensionLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PensionLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201302552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">Deferred Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
12</i></font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b>Deferred
Revenues:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
February 2019, the Company entered into the EF License Agreement, to develop and commercialize its product candidate, Nolazol, in Latin
American countries with Eurofarma, a Brazilian pharmaceutical company. The EF License Agreement covers the grant of non-transferable
licenses, without the right to sublicense, to Eurofarma to develop and commercialize Nolazol in Latin America. The EF License Agreement
also specifies the Company&#x2019;s obligation to advance ongoing development activities with respect to Nolazol in the United States.
A joint steering committee will oversee the development and regulatory activities directed towards marketing approval, manufacturing
and commercialization phases. The Company believes its participation in the joint steering committee is not of material significance
to the licenses in the context of the EF License Agreement on the whole and, as such, management has excluded these activities in the
determination of its performance obligation(s) under the EF License Agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
EF License Agreement provides that the parties shall enter into a separate manufacturing and supply agreement during the term of the
EF License Agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Under
the EF License Agreement, the Company received a non-refundable, upfront payment, of $2,500,000 and is further eligible to receive non-refundable
milestone payments of up to $16,000,000, based on the achievement of milestones related to regulatory filings, regulatory approvals and
the commercialization of Nolazol. The achievement and timing of the milestones depend on the success of development, approval and sales
progress, if any, of Nolazol in the future. In addition, the Company is also eligible for tiered royalty payments.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company identified the licenses granted to Eurofarma and its obligation to advance development activities with respect to Nolazol in
the United States as the material promises under the EF License Agreement. For purposes of identifying the Company&#x2019;s performance
obligations under the EF License Agreement, management believes that while the exclusive licenses were granted to Eurofarma at the outset
of the EF License Agreement, the grant of those licenses does not singularly result in the transfer of the Company&#x2019;s broader obligation
to Eurofarma under the EF License Agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company is obligated under the EF License Agreement to advance its development activities in the United States and those activities precede
Eurofarma&#x2019;s necessary regulatory approvals for commercialization of Nolazol, in Latin American countries. The Company intends to
apply its proprietary know-how to the ongoing development activities in the United States involving its intellectual property relating
to Nolazol. These development activities are specific to the Company and the Company believes they are not capable of being distinct
in the context of the EF License Agreement on the whole.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
licenses provided to Eurofarma are not transferable and without the right to sublicense therefore Eurofarma is not presently able to
monetize its investment in Nolazol as clinical development in the United States or any Latin American countries has yet to be completed
and Eurofarma has yet to seek or obtain regulatory approval in any Latin American country. The licenses to Eurofarma represent rights
to use the Company&#x2019;s intellectual property with respect to Nolazol for which revenue is recognized at a point in time which is
when Eurofarma is able to use and benefit from the licenses. The licenses are considered of limited value without the Company&#x2019;s
development activities with respect to Nolazol in the United States. As such, the licenses are not capable of being distinct until after
successful clinical development and regulatory approval and alone do not have standalone functionality to Eurofarma. Management has determined
that the licenses, while capable of being distinct, are not distinct as they do not have stand-alone value to Eurofarma without the Company&#x2019;s
planned development activities in the United States and the approval for sale in Latin America.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Bundled
together with the Company&#x2019;s development activities of Nolazol in the United States, the licenses granted under the EF License Agreement
will enable Eurofarma to seek regulatory approvals and ultimately seek to commercialize Nolazol in Latin America. Therefore, management
believes the licenses bundled together with the Company&#x2019;s development activities in the United States constitute a single distinct
performance obligation under the EF License Agreement for accounting purposes (the &#x201c;License Performance Obligation&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has initially estimated a total transaction price of $2,500,000, consisting of the fixed upfront payment determined to be an
advance on the License Performance Obligation. Upon execution of the EF License Agreement and as of December 31, 2020 and 2019, variable
consideration consisting of milestone payments has been constrained and excluded from the transaction price given the significant uncertainty
of achievement of the development and regulatory milestones.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has allocated the transaction price entirely to the single License Performance Obligation and recorded the $2,500,000 as deferred
revenue that is expected to be recognized upon Brazilian or other Latin American market approval or, in the event marketing approval
in the United States and/or Latin America is not achieved, whether by failure in clinical development or otherwise, when the Company&#x2019;s
performance obligations are contractually complete or the EF License Agreement is terminated.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Amounts
expected to be recognized as revenues within the 12 months following the balance sheet date are classified as a current portion of deferred
revenues in the accompanying condensed balance sheets. Amounts not expected to be recognized as revenues within the 12 months following
the balance sheet date are classified as deferred revenues, net of current portion. As of December 31, 2020 and 2019, the Company has
long-term deferred revenues of $2,500,000, which will be recognized when the development services of Nolazol are completed and the product
candidate receives applicable regulatory approval in Latin America that allows Eurofarma to commence commercialization of Nolazol in
accordance with the EF License Agreement.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 430<br> -URI http://asc.fasb.org/topic&amp;trid=2122452<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530278574616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
13</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Commitments
and Contingencies: </b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Commitments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
December 2019, the Company entered into a feasibility development agreement (the &#x201c;Development Agreement&#x201d;) with Adare Pharmaceuticals,
Inc. (&#x201c;Adare&#x201d;), pursuant to which the Company intends to utilize Adare&#x2019;s proprietary modified release technologies
in the development of mazindol for use in the Company&#x2019;s product candidates used for the treatment of narcolepsy and ADHD. The formulation
to be developed by Adare under this Development Agreement is intended to be owned solely by the Company. Upon completion of certain milestones,
as defined in the Development Agreement, the Company is obligated to pay Adare up to $840,000. <font>In
January 2021, the Company and Adare agreed to terminate the Development Agreement, effective as of December 19, 2020. The project was
never started and the Company has no liability to Adare.</font></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Litigation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company may become involved in miscellaneous litigation and legal actions, including product liability, consumer, commercial, tax and
governmental matters, which can arise from time to time in the ordinary course of the Company&#x2019;s business. Litigation and legal
actions are inherently unpredictable, and excessive verdicts can result in such situations. The Company is not currently involved in
any such matters.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; "><b><i>COVID-19</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">In
December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) emerged in Wuhan, China. Since then, it has spread to several other
countries and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak
of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in the United States, Canada and internationally,
including in Switzerland, have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions,
border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19
outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals,
including unprecedented business, employment and economic disruptions. The continued spread of COVID-19 in the United States, Canada
and globally, including in Switzerland, could have an adverse impact on our business, operations and financial results, including through
disruptions in our cultivation and processing activities, supply chains, as well as a deterioration of general economic conditions including
a possible national or global recession. Shelter-in-place orders and social distancing practices designed to limit the spread of COVID-19
may affect our ability to conduct clinical studies. </font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">The
Company has not been adversely affected from the effects of the COVID-19 outbreak, neither from any delay in its clinical development
activities nor by its ability to source necessary financing to fund its operations. In view of the continuing uncertainty about the further
development of COVID-19, an adverse development can be expected in 2021, but its financial impact on the Company cannot yet to be adequately
and conclusively assessed.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199528040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Deficit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
14</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Shareholders&#x2019;
Deficit:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company had 6,960,000 registered and issued common shares.</font></p><br/><p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
March 2019, the Company issued a total of 580,000 of its common shares to creditors in exchange for payment of $5,131,481 of the credit
facilities, $2,000,000 of the interest-free $2 million bridge loan and $529,769 of convertible promissory notes. </font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
July 2018, the Company issued 260,000 of its common shares to the creditors in exchange for payment of $3,418,519 due under the $7.1
million credit facility.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272240728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
15</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Income
Taxes</b>:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has Swiss tax loss carryforwards of $15.5 million as of December 31, 2020 (December 31, 2019: $11.5 million) of which $9.7 million
will expire within the next five years, and $5.8 million will expire between 2025 - 2026.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
significant components of net deferred taxes as of December 31, 2020 and 2019 are shown in the following table:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    benefit from tax loss carryforwards</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,393,809</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,031,524</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Deferred
    revenues</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">224,997</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">224,997</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Other,
    net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,951</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(15,065</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,625,757</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,241,456</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company recorded a valuation allowance in 2020 and 2019 to reduce the net deferred taxes, as the Company deemed it to be more likely
than not that the future deferred tax assets would not be realized in the future based on the lack of sufficient positive evidence in
the jurisdictions related to the realization of the deferred tax assets.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
effective tax rate was 0% for the years ended December 31, 2020, 2019 and 2018. The following table shows the income taxes in 2020, 2019
and 2018:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">Current tax</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left">$<font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            -</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred
    income tax (benefit)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(384,301</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(325,572</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(289,462</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(384,301</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(325,572</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(289,462</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">384,301</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">325,572</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">289,462</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total income tax expense</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company files income tax returns in Switzerland. The Company&#x2019;s income tax position in Switzerland is finally assessed up to the
year ended December 31, 2018, so the years ended December 31, 2019 and 2020 are open for examination. Currently the Company does not
have any open tax assessments. The following table shows the reconciliation between expected and effective tax rate:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Statutory
    tax rate</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of permanent differences</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3.9</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(2.3</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3.7</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance on deferred tax assets</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(12.9</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(6.7</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5.3</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effective
    tax rate</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company had generated approximately $9,700,000 of net operating losses (&#x201c;NOLs&#x201d;) prior to the Merger, in which the Company&#x2019;s
preliminary analysis indicates that such NOLs would not be subject to significant limitations pursuant to applicable income tax regulations.
The permanent differences relate to the conversion to U.S. GAAP from Swiss accounting, mainly in the areas of debt, intangible amortization
and deferring financing costs</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, there were no unrecognized tax benefits. <font>If such matters were to
arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. </font>The Company did
not incur any material interest or penalties in connection with income taxes during the years ended December 31, 2020 and 2019.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201434664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party consulting agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party consulting agreements:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><i>Note
16</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b>Related
party consulting agreements:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company entered into consulting agreements with several of its senior management.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
January 2017, and as subsequently amended in October 2020, the Company entered into a consulting agreement with CHG BioVenture SA, an
entity controlled by Mr. Herv&#xe9; Girsault, the Company&#x2019;s current Head of Business Development. Pursuant to the consulting
agreement, the Company agreed to pay CHG BioVenture SA a monthly fee of CHF 17,500, as well as an opportunity to a bonus of up to 15%
of the annual fee, subject to the Company&#x2019;s discretion. In addition, the Company has agreed to pay CHG BioVenture SA a 1% fee tied
to the net proceeds actually received by the Company in certain transactions, such as, but not limited to, an M&amp;A transaction. The
consulting agreement may be terminated by either party for any reason at the end of each calendar quarter with three months&#x2019; prior
written notice, or immediately if Mr. Girsault breaches the confidentiality provision. The consulting agreement also provides for a 24-month
non-competition clause. The consulting agreement also provides for standard confidentiality provisions as well as reimbursement for certain
expenses. For the year ended December 31, 2020, 2019 and 2018, the Company recorded fees to CHG BioVenture SA of $285,859, $285,538 and
$286,206, respectively, included in general and administrative expenses on the statement of operations and comprehensive loss.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company provided BioVenture SA and Mr. Girsault notice of the Company&#x2019;s termination of the consulting agreement with CHG BioVenture
SA, pursuant to which Mr. Girsault provides his services to the Company, which will take effect on June 30, 2021. The Company is actively
in discussions with Mr. Girsault on continuing his engagement with the Company in his current role.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
March 2021, the Company entered into a consulting agreement with Mr. Subhasis Roy, the Company&#x2019;s current Interim Chief Financial
Officer, pursuant to which the Company agreed to pay Mr. Roy a daily rate of CHF 2,000 for his services. The consulting agreement may
be terminated by either party upon 30 days&#x2019; written notice or immediately by the Company in the event of a material breach by Mr.
Roy that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, the Company entered into a consulting agreement with Mr. Eric Konofal, the Company&#x2019;s current Interim Chief Scientific
Officer, pursuant to which the Company agreed to pay Mr. Konofal a daily rate of CHF 2,000 for his services. The consulting agreement
may be terminated by either party upon 30 days&#x2019; written notice or immediately by the Company in the event of a material breach
by Mr. Konofal that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month
non-solicitation clause as well as reimbursement for certain expenses.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
March 2021, the Company entered into a consulting agreement with Mr. Carlos Camozzi, the Company&#x2019;s current Interim Medical Director,
pursuant to which the Company agreed to pay Mr. Camozzi an hourly rate of CHF 230 plus 7.7% VAT for his services. The consulting agreement
may be terminated by either party upon 30 days&#x2019; written notice or immediately by us in the event of a material breach by Mr. Camozzi
that cannot be cured. The consulting agreement contains customary confidentiality provisions and provides for an 18-month non-solicitation
clause as well as reimbursement for certain expenses.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272240728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><i>Note
17</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Subsequent
Events</b>:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">In
January 2021, the loans listed below were further amended such that the maturity date of each instrument were scheduled to be March 31,
2021:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$85,737 under an old expired
    credit facility;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150,000 under the Second
    Credit Facility;</font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 500,000 (approximately
    $565,650) under the four convertible promissory notes from January 2019, each of which carried an interest rate of 10% per year;
    </font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 23,020 (approximately
    $26,043) under the Convertible Note with MRI, which carried an interest rate of 10% per year; </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 100,000 (approximately
    $113,130) under the Convertible loan with a related party, which carried an interest rate of 10% per year, and </font></td></tr>
<tr>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: left; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 0.25in; text-align: left; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHF 600,000 (approximately
    $678,780) under the Bridge Loan, which carried an interest rate of 10% per year.</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">On
February 2, 2021, the Company </font><font style="font-family: Times New Roman, Times, Serif">completed the closing of its Initial Public
Offering of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one Warrant. The common shares
and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the
Nasdaq Capital Market on January 29, 2021 under the symbols &#x201c;NLSP&#x201d; and &#x201c;NLSPW,&#x201d; respectively. The Company received
net proceeds of $17 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants
are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share. In addition,
the Company granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase
722,891 common shares, of which the underwriters exercised the option to purchase warrants to purchase up to 722,891 shares of common
shares. These Warrants were issued in the Company&#x2019;s Initial Public Offering and therefore have the same exercise price of $4.15
per share.</font></p><br/><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">In
February 2021, the Company repaid all of its various loans and notes, including accrued interest, in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
addition, on March 10, 2021, the Company entered into a License Agreement with Novartis Pharma AG (&#x201c;Novartis&#x201d;), whereby the
Company obtained, on an exclusive basis in the U.S., all <font>of the available data referred to and
included in the original NDA for Sanorex&#xae; (mazindol) submitted to the FDA in February 1972. The agreement encompasses all preclinical
and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation
data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety
reports from 1973 onwards. Under the Agreement, the Company has obtained the same rights on a non-exclusive basis in all territories
outside of the U.S. except for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed
territories. The Agreement includes the right to sublicense or assign the license to third parties, subject to such third parties meeting
certain obligations. As consideration for the license, the Company agreed to pay Novartis $250,000 upon the signing of the agreement
with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to
be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of
</font>Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time
payment upon the Company&#x2019;s product candidate reaching $250 million in cumulative sales.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199700200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
accompanying financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance
is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting
Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
amounts reported of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
periods. Actual results could differ from those estimates and be based on events different from those assumptions. As part of these financial
statements, the Company&#x2019;s significant estimates include (1) pension and other post-employment benefits, including certain asset
values that are based on significant unobservable inputs; (2) the inputs used in determining the fair value of equity per share; (3)
the beneficial conversion feature on the convertible loans and (4) valuation allowance relating to the Company&#x2019;s deferred tax assets.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">JOBS Act Accounting Election</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>JOBS
Act Accounting Election </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company is an &#x201c;emerging growth company&#x201d; or &#x201c;EGC&#x201d;, as defined in the Jumpstart Our Business Startups Act of 2012
(the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, an EGC has elected to delay adopting new or revised accounting standards issued subsequent
to the enactment of the JOBS Act until such time as those standards apply to private companies.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. The Company
generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding
operations.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Deferred
Offering Costs </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Specific
incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly
be deferred and charged against the gross proceeds of such an offering. As of December 31, 2020 and 2019, there were $946,912 and $260,211,
respectively, of Initial Public Offering costs, primarily consisting of legal, accounting and printing fees, that were capitalized in
other non-current assets on the balance sheet.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Concentration
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk include cash. At December 31, 2020 and 2019, substantially
all of the cash balances are deposited in one banking institution. At various times, the Company has deposits in financial institutions
which are in excess of federally insured limits.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Functional
Currency</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company has operations in Switzerland and the United States. The Company&#x2019;s functional currency is the U.S. dollar (&#x201c;USD&#x201d;).
The results of its non-USD based operations are translated to USD at the average exchange rates during the year. The Company&#x2019;s
assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#x2019; equity is
translated using historical rates. Foreign exchange transaction gains and losses are included in other income/expense in the Company&#x2019;s
results of operations.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, the Company has not recognized any revenue from its exclusive license agreement (the &#x201c;EF License Agreement&#x201d;),
as the upfront payment the Company received has been deferred. The EF License Agreement is to develop and commercialize its product candidate,
Nolazol, in Latin American countries with Eurofarma Laboratorios S.A. (&#x201c;Eurofarma&#x201d;), a Brazilian pharmaceutical company.
The EF License Agreement is within the scope of ASC 606, &#x201c;<i>Revenue from Contract with Customers</i>&#x201d; (&#x201c;ASC 606&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Under
ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue
to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification
of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations
including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when
(or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the
promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services
are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities
of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the
goods or services are integral to or dependent on other goods or services in the contract.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in
the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that
includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be
received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received
based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the
transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant
reversal in the amount of the cumulative revenue recognized will not occur in a future period.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The
Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified
in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations,
which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally,
in determining the stand-alone selling price for material rights, the Company may reference comparable transactions, clinical trial success
probabilities, and develop estimates of option exercise likelihood. Any variable consideration is allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each
performance obligation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or
services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress at each reporting
period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Development
and regulatory milestone payments are assessed under the most likely amount method and constrained if it is probable that a significant
revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such
as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting
period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary,
adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect license revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement
of development, regulatory, or commercial milestone revenue resulting from the EF License Agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">For
revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the
license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting
from any of the Company&#x2019;s license agreement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">To
the extent the Company receives payments, including non-refundable payments, in excess of the recognized revenue, such excess is recorded
as deferred revenue until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Costs
for research and development (&#x201c;R&amp;D&#x201d;) of products, including payroll, contractor expenses, and supplies, are expensed
as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where
contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when
the milestone results are probable of being achieved.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses </i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">General
and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses. Personnel
costs consist of salaries, cash bonuses and benefits. Outside professional services consist of legal fees (including intellectual property
and corporate matters), accounting and audit services, IT and other consulting fees.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with ASC 820, &#x201c;<i>Fair Value,&#x201d;</i> which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to
access as of the measurement date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level
3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity
for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted
as appropriate for liquidity, credit, market and/or other risk factors.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company&#x2019;s cash and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above.
The carrying values of the Company&#x2019;s accounts payable approximate their fair value due to the short-term nature of these liabilities.
The carrying value of the Company&#x2019;s debt is estimated to approximate its fair value, as the notes are near maturity and the interest
rates on the debts approximates market rates.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Debt Discount</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs and Debt Discount</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Debt
issuance costs related to a recognized debt liability are presented on the balance sheet as a direct deduction from the carrying amount
of that debt liability, consistent with debt discounts, and are amortized to interest expense over the term of the related debt using
the effective interest method.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from
future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that
all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax
expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Due
to the fact that the Company has a history of generating losses, and expects to generate losses in the foreseeable future, a full valuation
allowance has been recorded as no deferred taxes have been recognized.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif; ">The
Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, &#x201c;</font><font style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes </i><font>(</font><i>Accounting for Uncertainty in Income Taxes),&#x201d; </i><font>which
clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position
can be recognized in the financial statements only if the position is &#x201c;more-likely-than-not&#x201d; to be sustained were it to be
challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without
regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the &#x201c;more-likely-than-not&#x201d;
threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority
is recorded.</font></font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Employee Benefits (including Post Retirement Benefits)</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Benefits (including Post Retirement Benefits)</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
Company operates the mandatory pension plan for its employees in Switzerland. The plan is generally funded through payments to insurance
companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on
individual savings accounts. However, this plan is classified as a defined benefit plan under ASC 960 <i>&#x201c;Plan Accounting &#x2013;
Defined Benefit Pension Plans</i>.&#x201d;</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">The
net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of
plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected
unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#x2019;
projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating
the terms of the related liability.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Remeasurements
of the net defined benefit liability, which comprise actuarial gains and losses, and the return on plan assets (excluding interest),
are recognized immediately in Other Comprehensive Loss. Past service costs, including curtailment gains or losses, are recognized immediately
as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses
are recognized in either research and development and/or general and administrative expenses within the operating results. The Company
determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to
measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement
dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period
as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized
in the statement of operations and comprehensive loss.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Earnings
per Share</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted-average number of common
shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator
is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period
in which a net loss is reported or if their effect is anti-dilutive. The Company&#x2019;s potential common shares consist of convertible
promissory notes and convertible loans with their potential dilutive effect considered using the &#x201c;if-converted&#x201d; method. For
the years ended December 31, 2020 and 2019, 50,205 and 20,000 shares related to the convertible loans were excluded from the computation,
respectively.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></font></p><br/><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">The Company
manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s
singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company&#x2019;s
tangible assets are held in Switzerland.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Accounting Pronouncements &#8211; Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements &#x2013; Not Yet Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic 740)</i>: <i>Simplifying the Accounting for Income Taxes</i>.
The FASB issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining
usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology
for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the
amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate
consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes
in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance
will become effective for the Company beginning after December 15, 2021 and interim periods within fiscal years beginning after December
15, 2022. Because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from
the adoption of this standard.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements &#8211; Recently Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements &#x2013; Recently Adopted</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU No. 2018-13, <i>Fair Value Measurement (Topic 820): Disclosure Framework &#x2013; Changes to the Disclosure
Requirements for Fair Value Measurement</i>, which adds and modifies certain disclosure requirements for fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount and reasons for transfers between Level 1 and Level 2 of
the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public business entities will be required
to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related
changes in unrealized gains and losses included in other comprehensive income. ASU 2018-13 was effective for public and non-public business
entities for fiscal years beginning after December 15, 2019, including interim periods. The adoption of ASU 2018-13 did not have a material
impact on the Company&#x2019;s financial statements.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for new accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272121784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract', window );"><strong>Restatement Of Previously Issued Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of restatement in the financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As&#xa0;Previously<br/>
    Reported</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Adjustments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As
    Restated</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,702,117</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">($</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">804,329</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">897,788</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,494,922</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">804,329</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,299,251</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,197,039</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,197,039</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2018</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As&#xa0;Previously
    Reported</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Adjustments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As
    Restated</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,437,202</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">($</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">728,747</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">708,455</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,011,659</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">728,747</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,740,406</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; padding-left: 20pt; text-indent: -10pt"><font style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,448,861</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,448,861</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RestatementOfPreviouslyIssuedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530285206328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Vendor
    overpayments</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">27,380</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">37,445</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">VAT
    recoverable and other current assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">61,207</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">33,579</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loan funding</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">61,956</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">14,413</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">15,067</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">CEO
    receivable</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">13,432</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"><font style="font-family: Times New Roman, Times, Serif">Total
    prepaid expenses and other current assets</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">103,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">161,479</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272090072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes &#8211; Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract', window );"><strong>Convertible Promissory Notes Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible promissory notes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    promissory notes</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">591,693</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">540,071</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertiblePromissoryNotesRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530273917064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facilities, Subordinated &#8211; Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsAbstract', window );"><strong>Subordinated Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of credit facilities with related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Second
    Credit Facility, net of debt discount of $0</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">150,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">150,000</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530278574616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfConvertibleLoansTableTextBlock', window );">Schedule of convertible loans</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans, net of discount of $41,611</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">383,313</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans &#x2013; related party</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">113,130</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">496,443</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Less:
    current portion</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(463,980</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Convertible
    loans, long term</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">32,463</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">152,058</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfConvertibleLoansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfConvertibleLoansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530204217144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PensionLiabilityAbstract', window );"><strong>Pension Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of weighted average of the key assumptions used to compute the benefit obligations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Service
    cost</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">24,875</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,206</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,617</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,992</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,190</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Expected
    return on assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,713</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(4,249</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3,294</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of settlement</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,754</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5,810</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,185</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,946</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,053</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    periodic pension cost (benefit)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3,575</font></td><td style="padding-bottom: 2pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">20,085</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">26,566</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock', window );">Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, beginning of period</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">386,064</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">385,448</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Service
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">24,875</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,206</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    cost</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,992</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(169,942</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(40,147</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Actuarial
    (gain)/ loss</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,561</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,765</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -3pt; padding-left: 13.5pt"><font style="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">28,285</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,800</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Projected
    benefit obligation, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">273,675</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">386,064</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Plan
    assets, beginning of period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">205,816</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">226,428</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Actual
    return on plan assets</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(620</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,739</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Employer
    contributions</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">15,207</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">16,867</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Participant
    contributions</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,954</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9,608</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Transfers-in
    and (-out), net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(142,931</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(49,755</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Administration
    expenses</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,185</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,946</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 22.5pt"><font style="font-family: Times New Roman, Times, Serif">Currency
    conversion adjustments</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">12,165</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,875</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Plan
    assets, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">95,406</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">205,816</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    pension liability</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">178,269</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,248</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock', window );">Schedule of unrecognized pension cost in accumulated other comprehensive income/loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Net loss,
    beginning of period</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">11,254</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Other
    gain/loss during the period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,895</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,634</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of settlement</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5,212</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">5,810</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Amortization
    of pension related net loss</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Net
    loss, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">19,381</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Prior
    service cost, beginning of period</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Amortization
    of prior service cost</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Prior
    service cost end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-size: 1pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total
    unrecognized pension cost, end of period</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">19,381</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">18,698</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock', window );">Schedule of weighted average of the key assumptions used to compute the benefit obligations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Discount
    rate</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.15</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.35</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Rate
    of increase in compensation level</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Interest
    credit rate on savings accounts</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Expected
    long-term rate of return on plan assets</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2.00</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Inflation
    rate</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.60</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.60</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PensionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PensionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized pension cost in accumulated other comprehensive income/loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomelossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average of the key assumptions used to compute the benefit obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530204318328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    benefit from tax loss carryforwards</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,393,809</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,031,524</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Deferred
    revenues</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">224,997</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">224,997</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Other,
    net</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">6,951</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(15,065</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,625,757</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(1,241,456</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax provision</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">Current tax</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left">$<font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            -</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred
    income tax (benefit)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(384,301</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(325,572</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(289,462</font></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(384,301</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(325,572</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(289,462</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">384,301</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">325,572</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">289,462</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total income tax expense</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective reconciliation of the federal income tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2020</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Statutory
    tax rate</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">9.0</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effect
    of permanent differences</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3.9</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(2.3</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3.7</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance on deferred tax assets</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(12.9</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(6.7</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(5.3</font></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Effective
    tax rate</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.0</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530195030696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Sep. 14, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BackgroundDetailsLineItems', window );"><strong>Background (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,759,697)<span></span>
</td>
<td class="num">$ (26,898,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,711<span></span>
</td>
<td class="nump">$ 220,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_StockholdersEquity1', window );">Shareholders deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,984,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split of its issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 14, 2020, the Company filed an amendment to its Articles of Incorporation and effected a 5,000-for-1 stock split of its issued and outstanding common shares, whereby 1,392 outstanding common shares with a par value of CHF 100.00 per share were exchanged for 6,960,000 common shares with a par value of CHF 0.02 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BackgroundDetailsLineItems', window );"><strong>Background (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_InitialPublicOfferingUnits', window );">Initial public offering unit</a></td>
<td class="nump">4,819,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PricePerShareUnit', window );">Price per share unit</a></td>
<td class="nump">4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_GrossProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AdditionalPurchaseShare', window );">Additional purchase share</a></td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PublicOfferingPrice', window );">Public offering price</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AdditionalWarrantsShare', window );">Additional warrants share</a></td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_WarrantPurchaseCommonShare', window );">Warrant purchase common share</a></td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_WarrantOfferingPerShare', window );">Warrant offering per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Underwriters exercised share</a></td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AdditionalPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share additional purchase share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AdditionalPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AdditionalWarrantsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share additional warrants share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AdditionalWarrantsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BackgroundDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BackgroundDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_InitialPublicOfferingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share Initial public offering unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_InitialPublicOfferingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PricePerShareUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of price per share unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PricePerShareUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_StockholdersEquity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_StockholdersEquity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_WarrantOfferingPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrant offering per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_WarrantOfferingPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_WarrantPurchaseCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrant purchase common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_WarrantPurchaseCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530278505416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred offering costs</a></td>
<td class="nump">$ 946,912<span></span>
</td>
<td class="nump">$ 260,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage', window );">Tax benefits more likely to be recognized, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Convertible loans were excluded from computation</a></td>
<td class="nump">50,205<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefits more likely to be recognized, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_TaxBenefitsMoreLikelyToBeRecognizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530195013016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Schedule of restatement in the financial statements - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 1,702,117<span></span>
</td>
<td class="nump">$ 1,437,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,494,922<span></span>
</td>
<td class="nump">2,011,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,197,039<span></span>
</td>
<td class="nump">3,448,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">804,329<span></span>
</td>
<td class="nump">728,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">804,329<span></span>
</td>
<td class="nump">728,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">897,788<span></span>
</td>
<td class="nump">708,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,299,251<span></span>
</td>
<td class="nump">2,740,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 4,197,039<span></span>
</td>
<td class="nump">$ 3,448,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199613224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of prepaid expenses and other current assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PrepaidVendorOverpayments', window );">Vendor overpayments</a></td>
<td class="nump">$ 27,380<span></span>
</td>
<td class="nump">$ 37,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">VAT recoverable and other current assets</a></td>
<td class="nump">61,207<span></span>
</td>
<td class="nump">33,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Convertible loan funding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">14,413<span></span>
</td>
<td class="nump">15,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">CEO receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 161,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PrepaidVendorOverpayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid vendor overpayments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PrepaidVendorOverpayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530204271448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables, net &#8211; Related Party (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AnnualNetSalesPercentage', window );">Annual net sales, percentage</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RoyaltyPaymentPercentage', window );">Royalty payment, percentage</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term receivable</a></td>
<td class="nump">$ 67,954<span></span>
</td>
<td class="nump">$ 54,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AnnualNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual net sales, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AnnualNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530194388904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes &#8211; Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CHF (SFr) </div>
<div>SFr / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems', window );"><strong>Convertible Promissory Notes &#8211; Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Accrues interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The note had an original maturity date of April 30, 2019 at which time if it wasn&#x2019;t already converted, a new maturity date would be set at the discretion of MRI. The parties have amended the agreement to extend the maturity date to March 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate stated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,540<span></span>
</td>
<td class="nump">$ 3,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common shares fair value per share (in Francs per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate fair value</a></td>
<td class="nump">$ 550,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Loss on conversion loan</a></td>
<td class="nump">24,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Remaining loan</a></td>
<td class="nump">26,043<span></span>
</td>
<td class="nump">SFr 23,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nlsp_MagneticRockInvestmentsMember', window );">DebtInstrumentFaceAmount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems', window );"><strong>Convertible Promissory Notes &#8211; Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557,920<span></span>
</td>
<td class="nump">SFr 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,200<span></span>
</td>
<td class="nump">SFr 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DebtDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate amount</a></td>
<td class="nump">$ 526,769<span></span>
</td>
<td class="nump">SFr 526,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of common shares (in Shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertiblePromissoryNotesRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nlsp_MagneticRockInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nlsp_MagneticRockInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530205375544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes &#8211; Related Parties (Details) - Schedule of convertible promissory notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfConvertiblePromissoryNotesAbstract', window );"><strong>Schedule of convertible promissory notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes</a></td>
<td class="nump">$ 591,693<span></span>
</td>
<td class="nump">$ 540,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfConvertiblePromissoryNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfConvertiblePromissoryNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199599768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facilities, Subordinated &#8211; Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsAbstract', window );"><strong>Subordinated Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing from lenders</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AccruedInterestPercentage', window );">Accrued interest, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AccruedInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AccruedInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Imputed interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199908424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facilities, Subordinated &#8211; Related Parties (Details) - Schedule of credit facilities with related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember', window );">Second credit facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SecondCreditFacility', window );">Second Credit Facility, net of debt discount of $0</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_SecondCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second Credit Facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_SecondCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201339272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facilities, Subordinated &#8211; Related Parties (Details) - Schedule of credit facilities with related parties (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember', window );">Second credit facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DebtDiscount', window );">Debt discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=nlsp_SecondCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530197622808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Convertible debt description</a></td>
<td class="text">the Company entered into two loans for a total of CHF210,000 ($216,846) (the &#x201c;Convertible Loans&#x201d;). In February, March and June 2020, the Company entered into five additional convertible loans, on terms similar to those in December 2019, including one with a related party, for a total of CHF 265,606 ($300,480). The Convertible Loans accrued interest at 10% and have a conversion feature such that the lender could choose to convert the loan to equity at any time up to the maturity date of August 31, 2021. The conversion rate of CHF 9 ($11) per common share was at a discount to the CHF 11 ($13) per common share fair value of the Company. The proceeds from the loans were allocated between the debt instruments and the beneficial conversion feature, with the beneficial conversion feature valued at CHF 63,537 ($65,608) for the December 2019 convertible loans and CHF 37,779 ($49,011) for the 2020 convertible loans. On the date of issuance, the beneficial conversion feature value was calculated as the difference between the conversion price and the fair value per share, multiplied by the number of common shares into which the Convertible Loans are convertible. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,088<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 48,634<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530285370232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Loans (Details) - Schedule of convertible loans - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfConvertibleLoansAbstract', window );"><strong>Schedule of convertible loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Convertible loans, net of discount of $41,611</a></td>
<td class="nump">$ 383,313<span></span>
</td>
<td class="nump">$ 152,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Convertible loans &#8211; related party</a></td>
<td class="nump">113,130<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total Convertible loans</a></td>
<td class="nump">496,443<span></span>
</td>
<td class="nump">152,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Less: current portion</a></td>
<td class="num">(463,980)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible loans, long term</a></td>
<td class="nump">$ 32,463<span></span>
</td>
<td class="nump">$ 152,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfConvertibleLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfConvertibleLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530197344872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Loans (Details) - Schedule of convertible loans (Parentheticals)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems', window );"><strong>Convertible Loans (Details) - Schedule of convertible loans (Parentheticals) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DebtDiscount', window );">Debt discount</a></td>
<td class="nump">$ 41,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertibleLoansDetailsScheduleofconvertibleloansParentheticalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530200150408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Swiss Government Loan (Details) - 1 months ended Apr. 30, 2020<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SwissGovernmentLoanDisclosureAbstract', window );"><strong>Swiss Government Loan Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Bank loans percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_BankLoans', window );">Loan secured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_LoanFromBank', window );">Loan from bank</a></td>
<td class="nump">$ 281,015<span></span>
</td>
<td class="nump">SFr 248,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_LoanFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan from bank</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_LoanFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_SwissGovernmentLoanDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_SwissGovernmentLoanDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_BankLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term bank loan secured by broker-dealer customer's security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_BankLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530194590696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bridge Loan (Details) - 1 months ended Aug. 31, 2020<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nlsp_FirstTrancheMember', window );">First tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BridgeLoanDetailsLineItems', window );"><strong>Bridge Loan (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Company received | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Total value | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCollateralAggregateFairValue', window );">Aggregate value | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AdditionalValue', window );">Additional value | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_InterestRate', window );">interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AmendmentShare', window );">Amendment share | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BridgeLoanDetailsLineItems', window );"><strong>Bridge Loan (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Total value | $</a></td>
<td class="nump">$ 309,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AggregateBorrowings', window );">Aggregate borrowings | $</a></td>
<td class="num">(516,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AdditionalValue', window );">Additional value | $</a></td>
<td class="num">(206,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BridgeLoanValue', window );">Bridge loan value | $</a></td>
<td class="num">(527,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AmendmentPriceValue', window );">AmendmentPriceValue | $</a></td>
<td class="num">$ (633,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AdditionalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AdditionalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AggregateBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AggregateBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AmendmentPriceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AmendmentPriceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AmendmentShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AmendmentShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BridgeLoanDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BridgeLoanDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BridgeLoanValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BridgeLoanValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCollateralAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCollateralAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nlsp_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nlsp_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530198320104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PensionLiabilityAbstract', window );"><strong>Pension Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AccruedPensionLiability', window );">Accrued pension liability</a></td>
<td class="nump">$ 178,269<span></span>
</td>
<td class="nump">$ 180,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationsPercentageRate', window );">Projected benefit obligations percentage rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AmortizationCost', window );">Amortization cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_UnrecognizedPensionCosts', window );">Unrecognized pension costs</a></td>
<td class="nump">19,381<span></span>
</td>
<td class="nump">18,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">$ 273,675<span></span>
</td>
<td class="nump">$ 386,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AccruedPensionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued pension liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AccruedPensionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AmortizationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AmortizationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PensionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PensionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationsPercentageRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Projected benefit obligations percentage rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationsPercentageRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_UnrecognizedPensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_UnrecognizedPensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530199673752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability (Details) - Schedule of pension plan - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfPensionPlanAbstract', window );"><strong>Schedule of pension plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 24,875<span></span>
</td>
<td class="nump">$ 25,206<span></span>
</td>
<td class="nump">$ 25,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ExpectedReturnOnAssets', window );">Expected return on assets</a></td>
<td class="num">(1,713)<span></span>
</td>
<td class="num">(4,249)<span></span>
</td>
<td class="num">(3,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement', window );">Effect of settlement</a></td>
<td class="num">(28,754)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Administrative expenses</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetPeriodicPensionCost', window );">Net periodic pension cost (benefit)</a></td>
<td class="num">$ (3,575)<span></span>
</td>
<td class="nump">$ 20,085<span></span>
</td>
<td class="nump">$ 26,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ExpectedReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ExpectedReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NetPeriodicPensionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NetPeriodicPensionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfPensionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfPensionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530194563080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability (Details) - Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract', window );"><strong>Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationBeginningAndEnding', window );">Projected benefit obligation, beginning of period</a></td>
<td class="nump">$ 386,064<span></span>
</td>
<td class="nump">$ 385,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationServiceCost', window );">Service cost</a></td>
<td class="nump">24,875<span></span>
</td>
<td class="nump">25,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationInterestCost', window );">Interest cost</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationTransfersinAndoutNet', window );">Transfers-in and (-out), net</a></td>
<td class="num">(169,942)<span></span>
</td>
<td class="num">(40,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationActuarialgainLoss', window );">Actuarial (gain)/ loss</a></td>
<td class="nump">3,561<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments', window );">Currency conversion adjustments</a></td>
<td class="nump">28,285<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ProjectedBenefitObligationBeginningAndEnding', window );">Projected benefit obligation</a></td>
<td class="nump">273,675<span></span>
</td>
<td class="nump">386,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsBeginningAndEnding', window );">Plan assets, beginning of period</a></td>
<td class="nump">205,816<span></span>
</td>
<td class="nump">226,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(620)<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsEmployerContributions', window );">Employer contributions</a></td>
<td class="nump">15,207<span></span>
</td>
<td class="nump">16,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsParticipantContributions', window );">Participant contributions</a></td>
<td class="nump">6,954<span></span>
</td>
<td class="nump">9,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsTransfersinAndoutNet', window );">Transfers-in and (-out), net</a></td>
<td class="num">(142,931)<span></span>
</td>
<td class="num">(49,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsAdministrationExpenses', window );">Administration expenses</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(1,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsCurrencyConversionAdjustments', window );">Currency conversion adjustments</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PlanAssetsBeginningAndEnding', window );">Plan assets, end of period</a></td>
<td class="nump">95,406<span></span>
</td>
<td class="nump">205,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AccruedPensionLiability', window );">Accrued pension liability</a></td>
<td class="nump">$ 178,269<span></span>
</td>
<td class="nump">$ 180,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AccruedPensionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued pension liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AccruedPensionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsBeginningAndEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsBeginningAndEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsCurrencyConversionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsCurrencyConversionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsEmployerContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsEmployerContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsParticipantContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsParticipantContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PlanAssetsTransfersinAndoutNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PlanAssetsTransfersinAndoutNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationActuarialgainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial (gain)/ loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationActuarialgainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationBeginningAndEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Projected benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationBeginningAndEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency conversion adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationCurrencyConversionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Interest cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of service cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ProjectedBenefitObligationTransfersinAndoutNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers-in and (-out), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ProjectedBenefitObligationTransfersinAndoutNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfProjectedBenefitObligationAndTheChangesToTheFairValueOfThePlanAssetsOfThePensionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530197643080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Liability (Details) - Schedule of unrecognized pension cost in accumulated other comprehensive income/loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract', window );"><strong>Schedule of unrecognized pension cost in accumulated other comprehensive income/loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetLossinBeginningAndEnding', window );">Net loss, beginning of period</a></td>
<td class="nump">$ 18,698<span></span>
</td>
<td class="nump">$ 11,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_OtherGainlossDuringThePeriod', window );">Other gain/loss during the period</a></td>
<td class="nump">5,895<span></span>
</td>
<td class="nump">1,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_EffectOfSettlement', window );">Effect of settlement</a></td>
<td class="num">(5,212)<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AmortizationOfPensionRelatedNetLoss', window );">Amortization of pension related net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetLossinBeginningAndEnding', window );">Net loss, end of period</a></td>
<td class="nump">19,381<span></span>
</td>
<td class="nump">18,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PriorServiceCostBeginning', window );">Prior service cost, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_AmortizationOfPriorServiceCost', window );">Amortization of prior service cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PriorServiceCostBeginning', window );">Prior service cost end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_TotalUnrecognizedPensionCostEndOfPeriod', window );">Total unrecognized pension cost, end of period</a></td>
<td class="nump">$ 19,381<span></span>
</td>
<td class="nump">$ 18,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AmortizationOfPensionRelatedNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AmortizationOfPensionRelatedNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_AmortizationOfPriorServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_AmortizationOfPriorServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_EffectOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_EffectOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NetLossinBeginningAndEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NetLossinBeginningAndEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_OtherGainlossDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_OtherGainlossDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PriorServiceCostBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PriorServiceCostBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfUnrecognizedPensionCostInAccumulatedOtherComprehensiveIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_TotalUnrecognizedPensionCostEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_TotalUnrecognizedPensionCostEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530272143256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension Liability (Details) - Schedule of weighted average of the key assumptions used to compute the benefit obligations<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract', window );"><strong>Schedule of weighted average of the key assumptions used to compute the benefit obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_WeightedAverageDiscountRate', window );">Discount rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RateOfIncreaseInCompensationLevel', window );">Rate of increase in compensation level</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_InterestCreditRateOnSavingsAccountsinDollars', window );">Interest credit rate on savings accounts</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ExpectedLongtermRateOfReturnOnPlanAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_WeightedAverageInflationRate', window );">Inflation rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ExpectedLongtermRateOfReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ExpectedLongtermRateOfReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_InterestCreditRateOnSavingsAccountsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_InterestCreditRateOnSavingsAccountsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RateOfIncreaseInCompensationLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RateOfIncreaseInCompensationLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfWeightedAverageOfTheKeyAssumptionsUsedToComputeTheBenefitObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_WeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_WeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_WeightedAverageInflationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_WeightedAverageInflationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530271387544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NonrefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ReceiveNonrefundableMilestonePayments', window );">receive non-refundable milestone payments</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_EstimatedTotalTransactionPrice', window );">Estimated total transaction price</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_LongTermDeferredRevenue', window );">Long term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_EstimatedTotalTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_EstimatedTotalTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_LongTermDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_LongTermDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ReceiveNonrefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ReceiveNonrefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530201189608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Company obligated to pay adare</a></td>
<td class="nump">$ 840,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530195250520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_CommonSharesRegisteredAndIssued', window );">Common shares, registered and issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_CommonSharesToCreditors', window );">Common shares to creditors (in Shares)</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PaymentOfInitialCreditFacility', window );">Payment of initial credit facility</a></td>
<td class="nump">$ 5,131,481<span></span>
</td>
<td class="nump">$ 3,418,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent', window );">Credit facilities amount</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge loan</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ConvertiblePromissoryNote', window );">Convertible promissory note</a></td>
<td class="nump">$ 529,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_CommonSharesRegisteredAndIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares, registered and issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_CommonSharesRegisteredAndIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_CommonSharesToCreditors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares to creditors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_CommonSharesToCreditors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PaymentOfInitialCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of initial credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PaymentOfInitialCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current and noncurrent portions of a long-term real estate loan with an initial maturity beyond one year or beyond the normal operating cycle, if longer, to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConstructionLoanCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530205359240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_DescriptionOfIncomeTaxDescription', window );">Income tax expiration, description</a></td>
<td class="text">The Company has Swiss tax loss carryforwards of $15.5 million as of December 31, 2020 (December 31, 2019: $11.5 million) of which $9.7 million will expire within the next five years, and $5.8 million will expire between 2025 - 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetCapitalLossCarryforward', window );">Net capital loss carryforward</a></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetOperatingLoss', window );">Net operating loss</a></td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_DescriptionOfIncomeTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_DescriptionOfIncomeTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NetCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NetCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530285309544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of net deferred tax assets - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfNetDeferredTaxAssetsAbstract', window );"><strong>Schedule of net deferred tax assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net benefit from tax loss carryforwards</a></td>
<td class="nump">$ 1,393,809<span></span>
</td>
<td class="nump">$ 1,031,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">224,997<span></span>
</td>
<td class="nump">224,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_OtherDeferredTaxNet', window );">Other, net</a></td>
<td class="nump">6,951<span></span>
</td>
<td class="num">(15,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,625,757)<span></span>
</td>
<td class="num">(1,241,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_OtherDeferredTaxNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other deferred tax net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_OtherDeferredTaxNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfNetDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfNetDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530280642648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income tax provision - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfIncomeTaxProvisionAbstract', window );"><strong>Schedule of income tax provision [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax (benefit)</a></td>
<td class="num">(384,301)<span></span>
</td>
<td class="num">(325,572)<span></span>
</td>
<td class="num">(289,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="num">(384,301)<span></span>
</td>
<td class="num">(325,572)<span></span>
</td>
<td class="num">(289,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">384,301<span></span>
</td>
<td class="nump">325,572<span></span>
</td>
<td class="nump">289,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfIncomeTaxProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfIncomeTaxProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530285309544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of effective reconciliation of the federal income tax rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract', window );"><strong>Schedule of effective reconciliation of the federal income tax rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of permanent differences</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on deferred tax assets</a></td>
<td class="num">(12.90%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(5.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ScheduleOfEffectiveReconciliationOfTheFederalIncomeTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530195148264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party consulting agreements (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems', window );"><strong>Related party consulting agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_BonusAnnualFee', window );">Bonus annual fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">General and administrative expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,859<span></span>
</td>
<td class="nump">$ 285,538<span></span>
</td>
<td class="nump">$ 286,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_CHGBioVentureSAMember', window );">CHG BioVenture SA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems', window );"><strong>Related party consulting agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_OtherTransactionPercentage', window );">Other transaction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrRoyMember', window );">Mr. Roy [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems', window );"><strong>Related party consulting agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Service payable</a></td>
<td class="nump">SFr 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrKonofalMember', window );">Mr. Konofal [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems', window );"><strong>Related party consulting agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Service payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_VATServicesPercentage', window );">VAT services percentage</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrCamozziMember', window );">Mr. Camozzi [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems', window );"><strong>Related party consulting agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Service payable</a></td>
<td class="nump">SFr 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_BonusAnnualFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of bonus annual fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_BonusAnnualFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_OtherTransactionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other transaction percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_OtherTransactionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_RelatedpartyconsultingagreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_RelatedpartyconsultingagreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_VATServicesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of VAT services percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_VATServicesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_CHGBioVentureSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_CHGBioVentureSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrRoyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrRoyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrKonofalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrKonofalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrCamozziMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nlsp_MrCamozziMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140530194575320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Description of loan related transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In January 2021, the loans listed below were further amended such that the maturity date of each instrument were scheduled to be March 31, 2021: &#x25cf; $85,737 under an old expired credit facility; &#x25cf; $150,000 under the Second Credit Facility; &#x25cf; CHF 500,000 (approximately $565,650) under the four convertible promissory notes from January 2019, each of which carried an interest rate of 10% per year; &#x25cf; CHF 23,020 (approximately $26,043) under the Convertible Note with MRI, which carried an interest rate of 10% per year; &#x25cf; CHF 100,000 (approximately $113,130) under the Convertible loan with a related party, which carried an interest rate of 10% per year, and &#x25cf; CHF 600,000 (approximately $678,780) under the Bridge Loan, which carried an interest rate of 10% per year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Price per unit (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_WarrantExpireTerm', window );">Warrant expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Additional common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_PurchaseWarrants', window );">Purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_NetSalesOfMilestonePayments', window );">Net sales of milestone payments (in Dollars)</a></td>
<td class="nump">$ 4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event description</a></td>
<td class="text">As consideration for the license, the Company agreed to pay Novartis $250,000 upon the signing of the agreement with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company&#x2019;s product candidate reaching $250 million in cumulative sales.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlsp_ClosingValue', window );">Closing value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,819,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_ClosingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_ClosingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_NetSalesOfMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net sales of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_NetSalesOfMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_PurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_PurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlsp_WarrantExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant expire term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlsp_WarrantExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlsp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/1L'XQF"%0:MPP6#P.J(>N2%5 ;6"%:/F5)W6ARN^(PZ4'C@O>$0LB>9E<)
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M5H#OMU*:SQ?;0?.[QO(_4$L#!!0    ( *Z(KE*]HS/\?@8  %\9   8
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M 0Q97%:+B18[>QM;"0UW.SO,X()/I#& ]QLA]/O$7/"JOPRS7U!+ P04
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MB_GMR\VC"39>.Q2>\>>-^&N27VT(?,-U0(*\G/#JMUY]X]4?\7H/$IA(MF9
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MN[W9O!^_,U</QI$]04.E$<2!@S_]%%F D3\$WMJ ;A?8S9,6+]V6DP2@TQK
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MR3,6$2M+N>-'9<B+)W'<B.,4DV(\-ZX<SI/B@#?VD^.1BZ,\HQ.HA@X AUN
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ML^L0_[Z8<M/9I\8VBYI2PY *;0!5K%XF;0!F+*LLI^( +C#N6I<"*&<Y<>N
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M(=A*/G)C(L<'\'YA86+ZP@+Z'_I?_Q]02P,$%     @ KHBN4A]XF F]&P
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M-;0,BLED.V/46F(.XD0'">R TV9T-;'1@%K"A1K4F4S4&:B*ZD8,)K-L@;7
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ML!U 0-X<LZY%^\DT.Y];=P1L.5T2>=5F$P&24:]PF>SO@^L@@@XO-=5%(W7
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M1.\=9N%2"CD9W,O&(E6$/^&KJKZAA'*1Q\WVR@'1PR]">BJ6;I>D;#N70=,
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MG:PS3M>9T"]A84$OHT%3YDH8+V#E52B7'>%&)1U>7XW@R!':</,8EH!2!^[
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MS3^NC"9]PP#Z?&$)><(OV"!]E>*/_PM02P,$%     @ KHBN4D\5_/,"!
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MB(+W:@IPW2DNMIZI$%A7<L?>3JYDTS+Q\/57>1)GWVO8C,[ZT9D:BS-^0*8
M;74 Y1:;-:HQO\$Q'/"2'/F&DR43@$H1 A?.Q"U($#CM>&]@P86A34]=H*/
MK:)^ILP#X#WU-8W:>B91/".HT@[R,_CX[TZZDEU=0L5V"&M$ 47-M!XX:=BB
M0$6.A.FQDK8MMU5B^\]Q7&VHBUJM+&FFBLIQ*'%'K;)U57 PMIRX]LB.F@V%
M(,[,>HWE8B044BGB:R4XY$QA*Y6U9XWLK-:#2L_FX6G.GJ1%?Y87K\_+9Z)Q
M30$/.A0N!19T7'!%BQ42..$33?III"$*5EHR%MO1,@!!IU$M-8WL$\B"%&<*
M82"U9C4M #W7]US"O(VLZ8"Q,(:M:PHWE$)? D/,?HG'PIU2Y)0$\(4$%QX=
M$VX/_&XK^>WSYMY*'^^J5?D7]?@^W$I[P_8K[<!5A/=21< ;B(,L2H(XSN";
M-Y!':3!)9O M_<AG69#EN?=#7X4.XZ4J3()TE@:S)!D1)D$RFP7)-/8^VOQX
M7^:'0J1!3$&BR8S&WQW/7R-"_E0$6NQ0IO]-C722!=0LK!I9D@=9FCDULB@/
MTNGTE6I$<1R<3V<C0D+/*$BC\U-J3((TS8/\/![4>)P_=RJ$1Z=U@VKK[B2:
M]B]MT?[@'K^.UYY5?]H_FO=WI@],;:F/0(T;<HW.,KIEJ/X>TD^,;-W9OY:&
M;A)N6%'3064-Z/]&4M\?)C; >!E<_@-02P,$%     @ KHBN4DRSLZ'L P
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M[[\[3>+9A85-+Q"/X=K#\QXN/!QR34?1.J3M$L@ 2BWI3-=J31:\1N7!9D7
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M&A] _K6F^[N;^ 7&%W7Y+U!+ P04    " "NB*Y2500_>^4#  !*"   &0
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M'06,0,F4GA_"FU:?2 SKEX^?>]$XVSA% 4HC:ENJM4)Z#FJ %A:!BLI8;3>
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M-<1MJAD6_%U ZPMX/S=\CMW$"_1?FLT?4$L#!!0    ( *Z(KE*5RU9M0P8
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MMI!^B["$7@G'JVL/%!8+H2$\GGK$P$!87"[1[S#^BR$86%-$DE?$->-5?3T
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M1,,"]'VIZ1#;O? "FWOFR7]02P,$%     @ KHBN4F>H=SU#!@  M!(  !D
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M"D(==$:03+%[GI6F%U&:7LR*P)M@RGY%CX0HOP97,"E+CP.DAH#T+1P?B:O
MD3AR6W"\QJR+9I'K9')%*R-^LZ3U%<0190=D+[K.U<N^(U^",210SB)Q*J1R
MP9[9ALV!8![H[CA$V()AP*>-:_8*1"L:<-H'_,D:/Z_!NWD62;!^()^PI#2F
M(J$@C4?IEAW(1</WD$^8[1+P#CD%P03#]@UY9W!!]_B_OWWSU?/%-Y#.X*]_
MNWY^N;B^NEHHX/W.4%+9[!<([GT+&,-!/O1+B) 35X@8BTS&22M])V>=)B@\
MS7\@31?LJPD;$;/Z3[+8B@G?VO8,*$9AB81:XCV714-^D5+$.:G[)DK=-_.&
MQP*XMDMAYFM@1MWIC[7_/"5Z?P&:&D)+,;I"YKJ>=91(L8-TI$5J SG!!?P.
MC,C=/0I9.4:T9- .08>0"JT/B$,W*POH8\!#\'8*+:EX%K)=0F%/H938'_:F
M8+W@UQ9MF<83U%V/N-!^=R *MO?DB(;!(/G&9"+;+"+.@'AUOZE1K!TE:>9+
MB589;8VIQ-C!TSTJ2E-#G#]K<:XN4[G@<I9?[_J6HA! YC7)6[F?K P\%HH*
M4 9N"RF0;"6>[Q8\U)]@ BCOD&3@4TN$OL68>NAA8K2W2NB68:/:\VK,>"K;
M-(6+>=ZGVS<Q>E&_41[!V0+0%9F!:@;/A( Y88A< $EK/3@+CFCP,?&1D($[
MR*201YNBA0^.O%66KNQ-X28/H([E3</],$9C2,$(#/9"1RD2.S '[+T1-L7E
M&]M@J"![A["]]NI@IPU8+P@52LRGF/COK#.0/*1]:4W!$2L99SX#F&9!7S20
M%86,&'QCM^9"\KD0CHXIDK'D<>[T*JN%7<V*Y4=,\2!G^6A*NT9C/AV[/PZ*
MRJ" OU%3_N90[S$V<;SP3_)Q6(QAK"C=1"D$&C? !P@[P,T0J8HU1&@4\N8!
M^=MW^B=YX"8\$,1[H0I6@WX'<&'AKN#L,4<($#&P346840TI.%\6UJD-2+TP
MH >W:'<2#&PA,T$#!F>B$X!SKGJPV)!H5C4*X4+]8IOB3]M@TJI_P@Q.W\ B
M3$4U^46'8D]AZMO>V57AM@4\M[0@ "")%H*5\YOSJ,CQF7A>B#E>N>)/4""
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MOL( FQN,O,3:<AX+4# I,7MG\3H,98#1B^;-3HPFS@7;:\ V5+)DEAUQM)(
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MECYN3 $*C _ [RL++D7^P WB:ZM_^%]02P,$%     @ KHBN4O:N5G/U @
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M-U]@88BNQW4+Q1O35W9<89<RTP+_%H#0 GB><ZZ&A38P_M'8_@]02P,$%
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M.YF.2%1J([,&C HRD=??_+E)Q & #@%8 V!O  M_ #!I )-3&:8-8'HJ8-8
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M:/S?\/CV@IQVT]"VYVN?X3O5N9_#N45#)_;7A02=)D'')^B<%5R ,9#3EM'
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M=9VPS5Q7<I F0,^OA<!CQRS0_C<D/P%02P,$%     @ KHBN4O:?>SBJ!0
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M1E]. ]#=1>T"JQI_UE?*TLWQPXK>-M0N@=9+I>PV<-=G>"VS?U!+ P04
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M +43H/-<*;M;. /=KXWY?U!+ P04    " "NB*Y2;7T).:D"  "0!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R555UOFS 4_2L6JZ96:LLW23."
MU"::-JF3JF;='J8].'"3H!K,;"=I__VN#45IH*A] 1O?<^XYU_8EWG/Q*#<
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M>]J+I2O=<^XY\I6RDS;/M@% \B*%LJNH06QO*+5E Y+9F6Y!N9U:&\G0A>9
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MIT2J*8]LL>) PAR4)K;K.(&=$II9PWY^;\J'?;:6"<U@RI%8IRGA[S>0L.W
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M@WBN5DR.S,Y*2@HH.:$E8I#-C(5]%X4*7P-^$CCPLV^DE&PH?5&#;^G,L%1
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M9"6M/W>R.0*F '(]HU2<!LI!UV[-_P%02P,$%     @ KHBN4C=_F/ML!
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M3(&R"W"^D-+L.M9!]_"EOP%02P,$%     @ KHBN4JD"J.OL 0  Z0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULG5/!;MLP#/T5P=BA X;(<9JV
M*QP#38)A.PP(&G0[##LH-F,+E41/8N+F[R?)CA$,RP[SP2(EOL='4<P[M*^N
M 2#VII5QBZ0A:A\Y=V4#6K@)MF#\R1ZM%N1=6W/76A!5!&G%LS2]XUI(DQ1Y
MW-O8(L<#*6E@8YD[:"WL:0D*NT4R3<X;S[)N*&SP(F]%#5N@EW9CO<='EDIJ
M,$ZB81;VB^1I^KB<A?@8\$U"YRYL%BK9(;X&YTNU2-(@"!24%!B$7XZP J4"
MD9?Q:^!,QI0!>&F?V3_%VGTM.^%@A>J[K*A9) \)JV O#HJ>L?L,0SWSP%>B
M<O'/NCYVGB6L/#A"/8"] BU-OXJWX1XN -GT"B ; %G4W2>**M>"1)%;[)@-
MT9XM&+'4B/;BI E-V9+UI]+CJ%BAUI+\+9-CPE1LA8:DJ<&4$AR[60,)J=S[
MG)-/%B"\'(B7/7%VA7@-Y83-IA]8EDX_OFS7[.;='RS<2QWU9J/>+-+._DOO
M6KI2H3M88#^>=HZL;_K/?V2=C5EG,>OM]:RM,">&.R5K05 Q0M:*$Q.5L/"W
MR^GY[B)?&(QC\7";^B_GQTL=_*)S80B^"EM+XYB"O0>FD_MYPFS_L'J'L(W-
MW"'YIQ'-QL\BV!#@S_>(=';"^QBGN_@-4$L#!!0    ( *Z(KE*8PL/W.P,
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MB9=XD.&:[83]H@X?L(ZG[^RE2ICR%P[5W'CD0;HS5A6UF @*+JM_]J/.PY&
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M%7!MH)ZGC,G=1CMHI[7P'U!+ P04    " "NB*Y2#^(+X]<"  !1"0  &0
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MHF,!O0K0<\Z44IP/<XIT,E)R391=;=ALPYGIT$8^$S;M#ZC,+#,XG-R(6.9
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MO)!(=9 *4_-W[,1!/W-O,<]8L6RMC?/SC$K0,U[,GN@.2E!'B;=VOPJ-MWK
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MGOL!  #+(P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J-
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M<',O87!P+GAM;%!+ 0(4 Q0    ( *Z(KE+AI1SM[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "NB*Y2K&/\UHL#   ^#   &
M    @($^$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MKHBN4G?V!(. !0  TA(  !@              ("!_Q8  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *Z(KE)\LOV PP4  !4>   8
M          " @;4<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "NB*Y2FR9K&>0&   7'   &               @(&N(@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ KHBN4B=K@MJ7#   ]!\
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *Z(KE(#+I\ZH0<  )83   9
M      " @;E?  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ KHBN4G=AUHDR!0  )PT  !D              ("!D6<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "NB*Y2F3.CYE\#  !=!P
M&0              @('Z;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( *Z(KE)5!#][Y0,  $H(   9              " @9!P  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ KHBN4EV$7>4>
M P  GP8  !D              ("!K'0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "NB*Y2W;'7N18)  "M%@  &0
M@($!>   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *Z(
MKE*N:NFWMPD  % =   9              " @4Z!  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ KHBN4F)@=<%V!P  "1$  !D
M         ("!/(L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " "NB*Y2&2HQ.>D"  !U!@  &0              @('ID@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *Z(KE*5RU9M0P8  ',.
M   9              " @0F6  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ KHBN4F>H=SU#!@  M!(  !D              ("!@YP
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "NB*Y2P I_
MR]$'   L$@  &0              @(']H@  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( *Z(KE)D+VGYY1P  ,):   9
M  " @06K  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MKHBN4O:N5G/U @  VP8  !D              ("!(<@  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "NB*Y28NJX*;,"  "O!0  &0
M            @(%-RP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( *Z(KE+Z,9)"1@(  /L$   9              " @3?.  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ KHBN4C $#5%> @
M"04  !D              ("!M-   'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "NB*Y2PS2=GX@"  !6!0  &0              @(%)
MTP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *Z(KE+A
M"4%3;P4  ,D-   9              " @0C6  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ KHBN4F]>,!I_ P  = @  !D
M     ("!KML  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z(KE+$^UV$=P(  "<&   9              "
M@>'M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ KHBN
M4O:?>SBJ!0  ZQ4  !D              ("!C_   'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "NB*Y2NEY\4QD"  ##!   &0
M        @(%P]@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( *Z(KE(YHE>PX0(  %((   9              " @<#X  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ KHBN4N&?0:1$ @  .04
M !D              ("!V/L  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "NB*Y25&],X#L"   ;!0  &0              @(%3_@
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *Z(KE*9(B!?
MT00  'D,   9              " @<4  0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ KHBN4FU]"3FI @  D <  !D
M ("!S04! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "N
MB*Y29EQ;Q_\!  !^!   &0              @(&M" $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *Z(KE+?PD&S5 (  /\%   9
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M970T.2YX;6Q02P$"% ,4    " "NB*Y2L@B=+6P#   Y#   &0
M    @(&Q&P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M *Z(KE*'W5@ML@(  %T(   9              " @50? 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ KHBN4L:ODP>D @  ! <  !D
M             ("!/2(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "NB*Y2J0*HZ^P!  #I P  &0              @($8)0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( *Z(KE*8PL/W.P,
M &,)   9              " @3LG 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ KHBN4A3RS!/U @  CP<  !D              ("!
MK2H! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "NB*Y2
MY8YPW=X"   +"   &0              @('9+0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( *Z(KE+*_553XP(  +D)   9
M      " @>XP 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ KHBN4@_B"^/7 @  40D  !D              ("!"#0! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "NB*Y23;Q::= #   (#P
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M+G)E;'-02P$"% ,4    " "NB*Y2'3[8$<X$  #%)P  #P
M@ $_10$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KHBN4I@;6I[[ 0
MRR,  !H              ( !.DH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ KHBN4G32QF+> 0  6B,  !,              ( !
M;4P! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $0 1 "3$@  ?$X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>77</ContextCount>
  <ElementCount>369</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements Of Changes In Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements Of Changes In Shareholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/Background</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Receivables, net ??? Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty</Role>
      <ShortName>Other Receivables, net ??? Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Convertible Promissory Notes ??? Related Parties</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties</Role>
      <ShortName>Convertible Promissory Notes ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Credit Facilities, Subordinated ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties</Role>
      <ShortName>Credit Facilities, Subordinated ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertibleLoans</Role>
      <ShortName>Convertible Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Swiss Government Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SwissGovernmentLoan</Role>
      <ShortName>Swiss Government Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Bridge Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/BridgeLoan</Role>
      <ShortName>Bridge Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Pension Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/PensionLiability</Role>
      <ShortName>Pension Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Deferred Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/DeferredRevenues</Role>
      <ShortName>Deferred Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ShareholdersDeficit</Role>
      <ShortName>Shareholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Related party consulting agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/Relatedpartyconsultingagreements</Role>
      <ShortName>Related party consulting agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Convertible Promissory Notes ??? Related Parties (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables</Role>
      <ShortName>Convertible Promissory Notes ??? Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedParties</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Credit Facilities, Subordinated ??? Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables</Role>
      <ShortName>Credit Facilities, Subordinated ??? Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedParties</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Convertible Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertibleLoansTables</Role>
      <ShortName>Convertible Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertibleLoans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Pension Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/PensionLiabilityTables</Role>
      <ShortName>Pension Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiability</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Background (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/BackgroundDetails</Role>
      <ShortName>Background (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/Background</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of restatement in the financial statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofrestatementinthefinancialstatementsTable</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details) - Schedule of restatement in the financial statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Other Receivables, net ??? Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/OtherReceivablesnetRelatedPartyDetails</Role>
      <ShortName>Other Receivables, net ??? Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/OtherReceivablesnetRelatedParty</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Convertible Promissory Notes ??? Related Parties (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesDetails</Role>
      <ShortName>Convertible Promissory Notes ??? Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Convertible Promissory Notes ??? Related Parties (Details) - Schedule of convertible promissory notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofconvertiblepromissorynotesTable</Role>
      <ShortName>Convertible Promissory Notes ??? Related Parties (Details) - Schedule of convertible promissory notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertiblePromissoryNotesRelatedPartiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Credit Facilities, Subordinated ??? Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesDetails</Role>
      <ShortName>Credit Facilities, Subordinated ??? Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Credit Facilities, Subordinated ??? Related Parties (Details) - Schedule of credit facilities with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable</Role>
      <ShortName>Credit Facilities, Subordinated ??? Related Parties (Details) - Schedule of credit facilities with related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Credit Facilities, Subordinated ??? Related Parties (Details) - Schedule of credit facilities with related parties (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofcreditfacilitieswithrelatedpartiesTable_Parentheticals</Role>
      <ShortName>Credit Facilities, Subordinated ??? Related Parties (Details) - Schedule of credit facilities with related parties (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/CreditFacilitiesSubordinatedRelatedPartiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Convertible Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ConvertibleLoansDetails</Role>
      <ShortName>Convertible Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertibleLoansTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Convertible Loans (Details) - Schedule of convertible loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofconvertibleloansTable</Role>
      <ShortName>Convertible Loans (Details) - Schedule of convertible loans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertibleLoansTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Convertible Loans (Details) - Schedule of convertible loans (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofconvertibleloansTable_Parentheticals</Role>
      <ShortName>Convertible Loans (Details) - Schedule of convertible loans (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ConvertibleLoansTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Swiss Government Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SwissGovernmentLoanDetails</Role>
      <ShortName>Swiss Government Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/SwissGovernmentLoan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Bridge Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/BridgeLoanDetails</Role>
      <ShortName>Bridge Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/BridgeLoan</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Pension Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/PensionLiabilityDetails</Role>
      <ShortName>Pension Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiabilityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Pension Liability (Details) - Schedule of pension plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofpensionplanTable</Role>
      <ShortName>Pension Liability (Details) - Schedule of pension plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiabilityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Pension Liability (Details) - Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofprojectedbenefitobligationandthechangestothefairvalueoftheplanassetsofthepensionplanTable</Role>
      <ShortName>Pension Liability (Details) - Schedule of projected benefit obligation and the changes to the fair value of the plan assets of the pension plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiabilityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Pension Liability (Details) - Schedule of unrecognized pension cost in accumulated other comprehensive income/loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofunrecognizedpensioncostinaccumulatedothercomprehensiveincomelossTable</Role>
      <ShortName>Pension Liability (Details) - Schedule of unrecognized pension cost in accumulated other comprehensive income/loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiabilityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Pension Liability (Details) - Schedule of weighted average of the key assumptions used to compute the benefit obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofweightedaverageofthekeyassumptionsusedtocomputethebenefitobligationsTable</Role>
      <ShortName>Pension Liability (Details) - Schedule of weighted average of the key assumptions used to compute the benefit obligations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/PensionLiabilityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Deferred Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/DeferredRevenuesDetails</Role>
      <ShortName>Deferred Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/DeferredRevenues</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Shareholders??? Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ShareholdersDeficitDetails</Role>
      <ShortName>Shareholders??? Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/ShareholdersDeficit</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofnetdeferredtaxassetsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of net deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Income Taxes (Details) - Schedule of income tax provision</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofincometaxprovisionTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income tax provision</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Income Taxes (Details) - Schedule of effective reconciliation of the federal income tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/ScheduleofeffectivereconciliationofthefederalincometaxrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of effective reconciliation of the federal income tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Related party consulting agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/RelatedpartyconsultingagreementsDetails</Role>
      <ShortName>Related party consulting agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/Relatedpartyconsultingagreements</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="nlsp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nlspharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nlspharma.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nlsp-20201231.xml</File>
    <File>nlsp-20201231.xsd</File>
    <File>nlsp-20201231_cal.xml</File>
    <File>nlsp-20201231_def.xml</File>
    <File>nlsp-20201231_lab.xml</File>
    <File>nlsp-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001213900-21-026511-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-026511-xbrl.zip
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MF.T.RN(Z!VF_?97^O@-2K4;IZ1Z4A'LUVN_]Y)NE)W_0+?:)PEOE%'Y027;
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MQT.=_1W6V5=F%LW-F<6*G11^?W_QZ7#6:P"QQ*^ET;J?[1QZ)SFMJ-E0TNG
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M7<3"B;DHU7/2R!E%<2Q&*7W0+D!UHK'C _<- OC[S V<:1P!>TYO'<%8!$@
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M:4YAW<Y&[_ZRMEN#0:O;?.B-WOVM;?4ZC4[C9/V-?IIB%0&H26]5FX)MW#-
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M8^ZWE+W0;M@M+0O7FF?&ZT!5F3ET.WUSEL!Z4!E!VVWU6LY/A5^PW.DVX%J
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M8A@3SHBL6TV;K.?VO!5VPC(IE50U"J($I0Y<'C_%"P(7!>["=#8,4.C@&49
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MLA: 5L3/*$P"S%C]-HVF6[3!Z=G$_T/PF<UMJ=4=C<LW5?D$[@-BO/O SZY
MJBG?VZ>_O7]3;PX83" *3TR 5R$/) ,?Z&1$)B.(4B+$$,2B%IEI#!0.ZQH\
M"]_,B%^SIE($\8_RLJYQ<1_FJJY 5W=Y.5>#>;=Q:EZ$]7C8D[X*>\>G0+VZ
MBI52/:),>^!9CKK&Q(]B4<^K[[4\=S*#7R5&@./JW.F?YMVHA??S<$$/O.K
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M(UA_)/T8*-B VJU#'M>A,%D'E4>9?6GU!]4PW(5WUJ1\D%(8%>2=CR,,H'!
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MH<:M64:U$AAD%C(V4D2%T4.!-56SY<*MO"'*3+?TDUQ%8$&/R[GV#9F.K L
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M(CZ-W^J6Z$^%T&';3.5ZZT^&Q"E9A4<@&043A:3N4X=Q]&?R]"Z3KK/Z(Z/
MG7)2O@FCQSX9O/D^*++5K33O5?M#%>DHK<M1(26C06\AV%F2AORD6@,-:17S
M-8)@<ZV)T2'*G:948[81!9JXKD>%!5 !LS<Z-*9AR+"Z*@5*S;<,A%!3%^5N
M8L8X-J9Z9[NJE6L/5C1? Z0B:\^;+W0FDM&\/4K2.N<ST<FI1EU6?HG4X;D6
M#0]+5D/K-AIZMTO4S)^<YZT7TM=@-9/)3XVPT\_DX%\=7H3/M%\H=9PA'G%0
M"^,X7 0E9"6UG@F5B_#0J+#.B\*J'])KC:+QJDZ#Y:S99K.G.2WL4WSEAOX?
M!,ZY=C+!/R1'-U61UU+9?4.UZW2)SD)O@=*W 4]_7!G1?_GT^A*-:^ LAI!]
MB^ZTIS*8&!F\3GSFSERF3@&<!"&Z<J[BZ'MZK6;A6D%7,)JL";N_6CH1]0E0
M.3)2R_H+\#+@4\#"/LUB1]U/U&[B=#9-D)4B,</[+>=H;IPQG1H\DIN _E4W
MYU</T'Q8 (<2HT6@"RH](-I;:9EA9V# $=7=W= ,,\,]G&AU2WI:DMF0:UQ3
M73&6>3JE@%&KRR; Y%4&*A;<+P&9>?992NZBW.S8OU&^5LK[7LX@[I0%Y/G-
MN9M<PQOX/V^SUAH[9O3=9PMAQ 1K(R =Z!\&7IX*X\@X1S:8$C.Y[;QD'P2J
M&G>@2N_ %@-XW2!+2";JB06.U@C3:T[YE"-/3!5N.HM'UYB7R/5 (SZ&(Z/?
MBYVGZ0FJ8^(X/3T-I ;8\CF1=G0M1AANK^&RXC9K"Z6;.63YUZC<L!W((7SY
MZ5Q>Z%%6ZY%Y_-$SQ/F-)C*D3Y$T)YS:-14C-?E!I0K4, 1SS7;L5(83Y%:F
M8,T&^=P"ZC UXW0FL%9T7L)R=E*)PO-L057=GU.-\Q;YP>/2(W3S <#.)]3>
M$?W<S.4IL()+.<Z,(HPC]OO"U:2VO'-===F8H&:]'.1.R.:1C?+<E%-T52ZC
M2YU[HX3SV5PVL2*%8O16 \W$;.QA72/W^:6,]:%1TT\KT1V%G\G3S%P%M)HD
M81\\1IS5F!AD4'(-LK;@]XN2QU)J,D>)8'\:=$YJ U!;\*]_:ITT:JUFLZ9Z
M560I8#7\)B<&!,X%.Z7US9%I^QFCDDEW<LO%>(6G0]V.6#9#() DIU#9\N2K
MI#- ?[B.2<L&DP5]<Y:SCL5<X+288^ >S^7J6*5#3&*6>,]LKM'\_0QTF8Q7
M4#;4Q V27YX!XP!L [(+(#&^?EK"LBH"T#(!: YR , )PP&O!, Y5@>%*3/F
MSW[R[9S*D_"GAU:@[LV99N& J0,N-B/"04P\!;;YSO#:($>*9\9H+YT=BS-G
M9L-_T:S$:ZNMX,A"(B;D,OZH[:+RY:#*0].U%C$P-&M25RVGVD_H6;?4HIU9
M@NJL0YJ/C,V%R#!"6<(!7"J=Z;G,.(\RPCI!1H"Y@6LR"Y5R%AH^+.,CB9I:
MRH.^C4$M8^%)+8O*9JE*;>)7<:PLH+_Y:->[*!9P!YB2@:D9731!6:)_!JQA
M[9@M=']MX6?A2":^@SD@\?04R/?+=:X?/-YH(Q/8SG'5+N:O(1'.94HM#LLS
M>L<97D<2JZJ*ESSJ7A1@MJ\5 ?IZ^2;G%*&T1>62ENF)*/?A2>6*-7*78SDP
M5Z>\XV/2 %,9 D""%+^7V6-SE2'E*<I8D%6:,&6LF^7\*^W$6M-H9%U0ETR3
M98S*%ZON5GJ'.6 [MR+W]Z&N&]Q_TI'4GZUOMHV?2UA@'I5/6N TA9=&CE^I
MG_C(.*A53+>UF=1IGMU]YOE5G[/><$_5I).8<&1-0]8K[RFPMC.5T3"G-%2:
M=:>FH%'\BIN/ 55P26-^/ITSY]XMFOQH<;4:*RC,"V=36"74)9P6>'I@A.Z@
MI0Q"9E-%*Q&/S9*;9!ZV'%V)#9EQ/W+@%6A&H>?S"$" Z&,4N'_@ %6@\0\8
M%7+.L'L/=B\B2RWV986Q\W861V,WGKCP''6 ![83)<[E\=FQS=#U@SD$N,[K
MV/T#^"=\>WJ-#XRHLH/+M7#SV /X:-$FC5+G9 3<AA.4SIV3QDG)<)+/YK&>
M1^9 ^W,YSM[T?)HA@GS2!*Y2*57AT9*03$BDW$V%53-G>VX@)J7#DV=/XM*)
MABF)&#V]=ZP&:!OSN;/Q1)QD;TY.L3+#53IZ-OLOZSXIH3+:UZF9[+XA_-C5
MB$[&N=5Y%J:>N$WZ@M$S/FOW%&NV>C37T(D*'(W!:&8#3WYXX9TU*5]/6Z0(
M,8T9X>RD&XR^B&GRB@:.\H -G=JCFC^48UF);S4\[B>>2#K7Y-\<.;[@:]2T
MN&2>NDS85Y%UXXNW<AX%.H2RIJ)2,&NCS8000#2+]%4CLOR(XGSM1S8&&:5!
M2-8<.>:L>X0KW+Q0=0]&@LC<]U60O&3+/W&D';Z5ZTUKD0C-8W63%]9YJZFL
M"4^.+E[ =M13FSB71Q#*Q) ;4<?+@2G)(I 6-B$Q4=1IS?'&I (W-0F(<F]'
M$4T=RP_:Y-[J^%R@ZICSI%5 6-1S3J<=JR)4R2'VCFE>&.>&5RXW$W$Q7;KZ
MN')SH#2EX&O&6WETZL;=1OVQ?I=K5O 6(..P7N/VA-S\0=?_YM>*F+E'WT/J
MZ!5=,3GSV)>4^Y>X'CI[L]:V8 Y$LU@5 1&G49S<0H6Y#M:*<*H6M8J1#([[
MC2)L,I>'7Y_C9UQ1I4M3%=-9@'ANR*+09'/A+"@HAX#H$JN4^V!PPKG9JT6R
M#FH-QFU/"L?XU:1C:IIKP:R8GSH:0Y-394OS(P'MHS%9M\ZA1\D8ISZ/QIX_
M*$JE-]XC6(K9/8)PA?5S %J$4TQ5+ZM(&8Q+A<[>D;T=2L[RT8J%B-7+6VH6
M9KML<U*<6;61M8=9R$9T\49&$U^N<R*/0DW*PSKV?P@O]W<J\2@2EN05Y:NH
MZBHQ:\TE%Z=6?5A]T_(? "O^FDUNJBMT8F(&E4;=:"&;6RN=446]0O5#JI*$
M0E>,4%N$@L41D XK.S#AVQ.L7I4M.R4(7"GJR ' HRR]4OT%#DT=>I5#S<;E
ML08KOS+$ECTXI=Y7*N_B[\CZ#(VF8A3+-7R['D6QX?G;J9JK*M5)=0F9?W_^
M75))[&[H1D]SK7=P+J650'G$/>+)>9X[?>:'$Y58D(V6UWJW[G(>C4:SF$6I
M["+.R:U[R7"R!M*R8+<2O\F&XU 2%\")X0^<1DFM'/@8)4$K:Z)8V^7K9_"]
M"1;X:;]#/@%:S0K3 \'2O,%5#A!RP05ZL=82D+9L18K3=3*%LYC\OXE;&^#5
M0-,J4H:<FHK[F(PV*P*3H\W,F68U/4;.T-Y@,Z&XBJCZ7C)_\WP5%\P.E2+O
MP*-U,Q^,U'/A=#[O>/&>=#U7C 5VN= 7;BHK;RG=T,@>?0ZZTTB7K#$SD+I/
MS6QY9\A/<B/33L4/=& E)L/G*IL2IN<GQDCG1*9W4+0-U1;8,6X1NS0?E9FO
MN7LD9_'9_25+%N=:03WRBDP[>6(+2<K1^7BI#GID\WS,'6DEWYCBDW%->WX;
M-XR2-=N&9T29;'GXB-"<,L3L)2LM\"UEN$;AOHCW));W..</4ZXO=,HJ-4ZI
M===9@U*MR&']@W9)81.HLNNI&GAF,\391VK.1E1&DDV\FNN9G)A-)GI.SF6S
MS)%H,B1-H 0'%K\T[8AE+Z*Q)ST?GAPHA8G&Z"!):<()N6ZX[X.OQJWXX^S1
MVIRK3BEK8V-J+_SU"L@IEUEIJYNJ_20[*>EQ!(*./JN64>4R&I)0($]SXULU
M<7+^:[GV2.K,<XK,7A+7&\,REJPM%MCEB?J1PZ> UR,WSO3Z6$T<P*BF3H@O
M5\K5-!BEJ_KCJMHFXUYJG<PD27\\=GZ;ATN7_Z"::7AQBR<Y*G]W+&T4HDQ1
M^%"-70HJ(F1@ARXU7%'9V!87-C0#O3VX84-!4F)TC4.'/)FV+\NNU$=4/T]I
M.9PIMY^G6?Y<29C--F)1MPDFD^"4^RR75TX0VI7I&-&'+0ODZ).Z:[MTT]94
M1T*#K(X475$@3IE9DC,A(\!,GSFME[4#=M?0^]G]TE-H(A+QF6D!_'YT79]-
M>5J6:O3 5P./ATOX5 10WB'MW5"=9\?&@AQ6H/A:A;!CD1:A&_>9^&7.;&"W
M9EP<ZL^0A?P,*LMNO=(LM+>O*,BV=]P(Y:E)^QJ_P %$(OLEQ=&M&Y!#+G/"
M()84%5OE@@4<S+*V FHM@>2 *]"P7-GA&,]0W20:@ PH5P8^4Y?PJ(LH3103
M$_Q3%N\R@0SFKE=!<$ZZ1O!9ZC:*/F"MTQXI5!"4S 7I%I''5C]6+OP9L"22
MHCO+O&,X;[/X=:96Z5]E"@ A!:,C6!PJ,P?5'U]LB93FC_JV@"ZP'QC/];E=
MV"-P+AM@[V@&D'YDN7/FLA,2??=-RL <+3 1083S%#?C$2,)DG5@?7+R(*1,
ME(\9$V^DD-19\>K@E,0KB)^28]S0F[5.@:=FQ&I!7B@KRQ01KC'KF/?+D3,9
M2BF]&&0URPB<;9;.0OB5LLZ7IT8M36C*5[1\EEWDST+/T+[><O86O_O0J9WW
M6>:FT,'*IX&1IY &Q14\CNQN6#I?P$IN^4S_P/_8J9C2,,*T(8O0@;)!C0UJ
MVE<295WF69U+9ARDKNG!H&%";9VX5>&,\YG.;6=19L6:D'*QC7J)FX+[L<<"
M0R3V C),I^!"1S%V!O,3Q1UPV;^31&;S'UF_I:K:=HD>8VZNR/RD?'2#P6)8
M<.5CPIK5$$-1L1M3:>.42AD_+E'ZJS"2I7PASTHNV2OX*]<#8KVM-75"OOMD
MB^8D7IBSV*AQ%&Z>1+:E0H0R\<N&DR@_.)!?$H6A"%2AF'X"V10VM/<]'OR*
M87S*(,^RQ&@!U#").63ZI/K&L7.A/W_$_,+PDF63BK@H) IGRF>FVH$<.Y\6
M06#YW+"0C4L!G]MMU.:#] HYV9 CL&-!&T]>S%7"N3.L@LFV_/Z+P0YQ>66]
MB2IE]NM1<9X78%M$ZHIH-$5\VHW3J%$D'>M<M\BG4S]OQ?\8 4Q-JE]C8O:W
M*6B:AMF/_5;!L-I<^T]K\FN&7FEZ<GL.<ZV:,<R:2S>P$[)L#DI#GLATT=W7
M> 2IBHVQ<U'V[*%PF/8EFTO(D<DN#BO+NGX" H8XV;2T!R:"\\[ "C4MP3[9
M*HLQ%G+.G8+'3(IE?Y293X!F+97XJ[Y%9$+[7BZ-S!BF%W(+ X\KC7-Y 'HL
M$K<2($T'6UB3'I2:[FVC/_(9YT;5K.-.J#$D?D5:W.9[M)GD6NW&R)7-\B/F
MHLA%,#%"9ER;HH*H)BZR\6\(ILON/3I6<XZX3.W*%I2Z&*F4/LH1UZ$&#W50
M_+B3:WVN-2I?1P ">_61!X9S9:P.4$67B1OY89YO\FK?. 4W6#UJ.G50E]DY
M"HC /Y,C6Z>69?EHQ"A(>> #Y]/B,#_:"*K:.[;*L K'GA/YR'M/H\:PWR,%
M=[0'8NXV[^<!P-9;< 2*0N2E1,1',F '1&.?ROPYZ$"([GA@=#Y38<UYRN.!
M;/J=(^,E-4D6Y *8-Y'*6J*\TNPI2?AP/.[>'@\<4+OX@*S^<@K+Z&++BHX+
M<$Y*(Z9D$>-1#BL>;P4/I(&@$"902BWK&P.GS9.FJR]3)A.^9*R/6L?@4W.5
M!@8+5"E"9J@.D6)T6]0Q:_0R<"R(DA)M<6K($JZ,-%)4Y$;-3!5#N\Y:Y&7C
M(=AUH=@6#>4SXLUCP@7V":)1@%S"GN&31S?*!&FL:Y>9Q'MWB;]<^RPRM33,
MVF6:/!GN 8KJ8M*NR:$:2A#(Z:,13NOU)UB]1LG5W":HJ+<WO6YF.L$]UE=C
M#W%N)N#EXLMHWY+!B3\8[:4X><B-8QING5H*K4$XK*@;G2&+>L'C>.Y1[ _Q
M^6&$\]@<5;:'*U#^NVR@N2B,HEWL4_>6\]'U<%\Z<=]JG*_]<%@W'<5I'6%6
M:2NZI:BA&)1"M1 H3PRYY$4GUW'C9@T8AA8L:T#FS_#T. S9"S<V!A;+O"X]
MG9/RDCG/+92\<9@FYA*)H@TNYUY>1UW52,^WM!FF3]6)AWO'@W@/BC\9@NPS
MYV !_.F-'%C[%"QZB0MJ0RZQP0XT(W[JFO$Z(A%#$8CU@/8L!&ZW.*#I<JP&
MPML83* .MGKHH")/:?!R IJ;YE:JS24_TM_5<&'E)8S)<(Y3@I4*UG)S<3F-
M3&9UYH>&TR=9?5!>^6PR@_Z4'-BXE#0+:&RN>0'/[OKB_GBJQ"B'ES&WMB>8
M[2_5V<5#6A22P6O.(,NZBK .;C8AN97W4#D@+,TK5XQ:90)4IOWKVA-94($O
M(?%1$]D1RW79]YL(-1N58,\X)PVBJ',Y3^HNE<*X'DM*&C\/LOR- ;]NYZ35
M%BO]1G4BQR((Z=0J@8.E,ZS%OJ'RANP$"Q^%&E"FYHR1N:P&U?)*/(3%-TO5
M,YBR<*4J[N%T1-"BSK,),Y6.R\G&RL=&A8Z>ES=WF^Q,6)EQF1265/EI\=2P
M;$[/"/FHRI,ZRBZ*5,QI5<J7M4N#?&S!'F#X$HB"SVTVE2?'<WWH'+132-R@
M V@D:F91$27QR\Q0<F!@,A#]G3N T<AAE %9\GWI9O!5VA W&\0N%44MTUDG
ME+YE3_LO7-F@48YX5L/Z\&RDO#&')W- GC!W6T:5N)!,N:18MS)X5>-X&]$8
MK>)>):I&+?0L!R>77<P\==W'H"12EWA<$H>^A]PR&N_RU8(.SH^6T[Z9"4>W
MO1Y3G761Q]"5C93H7+@9+N&<NR1IK[_J-"&?$-G8)_Y^A)J08(\-G52-RM+@
MGF67BBE7WRR=$V?F'X61=3E$4LAC]^2P?G+F DS%HA%'[/&H!KJ]V(5/E^WD
M0DS45$0.U,0#PY"3'K):;Q;$GBP\;DW7L50<UF]RZ0%JV>=S0.1'#2(*OBH4
M<$3'G/SZP@J7E:S",NEHA!%QRK_D-&-KC9F]AH5KE"$8XM&X)7'CF8YX&@Y*
M$C%Q9$)ER<G)&ASJ1%!9=4#?IIYY+[_C)]9QHGRHLWRHHWRH Y.W<,,IM\DL
M2;F @%K.^JG\/4-U#20JPBOFPB["33:*',ET*PMQ28A:_4G,_?DJ-3B) A16
MD:HG&UUSWA.V6DJUGT2]5Z,[C.%$5H(P2JGD:%'QL[6FJN75\!\[[\<+SF B
MA*Q?60F%TCX"?H<]ZVHRTQ@[Z:9F'2]J5[++! MP*;U);'<;_Z'%>+ZO#FD%
MF/- ;A<0C6G 2INN>\N?"$_24ERT@#<N,M7*S#!MKX5!,GT%?W\M,T9^@UU\
M(-B_1*]5JB8 ?B%B;-2)72)T?]XI"()G50TZHU5OZ]EIX[C;^/GEZHO/-P4]
M0_WBLTCE:,I/64K:Q@FBC\O@?$O3@(2D<X52,YGG BN/,E0YZID7-D]]"J8I
M=W14Y7(X 824)#5H"35(MC-0"96(S7<1959)CP*!9I,&,%'<T*6SNJN(V^-R
M1YTC/5V$:JMBC,B(NDHW8QL$/I2S;EBGL\ $(05X8Z-KZNH]&-4;( >Y,(CK
MD[BI.SVB9!6&,T'<89)7XM[ 7<G\V,:84QI^K/8+HC9)6-:R(TQ.E5%LD9[C
MC%)44@8GC6P2KLF1+_ Y0QNPAMWB('K^K+RKSH7<.KYF#H6?2ZG9MZL+N @Q
MLI1#LY$(HTK9R&EI!P7R;QDE+U+6%G1OA9LX2_+A$AZH"\97H+)2Y U=L(3/
MJFP09)7X(Q?-"S6CG@P\G'@.U#-$Y2SKQ$-3!JA98^8S MWL7VP6D@,#Q)'J
MMIWW',F6>SK?,<:ORFSKC*Q5.%?6XFF3AE+#58IC8N734+OOF(Q,_1VKNZVT
M4!6@6:ZFHET:SD!8,*::**^O],$ ,/;TEBSA<AAAHA;ODVPH+N:G"7XJ2*.#
M+])B9L>O5?6O',196M&^$<]G82:L&87@"ZFIIHO2)],8>S7(>PA7-]]JN&8,
M+$2WGJ,8L_1\/*>&J]E08M DJ6NJ]G(IZV R@3LL6X6%SB<*LY];4Y8_1%CW
M?>$F.J-691T;4_]FJ P'). 95 SJ*TC+E^1D ">9!CZY_,K+ ##A4&9)+\J0
M-BJ+9?]D@$Y6 !S#*6G--P?E/&)"U=-H$4R8FK Y6*:L)8K1[MA$7YJYT,MS
M=I&]4';08CZMAP1QC>V0&Q_>*N9FL0 ]WYMS1V0A?D6.KL=ERPO/+%;7]I*O
M&ODP>2:QP-B<0\EN<)T^:>3#$%;<-..;\!^PHQ934^K*D008=F-AS[6-F7-X
M.>:,]N9R$WQG^?1HZ(*EW1B9\%H+.P:.47"$6=:,OBA&H+!(MTGRQ.3(W@[7
MPG#%6\W#50-C@Z+QRB\/N"VS<>P0^%N7!%,"5M,E-E]_JDGM"@\LBN%H"1M/
MP=;!H8,CI3$&-%6)FS5-<-;KM<MI<W@39](=3^J_(B[]EC':F\H_L_=E0W^N
M6E,A#N'5U6""<$:=RHDDZ2UL!H,O)E03@^V:<+6Y@05O_(! 6@YTX@-*7.HJ
M.:3MZE?HV1J5W$X-MSBHDU2$GE)K&G*J*!U,1M2YHH<PH,%W=?<IHW6?"51B
M9K)GWFQSE]JM5_R^<W3M>OR6G&PI&T<0T\[6M]\BWYZ'Z/)OK&B,_1B'Y62S
MNRPW@;#(XF+,<25FJ,S#Y)B7["+XYH#G6,(&-H&*$")K2_UZ!HXA1^T8:!D2
MC$HD<^BO[*V:H'$NDY$X$I0;"ZR\9WYLK*# 46 :+4<R8\*T1?UQ77Y:>)97
M4&9&4!>CHRP8*LC07S3,I]NHM1I=^8M:H]%0^\UUQ"C8D5AV<C4G-\=LN2!9
M(AKFLCC. )$*BY=ZN-M;"15*CO,,GD_C_.>Y##US&/+>UW$9OO_X[MEI%W[9
M-:3B-H![D"VWC2TW!WK+]D SVG(+KDSCKK=\*2@/^;-JFK,CM7#WHB3(O>-8
M$;G[;2D(.;%?%0EWY#]21HU,0)?-) S5E(P_V'Z 40G&26Z<J4XEX7[4^5Y@
M$U;Q,Z,*KW*2==<LGD-TA-^:H2 ?1Z,929HH5+:=Y-&Q.Z6!&HF&* 6QK><\
MAV(61T,!LM>/E/5'OY.I0C=D5%&%&+;&R#JZE$Q& @X/1@FQ8I6C JSX6@1>
MW@&\E-]6HJQ3(Q(#9VD,@HZC,,+P%EDN'Z/TGR(]PT'9PML1$GT@S=YP%P/N
M;#39#F1 F@-8<R3:GH+R_YX[+VBM1(]%==Z=7;Y6*N;9Y5= SC']M=YLU3+G
MO!E[=Y[KY (C2/0J>_C2GX"),-;>BUQ8W_R6X:R7">PF/!1;F$T].5,,BR+5
MB#2YAAH,PH-:B:Q1:Y]@I![[WP@N@OOU[.Q"]B;T9M)!I@WO "M3;U&_I5H-
M/\2XL;Q&LT2,9T%H=/,I"M0S+\-7LXPTU.8F"(0*1+/IP8UC[2D>^B]*\5,N
MJZQ$!QU/E+*HO./L.#&R)[GDE7P8_D1I[EQL0HII/8WJGLKBH25QGBZ[@+C4
M5)M8BJ&R]87S!J2]P3>&<WI44D2"1A<=MYD49F19J'[7=!9JO  _*HMFQQC]
MND:'*FT%K#2<%!EFB6 RVU-'S%13!$Y> (P"R_,XDJ6FY9(OT,@X,Z:[J0/!
M*99R8B:Z!LU59!6@,0W(F-,C#0?,"Y4)DLIAI;P]L%[@?B?WI<Z;-)QM69:U
MRJRT;"_Y<.XH.:- =9LG.'#U7#6:+O<F6&0&(YU*MJ@Z7B7],Y^@.\;N:9I)
M-+MDNC39]+3 T2[3L9]@;@>;/J5?<H[DMUK'SFLQ<K' :4%=RO*$4!2^F&IV
MZ\B1Z]BL-#7FN7,W8#<++L$EQ80X3N%D(SK2[?V)T9!I[L8+)/CFTCC?=6+!
MQW9$FM^_[%XBO3\+3/N DW]RXMLY.IM=80]Z0$1_H?3NUYMM0WIG72;,)AY*
MCO=;C1>OJ Z(VSLX[W0?"0OQ*F=;"BGC!;"3# :-_*5XQ>RH5"@-) L3]R3R
M?!H/I;ASUF["9O_X]=+&$W*FVQ$[++]K=EAC1L[C_2@1&B0=;";F1"PY0P:=
M^K*K![/KB0Q)H-[@)BC3S7$E622$ZYN93_+/+1D3/\I%RHU."I%9C$L#[A/5
M(8B_T2[?I\Z^F/)@^B&ZKE!)L;=I;H[R@JWM4>,NGHPC/;5ZA"PV$C("/T6%
MJ"H(I9K:+X&Y9K6&EDF'*LHS"U5*^OS,UOEYK7:PA#6)8[K]\N8[WT'#L.6=
MQ!-9@5%8SZ.-D]@5[NB*59)K+-50E;:[(QF"4N9.&L+&A-3S/9)7Y",VI!6K
M$BRRH@75(X7:Z%(+=%6IP\ZAG_]7O>[\W[__]K?N__N__QA-9S_^&78'WA^]
MFZM_WH9?W\R^_]J+![V_MO[U]<MM$O1N1G\T@K^D+]-+\9<_>NUO/YJC#VGC
M?]Z]:UW^]>7-C]?G_VS<>)?Q\-N[[Z]OWXDSKWD^]#_\3;Q]>?O'7X?C\!^_
M_DC;'[U?+_[^Y8__.?O\^O/GRW_\^:_>K/'VDS?X.QQLY)Z,KSY]_)?XXW]&
M-_\==^(OX<NKX&_-X3^"_[X6'[Z./O[ZC__ZY]_.;[YUWOS:_.._7G_^YW__
MX<;M^!\WP]>#=/S::WYKQ)-O/Z;ODC^_>__;?W=^^^T?+W_[KU[GGQ>]L>A[
M__/UV^W+^'O2"=Z^[O^C/1V$W>#EF]'HQ^CMY=O_^M=$_.6_/C?>_+TEHK_]
MSW]=O!V_B6?CR][)S3^^]?Z?<W[YN5ZW,RH_"WU(G\87L;C!R>O![7MBWWK6
M_*4^R*=0'T?2 /0FUN7;.6&^H@C?]<T..?<DBP0[,O4DNPP.WP9'7P<GNP_[
MJ]^\X9 ?Z^74'&Z1-ZXP5]XT6LMB,'9G96.H#EIZ<9Q5ZLE\.5W#HM*#BCO?
M&?W_2!JH4$]?=0A9^)+L$)5%">TD2C-]A0SOTMZ#22I<CZ=QEF3$Z!:"^W9_
MN#>'G,[.N@)E@&A"HTAU3%79TXS6=/A2C9596(QAW4CKOLT%_8"3-6OS=X%3
M]N7Q9J-8]1EBR#>,'$/N1RD D7G/L[ZS*@I;RX6XU4P&E;IY1+F;>WC@@CUB
M:G PEBN*1">Z$K%*-*JDQNPV+#KFA><Z=ZH56YFE/$0)V, 4?6GAE=RZ%#3T
MEP2@G?^+B:@AA2OJ.+[6G2;BE:-^^@G4?2^]QL-J_,<Z427B+ 1H;*U(X6?0
M@]5I#J,TC29KKX#_1:MXI6);ML[^R9&(JN,%XJ7DQ?(I!_B54^??J><8-'CR
MN#M=0?#?A:1G8>4V"L1TZNDKX:U);(4;?I!MY,\4KB-<XE"NV2RZPM6W:5X*
M=/B(^"='$H#:^>O !=V8]N^0"_@.L, C-7"3R!3^B<K%VV*>L.>'S3_&=.X'
M5G%@%=MD%:U]X!1G28:&S)XS% %&P&>I<^[Y@>_)-IRG<'&S\6%[?II[LHV]
MOY!)1G;26_84V*72KAZK>K6O>M1#"9[5J+SPZ'9ZBX_M2!X;O(<+=(#W<('V
MZ4#6]<$,06>[BJ-9Z*'S.(I?.?'5\'FKT:FUVOU:J]M]L:XB4:I)2(?T26<%
M?W3A$,6J^L<='(@>K2BW619.6^%Z*3_]6E[ZA[1[-]S$O02%_K3Z00S6W@,-
M0+V#331KO4:KUFSV[O96W4^1QCH<^!&1R&,CD.=[02%]D%OMUBKQEET]CQ<'
MLMB%8]@/JACT:KU^?P^H8D5OV8.F+FQ)M<U%)!],X\T&W6J%MR3?;,_]L0OU
MWV4N\4=)3_>TQ[MB?ZU:9]"I#5JM%?:X83[ [A[>XZ2X [D]'G);70<_$-M.
M$=M!O#TJ>FO76H-!K=5M/DF*,W3]'7=[;]D>Z,Q; ZW[LP:^4/6!VNU\%<*]
M,,G.CF0L+N4> *CC1;-A(':,QE9Q;]S1SNZ*+79JS4&OUFAOHHAT'BE3W ,*
M.]#7CM-7_4!7CY&N#I2U\Y3UE"77(R\CVNGPVP8<[*&8U3V6$!Z.Y&F0Z*'2
M;T<K_9Y84? JX?C'>-@'5G%@%7?%*O:DE*VH*-@L;SM4 S^>;1RJ@??I-/=D
M&WM_(0_5P(]1K]I7!6KWO"2'6KP#O(=BSD=W((\-WL,%VD%X#]7 AVK@!TX7
MW=4RHKVHZFK6.NU>K=58I:QA5P_D4 V\6^>Q']7 O5:_UNOL0[7\H1IX)XYA
M/ZBBT:]UNMT]H(I#-?"A&OBA_;&'<JE'5B[5JC6:S=I)]U"@^&@I[D!NCX?<
M5M?!#\2V4\1V$&^/BMY:0&V-6J=Q\B0I[E -?*@&?NA4Q4--U0[65+5KG4Z_
MUC_9I$G"8ZVIV@,*.]#7CM/7H1KX4=+5@;)VGK*>LN2R4EA>TJ14]2<Y..WG
MEYN-3S^E$>Q)G+ZZ'%T+;Q:(3^/S"-7EI/A%A&&]X>N/8=#K8\TH/E1J[6BE
MUA,KZCQ,>CVPB@.K6(]5[$E%4E%1IZ&P'&H[']\V#K6=^W2:>[*-O;^0A]K.
MQZA>[:L>]5""YU!9=8#W4)JW1P?RV. ]7* =A/=0VWFH[7S@Y+]=+0K9BQJ=
MPZ37QT,BCXU ]J.V\S#I]4 6![DQ1Q6'2:\/X##;DFI[J.W<,7_LH?CET16_
M= Z37A\WQ1W([?&0VV'2ZR,GMH-X>U3T=ICTJA3QW79[;]D>.-1V'BID#A4R
MY5M[RO/R]H#"#O2UX_1UJ.U\E'1UH*R=IZRG++D>>1G13H??-N!@#\6L#I->
M=^M(]H!$#Y5^.UKI]\2*@@^37@^LXL JUF,5>U+*5E04;):W':J!'\\V#M7
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M+_(^BU'@)HD_!O,OA3\NV]6@U^OWUSX2&1V!I\^LH,B]WJM69] 9M%K9)I9
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M8$<&V1W&4Z#"^4G#_%I:W#CDT:1G&2,]QLA'6,L*,3E;'EF0M1S/?,,(I@X
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M97P7P<!W[)@P?4%N+OP \0#3^?CY [K!0@RUEJY%LLEFF]N_9&_ZBD>F1>&
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M526\JH2W&;6%JH2WYG:FS*P.9J9*>!>5\):O79=<72RXHHQ'K/H [T)^]8.
MX:+*V#?D./# ?<;6AL,#!]1V(JX)'X@EFI/!]W.J<,X(P57Q@3D[QRDGSQX4
M6%UFR'UXK"X4FW^.K&RPKC;8F,L;=:%8(WU4%XI-TDEUH:@N%'=DG;K+J;<&
MJ@O%<U3"&EXHBI7C6%<!=]3R$16'34,<A8E3L"?>.-<?+X"#J!++UO+^0]U^
MU.#VP^!8BSO$L/6]_6B"D:E+1F5FDIM98W&"!=XM;XN^'"98"WF 4+S6><I!
M+<PU.Q<A12F8R+YAOWU51! K@@1?S'=/1X2'H-@D/L'9^N%,XRD>GHBK6HVU
M*6<36DP'AQ%Z+K"\^&N6?),C"RX"Z2N#0PT2Z+HB4!<!B;ZXTF["5?0DN'8E
MR#,=)I< !>LY#%P$TLLC'&-LIF?(79&/N+/%@(W1IL$7$#K3YPVH'8$7P3&3
M4RBX!%PI ;!=C6J*6(J(XI@#_LI!C:;C(T+6H4&\YFVXWC>O',L[]JB 12WW
M-F<=T;E=S%EL>G&-P"F9H2+@)4-67*&-7'S%-S QIV^QZ9@B:G$*I)V@N"U3
M[\7M[4O8M#DL<L1O1O26&8(V.V/MI?.J,%MF!$#!@V^!)T;P28;]'17HA@\L
MESC3\"U"]+UTX!V.P!]C'W,OD$+2X(@<(C11?'B*755;SHQS(?U# >.T<7IW
MPQF\&-NZB$TZ(F[>$2V1/P,I%)CH*%L_JX%.%3E-"EB(Y<,(LM#F>0X"XFN7
M5J.**-+S,,]SKIOA^W7U?KLOO!]72-PIEP?G'($_Q1YSG\MG1:)=*4_DC*+Z
MGF#(5@%U!3>[($.#8[RB2>P$\LI7IP3F56&\'F)1F,-67&*4*YURHJ+S:E_0
M];*R<A1@'B$@)1M#,%9.KROA8GP"I?XRYK-()O$'C_W2U]P2S/-9#970[130
M^;IK8 *K#'N=H6R5,+@VA(7J=ED285>0ADF$"ZAD"%%(X^J1<M1\Y&';YE!V
M*Z !4S2M96^N %6W<08EJOEEJWW9-C;!:;M>JSC;H( L)Z\$2M-=KT'+P4#F
MF3?S0R?ZY)"1<-458.560!(R,)!^'J!K[4@E@[RS)M2.79C;@AGF852;A@ZB
M4HED3]U0Z7S-S^)0-EA7&VQ,ZI1*YZN1/JITOB;II$KG4^E\.[).95+56P-5
M.M\Y*J%*YU/I?"J=3^49-3#/J E&IM+YE)E);F8;889L?+EQG6NMPU?>XDW/
MRJO(7O%^YN]%+UC<C4'<,2T=-KV$VXZP?JGWSZ$(V[09T?:<:BUI0U2=A*UY
MLHJ$_&6FA! S!SST< LH,P-FB*=%F3GL9#G03 &^[^(3=CV5 3OF<%/?!CXF
MQR36%_:,D&+4K9;<MPCJ9KGY%PK*!NMJ@XVYQ5,WRS721W6SW"2=/-S-LEPK
MP=&MI)J)G#6S3B,A): C.(J]W4;F\U1VO)D\@-Q*!QTX![:5SRX@\W>/'4/O
M&540K',WTY(O*9OD*$AVC%[EYB.7QB#;'4=[T-;;1I7V _**9-?T#=F-9+-<
M'LF$TA [,;JFWNH.SLA.JN<0;1+>[[@('V]+NZB'$#]GS\[AVV\+<.U/9["+
MKY2XD-MLU]0(CC;+@_DMHZT;[:,>E,DKOKH:G;*ZFEG=Y9G:6[K;/\%67ZZC
MEKUD0YS>P=12"_<TAT,YA\ZPIW<Z5;;<YR4%Z3;7Y\5^6??3M93"%@MBHW;1
MGV@8ODE,RXH#!H$U0VQ#WSN'P%V%[G4+W5]V>FU].&C>COF5LC=E;_+9F]HJ
MG_M669HS;&ET8P5=4I6^2\0PB;:+$G%%J=%V/EGV[=IA*I<+5Y[Y;"371V!R
M&DR/%$*>L#!;56;7H3*[;>JP3=LA<JQO878CS$P960V,K/H1;7.LK+'=C-+*
M12Q56='/*'KT1;K3V \T(MKE^&/M]O</IL&[5+Q\;AH]?=#IO9KO;92/)5@!
M=_9'UI0HF94@+,7JUT4G!RQ:%EU=DH8:"^D<8^^;7%^>N;)HG2'\0^P2:J$#
M_"(!MHN()CYOZ5/B!Y.WXUENS/IN^$  ZYU BHE>^@*N:&:OJ_=:/6!+N]72
M.X/6JV+%->O?,L>7A<V0C-8+QH$)>6"9X43,B_6G&%-$<:>\P4?:O\)E75_@
M>[%K:];$Q_G!1 4_^%=@/-9'XW\QZVV #8^>M B418MGG"OESAHP-='_"LO)
M&7=X?PV<2XZFI+$1\F$('#",5]J,D3.=^J)Q%>N*P-H@I6GM8DQ\RC#PL?:"
MQ\;$";0'XL:TW%.&$X2DS +?HM0&;0W\:3I9T;V&N*YO,>&-:/1(J9>U1"HW
MW, _C*A'QP[KQS'/=3WKI;'X>]I%(A]&LHTSQOGUVGJWW8<Y,BT9O&(:A*\I
M:."BLGYL2P$O:/?U?A]YVQGJ+>1O\@)6Y#_WW)5V\45,5,@F:8BEKY^E8#<*
M##8\5LQ5GW X@J27B44+_,R]918X\,>$GTQ(.2&B@)ED=6T:NY$S<QT4S1/[
MLA<S7@"Y>1T(N;'S]BO18C/*VA3AIUQ#D;$VMI3)"RB3$,X/NZB,G'$<6,D<
MG2AMKS*E-$+U212/NE2T<AJC&H-_?2#8?>M*^R"$\82M8'@;FP5]@41;+Y*V
MBV)U'0.]-1B(MC'H>9@SF._ZA?Q\;G9T0S0(6OGEI4FJ#@T74IM?&T2SMF&)
M8-;JQUP_^)7P=-Q=3\@"'S<C3PQF0LR_U^[PZ1E]4^B+H'"!H-? 7&"/MW#&
MNZ*YS>L[]9$K3JFW34Y'YSBF:]F"5A:$SCUD0)-N-94[U2S!Y"FUP2BV(<F1
M^!U7YB_CV]0^/PC;+,(*#3BHCT 52D%]C.&SZY.%," )2:*6_04LV\8HD@0H
M,L4F<H4EL@0EDL0D\H0C^X]%EC5_VL#KSG=6NK'Q$!H?AYCA)A\-[*$)%+B<
MP2 C=^E8Q5952:>E]SS:P$F^_R$<X+XI-#M&ODO5ID-?[\[#=H["XHI7ZD]E
MMC;B8$FN:2<T'HC=\M2L&\_^['M)GM;6/;,Z PCHYKFV8JS%$MZ2.+.(05@&
M7^R;%4G3\B"1*>1ESIR8R7\GS+ :V\ZKT3@?3<A^4JAKATT>DN$P6ME@76VP
M,0A7"G6M1OI8SFAHJ$XJU+5&K00GS4=0H%[R#:H$= Q'H5#7%.K:]E.0+N%*
M8C0IA;I6'R-9[^<D%$I#[$2AKDE:@*!0UTZV/U%%K?(7M2K4M088G;*ZFEF=
M*B4__E9?KJ.6W0>2PL'44@LE!YQ2J&MRVH R JGWT[64@D)=4ZAK*G2O4^BN
M4->4O4DAKS.Q-[55/O>MLC1GV-+HAH++DE^)E!HU3XT4ZII"75. 4#4 A%*H
M:_4V,V5D-3 RA;JV$'7ME]>5RF^O2^7.Q4KX/SV!:T/M=R+7]VM ITX\_4QW
M*'N^; _:;:.]K/Y^Y:AS!=I[HGAU+?0E:!LHVVX4,\$D,# L;WH%/=UAD85_
MY^2([_B#57B6Z\F-GF$(#<@/5 *9*;UJA_KU8:_3R<FQ].+MAUU3F5X2QN)A
MN1T\.F'XFP]_]E!0: $+0'@J%:'7!P()7^3@#Y_]2,"+\?HO)W4D!0=3;\ G
M1CC^P&3.9IL)GJ&-O&&S'#5Q\@RS\F86.*Z 5'(\!N_E>QP]B(&O?/GKXSO-
M&$*DY=G@G2P.)L/9]8'"\D]<[1;\A05O0< 9:F?/7<)S7P)8/Q&%!D&7_NT[
M7L1P8N[H WOTMY@$!.P(R4/N$\OR X:VE&+ 6 STQX$9V3X0X+@<& U(B'[2
MP.6H,P@O%%"-@E'BEXCK/FED/*96E.'-I#0E<]$LXFED-H/O(K3.F!&* #E(
M21C/\%8/AV*@-GXPQ9H5.J7!/?6L)VU$O']$_BQ\SC&4$+>)0\@X MXG@(EZ
M,1#/(**FY(<SC:<I2%1+ XFYB%8RCY"54(M:F/V!H6-=?)\XH5;X!L.X":D5
M!]F$N93 TXV9H/"&DF/E(%P4\ABG$ *)%G4>&'*.BZF_*)?2K/^;"BX4@KM/
M!7<E8"(3,*[T=:1$(<-I<J*0<PXYSGC0&>@=CA8V,/26T7VE)X(G0>"P]P!7
M4W0LACB%E."$[9A!=O6 CV  $Z2%$\/0KC@<UHAJ=D >/5 ?^ ]:=SH)A(("
M52EB0678>G;^008+Y$4.@DM-<8&\TK[& 2(LI7!6'%-,0 @A)87Y%R'+.&V(
M/30C3PR*RW8>'!L$$\(B%Z$U10PZ[BGD6%]L1IN#R!W(%1WN;)UA[Y6A]PIF
MFZKY%HAZ%1;VU>%M FKS#=3P71R %7V%>?AV%IG,X&6ET*0GP@-PMB(\:(D?
M\U&*^>RZ=66TE@6,RT9.Z V#Z,VO8%D<(RLEQYJ,R]2( &T1#9>]9]=FB__O
ME]>%5UYG$1+^CA/"OVT[$@. &G1PF+EWKAUJ/OI;-]3  ->R=*B$XW?QB"T_
M6 #QJQ\$_B.P.<_X?8DY#WRU=M#K_&;@U\"Q[]FV3)I0]( 7;N5H],)H21"-
M'G;"+-CD8F93;GX8>B%@)N>1/=-@@D4C3@!?BB#NL"8IZB3":W*TT79KJ/<'
MK5?:++<N$VW$.<G6S[DH2[!Y08RE7927]]QW%ZWE(V:Z(A#$P/+^/J#W.7S,
M;DIIU^CI0#=$.A@5>GFT4AX6I@"JK9X.&U?XXD4\0X3$V+)H&,*R!\QP&2CI
MF(54'S!0^W!I)+&3;['4-+9(YIC+PS\.5)J;S@(*S;[>ZP(OTR L!T6,2ID
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MT)<&%W_W7@U*&7;N\B&--NS>)>'T^]03MSU8X"[%AXYG4_3EEX8YGT>-GQV
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MH61CD#Q2'(\)L;5[ZE$,]FR-S&:!_\.9PB_ND_9\J/=;+;W5:F%ZGT<C1+>
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M,<H(OA]&C(H9!3V-G%0I;'Q/3J62(1QO ;@@IRJ5VO<\S(QC\_FC?L.3<<"
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ML\ONLVNCVVWA_P0]R\?8F1 S3X@QG"/$J$1(HJ#I<4?*O&]@3]\*0$SPX6U
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MU#2>>6[V]%:GG;?5VYR9LE,Y?@_^[:->V1(W-$$5()T%>2I 4F[W7-RNL2I
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MQSR]?U1(4=NA?U<YGG(C<(32CE7*KEBNDK.<P#8* DO_]@$=@,NQ,"]Y21]
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M8.:[F:'25Z,N9MC";)7\<)IK&MJQU_@D0)6T*EX;IL620RU_$*"52C.#B:#
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M6H:SO.2T:E&:KWP6D@6.8S^?9"VKCF ZF3/D='JF.#?^X5PLQ_V:4Z7RO<
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ME5O_-<7!BZ*0;--Y-=*L-"^\LO25C#IEHKK7=5E&:H:<.E5;5WU=Z95VFP:
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MA:>R/\%X(_CL9J1D?:"!U#H_"PGV5D&6T^74+^^!F_[53T<SAM;I#V8^(AX
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MMRE9&*-;9]CE3>59D/S/+;8U[E'Y779%S\2-OGMRN6D#;#>.5OJ@[IFX9,C
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M;@1+FZIA+;I!#6PC>-Z-/;<CCJLQY88N:/PHCN@9[V/5-CX#Q13[H]I:,_)
M#"8:%LF2@J'H:D4]R])'FI<Q6_":P1,7198_?\A*6MS0!*I>74=YB1K?D/MU
M]*(^GY5C@4,3%YIE2+L.X0N1:B52+74HMZDKLYM[U(EV8P^MWHV-[^FH\UDL
M&$#3,T-EH=\M)*'<MD*9<J$\+'N&/5L56IPEL294-MG=9_DR3D&F3[,\SS['
MZ7K>X%C]COO7V+31L5I@,$&4)I%VUN$\:NV8VHF1-=-AZNF6TV5<7D2+JFC
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MW.I6F461="[HGC[2O(S9:E #V<,M9]@Q@*ZNAP@MU-Y,@CJAF[@HLOR9I+"
M\@')%).P-GLK3G=KLQOILF_7+-OO/IO*+56;'AV[PA;0WS]7'/I+MEIT2HNK
MU5E.E_&<QB3E/D&>Z4,X#,\CGA0D:JTN^#2RBA;5R^.(%+O[+&>7.?_LC<=
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M7/1TA-B3Z+4G:E-O&'LASB.">@""> M& (BZ$>[+5B"A%G5X0\0D"=#)J)E
M^ZG:*N]TRVO&A)+4P>[A3TP<.#0G4)9.48/G@*YK&V;;":62'HZG9[UN50U1
M3DR=0P)UV_D7.0TT)AFKFM"17"Z&'K@EG9&3W;9T>MPGW,;"70(5HRK'"5ST
MM2"+E_HL&5?6>P>Z@VU@PU3"]3KG!3G[UII Q]H8%O</-6LRN%ZR[095O0<1
MW]CL-D^ZGW'3(*E])JBT'L^B:EDHQ^2+I%*Q3-@BP-9L'I::,A%D0G5S^=*6
M_,;MOCQ9:+;SSVYSWZ7,K"$SBV,OKU1.<6Y_&RS9V5D.<,W/1*T)D9E *D5*
MX9YB,-O50Z0$-+NC(B6?::LHSGF/L;YH7>11NE!*5HBPRP'#.@&6793WG'@"
M9?GI!_J9_V6>&EE6&P>*W#7!9=3;6@D+'[EKRUV+U!$%%?;R<KC*XW6<1@G\
MUMN30;5I"*W-"!7JSBT*Z(JX:*]+"%<[G,>"AJOX*P'#W[WKUD.6EV7EFSMA
MNT1K>K4KBS)*ETRPYXL3L-LXP EG Q=:LVT3Q:E(9 HK:J/8VKTX;=%W/-K>
MQ2F]6O4*(D=/\6:W.<WR//O,=CF+MNPO\UC=1NWO/YI@!'2HNY8/)_?U>!&2
MFU#(YPR=7>?"_4XDP5CZ.(?7=IUR8^-KT=F^\QY02"S]K0>3RF!D2!MEJT79
MJ;(DA'*W*PZCG;"2DHIY?B-K%1!@UGPQLNO7#%=T0D/RMG D@MR4UE58;(C?
M8*' 1BD9%)N@H(/R>:NX9A?_,U%X5'>33XUZU/X'H=F,5*^E<:UV$[3'O0O+
M3>J,2>EV/]NV61&7[^+H'O:):>$E),VT:1B;@@$J2^4H^+EGR='N\6>#^_Z=
M/A#_6S!9;TP9%Q2.7@\7JPT0@9,3+$"T2,=<0ES:8<;GCA $*^^/EDH3#LFV
M<]=%EI^(OL_17,'B^&8!G$0H,-A9* T)F^-K8EDG;U>+I:N;J!<_!%(K4H'%
MY3VK$%GO'4"F;&&S## +J>F-9;$FO$Q/AJDR>"WBXZL"(2?I\@-#;KXJ,#;;
M!I0\#5@FH3N 1(,1/%7)FPGY_0=NR][0^14[=.=0?DHS:(C0G4;IIZJ:QJ\@
MDT#%9;MH[0$IG+KX K4@6]<F\L*J,V^[H"^[6V=774)R <5% L7N*VE=-\+M
M0N]4@PJF0ZD46,K*GMZ9X+DSC[RWCF'<V7;/!@4L1:$B;&,U'R RX;ETN[O/
M<J;&0+A\XW^;.RG<O&F(\]\(E4VF3N!FHW:\[+44M,#:V9I4]\$!>;V@M+CA
M)3SF*>^,[N7=-H1!@D=O;J/TN:IO(M\5810'$]-D^=&B.LF.4_<D.(-X:$;R
M*&GB#R^B..>Q>O,8=:QV#G%$V8%FC-[L!6Z&L?F,86_7 &1- \<V1?5BS7%H
MUY].-<]S-;8A!$99".N&,Q&\#0E!4)O<HD9QC!A;T\@'@$?N=O<W=Z()^)GK
MB*QH.]/Y9$<S\S2/EVL*6K$],_MS?#.SMS]F5>"CN%UAP$WO[$3(W+!3A9);
M%^"Q05J#EX/'\"SS^^!0XK&T@5A[*-TDOND-39=@-!K1\JL[Q?.5V=D<]915
M@P)W\%$3MSU/A[BX7H_U2CP!:\05J9@7B)\M!":FMB/#AL?B-!]RN(>=(YO9
MV^T?= $/?U$D_.H^B=?<D265MK4^ANU7\]K$S1HLM%%W-;^N'$^R=@7)V-\[
MWKW+SVAF2HV]QU#(\5$E>4FA_X'E<=*;Y%5P^KM;A%'P;A2!3Q$UG:4C1(&5
M&T\_IKG41B MJA7M7LOH9+_W!08&VE*M'4ZV8GR_!8EOEIO8T+!>BZNKIK!8
M[#8[7FUG<'K8?>.Z!?QW?=5 @X>4UE,4-T3HC!LC<^2D&SWJ3A["#QD3NM4N
M74(<P\<M RXMJ[KI5N*AF^_YJ:<!!1$--N-%.X7LQ)RZZGW(M[P%6QK!,.'M
M^E2L/ 6=Y=_'"7N%9BFM-K"[2^Q6\BPN5D A@E,Y@DC:%:!-/;T6H2+H\3**
M@6WS!&NZN K6>5'&&SC'[K(R2N[R*"VB15G7F;&2*,,2OJV%>G 0(6HFD1)F
MD;*=UF]*'T!X[)C42(T%!29VV[NACS3=T>8_M:8T4Z4.TZ9A(N ,4)FZ\N5B
M1O"X-TN.JIKSZ7%W>RBUU?,[>UB=1-A<[ZHQ @@:296N"52A@#ZQ:N'P'U.E
MY8(47H4C.JEW-!3IBLNAZKO'QC[2%J$Z1K<@&*)=JD<2OY] H2'1LMN8G$'_
MQ__]X@7Y^:?W/_[[WW[^RV*[>_IK^N_?+7_Y]G']U^?TXYO=Y[??YM]]^\/K
M?WR\>RZ2;Q\7O[Q*_K-\6=[2__SEVZ\_/1TOWI6O_OOBXO7M#R\?GT[/_OKJ
M<7F;WW^Z^'SZ?$%/EL=G]_&['^GYR^=??KA?I7]Y^U1^_6'Y]OJGNU_^^^3F
M].;F]B]__F&Y>W5^M?SN)Z:U9-'O5NNK#_^@O_SWXO&_\F_RN_3E.OGQ^/XO
MR7\]T'<?%Q_>_N7?_OKCV>.G;]Z\/?[EWTYO_OI?OT3YU_E?'N]/ORM7I\OC
M3Z_RS:>G[47QYXO+]__US?OW?WGY_M^^_>:OU]^NZ.^7__WQT_/+_'/Q37)^
M^ON_?+W]+OWWY.6;Q>)I<7Y[_F__V-#__+>;5R<W5__]>/*7RT_)[?GV\<U_
MG?SNF]=WMW\C9[<W+UZ$.G41$1^T1.K)A].K4I2[$\4N;^@Z+L![M3Q)EZ*D
ME]7!:EK#JZW1 (Q-U;\C=L#6$TF4+JO.RLH"I[Z/7DM^-4>P#3G<KF)YY;M,
MY&UGN=TS$YOK_2I& +&J#<G.VD4]05W\-JAT*'BBE(H^VD['2/7:O%I=IG$9
M1TDWC=_.Z:5?PO=#40\.YN$2DWA'=C&M$A&RJB8&.SCL.-1ZLLSHNQ8]8THA
MJ+-G&4^+X4]/"'7QE:4W:O\@+=1LH<-.J8[$Q>RD&G3R"U$>Q('M_;YIHPCC
M:O.2,NNO&0;L[L_RYP^9I>L>G^W[ $,AL:B>L&TFD#0+5M/(CAW2I:9#V"5^
M3FJ"!@?A(MO0N^@);9N'B(1Y%>]JCQ$D-$$'AI(R>H(\]#CG+JTC=9T-_Z)B
MS:Y&9.SHX.:NH^59M(W+*('JNV=1GC^OLOQSE-N]J333O3ZG<#@P3QTMR4+,
M( G4'5Y(<\*Y]LWL:+UT>I2=$[B:GF&-H$$D$-A%4[BI^;?$?BFN[UDJJ8^$
MP'?AO7'@8;Z:>A%^2O4BR4(H/FYLEU4?![HXQJ PT;_:4CC6TS4(O^U1U9WD
M^X#J[*XYEK)Z'#^8@KW$,"++!] 0)>=C!S2@HBI_(77S8N\"7R^ND1#X/G;&
M@8?5 ,W2\B%Y)BL:MH^#&[?ET\:!'(ZGS6F6[HJ3--U%R06U3#;J3O$;X=C=
M'$LT@D$DXJ- &M1%3+QG'"E)W28<#3%SY"EW3,A!!>.*A6NF>[U5<#BP>JPP
MH1L8$K1GO24S&@DP(.Q\^\C](Z7E;VG"1J_?TI0G':?+D^4F3N.BA%OOD5;5
MP7@JO#2K^"DN'^9N13HSQ-XMBO/B@WP.U;+<>Q9U%JX+V!5RA[:P#0/]R*A\
MQWK@R91*-@*,:KLYOK'>#MZ_B>[^B S?TOR1]Q3L%;\+\XQ4,Z53?V:(E*L-
M_,>3NPK[8N0%KI[I]>Y6@H#PF(TE137X$&YL+>&;RQK'<$^UJE$3]QRE"X>6
M\(#%"LTV<&D$^'EY18&ZV[>D_P4+*+?F*%ZF<"\&\+,D*]AQ9)_RW)G@.<5
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MH0/5O)^HB')HX59"U?&0/EX,G0%O]'B'^,9^/+FKK.HVY8,:-K!IM8^A.(C
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MD'28>GR6C2ZGKNVQ8K5*V">=[_+S7LT:[_.S:)/]\DML4@$ZPX*J !U(%"J
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MU4A5S(")=8U'IO=TI];5J$-^.4;,5*RQ)$=0!\0;6BSRF.=(V'H@H!YN,^F
M'! 25!8>B 'BG@ZLX3-%A-*->I!5(8/=)YGGTTJ+B/YA-L#8\V5Q0\L(?.?G
M49ZRC[+0*U+U:%(/5ZA5@8+756BH9%^'L.^P34NGA+B3+;P0H?S1%CX'%-T
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M2U$&;'!1#-T2(/_T:0EQ"$. _2NVX]#CF/*]9Q*&4&$A4L!,VET"_@9Z$*W
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M#4W1I&37M_^^C#;8!&.XUZKBZ+(T4?^6P7I#Z-M7NHI:> L<NG18!K&V 6[
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M\P9?"6H9^23W :=,EC&#M2[]L@T;-$&6Z].[K\84;=F(F!R/,9!90WXBG6+
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M)(.=%=,TNQU7%,T1!@'_V\'\NB:DS^$\EV"ML;(>O:V;T"C*G@ORH:)Q%$8
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MX**C?LW;)O,E"J7,3_3M2(0C7+K![LU#5ETN%BB=A0*P?TR2^9T0>[W;M10
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M+3(P,C Q,C,Q+GAM;%!+ 0(4 Q0    ( *Z(KE*MY(R1V!4  !3T   1
M          "  4;E  !N;'-P+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( *Z(
MKE+I[LN%! H  $QJ   5              "  4W[  !N;'-P+3(P,C Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "NB*Y2:IHP$E8V   -$P, %0
M    @ &$!0$ ;FQS<"TR,#(P,3(S,5]D968N>&UL4$L! A0#%     @ KHBN
M4M*U@3TA?@  02H& !4              ( !#3P! &YL<W M,C R,#$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( *Z(KE)O.J#GL#8  ,E  P 5
M  "  6&Z 0!N;'-P+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0
&1/$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
